```
NEWS 1
                Web Page for STN Seminar Schedule - N. America
 NEWS 2 JAN 02
                 STN pricing information for 2008 now available
 NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified
                 prophetic substances
 NEWS 4 JAN 28
                 USPATFULL, USPAT2, and USPATOLD enhanced with new
                 custom IPC display formats
 NEWS 5 JAN 28
                 MARPAT searching enhanced
 NEWS 6 JAN 28
                 USGENE now provides USPTO sequence data within 3 days
                 of publication
 NEWS 7 JAN 28
                 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 9 FEB 08
                 STN Express, Version 8.3, now available
 NEWS 10 FEB 20 PCI now available as a replacement to DPCI
 NEWS 11 FEB 25 IFIREF reloaded with enhancements
 NEWS 12 FEB 25
                 IMSPRODUCT reloaded with enhancements
 NEWS 13 FEB 29
                 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                 U.S. National Patent Classification
 NEWS 14
         MAR 31
                 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                 IPC display formats
 NEWS 15
         MAR 31
                 CAS REGISTRY enhanced with additional experimental
                 spectra
 NEWS 16
         MAR 31
                 CA/CAplus and CASREACT patent number format for U.S.
                 applications updated
 NEWS 17 MAR 31
                 LPCI now available as a replacement to LDPCI
 NEWS 18 MAR 31
                 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19
         APR 04
                 STN AnaVist, Version 1, to be discontinued
 NEWS 20 APR 15
                 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
 NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
 NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family
                 searching
 NEWS 24 MAY 30
                 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
 NEWS 25
         JUN 06
                 EPFULL enhanced with 260,000 English abstracts
 NEWS 26
         JUN 06 KOREAPAT updated with 41,000 documents
 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
             AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008
 NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN
              Welcome Banner and News Items
 NEWS IPC8
              For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008

=> file caplus COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2008 VOL 148 ISS 24 FILE LAST UPDATED: 10 Jun 2008 (20080610/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> e us2007-599748/apps
                     1 US2007-599745/AP
E_2
                      1
                                 US2007-599747/AP
                     0 --> US2007-599748/AP
Е3
                    0 --> US2007-599748/AP

0 US2007-599748/PRN

1 US2007-599750/AP

1 US2007-599753/AP

1 US2007-599779/AP

1 US2007-599793/AP

1 US2007-599811/AP

1 US2007-599813/AP

1 US2007-599816/AP

1 US2007-599856/AP
E4
E5
Ε6
E7
E8
E9
E10
E11
E12
                      1
                               US2007-599856/AP
=> e us2006-599748/apps
                      1
                                US2006-599741/AP
E2
                      1
                                US2006-599744/AP
E3
                      1 --> US2006-599748/AP
                1 --> US2006-599748/AP

0 US2006-599748/PRN

1 US2006-599749/AP

1 US2006-599753/AP

1 US2006-599754/AP

2 US2006-599758/AP

3 US2006-599760/AP

2 US2006-599763/AP

1 US2006-599766/AP
E4
E.5
E.6
E7
E8
E9
E10
E11
E12
=> s e3
L1
                       1 US2006-599748/AP
=> sel rn 11
E1 THROUGH E162 ASSIGNED
=> file reg
```

COST IN U.S. DOLLARS

FULL ESTIMATED COST ENTRY SESSION 3.17 3.38

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2 DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

#### => s e1-e162

1 10453-86-8/BI (10453-86-8/RN)1 1072-84-0/BI (1072-84-0/RN)1 115926-52-8/BI (115926-52-8/RN) 1 122-04-3/BI (122-04-3/RN)1 129-46-4/BI (129-46-4/RN)1 129318-43-0/BI (129318-43-0/RN) 1 130-15-4/BI (130-15-4/RN)1 145-73-3/BI (145-73-3/RN)1 146903-18-6/BI (146903-18-6/RN)1 150560-58-0/BI (150560-58-0/RN)1 15084-51-2/BI (15084-51-2/RN)1 16037-91-5/BI (16037-91-5/RN)1 162086-14-8/BI (162086-14-8/RN) 1 1710-98-1/BI (1710-98-1/RN)1 17325-26-7/BI (17325-26-7/RN)1 17630-76-1/BI

(17630-76-1/RN)

```
1 1821-12-1/BI
    (1821-12-1/RN)
1 18496-54-3/BI
    (18496-54-3/RN)
1 18711-13-2/BI
    (18711-13-2/RN)
1 2058-74-4/BI
    (2058-74-4/RN)
1 20780-76-1/BI
    (20780-76-1/RN)
1 220965-34-4/BI
    (220965-34-4/RN)
1 2243-83-6/BI
    (2243-83-6/RN)
1 237756-11-5/BI
    (237756-11-5/RN)
1 2632-13-5/BI
    (2632-13-5/RN)
1 2650-44-4/BI
    (2650-44-4/RN)
1 27318-90-7/BI
    (27318-90-7/RN)
1 296771-71-6/BI
    (296771-71-6/RN)
1 296773-88-1/BI
    (296773-88-1/RN)
1 301166-54-1/BI
    (301166-54-1/RN)
1 303092-45-7/BI
    (303092-45-7/RN)
1 303149-87-3/BI
    (303149-87-3/RN)
1 303998-01-8/BI
    (303998-01-8/RN)
1 304883-18-9/BI
    (304883-18-9/RN)
1 311321-81-0/BI
    (311321-81-0/RN)
1 312519-17-8/BI
    (312519-17-8/RN)
1 315671-49-9/BI
    (315671-49-9/RN)
1 339205-70-8/BI
    (339205-70-8/RN)
1 339205-73-1/BI
    (339205-73-1/RN)
1 345630-40-2/BI
    (345630-40-2/RN)
1 345630-42-4/BI
    (345630-42-4/RN)
1 36043-49-9/BI
    (36043-49-9/RN)
1 376383-76-5/BI
    (376383-76-5/RN)
1 39755-95-8/BI
    (39755-95-8/RN)
1 401646-54-6/BI
    (401646-54-6/RN)
1 42494-71-3/BI
```

(42494-71-3/RN)

1 42494-73-5/BI

```
(42494-73-5/RN)
1 43100-25-0/BI
    (43100-25-0/RN)
1 43100-38-5/BI
    (43100-38-5/RN)
1 443-69-6/BI
    (443-69-6/RN)
1 458553-48-5/BI
    (458553-48-5/RN)
1 477847-81-7/BI
    (477847 - 81 - 7/RN)
1 478063-72-8/BI
    (478063-72-8/RN)
1 478077-73-5/BI
    (478077-73-5/RN)
1 478077-74-6/BI
    (478077-74-6/RN)
1 478077-78-0/BI
    (478077-78-0/RN)
1 478077-79-1/BI
    (478077-79-1/RN)
1 478257-55-5/BI
    (478257-55-5/RN)
1 478257-73-7/BI
    (478257-73-7/RN)
1 478257-76-0/BI
    (478257-76-0/RN)
1 484-17-3/BI
    (484-17-3/RN)
1 511518-73-3/BI
    (511518-73-3/RN)
1 512796-41-7/BI
    (512796-41-7/RN)
1 512796-49-5/BI
    (512796-49-5/RN)
1 512796-50-8/BI
    (512796-50-8/RN)
1 512796-65-5/BI
    (512796-65-5/RN)
1 512796-67-7/BI
    (512796-67-7/RN)
1 512796-72-4/BI
    (512796-72-4/RN)
1 512796-76-8/BI
    (512796-76-8/RN)
1 512796-99-5/BI
    (512796-99-5/RN)
1 51630-58-1/BI
    (51630-58-1/RN)
1 52315-07-8/BI
    (52315-07-8/RN)
1 524-42-5/BI
    (524-42-5/RN)
1 52918-63-5/BI
    (52918-63-5/RN)
1 5315-25-3/BI
    (5315-25-3/RN)
1 547730-75-6/BI
    (547730-75-6/RN)
1 5725-96-2/BI
    (5725-96-2/RN)
```

```
1 585557-83-1/BI
    (585557-83-1/RN)
1 5908-27-0/BI
    (5908-27-0/RN)
1 604-95-5/BI
    (604-95-5/RN)
1 611-09-6/BI
    (611-09-6/RN)
1 650620-84-1/BI
    (650620 - 84 - 1/RN)
1 68782-46-7/BI
    (68782-46-7/RN)
1 694-83-7/BI
    (694-83-7/RN)
1 69736-76-1/BI
    (69736-76-1/RN)
1 701-99-5/BI
    (701-99-5/RN)
1 722494-26-0/BI
    (722494-26-0/RN)
1 731831-41-7/BI
    (731831-41-7/RN)
1 7440-62-2/BI
    (7440-62-2/RN)
1 75899-68-2/BI
    (75899-68-2/RN)
1 774184-51-9/BI
    (774184-51-9/RN)
1 79183-26-9/BI
    (79183-26-9/RN)
1 819-83-0/BI
    (819-83-0/RN)
1 827034-63-9/BI
    (827034-63-9/RN)
1 84-11-7/BI
    (84-11-7/RN)
1 847363-06-8/BI
    (847363-06-8/RN)
1 860207-88-1/BI
    (860207-88-1/RN)
1 867339-05-7/BI
    (867339-05-7/RN)
1 867375-71-1/BI
    (867375-71-1/RN)
1 867375-74-4/BI
    (867375-74-4/RN)
1 867375-77-7/BI
    (867375-77-7/RN)
1 867375-78-8/BI
    (867375-78-8/RN)
1 867375-79-9/BI
    (867375-79-9/RN)
1 867375-82-4/BI
    (867375-82-4/RN)
1 867375-88-0/BI
    (867375-88-0/RN)
1 867375-89-1/BI
    (867375-89-1/RN)
```

1 867375-90-4/BI

1 867375-91-5/BI

(867375-90-4/RN)

```
(867375-91-5/RN)
1 867375-92-6/BI
    (867375-92-6/RN)
1 867375-93-7/BI
    (867375-93-7/RN)
1 867375-94-8/BI
    (867375-94-8/RN)
1 867375-96-0/BI
    (867375-96-0/RN)
1 867375-97-1/BI
    (867375-97-1/RN)
1 867375-99-3/BI
    (867375-99-3/RN)
1 867376-00-9/BI
    (867376-00-9/RN)
1 867376-01-0/BI
    (867376-01-0/RN)
1 867376-02-1/BI
    (867376-02-1/RN)
1 867376-03-2/BI
    (867376-03-2/RN)
1 867376-04-3/BI
    (867376-04-3/RN)
1 867376-05-4/BI
    (867376-05-4/RN)
1 867376-06-5/BI
    (867376-06-5/RN)
1 867376-07-6/BI
    (867376-07-6/RN)
1 867376-08-7/BI
    (867376-08-7/RN)
1 867376-10-1/BI
    (867376-10-1/RN)
1 867376-11-2/BI
    (867376-11-2/RN)
1 867376-12-3/BI
    (867376-12-3/RN)
1 867376-13-4/BI
    (867376-13-4/RN)
1 867376-14-5/BI
    (867376-14-5/RN)
1 867376-15-6/BI
    (867376-15-6/RN)
1 867376-16-7/BI
    (867376-16-7/RN)
1 867376-17-8/BI
    (867376-17-8/RN)
1 867376-18-9/BI
    (867376-18-9/RN)
1 867376-19-0/BI
    (867376-19-0/RN)
1 867376-20-3/BI
    (867376-20-3/RN)
1 867376-27-0/BI
    (867376-27-0/RN)
1 867376-28-1/BI
    (867376-28-1/RN)
1 867376-29-2/BI
    (867376-29-2/RN)
1 867376-33-8/BI
```

(867376-33-8/RN)

```
1 867376-34-9/BI
    (867376-34-9/RN)
1 867376-35-0/BI
    (867376-35-0/RN)
1 867376-36-1/BI
    (867376-36-1/RN)
1 867376-37-2/BI
    (867376-37-2/RN)
1 867376-38-3/BI
    (867376-38-3/RN)
1 867376-39-4/BI
    (867376-39-4/RN)
1 867376-46-3/BI
    (867376-46-3/RN)
1 867376-63-4/BI
    (867376-63-4/RN)
1 867376-74-7/BI
    (867376-74-7/RN)
1 867376-75-8/BI
    (867376-75-8/RN)
1 867376-76-9/BI
    (867376-76-9/RN)
1 867376-77-0/BI
    (867376-77-0/RN)
1 867376-80-5/BI
    (867376-80-5/RN)
1 867376-81-6/BI
    (867376-81-6/RN)
1 867376-83-8/BI
    (867376-83-8/RN)
1 867376-85-0/BI
    (867376-85-0/RN)
1 867376-86-1/BI
    (867376-86-1/RN)
1 867380-85-6/BI
    (867380-85-6/RN)
1 87-48-9/BI
    (87-48-9/RN)
1 91-56-5/BI
    (91-56-5/RN)
1 939-97-9/BI
    (939-97-9/RN)
1 98-59-9/BI
    (98-59-9/RN)
1 98-74-8/BI
    (98-74-8/RN)
1 99304-37-7/BI
    (99304-37-7/RN)
```

L2

162 (10453-86-8/BI OR 1072-84-0/BI OR 115926-52-8/BI OR 122-04-3/BI OR 129-46-4/BI OR 129318-43-0/BI OR 130-15-4/BI OR 145-73-3/BI OR 146903-18-6/BI OR 150560-58-0/BI OR 15084-51-2/BI OR 16037-91 -5/BI OR 162086-14-8/BI OR 1710-98-1/BI OR 17325-26-7/BI OR 1763 0-76-1/BI OR 1821-12-1/BI OR 18496-54-3/BI OR 18711-13-2/BI OR 2058-74-4/BI OR 20780-76-1/BI OR 220965-34-4/BI OR 2243-83-6/BI OR 237756-11-5/BI OR 2632-13-5/BI OR 2650-44-4/BI OR 27318-90-7/BI OR 296771-71-6/BI OR 296773-88-1/BI OR 301166-54-1/BI OR 3030 92-45-7/BI OR 303149-87-3/BI OR 303998-01-8/BI OR 304883-18-9/BI OR 311321-81-0/BI OR 312519-17-8/BI OR 315671-49-9/BI OR 339205-70-8/BI OR 339205-73-1/BI OR 345630-40-2/BI OR 345630-42-4/BI OR 36043-49-9/BI OR 376383-76-5/BI OR 39755-95-8/BI OR 401646-54-6/BI OR 42494-71-3/BI OR 42494-73-5/BI OR 43100-25-0/BI OR 4310

0-38-5/BI OR 443-69-6/BI OR 458553-48-5/BI OR 477847-81-7/BI OR 478063-72-8/BI OR 478077-73-5/BI OR 478077-74-6/BI OR 478077-78-0/BI OR 478077-79-1/BI OR 478257

=> s 12 and dione

1031736 DIONE

2 DIONES

1031736 DIONE

(DIONE OR DIONES)

L3 22 L2 AND DIONE

=> d scan 13

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-methoxy-

MF C9 H7 N O3

CI COM

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):22

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-bromo-

MF C8 H4 Br N O2

CI COM

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 4,7-dichloro-

MF C8 H3 C12 N O2

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 1-[(4-chlorophenyl)methyl]-5-methyl-

MF C16 H12 Cl N O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 9,10-Phenanthrenedione, 2-nitro-

MF C14 H7 N O4

CI COM

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-bromo-1-ethyl-

MF C10 H8 Br N O2

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione

MF C8 H5 N O2

CI COM

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-iodo-

MF C8 H4 I N O2

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 1-[(4-fluorophenyl)sulfonyl]-

MF C14 H8 F N O4 S

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-nitro-

MF C8 H4 N2 O4

CI COM

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 1-[(4-methylphenyl)methyl]-

MF C16 H13 N O2

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1,4-Naphthalenedione

MF C10 H6 O2

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1,10-Phenanthroline-5,6-dione

MF C12 H6 N2 O2

CI COM

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 9,10-Phenanthrenedione, 2-[(phenylmethyl)amino]-

MF C21 H15 N O2

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 1-methyl-

MF C9 H7 N O2

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-(1-methylethyl)-

MF C11 H11 N O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-fluoro-

MF C8 H4 F N O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 9,10-Phenanthrenedione, 2-amino-

MF C14 H9 N O2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 9,10-Phenanthrenedione

MF C14 H8 O2

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 5-chloro-

MF C8 H4 Cl N O2

CI COM

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1H-Indole-2,3-dione, 1-[(2,4-dichlorophenyl)methyl]-5-nitro-

MF C15 H8 C12 N2 O4

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 22 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1,2-Naphthalenedione

MF C10 H6 O2

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS E US2006-599748/APPS

L1 1 S E3

SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162

L3 22 S L2 AND DIONE

=> s 12 and phenanthrolinedione

5 PHENANTHROLINEDIONE

L4 0 L2 AND PHENANTHROLINEDIONE

=> s 12 and phenanthroline

53251 PHENANTHROLINE

L5 2 L2 AND PHENANTHROLINE

=> d scan 15

L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 1,10-Phenanthroline-5,6-dione

MF C12 H6 N2 O2


CI COM

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L5 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

```
IN Vanadate(1-), oxodiperoxy(1,10-phenanthroline-\kappaN1,\kappaN10)-, potassium, (PB-7-23-111'1'3)- (9CI)
MF C12 H8 N2 O5 V . K
CI CCS
```



• K+

FULL ESTIMATED COST

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

```
=> s "substituted phenanthroline"
           902 "SUBSTITUTED"
         53251 "PHENANTHROLINE"
             0 "SUBSTITUTED PHENANTHROLINE"
L6
                  ("SUBSTITUTED"(W) "PHENANTHROLINE")
=> d his
     (FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)
     FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
                E US2007-599748/APPS
                E US2006-599748/APPS
              1 S E3
L1
                SEL RN L1
     FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
            162 S E1-E162
L2
             22 S L2 AND DIONE
L3
L4
              0 S L2 AND PHENANTHROLINEDIONE
L5
              2 S L2 AND PHENANTHROLINE
L6
              0 S "SUBSTITUTED PHENANTHROLINE"
=> file caplus medline embase biosis scisearch
COST IN U.S. DOLLARS
                                                  SINCE FILE
```

TOTAL

34.65

SESSION

ENTRY

31.27

```
FILE 'CAPLUS' ENTERED AT 09:54:34 ON 11 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'MEDLINE' ENTERED AT 09:54:34 ON 11 JUN 2008
FILE 'EMBASE' ENTERED AT 09:54:34 ON 11 JUN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.
FILE 'BIOSIS' ENTERED AT 09:54:34 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation
FILE 'SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation
=> s 12
L7 224329 L2
=> s 13
L8
        13877 L3
=> s 15
L9
          406 L5
=> d his
     (FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)
     FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
               E US2007-599748/APPS
                E US2006-599748/APPS
L1
              1 S E3
                SEL RN L1
     FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
L2
            162 S E1-E162
L3
             22 S L2 AND DIONE
L4
              0 S L2 AND PHENANTHROLINEDIONE
L5
              2 S L2 AND PHENANTHROLINE
L6
              0 S "SUBSTITUTED PHENANTHROLINE"
     FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
     11 JUN 2008
        224329 S L2
L7
         13877 S L3
L8
            406 S L5
L9
=> s 17 or 18 or 19
    224329 L7 OR L8 OR L9
L10
=> s 10 and antiangiogenic
     3300 10 AND ANTIANGIOGENIC
=> s lll and ischemia
L12
           56 L11 AND ISCHEMIA
=> s l11 and ("heart disease")
L13
           28 L11 AND ("HEART DISEASE")
```

```
=> s 113 and 112
```

2 L13 AND L12 L14

=> d l14 1-2 hitstr ibib all

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:143140 CAPLUS

DOCUMENT NUMBER: 140:181449

TITLE: Preparation of imidazolylmethylaminobenzopyrans as

antiangiogenic agents

INVENTOR(S): Yi, Kyu Yang; Lee, Sun Kyung; Yoo, Sung-eun; Suh, Jee

Hee; Kim, Nak Jeong; Hwang, Sun Kyung; Lee, Byung-ho;

Seo, Ho Won; Lee, Chong Ock; Choi, Sang-un

Korea Research Institute of Chemical Technology, S. PATENT ASSIGNEE(S):

Korea

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.					D	DATE		APPLICATION NO.									
WO					A1		20040219		WO 2003-KR1534									
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KΖ,	LC,	LK,	LR,	LS,	
		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW							
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,	
		KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
		FI,	FR,	GB,	GR,	HU,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,	
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG	
KR	KR 2004014023				A 20040214				KR 2002-47189						20020809			
CA	CA 2493966				A1 20040219				CA 2003-2493966						20030730			
	AU 2003247213				A1 20040225				AU 2003-247213						20030730			
	AU 2003247213				B2 20070405													
EP	EP 1546136				A1 20050629				EP 2003-784665					20030730				
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,	
							RO,											
										CN 2003-819195								
								JP 2004-527422										
								US 2005-523015						20050202				
US	US 7279497					B2 20071009												
PRIORIT	PRIORITY APPLN. INFO.:									KR 2	002-	4718	9	1	A 2	0020	809	
											003-					0030	730	
OTHER S	OURCE	(S):			CASREACT 140:181449; MARPAT 140:181449													

ASREACT 140:181449; M .40:181449

2004:143140 CAPLUS AN

DN140:181449

Entered STN: 22 Feb 2004 ED

Preparation of imidazolylmethylaminobenzopyrans as antiangiogenic ΤI agents

Yi, Kyu Yang; Lee, Sun Kyung; Yoo, Sung-eun; Suh, Jee Hee; Kim, Nak Jeong; INHwang, Sun Kyung; Lee, Byung-ho; Seo, Ho Won; Lee, Chong Ock; Choi, Sang-un

PΑ Korea Research Institute of Chemical Technology, S. Korea

SO PCT Int. Appl., 93 pp. CODEN: PIXXD2

DТ Patent LA English IC ICM C07D405-12 28-9 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1, 27, 63 FAN.CNT 1 PATENT NO. APPLICATION NO. KIND DATE -----W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG KR 2004014023 A 20040214 KR 2002-47189 20020809
CA 2493966 A1 20040219 CA 2003-2493966 20030730
AU 2003247213 A1 20040225 AU 2003-247213 20030730
AU 2003247213 B2 20070405 AU 2003247213 20070405 20050629 EP 1546136 Α1 EP 2003-784665 20030730 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK A 20050928 CN 2003-819195 20030730 CN 1675202 T JP 2004-527422 JP 2006509725 20060323 20030730 US 2005-523015 A1 20051201 US 20050267188 20050202 US 7279497 B2 20071009 WO 2003-KR1534 PRAI KR 2002-47189 A 20020809 W 20030730 CLASS PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES \_\_\_\_\_ \_\_\_\_\_ WO 2004014898 ICM C07D405-12 IPCI C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C\*] IPCR C07D0405-00 [I,C\*]; C07D0405-12 [I,A] ECLA C07D405/12+311C+233 KR 2004014023 IPCI C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C\*] ECLA C07D405/12+311C+233 CA 2493966 IPCI C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C\*] IPCR C07D0405-00 [I,C\*]; C07D0405-12 [I,A] ECLA C07D405/12+311C+233 AU 2003247213 IPCI C07D0405-00 [I,C\*]; C07D0405-12 [I,A] IPCR C07D0405-00 [I,C\*]; C07D0405-12 [I,A] C07D405/12+311C+233 ECLA C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C\*] EP 1546136 IPCI C07D0405-00 [I,C\*]; C07D0405-12 [I,A] IPCR C07D405/12+311C+233 ECLA C07D0405-12 [ICM, 7]; C07D0405-00 [ICM, 7, C\*] CN 1675202 IPCI IPCR C07D0405-00 [I,C\*]; C07D0405-12 [I,A] ECLA C07D405/12+311C+233 JP 2006509725 IPCI C07D0405-12 [I,A]; C07D0405-00 [I,C\*]; A61K0031-4178 [I,A]; A61K0031-4164 [I,C\*]; A61P0009-00 [I,A]; A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0025-02 [I,A]; A61P0025-28 [I,A]; A61P0025-00 [I,C\*]; A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0027-00 [I,C\*]; A61P0029-00 [I,A]; A61P0035-00 [I,A]; A61P0039-06 [I,A]; A61P0039-00 [I,C\*]; C07B0061-00

C07D0405-00 [I,C]; C07D0405-12 [I,A]; A61K0031-4164

[N,A]

TPCR

```
[I,C]; A61K0031-4178 [I,A]; A61P0009-00 [I,C];
                        A61P0009-00 [I,A]; A61P0009-04 [I,A]; A61P0009-10
                        [I,A]; A61P0025-00 [I,C]; A61P0025-02 [I,A];
                        A61P0025-28 [I,A]; A61P0027-00 [I,C]; A61P0027-02
                        [I,A]; A61P0027-06 [I,A]; A61P0029-00 [I,C];
                        A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00
                        [I,A]; A61P0039-00 [I,C]; A61P0039-06 [I,A];
                        C07B0061-00 [N,C]; C07B0061-00 [N,A]
                 FTERM
                       4C063/AA01; 4C063/BB09; 4C063/CC79; 4C063/DD25;
                        4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03;
                        4C086/AA04; 4C086/BC82; 4C086/GA02; 4C086/GA07;
                        4C086/GA16; 4C086/MA01; 4C086/MA04; 4C086/NA14;
                        4C086/ZA02; 4C086/ZA15; 4C086/ZA20; 4C086/ZA33;
                        4C086/ZA36; 4C086/ZA45; 4C086/ZB15; 4H039/CA60;
                        4H039/CA71; 4H039/CB40; 4H039/CF30
 US 20050267188
                 IPCI
                        A61K0031-4164 [I,A]; C07D0233-54 [I,A]; C07D0233-00
                        [I,C*]
                 IPCR
                        C07D0405-00 [I,C*]; C07D0405-12 [I,A]
                 NCL
                        514/397.000; 548/311.400; 514/385.000; 514/396.000;
                        548/300.100; 548/311.100
                 ECLA
                        C07D405/12+311C+233
OS
     CASREACT 140:181449; MARPAT 140:181449
GΙ
```

$$R^4$$
 $R^3$ 
 $N$ 
 $N$ 
 $N$ 
 $N$ 
 $H$ 
 $OH$ 
 $OH$ 
 $OH$ 
 $R^2$ 
 $I$ 

AB Imidazolylmethylaminobenzopyrans I [R1 = H, CN, NO2, NH2; R2 = dialkoxymethyl, alkylenedioxymethyl; R3, R4 = H, Cl, Br, F, alkyl, CF3, OCF3, NO2, (un)substituted OH, CO2H] were prepared for use in the treatment of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, and in the protection of heart and neuronal cells against ischemia-reperfusion injury or preserving organs. Thus, (2S,3R,4R)-3,4-dihydro-2-dimethoxymethyl-3,4-epoxy-2-methyl-6-nitro-2H-1-benzopyran was treated with N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amine to give (2S,3R,4R)-I [R1 = NO2, R2 = CH(OMe)2, R3 = 4-Cl, R4 = H] which showed strong inhibition of HUVEC tube formation at 10  $\mu$ M.

ST imidazolylmethylaminobenzopyran prepn antiangiogenic

IT Heart, disease

(angina pectoris; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Nerve, disease

(diabetic neuropathy; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Eye, disease

(diabetic retinopathy; preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

IT Heart, disease

```
(failure; preparation of imidazolylmethylaminobenzopyrans as
        antiangiogenic agents)
ΤТ
    Asphyxia
        (infant; preparation of imidazolylmethylaminobenzopyrans as
        antiangiogenic agents)
ΙT
     Heart, disease
        (infarction; preparation of imidazolylmethylaminobenzopyrans as
        antiangiogenic agents)
ΙΤ
     Angiogenesis
     Antiarthritics
     Antitumor agents
     Atherosclerosis
     Glaucoma (disease)
     Human
    Neoplasm
     Rheumatoid arthritis
        (preparation of imidazolylmethylaminobenzopyrans as antiangiogenic
        agents)
ΙT
    Mental and behavioral disorders
        (senile psychosis; preparation of imidazolylmethylaminobenzopyrans as
        antiangiogenic agents)
ΙΤ
     Head and Neck, disease
        (trauma; preparation of imidazolylmethylaminobenzopyrans as
        antiangiogenic agents)
ΙT
     571141-37-2P
                   571141-39-4P
                                   660404-73-9P
                                                  660404-74-0P
                                                                 660404-75-1P
     660404-76-2P
                    660404-77-3P
                                  660404-78-4P
                                                  660404-80-8P
                                                                 660404-81-9P
     660404-82-0P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of imidazolylmethylaminobenzopyrans as antiangiogenic
        agents)
                                                  571141-49-6P
                                                                 660404-90-0P
ΤТ
     571141-36-1P
                    571141-38-3P
                                   571141-47-4P
     660404-91-1P
                    660404-92-2P 660404-93-3P
                                                660404-94-4P
                                                                 660404-95-5P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (preparation of imidazolylmethylaminobenzopyrans as antiangiogenic
ΙT
     106-47-8, 4-Chloroaniline, reactions
                                            10111-08-7, 2-
     Imidazolecarboxaldehyde 380912-55-0
                                             380912-56-1 380912-57-2
     380912-58-3
                   660405-19-6
                                 663598-14-9
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of imidazolylmethylaminobenzopyrans as antiangiogenic
        agents)
ΤТ
     166096-16-8P
                    166096-17-9P
                                   660405-04-9P
                                                  660405-05-0P
                                                                 660405-06-1P
     660405-07-2P
                                   660405-09-4P
                                                  660405-10-7P
                                                                 660405-11-8P
                    660405-08-3P
                                   660405-14-1P
                                                  660405-15-2P
                                                                 660405-16-3P
     660405-12-9P
                    660405-13-0P
     660405-17-4P
                    660405-18-5P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of imidazolylmethylaminobenzopyrans as antiangiogenic
        agents)
     660404-79-5P
                    660404-83-1P
                                   660404-84-2P
                                                  660404-89-7P
ΤТ
     RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
     USES (Uses)
        (preparation of imidazolylmethylaminobenzopyrans as antiangiogenic
        agents)
     660404-85-3P
                   660404-86-4P
                                  660404-87-5P
ΤТ
                                                660404-88-6P
                                                                660404-96-6P
     660404-97-7P 660404-98-8P 660404-99-9P 660405-00-5P 660405-01-6P
```

660405-02-7P 660405-03-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolylmethylaminobenzopyrans as antiangiogenic agents)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

- (1) Bristol-Myers Squibb Co; EP 648758 A1 1995 CAPLUS
- (2) Bristol-Myers Squibb Co; US 5629429 A 1997 CAPLUS
- (3) Bristol-Myers Squibb Co; US 5837702 A 1998 CAPLUS
- (4) Ding, C; Journal of Medicinal Chemistry 1999, V42(18), P3711 CAPLUS
- (5) Grover, G; The Journal of Pharmacology and Experimental Therapeutics 2001, V297(3), P1184 CAPLUS
- (6) Merck And Co Inc; US 20020082292 A1 2002
- (7) Rovnyak, G; Journal of Medicinal Chemistry 1997, V40(1), P24 CAPLUS

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:492385 CAPLUS

DOCUMENT NUMBER: 136:288753

TITLE: Effects of hyaluronidase and hyaluronan on

proliferation of vascular endothelial cells and

expression of CD44

AUTHOR(S): Wang, Yongmei; Wu, Zonggui; Li, Li; Zhang, Lingzhen;

Zhong, Rengian

CORPORATE SOURCE: Department of Cardiovasology, Changzheng Hospital,

Second Military Medical University, Shanghai, 200003,

Peop. Rep. China

SOURCE: Dier Junyi Daxue Xuebao (2001), 22(2), 144-147

CODEN: DJXUE5; ISSN: 0258-879X

PUBLISHER: Dier Junyi Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal LANGUAGE: Chinese

AN 2001:492385 CAPLUS

DN 136:288753

- ED Entered STN: 09 Jul 2001
- ${\tt TI}$  Effects of hyaluronidase and hyaluronan on proliferation of vascular endothelial cells and expression of CD44
- AU Wang, Yongmei; Wu, Zongqui; Li, Li; Zhang, Lingzhen; Zhong, Renqian
- CS Department of Cardiovasology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, Peop. Rep. China
- SO Dier Junyi Daxue Xuebao (2001), 22(2), 144-147 CODEN: DJXUE5; ISSN: 0258-879X
- PB Dier Junyi Daxue Xuebao Bianjibu
- DT Journal
- LA Chinese
- CC 1-8 (Pharmacology)
- AB The effects of hyaluronidase (HAase) and hyaluronan (HA) on proliferation of vascular endothelial cells and its mechanism were studied. The cultured aortic endothelial cells (BAEC) were treated with HAase or HA, cell proliferation rate was detected by MTT assay, and expression of CD44 and DNA content of the cells were measured by flow cytometry. The cell proliferation was increased by (50.10  $\pm$  1.23)%, S phase cell rate was increased, and expression of CD44 was induced by HAase (50  $\mu g$  mL-1). The cell proliferation and expression of CD44 were inhibited by HA (100  $\mu g$  mL-1). The results showed that HAase may degrade antiangiogenic HA of extracellular matrix, which may stimulate proliferation of endothelial cells and enhance the curative effect of growth factors to myocardial ischemia.
- $\operatorname{ST}$  hyaluronidase hyaluronan angiogenesis vascular endothelium  $\operatorname{CD44}$  myocardial ischemia
- IT Ischemia

```
vascular endothelial cells and expression of CD44)
ΤТ
     Cardiovascular agents
     Cytoprotective agents
        (cardioprotective agents; effects of hyaluronidase and hyaluronan on
        proliferation of vascular endothelial cells and expression of CD44)
ΙT
     Angiogenesis
     Cell cycle
     Cell proliferation
     Extracellular matrix
        (effects of hyaluronidase and hyaluronan on proliferation of vascular
        endothelial cells and expression of CD44)
ΙT
     CD44 (antigen)
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (effects of hyaluronidase and hyaluronan on proliferation of vascular
        endothelial cells and expression of CD44)
ΤТ
     Blood vessel
        (endothelium; effects of hyaluronidase and hyaluronan on proliferation
        of vascular endothelial cells and expression of CD44)
ΤT
     Heart, disease
        (ischemia; effects of hyaluronidase and hyaluronan on
        proliferation of vascular endothelial cells and expression of CD44)
ΙT
     Endothelium
        (vascular; effects of hyaluronidase and hyaluronan on proliferation of
        vascular endothelial cells and expression of CD44)
     9004-61-9, Hyaluronan
ΤT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (effects of hyaluronidase and hyaluronan on proliferation of vascular
        endothelial cells and expression of CD44)
     37326-33-3, Hyaluronidase
ΤТ
     RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
     (Therapeutic use); BIOL (Biological study); USES (Uses)
        (effects of hyaluronidase and hyaluronan on proliferation of vascular
        endothelial cells and expression of CD44)
=> d his
     (FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)
     FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
                E US2007-599748/APPS
                E US2006-599748/APPS
              1 S E3
T.1
                SEL RN L1
     FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
            162 S E1-E162
L2
L3
             22 S L2 AND DIONE
L4
              0 S L2 AND PHENANTHROLINEDIONE
              2 S L2 AND PHENANTHROLINE
L5
              0 S "SUBSTITUTED PHENANTHROLINE"
L6
     FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
     11 JUN 2008
L7
         224329 S L2
          13877 S L3
L8
L9
            406 S L5
L10
         224329 S L7 OR L8 OR L9
           3300 S 10 AND ANTIANGIOGENIC
L11
```

(cardiac; effects of hyaluronidase and hyaluronan on proliferation of

56 S L11 AND ISCHEMIA T.12

L13 28 S L11 AND ("HEART DISEASE")

T.14 2 S L13 AND L12

=> s (13 or 15) and antiangiogenic

7 (L3 OR L5) AND ANTIANGIOGENIC

=> d 115 1-7 hitstr ibib all

L15 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ΙΤ 91-56-5, Isatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(isatin and its analog acted on large number of biol. targets and had variety of actual and potential pharmacol. action)

91-56-5 CAPLUS RN

1H-Indole-2, 3-dione (CA INDEX NAME) CN



ACCESSION NUMBER: 2008:344354 CAPLUS

TITLE: Biological targets for isatin and its analogues:

implications for therapy

AUTHOR(S): Medvedev, Alexei; Buneeva, Olga; Glover, Vivette CORPORATE SOURCE:

Institute of Biomedical Chemistry, Russian Academy of

Medical Sciences, Moscow, Russia

SOURCE: Biologics: Targets & Therapy (2007), 1(2), 151-162

CODEN: BTTICT; ISSN: 1177-5475 Dove Medical Press (NZ) Ltd.

PUBLISHER: DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

ΑN 2008:344354 CAPLUS

EDEntered STN: 20 Mar 2008

ΤI Biological targets for isatin and its analogues: implications for therapy

ΑU Medvedev, Alexei; Buneeva, Olga; Glover, Vivette

CS Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia

Biologics: Targets & Therapy (2007), 1(2), 151-162 SO CODEN: BTTICT; ISSN: 1177-5475

Dove Medical Press (NZ) Ltd. PΒ

Journal; General Review DT

English LA

CC 1-0 (Pharmacology)

AΒ A review. Isatin and its metabolites are constituents of many natural substances. They are also components of many synthetic compds. exhibiting a wide range of effects, including antiviral activity, antitumor and antiangiogenic activity, antibacterial, antitubercular, antifungal, antiaptotic, anticonvulsant and anxyolytic activities. Isatin itself is an endogenous oxidized indole with a wide spectrum of behavioral and metabolic effects. It has a distinct and discontinuous distribution in the brain, peripheral tissues and body fluids and isatin binding sites are widely distributed also. Its output is increased during stress. Its most potent known in vitro actions are as an antagonist of atrial

natriuretic peptide (ANP) function and NO signaling. As we understand more about its function and sites of action we may be able to develop new pharmacol. agents to mimic or counteract its activity. We consider here the most promising biol. targets for various isatin analogs and/or metabolites, which are employed for the development of various groups of therapeutics. It is also possible that the level of endogenous isatin may influence the in vivo pharmacol. activity of compds. possessing the isatin moiety.

ST review isatin analog drug target sensitivity

IT Drug targets

(isatin and its analog acted on large number of biol. targets and had variety of actual and potential pharmacol. action)

IT 91-56-5, Isatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(isatin and its analog acted on large number of biol. targets and had variety of actual and potential pharmacol. action)

L15 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

IT 87-48-9, 5-Bromo-2,3-indoledione 91-56-5,

2,3-Indoledione 17630-76-1, 5-Chloro-2,3-indoledione

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

RN 87-48-9 CAPLUS

CN 1H-Indole-2,3-dione, 5-bromo- (CA INDEX NAME)

RN 91-56-5 CAPLUS

CN 1H-Indole-2, 3-dione (CA INDEX NAME)

RN 17630-76-1 CAPLUS

CN 1H-Indole-2,3-dione, 5-chloro- (CA INDEX NAME)

ACCESSION NUMBER: 2006:374270 CAPLUS

DOCUMENT NUMBER: 145:62745

TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and

antiangiogenic agents

AUTHOR(S): Abadi, Ashraf H.; Abou-Seri, Sahar M.; Abdel-Rahman,

Doaa E.; Klein, Christian; Lozach, Olivier; Meijer,

Laurent

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of

Pharmacy, Cairo University, Cairo, 11562, Egypt

SOURCE: European Journal of Medicinal Chemistry (2006), 41(3),

296-305

CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:62745

AN 2006:374270 CAPLUS

DN 145:62745

ED Entered STN: 25 Apr 2006

TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents

AU Abadi, Ashraf H.; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent

CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

SO European Journal of Medicinal Chemistry (2006), 41(3), 296-305 CODEN: EJMCA5; ISSN: 0223-5234

PB Elsevier B.V.

DT Journal

LA English

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

OS CASREACT 145:62745

GΙ

AB Several analogs of the 3-substituted-2-oxoindole chemotype were synthesized by condensing isatin or haloisatin with some amino acids or histamine under neutral conditions. All the imino derivs. produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and GSK3 $\alpha/\beta$ . Most of the histidine derivs. showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivs. were less potent against CDK1/cyclin B and CDK5/p25 and totally inactive against GSK3 $\alpha/\beta$ . So, the management of the carboxyl function may be a tool to impart selectivity in such family of kinases. Docking of

oxindoline I [R = Br] to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3 $\beta$ , the ligand poses itself in another orientation, and four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compds. were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compds. was cytotoxic at 10-4 molar concentration Moreover, I [R = H, Br] were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only I [R = Br] showed moderate inhibitory properties to HUVECs proliferation and cord formation while I [R = H] did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases.

- ST oxindole prepn kinase neoplasm angiogenesis inhibitor
- IT Angiogenesis

Angiogenesis inhibitors

Antitumor agents

Human

Neoplasm

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

- IT 9031-44-1, Kinase (phosphorylating)
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

- IT 153535-71-8P 167489-36-3P 891192-12-4P 891192-13-5P 891192-14-6P 891192-15-7P 891192-16-8P 891192-17-9P 891192-18-0P 891192-19-1P
  - 891192-20-4P 891192-21-5P 891192-22-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

- IT 51-45-6, Histamine, reactions 71-00-1, L-Histidine, reactions 72-18-4
  - L-Valine, reactions 72-19-5, L-Threonine, reactions 87-48-9,
  - 5-Bromo-2,3-indoledione 91-56-5, 2,3-Indoledione 6341-92-0,
  - 6-Chloroisatin 6344-05-4, 4-Chloroisatin 7477-63-6, 7-Chloroisatin 17630-76-1, 5-Chloro-2, 3-indoledione
  - RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3-substituted-2-oxoindoles and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents)

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

- (1) Aly, M; Tetrahedron 1994, V50, P895 CAPLUS
- (2) Andreani, A; J Med Chem 2002, V45, P2666 CAPLUS
- (3) Belotti, D; Clin, Cancer Res 1996, V2, P1843 CAPLUS
- (4) Borgne, A; J Biol Chem 1996, V271, P27847 CAPLUS
- (5) Bramson, H; J Med Chem 2001, V44, P4339 CAPLUS
- (6) Clark, R; J Soc Dyers Colour 1997, V113, P316 CAPLUS
- (7) Cohen, P; Eur J Biochem 2001, V268, P5001 CAPLUS
- (8) Cohen, P; Nat Rev Drug Discov 2002, V1, P309 CAPLUS
- (9) Cornell, R; Expert Opin, Ther Patents 2003, V13, P738
- (10) De Strooper, B; Nature 2003, V423, P392 CAPLUS
- (11) Delano, W; The PYMOL Molecular Graphics Sysyem, http://www.pymol.org 2002
- (12) Folkman, J; J Natl Cancer Inst 1990, V82, P4 MEDLINE
- (13) Fong, T; Cancer Res 1999, V59, P99 CAPLUS
- (14) Ganellin, C; J Med Chem 1973, V16, P610 CAPLUS
- (15) Ganellin, R; J Med Chem 1996, V39, P3806
- (16) GraBman, S; Bioorg Med Chem 2003, V11, P2163
- (17) Greever, M; Semin Oncol 1992, V19, P622

(18) Ham, N; J Med Chem 1973, V16, P470 CAPLUS

(19) Haspel, H; Microvasc Res 2002, V63, P304 CAPLUS

(20) Hassaan, A; Egypt J Pharm Sci 1992, V33, P679 CAPLUS

(21) Hassaan, A; Egypt J Pharm Sci 1993, V34, P253 CAPLUS

(22) Hassaan, A; Egypt J Pharm Sci 1994, V35, P165 CAPLUS

(23) Hassaan, A; Egypt J Pharm Sci 1995, V36, P309 CAPLUS

(24) Huang, C; Pacific Symposium on Biocomputing 1996, V1, P724

(25) Jianguo, M; J Pharmcol Exp Ther 2003, V305, P833

(26) Knockaert, M; Trends Pharmacol Sci 2002, V23, P417 CAPLUS

(27) Lane, M; Cancer Res 2001, V15, P6170

(28) Leclerc, S; J Biol Chem 2001, V276, P251 CAPLUS

(29) Malumbres, M; Nat Rev Cancer 2001, V1, P222 CAPLUS

(30) Marzola, P; Clin Cancer Res 2004, V15, P739

(31) Meijer, L; Trends Pharmacol Sci 2004, V25, P471 CAPLUS

(32) Milne, G; J Am Chem Soc 1970, V92, P5170 CAPLUS

(33) Mohamadi, F; J Comput Chem 1990, V11, P440 CAPLUS

(34) Monks, A; J Natl Cancer Inst 1991, V83, P757 CAPLUS

(35) Noble, W; Neuron 2003, V38, P555 CAPLUS

(36) Polychronopoulos, P; J Med Chem 2004, V47, P935 CAPLUS

(37) Primot, A; Protein Expr Purif 2000, V20, P394 CAPLUS

(38) Rehn, S; Eur J Org Chem 2004, P413 CAPLUS

(39) Roth, G; DE 10117204 A1 2002 CAPLUS

(40) Roublevskaia, I; Anticancer Res 2000, V20, P3163 CAPLUS

(41) Sridhar, R; Pharm Res 2000, V17, P1345 CAPLUS

(42) Sun, L; J Med Chem 1998, V41, P2588 CAPLUS(43) Sun, L; J Med Chem 1999, V42, P5120 CAPLUS

(44) Tarabolleti, G; Clin Cancer Res 2002, V8, P1182


L15 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

130-15-4, 1,4-Naphthalenedione ΤТ

RL: PAC (Pharmacological activity); BIOL (Biological study) (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use)

RN 130-15-4 CAPLUS

CN 1,4-Naphthalenedione (CA INDEX NAME)



2005:322408 CAPLUS ACCESSION NUMBER:

142:367706 DOCUMENT NUMBER:

TITLE: 2-Methylthio-1, 4-naphthoquinone and derivatives

thereof, method for production thereof, pharmaceutical

compositions, and therapeutic use

INVENTOR(S): Muller, Werner E. G.; Thakur, Narsinh L.; Thakur,

Arachana N.; Schroder, Heinz C.; Lang, Gerhard;

Tsuruta, Hideyuki; Bringmann, Gerhard

PATENT ASSIGNEE(S): Johannes-Gutenberg-Universitat Mainz, Germany;

Julius-Maximilians-Universitat Wurzburg

Ger. Offen., 19 pp. SOURCE:

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
PATENT NO.
                                        KIND DATE
                                                                        APPLICATION NO.
                                                                                                                  DATE
                                                                        _____
                                        ----
        _____
                                                                                                                  _____
        DE 10343798
                                        A1 20050414
                                                                      DE 2003-10343798
                                                                                                                  20030922
        WO 2005042442
                                         A2 20050512
                                                                         WO 2004-EP10465
                                                                                                                 20040917
                                          A3 20050707
        WO 2005042442
                    AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
                      CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
                      GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
                      LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
                      NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
                      TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
               RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
                      AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
                      EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
                      SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
                      SN, TD, TG
PRIORITY APPLN. INFO.:
                                                                           DE 2003-10343798 A 20030922
                                          MARPAT 142:367706
OTHER SOURCE(S):
        2005:322408 CAPLUS
DN
        142:367706
ED
        Entered STN: 15 Apr 2005
ΤI
        2-Methylthio-1,4-naphthoquinone and derivatives thereof, method for
        production thereof, pharmaceutical compositions, and therapeutic use
        Muller, Werner E. G.; Thakur, Narsinh L.; Thakur, Arachana N.; Schroder,
IN
        Heinz C.; Lang, Gerhard; Tsuruta, Hideyuki; Bringmann, Gerhard
PA
        Johannes-Gutenberg-Universitat Mainz, Germany; Julius-Maximilians-
        Universitat Wurzburg
        Ger. Offen., 19 pp.
SO
        CODEN: GWXXBX
        Patent
DT
        German
LA
        ICM C07C323-22
IC
        ICS C07C319-14
CC
        1-12 (Pharmacology)
        Section cross-reference(s): 10, 63
FAN.CNT 1
                                        KIND DATE APPLICATION NO. DATE
        PATENT NO.
PΙ
        DE 10343798
                                        A1 20050414
                                                                        DE 2003-10343798 20030922
        WO 2005042442
                                          A2
                                                    20050512
                                                                         WO 2004-EP10465
                                   A3 20050707
        WO 2005042442
               W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
                      CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
                      GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
                      LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
                      NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
                      TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
               RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, CT, CF, TD, DE, DI, CF, CO, CT, CM, CZ, CM
                      SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
                      SN, TD, TG
PRAI DE 2003-10343798
                                                   20030922
                                         Α
CLASS
 PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
 _____
                            ____
 DE 10343798 ICM C07C323-22
                            ICS C07C319-14
```

```
TPCT
                        C07C0323-22 [ICM, 7]; C07C0323-00 [ICM, 7, C*];
                        C07C0319-14 [ICS,7]; C07C0319-00 [ICS,7,C*]
                 TPCR
                        C07C0323-00 [I,C*]; C07C0323-22 [I,A]; C12P0011-00
                        [I,C*]; C12P0011-00 [I,A]
                        C07C323/22; C12P011/00
                 ECLA
 WO 2005042442
                 IPCI
                        C07C [ICM, 7]
                        C07C0323-00 [I,C*]; C07C0323-22 [I,A]; C12P0011-00
                 IPCR
                        [I,C*]; C12P0011-00 [I,A]
                 ECLA
                        C07C323/22; C12P011/00
OS
    MARPAT 142:367706
AΒ
     2-Methylthio-1,4-naphthoquinone (MTN) and derivs. thereof are disclosed,
     as are methods for the production and/or isolation thereof. MTN and MTN
     derivs. have antitumor and antiangiogenic properties in cell
     culture models. These compds. also have neointimal proliferation-
     inhibiting properties. The compds. can also be used to treat infections
     by Gram-neg. bacteria.
    methylthionaphthoquinone compd prodn antitumor antibacterial; angiogenesis
ST
     inhibitor methylthionaphthoquinone compd; neointimal proliferation
     inhibitor methylthionaphthoquinone compd
     Animal cell line
ΤT
        (PC12; methylthionaphthoquinone compds., production method, pharmaceutical
        compns., and therapeutic use)
ΙT
     HeLa cell
        (S3; methylthionaphthoquinone compds., production method, pharmaceutical
        compns., and therapeutic use)
ΙT
     Proteobacteria
        (alpha group, MBIC3368; methylthionaphthoguinone compds., production
        method, pharmaceutical compns., and therapeutic use)
ΙT
     Infection
        (bacterial; methylthionaphthoquinone compds., production method,
        pharmaceutical compns., and therapeutic use)
ΙΤ
     Drug delivery systems
        (capsules; methylthionaphthoquinone compds., production method,
        pharmaceutical compns., and therapeutic use)
ΙT
     Uterus, neoplasm
        (cervix, carcinoma; methylthionaphthoquinone compds., production method,
        pharmaceutical compns., and therapeutic use)
ΙT
     Carcinoma
        (cervix; methylthionaphthoquinone compds., production method,
        pharmaceutical compns., and therapeutic use)
ΙT
     Drug delivery systems
        (drops; methylthionaphthoquinone compds., production method, pharmaceutical
        compns., and therapeutic use)
     Gram-negative bacteria
ΙT
        (infection; methylthionaphthoquinone compds., production method,
        pharmaceutical compns., and therapeutic use)
ΤТ
     Drug delivery systems
        (infusions; methylthionaphthoquinone compds., production method,
        pharmaceutical compns., and therapeutic use)
ΙT
     Drug delivery systems
        (injections; methylthionaphthoquinone compds., production method,
        pharmaceutical compns., and therapeutic use)
ΙΤ
     Angiogenesis
     Angiogenesis inhibitors
     Antibacterial agents
     Antitumor agents
     Bacillus subtilis
     Chemotherapy
     Combination chemotherapy
     Drug delivery systems
     Dysidea avara
```

Escherichia coli Fermentation Human Lymphoma Neoplasm Pheochromocytoma (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Natural products, pharmaceutical RL: DEV (Device component use); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Blood vessel Cytotoxic agents (neointimal proliferation inhibitors; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΤT Cell proliferation (neointimal; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Drug delivery systems (oral; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Drug delivery systems (parenterals; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Drug delivery systems (rectal; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙΤ Drug delivery systems (solns.; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Medical goods (stents; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Drug delivery systems (suppositories; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Drug delivery systems (suspensions; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT Drug delivery systems (tablets; methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) 55699-85-9P ΤТ 26037-60-5P RL: DEV (Device component use); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT 849658-75-9 849658-76-0 RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methylthionaphthoquinone compds., production method, pharmaceutical compns., and therapeutic use) ΙT 130-15-4, 1,4-Naphthalenedione RL: PAC (Pharmacological activity); BIOL (Biological study)

(methylthionaphthoquinone compds., production method, pharmaceutical

compns., and therapeutic use)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

- (1) Anon; EP 0863442 A2 CAPLUS
- (2) Coll, G; J Org Chem 1998, V53, P5345
- (3) Kametani, T; J Chem Soc Perkin Trans 1 1977, P386 CAPLUS
- (4) Prakash, G; J Med Chem 1978, V21(4), P369 CAPLUS

L15 ANSWER 4 OF 7 MEDLINE on STN ACCESSION NUMBER: 2006264196 MEDLINE DOCUMENT NUMBER: PubMed ID: 16494969

TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their

evaluation as kinase inhibitors, anticancer and

antiangiogenic agents.

AUTHOR: Abadi Ashraf H; Abou-Seri Sahar M; Abdel-Rahman Doaa E;

Klein Christian; Lozach Olivier; Meijer Laurent

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of

Pharmacy, Cairo University, Egypt.. ahabadi@yahoo.com

SOURCE: European journal of medicinal chemistry, (2006 Mar) Vol.

41, No. 3, pp. 296-305. Electronic Publication:

2006-02-21.

Journal code: 0420510. ISSN: 0223-5234.

PUB. COUNTRY: France

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

(RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200609

ENTRY DATE: Entered STN: 13 May 2006

Last Updated on STN: 30 Sep 2006 Entered Medline: 29 Sep 2006

AN 2006264196 MEDLINE DN PubMed ID: 16494969

TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.

AU Abadi Ashraf H; Abou-Seri Sahar M; Abdel-Rahman Doaa E; Klein Christian; Lozach Olivier; Meijer Laurent

CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Egypt.. ahabadi@yahoo.com

SO European journal of medicinal chemistry, (2006 Mar) Vol. 41, No. 3, pp. 296-305. Electronic Publication: 2006-02-21. Journal code: 0420510. ISSN: 0223-5234.

CY France

DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 200609

ED Entered STN: 13 May 2006
Last Updated on STN: 30 Sep 2006
Entered Medline: 29 Sep 2006

AB Several analogues of the 3-substituted-2-oxoindole chemotype were synthesized by condensing isatin or the appropriate haloisatin with some amino acids or histamine under neutral conditions. All the imino derivatives produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and GSK3alpha/beta. Most of the histidine derivatives showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivatives were less potent against CDK1/cyclin B and CDK5/p25 and totally inactive against GSK3alpha/beta. So, the management of the carboxyl function may be a tool to impart selectivity in such family of

kinases. Docking of 2-[[-5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1Himidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compounds were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compounds was cytotoxic at 10(-4) molar concentration. Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord formation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases. \*Angiogenesis Inhibitors: CS, chemical synthesis Angiogenesis Inhibitors: CH, chemistry Angiogenesis Inhibitors: PD, pharmacology \*Antineoplastic Agents: CS, chemical synthesis Antineoplastic Agents: CH, chemistry Antineoplastic Agents: PD, pharmacology Cell Line Cell Proliferation: DE, drug effects Drug Screening Assays, Antitumor Endothelial Cells: DE, drug effects Histidine: AA, analogs & derivatives Histidine: CS, chemical synthesis Histidine: PD, pharmacology Humans Indoles: CS, chemical synthesis \*Indoles: CH, chemistry \*Indoles: PD, pharmacology Inhibitory Concentration 50 Isatin: AA, analogs & derivatives Isatin: CH, chemistry Models, Molecular Molecular Structure Protein Kinase Inhibitors: CS, chemical synthesis \*Protein Kinase Inhibitors: CH, chemistry \*Protein Kinase Inhibitors: PD, pharmacology Umbilical Veins: CY, cytology 61-71-2 (3-hydroxy-2-oxoindole); 71-00-1 (Histidine); 91-56-5 (Isatin) 0 (Angiogenesis Inhibitors); 0 (Antineoplastic Agents); 0 (Indoles); 0

L15 ANSWER 5 OF 7 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 2006190028 EMBASE

(Protein Kinase Inhibitors)

CT

RN

CN

TITLE: Synthesis of 3-substituted-2-oxoindole analogues and their

evaluation as kinase inhibitors, anticancer and

antiangiogenic agents.

AUTHOR: Abadi, Ashraf H. (correspondence); Abou-Seri, Sahar M.;

Abdel-Rahman, Doaa E.

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of

Pharmacy, Cairo University, Kasr El-Aini street, Cairo,

11562, Egypt. ahabadi@yahoo.com

AUTHOR: Klein, Christian

CORPORATE SOURCE: Pharmaceutical and Medicinal Chemistry, Saarland

University, P.O. Box 151150, D-66041 Saarbrucken, Germany.

AUTHOR: Lozach, Olivier; Meijer, Laurent

CORPORATE SOURCE: CNRS, Station Biologique, BP 74, 29682 Roscoff cedex,

France.

SOURCE: European Journal of Medicinal Chemistry, (Mar 2006) Vol.

41, No. 3, pp. 296-305.

Refs: 45

ISSN: 0223-5234 E-ISSN: 1768-3254 CODEN: EJMCA5

PUBLISHER IDENT.: S 0223-5234(06)00020-1

COUNTRY: France

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 030 Clinical and Experimental Pharmacology

037 Drug Literature Index

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 6 Jun 2006

Last Updated on STN: 6 Jun 2006

AN 2006190028 EMBASE

TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.

AU Abadi, Ashraf H. (correspondence); Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.

CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini street, Cairo, 11562, Egypt. ahabadi@yahoo.com

AU Klein, Christian

CS Pharmaceutical and Medicinal Chemistry, Saarland University, P.O. Box 151150, D-66041 Saarbrucken, Germany.

AU Lozach, Olivier; Meijer, Laurent

CS CNRS, Station Biologique, BP 74, 29682 Roscoff cedex, France.

SO European Journal of Medicinal Chemistry, (Mar 2006) Vol. 41, No. 3, pp. 296-305.

Refs: 45

ISSN: 0223-5234 E-ISSN: 1768-3254 CODEN: EJMCA5

PUI S 0223-5234(06)00020-1

CY France

DT Journal; Article

FS 030 Clinical and Experimental Pharmacology 037 Drug Literature Index

LA English

SL English

ED Entered STN: 6 Jun 2006

Last Updated on STN: 6 Jun 2006

AΒ Several analogues of the 3-substituted-2-oxoindole chemotype were synthesized by condensing isatin or the appropriate haloisatin with some amino acids or histamine under neutral conditions. All the imino derivatives produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDK1/cyclin B, CDK5/p25 and  $GSK3\alpha/\beta$ . Most of the histidine derivatives showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivatives were less potent against CDK1/cyclin B and CDK5/p25 and totally inactive against GSK3 $\alpha/\beta$ . So, the management of the carboxyl function may be a tool to impart selectivity in such family of kinases. Docking of 2-{[-5-bromo-2-oxoindolin-3-ylidene]amino}-3-(1Himidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for  $GSK/3\beta$ , the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compounds were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compounds was cytotoxic at 10(-4) molar concentration.

Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord formation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases. . COPYRGT. 2006 Elsevier SAS. All rights reserved. Medical Descriptors: antiangiogenic activity antineoplastic activity article breast cell bromination cancer cell culture cell migration cell proliferation central nervous system concentration (parameters) controlled study cytotoxicity drug synthesis endothelium cell enzyme inhibition human human cell hydrogen bond hydrophobicity lung alveolus cell polymerization protein family protein protein interaction umbilical vein Drug Descriptors: 2 [(4 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development 2 [(4 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid: PD, pharmacology 2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development 2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology 2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 hydroxybutanoic acid: DV, drug development 2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 hydroxybutanoic acid: PD, pharmacology 2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 methylbutanoic acid: DV, drug development 2 [(5 bromo 2 oxoindolin 3 ylidene)amino] 3 methylbutanoic acid: PD, pharmacology 2 [(5 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development 2 [(5 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology 2 [(6 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development 2 [(6 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : PD, pharmacology 2 [(7 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic acid : DV, drug development 2 [(7 chloro 2 oxoindolin 3 ylidene)amino] 3 (1h imidazol 2 yl)propanoic

CT

CT

```
acid : PD, pharmacology
     3 (1h imidazol 2 yl) 2 [(2 oxoindolin 3 ylidene)amino]propanoic acid: DV,
     drug development
     3 (1h imidazol 2 yl) 2 [(2 oxoindolin 3 ylidene)amino]propanoic acid: PD,
     pharmacology
     3 [2 (1h imidazol 4 yl)ethylimino] 5 bromoindolin 2 one: DV, drug
     development
     3 [2 (1h imidazol 4 yl)ethylimino] 5 bromoindolin 2 one: PD, pharmacology
     3 [2 (1h imidazol 4 yl)ethylimino] 5 chloroindolin 2 one: DV, drug
     development
     3 [2 (1h imidazol 4 yl)ethylimino] 5 chloroindolin 2 one: PD, pharmacology
     3 [2 (1h imidazol 4 yl)ethylimino]indolin 2 one: DV, drug development
     3 [2 (1h imidazol 4 yl)ethylimino]indolin 2 one: PD, pharmacology
     3 hydroxy 2 [(2 oxoindolin 3 ylidene)amino]butanoic acid: DV, drug
     development
     3 hydroxy 2 [(2 oxoindolin 3 ylidene)amino]butanoic acid: PD, pharmacology
     3 methyl 2 (2 oxoindolin 3 ylideneamino) butanoic acid: DV, drug
     development
     3 methyl 2 (2 oxoindolin 3 ylideneamino) butanoic acid: PD, pharmacology
     amino acid
     *angiogenesis inhibitor: DV, drug development
     *angiogenesis inhibitor: PD, pharmacology
     *antineoplastic agent: DV, drug development
     *antineoplastic agent: PD, pharmacology
     carboxyl group
     cyclin B
     cyclin dependent kinase 1
     cyclin dependent kinase 5
     histamine
     histamine derivative
     histidine derivative
     *indole derivative: DV, drug development
     *indole derivative: PD, pharmacology
     isatin
     *phosphotransferase inhibitor: DV, drug development
     *phosphotransferase inhibitor: PD, pharmacology
     propionic acid derivative: DV, drug development
     propionic acid derivative: PD, pharmacology
     protein p25
     protein serine threonine kinase
    unclassified drug
    unindexed drug
     (amino acid) 65072-01-7; (histamine) 51-45-6, 56-92-8, 93443-21-1;
     (isatin) 91-56-5
L15 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
                    2006:437778 BIOSIS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                    PREV200600440686
TITLE:
                    Synthesis of 3-substituted-2-oxoindole analogues and their
                    evaluation as kinase inhibitors, anticancer and
                    antiangiogenic agents.
AUTHOR(S):
                    Abadi, Ashraf H. [Reprint Author]; Abou-Seri, Sahar M.;
                    Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier;
                    Meijer, Laurent
CORPORATE SOURCE:
                    Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Kasr El Aini
                    St, Cairo 11562, Egypt
                    ahabadi@yahoo.com
SOURCE:
                    European Journal of Medicinal Chemistry, (MAR 2006) Vol.
                    41, No. 3, pp. 296-305.
                    CODEN: EJMCA5. ISSN: 0223-5234.
DOCUMENT TYPE:
                   Article
```

RN

LANGUAGE: English

ENTRY DATE: Entered STN: 6 Sep 2006

Last Updated on STN: 6 Sep 2006

AN 2006:437778 BIOSIS

DN PREV200600440686

TI Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.

- AU Abadi, Ashraf H. [Reprint Author]; Abou-Seri, Sahar M.; Abdel-Rahman, Doaa E.; Klein, Christian; Lozach, Olivier; Meijer, Laurent
- CS Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Kasr El Aini St, Cairo 11562, Egypt

ahabadi@yahoo.com

- SO European Journal of Medicinal Chemistry, (MAR 2006) Vol. 41, No. 3, pp. 296-305.

  CODEN: EJMCA5. ISSN: 0223-5234.
- DT Article
- LA English
- ED Entered STN: 6 Sep 2006

  Last Updated on STN: 6 Sep 2006
- Several analogues of the 3-substituted-2-oxoindole chemotype were AΒ synthesized by condensing isatin or the appropriate haloisatin with some amino acids or histamine under neutral conditions. All the imino derivatives produced were tested for kinase inhibitory properties against three serine/threonine kinases, namely CDKI/cyclin B, CDK5/p25 and GSK alpha/beta. Most of the histidine derivatives showed inhibitory properties to the three kinases in the low micromolar range. The histamine derivatives were less potent against CDKI/cyclin B and CDK5/p25 and totally inactive against GSU alpha/beta. So, the management of the carboxyl function may be a tool to impart selectivity in such family of kinases. Docking of 2-{[-5bromo-2-oxoindolin-3-ylidene]amino)-3-{]Himidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3 beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate. Also, all the final compounds were tested for their in vitro antitumor properties against MCF7 (breast), NCI-H460 (lung) and SF268 (CNS) cancer cell lines. None of the synthesized compounds was cytotoxic at 10(-4) molar concentration. Moreover, compounds 13 and 14 were tested for potential antiangiogenic properties by testing their ability to inhibit the proliferation of human umbilical vein endothelial cells (HUVECs), cord formation and migration in response to chemoattractant. Only compound 14 showed moderate inhibitory properties to HUVECs proliferation and cord fort-nation while its non-brominated derivative 13 did not. Thus, the antiangiogenesis properties are not apparently caused by inhibition of any of the tested kinases. (c) 2006 Elsevier SAS. All rights reserved.

CC Cytology - Human 02508

Biochemistry studies - Proteins, peptides and amino acids 10064 Enzymes - General and comparative studies: coenzymes 10802 Pathology - Therapy 12512

Respiratory system - Physiology and biochemistry 16004

Respiratory system - Pathology 16006

Reproductive system - Physiology and biochemistry 16504

Reproductive system - Pathology 16506

Nervous system - Physiology and biochemistry 20504

Nervous system - Pathology 20506

Pharmacology - General 22002

Neoplasms - Pathology, clinical aspects and systemic effects 24004 Neoplasms - Therapeutic agents and therapy 24008

IT Major Concepts

Pharmaceuticals (Pharmacology); Enzymology (Biochemistry and Molecular

```
Biophysics); Tumor Biology
ΤТ
     Parts, Structures, & Systems of Organisms
        breast: reproductive system; lung: respiratory system; glia: nervous
        system
ΤТ
     Diseases
        glioblastoma: nervous system disease, neoplastic disease
        Glioblastoma (MeSH)
ΙT
        breast cancer: neoplastic disease, reproductive system disease/female
        Breast Neoplasms (MeSH)
ΤТ
     Diseases
        lung cancer: respiratory system disease, neoplastic disease
        Lung Neoplasms (MeSH)
ΙT
     Chemicals & Biochemicals
        histidine; isatin; histamine; threonine kinase; serine kinase;
        3-substituted-2-oxoindole: synthesis; haloisatin; 2-{[-5-bromo-2-
        oxoindolin-3-ylidene]amino}-3-(1H-imidazol2-yl)propionic acid;
        CDK1/cyclin B: antineoplastic-drug; CDK5/p25: antineoplastic-drug;
        GSK-3 alpha/beta [glycogen synthase kinase-3 alpha/beta]:
        antineoplastic-drug
ORGN Classifier
        Hominidae
                    86215
     Super Taxa
        Primates; Mammalia; Vertebrata; Chordata; Animalia
     Organism Name
        MCF-7 cell line (cell_line): human breast cancer cells
        NCI-H460 cell line (cell_line): human lung cancer cells
        SF268 cell line (cell_line): human glioblastoma cells
        HUVECs cell line (cell_line): human umbilical vein endothelial cells
     Taxa Notes
        Animals, Chordates, Humans, Mammals, Primates, Vertebrates
RN
     4998-57-6 (histidine)
       91-56-5 (isatin)
     51-45-6 (histamine)
     9026-43-1 (serine kinase)
L15 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ACCESSION NUMBER:
                    2005:450611 BIOSIS
DOCUMENT NUMBER:
                    PREV200510241116
TITLE:
                    Comparison of the antiinflammatory effects of Drosera
                    rotundifolia and Drosera madagascariensis in the HET-CAM
                    assay.
AUTHOR(S):
                    Paper, Dietrich H.; Karall, Elisabeth; Kremser, Michaela;
                    Krenn, Liselotte [Reprint Author]
CORPORATE SOURCE:
                    Univ Vienna, Inst Pharmakognosie, Althanstr 14, A-1090
                    Vienna, Austria
                    liselotte.krenn@univie.ac.at
SOURCE:
                    PHYTOTHERAPY RESEARCH, (APR 2005) Vol. 19, No. 4, pp.
                    323-326.
                    ISSN: 0951-418X.
DOCUMENT TYPE:
                    Article
LANGUAGE:
                    English
ENTRY DATE:
                    Entered STN: 3 Nov 2005
                    Last Updated on STN: 3 Nov 2005
     2005:450611 BIOSIS
ΑN
     PREV200510241116
DΝ
TΙ
     Comparison of the antiinflammatory effects of Drosera rotundifolia and
     Drosera madagascariensis in the HET-CAM assay.
     Paper, Dietrich H.; Karall, Elisabeth; Kremser, Michaela; Krenn, Liselotte
ΑIJ
     [Reprint Author]
     Univ Vienna, Inst Pharmakognosie, Althanstr 14, A-1090 Vienna, Austria
CS
```

liselotte.krenn@univie.ac.at PHYTOTHERAPY RESEARCH, (APR 2005) Vol. 19, No. 4, pp. 323-326. SO ISSN: 0951-418X. DTArticle LA English Entered STN: 3 Nov 2005 ED Last Updated on STN: 3 Nov 2005 The antfinflammatory effects of ethanol and aqueous extracts from Drosera AΒ rotundifolia and from Drosera madagascariensis were compared in vivo in the HET-CAM assay. Both extracts from D. rotundifolia and the ethanol extract from D. madagascariensis showed remarkable efficacy at doses of 500 mu g/pellet. The inhibition of the inflammation by the extracts was stronger than that by 50 mu g hydrocortisone/pellet. In contrast, there was only a very weak effect observed at a dose of 500 mu g/pellet of the water extract from D. madagascariensis. The chemical analyses of the extracts showed that the effect cannot be attributed to naphthoquinones, but might be due to flavonoids. Ellagic acid obviously plays an important role in the antiangiogenic effect of the Drosera extracts. Copyright (c) 2005 John Wiley & Sons, Ltd. CC Biochemistry studies - General 10060 12512 Pathology - Therapy Pharmacology - Connective tissue, bone and collagen-acting drugs Pharmacology - Immunological processes and allergy Pharmacognosy and pharmaceutical botany ΙT Major Concepts Methods and Techniques; Pharmacognosy (Pharmacology) Chemicals & Biochemicals ΙT flavonoids; ellagic acid; naphthoquinone; ethanol extract: antiinflammatory-drug, immunologic-drug, dosage, crude drug, efficacy, inhibition; aqueous extract: antiinflammatory-drug, immunologic-drug, dosage, crude drug, efficacy, inhibition Methods & Equipment ΙT hen's egg test-chorioallantoic membrane assay: laboratory techniques Miscellaneous Descriptors ΙT antiinflammatory effect ORGN Classifier Droseraceae 25990 Super Taxa Dicotyledones; Angiospermae; Spermatophyta; Plantae Organism Name Drosera madagascariensis (species): medicinal plant Drosera rotundifolia (species): medicinal plant Taxa Notes Angiosperms, Dicots, Plants, Spermatophytes, Vascular Plants RN 476-66-4 (ellagic acid) 130-15-4 (naphthoquinone) => s 1,1"-Phenanthroline-5,6-dione MISMATCHED QUOTE '1,1"-PHENANTHR' Quotation marks (or apostrophes) must be used in pairs, one before and one after the expression you are setting off or masking. => s "1,10-Phenanthroline-5,6-dione" 587 "1,10-PHENANTHROLINE-5,6-DIONE" => s 116 and phenanthrene L17 4 L16 AND PHENANTHRENE

=> d l17 1-4 hitstr ibib all

```
L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
                         2006:943703 CAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         147:117706
TITLE:
                         Product class 6: phenanthrene-9, 10-diones,
                         stilbenequinones, diphenoquinones, and related ring
                        assemblies
AUTHOR(S):
                        Echavarren, A. M.; Porcel, S.
CORPORATE SOURCE:
                        Institute of Chemical Research of Catalonia (ICIQ),
                         Tarragona, 43007, Spain
SOURCE:
                         Science of Synthesis (2006), 28, 507-560
                        CODEN: SSCYJ9
PUBLISHER:
                        Georg Thieme Verlag
DOCUMENT TYPE:
                         Journal; General Review
LANGUAGE:
                         English
     2006:943703 CAPLUS
ΝA
     147:117706
DN
ΕD
     Entered STN: 14 Sep 2006
     Product class 6: phenanthrene-9,10-diones, stilbenequinones,
ΤI
     diphenoquinones, and related ring assemblies
ΑU
     Echavarren, A. M.; Porcel, S.
CS
     Institute of Chemical Research of Catalonia (ICIQ), Tarragona, 43007,
     Spain
     Science of Synthesis (2006), 28, 507-560
SO
     CODEN: SSCYJ9
     Georg Thieme Verlag
PB
DT
    Journal; General Review
LA
     English
CC
     21-0 (General Organic Chemistry)
AΒ
    A review of methods to prepare phenanthrene-9,10-diones,
     stilbenequinones, diphenoquinones, and related ring assemblies.
ST
     review phenanthrenedione analog prepn; stilbenequinone analog prepn
     review; diphenoquinone analog prepn review
ΙT
     Quinones
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (review preparation of phenanthrenedione, stilbenequinones, diphenoquinones,
        and related ring analogs)
ΙT
     141-78-6, Acetic acid ethyl ester, uses
     RL: CAT (Catalyst use); USES (Uses)
        (review preparation of phenanthrenedione, stilbenequinones, diphenoquinones,
        and related ring analogs)
ΙT
     56-53-1
              66-71-7, 1,10-Phenanthroline
                                            67-64-1, 2-Propanone, reactions
     78-94-4, 3-Buten-2-one, reactions
                                       85-01-8, Phenanthrene,
     reactions
               85-02-9, Benzo[f]quinoline 85-97-2 87-65-0
                                                                  91 - 10 - 1
     92-88-6, [1,1'-Biphenyl]-4,4'-diol 93-58-3
                                                    93-89-0
                                                              94-08-6
                                                                        99 - 75 - 2
     100-42-5, reactions 110-18-9 128-38-1
                                                128-39-2 129-00-0, Pyrene,
                                                        484-11-7 527-60-6
                134-81-6
                           230-27-3, Benzo[h]quinoline
     reactions
                576-26-1
                           584-03-2, 1,2-Butanediol 603-35-0, reactions
     554-34-7
                                                             1519-46-6
                617-04-9
                         951-06-4
                                    1068-47-9 1188-33-6
     604-95-5
               1629-58-9, 1-Penten-3-one 1879-09-0
                                                         2078-54-8
     1576-69-8
                                                                     2219-82-1
     2416-98-0
                 2417-04-1
                             2432-11-3, [1,1':3',1''-Terphenyl]-2'-ol
                             3697-13-0, 1,7-Phenanthrolin-6-ol
     2950-01-8
                 3011-45-8
     4844-17-1
                 5398-75-4
                            5417-63-0 5807-64-7 7693-47-2
     14328-91-7
                 14970-83-3
                               15058-36-3
                                            17755-10-1
                                                        20185-55-1
                               24415-26-7, 1-Nonen-3-one
     21509-95-5
                  24300-91-2
                                                           24620-40-4
                  27018-91-3, 4H-Cyclopenta[def]phenanthrene
     24909-10-2
                  28622-70-0
                                                        38256-25-6
     -8,9-dione
                               28713-50-0
                                           29176-55-4
                                           54258-41-2, 1,10-Phenanthrolin-5-
     40152-05-4
                 40352-56-5
                              53622-33-6
                        65564-60-5
            58245-82-2
                                      70005-88-8
                                                  73049-18-0
                                                                 74825-06-2
     amine
     74825 - 07 - 3 \qquad 74825 - 08 - 4 \qquad 74825 - 09 - 5 \qquad 74825 - 11 - 9 \qquad 74825 - 12 - 0
                                          80232-65-1 80721-43-3
     74825-13-1
                78891-39-1 78939-36-3
```

```
84405-44-7
               85575-93-5 92346-53-7 92599-23-0 95912-03-1
    98126-29-5
                 99248-71-2 100125-12-0 102420-54-2 124974-15-8
    127753-94-0 138145-24-1 138145-26-3 138145-28-5
                                                         139975-70-5
                                            155587-72-7
    152660-60-1 153399-67-8
                              155587-64-7
                                                          155587-84-1
    156235-29-9 156235-35-7
                              156235-36-8 176956-19-7
                                                          176956-23-3
    176956-24-4 176956-29-9
                              188677-27-2 188677-28-3 188677-29-4
    188677-30-7 190127-31-2
                              206200-31-9 206200-32-0 216657-09-9
    268538-85-8 336184-07-7
                              682750-08-9 682750-11-4 682750-15-8
    682750-26-1 697299-12-0
                              791637-63-3 791637-64-4 791637-65-5
    837421-16-6 855360-67-7 872809-85-3 943126-95-2
    RL: RCT (Reactant); RACT (Reactant or reagent)
       (review preparation of phenanthrenedione, stilbenequinones, diphenoquinones,
       and related ring analogs)
ΙT
    84-11-7P, 9,10-Phenanthrenedione
                                     128-37-0P, preparation
                                                             809-73-4P
    2607-52-5P
                 5664-37-9P 6217-22-7P, 4,5-Pyrenedione 6546-78-7P
                  60373-54-8P
                               72909-34-3P
                                            74447-88-4P
    60373-53-7P
                                                          78939-38-5P
                               92346-54-8P
    78939-39-6P
                  78939-40-9P
                                             92346-55-9P
                                                          95912-14-4P
                  99248-72-3P
                               99248-73-4P
                                           121793-75-7P
                                                          139975-66-9P
    98126-30-8P
                 142422-24-0P
                                161470-06-0P 190127-32-3P 524746-74-5P
    142422-23-9P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (review preparation of phenanthrenedione, stilbenequinones, diphenoquinones,
       and related ring analogs)
ΙT
    84-12-8P, 4,7-Phenanthroline-5,6-dione 96-09-3P 110-01-0P
                         482-05-3P, [1,1'-Biphenyl]-2,2'-dicarboxylic acid
    Benzo[b]triphenvlene
    493-74-3P
                494-72-4P
                           604-84-2P, 9,10-Phenanthrenediol 1072-43-1P
                             1613-51-0P
    1498-99-3P
                 1516-94-5P
                                         1620-98-0P
                                                     2178-51-0P
    2179-51-3P
                 2455-14-3P
                             3457-53-2P
                                          3550-01-4P
                                                     4906-22-3P
                                                        14387-17-8P
    6787-57-1P
                 13421-38-0P
                              13693-18-0P
                                            14328-90-6P
    17816-26-1P
                                            20246-79-1P 20851-85-8P
                 17816-27-2P
                               17825-35-3P
    21736-38-9P
                 24378-09-4P
                               27318-90-7P, 1,10-
    Phenanthroline-5,6-dione
                                             39250-93-6P
    27728-29-6P 35495-11-5P
                               36909-24-7P
                                                          54389-66-1P
    54389-67-2P
                 58856-98-7P
                               59869-79-3P
                                           60373-56-0P
                                                          60566-01-0P
    65938-98-9P, Benzo[h]quinoline-5,6-dione 65938-99-0P,
    Benzo[f]quinoline-5,6-dione 66788-08-7P, Benzo[e]pyrene-4,5-dione
    67080-37-9P 69097-25-2P 73030-04-3P 73049-19-1P 74809-56-6P
    74809-57-7P
                 74809-58-8P
                              74809-59-9P
                                            74809-60-2P
                                                          74809-61-3P
    74825-14-2P 80721-44-4P
                              82701-91-5P, 1,7-Phenanthroline-5,6-dione
    84405-38-9P 92599-27-4P
                              99248-74-5P
                                           99419-91-7P 99420-18-5P
    99520-63-5P, Indeno[1,2,3-cd]pyrene-1,2-dione
                                                  102331-54-4P
    102331-58-8P
                 108744-18-9P
                               113736-80-4P
                                                117745-54-7P
                                                             121793-76-8P
    137936-95-9P
                 139220-15-8P
                                139975-73-8P
                                               139975-74-9P
                                                             139975-75-0P
    141622-77-7P
                 142422-22-8P
                                143255-68-9P, 4H-
    Benzo[b]cyclopenta[jkl]triphenylene
                                       147120-00-1P 153399-73-6P
                                155306-04-0P
                                                155587-66-9P 155587-67-0P
    153399-74-7P
                 153399-75-8P
                  156235-18-6P
    155587-81-8P
                                 156235-19-7P
                                                157488-04-5P
                                                              176956-25-5P
    180999-63-7P
                                 180999-67-1P
                                                              188677-34-1P
                   180999-65-9P
                                                180999-68-2P
                                 188677-37-4P
    188677-35-2P
                   188677-36-3P
                                                190127-36-7P
                                                              215674-97-8P
    216656-90-5P
                   336184-12-4P
                                 337312-91-1P
                                                337312-93-3P
                                                              337312-94-4P
    337312-95-5P
                   337312-96-6P
                                 337312-97-7P
                                                337312-98-8P
                                                              379711-32-7P
    602331-25-9P
                   682749-93-5P
                                 682749-96-8P
                                                682749-99-1P
                                                              704860-92-4P
    791637-66-6P
                   791637-67-7P
                                 791637-69-9P
                                                791637-70-2P
                                                              837421-17-7P
    943126-96-3P
    RL: SPN (Synthetic preparation); PREP (Preparation)
        (review preparation of phenanthrenedione, stilbenequinones, diphenoquinones,
       and related ring analogs)
RE.CNT 229
             THERE ARE 229 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Abul-Hajj, Y; J Am Chem Soc 1995, V117, P5600 CAPLUS
```

- (2) Altwicker, E; Chem Rev 1967, V67, P475 CAPLUS

- (3) Amouyal, E; J Chem Soc, Dalton Trans 1990, P1841 CAPLUS
- (4) Andres, J; J Am Chem Soc 1995, V117, P8807 CAPLUS
- (5) Anthony, C; Biochim Biophys Acta 2003, V1647, P18 CAPLUS
- (6) Azuma, J; JP 2003270821 2003 CAPLUS
- (7) Bacon, R; Chem Commun 1967, P977 CAPLUS
- (8) Badesha, S; US 5166016 1992 CAPLUS
- (9) Balog, V; J Org Chem 1971, V36, P1339
- (10) Balogh-Hergovich, E; Synthesis 1982, P731 CAPLUS
- (11) Basavaiah, D; Tetrahedron Lett 2001, V42, P1147 CAPLUS
- (12) Bauer, R; Tetrahedron 1963, V19, P1201 CAPLUS
- (13) Becker, H; J Org Chem 1965, V30, P982 CAPLUS
- (14) Becker, H; J Org Chem 1982, V47, P1095 CAPLUS
- (15) Becker, H; Tetrahedron Lett 1976, P4883 CAPLUS
- (16) Bedell, S; J Am Chem Soc 1985, V107, P7909 CAPLUS
- (17) Benjamin, B; J Org Chem 1978, V43, P2986 CAPLUS
- (18) Bing, Y; Tetrahedron Lett 2004, V45, P6361 CAPLUS
- (19) Bodine, R; J Org Chem 1978, V43, P4025 CAPLUS
- (20) Bolton, J; Chem Res Toxicol 2000, V13, P135 CAPLUS
- (21) Bonhote, P; Synlett 1997, P897 CAPLUS
- (22) Bora, U; Tetrahedron 2001, V57, P2445 CAPLUS
- (23) Braven, J; J Heterocycl Chem 1995, V32, P1051 CAPLUS
- (24) Brink, G; J Org Chem 2001, V66, P2429
- (25) Brooks, H; Biochemistry 1993, V32, P2725 CAPLUS
- (26) Bruce, J; J Chem Soc, Perkin Trans 1 1974, P295 CAPLUS
- (27) Buchi, G; J Am Chem Soc 1985, V107, P5555 CAPLUS
- (28) Byrne, L; J Chem Soc, Perkin Trans 1 1982, P2855 CAPLUS
- (29) Chae, K; Steroids 1998, V63, P149 CAPLUS
- (30) Cho, A; Aerosol Sci Technol 2004, V38(Suppl 1), P68
- (31) Cisek, J; Tetrahedron Lett 2004, V45, P2801
- (32) Cook, C; J Am Chem Soc 1955, V77, P1783 CAPLUS
- (33) Cook, C; J Org Chem 1953, V18, P261 CAPLUS
- (34) Corey, E; J Am Chem Soc 1981, V103, P5599 CAPLUS
- (35) Cosgrove, S; J Chem Soc 1951, P388 CAPLUS
- (36) Cozzi, F; Org Biomol Chem 2003, V1, P157 CAPLUS
- (37) Crivello, J; J Org Chem 1981, V46, P3056 CAPLUS
- (38) DaRooge, M; J Org Chem 1967, V32, P1 CAPLUS
- (39) Davidson, V; Biochem J 1995, V308, P487 CAPLUS
- (40) Davidson, V; Biochemistry 1992, V31, P3385 CAPLUS
- (41) Dekker, R; Eur J Biochem 1982, V125, P69 CAPLUS
- (42) Denes, V; J Prakt Chem 1976, V318, P459 CAPLUS
- (43) Dickeson, G; Aust J Chem 1970, V23, P1023
- (44) Douglas, N; Synlett 1996, P793 CAPLUS
- (45) Druey, J; Helv Chim Acta 1950, V33, P1080 CAPLUS
- (46) Dudley, K; J Org Chem 1967, V32, P3210 CAPLUS
- (47) Duine, J; J Biosci Bioeng 1999, V88, P231 CAPLUS
- (48) Eckert, T; J Am Chem Soc 1983, V105, P4431 CAPLUS
- (49) Edelmann, M; Helv Chim Acta 2002, V85, P2195 CAPLUS
- (50) Edge, M; Polym Degrad Stab 1996, V53, P141 CAPLUS
- (51) Firouzabadi, H; Synthesis 1986, P285 CAPLUS
- (52) Firouzabadi, H; Synthesis 1986, P946 CAPLUS
- (53) Firouzabadi, H; Tetrahedron 1986, V42, P719 CAPLUS
- (54) Flowers-Geary, L; Chem-Biol Interact 1996, V99, P55 CAPLUS
- (55) Foster, E; Chem Commun (Cambridge) 2004, P2052 CAPLUS
- (56) Fouchard, D; J Org Chem 2004, V69, P2626 CAPLUS
- (57) Fujiyama, H; J Catal 1999, V188, P417 CAPLUS
- (58) Fukuzumi, S; J Am Chem Soc 2000, V122, P8435 CAPLUS
- (59) Gainor, J; J Org Chem 1981, V46, P4317 CAPLUS
- (60) Gainor, J; J Org Chem 1982, V47, P2833 CAPLUS
- (61) Garas, A; J Heterocycl Chem 2000, V37, P151 CAPLUS
- (62) Ge, Y; J Org Chem 2000, V65, P8831 CAPLUS
- (63) Goh, S; J Am Chem Soc 1973, V95, P242 CAPLUS

- (64) Guo, H; Res Chem Intermed 1992, V17, P137 CAPLUS
- (65) Gupta, R; Tetrahedron Lett 2000, V41, P7763 CAPLUS
- (66) Hatchard, W; J Am Chem Soc 1958, V80, P3640
- (67) Hav, A; US 3210384 1965 CAPLUS
- (68) Hebri, H; Synlett 1991, P901 CAPLUS
- (69) Hendrickson, J; J Org Chem 1982, V47, P1148 CAPLUS
- (70) Hendrickson, J; J Org Chem 1985, V50, P1688 CAPLUS
- (71) Hense, A; J Chem Soc, Perkin Trans 1 1997, P2023 CAPLUS
- (72) Hewgill, F; J Chem Soc, Perkin Trans 1 1983, P131 CAPLUS
- (73) Hewitt, D; J Chem Soc C 1971, P2967 CAPLUS
- (74) Higashimura, H; JP 2002030026 2002 CAPLUS
- (75) Higuchi, T; J Am Chem Soc 1995, V117, P8879 CAPLUS
- (76) Hiort, C; J Am Chem Soc 1993, V115, P3448 CAPLUS
- (77) Hirano, M; Bull Chem Soc Jpn 1991, V64, P1434 CAPLUS
- (78) Hirao, T; Tetrahedron Lett 1990, V31, P6039 CAPLUS
- (79) Horhold, H; Z Chem 1987, V27, P438
- (80) Hu, J; J Org Chem 2005, V70, P707 CAPLUS
- (81) Husain, M; Biochemistry 1987, V26, P4139 CAPLUS
- (82) Hyun, Y; Biochemistry 1995, V34, P816 CAPLUS
- (83) Imor, S; Synth Commun 1996, V26, P2197 CAPLUS
- (84) Ishida, T; J Am Chem Soc 1989, V111, P6822 CAPLUS
- (85) Ishida, T; J Am Chem Soc 1995, V117, P3278 CAPLUS
- (86) Itoh, S; J Am Chem Soc 1993, V115, P9960 CAPLUS (87) Itoh, S; J Am Chem Soc 1997, V119, P439 CAPLUS
- (88) Itoh, S; J Chem Soc, Perkin Trans 2 1992, P1245 CAPLUS
- (89) Itoh, S; J Org Chem 1992, V57, P2788 CAPLUS
- (90) Itoh, S; J Org Chem 1992, V57, P4452 CAPLUS(91) Itoh, S; J Org Chem 1996, V61, P8967 CAPLUS
- (92) Iwai, K; Chem Lett 2003, V32, P58 CAPLUS
- (93) Jacob, J; Inorg Chim Acta 1998, V270, P55 CAPLUS
- (94) Jagnandan, I; J Pharm Sci 1979, V68, P916 CAPLUS
- (95) Jerussi, R; J Org Chem 1970, V35, P2105 CAPLUS
- (96) Jeyaraman, R; J Am Chem Soc 1984, V106, P2462 CAPLUS
- (97) Jungclaus, G; Environ Sci Technol 1978, V12, P88 CAPLUS
- (98) Kaplan, G; WO 2004018401 2004 CAPLUS
- (99) Karnes, H; J Am Chem Soc 1968, V90, P458 CAPLUS
- (100) Kasahara, T; Nature (London) 2003, V422, P832 CAPLUS
- (101) Kawase, M; Tetrahedron 1989, V45, P1653 CAPLUS
- (102) Kay, C; J Am Chem Soc 2005, V127, P7974 CAPLUS
- (103) Kelly, J; J Org Chem 1986, V51, P4473 CAPLUS
- (104) Kessler, H; Tetrahedron Lett 1966, P5257 CAPLUS
- (105) Kikuchi, N; JP 9281728 1997 CAPLUS
- (106) Kikuchi, N; JP 9281729 1997 CAPLUS
- (107) Kikugawa, Y; Tetrahedron Lett 1988, V29, P4297 CAPLUS
- (108) Kitahara, Y; Tetrahedron 1997, V53, P6001 CAPLUS
- (109) Kitajima, N; J Am Chem Soc 1990, V112, P8833 CAPLUS
- (110) Kloc, K; J Prakt Chem 1977, V319, P959 CAPLUS
- (111) Komissarov, V; Izv Akad Nauk SSSR, Ser Khim 1991, V5, P1121
- (112) Konig, K; Chem Ber 1960, V93, P554 CAPLUS
- (113) Kovarova, J; Can J Chem 1995, V73, P1862 CAPLUS
- (114) Kuhn, R; Chem Ber 1950, V83, P412
  (115) Kumagai, Y; Free Radical Biol Med 1997, V22, P479 CAPLUS
- (116) Kuwabata, S; J Am Chem Soc 1994, V116, P5437 CAPLUS
- (117) Lantos, I; Tetrahedron Lett 1978, P2761 CAPLUS
- (118) Lehr, R; J Org Chem 1978, V43, P3462 CAPLUS
- (119) Leventhal, B; Food Sci 1976, V41, P467 CAPLUS
- (120) Levin, J; J Org Chem 1984, V49, P4325 CAPLUS
- (121) Levin, R; US 6080518 2000 CAPLUS
- (122) Li, N; Environ Health Perspect 2003, V111, P455 CAPLUS
- (123) Lin, L; US 2004096761 2004 CAPLUS
- (124) Linsker, F; J Am Chem Soc 1946, V68, P403 CAPLUS

- (125) Lissel, M; Tetrahedron Lett 1992, V33, P1795 CAPLUS
- (126) Loy, B; J Org Chem 1966, V31, P2386 CAPLUS
- (127) Magnusson, O; J Am Chem Soc 2004, V126, P5342 CAPLUS
- (128) Magnusson, R; Acta Chem Scand 1966, V20, P2211 CAPLUS
- (129) Mahjoub, A; Tetrahedron Lett 2003, V44, P4555 CAPLUS
- (130) Mahoney, L; J Am Chem Soc 1967, V89, P5619 CAPLUS
- (131) Margiotta, N; Inorg Chim Acta 2004, V357, P149 CAPLUS
- (132) Martin, P; Helv Chim Acta 1994, V77, P100 CAPLUS
- (133) Martin, P; Helv Chim Acta 1994, V77, P111 CAPLUS
- (134) Matsuse, T; JP 6027693 1994 CAPLUS
- (135) McLachlan, J; Steroids 1979, V33, P543 CAPLUS
- (136) Meier, H; Eur J Org Chem 2001, P779 CAPLUS
- (137) Menger, F; J Org Chem 1985, V50, P3927 CAPLUS
- (138) Mervic, M; J Org Chem 1980, V45, P4720 CAPLUS
- (139) Mincey, T; Biochemistry 1981, V20, P7502 CAPLUS
- (140) Mirifico, M; J Electroanal Chem 2004, V566, P7 CAPLUS
- (141) Miyamoto, E; JP 2002148834 2002 CAPLUS
- (142) Mohr, B; J Org Chem 1994, V59, P635 CAPLUS
- (143) Moore, R; J Chem Soc 1954, P243 CAPLUS
- (144) Moriarty, R; Tetrahedron Lett 1975, P2557 CAPLUS
- (145) Mure, M; Acc Chem Res 2004, V37, P131 CAPLUS
- (146) Musgrave, O; J Chem Soc D 1970, P1461 CAPLUS
- (147) Nakamori, H; EP 0591010 1994 CAPLUS
- (148) Neureiter, N; J Org Chem 1963, V28, P3486 CAPLUS
- (149) Nishino, H; J Chem Soc, Perkin Trans 2 1999, P1919 CAPLUS
- (150) Noar, J; J Am Chem Soc 1985, V107, P7198 CAPLUS
- (151) Nyquist, E; J Heterocycl Chem 1967, P539 CAPLUS
- (152) Obare, S; Inorg Chem 2001, V40, P6080 CAPLUS
- (153) Ohkura, K; JP 2000204083 2000 CAPLUS
- (154) Okubo, H; J Org Chem 2001, V66, P557 CAPLUS
- (155) Omura, K; J Am Oil Chem Soc 1992, V69, P461 CAPLUS
- (156) Omura, K; J Am Oil Chem Soc 1995, V72, P1565 CAPLUS
- (157) Omura, K; J Org Chem 1984, V49, P3046 CAPLUS
- (158) Omura, K; J Org Chem 1991, V56, P921 CAPLUS
- (159) Omura, K; J Org Chem 1992, V57, P306 CAPLUS
- (160) Oyaizu, K; Chem Lett 2000, P1318 CAPLUS
- (161) O'Brien, P; Chem-Biol Interact 1991, V80, P1 CAPLUS
- (162) Pandey, G; IN 180089 1989 CAPLUS
- (163) Pandey, G; Tetrahedron Lett 1990, V31, P3771 CAPLUS
- (164) Paruch, K; J Org Chem 2000, V65, P7602 CAPLUS
- (165) Pascal, R; J Am Chem Soc 1987, V109, P4660 CAPLUS
- (166) Paw, W; Inorg Chem 1997, V36, P2287 CAPLUS
- (167) Pelter, A; Tetrahedron Lett 1988, V29, P677 CAPLUS
- (168) Plietker, B; Org Biomol Chem 2004, V2, P1116 CAPLUS
- (169) Pospisil, J; Polym Degrad Stab 2002, V78, P251 CAPLUS
- (170) Putala, M; Tetrahedron: Asymmetry 2001, V12, P3333
- (171) Qian, W; J Am Chem Soc 2000, V122, P8333 CAPLUS
- (172) Rabinovitz, M; J Org Chem 1987, V52, P3472
- (173) Ranganathan, S; Tetrahedron 1984, V40, P3145 CAPLUS
- (174) Ranganathan, S; Tetrahedron Lett 1985, V26, P4955 CAPLUS
- (175) Rayne, S; Photochem Photobiol Sci 2005, P876 CAPLUS
- (176) Rebelo, S; Chem Commun (Cambridge) 2004, P608 CAPLUS
- (177) Rice, J; J Org Chem 1986, V51, P2428 CAPLUS
- (178) Rockcliffe, D; J Chem Soc, Chem Commun 1992, P1758 CAPLUS
- (179) Rodriguez, C; Chem-Biol Interact 2005, V155, P97 CAPLUS
- (180) Rodriguez, E; J Am Chem Soc 1989, V111, P7947 CAPLUS
- (181) Rubin, M; J Org Chem 1980, V45, P1847 CAPLUS
- (182) Sain, B; Tetrahedron Lett 1994, V35, P5083 CAPLUS
- (183) Sakamoto, T; J Org Chem 1994, V59, P6859 CAPLUS
- (184) Salisbury, S; Nature (London) 1979, V280, P843 CAPLUS
- (185) Schmidt, P; Helv Chim Acta 1957, V40, P350 CAPLUS

```
(186) Schroeter, S; J Org Chem 1969, V34, P4012 CAPLUS
(187) Schuetzle, D; Int J Environ Anal Chem 1981, V9, P93 MEDLINE
(188) Schulte-Frohlinde, D; Justus Liebigs Ann Chem 1964, V671, P92 CAPLUS
(189) Seiglie, C; Steroids 1984, V43, P529 CAPLUS
(190) Shimada, H; Chem Res Toxicol 2004, V17, P1145 CAPLUS
(191) Simandi, L; J Mol Catal A: Chem 1997, V117, P299 CAPLUS
(192) Sleath, P; J Am Chem Soc 1985, V107, P3328 CAPLUS
(193) Smith, G; J Org Chem 1947, V12, P781 CAPLUS
(194) Speck, M; J Chem Soc, Perkin Trans 2 2002, P455 CAPLUS
(195) Srinivasan, R; Synth Commun 1997, V27, P2057 CAPLUS
(196) Starnes, W; J Org Chem 1969, V34, P3404 CAPLUS
(197) Taimr, L; Tetrahedron Lett 1971, P2809 CAPLUS
(198) Taimr, L; Tetrahedron Lett 1972, P4279 CAPLUS
(199) Takizawa, Y; J Org Chem 1985, V50, P4383 CAPLUS
(200) Takuwa, A; J Org Chem 1997, V62, P2658 CAPLUS
(201) Thomas, R; Carcinogenesis 2004, V25, P787 CAPLUS
(202) Thomas, R; Int J Mol Med 2001, V7, P389 CAPLUS
(203) Thomas, R; Oncol Rep 2001, V8, P1035 CAPLUS
(204) Togashi, D; Synth Commun 1998, V28, P1051 CAPLUS
(205) Tommasi, L; Inorg Chem 1995, V34, P1514 CAPLUS
(206) Toshikazu, T; J Org Chem 1983, V48, P4764
(207) Vakhitova, M; Izv Akad Nauk SSSR, Ser Khim 1987, V8, P1808
(208) Villemin, D; Synlett 1994, P435
(209) Vladimir, A; J Am Chem Soc 2001, V123, P5292
(210) Wan, P; J Chem Soc, Chem Commun 1993, P409
(211) Wang, X; Tetrahedron Lett 1991, V32, P4883 CAPLUS
(212) Wang, Z; Angew Chem 2004, V116, P2006
(213) Wang, Z; Angew Chem Int Ed 2004, V43, P1972 CAPLUS
(214) Wang, Z; J Am Chem Soc 2004, V126, P7794 CAPLUS
(215) Warncke, K; J Am Chem Soc 1993, V115, P6464 CAPLUS
(216) Wenz, G; Makromol Chem, Rapid Commun 1985, V6, P577 CAPLUS
(217) Wyllie, S; Arch Biochem Biophys 1997, V346, P180 CAPLUS
(218) Xia, T; Environ Health Perspect 2004, V112, P1347 CAPLUS
(219) Yamada, M; Bull Chem Soc Jpn 1992, V65, P1006 CAPLUS
(220) Yamamoto, T; Macromolecules 2003, V36, P6722 CAPLUS
(221) Yamazaki, S; Tetrahedron Lett 2001, V42, P3355 CAPLUS
(222) Yang, C; Synlett 1992, P799 CAPLUS
(223) Yohe, G; J Am Chem Soc 1953, V75, P2688 CAPLUS
(224) Young, E; J Org Chem 1998, V63, P9995 CAPLUS
(225) Zabik, M; J Org Chem 1967, V32, P300 CAPLUS
(226) Zbiral, E; Monatsh Chem 1964, V95, P512 CAPLUS
(227) Zhang, J; J Org Chem 1998, V63, P8125 CAPLUS
(228) Zhang, J; Tetrahedron 1999, V55, P625 CAPLUS
(229) Zhang, Z; Synthesis 1996, P377 CAPLUS
L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
                         2005:695873 CAPLUS
ACCESSION NUMBER:
                         143:183097
DOCUMENT NUMBER:
TITLE:
                         Contact charging type electrophotographic
                         photoconductor showing excellent faulty image
                         suppression, process cartridge, and
                         electrophotographic apparatus
INVENTOR(S):
                         Nagasaka, Hideaki; Sekido, Kunihiko; Sekiya, Michiyo;
                         Miki, Nobumichi; Morikawa, Yosuke
                         Canon Inc., Japan
Jpn. Kokai Tokkyo Koho, 44 pp.
PATENT ASSIGNEE(S):
SOURCE:
                         CODEN: JKXXAF
DOCUMENT TYPE:
                         Patent
LANGUAGE:
                         Japanese
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
```

```
PATENT NO.
                   KIND DATE
                                      APPLICATION NO. DATE
    JP 2005208618 A 20050804 JP 2004-373350 20041224 US 20060292469 A1 20061228 US 2005-159307 20050623
                                          JP 2003-434017 A 20031226
PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 143:183097
    2005:695873 CAPLUS
DN
   143:183097
ED Entered STN: 05 Aug 2005
TI Contact charging type electrophotographic photoconductor showing excellent
    faulty image suppression, process cartridge, and electrophotographic
     apparatus
ΤN
    Nagasaka, Hideaki; Sekido, Kunihiko; Sekiya, Michiyo; Miki, Nobumichi;
    Morikawa, Yosuke
PA
    Canon Inc., Japan
    Jpn. Kokai Tokkyo Koho, 44 pp.
SO
    CODEN: JKXXAF
DT
    Patent
LA
    Japanese
TC.
    ICM G03G005-06
CC
     74-3 (Radiation Chemistry, Photochemistry, and Photographic and Other
     Reprographic Processes)
FAN.CNT 2
                                         APPLICATION NO.
    PATENT NO.
                       KIND DATE
                                                                DATE
                       ____
                       A 20050804
A1 20061228
A 20031226
                                         JP 2004-373350
US 2005-159307
    JP 2005208618
                       Α
PI JP 2005208618
US 20060292469
PRAI JP 2003-434017
                                                                20041224
CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
 ______
 JP 2005208618 ICM G03G005-06
                IPCI G03G0005-06 [ICM, 7]
                IPCR G03G0005-06 [I,A]; G03G0005-06 [I,C*]
                FTERM 2H068/AA14; 2H068/AA19; 2H068/AA34; 2H068/AA35;
                      2H068/BA39; 2H068/BA63; 2H068/BA64; 2H068/FA27
 US 20060292469 IPCI G03G0005-047 [I,A]; G03G0005-043 [I,C*]
                IPCR G03G0005-043 [I,C]; G03G0005-047 [I,A]
                NCL
                      430/059.400; 399/159.000; 430/059.100
                ECLA G03G005/06H6; G03G005/05C2D; G03G005/05C4B;
                       G03G005/06B3; G03G005/06B5; G03G005/06B5B;
                       G03G005/06D4B3; G03G005/10C; G03G005/14B
OS
    MARPAT 143:183097
     The title electrophotog. photoconductor contains an electron transport
AΒ
     material dispersed in a binder resin of a charge generation layer. The
     electron transport material shows a reduction potential between -0.8 and 0 V.
     The electron transport material may be selected from a specified
     naphthalenetetracarboxylic diimide compound, a specified
     phenanthrene compound, a specified phenanthroline compound, and a
     specified acenaphthoquinone compound A charge generation material is Ga
     phthalocyanine, preferably hydroxygallium phthalocyanine.
ST
     electrophotog photoconductor electron transport material process cartridge
     app
     Polyvinyl butyrals
ΤT
     RL: DEV (Device component use); USES (Uses)
        (binder resin in charge generation layer of contact charging type
        electrophotog. photoconductor showing excellent faulty image
       suppression)
ΙΤ
     Electrophotographic apparatus
```

Electrophotographic photoconductors (photoreceptors)

(contact charging type electrophotog. photoconductor showing excellent faulty image suppression, process cartridge, and electrophotog. apparatus)

IT 84-65-1, 9,10-Anthracenedione 809-73-4 20725-71-7 27318-90-7,

1,10-Phenanthroline-5,6-

dione 27471-02-9 56403-67-9 56403-73-7 56961-98-9

171258-57-4 860806-49-1 860806-50-4

RL: DEV (Device component use); USES (Uses)

(electron transport material in charge generation layer of contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

IT 63371-84-6P, Hydroxygallium phthalocyanine

RL: DEV (Device component use); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of hydroxygallium phthalocyanine charge generation material for contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

IT 91-15-6, 1,2-Benzenedicarbonitrile 13450-90-3, Gallium trichloride
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of hydroxygallium phthalocyanine charge generation material for contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

IT 19717-79-4P, Chlorogallium phthalocyanine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hydroxygallium phthalocyanine charge generation material for contact charging type electrophotog. photoconductor showing excellent faulty image suppression)

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:41818 CAPLUS

DOCUMENT NUMBER: 140:119650

TITLE: Charge transport compositions and electronic devices

made with such compositions

INVENTOR(S): Lecloux, Daniel David; Guidry, Mark A.; Herron,

Norman; Radu, Nora S.; Smith, Eric Maurice; Wang, Ying

PATENT ASSIGNEE(S): E.I. Du Pont De Nemours and Company, USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.				KIND		DATE		APPLICATION NO.				DATE					
WO 2004006355 WO 2004006355				A2 20040115 A3 20040318		WO 2003-US21618					20030709						
WU	∠004 W:				A3 AM,			AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
								DM,									
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NΙ,	NO,	NΖ,	OM,
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ΤJ,	TM,	TN,
		TR,	TT,	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW				
	RW:	GH,	GM,	KΕ,	LS,	MW,	MZ,	SD,	SL,	SZ,	TΖ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	BY,
		KG,	KΖ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FΙ,	FR,	GB,	GR,	HU,	IE,	ΙΤ,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,
		BF,	ВJ,		•			GΑ,	•			•					
US	20040066135				A1		20040408			US 2003-612482					20030702		
US	S 7265378 B2 20070																
US	S 20040068115			A1		2004	0408	US 2003-612493				20030702					

```
US 6962995 B2 20051108
US 20040092687 A1 20040513 US 2003-612237
US 7074534 B2 20060711
                                                                                         20030702
                               A1 20040520 US 2003-612244
      US 20040097725
                                                                                        20030702
                                A1 20040115 CA 2003-2492692
      CA 2492692
                                                                                        20030709
                           A1 20040123 AU 2003-247965
A2 20050406 EP 2003-763463
      AU 2003247965
                                                                                        20030709
      EP 1520305
                                                                                        20030709
            R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                         20050907 CN 2003-816185
      CN 1666357
                       A
                                                                                        20030709
      CN 1666577
                                 Α
                                         20050907 CN 2003-816188
                                                                                        20030709
      CN 1668703
CN 1668616
                                Α
                                         20050914 CN 2003-816415
      CN 1668616 A 20050914
JP 2005533343 T 20051104
CN 1726603 A 20060125
US 20040077860 A1 20040422
US 20050236980 A1 20051027
                                        20050914 CN 2003-816462
                                                                                        20030709
                                        20051104 JP 2004-520125
                                                                                        20030709
                                        20060125 CN 2003-816467
                                                                                        20030709
                                                       US 2003-612704
US 2005-155068
                                                                                        20031208
                                                                                         20050617
      US 7119204 B2 20061010
US 20070194698 A1 20070823
US 20070267968 A1 20071122
                                                          US 2007-676401
                                                                                         20070219
                                                          US 2007-676401 20070219

US 2007-835085 20070807

US 2002-394767P P 20020710

US 2003-458277P P 20030328

US 2003-612244 B3 20030702

US 2003-612482 A3 20030702

US 2003-612493 A3 20030702

WO 2003-US21618 W 20030709
PRIORITY APPLN. INFO.:
OTHER SOURCE(S):
                               MARPAT 140:119650
     2004:41818 CAPLUS
DN
      140:119650
ED
      Entered STN: 18 Jan 2004
ΤI
      Charge transport compositions and electronic devices made with such
      compositions
      Lecloux, Daniel David; Guidry, Mark A.; Herron, Norman; Radu, Nora S.;
ΙN
      Smith, Eric Maurice; Wang, Ying
      E.I. Du Pont De Nemours and Company, USA
PA
SO
      PCT Int. Appl., 54 pp.
      CODEN: PIXXD2
DT
      Patent
      English
LA
IC
      ICM H01L051-50
      ICS H01L051-30; C07D471-14; C07D241-46; C07D241-44; C07D241-42;
             C07D401-14; C07F007-08; C07F015-00; C07D519-00; C07D409-14
CC
      73-11 (Optical, Electron, and Mass Spectroscopy and Other Related
      Properties)
      Section cross-reference(s): 28, 72, 76
FAN.CNT 5
                               KIND DATE APPLICATION NO. DATE
      PATENT NO.
      _____
                                          _____
                                ____
                                                         ______
                                                                                         _____
      WO 2004006355
                                A2
                                        20040115
                                                       WO 2003-US21618
                                                                                        20030709
PΙ

      WO 2004006355
      A2 20040115

      WO 2004006355
      A3 20040318

           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
            RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
                 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
      US 20040066135
                           A1 20040408 US 2003-612482 20030702
```

```
US 7265378 B2 20070904
US 20040068115 A1 20040408
US 6962995
                               20040408
                                            US 2003-612493
                                                                     20030702
                        В2
     US 6962995
                               20051108
                       A1 20040513
     US 20040092687
                                            US 2003-612237
                                                                     20030702
                        B2 20060711
     US 7074534
                        A1 20040520
     US 20040097725
                                           US 2003-612244
                                                                     20030702
     CA 2492692
                         A1 20040115 CA 2003-2492692
                                                                    20030709
     AU 2003247965
                        A1 20040123 AU 2003-247965
A2 20050406 EP 2003-763463
                                                                    20030709
     EP 1520305
                                                                    20030709
           AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                  А
                               20050907 CN 2003-816185 20030709
     CN 1666357
     CN 1666577
                         А
                                20050907
                                           CN 2003-816188
                                                                    20030709
     CN 1668703
CN 1668616
                         А
                                20050914 CN 2003-816415
                                                                    20030709
                        A
T
                               20050914 CN 2003-816462
                                                                    20030709
    US 2005533343 T

US 20040077860 A1

US 20050236980 A1

US 7119204 B2

US 20070194698 A1

US 20070267968 A1

US 2002-394767P P

US 2003-458277P P

US 2003-612244 B3

US 2003-612442 A3

US 2003-US21618 W
     JP 2005533343
CN 1726603
                               20051104 JP 2004-520125
                                                                    20030709
                                            CN 2003-816467
                               20060125
                                                                    20030709
                               20040422
                                          US 2003-612704
US 2005-155068
                                                                    20031208
                               20051027
                                                                    20050617
                               20061010
                               20070823
                                            US 2007-676401
                                                                    20070219
                                            US 2007-835085
                               20071122
                                                                     20070807
PRAI US 2002-394767P
                                20020710
                                20030328
                              20030702
20030702
                         A3 20030702
                               20030709
CLASS
 PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
                _____
 WO 2004006355 ICM H01L051-50
                 ICS
                        H01L051-30; C07D471-14; C07D241-46; C07D241-44;
                        C07D241-42; C07D401-14; C07F007-08; C07F015-00;
                        C07D519-00; C07D409-14
                 IPCI
                        H01L0051-50 [ICM, 7]; H01L0051-30 [ICS, 7]; H01L0051-05
                        [ICS, 7, C*]; C07D0471-14 [ICS, 7]; C07D0471-00
                        [ICS, 7, C*]; C07D0241-46 [ICS, 7]; C07D0241-44 [ICS, 7];
                        C07D0241-42 [ICS, 7]; C07D0241-00 [ICS, 7, C*];
                        C07D0401-14 [ICS, 7]; C07D0401-00 [ICS, 7, C*];
                        C07F0007-08 [ICS, 7]; C07F0007-00 [ICS, 7, C*];
                        C07F0015-00 [ICS,7]; C07D0519-00 [ICS,7]; C07D0409-14
                        [ICS, 7]; C07D0409-00 [ICS, 7, C*]
                        H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                 IPCR
                        [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                        C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                        [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                        C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                        [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                        C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                        [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                        C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                        [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                        C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                        [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                        C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                        [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                        C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                        [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                        C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                        [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
```

```
C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C^*]; H01L0051-30 [I,A]; H05B0033-14 [I,C^*];
                       H05B0033-14 [I,A]
                       C07D241/42; C07C211/49; C07C211/52; C07C211/54;
                ECLA
                       C07C215/74; C07C217/80; C07C255/58; C07D209/86;
                       C07D213/38; C07D241/38B; C07D401/14; C07D401/14R;
                       C07D409/14; C07D471/04+221A+221A;
                       C07D471/14+241A+221A+221A; C07D487/04+241B+239B;
                       C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B;
                       C08L065/00; C09B011/10; H01L051/00M6H14; H01L051/00M16;
                       T01L; T01L; T01L; T01L; T01L; T01L; M07D; M07D
US 20040066135
                IPCI
                       H01L0051-00 [I,A]
                IPCR
                       H01L0051-00 [N,C*]; H01L0051-00 [N,A]; H01L0051-05
                       [N,C*]; H01L0051-30 [N,A]; H01L0051-50 [I,C*];
                       H01L0051-50 [I,A]
                NCL
                       313/503.000; 428/690.000; 257/040.000; 136/263.000;
                       257/431.000; 257/E51.049; 313/504.000; 313/506.000;
                       428/917.000
                ECLA
                       H01L051/50E3; H01L051/50G; T01L; T01L
US 20040068115
                IPCI
                       C07D0471-04 [ICM, 7]; C07D0471-02 [ICS, 7]; C07D0471-00
                       [ICS, 7]
                IPCR
                       C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00
                       [I,C*]; C07D0213-38 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C08G0061-00 [I,C*]; C08G0061-12
                       [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A];
                       C09K0011-06 [I,C*]; C09K0011-06 [I,A]; H01L0051-00
                       [I,C*]; H01L0051-00 [I,A]; H01L0051-05 [I,C*];
                       H01L0051-30 [I,A]; H01L0051-50 [N,C*]; H01L0051-50
                       [N,A]; H05B0033-14 [I,C^*]; H05B0033-14 [I,A]
                NCL
                       546/088.000; 546/081.000
                ECLA
                       C07D209/86; C07D213/38; C08G061/12D; C08G061/12D1B;
                       C08L065/00; H01L051/30D6; H01L051/30H4; H01L051/30H6;
                       H01L051/30H8; H01L051/30S; C09K011/06;
                       C07D471/04+221A+221A; H01L051/00M2F; H01L051/00M6D;
                       H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14
US 20040092687
                IPCI
                       G03G0005-04 [I,A]; C07D0241-38 [I,A]; C07D0241-00
                       [I,C*]; C08F0032-08 [I,A]; C08F0032-00 [I,C*];
                       C08F0132-08 [I,A]; C08F0132-00 [I,C*]
                       C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00
                IPCR
                       [I,C*]; C07D0213-38 [I,A]; C08G0061-00 [I,C*];
                       C08G0061-12 [I,A]; C08L0065-00 [I,C*]; C08L0065-00
                       [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A];
                       H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H01L0051-50
                       [N,C*]; H01L0051-50 [N,A]
                       526/259.000; 430/076.000; 428/917.000; 430/096.000;
                NCL
                       544/349.000; 544/353.000; 548/428.000
                       C07D209/86; C07D213/38; C08G061/12D; C08G061/12D1B;
                ECLA
                       C08L065/00; H01L051/30D2; H01L051/30D6; H01L051/30H4;
                       H01L051/30H6; H01L051/30H8; H01L051/30S; H01L051/00M2B;
                       H01L051/00M2F; H01L051/00M6D; H01L051/00M6F;
                       H01L051/00M6H; H01L051/00M16
US 20040097725
                       C09B0011-04 [ICM, 7]; C09B0011-00 [ICM, 7, C*];
                IPCI
                       C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
                IPCR
                       C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00
                       [I,C*]; C07D0213-38 [I,A]; C08G0061-00 [I,C*];
                       C08G0061-12 [I,A]; C08L0065-00 [I,C*]; C08L0065-00
                       [I,A]; H01L0051-00 [I,C*]; H01L0051-00 [I,A];
                       H01L0051-05 [I,C*]; H01L0051-30 [I,A]; H01L0051-50
                       [N,C*]; H01L0051-50 [N,A]
```

```
540/472.000; 552/101.000
                NCL
                ECLA
                       T01L; T01L; T01L
CA 2492692
                IPCI
                       H01L0051-00 [ICM, 7]; C07D0519-00 [ICS, 7]; C07F0015-00
                       [ICS,7]; C07F0007-08 [ICS,7]; C07F0007-00 [ICS,7,C*];
                       C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*];
                       C07D0409-14 [ICS, 7]; C07D0409-00 [ICS, 7, C*];
                       C07D0471-14 [ICS, 7]; C07D0471-00 [ICS, 7, C*];
                       H01L0051-30 [ICS, 7]; H01L0051-05 [ICS, 7, C*];
                       C07D0241-42 [ICS,7]; C07D0241-44 [ICS,7]; C07D0241-46
                       [ICS, 7]; C07D0241-00 [ICS, 7, C*]
                IPCR
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                       C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                       [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                       [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*];
                       H05B0033-14 [I,A]
                ECLA
                       C07D241/42; C07C211/49; C07C211/52; C07C211/54;
                       C07C215/74; C07C217/80; C07C255/58; C07D209/86;
                       C07D213/38; C07D241/38B; C07D401/14; C07D401/14R;
                       C07D409/14; C07D471/04+221A+221A;
                       C07D471/14+241A+221A+221A; C07D487/04+241B+239B;
                       C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B;
                       C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F;
                       H01L051/00M6D; H01L051/00M6F; H01L051/00M6H;
                       H01L051/00M16; H05B033/14
AU 2003247965
                IPCI
                       C07F0015-00 [ICM, 7]; C07D0519-00 [ICS, 7]; C07D0409-14
                       [ICS, 7]; C07D0409-00 [ICS, 7, C*]; H01L0051-30 [ICS, 7];
                       H01L0051-05 [ICS, 7, C*]; C07D0471-14 [ICS, 7];
                       C07D0471-00 [ICS,7,C*]; C07D0241-46 [ICS,7];
                       C07D0241-44 [ICS, 7]; C07D0241-42 [ICS, 7]; C07D0241-00
                       [ICS,7,C*]; C07D0401-14 [ICS,7]; C07D0401-00
                       [ICS, 7, C*]; C07F0007-08 [ICS, 7]; C07F0007-00 [ICS, 7, C*]
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                IPCR
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
```

```
[I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                       [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*];
                       H05B0033-14 [I,A]
EP 1520305
                IPCI
                       H01L0051-00 [ICM, 7]
                IPCR
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                       C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                       [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                       [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*];
                       H05B0033-14 [I,A]
                ECLA
                       C07D241/42; C07C211/49; C07C211/52; C07C211/54;
                       C07C215/74; C07C217/80; C07C255/58; C07D209/86;
                       C07D213/38; C07D241/38B; C07D401/14; C07D401/14R;
                       C07D409/14; C07D471/04+221A+221A;
                       C07D471/14+241A+221A+221A; C07D487/04+241B+239B;
                       C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B;
                       C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F;
                       H01L051/00M6D; H01L051/00M6F; H01L051/00M6H;
                       H01L051/00M16; H05B033/14
CN 1666357
                       H01L0051-30 [ICM, 7]; H01L0051-05 [ICM, 7, C*];
                IPCI
                       C08G0061-00 [ICS, 7]; C08G0061-12 [ICS, 7]
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                IPCR
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                       C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                       [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
```

C07D0519-00 [I,A]; C07F0007-00 [I,C\*]; C07F0007-21

```
[I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C^*]; H01L0051-30 [I,A]; H05B0033-14 [I,C^*];
                       H05B0033-14 [I,A]
                ECLA
                       C07D241/42; C07C211/49; C07C211/52; C07C211/54;
                       C07C215/74; C07C217/80; C07C255/58; C07D209/86;
                       C07D213/38; C07D241/38B; C07D401/14; C07D401/14R;
                       C07D409/14; C07D471/04+221A+221A;
                       C07D471/14+241A+221A+221A; C07D487/04+241B+239B;
                       C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B;
                       C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F;
                       H01L051/00M6D; H01L051/00M6F; H01L051/00M6H;
                       H01L051/00M16; H05B033/14
                IPCI
                       H05B0033-14 [ICM, 7]; H01L0051-30 [ICS, 7]; H01L0051-05
CN 1666577
                       [ICS,7,C*]; H01L0027-00 [ICS,7]; C09K0011-06 [ICS,7]
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                IPCR
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                       C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                       [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                       [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*];
                       H05B0033-14 [I,A]
                ECLA
                       C07D241/42; C07C211/49; C07C211/52; C07C211/54;
                       C07C215/74; C07C217/80; C07C255/58; C07D209/86;
                       C07D213/38; C07D241/38B; C07D401/14; C07D401/14R;
                       C07D409/14; C07D471/04+221A+221A;
                       C07D471/14+241A+221A+221A; C07D487/04+241B+239B;
                       C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B;
                       C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F;
                       H01L051/00M6D; H01L051/00M6F; H01L051/00M6H;
                       H01L051/00M16; H05B033/14
CN 1668703
                IPCI
                       C09B0011-00 [ICM, 7]; C09K0011-06 [ICS, 7]
                IPCR
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
```

```
[I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                       C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                       [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                       [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*];
                       H05B0033-14 [I,A]
                ECLA
                       C07D241/42; C07C211/49; C07C211/52; C07C211/54;
                       C07C215/74; C07C217/80; C07C255/58; C07D209/86;
                       C07D213/38; C07D241/38B; C07D401/14; C07D401/14R;
                       C07D409/14; C07D471/04+221A+221A;
                       C07D471/14+241A+221A+221A; C07D487/04+241B+239B;
                       C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B;
                       C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F;
                       H01L051/00M6D; H01L051/00M6F; H01L051/00M6H;
                       H01L051/00M16; H05B033/14
CN 1668616
                IPCI
                       C07D0471-04 [ICM, 7]; C07D0471-00 [ICM, 7, C*];
                       C07F0015-00 [ICS, 7]; H01L0051-00 [ICS, 7]; C09K0011-06
                       [ICS, 7]
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                IPCR
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                       C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                       [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                       [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*];
                       H05B0033-14 [I,A]
                ECLA
                       C07D241/42; C07C211/49; C07C211/52; C07C211/54;
                       C07C215/74; C07C217/80; C07C255/58; C07D209/86;
                       C07D213/38; C07D241/38B; C07D401/14; C07D401/14R;
                       C07D409/14; C07D471/04+221A+221A;
                       C07D471/14+241A+221A+221A; C07D487/04+241B+239B;
                       C07D519/00+471/00+471/00; C08G061/12D; C08G061/12D1B;
                       C08L065/00; C09B011/10; C09K011/06; H01L051/00M2F;
                       H01L051/00M6D; H01L051/00M6F; H01L051/00M6H;
                       H01L051/00M16; H05B033/14
JP 2005533343
                IPCI
                       H05B0033-22 [ICM, 7]; H05B0033-14 [ICS, 7]; C07D0241-40
                       [ICS, 7]; C07D0241-00 [ICS, 7, C*]; C07F0007-21 [ICS, 7];
                       C07F0007-00 [ICS,7,C*]; C07F0015-00 [ICS,7]
```

```
TPCR
                       H01L0051-50 [I,C*]; H01L0051-50 [I,A]; C07C0211-00
                       [I,C*]; C07C0211-49 [I,A]; C07C0211-52 [I,A];
                       C07C0211-54 [I,A]; C07C0215-00 [I,C*]; C07C0215-74
                       [I,A]; C07C0217-00 [I,C*]; C07C0217-80 [I,A];
                       C07C0255-00 [I,C*]; C07C0255-58 [I,A]; C07D0209-00
                       [I,C*]; C07D0209-86 [I,A]; C07D0213-00 [I,C*];
                       C07D0213-38 [I,A]; C07D0241-00 [I,C*]; C07D0241-38
                       [I,A]; C07D0241-40 [I,A]; C07D0241-42 [I,A];
                       C07D0401-00 [I,C*]; C07D0401-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C07D0471-14 [I,A]; C07D0487-00
                       [I,C*]; C07D0487-04 [I,A]; C07D0519-00 [I,C*];
                       C07D0519-00 [I,A]; C07F0007-00 [I,C*]; C07F0007-21
                       [I,A]; C07F0015-00 [I,C*]; C07F0015-00 [I,A];
                       C08G0061-00 [I,C*]; C08G0061-00 [I,A]; C08G0061-12
                       [I,A]; C08K0005-00 [I,C*]; C08K0005-18 [I,A];
                       C08L0065-00 [I,C*]; C08L0065-00 [I,A]; C08L0083-00
                       [I,C*]; C08L0083-08 [I,A]; C09B0011-00 [I,C*];
                       C09B0011-10 [I,A]; C09K0011-06 [I,C*]; C09K0011-06
                       [I,A]; H01L0033-00 [I,C*]; H01L0033-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H05B0033-14 [I,C*];
                       H05B0033-14 [I,A]
                       3K007/AB03; 3K007/DB03; 4H049/VN01; 4H049/VP02;
                FTERM
                       4H049/VQ67; 4H049/VQ78; 4H049/VR23; 4H049/VR41;
                       4H049/VU29; 4H049/VW02; 4H050/AA03; 4H050/AB91;
                       4H050/WB11; 4H050/WB14; 4H050/WB21
CN 1726603
                IPCI
                       H01L0051-00 [I,A]; H01L0051-30 [I,A]; H01L0051-05
                       [I,C*]; C07D0471-14 [I,A]; C07D0471-00 [I,C*];
                       C07D0241-46 [I,A]; C07D0241-44 [I,A]; C07D0241-42
                       [I,A]; C07D0241-00 [I,C*]; C07D0401-14 [I,A];
                       C07D0401-00 [I,C*]; C07F0007-08 [I,A]; C07F0007-00
                       [I,C*]; C07F0015-00 [I,A]
                IPCR
                       H01L0051-00 [I,A]; H01L0051-00 [I,C]
US 20040077860
                IPCI
                       A61K0031-498 [ICM,7]; C07D0043-02 [ICS,7]; C07D0241-36
                       [ICS, 7]; C07D0241-00 [ICS, 7, C*]
                IPCR
                       C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00
                       [I,C*]; C07D0213-38 [I,A]; C07D0241-00 [I,C*];
                       C07D0241-38 [I,A]; C07D0241-42 [I,A]; C07D0401-00
                       [I,C*]; C07D0401-04 [I,A]; C07D0403-00 [I,C*];
                       C07D0403-04 [I,A]; C07D0409-00 [I,C*]; C07D0409-04
                       [I,A]; C07D0471-00 [I,C*]; C07D0471-16 [I,A];
                       C07D0475-00 [I,C*]; C07D0475-00 [I,A]; C07D0519-00
                       [I,C*]; C07D0519-00 [I,A]; C07F0007-00 [I,C*];
                       C07F0007-08 [I,A]; C08G0061-00 [I,C*]; C08G0061-12
                       [I,A]; C08L0065-00 [I,C*]; C08L0065-00 [I,A];
                       H01L0051-00 [I,C*]; H01L0051-00 [I,A]; H01L0051-05
                       [I,C*]; H01L0051-30 [I,A]; H01L0051-50 [N,C*];
                       H01L0051-50 [N,A]
                NCL
                       544/353.000; 257/E51.051
                ECLA
                       C07D409/04; C07D209/86; C07D213/38; C07D241/38B;
                       C07D241/42; C07D401/04; C07D403/04;
                       C07D471/16+241B+221B+221B+2; C07D475/00;
                       C07D519/00+471/00+471/00; C07F007/08D4H4F; C08G061/12D;
                       C08G061/12D1B; C08L065/00; H01L051/00M2F;
                       H01L051/00M6D; H01L051/00M6F; H01L051/00M6H;
                       H01L051/00M16
US 20050236980
                IPCI
                       C07D0471-02 [I,A]; C07D0471-00 [I,A]
                IPCR
                       C07D0209-00 [I,C*]; C07D0209-86 [I,A]; C07D0213-00
                       [I,C*]; C07D0213-38 [I,A]; C07D0471-00 [I,C*];
                       C07D0471-04 [I,A]; C08G0061-00 [I,C*]; C08G0061-12
```

[I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A]; C09K0011-06 [I,C\*]; C09K0011-06 [I,A]; H01L0051-00 [I,C\*]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H01L0051-50 [N,C\*]; H01L0051-50 [N,A]; H05B0033-14 [I,C\*]; H05B0033-14 [I,A] NCL 313/504.000; 546/002.000; 546/088.000; 546/081.000 ECLA C09K011/06; C07D209/86; C07D213/38; C07D471/04+221A+221A; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/00M2F; H01L051/00M6D; H01L051/00M6F; H01L051/00M6H; H01L051/00M16; H05B033/14 US 20070194698 IPCI H01J0001-62 [I,A]; H01J0001-00 [I,C\*]; H01J0063-04 [I,A]; H01J0063-00 [I,C\*]; H01L0051-00 [I,A] IPCR H01J0001-00 [I,C]; H01J0001-62 [I,A]; C07D0209-00 [I,C\*]; C07D0209-86 [I,A]; C07D0213-00 [I,C\*]; C07D0213-38 [I,A]; C08G0061-00 [I,C\*]; C08G0061-12 [I,A]; C08L0065-00 [I,C\*]; C08L0065-00 [I,A]; H01J0063-00 [I,C]; H01J0063-04 [I,A]; H01L0051-00 [I,C]; H01L0051-00 [I,A]; H01L0051-05 [I,C\*]; H01L0051-30 [I,A]; H01L0051-50 [N,C\*]; H01L0051-50 [N,A]NCL 313/504.000; 257/040.000 **ECLA** C07D213/38; C07D209/86; C08G061/12D; C08G061/12D1B; C08L065/00; H01L051/00M6; H01L051/00M6F; H01L051/00M6H14; H01L051/00M16; T01L; T01L; T01L US 20070267968 IPCI H01J0063-02 [I,A]; H01J0063-00 [I,C\*] IPCR H01J0063-00 [I,C]; H01J0063-02 [I,A]; H01L0051-00 [N,C\*]; H01L0051-00 [N,A]; H01L0051-05 [N,C\*]; H01L0051-30 [N,A]; H01L0051-50 [I,C\*]; H01L0051-50 [I,A]NCL 313/503.000 ECLA H01L051/50E3; H01L051/50G; T01L; T01L MARPAT 140:119650 OS GΙ

AB Compns. are described which comprise quinoxaline derivs. described by the general formula I (R1 and R2 are the same or different at each occurrence and are selected from H, F, Cl, Br, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylenearyl, alkenylaryl, alkynylaryl, alkyleneheteroaryl, alkenylheteroaryl, alkynylheteroaryl, CnHaFb, OCnHaFb, C6HcFd, and OC6HcFd; both R2 together may constitute an arylene or heteroarylene group; a, b, c, and d = 0 or an integer such that a+b = 2n + 1, and c + d = 5; n = an integer; and z = 0-4). Electronic devices (e.g., light-emitting diodes, light-emitting electrochem. cells, or photodetectors) comprising  $\geq 1$  photoactive layer and a second layer are also described in which  $\geq 1$  layer comprises the quinoxaline derivs.

ST quinoxaline deriv compn electronic device; electroluminescent device quinoxaline deriv; photodetector quinoxaline deriv; light emitting electrochem cell quinoxaline deriv

IT Electrochemical cells

(light-emitting; quinoxaline derivative-containing compns. and electronic

ΤТ Electroluminescent devices Optical detectors (quinoxaline derivative-containing compns. and electronic devices made using them) 647375-47-1P ΙT RL: DEV (Device component use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (quinoxaline derivative-containing compns. and electronic devices made using 4559-60-8P 17401-62-6P 19802-70-1P 32387-86-3P 36305-56-3P ΤТ 36305-63-2P 112657-94-0P 205367-28-8P 364067-15-2P 370851-72-2P 410526-67-9P 647375-50-6P 647375-53-9P 647375-59-5P 647375-61-9P 647375-62-0P 647375-63-1P 647375-64-2P 647375-65-3P 647375-66-4P 647375-67-5P 647375-68-6P 647375-69-7P RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses) (quinoxaline derivative-containing compns. and electronic devices made using them) 84-11-7, Phenanthrene quinone 95-54-5, 1,2-Phenylenediamine, ΤT reactions 128-37-0, 2,6-Di-tert-butyl-p-cresol, reactions 134-81-6, 492-73-9, 2,2'-Pyridil 496-72-0, 3,4-Diaminotoluene 766-98-3, 4-Fluorophenylacetylene 1226-42-2, 4,4'-Dimethoxybenzil 1746-23-2 1765-93-1, 4-Fluorophenylboronic acid 2050-89-7, [1,1'-Biphenyl]-3,3'-2627-95-4, 1,3-Divinyltetramethyldisiloxane 2687-25-4, 3141-27-3 3171-45-7, 4,5-Dimethyl-1,2-2.3-Diaminotoluene phenylenediamine 3363-97-1 4612-26-4 10025-83-9, Iridium trichloride 27318-90-7, 1,10-Phenanthroline-5, 6-dione 35578-47-3, 4,4'-Dibromobenzil 36692-49-6, Methyl 3,4-diaminobenzoate 52334-81-3, 2-Chloro-5-647375-45-9 trifluoromethylpyridine RL: RCT (Reactant); RACT (Reactant or reagent) (quinoxaline derivative-containing compns. and electronic devices made using them) 370878-58-3P 647375-70-0P 647375-71-1P ΙT RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (quinoxaline derivative-containing compns. and electronic devices made using L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2002:628032 CAPLUS DOCUMENT NUMBER: 138:4578 TITLE: Dramatically enhanced fluorescence of heteroaromatic chromophores upon insertion as spacers into oligo(triacetylene)s Edelmann, Michael J.; Raimundo, Jean-Manuel; Utesch, AUTHOR(S): Nils F.; Diederich, Francois CORPORATE SOURCE: Lab. Organische Cheie, ETH-Hoenggerberg, HCI, Zurich, CH-8093, Switz. SOURCE: Helvetica Chimica Acta (2002), 85(7), 2195-2213 CODEN: HCACAV; ISSN: 0018-019X PUBLISHER: Verlag Helvetica Chimica Acta Journal DOCUMENT TYPE: LANGUAGE: English CASREACT 138:4578 OTHER SOURCE(S): ΑN 2002:628032 CAPLUS DN 138:4578 ΕD Entered STN: 21 Aug 2002 Dramatically enhanced fluorescence of heteroaromatic chromophores upon TΤ

insertion as spacers into oligo(triacetylene)s

devices made using them)

```
Edelmann, Michael J.; Raimundo, Jean-Manuel; Utesch, Nils F.; Diederich,
ΑU
     Francois
```

CS Lab. Organische Cheie, ETH-Hoenggerberg, HCI, Zurich, CH-8093, Switz.

SO Helvetica Chimica Acta (2002), 85(7), 2195-2213 CODEN: HCACAV; ISSN: 0018-019X

PB Verlag Helvetica Chimica Acta

DTJournal

LA English

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 22, 72, 73, 78

OS CASREACT 138:4578

GΙ

Ι

AΒ In continuation of a previous study on the modulation of  $\pi\text{-electron}$ conjugation of oligo(triacetylene)s by insertion of central hetero-spacer fragments between two (E)-hex-3-ene-1, 5-diyne ((E)-1, 2-diethynylethene,DEE) moieties, trimeric hybrid oligomers (I; A = spacer, R = SiEt3, SiMe3) were prepared Spacers used were both electron-deficient (quinoxaline-based heterocycles, pyridazine) and electron-rich (2,2'-bithiophene, 9,9-dioctyl-9H-fluorene)chromophores. With a dipyridophenazine spacer, transition metal complexes were synthesized as potential precursors for nanoscale scaffolding based on both covalent acetylenic coupling and supramol. assembly. The UV/visible spectra revealed that the majority of spacers provided heterotrimers featuring extended  $\pi$ -electron delocalization. The new hybrid chromophores show a dramatically enhanced fluorescence compared with the DEE dimer and homo-trimer. This increase in emission intensity appears as a general feature of these systems: even if the spacer mol. is nonfluorescent, the corresponding hetero-trimer may show a strong emission. The redox properties of the new hybrid chromophores were determined by cyclic voltammetry (CV) and rotating disk voltammetry (RDV). In each case, the first 1-electron reduction step in the hetero-trimers appeared anodically shifted compared with DEE dimer and homo-trimer. With larger spacer chromophore extending into two dimensions, the anodic shift (by 240-490 mV) seems to originate from inductive effects of the two strongly electron-accepting DEE substituents rather than from extended  $\pi$ -electron conjugation along the oligomeric backbone, as had previously been observed for DEE substituted porphyrins. hexenediyne benzopyrazine benzothiadiazole phenazine bithiophene pyridazine fluorene prepn fluorescence; benzopyrazine hexenediyne prepn fluorescence electrochem; benzothiadiazole hexenediyne prepn fluorescence electrochem; phenazine hexenediyne prepn fluorescence electrochem; bithiophene hexenediyne prepn fluorescence electrochem; fluorene hexenediyne prepn fluorescence electrochem; transition metal dipyridophenazine prepn fluorescence electrochem

ΙT Fluorescence

Oxidation, electrochemical

Redox potential

```
(preparation, electrochem. properties and dramatically enhanced fluorescence
        of compds. consisting of heteroarom. chromophores inserted as spacers
        into oligo(triacetylene)s)
     Transition metal complexes
ΤТ
     RL: CPS (Chemical process); PEP (Physical, engineering or chemical
     process); PRP (Properties); SPN (Synthetic preparation); PREP
     (Preparation); PROC (Process)
        (preparation, electrochem. properties and dramatically enhanced fluorescence
        of compds. consisting of heteroarom. chromophores inserted as spacers
        into oligo(triacetylene)s)
     198277-07-5
                  198277-13-3
ΤТ
     RL: PRP (Properties)
        (fluorescence and redox potentials)
ΙT
     273-13-2, 2,1,3-Benzothiadiazole
     RL: CPS (Chemical process); PEP (Physical, engineering or chemical
     process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant
     or reagent)
        (fluorescence, electrochem. properties and reactant for preparation of
        compds. having enhanced fluorescence consisting of heteroarom.
        chromophores inserted as spacers into oligo(triacetylene)s)
ΙT
     15155-41-6P 27318-90-7P, 1,10-Phenanthroline
     -5,6-dione
                 69272-50-0P,
     3,6-Dibromobenzene-1,2-diamine
                                     94544-77-1P
                                                    148231-12-3P
                                                                    200503-12-4P
     285129-85-3P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate product in preparation of compds. having enhanced fluorescence
        consisting of heteroarom. chromophores inserted as spacers into
        oligo(triacetylene)s)
ΙT
     19535-47-8P, Dipyrido[3,2-a:2',3'-c]phenazine
     RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
        (preparation and redox potentials)
     477293-98-4P 477293-99-5P 477294-00-1P
TТ
                                                  477294-01-2P
                                                                 477294-02-3P
                                                  477294-09-0P
     477294-04-5P
                    477294-06-7P
                                   477294-08-9P
                                                                  477294-10-3P
     477294-11-4P
     RL: CPS (Chemical process); PEP (Physical, engineering or chemical
     process); PRP (Properties); SPN (Synthetic preparation); PREP
     (Preparation); PROC (Process)
        (preparation, electrochem. properties and dramatically enhanced fluorescence
        of compds. consisting of heteroarom. chromophores inserted as spacers
        into oligo(triacetylene)s)
ΙT
     108-31-6, 2,5-Furandione, miscellaneous
                                               111-83-1 123-33-1 141-30-0
     492-97-7, 2,2'-Bithiophene 16433-88-8
     RL: MSC (Miscellaneous)
        (preparation, electrochem. properties and dramatically enhanced fluorescence
        of compds. consisting of heteroarom. chromophores inserted as spacers
        into oligo(triacetylene)s)
                                   84-11-7, Phenanthrene-9,10-dione
TΤ
     66-71-7, 1,10-Phenanthroline
     95-54-5, Benzene-1,2-diamine, reactions 107-22-2, Glyoxal 134-81-6,
             3339-80-8, 5,5'-Diiodo-2,2'-bithiophene 20698-04-8,
dopyridazine 177500-78-6 198964-46-4, 2,7-Dibromo-9,9-
     3,6-Diiodopyridazine
     dioctylfluorene
                       309721-72-0
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (reactant for preparation of compds. having enhanced fluorescence consisting
        of heteroarom. chromophores inserted as spacers into
        oligo(triacetylene)s)
ΤТ
     91-19-0, Benzopyrazine
                              1684-14-6
     RL: PRP (Properties)
        (redox potentials)
RE.CNT 44
              THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

Reduction, electrochemical

RE

- (1) Albota, M; Science 1998, V281, P1653 CAPLUS
- (2) Amouyal, E; J Chem Soc, Dalton Trans 1990, V19, P1841
- (3) Bard, A; Electrochemical Methods: Fundamentals and Applications' 1980, P488
- (4) Birckner, E; J Phys Chem A 2001, V105, P10307 CAPLUS
- (5) Chung, S; J Phys Chem B 1999, V103, P10741 CAPLUS
- (6) Diaz, R; Tetrahedron Lett 2001, V42, P6463 CAPLUS
- (7) Dickeson, J; Aust J Chem 1970, V23, P1023 CAPLUS
- (8) Dieck, H; J Organomet Chem 1975, V93, P259 CAPLUS
- (9) Dorr, F; Ber Bunsen-Ges Phys Chem 1963, V67, P193
- (10) Druey, J; Helv Chim Acta 1950, V33, P1080 CAPLUS
- (11) Edelmann, M; Chimia 2001, V55, P132 CAPLUS
- (12) Edelmann, M; Helv Chim Acta 2001, V84, P473 CAPLUS
- (13) Guilbault, G; `Practical Fluorescence' 1990, P1
- (14) Halkyard, C; Macromolecules 1998, V31, P8655 CAPLUS
- (15) Hay, A; J Org Chem 1962, V27, P3320 CAPLUS
- (16) Huheey, J; `Anorganische Chemie Prinzipien von Struktur und Reaktivitat' 1988
- (17) Kraft, A; Angew Chem 1998, V110, P416
- (18) Kraft, A; Angew Chem, Int Ed 1998, V37, P402
- (19) Lopez, R; Tetrahedron Lett 1996, V37, P5437
- (20) Martin, R; Chem Eur J 1997, V3, P1505 CAPLUS
- (21) Martin, R; Chem Eur J 2000, V6, P3622 CAPLUS
- (22) Martin, R; Helv Chim Acta 1999, V82, P1470 CAPLUS
- (23) Meerholz, K; Electrochim Acta 1996, V41, P1839 CAPLUS
- (24) Miller, L; J Org Chem 1995, V60, P6813 CAPLUS
- (25) Miteva, T; Macromolecules 2000, V33, P652 CAPLUS
- (26) Mizzoni, R; J Am Chem Soc 1951, V73, P1873 CAPLUS
- (27) Moody, C; Tetrahedron 1992, V48, P3589 CAPLUS
- (28) Osipov, V; Teor Eksp Khim 1978, V14, P703 CAPLUS
- (29) Osipov, V; Theor Exp Chem 1978, V14, P549
- (30) Pilgram, K; J Heterocycl Chem 1970, V7, P629 CAPLUS
- (31) Rtishchev, N; Russ J Gen Chem 1999, V69, P1658 CAPLUS
- (32) Rtishchev, N; Zh Obshch Khim 1999, V69, P1731
- (33) Setayesh, S; J Am Chem Soc 2001, V123, P946 CAPLUS
- (34) Setayesh, S; Macromolecules 2000, V33, P2016 CAPLUS
- (35) Shin, M; J Heterocycl Chem 1999, V36, P1135 CAPLUS
- (36) Siemsen, P; Angew Chem 2000, V112, P2740
- (37) Siemsen, P; Angew Chem, Int Ed 2000, V39, P2632 CAPLUS
- (38) Skoog, D; `Molekulfluoreszenz-, Phosphoreszenz- und Chemilumineszenzspektroskopie' 1996
- (39) Sonogashira, K; `Metalcatalyzed Cross-coupling Reactions' 1998, P203 CAPLUS
- (40) Takahashi, S; Synthesis 1980, P627 CAPLUS
- (41) Tsubata, Y; J Org Chem 1992, V57, P6749 CAPLUS
- (42) Tykwinski, R; Helv Chim Acta 1996, V79, P2249 CAPLUS
- (43) Wytko, J; Helv Chim Acta 1998, V81, P1964 CAPLUS
- (44) Yamada, M; Bull Chem Soc Jpn 1992, V65, P1006 CAPLUS

## => FILE REG

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	164.00	198.65
DISCOUNT AMOUNTS (FOR OUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
, ~ ~	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2 DICTIONARY FILE UPDATES: 9 JUN 2008 HIGHEST RN 1026855-74-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> STR 27318-90-7

:END

L18 STRUCTURE CREATED

=> S L18 FAM SAM

SAMPLE SEARCH INITIATED 10:17:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 6 TO 266

PROJECTED ANSWERS: 1 TO 80

L19 1 SEA FAM SAM L18

=>

=> D SCAN

L19 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN IN 1,10-Phenanthroline-5,6-dione, radical ion(2+) (9CI)

MF C12 H6 N2 O2

CI RIS

ALL ANSWERS HAVE BEEN SCANNED

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L15 2

L15 WAS CREATED DURING MULTIFILE PROCESSING AND CANNOT BE USED WHEN CREATING E#S Enter SET SMARTSELECT ON before using SELECT to create an L-number of terms extracted from an L-number that contains answers or terms from more than one file. SET SMARTSELECT ON must be entered before you execute the SELECT command.

=> SET SMA ON

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L15 2

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

NO ANSWERS SELECTED.

THE ANSWER SET WAS CREATED IN FILES 'CAPLUS, MEDLINE, EMBASE, BIOSIS'. USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILES. To use the SELECT command, you must be in the same file environment in which the answer set was created.

=>

=> FIL

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.98	204.63
DISCOUNT AMOUNTS (FOR OUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
DIBOUNT INIONID (LON SOUTHILLING PROCESSES)	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.20

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

=> SEL RAN.CAPLUS(1) L15 2

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE Some commands only work in certain files. For example, the EXPAND

command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

## => d his

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008

E US2007-599748/APPS

E US2006-599748/APPS

L1 1 S E3 SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162

L3 22 S L2 AND DIONE

L4 0 S L2 AND PHENANTHROLINEDIONE

L5 2 S L2 AND PHENANTHROLINE

L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2

L8 13877 S L3

L9 406 S L5

L18

L10 224329 S L7 OR L8 OR L9

L11 3300 S 10 AND ANTIANGIOGENIC

L12 56 S L11 AND ISCHEMIA

L13 28 S L11 AND ("HEART DISEASE")

L14 2 S L13 AND L12

L15 7 S (L3 OR L5) AND ANTIANGIOGENIC

L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"

L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

STR 27318-90-7

L19 1 S L18 FAM SAM

SET SMA OFF SET SMA ON

FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008

## => s "1,4-naphthalenedione?"

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file medline caplus embase biosis scisearch COST IN U.S. DOLLARS

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
0.42
205.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE 0.00 -7.20

FILE 'MEDLINE' ENTERED AT 10:26:36 ON 11 JUN 2008

```
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'EMBASE' ENTERED AT 10:26:36 ON 11 JUN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.
FILE 'BIOSIS' ENTERED AT 10:26:36 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation
FILE 'SCISEARCH' ENTERED AT 10:26:36 ON 11 JUN 2008
Copyright (c) 2008 The Thomson Corporation
=> s ("1,4-naphthalenedione?")
         1303 ("1,4-NAPHTHALENEDIONE?")
L20
=> s 120 and (treat or treatment or treating)
          129 L20 AND (TREAT OR TREATMENT OR TREATING)
=> s 121 and ("heart attack")
            0 L21 AND ("HEART ATTACK")
=> s 121 and ("myocardial infarction")
   2 FILES SEARCHED...
             0 L21 AND ("MYOCARDIAL INFARCTION")
=> s 121 and ischemia
L24
             4 L21 AND ISCHEMIA
=> d scan 124
                  CAPLUS COPYRIGHT 2008 ACS on STN
L24
     4 ANSWERS
CC
     1-8 (Pharmacology)
ΤI
     Effect of venotropic drugs on the respiratory activity of isolated
     mitochondria and in endothelial cells
ST
     venotropic mitochondrion respiration vascular endothelium hypoxia; venous
     insufficiency mitochondrion respiration ischemia venotropic;
     oxidative phosphorylation venotropic ATP mitochondria
ΙΤ
     Transport proteins
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (ADP/ATP carrier; effect of venotropic drugs on respiratory activity of
        isolated mitochondria and in endothelial cells)
    Anti-ischemic agents
ΤТ
     Hypoxia, animal
     Oxidative phosphorylation, biological
        (effect of venotropic drugs on respiratory activity of isolated
        mitochondria and in endothelial cells)
ΙΤ
     Blood vessel
        (endothelium; effect of venotropic drugs on respiratory activity of
        isolated mitochondria and in endothelial cells)
ΙT
     Sweet clover (Melilotus officinalis)
        (exts.; effect of venotropic drugs on respiratory activity of isolated
        mitochondria and in endothelial cells)
TT
     Vein
        (insufficiency; effect of venotropic drugs on respiratory activity of
        isolated mitochondria and in endothelial cells)
ΙT
     Respiration, animal
        (mitochondrial; effect of venotropic drugs on respiratory activity of
        isolated mitochondria and in endothelial cells)
```

FILE 'CAPLUS' ENTERED AT 10:26:36 ON 11 JUN 2008

IT Procyanidins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(procyanidolic oligomers; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT Mitochondria

(respiration; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT Cardiovascular agents

(venotropics; effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT 130-15-4, 1,4-Naphthalenedione 153-18-4D,

Rutoside, Hydroxyethyl derivs. 372-66-7, Ginkor Fort 520-27-4, Diosmin 6805-41-0, Aescine 31329-57-4, Naftidrofuryl 205886-26-6, Cyclo 3 Fort RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

IT 56-65-5, 5'-ATP, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(effect of venotropic drugs on respiratory activity of isolated mitochondria and in endothelial cells)

## HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L24 4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN

IC ICM C07D

CC 1-12 (Pharmacology)

TI Quinone compound cysteine protease inhibitors, and therapeutic use

ST quinone compd cysteine protease inhibitor therapeutic; infectious disease treatment quinone compd cysteine protease inhibitor; caspase inhibitor quinone compd therapeutic

IT Nervous system, disease

(Huntington's chorea; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Biliary tract, disease

Inflammation

(cholangitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Inflammation

Intestine, disease

(colitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cysteine protease-like, inhibitors; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Nervous system, disease

(degeneration; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Biological transport

(drug; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Disease, animal

(endocerolitis; quinone compound cysteine protease inhibitors, and therapeutic use)

IT Allergy

(hypersensitivity; quinone compound cysteine protease inhibitors, and

```
therapeutic use)
    Virus
ТТ
        (immunodeficiency; quinone compound cysteine protease inhibitors, and
        therapeutic use)
TΤ
     Heart, disease
        (infarction; quinone compound cysteine protease inhibitors, and
        therapeutic use)
ΙΤ
     Nerve, disease
     Reperfusion
     Spinal cord, disease
        (injury; quinone compound cysteine protease inhibitors, and therapeutic
ΙΤ
     Drug delivery systems
        (nasal; quinone compound cysteine protease inhibitors, and therapeutic
ΙT
     Injury
        (neuronal; quinone compound cysteine protease inhibitors, and therapeutic
        use)
ΙT
     Transplant and Transplantation
        (organ damage; quinone compound cysteine protease inhibitors, and
        therapeutic use)
ΙΤ
     Inflammation
     Pancreas, disease
        (pancreatitis; quinone compound cysteine protease inhibitors, and
        therapeutic use)
     Alopecia
ΤT
     Alzheimer's disease
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
    Antiarthritics
     Antidiabetic agents
     Antiparkinsonian agents
     Antiviral agents
     Apoptosis
     Arthritis
     Autoimmune disease
     Blood-brain barrier
     Cardiovascular agents
     Cardiovascular system, disease
     Diabetes mellitus
     Drug delivery systems
     Encephalitis
     Hepatitis
     Hepatitis virus
     Immune disease
     Immunodeficiency
     Inflammation
     Influenza virus
       Ischemia
     Multiple sclerosis
     Nervous system, disease
     Nervous system agents
     Parkinson's disease
     Picornaviridae
     QSAR (quantitative structure-activity relationship)
     Rhinovirus
     Spinal muscular atrophy
        (quinone compound cysteine protease inhibitors, and therapeutic use)
IΤ
     Injury
        (reperfusion; quinone compound cysteine protease inhibitors, and
```

therapeutic use) Injury ΙT (spinal cord; quinone compound cysteine protease inhibitors, and therapeutic use) ΙT Brain, disease (stroke; quinone compound cysteine protease inhibitors, and therapeutic use) ΙT Reducing agents (sulfur reducing agents; quinone compound cysteine protease inhibitors, and therapeutic use) ΙT Multiple sclerosis (therapeutic agents; quinone compound cysteine protease inhibitors, and therapeutic use) ΙT Infection (viral; quinone compound cysteine protease inhibitors, and therapeutic 9002-07-7, Trypsin ΙT 9001-73-4, Papain 9004-07-3,  $\alpha$ -Chymotrypsin 37353-41-6, Cysteine protease 97162-88-4, 3C Protease 169592-56-7, Caspase 3 186322-81-6, Caspase RL: BSU (Biological study, unclassified); BIOL (Biological study) (quinone compound cysteine protease inhibitors, and therapeutic use) ΙT 70-18-8, Glutathione, biological studies 70-18-8D, Glutathione, adducts with naphthoquinone derivs. 81-54-9 83-61-4 84-79-7 116-85-8 117-80-6 130-15-4, 1,4 130-15-4D, 1,4--Naphthalenedione 389-08-2, Nalidixic acid Naphthalenedione, derivs. adducts 389-08-2D, Nalidixic acid, derivs. 475-38-7 480-40-0 481-39-0 481-42-5 517-88-4D, derivs. 517-88-4D, Alkannin, naphthoquinone 517-89-5D, Shikonin, derivs. 517-89-5, Shikonin 517-89-5D, derivs. naphthoguinone derivs. 520-36-5 569-77-7 583-63-1D, 3,5-Cyclohexadiene-1,2-dione, derivs. 930-68-7D, 2-Cyclohexen-1-one, derivs. 1015-62-9D, derivs. 2379-57-9D, derivs. 3483-12-3, DTT 3483-12-3D, DTT, derivs. 3952-78-1 4613-08-5 6041-00-5D, derivs. 13243-65-7 23444-65-7, Alkannin 33440-64-1 6336-72-7 40881-75-2 50614-69-2D, derivs. 59887-87-5 69008-03-3 69016-66-6 70730-92-6 71860-31-6D, derivs. 74839-40-0 75753-48-9 75753-51-4 75753-52-5 78651-40-8D, derivs. 81818-54-4D, derivs. 82789-18-2D, derivs. 85192-90-1 86703-96-0D, derivs. 88818-34-2D, derivs. 92629-07-7 93831-47-1 97136-23-7D, derivs. 100440-78-6 101068-35-3 108772-19-6 117746-18-6D, derivs. 133011-82-2D, derivs. 184529-66-6 192126-76-4D, Mycothiol, 187753-94-2D, derivs. 192126-76-4, Mycothiol adducts with naphthoquinone derivs. 202350-24-1D, derivs. 208254-19-7D, derivs. 215778-63-5D, derivs. 298208-05-6D, derivs. 304883-59-8 313253-12-2D, derivs. 313471-02-2 313493-32-2D, derivs. 313549-28-9D, derivs. 313955-32-7D, derivs. 313531-31-6 313955-40-7D, derivs. 313957-75-4D, derivs. 313957-76-5D, derivs. 313958-25-7D, derivs. 324527-07-3D, derivs. 317337-15-8 403496-99-1D, derivs. 399038-37-0D, derivs. 464157-05-9D, derivs. 464157-06-0D, derivs. 464157-07-1D, derivs. 464157-08-2D, derivs. 464157-10-6D, derivs. 464157-14-0D, derivs. 464157-09-3D, derivs. 464157-11-7D, derivs. 464157-13-9D, derivs. 464157-15-1D, derivs. 464157-17-3D, derivs. 464157-16-2D, derivs. 464157-18-4D, derivs. 464157-20-8D, derivs. 464157-19-5D, derivs. 464157-21-9D, derivs. 464157-22-0D, derivs. 464157-23-1D, derivs. 464157-24-2D, derivs. 464157-27-5D, derivs. 464157-25-3D, derivs. 464157-26-4D, derivs. 464157-28-6D, derivs. 464157-29-7D, derivs. 464157-30-0D, derivs. 464157-31-1D, derivs. 464157-32-2D, derivs. 464157-33-3D, derivs. 464157-34-4D, derivs. 464157-35-5D, derivs. 464157-36-6D, derivs. 464157-37-7 464157-38-8 464157-39-9 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(quinone compound cysteine protease inhibitors, and therapeutic use)

```
4 ANSWERS
                  CAPLUS COPYRIGHT 2008 ACS on STN
L24
CC
     1-10 (Pharmacology)
     Section cross-reference(s): 27, 62, 63
     Pharmaceutical composition for the treatment or prevention of
ΤI
     diseases involving obesity, diabetes, metabolic syndrome,
     neurodegenerative diseases and mitochondria dysfunction diseases
ST
     naphthoguinone deriv obesity diabetes metabolic syndrome neurodegenerative
     mitochondria disease; Danshen drug formulation cosmetic naphthoquinone
     deriv beta lapachone prepn
     Natural products, pharmaceutical
ΤТ
        (Salviae miltiorrhizae radix; pharmaceutical composition for
        treatment obesity, diabetes, metabolic syndrome,
        neurodegenerative diseases and mitochondria dysfunction diseases)
ΤТ
     Brain, disease
        (cerebrovascular; pharmaceutical composition for treatment
        obesity, diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
ΤT
     Disease, animal
        (degenerative; pharmaceutical composition for treatment obesity,
        diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
ΙT
     Eye, disease
        (diabetic retinopathy, diabetic; pharmaceutical composition for
        treatment obesity, diabetes, metabolic syndrome,
        neurodegenerative diseases and mitochondria dysfunction diseases)
ΙT
     Hyperlipidemia
     Hypertension
        (diabetic; pharmaceutical composition for treatment obesity,
        diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
    Mitochondria
TT
        (disease; pharmaceutical composition for treatment obesity,
        diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
ΙT
     Kidney, disease
        (failure, diabetic; pharmaceutical composition for treatment
        obesity, diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
ΙT
     Heart, disease
        (infarction; pharmaceutical composition for treatment obesity,
        diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
ΤТ
     Cosmetics
        (lotions; pharmaceutical composition for treatment obesity,
        diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
TΤ
     Metabolic disorders
        (metabolic syndrome X; pharmaceutical composition for treatment
        obesity, diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
ΙT
     Disease, animal
        (mitochondrial; pharmaceutical composition for treatment obesity,
        diabetes, metabolic syndrome, neurodegenerative diseases and
        mitochondria dysfunction diseases)
     Antidiabetic agents
ΙT
     Antiobesity agents
     Arteriosclerosis
     Cardiovascular system, disease
```

Claisen rearrangement

Diels-Alder reaction Drug delivery systems Inflammation Ischemia Liver, disease Obesity Salvia miltiorrhiza (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases) ΙT Drug delivery systems (prodrugs; pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases) 4707-32-8P,  $\beta$ -Lapachone TΤ RL: ADV (Adverse effect, including toxicity); COS (Cosmetic use); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases) ΙT 33404-57-8P, Dunnione 52436-88-1P 83156-01-8P,  $\alpha$ -Dunnione 90149-94-3P 90149-95-4P 90149-97-6P 359762-51-9P 906459-31-2P 906459-32-3P 906459-34-5P 906459-35-6P RL: ADV (Adverse effect, including toxicity); COS (Cosmetic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases) TТ 130-15-4DP, 1,4-Naphthalenedione, derivs. 15297-93-5P 17112-93-5P 32013-77-7P 52422-61-4P 82420-29-9P 83156-21-2P 90149-96-5P 90149-98-7P 90149-99-8P 104277-62-5P 476213-05-5P 118949-98-7P 118949-99-8P 195156-60-6P 855275-10-4P 906459-29-8P 906459-30-1P 906459-33-4P 906459-36-7P 906459-37-8P RL: COS (Cosmetic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases) 42164-69-2P ΤT RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent) (pharmaceutical composition for treatment obesity, diabetes, metabolic syndrome, neurodegenerative diseases and mitochondria dysfunction diseases) ΙT 78-79-5, 2-Methyl-1,3-butadiene, reactions 83-72-7, 2-Hydroxy-1,4-84-58-2 106-51-4, p-Benzoquinone, reactions naphthoquinone 115-19-5, 2-Methyl-3-butyn-2-ol 123-91-1, 1,4-Dioxane, reactions 673-84-7, 2,6-Dimethyl-2,4,6-octatriene 869-72-7, 1-Bromo-3-methyl-2-pentene 870-63-3, 1-Bromo-3-methyl-2-butene 932-86-5, 2-Bromo-1000-86-8, 2,4-Dimethyl-1,3-pentadiene ethylidenecyclohexane 3017-69-4, 1-Bromo-2-methylpropene 4392-24-9, 3-Phenylallyl bromide 6138-90-5, Geranyl bromide 6674-22-2, 1,8-Diazabicyclo[5.4.0]undec-7-ene 13961-36-9 17173-25-0 8013-00-1, Terpinene 21378-06-3, 1-Bromo-3-ethyl-2-pentene 30525-89-4, Paraformaldehyde 58472-21-2, 2-Hydroxy-6-methyl-1,4-naphthoquinone 74237-21-1, 6-Chloro-2-hydroxy-1,4-

Cyclization

Diabetes mellitus

```
naphthoquinone
                      90149-85-2
                                  114521-72-1
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (pharmaceutical composition for treatment obesity, diabetes,
        metabolic syndrome, neurodegenerative diseases and mitochondria
        dysfunction diseases)
     40432-22-2P, 4,5-Benzofurandione
                                         906459-39-0P
ΙT
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (pharmaceutical composition for treatment obesity, diabetes,
        metabolic syndrome, neurodegenerative diseases and mitochondria
        dysfunction diseases)
     125911-68-4
ΤТ
     RL: PRP (Properties)
        (unclaimed sequence; pharmaceutical composition for the treatment
        or prevention of diseases involving obesity, diabetes, metabolic
        syndrome, neurodegenerative diseases and mitochondria dysfunction
        diseases)
L24
      4 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
IC
     ICM C07D223-16
     ICS C07D401-04; C07D403-12; A61K031-55
CC
     27-21 (Heterocyclic Compounds (One Hetero Atom))
     Section cross-reference(s): 1, 63
ΤI
     2,5-Dioxo-2,5-dihydro-1H-benz[b] azepines as NMDA receptor antagonists
ST
     benzazepine prepn NMDA receptor antagonist
ΙT
     Nervous system agents
        (benzazepine derivs.)
ΙΤ
     Neurotransmitter antagonists
        (glycinergic, benzazepine derivs.)
ΙT
     Brain, disease
        (ischemia, treatment of, benzazepine derivs. for)
ΙT
     Neurotransmitter antagonists
        (methyl-D-aspartate, benzazepine derivs.)
ΙT
     Brain, disease
        (stroke, treatment of, benzazepine derivs. for)
TΤ
     3984-34-7, 3-(4-Chlorobenzoyl) propionic acid
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (Wolff-Kishner reduction of, in preparation of benzazepine NMDA receptor
        antagonists)
ΙT
     74-88-4, Methyl iodide, reactions
                                         100-39-0, Benzyl bromide
                                                                     2417-72-3,
     Methyl 4-(bromomethyl)benzoate
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (alkylation of benzazepinedione derivative by, in preparation of benzazepine
        NMDA receptor antagonists)
     51-45-6, 2-(4-Imidazolyl)ethylamine, reactions 62-53-3, Benzenamine,
ΤТ
                64-04-0, Phenethylamine
                                          74-89-5, Methylamine, reactions
     reactions
     92-54-6, 1-Phenylpiperazine 100-46-9, Benzylamine, reactions
                                                                        107-11-9.
                108-00-9, 2-(N,N-Dimethylamino) ethylamine 109-89-7,
     Allylamine
     Diethylamine, reactions 110-89-4, Piperidine, reactions
                                                                  110-91-8,
     Morpholine, reactions 111-42-2, Diethanolamine, reactions
                                                                  111-49-9,
     Perhydroazepine 123-75-1, Pyrrolidine, reactions 124-40-3,
     Dimethylamine, reactions 141-43-5, reactions 488-2516-47-4, Cyclopropylmethylamine 2627-86-3, (S)-\alpha-
                                                     488-43-7, D-Glucamine
     Methylbenzylamine
                        2759-28-6, 1-Benzylpiperazine
                                                          3202-33-3,
     4-Phenoxypiperidine
                           3886-69-9, (R)-\alpha-Methylbenzylamine
     16066-84-5, tert-Butoxycarbonylmethylamine 55536-65-7,
     3,4-Dibenzyloxyphenethylamine
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (aminolysis of methoxybenzazepinedione derivative by, in preparation of
        benzazepine NMDA receptor antagonists)
ΤТ
     52280-65-6
```

```
RL: RCT (Reactant); RACT (Reactant or reagent)
        (ammonolysis and aminolysis of, in preparation of benzazepine NMDA receptor
        antagonists)
     696-59-3, 2,5-Dimethoxytetrahydrofuran
ΙT
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (cyclocondensation of, with aminobenzazepine derivative, in preparation of
        benzazepine NMDA receptor antagonists)
ΙT
     55406-29-6P
                  154314-66-6P 154314-67-7P
                                               154314-68-8P
                                                               154314-69-9P
     154314-70-2P
                  154314-71-3P
                                 154314-72-4P
                                                154314-73-5P
                                                               154314-74-6P
     154314-75-7P 154314-76-8P
                                 154314-77-9P 154314-78-0P
                                                               154314-79-1P
     154314-80-4P 154314-81-5P
                                 154314-82-6P 154314-83-7P
                                                               154314-84-8P
     154314-85-9P 154314-86-0P 154314-87-1P 154314-88-2P
                                                               154314-89-3P
     154314-90-6P 154314-91-7P 154314-92-8P 154314-93-9P
                                                               154314-94-0P
     154314-95-1P 154314-96-2P
                                 154314-97-3P 154314-98-4P
                                                               154314-99-5P
     154315-00-1P 154315-01-2P
                                 154315-02-3P 154315-03-4P 154315-04-5P
                  154315-06-7P
     154315-05-6P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation of, as NMDA receptor antagonist)
ΤТ
     4619-18-5P, 4-(4-Chlorophenyl) butyric acid 26673-32-5P,
     7-Chloro-1-tetralone 90685-39-5P, 1,4-
     Naphthalenedione, 7-chloro-2-hydroxy- 90700-78-0P, 1,
     4-Naphthalenedione, 7-chloro-2-methoxy-
                                             144066-30-8P
     154315-07-8P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation of, as intermediate for benzazepine NMDA receptor antagonists)
ALL ANSWERS HAVE BEEN SCANNED
=> d his
     (FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)
     FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
               E US2007-599748/APPS
               E US2006-599748/APPS
L1
              1 S E3
               SEL RN L1
     FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
L2
           162 S E1-E162
L3
             22 S L2 AND DIONE
L4
              0 S L2 AND PHENANTHROLINEDIONE
L_5
              2 S L2 AND PHENANTHROLINE
              0 S "SUBSTITUTED PHENANTHROLINE"
1.6
     FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
     11 JUN 2008
         224329 S L2
L7
          13877 S L3
Γ8
L9
            406 S L5
L10
         224329 S L7 OR L8 OR L9
L11
           3300 S 10 AND ANTIANGIOGENIC
             56 S L11 AND ISCHEMIA
L12
             28 S L11 AND ("HEART DISEASE")
L13
L14
              2 S L13 AND L12
L15
              7 S (L3 OR L5) AND ANTIANGIOGENIC
L16
            587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L17
              4 S L16 AND PHENANTHRENE
```

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

```
T.18
                STR 27318-90-7
T.19
              1 S L18 FAM SAM
                SET SMA OFF
                SET SMA ON
     FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008
     FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON
     11 JUN 2008
           1303 S ("1,4-NAPHTHALENEDIONE?")
L20
L21
            129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L22
              0 S L21 AND ("HEART ATTACK")
L23
              0 S L21 AND ("MYOCARDIAL INFARCTION")
              4 S L21 AND ISCHEMIA
L24
=> s 116 and ("myocardial infarction")
   2 FILES SEARCHED...
             1 L16 AND ("MYOCARDIAL INFARCTION")
=> d scan 125
L25
      1 ANSWERS
                  CAPLUS COPYRIGHT 2008 ACS on STN
     ICM A61K
IC
     63-6 (Pharmaceuticals)
CC
     Section cross-reference(s): 78
     Therapeutic delivery of carbon monoxide employing Mn complexes having CO
ΤТ
     ligands, and additional halogen, monodentate and/or bidentate ligands
ST
     carbon monoxide manganese complex halogen monodentate bidentate ligand
     antiinflammatory; manganese complex carbon monoxide ligand
     neurotransmission vasodilation inflammation hypertension
ΙT
     Hyperoxia
        (-induced injury; therapeutic delivery of carbon monoxide employing
        manganese complexes having CO ligands, and addnl. halogen, monodentate
        and/or bidentate ligands)
     Respiratory distress syndrome
IT
        (adult; therapeutic delivery of carbon monoxide employing manganese
        complexes having CO ligands, and addnl. halogen, monodentate and/or
        bidentate ligands)
ΙT
     Ligands
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (bidentate; therapeutic delivery of carbon monoxide employing manganese
        complexes having CO ligands, and addnl. halogen, monodentate and/or
        bidentate ligands)
ΙT
     Radiation
        (damage; therapeutic delivery of carbon monoxide employing manganese
        complexes having CO ligands, and addnl. halogen, monodentate and/or
        bidentate ligands)
ΙT
     Ligands
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (halogen, monodentate; therapeutic delivery of carbon monoxide
        employing manganese complexes having CO ligands, and addnl. halogen,
        monodentate and/or bidentate ligands)
ΙT
     Shock (circulatory collapse)
        (hemorrhagic; therapeutic delivery of carbon monoxide employing
        manganese complexes having CO ligands, and addnl. halogen, monodentate
        and/or bidentate ligands)
ΙT
     Pharmaceutical injections
        (i.m. injections; therapeutic delivery of carbon monoxide employing
        manganese complexes having CO ligands, and addnl. halogen, monodentate
        and/or bidentate ligands)
     Pharmaceutical injections
TΤ
```

(i.p. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Pharmaceutical injections

(i.v. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Sexual disorders

(impotence; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Halogens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ligands; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Injury

(postischemic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Pharmaceutical injections

(s.c. injections; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Shock (circulatory collapse)

(septic; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Neurotransmission

(stimulation; therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Angina pectoris

Anti-inflammatory agents

Apoptosis

Arteriosclerosis

Cytotoxicity

Dissolution

Hypertension

Inflammation

Inhalation drug delivery systems

Myocardial infarction

Nasal drug delivery systems

Neoplasm

Oral drug delivery systems

Pharmaceutical solutions

Pharmaceutical suppositories

Sepsis

Solubility

Transdermal drug delivery systems

Transplant rejection

Vasodilators

(therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

IT Carbonyl complexes

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate

ligands) 14100-30-2P, Chloropentacarbonylmanganese 14516-54-2P, ΤТ Bromopentacarbonylmanganese 14879-42-6P, Pentacarbonyliodomanganese 38173-71-6P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands) 10170-70-4P 14321-60-9P 20480-91-5P 20624-20-8P 52841-89-1P ΤТ 59893-04-8P 108267-31-8P 115958-82-2P 178935-53-0P 438552-30-8P 1001014-97-6P 1001014-98-7P 1001014-99-8P 1001015-00-4P 1001015-02-6P 1001015-04-8P 1001015-06-0P 1001015-08-2P 1001015-09-3P 1001015-11-7P 1001015-13-9P 1001015-14-0P 1001015-16-2P 1001015-17-3P 1001015-18-4P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands) 630-08-0D, Carbon monoxide, manganese complexes, ligand of ΙT 7439-96-5D, Manganese, complexes RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands) 56-23-5, Carbon tetrachloride, reactions 64-19-7, Acetic acid, reactions ΤТ 65-85-0, Benzoic acid, reactions 67-48-1, Choline chloride Methylene chloride, reactions 75-15-0, Carbon disulfide, reactions 75-31-0, Isopropylamine, reactions 75-59-2, Tetramethylammonium hydroxide 107-22-2, Glyoxal 111-42-2, Diethanolamine, reactions 115-86-6, Triphenyl phosphate 119-91-5, 2,2'-Biquinolyl 121-45-9, Trimethyl phosphite 127-08-2, Potassium acetate 140-89-6 141-82-2, Malonic acid, reactions 148-18-5, Sodium diethyldithiocarbamate 366-18-7, 2,2'-Bipyridine 507-09-5, Thioacetic acid, reactions 1310-73-2, Sodium hydroxide (Na(OH)), reactions 2923-28-6, Silver 7553-56-2, Iodine, reactions 7647-15-6, Sodium bromide (NaBr), reactions 7726-95-6, Bromine, reactions 10170-69-1, Decacarbonyldimanganese 11110-52-4, Sodium amalgam 13442-87-0 14104-20-2, Silver fluoroborate (AgBF4) 15761-38-3 17773-10-3, Choline iodide 21050-13-5 27318-90-7, 1,10-Phenanthroline-5,6-dione 33100-27-5, 15-Crown-5 RL: RCT (Reactant); RACT (Reactant or reagent) (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands) 2801-04-9P, Sodium bis(2-hydroxyethyl)dithiocarbamate ΙT Tetramethylammonium acetate 24764-90-7P 25255-90-7P, 33299-53-5P, Tetramethylammonium malonate Tetramethylammonium benzoate 62698-51-5P, Tetramethylammonium thioacetate 63321-11-9P 81436-35-3P 89689-95-2P 1001015-19-5P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

630-08-0, Carbon monoxide, biological studies

ΙT

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic delivery of carbon monoxide employing manganese complexes having CO ligands, and addnl. halogen, monodentate and/or bidentate ligands)

ALL ANSWERS HAVE BEEN SCANNED

```
=> d his
     (FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)
     FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
                E US2007-599748/APPS
                E US2006-599748/APPS
L1
              1 S E3
                SEL RN L1
     FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
L2
            162 S E1-E162
L3
             22 S L2 AND DIONE
L4
              0 S L2 AND PHENANTHROLINEDIONE
              2 S L2 AND PHENANTHROLINE
L5
              0 S "SUBSTITUTED PHENANTHROLINE"
L6
     FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
     11 JUN 2008
L7
         224329 S L2
         13877 S L3
L8
L9
            406 S L5
L10
         224329 S L7 OR L8 OR L9
           3300 S 10 AND ANTIANGIOGENIC
L11
             56 S L11 AND ISCHEMIA
L12
L13
             28 S L11 AND ("HEART DISEASE")
L14
              2 S L13 AND L12
L15
              7 S (L3 OR L5) AND ANTIANGIOGENIC
            587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L16
L17
              4 S L16 AND PHENANTHRENE
     FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008
                STR 27318-90-7
L18
L19
              1 S L18 FAM SAM
                SET SMA OFF
                SET SMA ON
     FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008
     FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON
     11 JUN 2008
L20
           1303 S ("1,4-NAPHTHALENEDIONE?")
L21
            129 S L20 AND (TREAT OR TREATMENT OR TREATING)
              0 S L21 AND ("HEART ATTACK")
L22
              0 S L21 AND ("MYOCARDIAL INFARCTION")
L23
L24
              4 S L21 AND ISCHEMIA
L25
              1 S L16 AND ("MYOCARDIAL INFARCTION")
=> s 116 and ("angiogenesis inhibitor?")
L26
             0 L16 AND ("ANGIOGENESIS INHIBITOR?")
=> s 12 and ("angiogenesis inhibitor?")
L27
           552 L2 AND ("ANGIOGENESIS INHIBITOR?")
```

=> s 13 and ("angiogenesis inhibitor?")

L28 24 L3 AND ("ANGIOGENESIS INHIBITOR?")

=> s 15 and ("angiogenesis inhibitor?")

L29 2 L5 AND ("ANGIOGENESIS INHIBITOR?")

=> s (127 or 128 or 129) aND HEART

L30 53 (L27 OR L28 OR L29) AND HEART

=> S L30 AND ISCHEMIA

L31 24 L30 AND ISCHEMIA

=> S L31 and (treat or treating or treatment)

L32 19 L31 AND (TREAT OR TREATING OR TREATMENT)

=> d 132 1-19 hitstr ibib all

L32 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN


IT 5315-25-3, 2-Bromo-6-methylpyridine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

RN 5315-25-3 CAPLUS

CN Pyridine, 2-bromo-6-methyl- (CA INDEX NAME)



IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (  $\alpha$  and  $\gamma$  isoforms; preparation of thiazolidinedione derivs. as

PI3 kinase inhibitors useful in treatment of diseases)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*
ACCESSION NUMBER: 2008:127697 CAPLUS

DOCUMENT NUMBER: 148:191939

TITLE: Preparation of thiazolidinedione derivatives as PI3

kinase inhibitors

INVENTOR(S): Adams, Nicholas D.; Dhanak, Dashyant; Knight, Steven

David; Schaller, Lee; Tang, Jun

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 72pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIND		DATE		APPLICATION NO.						DATE			
WO 2008014219				A2 20080131			WO 2007-US74155						20070724				
W	: AE,	AG,	ΑL,	ΑM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	CA,	
	CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DO,	DZ,	EC,	EE,	EG,	ES,	FI,	
	GB,	GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	

```
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
            MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
            PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:
                                           US 2006-820147P
                                                                 20060724
                                           US 2006-820973P
                                                             P 20060801
                        MARPAT 148:191939
OTHER SOURCE(S):
    2008:127697 CAPLUS
AN
DN
    148:191939
    Entered STN: 01 Feb 2008
ED
ΤI
    Preparation of thiazolidinedione derivatives as PI3 kinase inhibitors
    Adams, Nicholas D.; Dhanak, Dashyant; Knight, Steven David; Schaller, Lee;
ΙN
    Tang, Jun
    Smithkline Beecham Corporation, USA
PA
    PCT Int. Appl., 72pp.
SO
    CODEN: PIXXD2
DT
    Patent
LA
    English
CC
    28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
    Section cross-reference(s): 1, 63
FAN.CNT 1
                              DATE
    PATENT NO.
                        KIND
                                          APPLICATION NO.
                                                                 DATE
                        ____
                              20080131
                                        WO 2007-US74155
    WO 2008014219
PΙ
                        A2
                                                                  20070724
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
            GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
            KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
            MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
            PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2006-820147P P 20060724
    US 2006-820973P
                        P
                               20060801
CLASS
PATENT NO.
             CLASS PATENT FAMILY CLASSIFICATION CODES
IPCI
WO 2008014219
                       A61K0031-519 [I,A]
                       A61K0031-519 [I,C]; A61K0031-519 [I,A]
                IPCR
    MARPAT 148:191939
OS
GΙ
```

AΒ Invented is a method of inhibiting the activity/function of PB kinases using thiazolidinedione derivs. I [R1 = H, alkyl, aryl, etc.; R2, R3 = H, halo, acyl, etc.; n = 0-3; m = 0-2; A, B, D, E and G together form a ring containing from 1 to 2 double bonds and from 1 to 4 N atoms; X, Y, Z = CH, CR3and N; provided that one and only one od A and B = N]. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiozolidinedione derivs. I. Twenty-six compds. I were prepared E.g., a multi-step synthesis of II, starting from 2-amino-5-bromopyridine and Et 2-chloro-3-oxopropanoate potassium salt, was described. Exemplified compds. I showed IC50 values from 1 nM to 10  $\mu\text{M}$  against PI3K $\alpha$ . Pharmaceutical composition comprising compound I is claimed.

thiazolidinedione imidazopyridine prepn phosphatidylinositol PI3 kinase inhibitor antiinflammatory cardiovascular; autoimmune disorder treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; neurodegenerative kidney disease treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; allergy inhibitor treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; pancreatitis multiorgan failure treatment thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; antiasthmatic antitumor immunosuppressant thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase; platelet aggregation inhibitor thiazolidinylidenemethyl imidazopyridine prepn PI3 kinase

IT Nervous system, disease

(Huntington's chorea; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Sarcoma

(Kaposi's; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Microtubule

(anti-microtubule agents, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Cytotoxic agents

(antimetabolites, codrugs; preparation of thiazolidinedione derivs. as PI3

kinase inhibitors useful in treatment of diseases)

IT Muscle, disease

(atrophy, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection

(bacterial, acute; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Infection

(bacterial, chronic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Alkylating agents, biological

Antibiotics

Antitumor agents

Immunotherapy

(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Hormones, animal, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease

(degeneration; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Skeletal muscle

(disease, atrophy; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Angiogenesis

(disease; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Sperm motility

(disorder; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Cardiomyocyte

(dysfunction; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung

(epithelium, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Kidney, disease

(fibrosis, progressive; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(glomerulonephritis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Muscle, disease

(hypertrophy, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Brain, disease

(infection; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Respiratory system, disease

(inflammation; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT Lung, disease

(injury, endothelial; preparation of thiazolidinedione derivs. as PI3 kinase

inhibitors useful in treatment of diseases) ΤТ Lung, disease (injury, epithelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Lung, disease ΤТ Reperfusion (injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΙT Neoplasm (leukocyte recruitment in; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΤТ (lung, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΙT Neoplasm (metastasis, invasion; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΙT Hypertrophy (muscular, skeletal muscle; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΤТ Angiogenesis inhibitors (non-receptor tyrosine kinase, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΙT Inflammation Pancreas, disease (pancreatitis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΙT Signal transduction (pathway inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Coordination compounds ТТ RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (platinum, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΤТ Inflammation Lung, disease (pneumonitis; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) ΙT Alleray Allergy inhibitors Alzheimer's disease Anaphylaxis Anti-Alzheimer's agents Anti-infective agents Anti-inflammatory agents Anti-ischemic agents Antiasthmatics Anticoagulants Antifibrotic agents Antihypertensives Antirheumatic agents Antiviral agents Asthma Atherosclerosis Autoimmune disease Cardiac hypertrophy

Cardiovascular agents

Cardiovascular system, disease Central nervous system agents

Combination chemotherapy Encephalitis Fibrosis Glomerulosclerosis Heart, disease Human Hypertension Immunosuppressants Inflammation Inflammatory bowel disease Ischemia Kidney, disease Leukemia Mammary gland, neoplasm Melanoma Meningitis Multiple organ failure Multiple sclerosis Neoplasm Nervous system agents Neuroprotective agents Ovary, neoplasm Pancreas, neoplasm Pharmaceutical carriers Platelet activation Platelet aggregation Platelet aggregation inhibitors Prodrugs Prostate gland, neoplasm Psoriasis Respiratory system agents Rheumatoid arthritis Sepsis Stroke Thrombosis Transplant rejection Vasoconstriction Vasodilators (preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Apoptosis (proapoptotic agents, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Injury (pulmonary, endothelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Injury (pulmonary, epithelial; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Epithelium (pulmonary, injury; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Injury (pulmonary; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Leukocyte (recruitment in cancer tissue; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases) Fibrosis

(renal, progressive; preparation of thiazolidinedione derivs. as PI3 kinase

inhibitors useful in treatment of diseases)

ΙT

ΙT

ΤТ

ΙT

ΙT

TT

ΙT

```
ΤТ
     Injury
        (reperfusion; preparation of thiazolidinedione derivs. as PI3 kinase
        inhibitors useful in treatment of diseases)
ΙT
     Inflammation
        (respiratory tract; preparation of thiazolidinedione derivs. as PI3 kinase
        inhibitors useful in treatment of diseases)
ΙT
     Cell cycle
        (signaling inhibitors, codrugs; preparation of thiazolidinedione derivs. as
        PI3 kinase inhibitors useful in treatment of diseases)
ΙT
     Lupus erythematosus
        (systemic; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors
        useful in treatment of diseases)
ΙT
     Central nervous system, disease
        (trauma; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors
        useful in treatment of diseases)
ΙT
     Infection
        (viral, acute; preparation of thiazolidinedione derivs. as PI3 kinase
        inhibitors useful in treatment of diseases)
ΙT
     Infection
        (viral, chronic; preparation of thiazolidinedione derivs. as PI3 kinase
        inhibitors useful in treatment of diseases)
ΙΤ
     7440-06-4D, Platinum, complexes
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (codrugs; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors
        useful in treatment of diseases)
     142805-56-9, Topoisomerase II
                                     143180-75-0
TΤ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitors, codrugs; preparation of thiazolidinedione derivs. as PI3 kinase
        inhibitors useful in treatment of diseases)
ΙT
     866261-76-9
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in
        treatment of diseases)
ΙT
     1004549-86-3P
                     1004549-93-2P
                                     1004549-94-3P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in
        treatment of diseases)
ΙT
     1004549-83-0P
                    1004549-84-1P
                                      1004549-85-2P 1004549-87-4P
     1004549-88-5P 1004549-89-6P
                                    1004549-90-9P 1004549-91-0P
     1004549-92-1P 1004549-95-4P 1004549-96-5P 1004549-97-6P
     1004549-98-7P 1004549-99-8P
                                     1004550-00-8P
                                                      1004550-01-9P
     1004550-02-0P 1004550-03-1P
                                      1004550-04-2P
                                                      1004550-05-3P
     1004550-06-4P 1004550-07-5P
                                      1004550-08-6P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in
        treatment of diseases)
     109-04-6, 2-Bromopyridine
                                 431-35-6, 3-Bromo-1,1,1-trifluoro-2-propanone
TΤ
     626-55-1, 3-Bromopyridine
                                 816-40-0, 1-Bromo-2-butanone
                                                                  1072-97-5,
                              1532-97-4, 4-Bromoisoquinoline
1694-29-7, 3-Chloroacetylacetone
     2-Amino-5-bromopyridine
                                                                  1692-15-5,
     Pyridine-4-boronic acid
     2,4-Thiazolidinedione 5315-25-3, 2-Bromo-6-methylpyridine
     5469-26-1, 1-Bromo-3,3-dimethyl-2-butanone
                                                   7752-82-1,
                                 20503-40-6 29681-44-5, Methyl
     2-Amino-5-bromopyrimidine
     5-bromonicotinate
                        35216-39-8, 3-(Methylsulfonyl)aniline 40235-68-5,
     3-Chloro-2-oxopropyl acetate 116355-16-9, Imidazo[1,2-a]pyridine-6-carboxaldehyde 132213-07-1, Imidazo[1,2-a]pyridine-6-methanol
```

387350-88-1 1004550-24-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 6188-23-4P 30493-41-5P 138888-98-9P 154877-65-3P 167884-21-1P 372198-69-1P 474706-74-6P 474708-98-0P 865156-68-9P 936638-00-5P

1004550-21-3P 1004550-22-4P 1004550-23-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$  and  $\gamma$  isoforms; preparation of thiazolidinedione derivs. as PI3 kinase inhibitors useful in treatment of diseases)

L32 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 129318-43-0, Fosamax

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

RN 129318-43-0 CAPLUS

CN Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt (1:1) (CA INDEX NAME)

## ● Na

ACCESSION NUMBER: 2008:123834 CAPLUS

DOCUMENT NUMBER: 148:183423

TITLE: Preparation of indole compounds having CRTH2 antagonist activity for treating allergic

diseases, asthma, and inflammatory conditions

INVENTOR(S): Armer, Richard Edward; Wynne, Graham Michael

PATENT ASSIGNEE(S): Oxagen Limited, UK SOURCE: PCT Int. Appl., 68pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIND		DATE		APPLICATION NO.						DATE				
					_													
WO 2008012511					A1		20080131			WO 2007-GB2761						20070720		
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	CA,	
		CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK.	DM,	DO,	DZ.	EC,	EE,	EG,	ES,	FI,	

```
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
            MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:
                                           GB 2006-14608
                                                              A 20060722
                                           GB 2006-24176
                                                              A 20061204
OTHER SOURCE(S):
                       MARPAT 148:183423
     2008:123834 CAPLUS
ΑN
     148:183423
DN
     Entered STN: 31 Jan 2008
ED
     Preparation of indole compounds having CRTH2 antagonist activity for
ΤI
     treating allergic diseases, asthma, and inflammatory conditions
IN
     Armer, Richard Edward; Wynne, Graham Michael
     Oxagen Limited, UK
PA
SO
     PCT Int. Appl., 68pp.
     CODEN: PIXXD2
DT
     Patent
     English
LA
     1-7 (Pharmacology)
CC
     Section cross-reference(s): 27
FAN.CNT 1
     PATENT NO.
                        KIND
                              DATE
                                          APPLICATION NO.
                                                                 DATE
                       ____
                               _____
                                           _____
                              20080131
                                          WO 2007-GB2761
                                                                  20070720
    WO 2008012511
                        A1
PΤ
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
            MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRAI GB 2006-14608
                         Α
                               20060722
     GB 2006-24176
                         Α
                               20061204
CLASS
             CLASS PATENT FAMILY CLASSIFICATION CODES
PATENT NO.
                IPCI
 WO 2008012511
                       C07D0209-10 [I,A]; C07D0209-00 [I,C*]; A61K0031-405
                        [I,A]; A61K0031-403 [I,C*]
                        C07D0209-00 [I,C]; C07D0209-10 [I,A]; A61K0031-403
                 IPCR
                        [I,C]; A61K0031-405 [I,A]
    MARPAT 148:183423
OS
GΙ
```

AB Compds. of general formula I (wherein R is Ph optionally substituted with one or more halo substituents) and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are antagonists at the CRTH2 receptor and are useful in the treatment of conditions mediated by PGD2 or other agonists binding to CRTH2. These include allergic diseases, asthmatic conditions and inflammatory diseases. A process for preparing I was addnl. claimed. Example compound II was prepared by

ΙI

reacting 2-(phenylsulfonyl)benzaldehyde with 2-(5-fluoro-2-methyl-1H-indol-1-yl)acetic acid and saponification of the resulting ester. In an assay measuring

inhibition of 13,14-dihydro-15-keto-prostaglandin D2 induced blood eosinophilia in rats, II had an ED50 of 0.0025  $\mu g/mL$ .

 $\operatorname{ST}$  indole compd prepn  $\operatorname{CRTH2}$  antagonist immune inflammatory disease treatment

IT Bradykinin receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(B1, antagonists, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bradykinin receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(B2, antagonists, as codrugs; preparation of indole compds. having CRTH2
antagonist activity for treating allergic diseases, asthma,
inflammatory conditions, and other diseases)

IT Inflammatory bowel disease

(Crohn's disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Hand

(Dupuytren's disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FLAP (arachidonate lipoxygenase-activating protein), inhibitors as
codrugs; preparation of indole compds. having CRTH2 antagonist activity for
treating allergic diseases, asthma, inflammatory conditions,
and other diseases)

IT Fever and Hyperthermia

(Familial Hibernian fever; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Ulcer

(Hunner's ulcer; preparation of indole compds. having CRTH2 antagonist

activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antihistamines

(H4, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Tumor necrosis factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (IGs as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(IgE, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(Kikuchi disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Monoamine oxidase inhibitors

(MAOB inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(Muckle-Wells syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Muscarinic antagonists

(M1, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Muscarinic antagonists

(M2, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Glutamate antagonists

(NMDA antagonists, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT P2x purinoreceptor antagonists

(P2X7, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)  $\frac{1}{2}$ 

IT Peroxisome proliferators

(PPAR- $\gamma$  agonists as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(Peyronie's; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(Sweet's syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(Weber-Christian syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Allergy

Eye, disease

Inflammation

(allergic conjunctivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Transplant rejection

(allotransplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Edema

(angioneurotic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Spinal column, disease

(ankylosing spondylitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gout

(anti-gout drugs, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-idiotypic, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antitumor agents

(antibiotic, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Cytotoxic agents

(antimetabolites, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mitosis

(antimitotic agents, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibiotics

(antitumor, codrug; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Artery, disease

(aorta, aortitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alopecia

(areata; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(arthropathy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gene therapy

(as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis

(atopic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Autoimmune disease

Inflammation

Thyroid gland, disease

(autoimmune thyroiditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pain

(back; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Leukotrienes

RL: BSU (Biological study, unclassified); BIOL (Biological study) (biosynthesis inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease

Inflammation

(blepharitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Drug delivery systems

(bronchial; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bronchi, disease

(bronchiectasis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bronchi, disease

Inflammation

(bronchitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Fibrosis

(cardiac; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

(cellulitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gallbladder, disease

Inflammation

(cholecystitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease

(choroiditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases,

```
asthma, inflammatory conditions, and other diseases)
    Anti-infective agents
ΤТ
    Antiandrogens
    Antiestrogens
     Aromatase inhibitors
     Cytotoxic agents
     Fungicides
     H1-antihistamines
     H2-antihistamines
     \beta1-Adrenoceptor agonists
     \beta2-Adrenoceptor agonists
     \beta3-Adrenoceptor agonists
        (codrug; preparation of indole compds. having CRTH2 antagonist activity for
        treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
ΤТ
     Anthracyclines
    Antisense oligonucleotides
     Progestogens
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (codrug; preparation of indole compds. having CRTH2 antagonist activity for
        treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
    Angiogenesis inhibitors
     Angiotensin AT2 receptor antagonists
     Angiotensin-converting enzyme inhibitors
     Anti-Alzheimer's agents
     Antidepressants
    Antimicrobial agents
     Antiosteoporotic agents
     Antiparkinsonian agents
    Calcium channel blockers
     Central nervous system agents
     Cholinergic antagonists
     Cyclooxygenase 1 inhibitors
     Cyclooxygenase 2 inhibitors
     Dopamine agonists
     Enzyme inhibitors
     HMG-CoA reductase inhibitors
     Hypolipemic agents
     Immunomodulators
     Leukotriene antagonists
     Nicotinic antagonists
     Platelet aggregation inhibitors
     Uricosuric agents
     \beta-Adrenoceptor antagonists
        (codrugs; preparation of indole compds. having CRTH2 antagonist activity for
        treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
    Corticosteroids, biological studies
ΙT
     Fibrates
     Growth hormone secretagogues
     Interferons
     Platelet-derived growth factors
     Transforming growth factor \beta
     Tumor necrosis factors
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (codrugs; preparation of indole compds. having CRTH2 antagonist activity for
        treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
```

IT Lung, disease

(complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Central nervous system, disease

Peripheral nervous system, disease

(complications of malignant, infectious, or autoimmune disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease

Inflammation

(conjunctivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis

(contact; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eosinophilia

Lymphoma

(cutaneous; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Bladder, disease

Inflammation

(cystitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Neoplasm

(cytokine-transfected tumor cell lines as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Nerve, disease

(degeneration; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mental and behavioral disorders

(dementia; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lupus ervthematosus

(discoid; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Penis

(disease, Peyronie's; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Oviduct

(disease, salpingitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Urethra

(disease, urethritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Joint, anatomical

(disease; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (down regulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(dysplasia; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(eosinophilic paschiitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease

(epidermolysis bullosa; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Reproductive system, disease

(epididymitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Esophagus, disease

Inflammation

(esophagitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Amyloidosis

(familial Mediterranean fever; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Fever and Hyperthermia

(familial Mediterranean; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lung, disease

(farmer's lung; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Heart, disease

(fibrosis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gene therapy

(gene-directed enzyme prodrug therapy, as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Gingiva, disease

Inflammation

(gingivitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Kidney, disease

(glomerulonephritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Tongue, disease

(glossitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis

(herpetiformis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Allergy

Inflammation

Lung, disease

(hypersensitivity pneumonitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Purpura (disease)

(idiopathic thrombocytopenic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Sexual disorders

(impotence; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Growth factor receptors

Growth factors, animal

Urokinase-type plasminogen activator receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Hepatocyte growth factor

Platelet-derived growth factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Cell adhesion molecules

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors, codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Reperfusion

(injury; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pneumonia

(interstitial; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Rheumatoid arthritis

(juvenile; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mouth, disease

Skin, disease

(lichen planus; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Sclerosis

(lichen sclerosis et atrophica; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Transplant and Transplantation

(lung, complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Alopecia

(male pattern; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Interleukin 4

Interleukin 5

RL: BSU (Biological study, unclassified); BIOL (Biological study) (modulators as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (modulators, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antibodies and Immunoglobulins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal, anti-TNF, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Erythema

(multiforme; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Kidney, disease

(nephritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, neoplasm

(non-melanoma; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pharmacokinetics

(of indole compds.; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Ovary, disease

(oophoritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Eye, disease

Inflammation

(ophthalmitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Pancreas, disease

(pancreatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Disease, animal

(panniculitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Neoplasm

(paraneoplastic syndrome; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease

(pemphigoid; preparation of indole compds. having CRTH2 antagonist activity

for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease

(pemphigus; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Pericardium

(pericarditis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Vein, disease

(phlebitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease

(photodermatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Dermatitis

(phytodermatitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Rheumatic diseases

(polymalgia rheumatica; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Nose, neoplasm

(polyp; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT AIDS (disease)

Acne

Addison's disease

Allergy

Allergy inhibitors

Alzheimer's disease

Analgesics

Anti-AIDS agents

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiarthritics

Antiasthmatics

Antidiabetic agents

Antifibrotic agents

Antiphospholipid syndrome

Antirheumatic agents

Antitumor agents

Antitussives

Antiulcer agents

Antiviral agents

Asthma

Atherosclerosis

Autoimmune disease

Behcet's syndrome

Bone, disease

Cardiomyopathy

Cardiovascular agents

Celiac disease

```
Cirrhosis
Connective tissue, disease
Cough
Cystic fibrosis
Dermatological agents
Diabetes mellitus
Drug delivery systems
Eczema
Emphysema
Endocarditis
Fibrosis
Food allergy
Gastrointestinal agents
Graves' disease
Hepatitis
Human
Inflammatory bowel disease
  Ischemia
Leprosy
Mastocytosis
Multiple sclerosis
Myasthenia gravis
Myocarditis
Myositis
Nasal drug delivery systems
Neoplasm
Nervous system agents
Oral drug delivery systems
Osteoarthritis
Pain
Parenteral drug delivery systems
Periodontitis
Proctitis
Psoriasis
Rectal drug delivery systems
Retinal disease
Rheumatic fever
Rheumatoid arthritis
Sarcoidosis
Scleroderma
Seborrhea
Sezary syndrome
Sjogren syndrome
Thrombosis
Topical drug delivery systems
Urticaria
Uveitis
Vaginal drug delivery systems
Vascular restenosis
Vasculitis
   (preparation of indole compds. having CRTH2 antagonist activity for
   treating allergic diseases, asthma, inflammatory conditions,
   and other diseases)
Wound healing
Wound healing promoters
   (promotion of healing without fibrotic scarring; preparation of indole
   compds. having CRTH2 antagonist activity for treating
   allergic diseases, asthma, inflammatory conditions, and other diseases)
Inflammation
Prostate gland, disease
   (prostatitis; preparation of indole compds. having CRTH2 antagonist activity
```

ΙT

ΙT

for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Pruritus

(pruritus ani; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis

(psoriatic arthritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Antihypertensives

Hypertension

(pulmonary; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease

(pyoderma, pyoderma gangrenosum; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis

(reactive; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Injury

(reperfusion; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

Nose, disease

(rhinitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Inflammation

(salpingitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Skin, disease

(sarcoid; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis

(septic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Spinal column, disease

(spondyloarthropathy, undifferentiated spondarthropathy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Mast cell

(stabilizers as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Arthritis

Synovial membrane, disease

(synovitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

IT Lupus erythematosus

(systemic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases)

Erythema ΤТ (toxic; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΤТ Animal cell (transfected immune cells as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙΤ Lung (transplant, complications of lung transplant; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Interleukin 2 Interleukin 4 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tumor cell transfection with interleukins as cotherapy; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) Prostanoid receptors ΤT RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (type DP2; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Tachykinin receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (type NK1, inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΤТ Tachykinin receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (type NK3, inhibitors, as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Inflammatory bowel disease (ulcerative colitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Colitis (ulcerative; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Inflammation (urethritis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Heart, disease (valvulitis; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Drugs (vascular damaging agents as codrugs; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) ΙT Lung, disease (vasculitic and thrombotic disorders; preparation of indole compds. having CRTH2 antagonist activity for treating allergic diseases, asthma, inflammatory conditions, and other diseases) Alkaloids, biological studies ΙT

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

```
(Biological study); USES (Uses)
   (vinca, codrug; preparation of indole compds. having CRTH2 antagonist
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
Infection
   (viral; preparation of indole compds. having CRTH2 antagonist activity for
   treating allergic diseases, asthma, inflammatory conditions,
   and other diseases)
Vagina, disease
   (vulvovaginitis; preparation of indole compds. having CRTH2 antagonist
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (\alpha v \beta 3, inhibitors, as codrugs; preparation of indole compds.
   having CRTH2 antagonist activity for treating allergic
   diseases, asthma, inflammatory conditions, and other diseases)
Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (\alpha 4\beta 1), antagonists, as codrugs; preparation of indole compds.
   having CRTH2 antagonist activity for treating allergic
   diseases, asthma, inflammatory conditions, and other diseases)
Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (\beta, codrugs; preparation of indole compds. having CRTH2 antagonist
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
\beta-Adrenoceptor agonists
   (\beta 4, \text{ as codrugs; preparation of indole compds. having CRTH2 antagonist}
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
141579-87-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (Abbott 79175, codrugs; preparation of indole compds. having CRTH2
   antagonist activity for treating allergic diseases, asthma,
   inflammatory conditions, and other diseases)
65154-06-5, Platelet activating factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (antagonists, as codrugs; preparation of indole compds. having CRTH2
   antagonist activity for treating allergic diseases, asthma,
   inflammatory conditions, and other diseases)
50-07-7, Mitomycin-C
                     50-18-0, Cyclophosphamide
                                                   50-33-9,
Phenylbutazone, biological studies 50-76-0, Dactinomycin
        51-21-8, 5-Fluorouracil
                                   52-67-5, D-Penicillamine 53-86-1,
Aspirin
                                          55-98-1, Busulfan
               55-86-7, Nitrogen mustard
Indomethacin
              58-55-9, Theophylline, biological studies 59-05-2,
Vincristine
              59-42-7, Phenylephrine 61-68-7 90-82-4, Pseudoephedrine
Methotrexate
101-40-6, Propylhexedrine 113-92-8 118-42-3, Hydroxychloroguine
127-07-1, Hydroxyurea 147-94-4, Cytosine arabinoside
                                                        148-82-3,
           305-03-3, Chlorambucil 317-34-0, Aminophylline
Melphalan
                                                              427-51-0,
Cyproterone acetate 446-86-6, Azathioprine
                                               522-48-5, Tetrahydrozoline
                550-99-2, Naphazoline hydrochloride
                                                      586-06-1,
hydrochloride
                 595-33-5, Megestrol acetate
                                             865-21-4, Vinblastine
Metaproterenol
1218-35-5, Xylometazoline hydrochloride 2315-02-8, Oxymetazoline
hydrochloride
               3198-07-0
                            5104-49-4, Flurbiprofen
                                                      6569-51-3, Borazole
6990-06-3, Fusidic acid 7683-59-2, Isoproterenol 7689-03-4,
Camptothecin 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13311-84-7,
Flutamide 13539-59-8, Apazone 14838-15-4, Phenylpropanolamine
15307-86-5, Diclofenac 15663-27-1, Cisplatin 15687-27-1, Ibuprofen
```

TΤ

ΙΤ

ΙΤ

ΙT

ΙT

ΙT

TΤ

ΙT

ΙT

```
18559-94-9, Albuterol 20830-81-3, Daunomycin 22071-15-4, Ketoprofen
     22204-53-1, Naproxen 23031-25-6, Terbutaline
                                                      23214-92-8, Doxorubicin
     23593-75-1, Clotrimazole 25316-40-9, Adriamycin 29679-58-1, Fenoprofen
     29767-20-2, Teniposide 30392-41-7, Bitolterol mesylate 30516-87-1, AZT
     33069-62-4, Paclitaxel 33419-42-0, Etoposide 34031-32-8, Auranofin
     36322-90-4, Piroxicam 38194-50-2, Sulindac 38677-81-5, Pirbuterol
     41575-94-4, Carboplatin 51264-14-3, Amsacrine 53123-88-9, Rapamycin
     53643-48-4, Vindesine 53714-56-0, Leuprorelin 56420-45-2, Epirubicin
     57982-77-1, Buserelin
                            58581-89-8, Azelastine 58957-92-9, Idarubicin
     59277-89-3, Acyclovir 59865-13-3, Cyclosporine 63612-50-0, Nilutamide
     63798-73-2, Cyclosporin E 65807-02-5, Goserelin 68844-77-9, Astemizole
     71125-38-7, Meloxicam 71486-22-1, Vinorelbine 73573-87-2, Formoterol
     75706-12-6, Leflunomide 79794-75-5, Loratidine 82413-20-5, Droloxifene
     83799-24-0, Fexofenadine 83881-51-0, Cetirizine 89365-50-4, Salmeterol
     89778-26-7, Toremifene 90357-06-5, Bicalutamide 94055-76-2, Suplatast
     tosylate 95058-81-4, Gemcitabine 98319-26-7, Finasteride 100643-71-8
     104227-87-4 104987-11-3, Tacrolimus 107868-30-4, Exemestane
     112809-51-5, Letrozole 112887-68-0, Raltitrexed 114977-28-5, Taxotere
     116057-75-1 117048-59-6, Combretastatin A4 120511-73-1
                                                                123948-87-8,
     Topotecan 126544-47-6, Ciclesonide 129453-61-8, Fulvestrant
     137071-32-0, Pimecrolimus 154039-60-8, Marimastat 159989-65-8,
     Viracept 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 180288-69-1,
     Trastuzumab 181695-72-7, Valdecoxib 202409-33-4, Etoricoxib
     205923-56-4, Cetuximab 242138-07-4, Omalizumab
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (codrug; preparation of indole compds. having CRTH2 antagonist activity for
        treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
ΙT
     50-24-8, Prednisolone
                           53-03-2, Prednisone 57-66-9, Probenecid
     57-96-5, Sulfinpyrazone 59-92-7, biological studies 64-86-8,
     Colchicine 76-25-5, Triamcinolone acetonide 315-30-0, Allopurinol
     321-64-2, Tacrine 404-86-4, Capsaicin 2323-36-6, Deprenyl 3385-03-3,
     Flunisolide 3562-84-3, Benzbromarone 5534-09-8, Beclomethasone
     dipropionate 7440-57-5D, Gold, compds. 9004-08-4, Cathepsin
     9004-61-9, Synvisc
                        9067-32-7, Hyalgan 14611-51-9, Selegiline
     22254-24-6, Ipratropium bromide 28797-61-7, Pirenzepine 30286-75-0,
     Oxitropium bromide
                         51333-22-3, Budesonide 55242-55-2, Propentofylline
     62031-54-3, Fibroblast growth factor 79617-96-2, Sertraline
     80474-14-2, Fluticasone propionate 80880-90-6, Telenzepine
                                                                    83869-56-1,
     Colony-stimulating factor 2 83919-23-7, Mometasone furoate 84088-42-6,
     Linomide 84449-90-1 91374-20-8, Requip 93211-49-5, L-651392
     96566-25-5, Ablukast 103177-37-3, Pranlukast 103475-41-8, Tepoxalin
     106096-93-9, Basic fibroblast growth factor 107753-78-6, Zafirlukast
                                                 120014-06-4, Donepezil
     111406-87-2, Zileuton 118414-82-7, MK-886
     120128-20-3, RG-12525
                           120443-16-5, Verlukast 122320-73-4,
     Rosiglitazone 128312-51-6, Ro-24-5913 129318-43-0, Fosamax
     134308-13-7, Tasmar 136236-51-6, Rasagiline 136310-93-5, Tiotropium
              140841-32-3, ZD2138 141579-54-6, Fenleuton 143538-27-6, BAY
     bromide
                                  147398-01-4, CGS-25019c
                                                             147432-77-7,
     x 7195
             147030-01-1, MK-591
     Ontazolast 151581-24-7, Iralukast 153259-65-5, Cilomilast
     154355-76-7, ABT-761 158930-07-5, L-739010 158966-92-8, Montelukast
    162750-10-9, SB-210661 168154-07-2, L-746530 171964-73-1, Z 174636-32-9, Talnetant 180916-16-9, Lasofoxifene 183321-74-Erlotinib 184475-35-2, Gefitinib 188039-54-5, Palivizumab 191217-81-9, Mirapex 204974-93-6, BIIL 284/260 216974-75-3,
                             168154-07-2, L-746530 171964-73-1, ZD-0892
                                                         183321-74-6,
     Bevacizumab
                 257892-34-5, D-4418 289499-45-2, CI 1033
                                                               350610-64-9,
     NKP 608C 446023-33-2, UT 77
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
```

15826-37-6, Sodium cromoglycate 17902-23-7, Tegafur 18378-89-7

```
(codrugs; preparation of indole compds. having CRTH2 antagonist activity for
   treating allergic diseases, asthma, inflammatory conditions,
   and other diseases)
1004293-19-9P, 2-[5-Fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1H-indol-
1-y1] acetic acid 1004293-21-3P, 2-[3-[2-(4-Chlorophenylsulfonyl)benzyl]-
5-fluoro-2-methyl-1H-indol-1-yl]acetic acid
                                            1004293-24-6P,
2-[5-Fluoro-3-[2-(4-fluorophenylsulfonyl)benzyl]-2-methyl-1H-indol-1-
yl]acetic acid
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
   (drug candidate; preparation of indole compds. having CRTH2 antagonist
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
9025-82-5, Phosphodiesterase
                             9026-43-1 9036-21-9, PDE4
                                                             62229-50-9,
Epidermal growth factor 79079-06-4, EGF receptor tyrosine kinase
80449-02-1 131384-38-8, Farnesyl transferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors as codrugs; preparation of indole compds. having CRTH2
   antagonist activity for treating allergic diseases, asthma,
   inflammatory conditions, and other diseases)
9004-06-2, Elastase 9081-34-9, 5\alpha Reductase
                                                80449-01-0,
Topoisomerase 80619-02-9, 5-Lipoxygenase 81669-70-7 86090-08-6,
             151769-16-3, TACE
Angiostatin
                                501433-35-8, INOS
                                                    506430-87-1,
Neuronal nitric oxide synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors, as codrugs; preparation of indole compds. having CRTH2
   antagonist activity for treating allergic diseases, asthma,
   inflammatory conditions, and other diseases)
           9012-25-3, Catechol methyltransferase
                                                  141907-41-7
9001-66-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (inhibitors, as codrugs; preparation of indole compds. having CRTH2
   antagonist activity for treating allergic diseases, asthma,
   inflammatory conditions, and other diseases)
9039-48-9, Aromatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors, codrug; preparation of indole compds. having CRTH2 antagonist
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
9001-40-5, Glucose-6-phosphate dehydrogenase
                                               9002-17-9, Xanthine oxidase
9015-82-1
           9028-35-7
                       9028-93-7, Inosine monophosphate dehydrogenase
97501-93-4, Tryptase
                      122191-40-6, Interleukin converting enzyme
                           329967-85-3
142243-02-5
             329900-75-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors, codrugs; preparation of indole compds. having CRTH2 antagonist
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
67763-96-6, Insulin-like growth factor I
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (mimetics as codrugs; preparation of indole compds. having CRTH2 antagonist
   activity for treating allergic diseases, asthma, inflammatory
   conditions, and other diseases)
9034-40-6, Luteinizing hormone-releasing factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (modulators as codrugs; preparation of indole compds. having CRTH2
```

ΙT

ΙT

ΤТ

TΤ

ΙT

TΤ

ΤТ

ΙT

41598-07-6, Prostaglandin D2 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

antagonist activity for treating allergic diseases, asthma,

inflammatory conditions, and other diseases)

```
treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
     371-42-6, 4-Fluorobenzenethiol 446-52-6, 2-Fluorobenzaldehyde
ΙT
     873-55-2, Benzenesulfinic acid sodium salt 107572-07-6,
     2-(4-Chlorophenylthio)benzaldehyde 646515-46-0, 2-(5-Fluoro-2-methyl-1H-
     indol-1-yl)acetic acid
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of indole compds. having CRTH2 antagonist activity for
        treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
     126076-76-4P, 2-(Phenylsulfonyl)benzaldehyde 643763-14-8P,
     2-(4-Fluorophenylthio)benzaldehyde 1004293-20-2P 1004293-22-4P,
     2-(4-Chlorophenylsulfonyl)benzaldehyde 1004293-23-5P, Ethyl
     2-[3-[[2-(4-chlorophenylsulfonyl)phenyl]methyl]-5-fluoro-2-methyl-1H-indol-
                  1004293-25-7P
                                    1004293-26-8P, 1-(Dimethoxymethyl)-2-(4-
     1-yl]acetate
     fluorophenylsulfonyl)benzene
                                    1004293-27-9P,
     2-(4-Fluorophenylsulfonyl)benzaldehyde 1004293-28-0P, Ethyl
     2-[5-fluoro-3-[[2-(4-fluorophenylsulfonyl)phenyl]methyl]-2-methyl-1H-indol-
     1-yl]acetate
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of indole compds. having CRTH2 antagonist activity for
        treating allergic diseases, asthma, inflammatory conditions,
        and other diseases)
     51-61-6, Dopamine, biological studies
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (reuptake inhibitors, as codrugs; preparation of indole compds. having CRTH2
        antagonist activity for treating allergic diseases, asthma,
        inflammatory conditions, and other diseases)
             THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 3
(1) Bach Nicholas J; US 5641800 A 1997 CAPLUS
(2) Boyd; WO 2005044260 A 2005 CAPLUS
(3) Shionogi & Co; EP 1505061 A1 2005 CAPLUS
L32 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ΙT
     129318-43-0, Fosamax
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (integrin-binding small mols. for treatment of diseases and
        combination with other agents)
RN
     129318-43-0 CAPLUS
CN
     Phosphonic acid, P,P'-(4-amino-1-hydroxybutylidene)bis-, sodium salt (1:1)
       (CA INDEX NAME)
      ОН
H_2O_3P-C-(CH_2)_3-NH_2
      PO3H2
```

(preparation of indole compds. having CRTH2 antagonist activity for

Na

ACCESSION NUMBER: 2007:563324 CAPLUS

DOCUMENT NUMBER: 147:2055

TITLE: Integrin-binding small molecules

Neamati, Nouri; Dayam, Raveendra INVENTOR(S):

PATENT ASSIGNEE(S): University of Southern California, USA

PCT Int. Appl., 112pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
KIND DATE
     PATENT NO.
                                           APPLICATION NO.
                        ----
                                          _____
     WO 2007059195
                         A1 20070524 WO 2006-US44305 20061114
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
                     A1 20070705
     US 20070155750
                                             US 2006-559857
                                                                     20061114
                                             US 2005-736780P P 20051114
PRIORITY APPLN. INFO.:
OTHER SOURCE(S):
                        MARPAT 147:2055
ΑN
    2007:563324 CAPLUS
DN
     147:2055
ED
     Entered STN: 24 May 2007
     Integrin-binding small molecules
ΤI
ΙN
     Neamati, Nouri; Dayam, Raveendra
     University of Southern California, USA
PA
SO
     PCT Int. Appl., 112pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
CC
     1-12 (Pharmacology)
FAN.CNT 1
                       KIND DATE APPLICATION NO. DATE
     PATENT NO.
                        ____
     WO 2007059195 A1 20070524
                                          WO 2006-US44305 20061114
PΤ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
                     A1 20070705
P 20051114
     US 20070155750
                                            US 2006-559857
                                                                     20061114
PRAI US 2005-736780P
                         P
                                20051114
CLASS
 PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
 _____
                ____
 WO 2007059195 IPCI A61K0031-52 [I,A]; A61K0031-519 [I,C*]; A61K0031-517
                        [I,A]
```

```
TPCR
                        A61K0031-519 [I,C]; A61K0031-52 [I,A]; A61K0031-517
                        [I,C]; A61K0031-517 [I,A]
 US 20070155750
                IPCI
                        A61K0031-519 [I,A]; A61K0031-525 [I,A]
                 IPCR
                        A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-525
                        [I,A]
                 NCL
                        514/249.000; 514/251.000; 514/264.100
OS
    MARPAT 147:2055
     The present invention relates in general to integrin-binding small mols.
AΒ
     More specifically, the invention provides novel compns. and methods of
     using these compns. for treating various diseases. Accordingly,
     in one aspect, the invention features a composition comprising a compound, or a
     pharmaceutically or cosmeceutically acceptable salt, solvate, or hydrate
     thereof, wherein the compound comprises one H-bond donor (HBD), one H-bond
     acceptor (HBA), two hydrophobic aromatic groups (HAR1 and HAR2), and one neg.
     ionizable group (NI).
ST
     integrin binding mol disease treatment
     Inflammatory bowel disease
ΙT
        (Crohn's disease; integrin-binding small mols. for treatment
        of diseases and combination with other agents)
     Bone, disease
ΤT
        (Paget's; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Blood vessel, disease
        (adhesion; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
     Respiratory distress syndrome
ΙT
        (adult; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Retinal disease
        (age-related macular degeneration; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
     Thrombosis
ТТ
        (arterial; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Disease, animal
        (arthropathy, hemophilic; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΙT
     Dermatitis
        (atopic; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
     Cardiovascular system
ΙT
     Immune system
     Inflammation
     Vascular endothelium
        (cells, integrins of; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΤТ
        (cerebral artery; integrin-binding small mols. for treatment
        of diseases and combination with other agents)
ΙT
     Ischemia
        (cerebral; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Gastroenteritis
        (chronic; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΤТ
     Estrogens
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (conjugated, Premarin; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
     Dermatitis
ΤТ
```

(contact; integrin-binding small mols. for treatment of diseases and combination with other agents) Transplant and Transplantation ΤТ (cornea, neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT (cornea, transplant, neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Radiation (damage, dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Dermatitis (dermatitis exfoliativa neonatorum; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Cosmetics and personal care products IR radiation Ionizing radiation UV radiation (dermatitis from; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Toxicity (dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Retinal disease (diabetic retinopathy, proliferative; integrin-binding small mols. for treatment of diseases and combination with other agents) TT Joint, anatomical (disease, hemophilic; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Mucous membrane (disease, inflammation; integrin-binding small mols. for treatment of diseases and combination with other agents) TΤ Lung, disease (embolism; integrin-binding small mols. for treatment of diseases and combination with other agents) TΤ Hyperplasia (endometrial; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Uterus, disease (endometriosis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Uterus, disease (endometrium, hyperplasia; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤТ Skin, disease (erythematosquamous dermatosis; integrin-binding small mols. for treatment of diseases and combination with other agents) Gingiva, disease ΙT Inflammation (gingivitis; integrin-binding small mols. for treatment of diseases and combination with other agents) TΤ Wound (granulation; integrin-binding small mols. for treatment of diseases and combination with other agents) Uterus, disease ΤT (hemorrhage; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Dermatitis (herpetiformis; integrin-binding small mols. for treatment of diseases and combination with other agents) Muscle, disease TΤ

```
(idiopathic inflammatory myopathy; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΤТ
     Blood vessel
        (imaging agents for; integrin-binding small mols. for treatment
        of diseases and combination with other agents)
     Radionuclides, biological studies
ΙT
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (imaging agents; integrin-binding small mols. for treatment
        of diseases and combination with other agents)
ΙT
     Platelet activation
        (inappropriate; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Adenoviridae
     Bunyaviridae
     Foot-and-mouth disease virus
     Hantavirus
     Human coxsackievirus
     Human echovirus
     Human immunodeficiency virus 1
     Human parechovirus
     Picornaviridae
     Reoviridae
     Retroviridae
     Rotavirus
        (infection, integrins in; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΙT
     Vascular restenosis
        (inhibitors; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Adhesion, biological
     Allergy
     Allergy inhibitors
     Angiogenesis
       Angiogenesis inhibitors
     Angioplasty
     Animalia
     Animals
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiarteriosclerotics
     Antiarthritics
     Antiasthmatics
     Anticoagulants
    Antiosteoporotic agents
     Antirheumatic agents
     Antitumor agents
     Arterial occlusion
     Arteriosclerosis
     Asthma
     Atherectomy
     Autoimmune disease
     Blood vessel, disease
     Combination chemotherapy
     Coronary artery disease
     Coronary bypass surgery
     Coronary thrombosis
     Cosmetics and personal care products
     Dermatitis
     Dermatomyositis
```

Drug screening

```
Duodenitis
Eczema
Embolism
Erythema
Eye, neoplasm
Gastritis
Hemangioma
Hematopoietic neoplasm
Hodgkin's disease
Human
Imaging agents
Immune disease
Inflammation
Inflammatory bowel disease
  Ischemia
Keloid
Leukemia
Mucosal drug delivery systems
Multiple myeloma
Multiple sclerosis
Myeloproliferative disorders
Myocardial infarction
Myocardial ischemia
Neoplasm
Non-Hodgkin lymphoma
Oral drug delivery systems
Osteoporosis
Parenteral drug delivery systems
Pharmaceutical carriers
Preeclampsia
Psoriasis
Radiopharmaceuticals
Rectal drug delivery systems
Rheumatoid arthritis
Seborrhea
Stroke
Sunburn
Telangiectasia
Thrombosis
Transdermal drug delivery systems
Transplant rejection
Uveitis
Wart
   (integrin-binding small mols. for treatment of diseases and
   combination with other agents)
Integrins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
unclassified); BIOL (Biological study)
   (integrin-binding small mols. for treatment of diseases and
   combination with other agents)
Thrombospondins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (integrin-binding small mols. for treatment of diseases and
   combination with other agents)
Tumor necrosis factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (integrin-binding small mols. for treatment of diseases and
   combination with other agents)
Structure-activity relationship
```

ΤТ

ΙT

ΙT

ΤT

(integrin-binding; integrin-binding small mols. for treatment of diseases and combination with other agents) Animal cell ΤТ Dendritic cell Leukocyte Macrophage Osteoclast Stromal cell Vascular smooth muscle (integrins of; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤТ Ervthema (intertrigo; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Drug delivery systems (intradermal; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Eye, disease (iris erythema; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤТ Brain, disease (ischemia, transient; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Brain, disease Lung, disease (ischemia; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Hemophilia (joint disease; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Dermatitis (juvenile; integrin-binding small mols. for treatment of diseases and combination with other agents) Skin, disease ΙT (lichen planus; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Retinal disease (macular degeneration; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Bone, neoplasm (metastasis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Inflammation (mucous membrane; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤТ Erythema (multiforme; integrin-binding small mols. for treatment of diseases and combination with other agents) TΤ Myeloproliferative disorders (myelofibrosis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Eye, disease (neovascularization, choroidal and iris; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤT Angiogenesis (neovascularization, eye, choroidal and iris; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Angiogenesis (neovascularization, heart; integrin-binding small mols. for

treatment of diseases and combination with other agents)

Heart, disease ΤТ (neovascularization; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Dermatitis (neurodermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Eve, disease Inflammation (ophthalmitis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤТ Keratosis (parakeratosis, variegate; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Bone, disease (pathol. resorption; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Allergy (photoallergic contact dermatitis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤT Dermatitis (photoallergic contact; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Myositis (polymyositis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Retinal disease (prematurity-associated; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Arthritis (psoriatic arthritis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤТ Embolism Ischemia (pulmonary; integrin-binding small mols. for treatment of diseases and combination with other agents) TΤ Granuloma (pyogenic; integrin-binding small mols. for treatment of diseases and combination with other agents) Skin, disease ΤT (rosacea; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Pharmaceutical injections (s.c. injections; integrin-binding small mols. for treatment of diseases and combination with other agents) Connective tissue, disease ΤТ (s.c., inflammation; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Neoplasm (solid; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Skin, disease (staphylococcal scalded-skin syndrome; integrin-binding small mols. for treatment of diseases and combination with other agents) Medical goods ΤТ (stents, placement; integrin-binding small mols. for treatment of diseases and combination with other agents) ΙT Skin, disease (subcorneal pustular dermatosis; integrin-binding small mols. for treatment of diseases and combination with other agents) ΤТ Surgery (thrombosis in; integrin-binding small mols. for treatment of

```
diseases and combination with other agents)
ΤТ
     Ischemia
        (transient cerebral; integrin-binding small mols. for treatment
        of diseases and combination with other agents)
     Blood vessel, disease
ΤТ
        (transplant vasculopathy; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΙT
     Inflammatory bowel disease
        (ulcerative colitis; integrin-binding small mols. for treatment
        of diseases and combination with other agents)
ΤТ
     Colitis
        (ulcerative; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Angina pectoris
        (unstable; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Adhesion, biological
        (vascular; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΤT
     Thrombosis
        (venous; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Infection
        (viral, integrins in; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΙT
     Granulation
        (wound; integrin-binding small mols. for treatment of
        diseases and combination with other agents)
ΙT
     Integrins
     RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
     unclassified); BIOL (Biological study)
        (\alpha v\beta 3; integrin-binding small mols. for treatment
        of diseases and combination with other agents)
TТ
     9002-64-6, Parathormone
     RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
     unclassified); BIOL (Biological study)
        (hypercalcemia mediated by; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΙT
     7440-70-2, Calcium, biological studies
     RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
     unclassified); BIOL (Biological study)
        (hypercalcemia, parathormone-mediated; integrin-binding small mols. for
        treatment of diseases and combination with other agents)
ΙT
     50-18-0, Cyclophosphamide
                               50-28-2, Climara, biological studies
     50-35-1, Thalidomide
                            57-22-7, Vincristine
                                                   362-07-2, 2-Methoxyestradiol
                          3275-78-3
                                                  7414-83-7, Didronel
     1084-65-7, Arresten
                                     4323-02-8
                       9007-12-9, Calcitonin 10098-06-3 15663-27-1,
     8015-12-1, Femhrt
                23214-92-8, Doxorubicin 24045-19-0
                                                       33069-62-4, Paclitaxel
     Cisplatin
     47931-85-1, Miacalcin 57248-88-1, Aredia 77728-33-7, Combipatch
     82640-04-8, Evista 82855-09-2, Combretastatin
                                                     86090-08-6, Angiostatin
     115436-72-1, Actonel 123948-87-8, Topotecan 129318-43-0,
              134461-48-6, Prefest 135843-32-2, Prempro
                                                             181427-78-1, NM-3
     187888-07-9, Endostatin 216974-75-3, Bevacizumab 232927-14-9
                  309732-80-7
     292034-65-2
                                 309949-29-9
                                               311795-57-0
                                                             312747-18-5
                                 353774-36-4
     326906-42-7
                  328130-39-8
                                               354125-43-2
                                                             354144-06-2
                                425664-72-8
                                              439946-76-6
     364623-94-9
                  385398-46-9
                                                             442150-15-4
                                             501108-10-7
     443876-79-7
                  500261-75-6
                                500577-98-0
                                                             501347-80-4
     593274-97-6
                  642000-26-8
                                670240-89-8
                                             675168-61-3
                                                           850544-78-4,
     Tumstatin 851717-89-0 892553-42-3, Vitaxin
                                                      905811-52-1
     906449-76-1, Canstatin 937237-42-8 937237-43-9
                                                        937237-44-0
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
```

(Biological study); USES (Uses) (integrin-binding small mols. for treatment of diseases and combination with other agents) THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 3 RE (1) Baell; Journal of Computer-Aided Molecular Design 2002, V16, P245 CAPLUS (2) Genentech Inc; WO 9845331 A2 1998 CAPLUS (3) Lee; Journal of Medicinal Chemistry 1974, V17(3), P326 CAPLUS L32 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN 301166-54-1, Protein, PTEN ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) 301166-54-1 CAPLUS RN Phosphatase, gene PTEN (CA INDEX NAME) CN \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* ACCESSION NUMBER: 2007:357681 CAPLUS DOCUMENT NUMBER: 146:357244 TITLE: Dual variable domain immunoglobulins and multispecific derivatives for treating acute and chronic inflammation, cancer and other diseases INVENTOR(S): Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.; Salfeld, Jochen G. PATENT ASSIGNEE(S): USA SOURCE: U.S. Pat. Appl. Publ., 126pp. CODEN: USXXCO DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE \_\_\_\_\_ \_\_\_\_ \_\_\_\_\_ A1 20070329 US 2006-507050 A2 20080228 WO 2007-US17340 US 20070071675 20060818 WO 2008024188 20070803 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM P 20050819 PRIORITY APPLN. INFO.: US 2005-709911P US 2005-732892P P 20051102 US 2006-507050 A 20060818 2007:357681 CAPLUS ΑN 146:357244 DN Entered STN: 30 Mar 2007 EDΤI Dual variable domain immunoglobulins and multispecific derivatives for treating acute and chronic inflammation, cancer and other diseases

Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.; Salfeld, Jochen G.

ΙN

PΑ

SO

USA

U.S. Pat. Appl. Publ., 126pp.

```
CODEN: USXXCO
DT
     Patent
LA
     English
INCL 424001490; 530388800; 530391100; 530388220; 424155100; 424178100;
     435069100; 435326000; 435252300; 435254210
     15-3 (Immunochemistry)
     Section cross-reference(s): 1, 2, 3, 63
FAN.CNT 1
     PATENT NO.
                       KIND DATE
                                       APPLICATION NO.
                        ____
     _____
                                           -----
                        A1 20070329 US 2006-507050 20060818
A2 20080228 WO 2007-US17340 20070803
     US 20070071675
PΤ
     WO 2008024188
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
                             20050819
PRAI US 2005-709911P P
                        P
     US 2005-732892P
                                20051102
     US 2006-507050
                        А
                                20060818
CLASS
 PATENT NO.
             CLASS PATENT FAMILY CLASSIFICATION CODES
 US 20070071675 INCL
                        424001490; 530388800; 530391100; 530388220; 424155100;
                        424178100; 435069100; 435326000; 435252300; 435254210
                        A61K0051-00 [I,A]; C07H0021-04 [I,A]; C07H0021-00
                 TPCT
                        [I,C*]; C12P0021-06 [I,A]; C12N0001-21 [I,A];
                        C12N0001-18 [I,A]; C12N0005-06 [I,A]
                 IPCR
                        A61K0051-00 [I,C]; A61K0051-00 [I,A]; C07H0021-00
                        [I,C]; C07H0021-04 [I,A]; C12N0001-18 [I,C];
                        C12N0001-18 [I,A]; C12N0001-21 [I,C]; C12N0001-21
                        [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A];
                        C12P0021-06 [I,C]; C12P0021-06 [I,A]
                 NCL
                        424/001.490; 424/155.100; 424/178.100; 435/069.100;
                        435/252.300; 435/254.210; 435/326.000; 435/348.000;
                        530/388.220; 530/388.800; 530/391.100; 536/023.530
                 ECLA
                        K61K; M07K; M07K; M07K
 WO 2008024188
                        A61K0051-00 [I,A]; C07H0021-04 [I,A]; C07H0021-00
                 IPCI
                        [I,C*]; C12P0021-06 [I,A]; C12N0001-21 [I,A];
                        C12N0001-18 [I,A]; C12N0005-06 [I,A]
                        A61K0051-00 [I,C]; A61K0051-00 [I,A]; C07H0021-00
                 IPCR
                        [I,C]; C07H0021-04 [I,A]; C12N0001-18 [I,C];
                        C12N0001-18 [I,A]; C12N0001-21 [I,C]; C12N0001-21
                        [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A];
                        C12P0021-06 [I,C]; C12P0021-06 [I,A]
AΒ
     The present invention relates to engineered multivalent and multispecific
     binding proteins, methods of making, and specifically to their uses in the
     prevention and/or treatment of acute and chronic inflammatory
     and other diseases.
     dual variable domain humanized chimeric multispecific antibody
ST
     inflammation cancer
ΤТ
     Gram-negative bacteria
        (-caused sepsis; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic inflammation, cancer and
```

other diseases) ΤТ Drugs (-induced interstitial lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Antibodies and Immunoglobulins IT RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (-mediated cytotoxicity; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Toll-like receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΤТ Cadherins RL: BSU (Biological study, unclassified); BIOL (Biological study) (12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΤT Glycoproteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (130; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Cadherins RL: BSU (Biological study, unclassified); BIOL (Biological study) (13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Cadherins RL: BSU (Biological study, unclassified); BIOL (Biological study) (18; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΤТ Cadherins Keratins RL: BSU (Biological study, unclassified); BIOL (Biological study) (19; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Keratins Syndecans Thrombospondins RL: BSU (Biological study, unclassified); BIOL (Biological study) (1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΤТ Cadherins RL: BSU (Biological study, unclassified); BIOL (Biological study) (20; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Interleukin receptors ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (21; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Interleukin receptors ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (22  $\alpha$ ; dual variable domain Igs and multispecific derivs . for treating acute and chronic inflammation, cancer and other diseases) Interleukin receptors TΤ RL: BSU (Biological study, unclassified); BIOL (Biological study) (22; dual variable domain Igs and multispecific derivs. for treating

```
acute and chronic inflammation, cancer and other diseases)
ΤТ
     Interleukin receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (22\alpha2; dual variable domain Igs and multispecific derivs
        . for treating acute and chronic inflammation, cancer and
        other diseases)
ΙT
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (25; dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
        diseases)
ΤТ
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (26; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΤТ
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (27; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΤT
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (27w; C19orf10; dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
        diseases)
ΙT
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (28B; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΙT
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (28\alpha; dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
        diseases)
ΙΤ
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (29; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΙT
     Thrombospondins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (2; dual variable domain Iqs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΙT
    Keratins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (2A; dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
        diseases)
ΤТ
     Interleukins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (30; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
IΤ
     Metallothioneins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (3; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΤT
     Thrombospondins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (4; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
     Cadherins
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (5; dual variable domain Igs and multispecific derivs. for
```

treating acute and chronic inflammation, cancer and other diseases) Insulin-like growth factor-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Cadherins RL: BSU (Biological study, unclassified); BIOL (Biological study) (7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) RL: BSU (Biological study, unclassified); BIOL (Biological study) (8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Cadherins RL: BSU (Biological study, unclassified); BIOL (Biological study) (9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Cyclins RL: BSU (Biological study, unclassified); BIOL (Biological study) (A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (A1CDA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Interleukin 10 receptors Interleukin 11 receptors Interleukin 12 RL: BSU (Biological study, unclassified); BIOL (Biological study) (A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ABCF1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ACVR1; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ACVR1B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ACVR2; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ACVR2B; dual variable domain Igs and multispecific derivs. for

IT Proteins

other diseases)

ΤТ

ΙT

ΤТ

ΤТ

ΙT

ΙT

TΤ

ΙT

ΙT

ΤТ

ΤТ

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ACVRL1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and

treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ADAM8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ADORA2A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AGR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AIF1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AIG1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AKAP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AKAP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AMH; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AMHR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPT1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPT2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPTL3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ANGPTL4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins

```
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (ANPEP; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Interleukin 1 receptors
Interleukin 18 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (AP; dual variable domain Iqs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
  diseases)
Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (APL1; dual variable domain Igs and multispecific derivs. for treating
   acute and chronic inflammation, cancer and other diseases)
Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (APL2; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (APOC1; dual variable domain Igs and multispecific derivs. for treating
   acute and chronic inflammation, cancer and other diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (AR; dual variable domain Igs and multispecific derivs. for treating
   acute and chronic inflammation, cancer and other diseases)
Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (AZGP1; dual variable domain Igs and multispecific derivs. for treating
   acute and chronic inflammation, cancer and other diseases)
Interleukin 12 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (B1; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and
   other diseases)
Interleukin 12 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (B2; dual variable domain Iqs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
  diseases)
Interleukin 10 receptors
Interleukin 12
Interleukin 17
Lipophilins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (B; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
  diseases)
Cytokines
Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (BAFF; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Bcl2-associated athanogene proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (BAG-1; dual variable domain Igs and multispecific derivs.
   for treating acute and chronic inflammation, cancer and other
  diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
```

ΤТ

ΤТ

ΙT

ΙT

ΙT

ΙT

ΙT

TΤ

ΙT

ΤТ

TΤ

ΙΤ

(BAI1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BCA-1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BLNK (B-cell linker); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BLR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 18

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BRAK; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BRCA1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BTNO2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Bad; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Bcl-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (BlyS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (C-X-C, GCP-2 (granulocyte chemotactic protein 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (C/EBP- $\beta$  (CCAAT box/enhancer element-binding protein  $\beta$ ); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

diseases)

IT Complement receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (C5R1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CANT1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CAP (catabolite gene activator protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CAV1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCBP2 (chemokine-binding protein 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCBP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCL1 (C-C motif ligand 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCL16 (C-C motif ligand 16); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCL17 (C-C motif ligand 17); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCL25 (C-C motif ligand 25); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCL27 (C-C motif ligand 27); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCL28 (C-C motif ligand 28); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCNA2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCND1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCNE1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCNE2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CCRL1 (chemokine (C-C motif) receptor-like 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CCRL2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD164; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD1 (antigen)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD1c; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD200; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD24; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD27; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD30 ligand; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD31; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD37; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Glycoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD40-L (antigen CD40 ligand); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD52; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD70; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CD72; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)  $\frac{1}{2}$ 

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD79a; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD83; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN1B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

Proteins

Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDKN3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CER1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CHGA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CHGB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell line

(CHO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CHST10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF2; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CKLFSF8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL25; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CLN3 (ceroid-lipofuscinosis, neuronal 3); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CMKLR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CMKOR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CNR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (COL18A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (COL1A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (COL4A3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (COL6A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell line

(COS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CSPG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CX3CR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCL16; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXCR6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CYB5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CYC1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CYSLTR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cln3 (cyclinlike 3); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease

Prion diseases

(Creutzfeldt-Jakob; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cripto; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammatory bowel disease

(Crohn's disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DAB21P; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DARC (Duffy antigen receptor for chemokines); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DES; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DKFZp451J0118; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DNCL1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DPP4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (E2F1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sphingosine-1-phosphate receptors

Sphingosine-1-phosphate receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EDG-1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (EFNA1; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (EFNA3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (EFNB2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Chemokines RL: BSU (Biological study, unclassified); BIOL (Biological study) (ENA-78; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ENG; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ENO1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ENO2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ENO3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

ΤТ

ΙT

ΤТ

ΤТ

ΤT

ΙT

ΙT

ΤТ

diseases)

ΙT Proteins

> RL: BSU (Biological study, unclassified); BIOL (Biological study) (EREG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

ΤТ Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ERK8; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

ΙT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ESR1; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

Proteins ΤТ

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ESR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

ΙT EphB receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphB4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

diseases)

- IT Interleukin 1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (F10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (F5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (F6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (F7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (F8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (F9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Prostaglandins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (F; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FADD (Fas-associated death domain protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FASN; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FCER1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FCER2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FCGR3A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FIL1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FLJ12584; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FLJ25530; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (FRA-1 (fos-related antigen 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Nervous system, disease (Friedreich's ataxia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT GABA receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GABAA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GAGEB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GAGEC1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GALNAC4S-6ST; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GATA-1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GATA-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GF-11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(GGT1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GNAS1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GNRH1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRCC10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP (glucose-regulated protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP31; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP44; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GRP81; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (GSTP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Kidney, disease
  - (Goodpasture's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (H1F1A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HAVCR2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

diseases)

- IT Keratins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HB6; hair-specific type II; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HDAC4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HDAC5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HDAC7A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HDAC9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HIP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Histocompatibility antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA-A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Histocompatibility antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA-DR, A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HM74; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HMOX1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Heat-shock proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HSP 75; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HUMCYT2A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Interleukin 1
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (HY1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Brain, disease

(Hallervorden-Spatz disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Purpura (disease)
  - (Henoch-Schoenlein; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Heart

(His bundle, arrhythmia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Nervous system, disease
  - (Huntington's chorea; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Chemokines
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (I-TAC; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ICE-BERG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ICOS (inducible co-stimulator), ligand; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ID2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Translation initiation factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (IF-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (IGBP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Insulin-like growth factor-binding proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (IGFBP-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Insulin-like growth factor-binding proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (IGFBP-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Interleukin 17
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (IL-17C; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ILK; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (INHA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (INHBA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (INSL3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (INSL4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Antibodies and Immunoglobulins
  - RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
    - (IgA, disease; linear; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (JAG1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Gene, animal
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Jun, protein product; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KITLG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLF5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLF6 (Kruppel-like factor 6); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK14; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK15; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLK9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Sarcoma
  - (Kaposi's; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1 receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (L1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1 receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(L2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (LAMA5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Lingo-Troy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Lingo-p75; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDC (macrophage-derived chemokine); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDK; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MIB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MIF; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MS4A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MSMB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MTSS1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mucins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MUC1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Mig (monokine induced by interferon- $\gamma$ ); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MyD88 (myeloid differentiation primary response protein 88); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 1 receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (N; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NCK, 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NFKB1 (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NFKB2 (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells, 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NME1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Kidney, disease
   (NOS; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NOX5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NPPB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NROB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NROB2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(NR1D1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1D2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1H4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1I2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR1I3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2C1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2C2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2E1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2E3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F2; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR2F6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR3C1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR3C2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR4A3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR5A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR5A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NR6A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NT5E; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NTN4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NgR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Nogo, A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Nogo, NgR-Lingo; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Nogo, NgR-Troy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Nogo, NgR-nogo66; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Nogo, NgR-p75; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ODZ1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Glycoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (OMGP (oligodendrocyte myelin glycoprotein), p; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (OPRD1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (P2RX7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PAP (pancreatitis-associated protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PART1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PATE; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PAWR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PCA3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Cell adhesion molecules
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PECAM-1 (platelet-endothelial cell adhesion mol. 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PED2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PF4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PGR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PIAS2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PIK3CG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PLG; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PLXDC1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Disease, animal
  - (POEMS syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PPID; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(PR-1 (pathogenesis-related, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRKCQ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRKD1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PROC; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PROK2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PSAP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PSCA (prostate stem cell antigen); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (PTAFR; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RARB; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGM A; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS (regulator of G protein signaling), 13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS-1 (regulator of G protein signaling 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RGS-3 (regulator of G protein signaling 3); dual variable domain Igs

and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNF110; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ROBO (Roundabout), 2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis

(Reiter's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (S100A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SBP (sex steroid-binding protein); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mammaglobins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCGB2A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mammaglobins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCGB2A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCYE1; endothelial monocyte-activating; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SDF-1 (stromal-derived factor-1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell line

(SF9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLA (swine leukocyte antigen), class II; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

Chemokines

Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLC (secondary lymphoid tissue chemokine); dual variable domain Igs and multispecific derivs. for treating acute and chronic

inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLC2A2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLC33A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLC43A1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Lung, disease
  - (SLE-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SLIT2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SPP1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SPRR1B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SPRR2A (small proline-rich protein 2A); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SPRR2B; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ST6GAL1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAB1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Transcription factor STAT
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (STEAP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (STEAP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (STRL33; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Autoimmune disease
  - (Schmidt's syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAC2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAPA-1 (target of antiproliferative antibody, 1); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TB4R2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TBX21; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TCP10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFA; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB111; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB1; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFB3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFBR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGFBR3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (THIL; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (THPO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TIMP3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

diseases)

- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Toll-like receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TLR-9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNFAIP2 (tumor necrosis factor  $\alpha$ -induced protein 2); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNFAIP3 (tumor necrosis factor  $\alpha$ -induced protein 3); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factor receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNFRSF21; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factor receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNFRSF5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factor receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNFRSF8; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tumor necrosis factor receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNFRSF9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Cytokines
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNFSF7 (tumor necrosis factor superfamily member 7); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TOLLIP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TPM1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TPM2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TRADD (tumor necrosis factor receptor 1-associated death domain); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TRAIL (tumor necrosis factor-related apoptosis-inducing ligand); dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TREM1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TREM2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TRPC6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (TSLP; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TWEAK; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Blood vessel, disease
   (Takayasu's disease; dual variable domain Igs and multispecific derivs.
   for treating acute and chronic inflammation, cancer and other
   diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Te38; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tyrosine kinase receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Tie-1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Tyrosine kinase receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Tie-2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (VHL C5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Granulomatous disease
  (Wegener's granulomatosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (XCR1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ZFPM2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Skin, disease
   (acanthosis nigricans; dual variable domain Igs and multispecific
   derivs. for treating acute and chronic inflammation, cancer
   and other diseases)
- IT Antibodies and Immunoglobulins
   (acquired hypogammaglobulinemia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Pain (acute and chronic; dual variable domain Igs and multispecific derivs.

for treating acute and chronic inflammation, cancer and other diseases) ΤТ Immune disease (acute or chronic; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Inflammation Pancreas, disease (acute pancreatitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Liver, disease ΤТ Rheumatic fever (acute; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Carcinoma ΙT (adenocarcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΤТ Endocrine system (adrenal-hypothalamus-pituitary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Respiratory distress syndrome ΙT (adult; dual variable domain Iqs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Gonadotropin receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (agonist; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) TΤ Cirrhosis (alc.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other ΙT Allergy (allergic asthma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Allergy Eve, disease Inflammation (allergic conjunctivitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Allergy (allergic contact dermatitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) TΤ Dermatitis (allergic contact; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Allergy ΙT Inflammation Nose, disease (allergic rhinitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

diseases)

IT Asthma

(allergic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant rejection

(allotransplant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hormones, animal, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anabolic steroids; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Spinal column, disease

(ankylosing spondylitis, lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Spinal cord

(anterior horn, cell degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Psoriasis

(anti-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytotoxicity

(antibody-mediated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytotoxic agents

(antimetabolites; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery

(aorta, dissection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery, disease

(aorta, occlusion; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

(aorta; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Aneurysm

(aortic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Alopecia

(areata; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(arthropathy, seroneg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chlamydia

Disease, animal

Salmonella

Yersinia

(arthropathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(asthenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease

Spinal column, disease

(ataxia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy

(atopy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hypothyroidism

(atrophic autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anemia (disease)

Autoimmune disease

(autoimmune hemolytic anemia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease

(autoimmune thrombocytopenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease

Inflammation

Thyroid gland, disease

(autoimmune thyroiditis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hypoglycemia

Thyroid gland, disease

(autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sperm

(autoimmunity; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection

(bacterial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain

(basal ganglia, disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Luminescent substances

(bioluminescent; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(bispecific; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Oral drug delivery systems

(bolus drug delivery systems; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation

(bone marrow, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation

(bone, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Bronchi, disease

(bronchiolitis obliterans syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease

(bullous, autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Heart, disease

(bundle branch block; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (c-jun; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pancreas, neoplasm

(carcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Neoplasm

(cardiac; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Shock (circulatory collapse)

(cardiogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

(cardiopulmonary bypass; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Aves

Birds

Insecta

Protista

(cell; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain

(cerebellar cortex, degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease

(cerebellar; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease

(cerebellum, degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tachycardia

(chaotic or multifocal atrial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chimeric; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease

(cholestasis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease

(chorea, senile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Viral hepatitis

(chronic active; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fatigue, biological

Fatigue, biological

(chronic fatigue syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Newborn

(chronic lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Candidiasis

(chronic mucocutaneous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease

(chronic, neonatal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Liver, disease

(chronic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Claudins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (claudin-3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Claudins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (claudin-7; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (co-stimulation mol.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Intestine, neoplasm

(colon; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Intestine, neoplasm

(colorectal carcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Carcinoma

(colorectal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(conjugates; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (conjugates; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Eye, disease

Inflammation

(conjunctivitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Dermatitis

(contact; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Heart, disease

(cor pulmonale; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system

(corticospinal tract, disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune hepatitis

(cryptogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (crystallized; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sepsis

(culture-neg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(cyanosis, acro-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease

(degeneration; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(degenerative, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders

(dementia, AIDS; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders

(dementia, pugilistica; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nerve, disease

(demyelination; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection

(dengue; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders

(depression; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arteriosclerosis

(diabetic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mental and behavioral disorders

(diffuse Lewy body disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cardiomyopathy

(dilated congestive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cardiomyopathy

(dilated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lupus erythematosus

(discoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Platelet (blood)

(disease, autoimmune thrombocytopenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Reticuloendothelial system

(disease, histiocytosis, malignant; dual variable domain Igs and

multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mitochondria

(disease, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Joint, anatomical

(disease, seroneg.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Platelet (blood)

(disease, thrombocytopenia, idiopathic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemotherapy

Joint, anatomical

(disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Dopamine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Blood coagulation disorders

(disseminated intravascular coagulation; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT AIDS (disease)

Acute lymphocytic leukemia
Acute myeloid leukemia
Addison's disease
Alkylating agents, biological
Allergy
Alopecia

Alzheimer's disease Analgesics

Anaphylaxis Anemia (disease)

Anesthetics

Angina pectoris

Angiogenesis inhibitors

Animal cell

Antiasthmatics

Antibiotics

Antimicrobial agents

Antiphospholipid syndrome

Antirheumatic agents

Arterial occlusion

Arteriosclerosis

Arteriosclerosis

Ast.hma

Asthma

Atherosclerosis

Atherosclerosis

Atrial fibrillation

Atrial flutter

B-cell lymphoma

Bladder, neoplasm

Buccal drug delivery systems

Burkitt lymphoma

Burn Cachexia Cardiac arrhythmia Cardiac arrhythmia Cardiomyopathy Cardiopulmonary bypass Chronic lymphocytic leukemia Chronic myeloid leukemia Connective tissue, disease Controlled-release drug delivery systems Coronary artery disease Cystic fibrosis Cytotoxic agents DNA sequences Dermatitis Dermatitis Diabetes mellitus Dissociation constant Down's syndrome Drug delivery systems Drugs Eczema Encephalomyelitis Endocarditis Endocrine system, disease Escherichia coli Eukaryota Fibrosis Fungi Genetic vectors Gout Granuloma Graves' disease Hairy cell leukemia Hay fever Heart block Heart failure Heart failure Hematopoietic neoplasm Hemochromatosis Hemodialysis Hemorrhage Hemorrhage Hepatitis Hepatitis Hepatitis A Hepatitis B Hepatitis C Hodgkin's disease Human Human immunodeficiency virus Hypertension Hypertension Hyperthyroidism Hypnotics and Sedatives Hypoparathyroidism Imaging agents Immunosuppressants Indicators Infection Inflammatory bowel disease

Influenza

Inhalation drug delivery systems

Intestine, disease

Intragastric drug delivery systems

Ischemia

Kawasaki disease

Kidney, disease

Legionella

Leprosy

Leukemia

Leukemia

Linking agents

Lung, neoplasm

Lyme disease

Lymphoma

Malaria

Mammary gland, neoplasm

Melanoma

Meningitis

Mental and behavioral disorders

Metabolic disorders

Molecular cloning

Mouse

Movement disorders

Multiple myeloma

Multiple sclerosis

Mus musculus

Muscle relaxants

Myasthenia gravis

Mycobacterium avium

Mycobacterium tuberculosis

Mycosis

Myelodysplastic syndromes

Myocardial infarction

Myocardial ischemia

Narcotics

Neoplasm

Nervous system stimulants

Neuromuscular blocking agents

Non-Hodgkin lymphoma

Nonsteroidal anti-inflammatory drugs

Osteoarthritis

Osteoarthritis

Osteoporosis

Ovary, neoplasm

Pancreas, neoplasm

Parasite

Parkinson's disease

Pharmaceutical carriers

Plant cell

Preeclampsia

Prokaryota

Prostate gland, neoplasm

Protein sequences

Radiotherapy

Raynaud disease

Refsum disease

Rheumatoid arthritis

Rodentia

Saccharomyces cerevisiae

Sarcoidosis

```
Sarcoma
Schizophrenia
Scleroderma
Scleroderma
Sepsis
Shock (circulatory collapse)
Sickle cell anemia
Skin, disease
Stomach, neoplasm
Streptococcus group B
Stroke
Sublingual drug delivery systems
Surface plasmon resonance
Syphilis
Telangiectasia
Transdermal drug delivery systems
Transplant rejection
Urticaria
Uveitis
Vaccines
Vaginal drug delivery systems
Valvular heart disease
Varicose vein
Vasculitis
Vein, disease
Ventricular fibrillation
Vitiligo
Wernicke-Korsakoff syndrome
Wilson's disease
Yeast
\beta-Adrenoceptor agonists
   (dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Antibodies and Immunoglobulins
Nucleic acids
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
   (dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
APC protein
Aggrecans
Antigens
Bone morphogenetic protein 1
Bone morphogenetic protein 2
Bone morphogenetic protein 4
Bone morphogenetic protein 6
Bone morphogenetic protein 8
Brain-derived neurotrophic factors
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD28 (antigen)
CD3 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD44 (antigen)
```

ΤT

ΙT

```
CD45RB (antigen)
CD69 (antigen)
CD8 (antigen)
CD80 (antigen)
CD80 (antigen)
CD86 (antigen)
CD86 (antigen)
CTLA-4 (antigen)
Cell adhesion molecules
Chemokines
Clusterin
Clusterin
Cytokines
Enzymes, biological studies
Eotaxin 1
Eotaxin 2
Eotaxin 3
Epidermal growth factor receptors
Fas antigen
Fas ligand
Fibronectins
Gelsolin
Hepatocyte growth factor
Histamine receptors
Insulin-like growth factor I receptors
Integrins
Interleukin 1
Interleukin 10
Interleukin 11
Interleukin 12
Interleukin 13
Interleukin 14
Interleukin 15
Interleukin 16
Interleukin 17
Interleukin 17 receptors
Interleukin 18
Interleukin 18 receptors
Interleukin 19
Interleukin 1\alpha
Interleukin 1B
Interleukin 2
Interleukin 20
Interleukin 22
Interleukin 23
Interleukin 24
Interleukin 3
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 6 receptors
Interleukin 7
Interleukin 8
Interleukin 9
Interleukin 9 receptors
Invariant chain (class II antigen)
Ki-67 antigen
Lipopolysaccharides
Lymphokine receptors
Lymphokines
Lymphotoxin
```

```
Macrophage inflammatory protein 2
Macrophage inflammatory protein 2\alpha
Macrophage inflammatory protein 2\beta
Macrophage inflammatory protein 3\alpha\,
Macrophage inflammatory protein 3\beta
Macrophage inflammatory protein 4
Macrophage inflammatory protein 5
Melanoma growth-stimulating activity-\alpha
Midkines
Monocyte chemoattractant protein-1
Monocyte chemoattractant protein-2
Monocyte chemoattractant protein-3
Monocyte chemoattractant protein-4
Monokines
Nerve growth factor receptors
Neutrophil-activating peptide-2
Proliferating cell nuclear antigen
RANTES (chemokine)
Receptors
Toll-like receptors
Transforming growth factor \beta
Tumor necrosis factors
Tumor necrosis factors
Versicans
neu (receptor)
neu (receptor)
p53 (protein)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Anthracyclines
Growth factors, animal
Radionuclides, biological studies
Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
   (dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Corticosteroids, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
CD3 (antigen)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (e; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Lung, disease
   (eosinophilia; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Epididymis
   (epididymitis; dual variable domain Igs and multispecific derivs. for
   treating acute and chronic inflammation, cancer and other
   diseases)
Respiratory system, disease
   (epiglottitis; dual variable domain Igs and multispecific derivs. for
```

ΙT

ΙT

ΤТ

ΙT

ΙT

ΙΤ

treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(erythromelalgia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease

(extrapyramidal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease

(failure, acute; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease

Ovary, disease

(failure; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(familial hematophagocytic lymphohistiocytosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fertility disorders

(female; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Embryo, animal

(fetus, thymus implant rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease

(fibrosis, cryptogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease

Radiation

(fibrosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(fistula, arteriovenous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (fos; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (fractalkines; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(fragments; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

CD3 (antigen) ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (g; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Necrosis (gas gangrene; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT (gastric; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene B29; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Transcription factors TΤ RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene BCL6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene ELAC2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Glycoproteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene KAI1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΤТ Arteritis (giant cell; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Inflammation Inflammation Kidney, disease Kidnev, disease (glomerulonephritis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΤТ Transplant and Transplantation (graft-vs.-host reaction; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) TΤ Transplant and Transplantation (heart; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) ΙT Antibodies and Immunoglobulins RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (heavy chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other

IT Anemia (disease) (hemolytic, Cooms-pos.; dual variable domain Igs and multispecific

diseases)

derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease

(hemolytic-uremic syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anemia (disease)

(hemolytic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Injury

(hepatic, alc.-induced; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(histiocytosis, malignant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(humanized; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Allergy

(hypersensitivity; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pharmaceutical injections

(i.m. injections; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pharmaceutical injections

(i.p. injections; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pharmaceutical injections

(i.v. injections; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Blood, disease

(idiopathic thrombocytopenia; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Leukocytopenia

(idiopathic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (immunoadhesins; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Thymus gland

(implant rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Human herpesvirus 4

Neisseria meningitidis

(infection; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases) Apoptosis Mitosis (inhibitors; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Liver, disease (injury, alc.-induced; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Reperfusion (injury; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Autoimmune disease (insulin-dependent diabetes mellitus; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Diabetes mellitus (insulin-dependent; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Chemokines RL: BSU (Biological study, unclassified); BIOL (Biological study) (interferon  $\gamma$ -inducible protein-10; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Inflammation Lung, disease (interstitial pneumonitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Lung, disease (interstitial, connective tissue disease-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Lung, disease (interstitial, post-inflammatory; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Lung, disease (interstitial, rheumatoid arthritis-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Nasal drug delivery systems Rectal drug delivery systems (intra-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases) Drug delivery systems (intraabdominal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

(intraarticular; dual variable domain Igs and multispecific derivs. for

(intrabronchial; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other

treating acute and chronic inflammation, cancer and other

ΤТ

ΙT

ΤТ

ΤТ

ΤT

ΙT

ΙT

ΙT

ΙT

ΙT

ΤТ

ΙT

ΤT

ΙT

Drug delivery systems

Drug delivery systems

diseases)

diseases)

IT Drug delivery systems

(intracapsular; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intracartilaginous; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intracavitary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intracelial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intracerebellar; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intracerebroventricular; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intracervical; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intracolic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intrahepatic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intramyocardial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intraosteal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intrapelvic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intrapleural; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intraprostatic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intrapulmonary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems
 (intrarenal; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)
IT Drug delivery systems
 (intraretinal; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other
 diseases)
IT Drug delivery systems
 (intraspinal; dual variable domain Igs and multispecific derivs. for
 treating acute and chronic inflammation, cancer and other

diseases)
IT Drug delivery systems

(intrasynovial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intrathoracic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intrauterine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(intravesical; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Eye, disease

Inflammation

(iridocyclitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Rheumatoid arthritis

Rheumatoid arthritis

Rheumatoid arthritis

(juvenile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (k6HF; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation

(kidney, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fluorescent substances

Luminescent substances

Magnetic materials

(label; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(labeled; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Infection

(leishmaniasis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Leukotriene receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (leukotriene B4, LTB4R2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Leukotriene receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (leukotriene B4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(light chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Peptides, biological studies

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(linker; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation

(liver, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anesthetics

(local; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Sjogren syndrome

(lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Edema

(lymph-; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lung, disease

(lymphocytic infiltrative; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (lymphotactin, XCL2 or SCM-1b; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (lymphotactin; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fertility disorders

(male; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lymphoma

(malignant; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Animal cell

(mammalian; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease

(microscopic vasculitis of; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Vasculitis

(microscopic; of kidney; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Headache

(migraine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(mitochondrial, multi-system; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Connective tissue, disease

(mixed connective tissue disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (monoclonal gammopathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal, therapy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(monoclonal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (monokine; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (myc; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Spinal cord, disease

(myelitis, acute transverse; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Edema

Hypothyroidism

(myxedema; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Carcinoma

(nasopharyngeal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pharynx, neoplasm

(nasopharynx, carcinoma; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Heart, disease

(neoplasm; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Kidney, disease

(nephritis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Kidney, disease

(nephrotic syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteoglycans, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (neurocan; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Muscular dystrophy

IT Nerve, disease

(neuropathy, HIV; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Agranulocytosis

(neutropenia, autoimmune; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fever and Hyperthermia

(neutropenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Steatohepatitis

(nonalc.; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Eye, disease

(ophthalmia, sympathetic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Nerve, disease

(optic neuritis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Testis, disease

(orchitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Immune disease

(organ transplant-associated; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Disease, animal

(organomegaly; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cyclin dependent kinase inhibitors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (p57KIP2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pBJ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pBV; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pEF6TOPO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pEFBOS; dual variable domain Igs and multispecific derivs.

for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pJV; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pTT3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pTT; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation

(pancreas, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Carcinoma

(pancreatic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Neoplasm

(paraneoplastic syndrome; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pcDNA3.1TOPO; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Plasmid vectors

(pcDNA; dual variable domain Igs and multispecific derivs.

for treating acute and chronic inflammation, cancer and other diseases)

IT Body, anatomical

(pelvis, inflammation; dual variable domain Igs and

multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease

(pemphigoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease

(pemphigus foliaceus; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Skin, disease

(pemphigus vulgaris; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Artery, disease

Inflammation

(periarteritis nodosa, pulmonary manifestation; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Drug delivery systems

(pericardiac; dual variable domain Igs and multispecific derivs . for treating acute and chronic inflammation, cancer and other diseases)

IT Animal organ

(pericardial, disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Peritoneum, disease

(peritonitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Anemia (disease)

(pernicious anemia, acquired or juvenile; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Uveitis

(phacogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (phosphacan; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (plectins; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease

Endocrine system, disease

(polyglandular syndrome, type I and II deficiency; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hormone receptors

Hormones, animal, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (polypeptide; dual variable domain Igs and multispecific derivs . for treating acute and chronic inflammation, cancer and other diseases)

IT Infection

(postinfectious interstitial lung disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Ovary, disease

(premature failure; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease

(primary biliary cirrhosis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Hepatitis

(primary sclerosing; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Paralysis

(pseudobulbar, progressive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis

(psoriatic arthritis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibrosis

(pulmonary, cryptogenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Fibrosis

Hypertension

(pulmonary; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis

(reactive; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Intestine, neoplasm

(rectum; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Injury

(reperfusion; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Nose, disease

(rhinitis, perenial; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Pharmaceutical injections

(s.c. injections; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Biliary tract, disease

Inflammation

(sclerosing cholangitis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis

Shock (circulatory collapse)

(septic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mucins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (sialomucin MUC-24; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation

(skin, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation

(small intestine, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Spinal column, disease

(spondylitis, rheumatoid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Spinal column, disease

Spinal column, disease

(spondyloarthropathy; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Mvositis

(streptococcal; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Encephalitis

(subacute sclerosing; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 11; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 12; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 13; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 14; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 18; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(superfamily 4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (superfamily 9; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (surface; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Brain, disease

(syncope; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Arthritis

Synovial membrane, disease

(synovitis, enteropathic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Lupus erythematosus

(systemic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Cytokines

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapy-associated disease; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Thrombosis

(thromboangiitis obliterans; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Purpura (disease)

(thrombocytopenic; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Autoimmune disease

(thyroid; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Inflammation

Thyroid gland, disease

(thyroiditis; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Shock (circulatory collapse)

(toxic shock syndrome; dual variable domain Igs and multispecific

```
derivs. for treating acute and chronic inflammation, cancer and
        other diseases)
ΤТ
    Cartilage
     Parathyroid gland
        (transplant rejection; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic
        inflammation, cancer and other diseases)
TΤ
     Bone marrow
     Kidney
     Liver
     Pancreas
     Skin
     Small intestine
        (transplant, rejection; dual variable domain Igs and
        multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΙT
     Heart
        (transplant; dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
        diseases)
ΙT
     Injury
        (trauma; dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
ΙT
    Psoriasis
        (type 1 and 2; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic inflammation, cancer and other
        diseases)
     Tumor necrosis factor receptors
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 1, TNFRSFB; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic inflammation, cancer and other
        diseases)
     Tumor necrosis factor receptors
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 1; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
ΙT
     Complement receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 2; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
ΙT
     Fibroblast growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 3; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
ΙT
     Autoimmune hepatitis
        (type I and II; dual variable domain Iqs and multispecific
        derivs. for treating acute and chronic inflammation, cancer and other
        diseases)
ΙT
     Spinal muscular atrophy
        (type I; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
     Interleukin 1 receptors
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type I; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
ΤТ
     Bone morphogenetic protein receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type IA; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
```

```
Bone morphogenetic protein receptors
ТТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type IB; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
     Bone morphogenetic protein receptors
ΤТ
     Interleukin 1 receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type II; dual variable domain Igs and
        multispecific derivs. for treating acute and chronic inflammation,
        cancer and other diseases)
     Spinal muscular atrophy
ΤТ
        (type III; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
ΙT
     Vascular endothelial growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type VEGFR-1; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic inflammation, cancer and other
        diseases)
     Vascular endothelial growth factor receptors
TΤ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type VEGFR-2; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic inflammation, cancer and other
        diseases)
ΙT
     Stomach, disease
        (ulcer; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other diseases)
ΙT
     Inflammatory bowel disease
        (ulcerative colitis, arthropathy; dual variable domain Igs
        and multispecific derivs. for treating acute and chronic inflammation,
        cancer and other diseases)
ΙT
     Inflammatory bowel disease
        (ulcerative colitis; dual variable domain Igs and
        multispecific derivs. for treating acute and chronic inflammation,
        cancer and other diseases)
     Colitis
ΙT
        (ulcerative, arthropathy; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic inflammation, cancer
        and other diseases)
     Colitis
ΤТ
        (ulcerative; dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
       diseases)
ΙT
     Sepsis
        (uro-; dual variable domain Igs and multispecific derivs. for treating
        acute and chronic inflammation, cancer and other diseases)
ΤТ
     Growth inhibitors, animal
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (vascular endothelial growth inhibitor; dual variable domain Igs
        and multispecific derivs. for treating acute and chronic
        inflammation, cancer and other diseases)
IΤ
        (vasculitic diffuse; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other
        diseases)
     Surgery
TΤ
     Vas deferens
        (vasectomy, orchitis; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic
        inflammation, cancer and other diseases)
ΤТ
     Thrombosis
        (venous; dual variable domain Igs and multispecific derivs. for
```

treating acute and chronic inflammation, cancer and other
diseases)
Infection
(viral; dual variable domain Igs and multispecific derivs. for treating
acute and chronic inflammation, cancer and other diseases)

IT Transplant and Transplantation (xenotransplant, rejection; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and

other diseases)

IT CD3 (antigen)

ΤТ

RL: BSU (Biological study, unclassified); BIOL (Biological study) (z; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 2 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$  chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ , 4; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ , 5; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ , 6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha, 7;$  dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other dispass)

IT Amyotrophic lateral sclerosis

 $(\alpha 1-$ antitrypsin-deficient; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

Interleukin 13 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

Interleukin 13 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

Interleukin 15 receptors

Interleukin 3 receptors

Interleukin 4 receptors

Interleukin 5 receptors

Interleukin 7 receptors

Interleukin 8 receptors

Platelet-derived growth factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha v$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1, ITGA1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 2, ITGA2; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 3, ITGA3; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 4\beta 1$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 6, ITGA6; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 2 receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$  chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Catenins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Interleukin 8 receptors

Lymphotoxin

Platelet-derived growth factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ 3; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

- IT Integrins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta 4$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interleukin 2 receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma$  chain; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interferons
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma$ ; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT Interferons
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\omega$ , 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT 203874-76-4, Fibroblast growth factor 12
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
    (B; dual variable domain Igs and multispecific derivs. for
    treating acute and chronic inflammation, cancer and other
    diseases)
- IT 37205-61-1, Proteinase inhibitor
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (SERPIN F 1; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- TT 930324-46-2P 930324-47-3P 930324-48-4P 930324-49-5P 930324-50-8P 930324-51-9P 930324-52-0P 930324-53-1P 930324-54-2P 930324-55-3P 930324-66-4P 930324-57-5P 930324-58-6P 930324-59-7P 930324-60-0P 930324-66-6P 930324-67-7P 930324-68-8P 930324-69-9P 930324-70-2P 930324-71-3P 930324-72-4P 930324-73-5P 930324-74-6P 930324-75-7P 930324-76-8P 930324-77-9P
  - RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (amino acid sequence; dual variable domain Igs and multispecific
    - (amino acid sequence; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- IT 69-72-7, Salicylic acid, biological studies
  - RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
    - (chronic intoxication; dual variable domain Igs and multispecific derivs. for treating acute and chronic inflammation, cancer and other diseases)
- 51-45-6, Histamine, biological studies ΙT 51-43-4D, Epinephrine, analogs 9001-92-7, Protease 9002-07-7, PTN 9002-62-4, 9001-06-3, Chitinase PRL, biological studies 9035-58-9, Blood-coagulation factor III 9041-92-3, SERPIN A 1 9047-22-7, Cathepsin B 9061-61-4, NGF 11096-26-7, EPO 62031-54-3, FGF 62229-50-9, EGF 67763-96-6, IGF-1 67763-97-7, IGF-2 80295-41-6, Complement C3 80295-49-4, Complement C4a 83869-56-1, GM-CSF 80295-53-0, Complement C5 81627-83-0, M-CSF 88232-92-2, SDF 2 106096-92-8, FGF 1 106096-93-9, FGF 2 122191-40-6, CASP-1 123584-45-2, FGF 4 127464-60-2, VEGF 129653-64-1, FGF 5 130939-41-2, FGF 6 140208-23-7, SERPIN E 1 141176-92-3, SERPIN A 3

```
146480-36-6, Mmp 9 147014-96-8, CDK-5 kinase 147014-97-9, CDK-4 kinase
    148348-14-5, FGF 3 148348-15-6, FGF 7 151185-16-9, FGF 9
    152478-56-3, JAK1 kinase 153190-71-7, CDK-3 kinase 157482-36-5, JAK3
    kinase 157857-21-1, SERPIN B 5 164003-41-2, FGF 8 167397-96-8,
                   169494-85-3, Leptin 171758-70-6, Fibroblast growth
    IRAK-1 kinase
               182762-08-9, CASP-4 182938-13-2, CDK-9 kinase 185915-21-3,
    factor 10
             185915-22-4, FGF 13 185915-23-5, Fibroblast growth factor 14
    188417-84-7, VEGFC 192662-83-2, Vascular endothelial growth factor B
    193363-12-1, VEGFD 193830-08-9, GDF-5 200578-48-9, IRAK-2 kinase
    204719-95-9, Fibroblast growth factor 16 214210-47-6, Neuropilin 1
    223121-69-5, Fibroblast growth factor 19 227018-38-4, Neuropilin 2
    245480-69-7, Fibroblast growth factor 20 271597-13-8, GDF-10
    301166-54-1, Protein, PTEN 303014-92-8, CDK-6 kinase
    314026-96-5, Fibroblast growth factor 23 322637-17-2, Fibroblast growth
    factor 17 322637-18-3, FGF 18 329900-75-6, Cox-2 330197-29-0, CDK-7
            335217-23-7, Fibroblast growth factor 22 341970-61-4,
    kinase
    Fibroblast growth factor 21 372092-80-3, Protein kinase
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (dual variable domain Igs and multispecific derivs. for
        treating acute and chronic inflammation, cancer and other
       diseases)
    58-85-5, Biotin
ΙT
    RL: BSU (Biological study, unclassified); BUU (Biological use,
    unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
        (dual variable domain Iqs and multispecific derivs. for
       treating acute and chronic inflammation, cancer and other
       diseases)
    59-05-2, Methotrexate 10028-17-8, Hydrogen-3, biological studies 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90,
ΙT
    biological studies 13967-65-2, Holmium-166, biological studies
    14133-76-7, Technetium-99, biological studies 14158-31-7, Iodine-125,
    biological studies 14265-75-9, Lutetium-177, biological studies
    14762-75-5, Carbon-14, biological studies 15117-53-0, Sulfur-35,
    biological studies 15750-15-9, Indium-111, biological studies
    15766-00-4, Samarium-153, biological studies
                                                   53123-88-9, Rapamycin
    79217-60-0, Cyclosporin 104987-11-3, FK 506
    RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
     (Therapeutic use); BIOL (Biological study); USES (Uses)
        (dual variable domain Igs and multispecific derivs. for
       treating acute and chronic inflammation, cancer and other
       diseases)
ΙT
    7439-89-6, Iron, biological studies
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hemosiderosis, lung disease; dual variable domain Igs and
       multispecific derivs. for treating acute and chronic
       inflammation, cancer and other diseases)
                                            532391-75-6 669774-82-7
    122024-47-9
                 500995-49-3
ΙT
                               500995-50-6
                                             930288-78-1
    865864-24-0
                 865864-26-2
                                923954-87-4
                                                            930288-80-5
                                              930289-05-7 930289-14-8
    930288-82-7
                 930288-91-8
                                930288-96-3
    930289-22-8 930289-25-1 930289-43-3
    RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (linker; dual variable domain Igs and multispecific derivs. for
       treating acute and chronic inflammation, cancer and other
       diseases)
ΙT
    930324-92-8 930324-93-9
                                930324-94-0
                                              930324-95-1
                                                            930324-96-2
                               930324-99-5
    930324-97-3 930324-98-4
                                             930325-00-1
                                                            930325-01-2
    930325-02-3 930325-03-4
                               930325-04-5 930325-05-6 930325-06-7
                              930325-09-0 930325-10-3 930325-11-4
    930325-07-8 930325-08-9
    930325-14-7 930325-15-8 930325-16-9 930325-17-0 930325-18-1
```

141349-86-2, CDK-2 kinase 143011-72-7, G-CSF 146480-35-5, Mmp 2

```
930325 - 19 - 2 \qquad 930325 - 20 - 5 \qquad 930325 - 21 - 6 \qquad 930325 - 22 - 7 \qquad 930325 - 23 - 8
     930325 - 24 - 9 \qquad 930325 - 25 - 0 \qquad 930325 - 26 - 1 \qquad 930325 - 27 - 2 \qquad 930325 - 28 - 3
     930325-29-4 930325-30-7 930325-31-8 930325-32-9 930325-33-0
     930325-34-1
     RL: PRP (Properties)
        (unclaimed nucleotide sequence; dual variable domain Igs and
        multispecific derivs. for treating acute and chronic
        inflammation, cancer and other diseases)
ΙΤ
     930324-80-4 930324-81-5 930324-82-6 930324-83-7 930324-84-8
     930324-85-9 930324-86-0 930324-87-1 930324-88-2 930324-89-3
     930324-90-6 930324-91-7 930325-12-5 930325-13-6 930325-35-2
     930325-36-3 930325-37-4 930325-38-5 930325-39-6 930325-40-9
     930325-41-0 930325-42-1 930325-43-2 930325-44-3 930325-45-4
     930325-46-5 930325-47-6 930325-48-7 930325-49-8 930325-50-1
     930325-51-2 930325-52-3
     RL: PRP (Properties)
        (unclaimed protein sequence; dual variable domain Igs and multispecific
        derivs. for treating acute and chronic inflammation, cancer
        and other diseases)
     362526-53-2
                  609338-75-2
                                930288-59-8 930288-63-4 930288-65-6
ΤТ
     930288-67-8 930288-69-0 930288-71-4 930288-73-6 930288-75-8
     RL: PRP (Properties)
        (unclaimed sequence; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other
        diseases)
     142805-56-9
ΤT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha, \alpha; dual variable domain Igs and multispecific derivs.
        for treating acute and chronic inflammation, cancer and other
        diseases)
L32 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
     115926-52-8, Phosphoinositide-3-kinase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
RN
     115926-52-8 CAPLUS
     Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
ACCESSION NUMBER: 2007:284115 CAPLUS
DOCUMENT NUMBER:
                        146:352574
TITLE:
                        Double-stranded RNAs and their use for downregulating
                        genes and treating cardiovascular diseases
                        Chajut, Ayelet; Pinner, Elhanan
INVENTOR(S):
                       Quark Biotech, Inc., USA
PATENT ASSIGNEE(S):
                        PCT Int. Appl., 145pp.
SOURCE:
                         CODEN: PIXXD2
DOCUMENT TYPE:
                         Patent
LANGUAGE:
                         English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
                    KIND DATE
                                       APPLICATION NO. DATE
     PATENT NO.
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
```

MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,

```
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:
                                           US 2005-715414P
                                                             P 20050909
                                           US 2005-732188P
                                                             P 20051031
    2007:284115 CAPLUS
AN
    146:352574
DN
    Entered STN: 16 Mar 2007
ED
TΙ
    Double-stranded RNAs and their use for downregulating genes and
    treating cardiovascular diseases
    Chajut, Ayelet; Pinner, Elhanan
ΤN
    Quark Biotech, Inc., USA
PA
    PCT Int. Appl., 145pp.
SO
    CODEN: PIXXD2
DT
    Patent
LA
    English
CC
    3-1 (Biochemical Genetics)
    Section cross-reference(s): 1
FAN.CNT 1
                                         APPLICATION NO.
    PATENT NO.
                       KIND
                              DATE
     _____
                       ____
                               -----
                                           _____
                                                                 20060906
    WO 2007029249
                        A2
                              20070315
                                          WO 2006-IL1036
PΙ
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
            KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
            MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
            RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI US 2005-715414P
                     P
                             20050909
    US 2005-732188P
                        Р
                               20051031
CLASS
            CLASS PATENT FAMILY CLASSIFICATION CODES
PATENT NO.
WO 2007029249 IPCI A61K0048-00 [I,A]; C07H0021-02 [I,A]; C07H0021-00
                       [I,C*]
                IPCR
                       A61K0048-00 [I,C]; A61K0048-00 [I,A]; C07H0021-00
                       [I,C]; C07H0021-02 [I,A]
AΒ
    The invention relates to a double-stranded compound, such as siRNAs, which
    down-regulates the expression of one or more cardiovascular-related gene.
    The invention also relates to a pharmaceutical composition comprising the
    compound, or a vector capable of expressing the oligoribonucleotide compound,
    and a pharmaceutically acceptable carrier. The present invention also
    contemplates a method of treating a patient suffering from a
    cardiovascular disorder or other diseases comprising administering to the
    patient the pharmaceutical composition in a therapeutically ED so as to thereby
    treat the patient.
ST
    siRNA cardiovascular disease treatment
ΙT
    Hemoglobins
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\zeta; double-stranded RNAs and their use for downregulating genes
```

and treating cardiovascular diseases)

```
ТТ
     Heat-shock proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (105kDa/110kDa, 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
     Cadherins
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (13; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙΤ
     Cadherins
     Keratins
     Kinesins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (14; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     G protein-coupled receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (162; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     Keratins
     Nexins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (17; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     Keratins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (18; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     Keratins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (19; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΤТ
     Ankyrins
     Calmodulins
     Calponin
     Fibrillins
     Thrombospondins
     Tropomyosins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (1; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (1B; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΤТ
    Metallothioneins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (1K; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
TΤ
     Nexins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (24; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     Heat-shock proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (27kDa protein 1; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     Heat-shock proteins
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (27kDa protein 3; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
    Calmodulins
ΤТ
```

```
Fibrillins
     Kinesins
     Presenilins
     Tropomyosins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (2; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
    Metallothioneins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (2A; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
     Cyclin dependent kinase inhibitors
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (2B; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΤТ
     Ankyrins
     Calponin
     Nexins
     Synaptobrevins
     Tropomyosins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (3; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     Splicing factors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (3a, subunit 3, 60kDa; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     Splicing factors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (3b, subunit 2, 145kDa; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΤТ
    Connexins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (43, 43kDa; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
TΤ
     Syndecans
     Tropomyosins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (4; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (5; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΤТ
     Kinesins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (5B; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
TΤ
     Heat-shock proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (70kDa protein 14; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     Heat-shock proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (70kDa protein 4; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     Heat-shock proteins
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (70kDa protein 5; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     Keratins
ΤТ
```

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Heat-shock proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (90kDa protein 1, alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Heat-shock proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (90kDa protein 1, beta; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription elongation factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (A-like 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Heterogeneous nuclear ribonucleoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (A/B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Heterogeneous nuclear ribonucleoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (A3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
    (ADF (actin-depolymg. factor); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ADP-ribosylation factor-like 2 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ADP-ribosylation factor-like 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ADP-ribosylation factor-like 6 interacting protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
    (ADP-ribosylation-like factor 6 interacting protein 5; double-stranded
    RNAs and their use for downregulating genes and
    treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (AI1-associated protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Clathrin adaptor proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
    (AP-1 (adaptor protein complex 1); double-stranded RNAs and their use
    for downregulating genes and treating
    cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (APC (anaphase-promoting complex); double-stranded RNAs and their use

```
for downregulating genes and treating cardiovascular diseases
ΤТ
     ADP ribosylation factor
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (ARF-3; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     ADP ribosylation factor
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (ARF-4; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
     ADP ribosylation factor
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (ARF-5; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (ASK interacting protein 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (AT2 domain containing 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     Transcription factors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (ATF-3 (activating transcription factor 3); double-stranded RNAs and
        their use for downregulating genes and treating
        cardiovascular diseases)
ΙT
     Transcription factors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (ATF-4 (activating transcription factor 4); double-stranded RNAs and
        their use for downregulating genes and treating
        cardiovascular diseases)
     Phosphoproteins
TΤ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (Anp32b (acidic nuclear phosphoprotein 32 family member B);
        double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Phosphoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (Anp32e (acidic nuclear phosphoprotein 32 family member E);
        double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Actin-related proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (Arp2; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΤТ
     Actin-related proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (Arp3; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     Small nuclear ribonucleoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (B and B1; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
     Cyclins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (B1; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     Cyclins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (B2; double-stranded RNAs and their use for downregulating genes and
```

treating cardiovascular diseases)

- IT Nexins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (BF1 interacting corepressor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (BP-like protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (BPAG1 (bullous pemphigoid antigen 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (C/EBP (CCAAT box/enhancer element-binding protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CBL; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT CD antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD151; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT CD antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD24; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT CD antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD31; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT CD antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD56; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT CD antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD63; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT CD antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD72; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT CD antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cell cycle regulatory proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDC20; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cell cycle regulatory proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDC2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDC42 effector protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT G proteins (guanine nucleotide-binding proteins)
  RL: BSU (Biological study, unclassified); BIOL (Biological study)
  (CDC42; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDC44; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDC45 cell division cycle 45-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDK2-associated protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDK2-associated protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDK5 regulatory subunit associated protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CDK5 regulatory subunit associated protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CENP-E (centromere protein E); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL2-antagonist of cell death; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL2-associated X protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL2-related protein A1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL2/adenovirus E1B 19kDa interacting protein 2; double-stranded RNAs

and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CL2/adenovirus E1B 19kDa interacting protein 3-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (COMM domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (COMM domain containing 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CR4-NOT transcription complex, subunit 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cellular retinol-binding proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CRBP-I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Collapsin response mediator proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CRMP-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Colony stimulating factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CSF2RB; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CXXC finger 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cbp/p300-interacting transactivator 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chloride channels

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ClC-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chloride channels

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ClC-4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Cripto; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (D-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cyclins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (D1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Small nuclear ribonucleoproteins
  RL: BSU (Biological study, unclassified); BIOL (Biological study)
  (D2, 165kDa; double-stranded RNAs and their use for downregulating
- genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (D2-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cyclins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (D2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Small nuclear ribonucleoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (D3, 18kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cyclins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (D3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DAZ associated protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 17; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 39; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 41; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 47; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 48; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 51; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAD box protein 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular

diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAH box protein 30; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (DEAH box protein 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (DNA fragmentation factor DFF35; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Enzymes, biological studies RL: BSU (Biological study, unclassified); BIOL (Biological study) (DNA helicase, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (DNA methyltransferase 1 associated protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (DNase I-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (DP (docking protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (DRP (dystrophin-related protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (DTW domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DiGeorge syndrome critical region gene 6-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Molecular chaperones

RL: BSU (Biological study, unclassified); BIOL (Biological study) (DnaJ, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Down syndrome cell adhesion mol. like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Down syndrome critical region gene 1-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

```
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (Down syndrome critical region gene 5; double-stranded RNAs and their use
   for downregulating genes and treating
   cardiovascular diseases)
Cyclins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (E; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
Sphingosine-1-phosphate receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (EDG-1; double-stranded RNAs and their use for downregulating
   genes and treating cardiovascular diseases)
Lysophosphatidic acid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (EDG-7; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
Translation elongation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (EF-1y; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular
   diseases)
Translation elongation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (EF-Tu; double-stranded RNAs and their use for downregulating
   genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (EF-hand domain family, member D2; double-stranded RNAs and their use
   for downregulating genes and treating cardiovascular
   diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (EGF-like-domain, multiple 7; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular
   diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (ES130-related protein; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular
   diseases)
Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (Egr-1; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
EphB receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (EphB3; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (F-box protein 16; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular
   diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (F-box protein 21; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular
   diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
```

(F-box protein 30; double-stranded RNAs and their use for

ΤТ

ΙT

ΙT

ΙT

ΙT

ΤТ

ΙT

TΤ

ΙT

ΤТ

ΤТ

ΤТ

ΙT

downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (F-box protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (F-box protein FBX29; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FABP3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FBP-interacting repressor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FERM domain containing 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FK506 binding protein 10, 65 kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FK506 binding protein 1A, 12kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FK506 binding protein 2, 13kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FK506 binding protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FK506 binding protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FK506 binding protein 9, 63 kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FKRP (fukutin-related protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (FLYWCH-type zinc finger 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

Transcription factors ТТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (FOXM1 (forkhead box M1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (FP291; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (FXYD domain containing ion transport regulator 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Fanconi anemia, complementation group L; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Fas apoptotic inhibitory mol. 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (G protein pathway suppressor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (G protein  $\beta 1/\gamma 2$  subunit-interacting factor 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (G protein-coupled receptor kinase interactor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Cvclins ΤT RL: BSU (Biological study, unclassified); BIOL (Biological study) (G1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Cvclins Small nuclear ribonucleoproteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (G; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (GAB1 (GRB2-associated binder 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (GADD153; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins IT RL: BSU (Biological study, unclassified); BIOL (Biological study) (GAS6 (growth arrest-specific 6); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Transcription factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GATA-1; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
  IT Transcription factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GATA-2; double-stranded RNAs and their use for downregulating genes)

and treating cardiovascular diseases)

- IT Transcription factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GC-rich promoter binding protein 1; double-stranded RNAs and their use
   for downregulating genes and treating cardiovascular
   diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GDI-1 (GDP dissociation inhibitor-1); double-stranded RNAs and their use
   for downregulating genes and treating cardiovascular
   diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GDI-2 (GDP dissociation inhibitor-2); double-stranded RNAs and their use
   for downregulating genes and treating
   cardiovascular diseases)
- IT G proteins (guanine nucleotide-binding proteins)
  RL: BSU (Biological study, unclassified); BIOL (Biological study)
  (GEM, associated protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GKLF (gut-enriched Kruppel-like factor); double-stranded RNAs and
   their use for downregulating genes and treating
   cardiovascular diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GLI pathogenesis-related 1; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (GTP cyclohydrolase I feedback regulator; double-stranded RNAs and
   their use for downregulating genes and treating
   cardiovascular diseases)
- IT G proteins (guanine nucleotide-binding proteins)
  RL: BSU (Biological study, unclassified); BIOL (Biological study)
  (Gi (adenylate cyclase-inhibiting); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HCLS1 associated protein X-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HIRA interacting protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HIV-1 enhancer binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA-A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA-B associated transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA-B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA-C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HLA-DRB1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HMG-box transcription factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT High-mobility group proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HMG14; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HMG2 like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HMP19; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HOXB9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HSPC038; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HSPC244; double-stranded RNAs and their use for downregulating genes

and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (HT-1080; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (Huntingtin interacting protein K; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Fibronectins ΤТ Profilins RL: BSU (Biological study, unclassified); BIOL (Biological study) (I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Insulin-like growth factor-binding proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (IGFBP-4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Insulin-like growth factor-binding proteins ΤT RL: BSU (Biological study, unclassified); BIOL (Biological study) (IGFBP-5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Insulin-like growth factor-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (IGFBP-7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Annexins Profilins Secretogranins RL: BSU (Biological study, unclassified); BIOL (Biological study) (II; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (IQ motif containing F3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (IQ motif containing GTPase activating protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (ISGF-2 (interferon-stimulated gene factor 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Myosins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (IXB; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ Voltage-gated potassium channels RL: BSU (Biological study, unclassified); BIOL (Biological study) (Isk-related family, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Molecular chaperones ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (J-type co-chaperone HSC20; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (JAB1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Jagged 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Jumonji AT rich interactive domain 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Blood-group substances
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (K (Kell); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KDEL endoplasmic reticulum protein retention, receptor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLF2 (Kruppel-like factor 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLF3 (Kruppel-like factor 3); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (KLF9 (Kruppel-like factor 9); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Heterogeneous nuclear ribonucleoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (L; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (LIM and senescent cell antigen-like domains 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (LIM domain binding 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (LIM domain-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (LMO4 (LIM domain only 4); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (LSM3 homolog, U6 small nuclear RNA associated; double-stranded RNAs and their use for downregulating genes and treating

cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LSM4 homolog, U6 small nuclear RNA associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LSM5 homolog, U6 small nuclear RNA associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

ΤТ

ΙT

RL: BSU (Biological study, unclassified); BIOL (Biological study) (LSM7 homolog, U6 small nuclear RNA associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (LTBP2 (latent transforming growth factor  $\beta$ -binding protein 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Heterogeneous nuclear ribonucleoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(M; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MAD2L1 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Microtubule-associated proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MAP1, light chain  $3\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Microtubule-associated proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MAP1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MARCKS-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MASL1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MBC3205; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MCM6 (minichromosome maintenance deficient 6); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDC9 (metalloprotease-disintegrin-cysteine-rich); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT P-glycoproteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (MDR3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MID1 interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MLAA-37; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MLAA-3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MMSA-10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Phosphoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MPP4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MSH6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MTERF domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Meisl, myeloid ecotropic viral integration site 1 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (MovOlO, Moloney leukemia virus 10, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Ionotropic glutamate receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (N-Me D-aspartate-like 1A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (N-acylsphingosine amidohydrolase 3-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (NAD(P) dependent steroid dehydrogenase-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cell adhesion molecules
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)
    (NCAM (neural cell adhesion mol.); double-stranded RNAs and their use
    for downregulating genes and treating
    cardiovascular diseases)
- IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (NDRG2 (N-myc downstream-regulated gene 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (NECAP endocytosis associated I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (NF $\kappa$ B-interacting Ras-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (NOL1/NOP2/Sun domain family 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Atrial natriuretic peptide receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (NPR-A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (NS5ATP13TP2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Voltage-gated sodium channels

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Nav1.1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Nedd4 family interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ninjurin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (OAZ1 (ornithine decarboxylase antizyme 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (P381P; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PA1-1 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PAK1 interacting protein I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PBX/knotted 1 homeobox 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PCOLCE (procollagen C-proteinase enhancer); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PDGFA associated protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PDZ and LIM domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PDZ and LIM domain 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PDZ and LIM domain 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cell adhesion molecules

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PECAM-1 (platelet-endothelial cell adhesion mol. 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PED; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PEST-containing nuclear protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PHD finger protein 5A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PIN2-interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PKCq-interacting protein PICOT; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PPAR binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRA1 domain family 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(PRP19PSO4 pre-mRNA processing factor 19 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)  $\frac{1}{2} \left( \frac{1}{2} + \frac{1}{$ 

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PRP39 pre-mRNA processing factor 39 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PSF (PTB-associated splicing factor); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PTK9L protein tyrosine kinase 9-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PWP2 periodic tryptophan protein homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (PWWP domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Quiescin Q6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (R; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAB18; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (quanine nucleotide-binding proteins)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAB1A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAB3A-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT G proteins (guanine nucleotide-binding proteins)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAB7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RABII family interacting protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAD23 homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAD9 homolog A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAG-1 (recombination-activating gene, 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAG-2 (recombination-activating gene, 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAN binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAN binding protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAN; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RATS1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RAVER; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (REX2, RNA exonuclease 2 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Translation termination factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RF-1 (release factor 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RFP (ret finger protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RI3 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RING1 and YY1 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA binding motif protein 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA binding motif protein 8A; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA binding protein, autoantigenic; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Enzymes, biological studies RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA helicase DDX3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding region containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding, 1,; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding, S1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding, cold shock domain containing E1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding, poly(A) binding protein, C1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding, poly(A) binding protein, nuclear 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding, poly(rC) binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RNA-binding, synaptotagmin-binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (RP42 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ Microtubule-associated proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (RPEB family, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (RRN3, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(RUN and SH3 domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RUNX2 (runt-related transcription factor 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RWD domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rab acceptor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT G proteins (guanine nucleotide-binding proteins)
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (Rac; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ras association domain family 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ras-GTPase activating protein SH3 domain-binding protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Ras-related GTP binding C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RasGEF domain family 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RelA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rho-GDI $\alpha$  (Rho-specific GDP dissociation inhibitor  $\alpha$ ); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rho-GDI $\gamma$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rho-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT GTPase-activating protein
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RhoGAP (Rho GTPase-activating protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT GTPase-activating protein
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (RhoGAP 22 (Rho GTPase-activating protein 22); double-stranded RNAs and

their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Rtf1, Paf1/RNA polymerase II complex component, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT S-100 proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (S-100A10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT S-100 proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (S-100C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SAA1 (serum amyloid A1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SAM and SH3 domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SAM domain and HD domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCP65 (synaptonemal complex protein 65); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SCP2 (sterol carrier protein 2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SEC31-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SECIS-binding protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SFRP1 (secreted frizzled-related protein 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SG2NA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SH2 domain binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SH3 domain binding glutamic acid-rich; double-stranded RNAs and their

use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SIN3 homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SM-11044 binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SMT3 suppressor of mif two 3 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Nexins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SNX22; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SOCS-2 (suppressor of cytokine signaling-2); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRP14 (signal recognition particle 14 kDa); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRP9 (signal recognition particle 9 kDa); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRY-box 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SRY-box 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins, specific or class

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SSB (single-stranded DNA-binding), 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT3-interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factor STAT

RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT5A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factor STAT

RL: BSU (Biological study, unclassified); BIOL (Biological study) (STAT5B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(STEAP family member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SUB1 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SUMO-1 activating; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Sec61; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Sip1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Sjogren syndrome B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (Sp1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (T-rich interactive domain 5B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (TACC3 (transforming acidic coiled-coil 3); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAF9 RNA polymerase II, TATA box binding protein-associated factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAPA-1 (target of antiproliferative antibody, 1); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT DNA-binding proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (TAR; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TBC1 domain family, member 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TCF-4 (T-cell factor 4); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TEA domain family member I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TERA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TFIIIC (transcription factor IIIC), polypeptide 3, 102kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGF- $\beta$  induced apoptosis protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGF $\beta$ -induced factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGF $\beta$ -inducible nuclear protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transforming growth factor  $\beta$ 
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TGF $\beta$ 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (THAP domain containing 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (THRSP (thyroid hormone-responsive protein); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TIP47; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TM2 domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (TNF receptor-associated factor 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins

```
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (TNF receptor-associated protein 1; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (TPMsk3; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (TPRDI; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
DNA-binding proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (TRF1 (telomeric repeat-binding factor 1); double-stranded RNAs and
   their use for downregulating genes and treating
   cardiovascular diseases)
Transient receptor potential cation channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (TRPM7; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
Proteins
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (TSC22 domain family, member 1; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (TSPY-like 4; double-stranded RNAs and their use for downregulating
   genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (Tax1 binding protein 1; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (Tax1 binding protein 3; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (U2 small nuclear RNA auxiliary factor 2; double-stranded RNAs and
   their use for downregulating genes and treating
   cardiovascular diseases)
Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (U2 small nuclear RNA-associated; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (UBX domain containing 5; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (V; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
Voltage-dependent anion channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (VDAC1; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
Voltage-dependent anion channels
RL: BSU (Biological study, unclassified); BIOL (Biological study)
```

(VDAC2; double-stranded RNAs and their use for downregulating genes and

ΙT

ΙT

ΤТ

ΙT

ΙT

ΤТ

ΙT

TΤ

ΙT

ΙT

ΤТ

ΙT

TT

treating cardiovascular diseases) Voltage-dependent anion channels TΤ RL: BSU (Biological study, unclassified); BIOL (Biological study) (VDAC3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (WD repeat domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (WD repeat domain 26; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (WNT1 inducible signaling pathway protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (WW domain binding protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Williams-Beuren syndrome chromosome region 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (Wilms tumor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (X-ray repair complementing defective repair in Chinese hamster cells 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (XPA binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (Y box binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (YEATS domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ RL: BSU (Biological study, unclassified); BIOL (Biological study) (YP1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (Zic family member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (abhydrolase domain containing 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΤТ

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (abhydrolase domain containing 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transforming proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (acidic coiled-coil containing protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (actin filament-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (actin-capping, gelsolin-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (actin-capping, muscle Z-line,  $\alpha 1$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (actin-capping, muscle Z-line,  $\alpha 2$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (actin-capping, muscle Z-line,  $\beta$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (actin-like 6A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (actin-related protein 23; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (acyl-CoA binding domain containing 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (adenylate cyclase-associated protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (adhesion regulating mol. 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (adiponectin, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (adipophilin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (afamin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (alanine-glyoxylate aminotransferase 2-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (amphiphysin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (amyloid beta precursor protein binding protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (amyloid beta precursor-like protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (angiopoietin-like 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ankyrin repeat and SOCS box-containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ankyrin repeat and SOCS box-containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ankyrin repeat domain 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ankyrin repeat domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ankyrin repeat domain 37; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ankyrin repeat, family A, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (anterior pharynx defective 1 homolog A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (antioxidant protein ATX1 homolog; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (aquarius homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arginine-glutamic acid dipeptide repeats; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arginine-rich, mutated in early stage tumors; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arginine/serine-rich 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arginine/serine-rich 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arginine/serine-rich 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Splicing factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arginine/serine-rich 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arginine/serine-rich coiled-coil 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (arrestin domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (astrotactin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ataxin 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ataxin 2-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (autoantigens, NOR-90; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (autoantigens, SjogrenNULLs syndrome nuclear autoantigen 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (autoantigens, calcium binding atopy-related autoantigen 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (autophagy 12-like protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (autophagy 7-like protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (baculoviral IAP repeat-containing 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (barren homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (barrier to autointegration factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (basic leucine zipper and W2 domains 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (basic leucine zipper nuclear factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (basic leucine zipper transcription factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (basic transcription factor 3-like 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (brain abundant, membrane attached signal protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (brain expressed, X-linked 1; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (brain protein 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (brain protein 44-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (brain protein 44; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (brain-specific angiogenesis inhibitor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (brain-specific; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (breast carcinoma-associated, isoform I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (brix domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (bromodomain and WD repeat domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (bromodomain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (bromodomain containing 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Growth factors, animal RL: BSU (Biological study, unclassified); BIOL (Biological study) (c-fos induced; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ Transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (cAMP responsive element binding protein-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Transcription factors ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (cAMP responsive element binding protein-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Chloride channels ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study)

(calcium activated, family member 3; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (calcyclin binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Calcium-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (calcyclins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (calsenilin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (calsyntenin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (carbon catabolite repression 4-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Troponin T RL: BSU (Biological study, unclassified); BIOL (Biological study) (cardiac, TNNT2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (carnitine deficiency-associated, expressed in ventricle 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins TΤ RL: BSU (Biological study, unclassified); BIOL (Biological study) (catenins  $\alpha 1$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Cell cycle regulatory proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (cell division cycle 2-like 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Cell cycle regulatory proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (cell division cycle associated 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (centaurin,  $\gamma$ 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (centractin  $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (centractin  $\beta$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (centrosome-associated protein 350; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

Proteins

ΤТ

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (cereblon; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (cervical cancer oncogene 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromatin accessibility complex 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromatin modifying 2A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromobox homolog 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromobox homolog 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromodomain helicase DNA binding 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 1 open reading frame 106; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 1 open reading frame 119; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 1 open reading frame 122; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 1 open reading frame 58; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 1 open reading frame 75; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 1 open reading frame 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(chromosome 1 open reading frame 91; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 1 open reading frame 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 10 open reading frame 119; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 10 open reading frame 56; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 10 open reading frame 88; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 11 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 11 open reading frame 31; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 12 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 12 open reading frame 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 13 open reading frame 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 14 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 14 open reading frame 111; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 14 open reading frame 166; double-stranded RNAs and their

use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 16 open reading frame 53; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 17 open reading frame 25; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 17 open reading frame 35; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 17 open reading frame 37; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 18 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 19 open reading frame 27; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 2 open reading frame 18; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 111; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 116; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 149; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 31; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 47; double-stranded RNAs and their use for downregulating genes and treating cardiovascular

diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 20 open reading frame 67; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 22 open reading frame 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 22 open reading frame 16; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 22 open reading frame 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 4 open reading frame 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 6 open reading frame 106; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 6 open reading frame 111; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 6 open reading frame 62; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 6 open reading frame 82; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 6 open reading frame 85; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 6 open reading frame 93; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 7 open reading frame 21; double-stranded RNAs and their use for downregulating genes and treating cardiovascular

diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 7 open reading frame 30; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 9 open reading frame 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 9 open reading frame 24; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 9 open reading frame 58; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 9 open reading frame 88; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (chromosome 9 open reading frame 89; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cingulin-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cingulins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Claudins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (claudin-15; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Claudins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (claudin-7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cleavage stimulation factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coated vesicle membrane protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coatomer, subunit alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coatomer, subunit beta; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coatomer, subunit zeta 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coenzyme Q7 homolog, ubiquinone; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cofilin, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cofilin, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coiled-coil domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coiled-coil domain containing 80; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coiled-coil-helix domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coiled-coil-helix domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coiled-coil-helix domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cold shock domain protein A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Molecular chaperones

RL: BSU (Biological study, unclassified); BIOL (Biological study) (containing TCP1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (copine I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (copine III; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (copper metabolism domain containing 1; double-stranded RNAs and their use downregulating genes and treating cardiovascular diseases)

IT Proteins

for

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cornichon homolog 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coronin, actin binding protein, 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coronin, actin binding protein, 1C; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (coronin, actin binding protein, 2B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cortactins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cross-immune reaction antigen PCIA1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cyclin D-binding myb-like, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cysteine and glycine-rich protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cysteine and glycine-rich protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cysteine and glycine-rich protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cysteine-rich, angiogenic inducer, 61; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cytoglobin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (cytokine induced apoptosis inhibitor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (cytoskeleton-associated protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT DNA-binding proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (damage-specific, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Guanine nucleotide exchange factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (deafness locus-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (death-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (defender against cell death 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (dendritic cell; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (dermokine; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (dickkopf homolog 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (differential display and activated by p53; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (dihydropyrimidinase-like 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (dihydrouridine synthase 1-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (disintegrin and metalloproteinase, domain 32; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (disks large homolog-associated protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

```
(dispatched homolog 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΤТ
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (disrupted in renal carcinoma 2; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (docking protein 4; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     Cardiac arrest
     Cardiac arrhythmia
     Cardiovascular system, disease
     Coronary artery disease
     Coronary thrombosis
     DNA sequences
     Human
     Myocardial infarction
     Myocardial ischemia
     Stroke
     Valvular heart disease
     cDNA sequences
        (double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
     Agglutinins and Lectins
     Albumins, biological studies
     Amyloid precursor proteins
     Benzodiazepine receptors
     Biglycans
     Bone morphogenetic protein 1
     Bone morphogenetic protein 2
     Bone morphogenetic protein 4
     C-reactive protein
     CD19 (antigen)
     CD3 (antigen)
     CD34 (antigen)
     CD4 (antigen)
     Caldesmon
     Calnexin
     Calreticulin
     Clusterin
     DNA formation factors
     DNA-binding proteins
     Decorins
     Desmins
     Desmoplakins
     Endothelin ETA receptors
     Ephrin-A2
     Ephrin-B1
     Ephrin-B3
     Epidermal growth factor receptors
     Erythropoietin receptors
     Ferritins
     Fibromodulins
     G protein-coupled receptors
     G proteins (guanine nucleotide-binding proteins)
     Gelsolin
     Glypicans
     Heat-shock proteins
```

Insulin-like growth factor II receptors

```
Interleukin 7 receptors
Leptin receptors
Leukemia inhibitory factor receptors
Lumicans
Macrophage inflammatory protein 1\beta
Macrophage migration inhibitory factor
Mdm2 protein
Midkines
Monocyte chemoattractant protein-5
Nicotinic receptors
Osteonectin
Platelet-derived growth factor receptors
Pleiotrophins
Prion proteins
Protamines
Proteins
Proteins
Signal sequence receptors
Stem cell factor
Synaptophysin
Thrombomodulin
Thyroid hormone receptors
Transferrin receptors
Transferrins
Translation initiation factors
Troponin C
Troponin I
Troponin I
Troponin T
Vimentins
Vinculin
Vitronectin
p53 (protein)
\alpha-Actins
\beta-Actins
\beta1-Adrenoceptors
\beta2-Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (down-regulated by Ctnnbl; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (down-regulator of transcription 1, TBP-binding; double-stranded RNAs
   and their use for downregulating genes and treating
   cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (dpy-30-like; double-stranded RNAs and their use for downregulating
   genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (dysferlin; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (dystonin; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
```

ΙT

ΤТ

ΙΤ

ΤТ

ΙT

- IT Translation elongation factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (eEF-1 $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- Translation elongation factors
  RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eEF-2; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-1A; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-2B; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-3; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
- IT Translation initiation factors
  RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-4A; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-4B; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-4E-BP1 (eIF-4E-binding protein 1); double-stranded RNAs and their
   use for downregulating genes and treating cardiovascular
   diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-4E; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-4G; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Translation initiation factors
  RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-5; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-5A; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Translation initiation factors
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (eIF-5B; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (echinoderm microtubule associated protein like 4; double-stranded RNAs
   and their use for downregulating genes and treating
   cardiovascular diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (egl nine homolog 2; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (elastin microfibril interfacer 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (elastin microfibril interfacer 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Flavoproteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (electron transfer flavoprotein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (emopamil binding protein-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (enabled, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (endophilin, B1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (endothelial differentiation-related factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (endozepine-like protein type 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (enhancer of rudimentary, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (epithelial membrane protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (epithelial membrane protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (epithelial membrane protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤT RL: BSU (Biological study, unclassified); BIOL (Biological study) (erythrocyte membrane protein band 41-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Enzymes, biological studies ΙT

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(essential meiotic endonuclease 1 homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (eukaryotic initiation factor-2-associated, p67; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Organelle

(exosome (exonuclease complex), components 5 and 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (far upstream element binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (fascin homolog 1, actin-bundling protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (fibrinogen-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (fibulin, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (fibulin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (filamin A interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (flightless I homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (follistatin-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (forty-two-three domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (four and a half LIM domains 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (fracture callus 1 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (fragile X mental retardation, autosomal homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (frizzled homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (frizzled homolog 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (frizzled homolog 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (fumarylacetoacetate hydrolase domain containing 2A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Agglutinins and Lectins RL: BSU (Biological study, unclassified); BIOL (Biological study) (galactose-binding, soluble, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Agglutinins and Lectins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (galactose-binding, soluble, 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Agglutinins and Lectins RL: BSU (Biological study, unclassified); BIOL (Biological study) (galactose-binding, soluble, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Agglutinins and Lectins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (galactose-binding, soluble, 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Agglutinins and Lectins RL: BSU (Biological study, unclassified); BIOL (Biological study) (galectin-3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (gap junction-specific,  $\alpha$ 7, 45kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene B29; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene HGFL; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Glycoproteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene KAI1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) G proteins (guanine nucleotide-binding proteins) ΤТ

RL: BSU (Biological study, unclassified); BIOL (Biological study)

```
(gene RAB10; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΤТ
     G proteins (quanine nucleotide-binding proteins)
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB14; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     G proteins (quanine nucleotide-binding proteins)
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB20; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     G proteins (guanine nucleotide-binding proteins)
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB22A; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     G proteins (guanine nucleotide-binding proteins)
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB40C; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
TΤ
     G proteins (guanine nucleotide-binding proteins)
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB4A; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     G proteins (quanine nucleotide-binding proteins)
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB5C; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     G proteins (quanine nucleotide-binding proteins)
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB8A; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     G proteins (guanine nucleotide-binding proteins)
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene RAB9A; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     Transcription factors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (gene SCL; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (glioma tumor suppressor candidate region gene 2; double-stranded RNAs
        and their use for downregulating genes and treating
        cardiovascular diseases)
ΙT
    Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (glycerophosphodiester phosphodiesterase domain containing 4;
        double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΤТ
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (glycine cleavage system protein H; double-stranded RNAs and their use
        for downregulating genes and treating cardiovascular
        diseases)
     Proteins
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (glycosyltransferase 25 domain containing 1; double-stranded RNAs and their
        use for downregulating genes and treating cardiovascular
        diseases)
ΙT
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
```

(golgi complex, 6; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (golgi complex, 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (golgi reassembly stacking protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (growth arrest and DNA-damage-inducible, gamma; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (growth arrest-specific 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (growth factor receptor-bound protein 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (growth factor receptor-bound protein 14; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (growth factor receptor-bound protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (heart and neural crest derivs. expressed 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Transcription factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (heat shock, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Myosins RL: BSU (Biological study, unclassified); BIOL (Biological study) (heavy chain 11, smooth muscle; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Clathrin ΙT Dyneins RL: BSU (Biological study, unclassified); BIOL (Biological study) (heavy chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (hematopoietic stem progenitor cells 176; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

Proteoglycans, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (heparitin sulfate-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

ΙT

```
Growth factors, animal
ТТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hepatoma-derived; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
TΤ
     High-mobility group proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (high mobility group AT-hook 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙΤ
     High-mobility group proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (high-mobility group box 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     High-mobility group proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (high-mobility group box 2; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     High-mobility group proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (high-mobility group nucleosomal binding domain 2; double-stranded RNAs
        and their use for downregulating genes and treating
        cardiovascular diseases)
ΙT
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (high-risk human papilloma viruses E6 oncoproteins targeted protein
        E6TP1\alpha; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     Heterogeneous nuclear ribonucleoproteins
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hnRNP A1; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Heterogeneous nuclear ribonucleoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hnRNP A2/B1; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     Heterogeneous nuclear ribonucleoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hnRNP C; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Heterogeneous nuclear ribonucleoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hnRNP F; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Heterogeneous nuclear ribonucleoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hnRNP H; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΤТ
     Heterogeneous nuclear ribonucleoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hnRNP K; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Heterogeneous nuclear ribonucleoproteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (hnRNP U; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
     Transcription factors
TΤ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (homeodomain-containing, iroquois homeobox protein 3; double-stranded RNAs
        and their use for downregulating genes and treating
        cardiovascular diseases)
ΙT
     Transcription factors
```

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(homeodomain-containing, iroquois homeobox protein 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (homeodomain-containing, msh homeo box homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (homeodomain-containing, msh homeo box homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Ras proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (huntingtin interacting protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (hypoxia up-regulated 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (immature colon carcinoma transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (immediate early response 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (influenza virus NSIA binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor of DNA binding 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor of DNA binding 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor of growth family, member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (insulin-induced gene 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (integrin  $\beta 1$  binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (integrin  $\beta$ 1 binding protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (integrin  $\beta 1$  binding protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (integrin  $\beta 4$  binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Post-transcriptional processing

(interference; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (interferon-induced transmembrane protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (interferon-induced transmembrane protein 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (interferon-related developmental regulator 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (interferon-stimulated transcription factor 3,  $\gamma$  48kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (interleukin 6 signal transducer; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Dyneins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (intermediate chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (intersectin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (jagunal homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (jumonji, AT-rich interactive domain 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (junB; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (junD; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (kelch domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (keratin associated protein 6-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (keratinocyte associated protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (kinase anchor protein 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (kinase anchor protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (kinase anchor protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (kinase insert domain receptor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (lamin AC; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Calcium-activated potassium channels
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (large-conductance, subfamily M, beta member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (late cornified envelope 1B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (latent transforming growth factor  $\beta$  binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT G protein-coupled receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (latrophilin, 3; double-stranded RNAs and their use for downregulating

genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (leucine rich repeat containing 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (leucine rich repeat containing 45; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (leucine rich repeat containing 8B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (leucine zipper protein 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (leucine-rich PPR-motif containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (leucine-rich repeats and Iq-like domains 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Receptors ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (leukocyte Ig-like receptor, subfamily A, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Myosins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (light chain, 1 slow a; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ Clathrin Dyneins RL: BSU (Biological study, unclassified); BIOL (Biological study) (light chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (low d. lipoprotein receptor adaptor protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (lymphocyte cytosolic protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (lymphocyte-specific protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Enzymes, biological studies ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (lysyl oxidase-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Enzymes, biological studies ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (lysyl oxidase-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (major facilitator superfamily domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (major nuclear matrix protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (major vault protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (makorin, ring finger protein, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (male-enhanced antigen 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Mannose receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (mannose 6-phosphate; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (mannose phosphate-dolichol utilization defect 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Agglutinins and Lectins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (mannose-binding, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (melanoma antigen family D, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (melanoma antigen family D, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, 2A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, integral membrane protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, integral membrane protein 2B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, lysosomal-associated membrane protein 1; double-stranded RNAs and their use for downregulating genes and treating

cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, lysosomal-associated membrane protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, lysosomal-associated protein transmembrane  $4\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, palmitoylated 1, 55kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, vesicle-associated, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane, vesicle-associated, 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (membrane-associated ring finger 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (mesoderm specific transcript homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (metaxin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (metaxin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (meteorin-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (meteorin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (methyl-CpG binding domain protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (microfibrillar-associated protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(microfibrillar-associated protein 3-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (microfibrillar-associated protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (midnolin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (milk fat globule-EGF factor 8 protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (modulator of estrogen induced transcription; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (monocyte to macrophage differentiation-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (mortality factor 4 like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (mucolipin 1, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (mucolipin 1, 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (muscleblind-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myc target 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myelin gene expression factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myelin protein zero-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myeloblastosis viral oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myeloid leukemia factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myeloid-associated differentiation marker-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myeloid/lymphoid or mixed-lineage leukemia; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myogenic factor 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myotubularin related protein 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (myristoylated alanine-rich protein kinase C substrate; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nasal embryonic LHRH factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nasopharyngeal carcinoma-related; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (necdin, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nerve growth factor receptor-associated protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neural precursor cell expressed, developmentally down-regulated 4-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neural precursor cell expressed, developmentally down-regulated 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neural precursor cell expressed, developmentally down-regulated 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (neural proliferation, differentiation and control, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neuralized-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neuroblastoma RAS viral oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neurofibromin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cytoskeleton
  - (neurofilament, light polypeptide 68kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cytoskeleton
  - (neurofilament; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neuroligin 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neuronatin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neurotrimin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (neutrophil cytosolic factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nexilin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nidogen 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear VCP-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear casein kinase and cyclin-dependent kinase substrate 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear factor I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear factor of activated T-cells 5, tonicity-responsive; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear factor, interleukin 3 regulated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear factor-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear protein E3-3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Nuclear receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear receptor subfamily 1, group D, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Nuclear receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear receptor subfamily 1, group H, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Nuclear receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear receptor subfamily 2, group F, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleic acid-binding, polypyrimidine tract binding protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleobindin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleolar complex associated 2, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleolar protein 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleolar protein 5A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleolar protein family A, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleolar protein family A, member 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleolar protein with MIF4G domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleophosmin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleoporin, 54 and 205kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleosome assembly protein 1-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (nucleotide binding protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (olfactomedin-like 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (optic atrophy 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (outer dense fiber of sperm tails 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (oxidase assembly 1-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cyclin dependent kinase inhibitors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (p19INK4D; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cyclin dependent kinase inhibitors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (p21CIP1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cyclin dependent kinase inhibitors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (p27KIP1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (p53 and DNA damage regulated 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  RL: BSU (Biological study, unclassified); BIOL (Biological study)

(p53-inducible nuclear protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (p53-inducible nuclear protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cyclin dependent kinase inhibitors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (p57KIP2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (paired box gene 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (partitioning defective 6 homolog alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (patatin-like phospholipase domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (pentatricopeptide repeat domain 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (peptide/histidine transporter 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (peripheral myelin protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (pern-like domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Peroxins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (peroxin 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (peroxisomal membrane protein 2, 22kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (peroxisome biogenesis factor 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (pescadillo homolog 1, containing BRCT domain; double-stranded RNAs and

their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (phosphatidylinositol transfer protein, alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Glycophospholipids

RL: BSU (Biological study, unclassified); BIOL (Biological study) (phosphatidylinositol-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (phosphofurin acidic cluster sorting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (phospholemman; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pim-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pinin, desmosome associated protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pleckstrin homol. domain containing, family B member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pleckstrin homol. domain containing, family C, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pleckstrin homol.—like domain, family A, member 3; double—stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pleckstrin homol.-like domain, family B, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (plectins, intermediate filament binding protein 500kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (poly binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (poly polymerase family, member 6; double-stranded RNAs and their use

for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (polycomb group ring finger 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (popeye domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (popeye domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (postsynaptic protein CRIPT; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (pre-B-cell leukemia transcription factor interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (prefoldin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (prefoldin 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (prefoldin 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (programmed cell death 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (programmed cell death 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (proliferation-associated 2G4, 38kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (proline-, glutamic acid-, leucine-rich protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (prosaposins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (prostaglandin F2 receptor neg. regulator; double-stranded RNAs and their use for downregulating genes and treating

cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (prostateins; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protein inhibitor of activated STAT, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protein regulator of cytokinesis I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protein tyrosine phosphatase domain containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (proteolipid protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Cadherins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(protocadherin, gamma subfamily A, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily A, 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily B, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily B, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily B, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily B, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily B, 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily C, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Cadherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (protocadherin, gamma subfamily C, 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pseudogene, UBBP4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pseudogene, UOX; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Gene

RL: BSU (Biological study, unclassified); BIOL (Biological study) (pseudogene, cytochrome c processed; double-stranded RNAs and their use for downregulating genes and treating cardiovascular

diseases)

- IT Gene
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (pseudogene, thioredoxin 1 pseudogene 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (px19-like protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (quaking homolog, KH domain RNA binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (ras homolog gene family, member A; double-stranded RNAs and their
   use for downregulating genes and treating cardiovascular
   diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (ras homolog gene family, member J; double-stranded RNAs and their
   use for downregulating genes and treating cardiovascular
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ras-related C3 botulinum toxin substrate 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ras-related C3 botulinum toxin substrate 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (regulator of chromosome condensation 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT DNA formation factors

diseases)

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (replication factor C 2, 40kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT DNA formation factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (replication protein A3, 14kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (restin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (reticulocalbin 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study) (reticulon 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (reticulon 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (reticulon 4a; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (retinitis pigmentosa GTPase regulator interacting protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (retinoblastoma binding protein 2 homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (retinoblastoma binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (retinoblastoma binding protein 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (retinoblastoma-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (retinoblastoma-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (retinol binding protein 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ribophorin I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ribophorin II; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ring finger protein 128; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (ring finger protein 149; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
   RL: BSU (Biological study, unclassified); BIOL (Biological study)

(ring finger protein 185; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (ring finger protein CKBBP1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (runt-related transcription factor 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (sarcolemma-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Antigens RL: BSU (Biological study, unclassified); BIOL (Biological study) (sarcoma antigen NY-SAR-77; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (selenium-binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (selenium-containing, K; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (selenium-containing, P, plasma, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (selenium-containing, X, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (selenium-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (selenocysteine-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (septin 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (septins, 11; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (septins, 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (septins, 5; double-stranded RNAs and their use for downregulating

genes and treating cardiovascular diseases)

RL: BSU (Biological study, unclassified); BIOL (Biological study)

ΤТ

ΙT

ΤТ

ΤТ

ΤT

ΙT

ΙT

ΤТ

TΤ

ΙT

ΙT

ΙT

ΙT

ΤТ

ΤТ

Proteins

(serine/arginine repetitive matrix 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (serine/arginine repetitive matrix I; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (serine/threonine kinase receptor-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (seven in absentia homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (sex comb on midleg homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (shroom; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Mucins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (sialomucin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (signal transducing adaptor mol. 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (sin3-associated; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

Proteins, specific or class

RL: BSU (Biological study, unclassified); BIOL (Biological study) (single-stranded DNA-binding, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (small EDRK-rich factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (small acidic; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Double stranded RNA

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small interfering; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (small muscle, X-linked; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (small nuclear RNA auxiliary factor 1-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Ribonucleoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (snoRNP (small nucleolar ribonucleoprotein), UTP1-like, U3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (soc-2 suppressor of clear homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 12, member 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 16, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 2, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 2, member 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 20, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 22, member 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 23, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 24, member 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 25, member 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 35, member A4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 36, member 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 36, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 37, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 39, member 13; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 39, member 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 6, member 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transport proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (solute carrier family 9, isoform 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (sortilin-related VPS10 domain-containing receptor 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (sparcosteonectin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (spen homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (sperm associated antigen 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (spermatogenesis associated 16; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (spermatogenesis associated 21; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (spinster; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (split handfoot malformation type 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (sprouty-related, EVH1 domain containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (stabilin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (stannin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (stathmin-like 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (stathmin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (steroid 5 alpha-reductase 2-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (steroid sensitive gene 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (sterol regulatory element binding, 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (sterol-C4-Me oxidase-like; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (stomatin-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(stress-induced, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (stromal cell derived factor 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Chemokines

RL: BSU (Biological study, unclassified); BIOL (Biological study) (stromal cell derived factor 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (structure-specific recognition protein 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Voltage-gated potassium channels

RL: BSU (Biological study, unclassified); BIOL (Biological study) (subfamily H, member 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (suppressor of S. cerevisiae gcr2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (suppressor of Ty 16 homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (surfeit 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (sushi domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (synaptopodin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (synaptoporin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (synaptotagmin IV; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (syncoilin, intermediate filament 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (syndecan-binding; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (syntaxin 16; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)
Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(t-complex-associated-testis-expressed 1-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

ΤТ

RL: BSU (Biological study, unclassified); BIOL (Biological study) (t-complex-associated-testis-expressed 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tafazzin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (talin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tankyrase 1 binding protein 1, 182kDa; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (taxilin  $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tensin 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (testis-expressed sequence 261; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tetraspan NET-4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tetratricopeptide repeat domain 7B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (thioredoxin domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (thioredoxin-like 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (thyroid hormone receptor interactor 10; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(thyroid hormone receptor interactor 12; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (thyroid hormone receptor interactor 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (thyrotrophic embryonic factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tight junction protein 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (timeless-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (toll-interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (torsin, family 1, member A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (trafficking protein particle complex 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Transcription factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (transcript release factor; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (transformer- $2\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (transforming growth factor  $\beta$ -induced; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (transforming growth factor  $\beta1$ -induced transcript 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (transgelin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (transgelin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(translocation protein-1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane trafficking; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 30A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 38A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 49; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, 64; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, BAX inhibitor motif containing 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, channel-like 7; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, emp24 protein transport domain containing 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, emp24 protein transport domain containing 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, growth hormone-inducible; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transmembrane, prostate androgen-induced; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (transportin 2; double-stranded RNAs and their use for downregulating

genes and treating cardiovascular diseases)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tribbles homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

RL: BSU (Biological study, unclassified); BIOL (Biological study)

ΤТ

ΙT

ΤТ

ΙT

ΙT

ΙT

ΙΤ

ΤТ

ΤТ

ΙT

ΤТ

TΤ

ΤТ

ΤТ

Proteins

Proteins

(tripartite motif-containing 23; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tripartite motif-containing 28; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tripartite motif-containing 41; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tripartite motif-containing 55; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tripartite motif-containing 65; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tripartite motif-containing 8; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (triple functional domain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tristetraprolin, C3H type, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tristetraprolin, C3H type-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Glycoproteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (trophoblast; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Molecular chaperones
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tubulin-specific, a; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tubulointerstitial nephritis antigen-like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor necrosis factor receptor superfamily, member 12A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor necrosis factor receptor superfamily, member 5 isoform 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(tumor necrosis factor  $\alpha$ -induced, 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor necrosis factor  $\alpha$ -induced, 6; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor protein D52; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor protein, translationally-controlled 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Antigens
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor rejection antigen 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor suppressor candidate 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tumor susceptibility gene 101; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Prostanoid receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (type FP; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (type I,  $\alpha$ 1(I)-chain, collagens, $\alpha$ 1(I); double -stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Bone morphogenetic protein receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Activin receptors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IIA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Voltage-gated sodium channels
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (type III; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Voltage-gated sodium channels
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (type IX,  $\alpha$  subunit; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (tyrosine ligase-like family, member 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ubinuclein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ubiquinol-cytochrome c reductase binding protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ubiquitin-activating; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ubiquitin-conjugating; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ubiquitin-like 3; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (unc-5 homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (unc-93 homolog B1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Angina pectoris

(unstable; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (upregulated during skeletal muscle growth 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (upstream transcription factor 2, c-fos interacting; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (v-fos FBJ murine osteosarcoma viral oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (v-jun sarcoma virus 17 oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (v-myb myeloblastosis viral oncogene homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (v-raf-1 murine leukemia viral oncogene homolog 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (v-ral simian leukemia viral oncogene homolog B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (vacuolar protein sorting 25; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (vacuolar protein sorting 29; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (vacuolar protein sorting 4A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (wingless-type MMTV integration site family, member 7B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (yeast INO80 protein homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (yrdC domain-containing; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT DNA-binding proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 11B; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT DNA-binding proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 161; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT DNA-binding proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 205; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT DNA-binding proteins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 23; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

DNA-binding proteins ТТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 336; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) DNA-binding proteins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 445; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 574; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 605; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 662; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 670; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 91, homolog; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) TΤ DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, BTB domain containing 16; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) DNA-binding proteins ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, CCCH-type containing 11A; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, CCHC domain containing 9; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, CSL-type containing 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins

(zinc finger proteins, Chk2-Interacting; double-stranded RNAs and
their use for downregulating genes and treating cardiovascular
diseases)
IT DNA-binding proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, FYVE domain containing 9; double-stranded RNAs and their use for downregulating genes and treating

cardiovascular diseases) ΤТ DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, GLIS family zinc finger 2; doublestranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT DNA-binding proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger proteins, matrin type 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤТ Proteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (zyxin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Antibodies and Immunoglobulins ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\kappa$ -chain, VJ region; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΤT Laminins RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$  subunit,  $\alpha$ 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Karvopherins RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha, \alpha 3; double-stranded RNAs and their use for$ downregulating genes and treating cardiovascular diseases) ΙT Spectrins RL: BSU (Biological study, unclassified); BIOL (Biological study) (lpha-, SPTAN1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Spectrins RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha-, \text{ non-erythrocytic 1; double-stranded RNAs and their use for }$ downregulating genes and treating cardiovascular diseases) TΤ Hemoglobins RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha-2;$  double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Tubulins RL: BSU (Biological study, unclassified); BIOL (Biological study) (a-; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Actining RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ -actinin 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Actinins RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha$ -actinin 4; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) ΙT Collagens, biological studies RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha 1(III); double-stranded RNAs and their use for downregulating$ genes and treating cardiovascular diseases) ΤТ Collagens, biological studies RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1(IV); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) Collagens, biological studies ТТ RL: BSU (Biological study, unclassified); BIOL (Biological study)

- $(\alpha 1 \, (\text{V}) \, ; \, \, \text{double-stranded RNAs}$  and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1(VIII); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1(XII); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1(XV); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1(XVIII); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT  $\alpha$ -Actins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2$ (I); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2$  (IV); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2$  (V); double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)  $(\alpha 2 \, (\text{VI}); \, \text{double-stranded RNAs} \, \text{and their use for downregulating genes and treating cardiovascular diseases)}$
- IT  $\alpha$ -Actins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 2$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Collagens, biological studies
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 3\,(\mathrm{VI})$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Platelet-derived growth factors
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Crystallins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha B$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Microglobulins
  - Tubulins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha 1-$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)
- IT Macroglobulins
  - RL: BSU (Biological study, unclassified); BIOL (Biological study)

( $\alpha 2\text{--};$  double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Fibrinogens

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$  chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Karyopherins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ ,  $\beta$ 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -, non-erythrocytic 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Spectrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -, non-erythrocytic 2; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Tubulins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -chimaerin; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -galactosidase protective protein; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ -like 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ 1; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Integrins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\beta$ 5; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Fibrinogens

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma$  chain; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Catenins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma$ -; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT γ-Actins

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\gamma 1-$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT Laminins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

```
(\gamma 1; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΤТ
     γ-Actins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\gamma 2-; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     Hemoglobins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\varepsilon-1); double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     Crystallins
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\mu-; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     71427-00-4, Ribonuclease P
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (14kDa subunit; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     37205-61-1, Proteinase inhibitor
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (16; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     9026-23-7, Carbamoyl-phosphate synthetase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (2; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
     9025-77-8, Phosphatidic acid phosphatase
TΤ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (2B; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     433940-25-1, MRNA splicing endonuclease
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (34 homolog; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
ΙT
     109136-49-4, Ubiquitin specific protease
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (5; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     95076-93-0, Peptidylprolyl isomerase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (A, B and C; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
                 9054-75-5, Guanylate cyclase
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (A; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΤТ
     9032-58-0, Farnesyltransferase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (CAAX box, \beta-; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     9013-93-8, Phospholipase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (D3; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
     9082-72-8, Branched-chain keto acid dehydrogenase
ΤT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (E1; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     9000-83-3, ATPase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
```

(H+, Ca2+, or Na+/K+-transporting; double-stranded RNAs and their use

```
for downregulating genes and treating cardiovascular
        diseases)
     9014-24-8
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (I, II and III; double-stranded RNAs and their use for downregulating
        genes and treating cardiovascular diseases)
     9001-85-8, Lysophospholipase
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (II or 3; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     80449-02-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (Ig-like and EGF-like domains-containing, 1; double-stranded RNAs and their
        use for downregulating genes and treating cardiovascular
        diseases)
     866261-76-9
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (MX; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
     9068-67-1, Sulfatase
ΤT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (SULF-2; double-stranded RNAs and their use for downregulating genes
        and treating cardiovascular diseases)
ΙT
     9031-98-5, Carboxypeptidase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (X; double-stranded RNAs and their use for downregulating genes and
        treating cardiovascular diseases)
ΙT
     96282-35-8, Serpin
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (clade A, member 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     139691-92-2, Serine proteinase inhibitor
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (clade G member 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
     9025-42-7
TΤ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (class 2A, member 1; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     9000-86-6, Glutamic-pyruvate transaminase 9000-95-7, Ectonucleoside
     triphosphate diphosphohydrolase
                                       9000-96-8, Arginase 9001-15-4,
     Creatine kinase
                      9001-16-5, Cytochrome c oxidase
                                                         9001-26-7, Coagulation
                9001-42-7, \alpha-Glucosidase
     factor II
                                           9001-52-9,
     Fructose-1,6-bisphosphatase
                                  9001-58-5, Isocitrate dehydrogenase
     9001-59-6, Pyruvate kinase
                                 9001-60-9, Lactate dehydrogenase
                                                                     9001-62-1,
     Lipase A 9001-63-2, Lysozyme 9001-64-3, Malate dehydrogenase
     9001-77-8, Acid phosphatase 9001-78-9, Alkaline phosphatase
                                                                     9001-80-3,
     Phosphofructokinase 9001-82-5, Phosphogluconate dehydrogenase
                                     9004-02-8, Lipoprotein lipase
     9001-88-1, Phosphorylase kinase
     9012-34-4, Acylphosphatase 9012-42-4, Adenylate cyclase
                                                                 9012-49-1,
                                  9012-52-6, Methionine adenosyltransferase
     Aspartate transcarbamylase
     9013-02-9, Adenylate kinase
                                 9013-10-9, Glucosamine-6-phosphate deaminase
     9013-18-7, Acyl-CoA synthetase 9013-66-5, Glutathione peroxidase
                        9014-20-4, Pyruvate dehydrogenase
     9014-08-8, Enolase
                                                             9014-34-0, Fatty
                     9016-12-0, Hypoxanthine phosphoribosyltransferase
     acid desaturase
     9023-44-3, Tryptophanyl-tRNA synthetase 9023-47-6, Valyl-tRNA synthetase
     9023-53-4, Phosphoribosylaminoimidazole synthetase
                                                          9023-58-9,
     Argininosuccinate synthetase
                                  9023-66-9, Formyltetrahydrofolate
                 9023-70-5, Glutamate-ammonia ligase
     synthetase
                                                       9023-78-3,
                               9023-93-2, Acetyl-Coenzyme A carboxylase
     Triosephosphate isomerase
     9024-25-3, Aconitase 9024-60-6, Ornithine decarboxylase 9024-93-5,
```

```
Dihydroorotase 9025-26-7, Cathepsin D 9025-32-5 9025-54-1,
S-Adenosylhomocysteine hydrolase 9025-83-6, 3'(2'),5'-Bisphosphate
nucleotidase 9026-39-5, Uridine-cytidine kinase 9026-43-1 9026-46-4,
Phosphomevalonate kinase 9026-59-9, Guanylate kinase 9027-03-6,
Ubiquinol-cytochrome c reductase 9027-13-8, Enoyl Coenzyme A hydratase
           9027-63-8, Sterol acyltransferase 9027-80-9, Adenine
9027-33-2
phosphoribosyltransferase 9027-81-0, Adenylosuccinate lyase
                                                                9027-95-6,
ATP citrate lyase 9027-97-8, Methenyltetrahydrofolate cyclohydrolase
9028-04-0, NADH dehydrogenase 9028-06-2 9028-39-1,
3-Hydroxyisobutyrate dehydrogenase 9028-40-4, 3-Hydroxyacyl-Coenzyme A
dehydrogenase 9028-86-8, Aldehyde dehydrogenase 9028-93-7, IMP
dehydrogenase 9029-12-3, Glutamate dehydrogenase 1 9029-14-5,
Methylenetetrahydrofolate dehydrogenase 9029-32-7, Guanosine
monophosphate reductase 9029-72-5, p-Hydroxyphenylpyruvate dioxygenase
9029-73-6, Phenylalanine hydroxylase 9029-78-1, Betaine-homocysteine
methyltransferase 9030-08-4, UDP glucuronosyltransferase 9030-66-4,
Glycerol kinase 9030-96-0, Isoleucine-tRNA synthetase 9031-19-0,
Saccharopine dehydrogenase 9031-26-9, Lysyl-tRNA synthetase
                                                                9031-37-2,
Ceruloplasmin 9031-50-9, Nucleotidyltransferase 9031-68-9,
Galactosyltransferase 9031-71-4, Alanyl-tRNA synthetase 9031-82-7,
Phosphoribosyl pyrophosphate amidotransferase 9031-86-1, Aspartoacylase 9031-99-6, Dipeptidase 9032-01-3 9032-02-4, Phosphoribosylglycinamide
formyltransferase 9032-25-1, Cytochrome b5 reductase 9032-59-1,
Fumarylacetoacetate hydrolase 9032-62-6, Phosphoglycerate mutase
9032-68-2, Cathepsin C 9032-95-5 9033-53-8, Retinol dehydrogenase
9033-55-0, Saccharopine dehydrogenase
                                      9036-20-8, Adenosylmethionine
decarboxylase 9036-37-7, \delta-Aminolevulinate dehydratase
9037-14-3, \delta-Aminolevulinate synthase 9037-42-7, DNA
methyltransferase 9037-62-1, Glycyl-tRNA synthetase
                                                        9037-65-4,
               9046-67-7, Serine carboxypeptidase 9047-22-7,
\alpha-L-Fucosidase
            9048-63-9, Epoxide hydrolase 9054-44-8,
Cathepsin B
Acetylgalactosaminyltransferase 9054-89-1, Superoxide dismutase
9055-65-6, Prostaglandin synthase 9055-67-8, Tankyrase 9055-72-5,
Pyridoxine-5'-phosphate oxidase 9059-22-7, Heme oxygenase 9059-25-0,
              9073-96-5, Saccharopine dehydrogenase 9074-01-5,
Lysyl oxidase
Pyruvate dehydrogenase kinase 9074-14-0, Thioredoxin reductase
9074-83-3, Aspartyl aminopeptidase 9074-87-7, Glutamate carboxypeptidase
9075-21-2, Pyroglutamyl-peptidase I 9075-29-0, Phosphoglycerate
               9075-59-6, Glutaminyl-tRNA synthetase
dehydrogenase
Prolylcarboxypeptidase 9077-14-9, Farnesyl diphosphate
farnesyltransferase
                    9080-21-1, 7-Dehydrocholesterol reductase
37228-72-1, Glycine N-methyltransferase 37256-26-1, Saccharopine
dehydrogenase
               37256-59-0, Cysteine dioxygenase 37256-73-8,
Flavin-containing monooxygenase 37270-94-3, Platelet factor 4
37278-25-4, Ribonuclease T2 37288-40-7, N-Acetyl-\alpha-glucosaminidase
37289-06-8, N-Acylsphingosine amidohydrolase 37318-49-3, Protein
                                  39391-18-9, Prostaglandin-endoperoxide
disulfide isomerase 37341-57-4
synthase 50812-36-7, Farnesyl diphosphate synthase 50812-37-8,
Glutathione S-transferase 52227-79-9, Prostaglandin E synthase
52660-18-1, Casein kinase 1 53096-17-6, Bleomycin hydrolase
55963-40-1, Vitamin K epoxide reductase
                                        55976-95-9 60382-71-0,
Diacylglycerol kinase 60571-91-7, Hydroxysteroid dehydrogenase 7
60748-73-4, Cathepsin H 62213-44-9, Dolichyl-phosphate
mannosyltransferase 62213-50-7, Serine palmitoyltransferase
65979-36-4, Signal peptidase 67763-97-7, IGF-II
                                                   71124-51-1,
\beta-Galactoside \alpha-2,3-sialyltransferase 71965-46-3, Cathepsin S
74506-58-4, Heparan 2-O-sulfotransferase 74812-43-4, Spermine synthase 74812-49-0, E3 Ubiquitin protein ligase 76901-00-3, Platelet-activating
factor acetylhydrolase 77114-08-0, Serine racemase 77642-24-1,
            78689-77-7, 6-Phosphofructo-2-kinase 80146-85-6,
Thymosin β4
Transglutaminase 80295-41-6, Complement C3 80295-50-7, Complement C4b
```

```
81611-75-8, Fructose-2,6-bisphosphatase 81627-83-0, Colony-stimulating
factor 1 83268-44-4 83380-83-0 86480-67-3, Ubiquitin
carboxyl-terminal hydrolase 87397-91-9, Thymosin \beta10
                                                        89964-14-7,
Prothymosin, alpha 90597-47-0, Peptidylglycine \alpha-amidating
               95328-48-6, Parathymosin 98668-52-1, ADP ribosylarginine
monooxygenase
hydrolase 106283-10-7, Inositol 1,4,5-trisphosphate 3-kinase
106640-75-9, Aldo-keto reductase 108658-39-5, Myosin phosphatase
109319-16-6, Von Willebrand factor 115926-52-8,
Phosphoinositide-3-kinase 116283-83-1, Elongation factor-2 kinase
117444-13-0, TRNA splicing endonuclease 120178-12-3, Telomerase reverse
transcriptase 124861-55-8 127464-60-2, Vascular endothelial growth
factor 130731-20-3, Prenylcysteine carboxymethyltransferase
137632-07-6, Protein kinase ERK1 137632-08-7, Mitogen-activated protein
kinase 1 139316-54-4, Epithelin 141349-86-2, Cyclin-dependent kinase 2
141436-78-4, Protein kinase C 142008-29-5, CAMP-dependent protein kinase
143375-65-9, CDC2 protein 145809-21-8, Tissue inhibitor of
metalloproteinase 3 146480-35-5, Matrix metalloproteinase 2
146480-36-6, Matrix metalloproteinase 9 146702-84-3, Mitogen-activated
protein kinase kinase kinase 147014-97-9, Cyclin-dependent kinase 4
149371-18-6, Legumain 149885-84-7 151125-25-6, Selenophosphate
synthetase 151662-36-1, Tripeptidyl peptidase I 151821-61-3, Ubiquitin
                             152478-57-4, Janus kinase 2 153190-63-7, 154531-34-7, Heparin-binding EGF-like
   151821-62-4, Ubiquitin C
AXL receptor tyrosine kinase
growth factor 156681-44-6, \alpha-Methylacyl-CoA racemase
165245-96-5, Mitogen-activated protein kinase 14
                                                  167397-96-8,
Interleukin-1 receptor-associated kinase 1 169277-44-5,
Sphingosine-1-phosphate phosphatase 171715-12-1, Cathepsin Z
172308-13-3, Mitogen-activated protein kinase kinase 3 178037-70-2,
Serum- and glucocorticoid-regulated protein kinase 180189-96-2, Caspase
   183257-54-7, Heparan sulfate 3-O-sulfotransferase 186270-49-5,
                186359-58-0, Protein kinase ZAK 189460-40-0, Connective
Angiopoietin 1
tissue growth factor 190396-38-4, Carboxypeptidase Z 192140-83-3,
p21-Activated kinase 2 192662-83-2, Vascular endothelial growth factor B
204719-95-9, Fibroblast growth factor 16 207137-51-7, Peroxiredoxin
207137-52-8, Nemo like kinase 214210-47-6, Neuropilin 1 220983-94-8,
Sorbitol dehydrogenase 252901-98-7, Tousled-like kinase 1 271597-11-6,
Growth differentiation factor 3
                                271597-13-8, Growth differentiation
          300855-77-0, Protein tyrosine phosphatase, non-receptor type 6
300857-36-7, Protein tyrosine phosphatase, receptor type, D
Receptor protein tyrosine phosphatase N 302355-88-0 336874-97-6,
                      353498-78-9, Mitogen-activated protein kinase 6
Cvtochrome P 450 3A5
370088-29-2, Mitogen-activated protein kinase kinase kinase 4
372092-80-3, Protein kinase
                             372170-33-7, Apelin
                                                  400653-73-8, Dual
specificity phosphatase 5
                          403648-87-3, Protein kinase Cdc28
403652-37-9, Cyclin-dependent kinase 8 423124-77-0, Inter-\alpha
trypsin inhibitor 4 438496-81-2, Sirtuin 443900-95-6, Glycogen
synthase kinase 3\beta 644991-16-2, Peroxiredoxin 6
                                                   676145-27-0,
Protein tyrosine phosphatase, non-receptor type 18
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
689772-77-8, Calpain 7 710319-61-2, Sestrin 2 859235-38-4, WNK kinase
905848-61-5, Cytochrome P 450 20A1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
929740-27-2
             929740-28-3
                           929740-29-4
                                         929740-30-7
                                                       929740-31-8
                                       929740-35-2
929740-32-9 929740-33-0
                           929740-34-1
                                                       929740-36-3
929740-37-4 929740-38-5
                          929740-39-6 929740-40-9 929740-41-0
929740-42-1 \qquad 929740-43-2 \qquad 929740-44-3 \qquad 929740-45-4 \qquad 929740-46-5
929740-47-6 929740-48-7
                          929740-49-8 929740-50-1 929740-51-2
```

ΙT

ΙT

```
929740-52-3
              929740-53-4
                            929740-54-5
                                           929740-55-6
                                                         929740-56-7
929740-57-8
              929740-58-9
                            929740-59-0
                                           929740-60-3
                                                         929740-61-4
929740-62-5
              929740-63-6
                            929740-64-7
                                           929740-65-8
                                                         929740-66-9
                                                         929740-71-6
929740-67-0
              929740-68-1
                            929740-69-2
                                           929740-70-5
                                           929740-75-0
929740-72-7
              929740-73-8
                            929740-74-9
                                                         929740-76-1
929740-77-2
              929740-78-3
                            929740-79-4
                                          929740-80-7
                                                         929740-81-8
929740-82-9
              929740-83-0
                            929740-84-1
                                          929740-85-2
                                                         929740-86-3
929740-87-4
              929740-88-5
                            929740-89-6
                                           929740-90-9
                                                         929740-91-0
929740-92-1
              929740-93-2
                            929740-94-3
                                           929740-95-4
                                                         929740-96-5
929740-97-6
              929740-98-7
                            929740-99-8
                                           929741-00-4
                                                         929741-01-5
929741-02-6
              929741-03-7
                            929741-04-8
                                           929741-05-9
                                                         929741-06-0
929741-07-1
              929741-08-2
                            929741-09-3
                                           929741-10-6
                                                         929741-11-7
929741-12-8
              929741-13-9
                            929741-14-0
                                           929741-15-1
                                                         929741-16-2
929741-17-3
              929741-18-4
                            929741-19-5
                                           929741-20-8
                                                         929741-21-9
929741-22-0
              929741-23-1
                            929741-24-2
                                           929741-25-3
                                                         929741-26-4
929741-27-5
                            929741-29-7
                                           929741-30-0
                                                         929741-31-1
              929741-28-6
              929741-33-3
                            929741-34-4
                                                         929741-36-6
929741-32-2
                                           929741-35-5
929741-37-7
              929741-38-8
                            929741-39-9
                                           929741-40-2
                                                         929741-41-3
              929741-43-5
                            929741-44-6
                                           929741-45-7
                                                         929741-46-8
929741-42-4
929741-47-9
              929741-48-0
                            929741-49-1
                                           929741-50-4
                                                         929741-51-5
929741-52-6
              929741-53-7
                            929741-54-8
                                           929741-55-9
                                                         929741-56-0
929741-57-1
              929741-58-2
                            929741-59-3
                                           929741-60-6
                                                         929741-61-7
929741-62-8
              929741-63-9
                            929741-64-0
                                           929741-65-1
                                                         929741-66-2
929741-67-3
              929741-68-4
                            929741-69-5
                                           929741-70-8
                                                         929741-71-9
929741-72-0
              929741-73-1
                            929741-74-2
                                           929741-75-3
                                                         929741-76-4
                            929741-79-7
                                           929741-80-0
929741-77-5
              929741-78-6
                                                         929741-81-1
929741-82-2
                            929741-84-4
                                          929741-85-5
              929741-83-3
                                                         929741-86-6
929741-87-7
              929741-88-8
                            929741-89-9
                                          929741-90-2
                                                         929741-91-3
929741-92-4
              929741-93-5
                            929741-94-6
                                          929741-95-7
                                                         929741-96-8
                                                         929742-01-8
929741-97-9
              929741-98-0
                            929741-99-1
                                          929742-00-7
                                                         929742-06-3
929742-02-9
              929742-03-0
                            929742-04-1
                                          929742-05-2
                                                         929742-11-0
929742-07-4
             929742-08-5
                            929742-09-6
                                         929742-10-9
                            929742-14-3
                                         929742-15-4
                                                         929742-16-5
929742-12-1
             929742-13-2
                                                         929742-21-2
929742-17-6
             929742-18-7
                            929742-19-8
                                         929742-20-1
929742-22-3
                            929742-24-5
                                         929742-25-6
                                                         929742-26-7
             929742-23-4
929742-27-8
             929742-28-9
                            929742-29-0
                                          929742-30-3
                                                         929742-31-4
929742-32-5
              929742-33-6
                            929742-34-7
                                          929742-35-8
                                                         929742-36-9
929742-37-0
              929742-38-1
                            929742-39-2
                                           929742-40-5
                                                         929742-41-6
929742-42-7
              929742-43-8
                            929742-44-9
                                           929742-45-0
                                                         929742-46-1
929742-47-2
              929742-48-3
                            929742-49-4
                                           929742-50-7
                                                         929742-51-8
929742-52-9
              929742-53-0
                            929742-54-1
                                           929742-55-2
                                                         929742-56-3
929742-57-4
              929742-58-5
                            929742-59-6
                                           929742-60-9
                                                         929742-61-0
929742-62-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene CTTN-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929742-63-2
              929742-64-3
                            929742-65-4
                                           929742-66-5
                                                         929742-67-6
                                                         929742-72-3
929742-68-7
              929742-69-8
                            929742-70-1
                                           929742-71-2
                                                         929742-77-8
929742-73-4
              929742-74-5
                            929742-75-6
                                           929742-76-7
929742-78-9
              929742-79-0
                            929742-80-3
                                           929742-81-4
                                                         929742-82-5
929742-83-6
              929742-84-7
                            929742-85-8
                                           929742-86-9
                                                         929742-87-0
```

929742-88-1 929742-89-2 929742-90-5 929742-91-6 929742-92-7 929742-93-8 929742-94-9 929742-95-0 929742-96-1 929742-97-2 929742-98-3 929743-00-0 929743-01-1 929743-02-2 929742-99-4 929743-03-3 929743-04-4 929743-05-5 929743-06-6 929743-07-7 929743-08-8 929743-09-9 929743-10-2 929743-11-3 929743-12-4 929743-15-7 929743-17-9 929743-13-5 929743-14-6 929743-16-8 929743-18-0 929743-20-4 929743-22-6 929743-19-1 929743-21-5 929743-26-0 929743-24-8 929743-25-9 929743-27-1 929743-23-7 929743-28-2 929743-29-3 929743-30-6 929743-31-7 929743-32-8

ΙT

```
929743-35-1
                                               929743-36-2
                                                              929743-37-3
     929743-38-4
                   929743-39-5
                                 929743-40-8
                                               929743-41-9
                                                              929743-42-0
     929743-43-1
                   929743-44-2
                                 929743-45-3
                                               929743-46-4
                                                              929743-47-5
                                                929743-51-1
                                                              929743-52-2
     929743-48-6
                   929743-49-7
                                 929743-50-0
                                                929743-56-6
                                                              929743-57-7
                                 929743-55-5
     929743-53-3
                   929743-54-4
     929743-58-8
                   929743-59-9
                                 929743-60-2
                                                929743-61-3
                                                              929743-62-4
     929743-63-5
                   929743-64-6
                                 929743-65-7
                                                929743-66-8
                                                              929743-67-9
     929743-68-0
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
        (gene CTTN-targeting siRNA; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     929743-69-1
                   929743-70-4
                                 929743-71-5
                                               929743-72-6
                                                              929743-73-7
     929743-74-8
                   929743-75-9
                                 929743-76-0
                                                929743-77-1
                                                              929743-78-2
                   929743-80-6
     929743-79-3
                                 929743-81-7
                                                929743-82-8
                                                              929743-83-9
                                                929743-87-3
                                                              929743-88-4
     929743-84-0
                   929743-85-1
                                 929743-86-2
     929743-89-5
                   929743-90-8
                                 929743-91-9
                                                929743-92-0
                                                              929743-93-1
     929743-94-2
                   929743-95-3
                                 929743-96-4
                                                929743-97-5
                                                              929743-98-6
     929743-99-7
                                                              929744-03-6
                   929744-00-3
                                 929744-01-4
                                                929744-02-5
     929744-04-7
                   929744-05-8
                                                929744-07-0
                                                              929744-08-1
                                 929744-06-9
     929744-09-2
                   929744-10-5
                                 929744-11-6
                                                929744-12-7
                                                              929744-13-8
     929744-14-9
                   929744-15-0
                                 929744-16-1
                                                929744-17-2
                                                              929744-18-3
     929744-19-4
                   929744-20-7
                                 929744-21-8
                                                929744-22-9
                                                              929744-23-0
     929744-24-1
                   929744-25-2
                                 929744-26-3
                                                929744-27-4
                                                              929744-28-5
     929744-29-6
                   929744-30-9
                                 929744-31-0
                                                929744-32-1
                                                              929744-33-2
     929744-34-3
                                                              929744-38-7
                   929744-35-4
                                 929744-36-5
                                                929744-37-6
     929744-39-8
                   929744-40-1
                                 929744-41-2
                                               929744-42-3
                                                              929744-43-4
     929744-44-5
                   929744-45-6
                                 929744-46-7
                                               929744-47-8
                                                              929744-48-9
     929744-49-0
                   929744-50-3
                                 929744-51-4
                                               929744-52-5
                                                              929744-53-6
                   929744-55-8
                                                              929744-58-1
     929744-54-7
                                 929744-56-9
                                               929744-57-0
                                                              929744-63-8
     929744-59-2
                   929744-60-5
                                 929744-61-6
                                               929744-62-7
     929744-64-9
                                                              929744-68-3
                   929744-65-0
                                 929744-66-1
                                               929744-67-2
                  929744-70-7
                                 929744-71-8
                                                              929744-73-0
     929744-69-4
                                              929744-72-9
     929744-74-1
                                 929744-76-3
                                              929744-77-4
                   929744-75-2
                                                              929744-78-5
     929744-79-6
                                 929744-81-0
                                              929744-82-1
                                                              929744-83-2
                  929744-80-9
     929744-84-3
                   929744-85-4
                                 929744-86-5
                                              929744-87-6
                                                              929744-88-7
     929744-89-8
                   929744-90-1
                                 929744-91-2
                                              929744-92-3
                                                              929744-93-4
     929744-94-5
                   929744-95-6
                                 929744-96-7
                                              929744-97-8
                                                              929744-98-9
     929744-99-0
                   929745-00-6
                                 929745-01-7
                                              929745-02-8
                                                              929745-03-9
     929745-04-0
                   929745-05-1
                                 929745-06-2
                                              929745-07-3
                                                              929745-08-4
     929745-09-5
                   929745-10-8
                                 929745-11-9
                                               929745-12-0
                                                              929745-13-1
     929745-14-2
                   929745-15-3
                                 929745-16-4
                                               929745-17-5
                                                              929745-18-6
     929745-19-7
                   929745-20-0
                                 929745-21-1
                                               929745-22-2
                                                              929745-23-3
     929745-24-4
                   929745-25-5
                                 929745-26-6
                                               929745-27-7
                                                              929745-28-8
     929745-29-9
                                 929745-31-3
                                               929745-32-4
                                                              929745-33-5
                   929745-30-2
                                               929745-37-9
     929745-34-6
                   929745-35-7
                                 929745-36-8
                                                              929745-38-0
     929745-39-1
                   929745-40-4
                                 929745-41-5
                                               929745-42-6
                                                              929745-43-7
                                                              929745-48-2
                                                929745-47-1
     929745-44-8
                   929745-45-9
                                 929745-46-0
                                                929745-52-8
                                                              929745-53-9
     929745-49-3
                   929745-50-6
                                 929745-51-7
     929745-54-0
                   929745-55-1
                                 929745-56-2
                                                929745-57-3
                                                              929745-58-4
     929745-59-5
                   929745-60-8
                                 929745-61-9
                                                929745-62-0
                                                              929745-63-1
     929745-64-2
                   929745-65-3
                                 929745-66-4
                                                929745-67-5
                                                              929745-68-6
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (gene FXYD5-targeting siRNA; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     929745-69-7
                   929745-70-0
                                 929745-71-1
                                                929745-72-2
                                                              929745-73-3
     929745-74-4
                   929745-75-5
                                 929745-76-6
                                                929745-77-7
                                                              929745-78-8
     929745-79-9
                   929745-80-2
                                 929745-81-3
                                               929745-82-4
                                                              929745-83-5
     929745-84-6
                   929745-85-7
                                 929745-86-8
                                               929745-87-9
                                                              929745-88-0
     929745-89-1
                   929745-90-4
                                 929745-91-5
                                               929745-92-6
                                                              929745-93-7
```

929743-33-9

929743-34-0

```
929746-04-3
                   929746-05-4
                                                               929746-08-7
                                                               929746-13-4
     929746-09-8
                   929746-10-1
                                  929746-11-2
                                                929746-12-3
                                  929746-16-7
                                                929746-17-8
                                                               929746-18-9
     929746-14-5
                   929746-15-6
     929746-19-0
                   929746-20-3
                                  929746-21-4
                                                929746-22-5
                                                               929746-23-6
     929746-24-7
                   929746-25-8
                                  929746-26-9
                                                929746-27-0
                                                               929746-28-1
     929746-29-2
                   929746-30-5
                                  929746-31-6
                                                929746-32-7
                                                               929746-33-8
     929746-34-9
                   929746-35-0
                                  929746-36-1
                                                929746-37-2
                                                               929746-38-3
     929746-39-4
                   929746-40-7
                                  929746-41-8
                                                929746-42-9
                                                               929746-43-0
                   929746-45-2
                                  929746-46-3
                                                929746-47-4
                                                               929746-48-5
     929746-44-1
                                                               929746-53-2
     929746-49-6
                   929746-50-9
                                  929746-51-0
                                                929746-52-1
     929746-54-3
                   929746-55-4
                                  929746-56-5
                                                929746-57-6
                                                               929746-58-7
     929746-59-8
                   929746-60-1
                                  929746-61-2
                                                929746-62-3
                                                               929746-63-4
     929746-64-5
                   929746-65-6
                                  929746-66-7
                                                929746-67-8
                                                               929746-68-9
                   929746-70-3
                                  929746-71-4
                                                929746-72-5
                                                               929746-73-6
     929746-69-0
     929746-74-7
                   929746-75-8
                                  929746-76-9
                                                929746-77-0
                                                               929746-78-1
     929746-79-2
                   929746-80-5
                                  929746-81-6
                                                929746-82-7
                                                               929746-83-8
     929746-84-9
                   929746-85-0
                                                929746-87-2
                                                               929746-88-3
                                  929746-86-1
     929746-89-4
                   929746-90-7
                                  929746-91-8
                                                929746-92-9
                                                               929746-93-0
     929746-94-1
                   929746-95-2
                                  929746-96-3
                                                929746-97-4
                                                               929746-98-5
     929746-99-6
                   929747-00-2
                                  929747-01-3
                                                929747-02-4
                                                               929747-03-5
     929747-04-6
                   929747-05-7
                                  929747-06-8
                                                929747-07-9
                                                               929747-08-0
     929747-09-1
                   929747-10-4
                                  929747-11-5
                                                929747-12-6
                                                               929747-13-7
                                                               929747-18-2
     929747-14-8
                   929747-15-9
                                  929747-16-0
                                                929747-17-1
     929747-19-3
                   929747-20-6
                                                929747-22-8
                                                               929747-23-9
                                  929747-21-7
     929747-24-0
                   929747-25-1
                                                929747-27-3
                                                               929747-28-4
                                  929747-26-2
     929747-29-5
                   929747-30-8
                                  929747-31-9
                                                929747-32-0
                                                               929747-33-1
     929747-34-2
                   929747-35-3
                                  929747-36-4
                                                929747-37-5
                                                               929747-38-6
     929747-39-7
                   929747-40-0
                                 929747-41-1
                                                929747-42-2
                                                               929747-43-3
     929747-44-4
                   929747-45-5
                                 929747-46-6
                                                929747-47-7
                                                               929747-48-8
     929747-49-9
                                                929747-52-4
                                                               929747-53-5
                   929747-50-2
                                 929747-51-3
     929747-54-6
                   929747-55-7
                                 929747-56-8
                                               929747-57-9
                                                               929747-58-0
     929747-59-1
                   929747-60-4
                                 929747-61-5
                                                929747-62-6
                                                               929747-63-7
     929747-64-8
                   929747-65-9
                                 929747-66-0
                                                929747-67-1
                                                               929747-68-2
     929747-69-3
                   929747-70-6
                                 929747-71-7
                                                929747-72-8
                                                               929747-73-9
     929747-74-0
                   929747-75-1
                                  929747-76-2
                                                929747-77-3
                                                               929747-78-4
     929747-79-5
                   929747-80-8
                                  929747-81-9
                                                929747-82-0
                                                               929747-83-1
     929747-84-2
                   929747-85-3
                                  929747-86-4
                                                929747-87-5
                                                               929747-88-6
     929747-89-7
                   929747-90-0
                                  929747-91-1
                                                929747-92-2
                                                               929747-93-3
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (gene HBEGF-targeting siRNA; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
                                                               929747-98-8
                   929747-95-5
                                                929747-97-7
ΤT
     929747-94-4
                                  929747-96-6
     929747-99-9
                   929748-00-5
                                  929748-01-6
                                                929748-02-7
                                                               929748-03-8
     929748-04-9
                   929748-05-0
                                  929748-06-1
                                                929748-07-2
                                                               929748-08-3
                                                929748-12-9
                                                               929748-13-0
     929748-09-4
                   929748-10-7
                                  929748-11-8
                                  929748-16-3
                                                929748-17-4
                                                               929748-18-5
     929748-14-1
                   929748-15-2
     929748-19-6
                   929748-20-9
                                  929748-21-0
                                                929748-22-1
                                                               929748-23-2
     929748-24-3
                   929748-25-4
                                  929748-26-5
                                                929748-27-6
                                                               929748-28-7
     929748-29-8
                   929748-30-1
                                  929748-31-2
                                                929748-32-3
                                                               929748-33-4
     929748-34-5
                   929748-35-6
                                  929748-36-7
                                                929748-37-8
                                                               929748-38-9
     929748-39-0
                   929748-40-3
                                                929748-42-5
                                                               929748-43-6
                                  929748-41-4
     929748-44-7
                                                929748-47-0
                                                               929748-48-1
                   929748-45-8
                                  929748-46-9
     929748-49-2
                   929748-50-5
                                  929748-51-6
                                                929748-52-7
                                                               929748-53-8
     929748-54-9
                   929748-55-0
                                  929748-56-1
                                                929748-57-2
                                                               929748-58-3
     929748-59-4
                   929748-60-7
                                  929748-61-8
                                                929748-62-9
                                                               929748-63-0
     929748-64-1
                   929748-65-2
                                  929748-66-3
                                                929748-67-4
                                                               929748-68-5
                                                929748-72-1
     929748-69-6
                                  929748-71-0
                                                               929748-73-2
                   929748-70-9
                   929748-75-4
     929748-74-3
                                  929748-76-5
                                                929748-77-6
                                                               929748-78-7
```

929745-96-0

929746-01-0

929746-06-5

929745-97-1

929746-02-1

929746-07-6

929745-98-2

929746-03-2

929745-94-8

929745-99-3

929745-95-9

929746-00-9

```
929748-79-8
              929748-80-1
                             929748-81-2
                                           929748-82-3
                                                          929748-83-4
929748-84-5
              929748-85-6
                             929748-86-7
                                           929748-87-8
                                                          929748-88-9
                             929748-91-4
                                           929748-92-5
                                                          929748-93-6
929748-89-0
              929748-90-3
929748-94-7
              929748-95-8
                             929748-96-9
                                           929748-97-0
                                                          929748-98-1
                                                          929749-03-1
929748-99-2
              929749-00-8
                             929749-01-9
                                           929749-02-0
929749-04-2
              929749-05-3
                             929749-06-4
                                           929749-07-5
                                                          929749-08-6
929749-09-7
              929749-10-0
                             929749-11-1
                                           929749-12-2
                                                          929749-13-3
929749-14-4
              929749-15-5
                             929749-16-6
                                           929749-17-7
                                                          929749-18-8
929749-19-9
              929749-20-2
                             929749-21-3
                                           929749-22-4
                                                          929749-23-5
929749-24-6
              929749-25-7
                             929749-26-8
                                           929749-27-9
                                                          929749-28-0
929749-29-1
                             929749-31-5
                                           929749-32-6
                                                          929749-33-7
              929749-30-4
929749-34-8
              929749-35-9
                             929749-36-0
                                           929749-37-1
                                                          929749-38-2
929749-39-3
              929749-40-6
                             929749-41-7
                                           929749-42-8
                                                          929749-43-9
929749-44-0
              929749-45-1
                             929749-46-2
                                           929749-47-3
                                                          929749-48-4
929749-49-5
              929749-50-8
                             929749-51-9
                                           929749-52-0
                                                          929749-53-1
                                           929749-57-5
                                                          929749-58-6
929749-54-2
              929749-55-3
                             929749-56-4
929749-59-7
              929749-60-0
                             929749-61-1
                                           929749-62-2
                                                          929749-63-3
                                           929749-67-7
                                                          929749-68-8
929749-64-4
              929749-65-5
                             929749-66-6
                             929749-71-3
                                           929749-72-4
                                                          929749-73-5
929749-69-9
              929749-70-2
929749-74-6
                             929749-76-8
                                           929749-77-9
                                                          929749-78-0
              929749-75-7
929749-79-1
              929749-80-4
                             929749-81-5
                                           929749-82-6
                                                          929749-83-7
929749-84-8
              929749-85-9
                             929749-86-0
                                           929749-87-1
                                                          929749-88-2
929749-89-3
              929749-90-6
                             929749-91-7
                                           929749-92-8
                                                          929749-93-9
929749-94-0
              929749-95-1
                             929749-96-2
                                           929749-97-3
                                                          929749-98-4
929749-99-5
                             929750-01-6
                                           929750-02-7
              929750-00-5
                                                          929750-03-8
929750-04-9
              929750-05-0
                             929750-06-1
                                           929750-07-2
                                                          929750-08-3
929750-09-4
              929750-10-7
                             929750-11-8
                                           929750-12-9
                                                          929750-13-0
929750-14-1
              929750-15-2
                             929750-16-3
                                           929750-17-4
                                                          929750-18-5
929750-19-6
                                                          929750-23-2
              929750-20-9
                             929750-21-0
                                           929750-22-1
                             929750-26-5
                                           929750-27-6
                                                          929750-28-7
929750-24-3
              929750-25-4
929750-29-8
```

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

```
ΤT
     929750-30-1
                   929750-31-2
                                 929750-32-3
                                                929750-33-4
                                                              929750-34-5
     929750-35-6
                   929750-36-7
                                 929750-37-8
                                                929750-38-9
                                                              929750-39-0
     929750-40-3
                   929750-41-4
                                 929750-42-5
                                                929750-43-6
                                                              929750-44-7
     929750-45-8
                   929750-46-9
                                 929750-47-0
                                                929750-48-1
                                                              929750-49-2
     929750-50-5
                                 929750-52-7
                                                929750-53-8
                                                              929750-54-9
                   929750-51-6
     929750-55-0
                   929750-56-1
                                 929750-57-2
                                                929750-58-3
                                                              929750-59-4
     929750-60-7
                   929750-61-8
                                 929750-62-9
                                                929750-63-0
                                                              929750-64-1
     929750-65-2
                   929750-66-3
                                 929750-67-4
                                                929750-68-5
                                                              929750-69-6
     929750-70-9
                   929750-71-0
                                 929750-72-1
                                                929750-73-2
                                                              929750-74-3
     929750-75-4
                   929750-76-5
                                 929750-77-6
                                                929750-78-7
                                                              929750-79-8
                                                              929750-84-5
     929750-80-1
                   929750-81-2
                                 929750-82-3
                                                929750-83-4
                   929750-86-7
                                 929750-87-8
                                                929750-88-9
                                                              929750-89-0
     929750-85-6
     929750-90-3
                   929750-91-4
                                 929750-92-5
                                                929750-93-6
                                                              929750-94-7
     929750-95-8
                   929750-96-9
                                 929750-97-0
                                                929750-98-1
                                                              929750-99-2
     929751-00-8
                   929751-01-9
                                 929751-02-0
                                                929751-03-1
                                                              929751-04-2
     929751-05-3
                   929751-06-4
                                 929751-07-5
                                                929751-08-6
                                                              929751-09-7
     929751-10-0
                   929751-11-1
                                  929751-12-2
                                                929751-13-3
                                                              929751-14-4
     929751-15-5
                                  929751-17-7
                                                929751-18-8
                                                              929751-19-9
                   929751-16-6
     929751-20-2
                   929751-21-3
                                  929751-22-4
                                                929751-23-5
                                                              929751-24-6
     929751-25-7
                   929751-26-8
                                  929751-27-9
                                                929751-28-0
                                                              929751-29-1
     929751-30-4
                   929751-31-5
                                 929751-32-6
                                                929751-33-7
                                                              929751-34-8
     929751-35-9
                   929751-36-0
                                 929751-37-1
                                                929751-38-2
                                                              929751-39-3
     929751-40-6
                   929751-41-7
                                 929751-42-8
                                                929751-43-9
                                                              929751-44-0
     929751-45-1
                   929751-46-2
                                 929751-47-3
                                                929751-48-4
                                                              929751-49-5
     929751-50-8
                   929751-51-9
                                 929751-52-0
                                                929751-53-1
                                                              929751-54-2
     929751-55-3
                   929751-56-4
                                 929751-57-5
                                                929751-58-6
                                                              929751-59-7
```

```
929751-65-5
              929751-66-6
                            929751-67-7
                                           929751-68-8
                                                         929751-69-9
929751-70-2
              929751-71-3
                            929751-72-4
                                           929751-73-5
                                                         929751-74-6
929751-75-7
              929751-76-8
                            929751-77-9
                                           929751-78-0
                                                         929751-79-1
              929751-81-5
                            929751-82-6
                                           929751-83-7
                                                         929751-84-8
929751-80-4
929751-85-9
              929751-86-0
                            929751-87-1
                                           929751-88-2
                                                         929751-89-3
929751-90-6
              929751-91-7
                            929751-92-8
                                           929751-93-9
                                                         929751-94-0
929751-95-1
              929751-96-2
                            929751-97-3
                                           929751-98-4
                                                         929751-99-5
929752-00-1
              929752-01-2
                            929752-02-3
                                           929752-03-4
                                                         929752-04-5
929752-05-6
              929752-06-7
                            929752-07-8
                                           929752-08-9
                                                         929752-09-0
929752-10-3
              929752-11-4
                            929752-12-5
                                           929752-13-6
                                                         929752-14-7
929752-15-8
              929752-16-9
                            929752-17-0
                                           929752-18-1
                                                         929752-19-2
929752-20-5
              929752-21-6
                            929752-22-7
                                           929752-23-8
                                                         929752-24-9
929752-25-0
              929752-26-1
                            929752-27-2
                                           929752-28-3
                                                         929752-29-4
929752-30-7
              929752-31-8
                            929752-32-9
                                           929752-33-0
                                                         929752-34-1
929752-35-2
                            929752-37-4
                                           929752-38-5
                                                         929752-39-6
              929752-36-3
929752-40-9
              929752-41-0
                            929752-42-1
                                           929752-43-2
                                                         929752-44-3
              929752-46-5
                            929752-47-6
                                           929752-48-7
                                                         929752-49-8
929752-45-4
                            929752-52-3
                                           929752-53-4
                                                         929752-54-5
929752-50-1
              929752-51-2
              929752-56-7
                            929752-57-8
                                           929752-58-9
                                                         929752-59-0
929752-55-6
929752-60-3
              929752-61-4
                            929752-62-5
                                           929752-63-6
                                                         929752-64-7
929752-65-8
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929752-66-9
              929752-67-0
                            929752-68-1
                                         929752-69-2
                                                         929752-70-5
929752-71-6
              929752-72-7
                            929752-73-8
                                           929752-74-9
                                                         929752-75-0
929752-76-1
              929752-77-2
                            929752-78-3
                                           929752-79-4
                                                         929752-80-7
              929752-82-9
                                           929752-84-1
929752-81-8
                            929752-83-0
                                                         929752-85-2
              929752-87-4
                            929752-88-5
929752-86-3
                                           929752-89-6
                                                         929752-90-9
              929752-92-1
                                                         929752-95-4
929752-91-0
                            929752-93-2
                                           929752-94-3
929752-96-5
                            929752-98-7
                                           929752-99-8
              929752-97-6
                                                         929753-00-4
929753-01-5
              929753-02-6
                            929753-03-7
                                           929753-04-8
                                                         929753-05-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene IQGAP1-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929753-06-0
              929753-07-1
                            929753-08-2
                                           929753-09-3
                                                         929753-10-6
929753-11-7
                                           929753-14-0
                                                         929753-15-1
              929753-12-8
                            929753-13-9
929753-16-2
              929753-17-3
                            929753-18-4
                                           929753-19-5
                                                         929753-20-8
929753-21-9
              929753-22-0
                            929753-23-1
                                           929753-24-2
                                                         929753-25-3
929753-26-4
              929753-27-5
                            929753-28-6
                                           929753-29-7
                                                         929753-30-0
929753-31-1
              929753-32-2
                            929753-33-3
                                           929753-34-4
                                                         929753-35-5
                            929753-38-8
                                           929753-39-9
                                                         929753-40-2
929753-36-6
              929753-37-7
929753-41-3
              929753-42-4
                            929753-43-5
                                           929753-44-6
                                                         929753-45-7
              929753-47-9
                            929753-48-0
                                           929753-49-1
                                                         929753-50-4
929753-46-8
929753-51-5
              929753-52-6
                            929753-53-7
                                           929753-54-8
                                                         929753-55-9
929753-56-0
              929753-57-1
                            929753-58-2
                                           929753-59-3
                                                         929753-60-6
929753-61-7
              929753-62-8
                            929753-63-9
                                           929753-64-0
                                                         929753-65-1
929753-66-2
              929753-67-3
                            929753-68-4
                                           929753-69-5
                                                         929753-70-8
929753-71-9
              929753-72-0
                            929753-73-1
                                           929753-74-2
                                                         929753-75-3
929753-76-4
              929753-77-5
                            929753-78-6
                                           929753-79-7
                                                         929753-80-0
929753-81-1
                                           929753-84-4
              929753-82-2
                            929753-83-3
                                                         929753-85-5
929753-86-6
              929753-87-7
                            929753-88-8
                                           929753-89-9
                                                         929753-90-2
929753-91-3
              929753-92-4
                            929753-93-5
                                           929753-94-6
                                                         929753-95-7
929753-96-8
              929753-97-9
                            929753-98-0
                                           929753-99-1
                                                         929754-00-7
                                                         929754-05-2
929754-01-8
              929754-02-9
                            929754-03-0
                                           929754-04-1
929754-06-3
              929754-07-4
                            929754-08-5
                                           929754-09-6
                                                         929754-10-9
929754-11-0
              929754-12-1
                            929754-13-2
                                           929754-14-3
                                                         929754-15-4
929754-16-5
              929754-17-6
                            929754-18-7
                                           929754-19-8
                                                         929754-20-1
```

929751-62-2

929751-63-3

929751-64-4

929751-60-0

ΙT

ΙT

929751-61-1

```
929754-26-7
                            929754-28-9
                                          929754-29-0
                                                        929754-30-3
              929754-27-8
                                          929754-34-7
929754-31-4
              929754-32-5
                            929754-33-6
                                                        929754-35-8
929754-36-9
              929754-37-0
                            929754-38-1
                                          929754-39-2
                                                        929754-40-5
929754-41-6
              929754-42-7
                            929754-43-8
                                          929754-44-9
                                                        929754-45-0
929754-46-1
              929754-47-2
                            929754-48-3
                                          929754-49-4
                                                      929754-50-7
929754-51-8
              929754-52-9
                            929754-53-0
                                          929754-54-1
                                                        929754-55-2
929754-56-3
              929754-57-4
                            929754-58-5
                                          929754-59-6
                                                        929754-60-9
929754-61-0
              929754-62-1
                            929754-63-2
                                          929754-64-3
                                                        929754-65-4
              929754-67-6
                            929754-68-7
                                          929754-69-8
                                                        929754-70-1
929754-66-5
                            929754-73-4
                                        929754-74-5
                                                        929754-75-6
929754-71-2
              929754-72-3
929754-76-7
              929754-77-8
                            929754-78-9
                                         929754-79-0
                                                        929754-80-3
929754-81-4
              929754-82-5
                            929754-83-6
                                          929754-84-7
                                                        929754-85-8
929754-86-9
              929754-87-0
                            929754-88-1
                                          929754-89-2
                                                        929754-90-5
929754-91-6
              929754-92-7
                            929754-93-8
                                          929754-94-9
                                                        929754-95-0
                            929754-98-3
                                          929754-99-4
                                                        929755-00-0
929754-96-1
              929754-97-2
929755-01-1
              929755-02-2
                            929755-03-3
                                          929755-04-4
                                                        929755-05-5
              929755-07-7
                                                        929755-10-2
929755-06-6
                            929755-08-8
                                          929755-09-9
929755-11-3
              929755-12-4
                            929755-13-5
                                          929755-14-6
                                                        929755-15-7
                                                        929755-20-4
929755-16-8
              929755-17-9
                            929755-18-0
                                          929755-19-1
929755-21-5
              929755-22-6
                            929755-23-7
                                          929755-24-8
                                                        929755-25-9
929755-26-0
              929755-27-1
                            929755-28-2
                                          929755-29-3
                                                        929755-30-6
929755-31-7
              929755-32-8
                            929755-33-9
                                          929755-34-0
                                                        929755-35-1
929755-36-2
              929755-37-3
                            929755-38-4
                                          929755-39-5
                                                        929755-40-8
929755-41-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene ODC1-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929755-42-0
            929755-43-1
                           929755-44-2
                                        929755-45-3
                                                        929755-46-4
929755-47-5
             929755-48-6
                            929755-49-7
                                          929755-50-0
                                                        929755-51-1
                                                        929755-56-6
929755-52-2
             929755-53-3
                           929755-54-4
                                        929755-55-5
929755-57-7
             929755-58-8
                           929755-59-9
                                        929755-60-2
                                                        929755-61-3
929755-62-4
                           929755-64-6
                                        929755-65-7
                                                        929755-66-8
             929755-63-5
929755-67-9
                                        929755-70-4
             929755-68-0
                           929755-69-1
                                                        929755-71-5
929755-72-6
             929755-73-7
                           929755-74-8 929755-75-9
                                                        929755-76-0
929755-77-1
             929755-78-2
                            929755-79-3
                                          929755-80-6
                                                        929755-81-7
929755-82-8
              929755-83-9
                            929755-84-0
                                          929755-85-1
                                                        929755-86-2
929755-87-3
              929755-88-4
                            929755-89-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene ODC1-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
                                                        929755-94-2
929755-90-8
              929755-91-9
                            929755-92-0
                                          929755-93-1
929755-95-3
              929755-96-4
                            929755-97-5
                                          929755-98-6
                                                        929755-99-7
929756-00-3
                                                        929756-04-7
              929756-01-4
                            929756-02-5
                                          929756-03-6
                                                        929756-09-2
929756-05-8
              929756-06-9
                            929756-07-0
                                          929756-08-1
929756-10-5
              929756-11-6
                            929756-12-7
                                          929756-13-8
                                                        929756-14-9
929756-15-0
              929756-16-1
                            929756-17-2
                                          929756-18-3
                                                        929756-19-4
929756-20-7
              929756-21-8
                            929756-22-9
                                          929756-23-0
                                                        929756-24-1
929756-25-2
              929756-26-3
                            929756-27-4
                                          929756-28-5
                                                        929756-29-6
929756-30-9
              929756-31-0
                            929756-32-1
                                          929756-33-2
                                                        929756-34-3
929756-35-4
                                          929756-38-7
              929756-36-5
                            929756-37-6
                                                        929756-39-8
929756-40-1
              929756-41-2
                            929756-42-3
                                          929756-43-4
                                                        929756-44-5
929756-45-6
              929756-46-7
                            929756-47-8
                                          929756-48-9
                                                        929756-49-0
929756-50-3
              929756-51-4
                            929756-52-5
                                          929756-53-6
                                                        929756-54-7
929756-55-8
              929756-56-9
                            929756-57-0
                                          929756-58-1
                                                        929756-59-2
929756-60-5
              929756-61-6
                            929756-62-7
                                          929756-63-8
                                                        929756-64-9
929756-65-0
              929756-66-1
                            929756-67-2
                                          929756-68-3
                                                        929756-69-4
929756-70-7
              929756-71-8
                            929756-72-9
                                          929756-73-0
                                                        929756-74-1
929756-75-2
              929756-76-3
                            929756-77-4
                                                        929756-79-6
                                          929756-78-5
```

929754-23-4

929754-22-3

929754-21-2

ΙT

ΙT

929754-25-6

929754-24-5

```
929756-85-4
             929756-86-5
                           929756-87-6
                                         929756-88-7
                                                       929756-89-8
929756-90-1
             929756-91-2
                           929756-92-3
                                         929756-93-4
                                                       929756-94-5
929756-95-6
             929756-96-7
                           929756-97-8
                                         929756-98-9
                                                       929756-99-0
             929757-01-7
                           929757-02-8
                                       929757-03-9
                                                       929757-04-0
929757-00-6
929757-05-1
             929757-06-2
                           929757-07-3
                                       929757-08-4 929757-09-5
929757-10-8
             929757-11-9
                           929757-12-0
                                       929757-13-1
                                                       929757-14-2
929757-15-3
             929757-16-4
                           929757-17-5
                                        929757-18-6
                                                       929757-19-7
929757-20-0
             929757-21-1
                           929757-22-2
                                         929757-23-3
                                                       929757-24-4
929757-25-5
             929757-26-6
                           929757-27-7
                                         929757-28-8
                                                       929757-29-9
929757-30-2
             929757-31-3
                           929757-32-4
                                        929757-33-5
                                                       929757-34-6
             929757-36-8
                           929757-37-9
                                        929757-38-0 929757-39-1
929757-35-7
929757-40-4
             929757-41-5
                           929757-42-6
                                         929757-43-7
                                                       929757-44-8
929757-45-9
             929757-46-0
                           929757-47-1
                                         929757-48-2
                                                       929757-49-3
929757-50-6
             929757-51-7
                           929757-52-8
                                         929757-53-9
                                                       929757-54-0
                                                       929757-59-5
929757-55-1
             929757-56-2
                           929757-57-3
                                         929757-58-4
                                         929757-63-1
                                                       929757-64-2
929757-60-8
             929757-61-9
                           929757-62-0
929757-65-3
             929757-66-4
                           929757-67-5
                                         929757-68-6
                                                       929757-69-7
929757-70-0
             929757-71-1
                           929757-72-2
                                         929757-73-3
                                                       929757-74-4
                           929757-77-7
929757-75-5
             929757-76-6
                                         929757-78-8
                                                       929757-79-9
929757-80-2
             929757-81-3
                           929757-82-4
                                         929757-83-5
                                                       929757-84-6
929757-85-7
             929757-86-8
                           929757-87-9
                                         929945-16-4
                                                       929945-17-5
929945-18-6
             929945-19-7
                           929945-20-0
                                         929945-21-1
                                                       929945-22-2
929945-23-3
             929945-24-4
                           929945-25-5
                                         929945-26-6
                                                       929945-27-7
929945-28-8
             929945-29-9
                           929945-30-2
                                         929945-31-3
                                                       929945-32-4
                           929945-35-7
                                         929945-36-8
929945-33-5
             929945-34-6
                                                       929945-37-9
                                         929945-41-5
929945-38-0
             929945-39-1
                           929945-40-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene PIM1-targeting siRNA; double-stranded RNAs and their use for
  downregulating genes and treating cardiovascular diseases)
929757-88-0
            929757-89-1
                          929757-90-4 929757-91-5 929757-92-6
929757-93-7
                                        929757-96-0
                                                       929757-97-1
             929757-94-8
                           929757-95-9
929757-98-2
             929757-99-3
                          929758-00-9 929758-01-0 929758-02-1
929758-03-2
             929758-04-3
                          929758-05-4 929758-06-5
                                                       929758-07-6
929758-08-7
             929758-09-8
                          929758-10-1 929758-11-2
                                                       929758-12-3
929758-13-4
             929758-14-5
                          929758-15-6
                                       929758-16-7
                                                       929758-17-8
929758-18-9
             929758-19-0
                           929758-20-3 929758-21-4 929758-22-5
929758-23-6
             929758-24-7
                           929758-25-8 929758-26-9 929758-27-0
929758-28-1
             929758-29-2
                           929758-30-5 929758-31-6 929758-32-7
929758-33-8
            929758-34-9
                           929758-35-0
                                        929758-36-1
                                                       929758-37-2
929758-38-3
            929758-39-4
                           929758-40-7
                                        929758-41-8 929758-42-9
929758-43-0
            929758-44-1
                           929758-45-2
                                        929758-46-3 929758-47-4
             929758-49-6
929758-48-5
                           929758-50-9
                                        929758-51-0 929758-52-1
                                                       929758-57-6
                           929758-55-4
                                        929758-56-5
929758-53-2
             929758-54-3
929758-58-7
             929758-59-8
                           929758-60-1
                                         929758-61-2
                                                       929758-62-3
929758-63-4
             929758-64-5
                                         929758-66-7
                                                       929758-67-8
                           929758-65-6
                                                       929758-72-5
929758-68-9
             929758-69-0
                           929758-70-3
                                         929758-71-4
                                         929758-76-9
                                                       929758-77-0
929758-73-6
             929758-74-7
                           929758-75-8
929758-78-1
             929758-79-2
                           929758-80-5
                                         929758-81-6
                                                       929758-82-7
929758-83-8
             929758-84-9
                           929758-85-0
                                         929758-86-1
                                                       929758-87-2
929758-88-3
             929758-89-4
                           929758-90-7
                                         929758-91-8
                                                       929758-92-9
929758-93-0
             929758-94-1
                           929758-95-2
                                         929758-96-3
                                                       929758-97-4
929758-98-5
                                         929759-01-3
             929758-99-6
                           929759-00-2
                                                       929759-02-4
```

929759-05-7

929759-10-4

929759-15-9

929759-20-6

929759-25-1

929759-30-8

929759-35-3

929759-06-8

929759-11-5

929759-16-0

929759-21-7

929759-26-2

929759-31-9

929759-36-4

929759-07-9

929759-12-6

929759-17-1

929759-22-8

929759-27-3

929759-32-0

929759-37-5

929756-82-1

929756-83-2

929756-84-3

929756-80-9

ΤТ

929759-03-5

929759-08-0

929759-13-7

929759-18-2

929759-23-9

929759-33-1

929759-28-4

929759-04-6

929759-09-1

929759-14-8

929759-19-3

929759-24-0

929759-29-5

929759-34-2

929756-81-0

```
929759-43-3
              929759-44-4
                            929759-45-5
                                           929759-46-6
                                                          929759-47-7
                            929759-50-2
                                                         929759-52-4
929759-48-8
              929759-49-9
                                           929759-51-3
              929759-54-6
                            929759-55-7
929759-53-5
                                           929759-56-8
                                                          929759-57-9
929759-58-0
              929759-59-1
                            929759-60-4
                                           929759-61-5
                                                          929759-62-6
929759-63-7
              929759-64-8
                            929759-65-9
                                           929759-66-0
                                                          929759-67-1
929759-68-2
              929759-69-3
                            929759-70-6
                                           929759-71-7
                                                          929759-72-8
929759-73-9
              929759-74-0
                            929759-75-1
                                           929759-76-2
                                                          929759-77-3
929759-78-4
              929759-79-5
                            929759-80-8
                                           929759-81-9
                                                          929759-82-0
929759-83-1
              929759-84-2
                            929759-85-3
                                           929759-86-4
                                                          929759-87-5
                            929759-90-0
929759-88-6
              929759-89-7
                                           929759-91-1
                                                          929759-92-2
929759-93-3
              929759-94-4
                            929759-95-5
                                           929759-96-6
                                                          929759-97-7
929759-98-8
              929759-99-9
                            929760-00-9
                                           929760-01-0
                                                          929760-02-1
                            929760-05-4
929760-03-2
              929760-04-3
                                           929760-06-5
                                                          929760-07-6
                            929760-10-1
                                           929760-11-2
                                                          929760-12-3
929760-08-7
              929760-09-8
                                           929760-16-7
                                                          929760-17-8
929760-13-4
              929760-14-5
                            929760-15-6
929760-18-9
              929760-19-0
                            929760-20-3
                                           929760-21-4
                                                          929760-22-5
929760-23-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene SGPP1-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929760-24-7
              929760-25-8
                             929760-26-9
                                           929760-27-0
                                                          929760-28-1
929760-29-2
                            929760-31-6
                                           929760-32-7
                                                          929760-33-8
              929760-30-5
929760-34-9
              929760-35-0
                            929760-36-1
                                           929760-37-2
                                                          929760-38-3
929760-39-4
              929760-40-7
                            929760-41-8
                                           929760-42-9
                                                          929760-43-0
929760-44-1
              929760-45-2
                            929760-46-3
                                           929760-47-4
                                                          929760-48-5
929760-49-6
              929760-50-9
                            929760-51-0
                                           929760-52-1
                                                          929760-53-2
929760-54-3
                            929760-56-5
              929760-55-4
                                           929760-57-6
                                                          929760-58-7
                            929760-61-2
                                                         929760-63-4
929760-59-8
              929760-60-1
                                           929760-62-3
929760-64-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene SGPP1-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929760-65-6
              929760-66-7
                            929760-67-8
                                           929760-68-9
                                                          929760-69-0
929760-70-3
              929760-71-4
                            929760-72-5
                                           929760-73-6
                                                          929760-74-7
929760-75-8
              929760-76-9
                            929760-77-0
                                           929760-78-1
                                                          929760-79-2
929760-80-5
              929760-81-6
                            929760-82-7
                                           929760-83-8
                                                          929760-84-9
929760-85-0
              929760-86-1
                            929760-87-2
                                           929760-88-3
                                                          929760-89-4
929760-90-7
              929760-91-8
                            929760-92-9
                                           929760-93-0
                                                          929760-94-1
929760-95-2
              929760-96-3
                            929760-97-4
                                           929760-98-5
                                                         929760-99-6
929761-00-2
              929761-01-3
                            929761-02-4
                                           929761-03-5
                                                         929761-04-6
929761-05-7
              929761-06-8
                            929761-07-9
                                           929761-08-0
                                                          929761-09-1
929761-10-4
              929761-11-5
                            929761-12-6
                                           929761-13-7
                                                         929761-14-8
929761-15-9
                            929761-17-1
                                           929761-18-2
                                                         929761-19-3
              929761-16-0
                                           929761-23-9
              929761-21-7
                                                          929761-24-0
929761-20-6
                            929761-22-8
                            929761-27-3
                                           929761-28-4
                                                         929761-29-5
929761-25-1
              929761-26-2
929761-30-8
              929761-31-9
                            929761-32-0
                                           929761-33-1
                                                          929761-34-2
929761-35-3
              929761-36-4
                            929761-37-5
                                           929761-38-6
                                                          929761-39-7
929761-40-0
              929761-41-1
                             929761-42-2
                                           929761-43-3
                                                          929761-44-4
929761-45-5
              929761-46-6
                             929761-47-7
                                           929761-48-8
                                                          929761-49-9
                             929761-52-4
                                           929761-53-5
929761-50-2
              929761-51-3
                                                          929761-54-6
929761-55-7
              929761-56-8
                             929761-57-9
                                           929761-58-0
                                                          929761-59-1
929761-60-4
              929761-61-5
                             929761-62-6
                                           929761-63-7
                                                          929761-64-8
929761-65-9
              929761-66-0
                            929761-67-1
                                           929761-68-2
                                                          929761-69-3
929761-70-6
              929761-71-7
                            929761-72-8
                                           929761-73-9
                                                          929761-74-0
                                           929761-78-4
929761-75-1
              929761-76-2
                            929761-77-3
                                                          929761-79-5
929761-80-8
              929761-81-9
                            929761-82-0
                                           929761-83-1
                                                          929761-84-2
929761-85-3
              929761-86-4
                            929761-87-5
                                           929761-88-6
                                                          929761-89-7
                            929761-92-2
                                           929761-93-3
                                                          929761-94-4
929761-90-0
              929761-91-1
```

929759-40-0

929759-41-1

929759-42-2

929759-38-6

ΙT

ΤT

929759-39-7

```
929762-05-0
                   929762-06-1
                                 929762-07-2
                                               929762-08-3
                                                             929762-09-4
     929762-10-7
                   929762-11-8
                                 929762-12-9
                                               929762-13-0
                                                              929762-14-1
                                 929762-17-4
                                               929762-18-5
                                                              929762-19-6
     929762-15-2
                   929762-16-3
     929762-20-9
                   929762-21-0
                                 929762-22-1
                                               929762-23-2
                                                              929762-24-3
     929762-25-4
                   929762-26-5
                                 929762-27-6
                                               929762-28-7
                                                              929762-29-8
     929762-30-1
                   929762-31-2
                                 929762-32-3
                                               929762-33-4
                                                              929762-34-5
     929762-35-6
                   929762-36-7
                                 929762-37-8
                                               929762-38-9
                                                              929762-39-0
     929762-40-3
                   929762-41-4
                                 929762-42-5
                                               929762-43-6
                                                              929762-44-7
                   929762-46-9
                                 929762-47-0
                                               929762-48-1
                                                              929762-49-2
     929762-45-8
     929762-50-5
                   929762-51-6
                                 929762-52-7
                                               929762-53-8
                                                              929762-54-9
     929762-55-0
                   929762-56-1
                                 929762-57-2
                                               929762-58-3
                                                              929762-59-4
     929762-60-7
                   929762-61-8
                                 929762-62-9
                                               929762-63-0
                                                              929762-64-1
     929762-65-2
                   929762-66-3
                                 929762-67-4
                                               929762-68-5
                                                              929762-69-6
     929762-70-9
                   929762-71-0
                                 929762-72-1
                                               929762-73-2
                                                              929762-74-3
                                               929762-78-7
     929762-75-4
                                 929762-77-6
                                                              929762-79-8
                   929762-76-5
                   929762-81-2
                                 929762-82-3
                                               929762-83-4
                                                              929762-84-5
     929762-80-1
     929762-85-6
                   929762-86-7
                                 929762-87-8
                                               929762-88-9
                                                              929762-89-0
                   929762-91-4
                                 929762-92-5
                                               929762-93-6
                                                              929762-94-7
     929762-90-3
     929762-95-8
                   929762-96-9
                                 929762-97-0
                                               929762-98-1
                                                              929762-99-2
     929763-00-8
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (gene SPTLC2-targeting siRNA; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     929763-01-9
                   929763-02-0
                                 929763-03-1
                                              929763-04-2
                                                             929763-05-3
     929763-06-4
                   929763-07-5
                                 929763-08-6
                                               929763-09-7
                                                              929763-10-0
     929763-11-1
                   929763-12-2
                                 929763-13-3
                                               929763-14-4
                                                             929763-15-5
     929763-16-6
                                 929763-18-8
                                                             929763-20-2
                   929763-17-7
                                               929763-19-9
     929763-21-3
                                 929763-23-5
                   929763-22-4
                                               929763-24-6
                                                             929763-25-7
                                                             929763-30-4
     929763-26-8
                  929763-27-9
                                929763-28-0
                                              929763-29-1
     929763-31-5
                                929763-33-7
                                              929763-34-8 929763-35-9
                  929763-32-6
     929763-36-0
                  929763-37-1
                                929763-38-2
                                              929763-39-3
                                                             929763-40-6
                                929763-43-9
                                              929763-44-0
                                                             929763-45-1
     929763-41-7
                  929763-42-8
     929763-46-2
                  929763-47-3
                                 929763-48-4
                                             929763-49-5
                                                             929763-50-8
     929763-51-9
                   929763-52-0
                                 929763-53-1
                                             929763-54-2
                                                             929763-55-3
     929763-56-4
                   929763-57-5
                                 929763-58-6
                                              929763-59-7
                                                             929763-60-0
     929763-61-1
                   929763-62-2
                                 929763-63-3
                                              929763-64-4
                                                             929763-65-5
                                 929763-68-8
                                              929763-69-9
                                                             929763-70-2
     929763-66-6
                   929763-67-7
     929763-71-3
                   929763-72-4
                                 929763-73-5
                                               929763-74-6
                                                             929763-75-7
     929763-76-8
                   929763-77-9
                                 929763-78-0
                                               929763-79-1
                                                             929763-80-4
     929763-81-5
                   929763-82-6
                                 929763-83-7
                                               929763-84-8
                                                             929763-85-9
     929763-86-0
                   929763-87-1
                                 929763-88-2
                                               929763-89-3
                                                             929763-90-6
                                                             929763-95-1
     929763-91-7
                   929763-92-8
                                 929763-93-9
                                               929763-94-0
     929763-96-2
                   929763-97-3
                                 929763-98-4
                                               929763-99-5
                                                             929764-00-1
                                                             929764-05-6
     929764-01-2
                   929764-02-3
                                               929764-04-5
                                 929764-03-4
     929764-06-7
                                                             929764-10-3
                   929764-07-8
                                 929764-08-9
                                               929764-09-0
     929764-11-4
                   929764-12-5
                                 929764-13-6
                                               929764-14-7
                                                              929764-15-8
     929764-16-9
                   929764-17-0
                                 929764-18-1
                                               929764-19-2
                                                              929764-20-5
     929764-21-6
                   929764-22-7
                                 929764-23-8
                                               929764-24-9
                                                              929764-25-0
     929764-26-1
                   929764-27-2
                                 929764-28-3
                                               929764-29-4
                                                              929764-30-7
     929764-31-8
                   929764-32-9
                                 929764-33-0
                                               929764-34-1
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (gene SPTLC2-targeting siRNA; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
                                 929764-37-4
ΙT
     929764-35-2
                   929764-36-3
                                               929764-38-5
                                                              929764-39-6
                                 929764-42-1
     929764-40-9
                                               929764-43-2
                                                              929764-44-3
                   929764-41-0
                                 929764-47-6
                                               929764-48-7
     929764-45-4
                   929764-46-5
                                                              929764-49-8
     929764-50-1
                   929764-51-2
                                 929764-52-3
                                               929764-53-4
                                                             929764-54-5
```

929761-97-7

929762-02-7

929761-98-8

929762-03-8

929761-99-9

929762-04-9

929761-95-5

929762-00-5

929761-96-6

929762-01-6

```
929764-55-6
              929764-56-7
                            929764-57-8
                                           929764-58-9
                                                          929764-59-0
929764-60-3
              929764-61-4
                            929764-62-5
                                           929764-63-6
                                                         929764-64-7
                                           929764-74-9
                                                         929764-75-0
929764-65-8
                            929764-67-0
              929764-66-9
929764-76-1
              929764-77-2
                            929764-78-3
                                           929764-79-4
                                                         929764-80-7
929764-81-8
              929764-82-9
                            929764-83-0
                                           929764-84-1
                                                          929764-85-2
929764-86-3
              929764-87-4
                            929764-88-5
                                           929764-89-6
                                                          929764-90-9
929764-91-0
              929764-92-1
                            929764-93-2
                                           929764-94-3
                                                          929764-95-4
929764-96-5
              929764-97-6
                            929764-98-7
                                           929764-99-8
                                                          929765-00-4
929765-01-5
              929765-02-6
                            929765-03-7
                                           929765-04-8
                                                          929765-05-9
929765-06-0
              929765-07-1
                            929765-08-2
                                           929765-09-3
                                                          929765-10-6
                            929765-13-9
                                                          929765-15-1
929765-11-7
              929765-12-8
                                           929765-14-0
929765-16-2
              929765-17-3
                            929765-18-4
                                           929765-19-5
                                                          929765-20-8
929765-21-9
              929765-22-0
                            929765-23-1
                                           929765-24-2
                                                          929765-25-3
929765-26-4
              929765-27-5
                            929765-28-6
                                           929765-29-7
                                                          929765-30-0
929765-31-1
              929765-32-2
                            929765-33-3
                                           929765-34-4
                                                          929765-36-6
              929765-38-8
                            929765-39-9
                                           929765-40-2
                                                          929765-41-3
929765-37-7
929765-42-4
              929765-43-5
                            929765-44-6
                                           929765-46-8
                                                          929765-47-9
                                           929765-51-5
                            929765-50-4
                                                          929765-52-6
929765-48-0
              929765-49-1
929765-53-7
              929765-54-8
                            929765-55-9
                                           929765-56-0
                                                          929765-57-1
                                                          929765-62-8
929765-58-2
              929765-59-3
                            929765-60-6
                                           929765-61-7
929765-63-9
              929765-64-0
                            929765-65-1
                                           929765-66-2
                                                          929765-67-3
929765-68-4
              929765-69-5
                            929765-70-8
                                           929765-71-9
                                                          929765-72-0
929765-73-1
              929765-74-2
                             929765-75-3
                                           929765-76-4
                                                          929765-78-6
929765-79-7
              929765-80-0
                             929765-81-1
                                           929765-82-2
                                                          929765-83-3
929765-84-4
                            929765-86-6
                                           929765-87-7
              929765-85-5
                                                          929765-88-8
                                           929765-93-5
929765-89-9
              929765-90-2
                            929765-92-4
                                                          929765-94-6
929765-95-7
              929765-96-8
                            929765-97-9
                                           929765-98-0
                                                          929765-99-1
929766-00-7
              929766-01-8
                            929766-02-9
                                           929766-03-0
                                                         929766-05-2
                                                         929766-10-9
929766-06-3
              929766-07-4
                            929766-08-5
                                           929766-09-6
929766-11-0
                            929766-13-2
                                           929766-14-3
                                                         929766-15-4
              929766-12-1
                                                         929766-21-2
929766-16-5
              929766-17-6
                            929766-19-8
                                           929766-20-1
                                           929766-25-6
                                                         929766-26-7
929766-22-3
              929766-23-4
                            929766-24-5
929766-27-8
              929766-28-9
                            929766-29-0
                                           929766-31-4
                                                         929766-32-5
929766-33-6
                                                         929766-37-0
                            929766-35-8
                                           929766-36-9
              929766-34-7
                                                         929766-43-8
929766-38-1
              929766-39-2
                            929766-41-6
                                           929766-42-7
929766-44-9
              929766-45-0
                            929766-46-1
                                           929766-47-2
                                                         929766-48-3
929766-49-4
              929766-50-7
                            929766-52-9
                                           929766-53-0
                                                         929766-54-1
929766-55-2
              929766-56-3
                            929766-57-4
                                           929766-58-5
                                                          929766-59-6
929766-60-9
              929766-61-0
                            929766-63-2
                                           929766-64-3
                                                         929766-65-4
                                                          929766-70-1
929766-66-5
              929766-67-6
                            929766-68-7
                                           929766-69-8
929766-71-2
              929766-72-3
                            929766-73-4
                                           929766-74-5
                                                          929766-75-6
929766-76-7
              929766-77-8
                            929766-78-9
                                           929766-79-0
                                                          929766-80-3
929766-81-4
              929766-82-5
                            929766-83-6
                                           929766-84-7
                                                         929766-85-8
929766-86-9
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
```

(gene SSAT-targeting siRNA; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

```
TΤ
     929766-87-0
                   929766-88-1
                                  929766-89-2
                                                929766-90-5
                                                               929766-91-6
     929766-92-7
                   929766-93-8
                                  929766-94-9
                                                929766-95-0
                                                               929766-96-1
     929766-97-2
                   929766-98-3
                                  929766-99-4
                                                929767-00-0
                                                               929767-01-1
     929767-02-2
                   929767-03-3
                                  929767-04-4
                                                929767-05-5
                                                               929767-06-6
     929767-07-7
                   929767-08-8
                                  929767-09-9
                                                929767-10-2
                                                               929767-11-3
     929767-12-4
                   929767-13-5
                                                               929767-16-8
                                  929767-14-6
                                                929767-15-7
     929767-17-9
                   929767-18-0
                                                               929767-21-5
                                  929767-19-1
                                                929767-20-4
     929767-22-6
                   929767-23-7
                                  929767-24-8
                                                929767-25-9
                                                               929767-26-0
     929767-27-1
                   929767-28-2
                                  929767-29-3
                                                929767-30-6
                                                               929767-31-7
                                  929767-34-0
     929767-32-8
                   929767-33-9
                                                929767-35-1
                                                               929767-36-2
     929767-37-3
                                  929767-39-5
                   929767-38-4
                                                929767-40-8
                                                               929767-41-9
     929767-43-1
                   929767-44-2
                                  929767-45-3
                                                929767-46-4
                                                               929767-47-5
     929767-48-6
                   929767-49-7
                                  929767-50-0
                                                929767-51-1
                                                               929767-52-2
```

```
929767-53-3
              929767-54-4
                            929767-55-5
                                           929767-56-6
                                                         929767-57-7
929767-58-8
              929767-59-9
                            929767-61-3
                                           929767-62-4
                                                         929767-63-5
              929767-65-7
929767-64-6
                            929767-66-8
                                           929767-67-9
                                                         929767-68-0
929767-69-1
              929767-71-5
                            929767-72-6
                                           929767-73-7
                                                         929767-74-8
929767-75-9
              929767-76-0
                            929767-77-1
                                           929767-78-2
                                                         929767-80-6
929767-81-7
              929767-82-8
                            929767-83-9
                                           929767-84-0
                                                         929767-85-1
929767-86-2
              929767-87-3
                            929767-89-5
                                           929767-90-8
                                                         929767-91-9
929767-92-0
              929767-93-1
                            929767-94-2
                                           929767-95-3
                                                         929767-96-4
929767-97-5
              929767-99-7
                            929768-00-3
                                           929768-01-4
                                                         929768-02-5
              929768-04-7
929768-03-6
                            929768-05-8
                                           929768-06-9
                                                         929768-07-0
              929768-09-2
                            929768-10-5
                                           929768-12-7
                                                         929768-13-8
929768-08-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene SSAT-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929768-14-9
              929768-15-0
                            929768-16-1
                                           929768-17-2
                                                         929768-18-3
929768-19-4
              929768-20-7
                            929768-21-8
                                           929768-22-9
                                                         929768-24-1
929768-25-2
              929768-26-3
                            929768-27-4
                                           929768-28-5
                                                         929768-29-6
                            929768-32-1
                                           929768-33-2
929768-30-9
              929768-31-0
                                                         929768-35-4
929768-36-5
              929768-37-6
                            929768-38-7
                                           929768-39-8
                                                         929768-40-1
929768-41-2
              929768-42-3
                            929768-44-5
                                           929768-45-6
                                                         929768-46-7
929768-47-8
              929768-48-9
                            929768-49-0
                                           929768-50-3
                                                         929768-51-4
929768-52-5
              929768-54-7
                            929768-55-8
                                           929768-56-9
                                                         929768-57-0
929768-58-1
              929768-59-2
                            929768-60-5
                                           929768-61-6
                                                         929768-62-7
929768-63-8
                            929768-66-1
                                           929768-67-2
                                                         929768-68-3
              929768-65-0
                                           929768-72-9
929768-69-4
              929768-70-7
                            929768-71-8
                                                         929768-73-0
                                           929768-78-5
929768-74-1
              929768-76-3
                            929768-77-4
                                                         929768-79-6
929768-80-9
              929768-81-0
                            929768-82-1
                                           929768-83-2
                                                         929768-84-3
929768-85-4
              929768-86-5
                            929768-88-7
                                           929768-89-8
                                                         929768-90-1
929768-91-2
                                                         929768-95-6
              929768-92-3
                            929768-93-4
                                           929768-94-5
929768-96-7
                            929768-99-0
                                                         929769-01-7
              929768-97-8
                                           929769-00-6
                                         929769-05-1
929769-02-8
              929769-03-9
                            929769-04-0
                                                         929769-06-2
                                                         929769-12-0
929769-07-3
                            929769-09-5
                                         929769-11-9
             929769-08-4
                                                         929769-17-5
929769-13-1
             929769-14-2
                            929769-15-3
                                         929769-16-4
929769-18-6
                            929769-21-1
                                         929769-22-2
                                                         929769-23-3
             929769-20-0
929769-24-4
             929769-25-5
                            929769-26-6
                                         929769-27-7
                                                         929769-28-8
929769-29-9
              929769-30-2
                            929769-31-3
                                           929769-32-4
                                                         929769-33-5
929769-34-6
              929769-35-7
                            929769-36-8
                                           929769-37-9
                                                         929769-38-0
929769-39-1
              929769-40-4
                            929769-42-6
                                           929769-43-7
                                                         929769-44-8
929769-45-9
              929769-46-0
                            929769-47-1
                                           929769-48-2
                                                         929769-49-3
929769-51-7
              929769-52-8
                            929769-53-9
                                           929769-54-0
                                                         929769-55-1
929769-56-2
              929769-57-3
                            929769-58-4
                                           929769-59-5
                                                         929769-60-8
929769-61-9
              929769-62-0
                            929769-63-1
                                           929769-64-2
                                                         929769-65-3
929769-66-4
              929769-67-5
                            929769-68-6
                                           929769-69-7
                                                         929769-70-0
929769-72-2
                                           929769-75-5
                            929769-74-4
                                                         929769-76-6
              929769-73-3
929769-77-7
                            929769-79-9
              929769-78-8
                                           929769-80-2
                                                         929769-81-3
929769-83-5
                            929769-85-7
                                           929769-86-8
                                                         929769-87-9
              929769-84-6
                                                         929769-92-6
929769-88-0
              929769-89-1
                            929769-90-4
                                           929769-91-5
                                                         929769-98-2
                                           929769-97-1
929769-93-7
              929769-95-9
                            929769-96-0
929769-99-3
              929770-00-3
                            929770-01-4
                                           929770-02-5
                                                         929770-03-6
929770-04-7
              929770-05-8
                            929770-06-9
                                           929770-07-0
                                                         929770-08-1
929770-09-2
              929770-10-5
                            929770-11-6
                                           929770-12-7
                                                         929770-13-8
929770-14-9
              929770-15-0
                            929770-16-1
                                           929770-17-2
                                                         929770-18-3
929770-19-4
              929770-20-7
                            929770-21-8
                                           929770-22-9
                                                         929770-23-0
929770-24-1
                            929770-26-3
              929770-25-2
                                           929770-27-4
                                                         929770-28-5
929770-29-6
              929770-30-9
                            929770-31-0
                                           929770-32-1
                                                         929770-33-2
929770-34-3
              929770-35-4
                            929770-36-5
                                           929770-37-6
                                                         929770-38-7
                            929770-41-2
929770-39-8
              929770-40-1
                                           929770-42-3
                                                         929770-43-4
929770-44-5
              929770-45-6
                            929770-46-7
                                           929770-47-8
                                                         929770-48-9
929770-49-0
                            929770-51-4
              929770-50-3
                                           929770-52-5
                                                         929770-53-6
```

929770-56-9

929770-57-0

929770-58-1

ΙT

929770-54-7

929770-55-8

```
929770-59-2
                   929770-60-5
                                  929770-61-6
                                                929770-62-7
                                                               929770-63-8
     929770-64-9
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
        (gene SSG1-targeting siRNA; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     929770-65-0
                   929770-66-1
                                  929770-67-2
                                                929770-68-3
                                                               929770-69-4
     929770-70-7
                   929770-71-8
                                  929770-72-9
                                                929770-73-0
                                                               929770-74-1
     929770-75-2
                   929770-76-3
                                  929770-77-4
                                                929770-78-5
                                                               929770-79-6
                   929770-81-0
                                  929770-82-1
                                                 929770-83-2
                                                               929770-84-3
     929770-80-9
                                  929770-87-6
                                                929770-88-7
                                                               929770-89-8
     929770-85-4
                   929770-86-5
     929770-90-1
                   929770-91-2
                                  929770-92-3
                                                929770-93-4
                                                               929770-94-5
     929770-95-6
                   929770-96-7
                                  929770-97-8
                                                929770-98-9
                                                               929770-99-0
     929771-00-6
                   929771-01-7
                                  929771-02-8
                                                929771-03-9
                                                               929771-04-0
     929771-05-1
                   929771-06-2
                                  929771-07-3
                                                929771-08-4
                                                               929771-09-5
                                  929771-12-0
                                                929771-13-1
                                                               929771-14-2
     929771-10-8
                   929771-11-9
     929771-15-3
                   929771-16-4
                                  929771-17-5
                                                929771-18-6
                                                               929771-19-7
                                                929771-23-3
                                                               929771-24-4
     929771-20-0
                   929771-21-1
                                  929771-22-2
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (gene SSG1-targeting siRNA; double-stranded RNAs and their use for
        downregulating genes and treating cardiovascular diseases)
ΙT
     929771-25-5
                   929771-26-6
                                  929771-27-7
                                                929771-28-8
                                                               929771-29-9
     929771-30-2
                   929771-31-3
                                  929771-32-4
                                                929771-33-5
                                                               929771-34-6
     929771-35-7
                                  929771-37-9
                                                929771-38-0
                                                               929771-39-1
                   929771-36-8
                                                929771-43-7
     929771-40-4
                   929771-41-5
                                  929771-42-6
                                                               929771-44-8
     929771-45-9
                   929771-46-0
                                  929771-47-1
                                                929771-48-2
                                                               929771-49-3
     929771-50-6
                   929771-51-7
                                  929771-52-8
                                                929771-53-9
                                                               929771-54-0
     929771-55-1
                   929771-56-2
                                  929771-57-3
                                                929771-58-4
                                                               929771-59-5
     929771-60-8
                                  929771-62-0
                                                929771-63-1
                                                               929771-64-2
                   929771-61-9
                                                               929771-69-7
     929771-65-3
                   929771-66-4
                                  929771-67-5
                                                929771-68-6
                   929771-71-1
     929771-70-0
                                  929771-72-2
                                                929771-73-3
                                                               929771-74-4
     929771-75-5
                   929771-76-6
                                  929771-77-7
                                                929771-78-8
                                                               929771-79-9
                                                               929771-84-6
     929771-80-2
                                  929771-82-4
                                                929771-83-5
                   929771-81-3
                                                929771-88-0
     929771-85-7
                   929771-86-8
                                  929771-87-9
                                                               929771-89-1
     929771-90-4
                   929771-91-5
                                  929771-92-6
                                                929771-93-7
                                                               929771-94-8
     929771-95-9
                   929771-96-0
                                  929771-97-1
                                                929771-98-2
                                                               929771-99-3
     929772-00-9
                   929772-01-0
                                  929772-02-1
                                                929772-03-2
                                                               929772-04-3
     929772-05-4
                   929772-06-5
                                  929772-07-6
                                                929772-08-7
                                                               929772-09-8
     929772-10-1
                                  929772-12-3
                                                929772-13-4
                                                               929772-14-5
                   929772-11-2
     929772-15-6
                   929772-16-7
                                  929772-17-8
                                                929772-18-9
                                                               929772-19-0
     929772-20-3
                   929772-21-4
                                  929772-22-5
                                                929772-23-6
                                                               929772-24-7
     929772-25-8
                   929772-26-9
                                  929772-27-0
                                                929772-28-1
                                                               929772-29-2
     929772-30-5
                   929772-31-6
                                  929772-32-7
                                                929772-33-8
                                                               929772-34-9
                                  929772-37-2
                                                929772-38-3
                                                               929772-39-4
     929772-35-0
                   929772-36-1
                                                               929772-44-1
     929772-40-7
                                  929772-42-9
                                                929772-43-0
                   929772-41-8
     929772-45-2
                                  929772-47-4
                                                929772-48-5
                                                               929772-49-6
                   929772-46-3
                                                               929772-54-3
     929772-50-9
                   929772-51-0
                                  929772-52-1
                                                929772-53-2
                                                               929772-59-8
     929772-55-4
                   929772-56-5
                                  929772-57-6
                                                929772-58-7
     929772-60-1
                   929772-61-2
                                  929772-62-3
                                                929772-63-4
                                                               929772-64-5
     929772-65-6
                   929772-66-7
                                  929772-67-8
                                                929772-68-9
                                                               929772-69-0
     929772-70-3
                   929772-71-4
                                  929772-72-5
                                                929772-73-6
                                                               929772-74-7
     929772-75-8
                   929772-76-9
                                  929772-77-0
                                                 929772-78-1
                                                               929772-79-2
                                  929772-82-7
                                                929772-83-8
     929772-80-5
                   929772-81-6
                                                               929772-84-9
     929772-85-0
                   929772-86-1
                                  929772-87-2
                                                929772-88-3
                                                               929772-89-4
     929772-90-7
                   929772-91-8
                                  929772-92-9
                                                929772-93-0
                                                               929772-94-1
     929772-95-2
                   929772-96-3
                                  929772-97-4
                                                929772-98-5
                                                               929772-99-6
     929773-00-2
                   929773-01-3
                                  929773-02-4
                                                929773-03-5
                                                               929773-04-6
     929773-05-7
                   929773-06-8
                                  929773-07-9
                                                929773-08-0
                                                               929773-09-1
     929773-10-4
                   929773-11-5
                                  929773-12-6
                                                929773-13-7
                                                               929773-14-8
     929773-15-9
                   929773-16-0
                                  929773-17-1
                                                929773-18-2
                                                               929773-19-3
```

```
929773-20-6
            929773-21-7
                         929773-22-8 929773-23-9 929773-24-0
929773-25-1 929773-26-2
                         929773-27-3 929773-28-4 929773-29-5
929773-30-8 929773-31-9
                         929773-32-0 929773-33-1 929773-34-2
929773-35-3 929773-36-4
                         929773-37-5 929773-38-6 929773-39-7
929773-40-0 929773-41-1
                         929773-42-2 929773-43-3 929773-44-4
929773-45-5 929773-46-6
                         929773-47-7 929773-48-8 929773-49-9
929773-50-2 929773-51-3
                         929773-52-4 929773-53-5 929773-54-6
929773-55-7
            929773-56-8
                         929773-57-9 929773-58-0 929773-59-1
929773-60-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
   (gene SYNPO2L-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929773-61-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (gene SYNPO2L-targeting siRNA; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
97002-67-0, Mak3 N-acetyltransferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (homolog; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
301167-57-7, Protein tyrosine phosphatase, type IVA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (member 2; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
139805-02-0, GenBank M22878 139811-39-5, DNA (human clone 137.)
139812-87-6, GenBank X07499
                           139841-85-3, DNA (human clone 5 gene flg
                   150835-03-3, DNA (human cell line CEPH 134702)
cDNA)
       145405-49-8
150946-39-7 151315-20-7, DNA (human gene CSF1 cDNA) 156132-00-2
161072-70-4 161073-44-5
                         161784-22-1 164244-73-9
                                                     170178-96-8
170896-07-8 172247-21-1, DNA (human myosin isoform IXb cDNA)
174518-29-7 177308-82-6 183100-56-3 183818-28-2
                                                    184892-27-1
185082-45-5 190047-47-3
                         191307-27-4, DNA (human clone 22QTEL001)
191307-34-3 197840-86-1
                         199496-62-3 200768-39-4 204565-11-7
206630-64-0 209999-07-5
                         210466-21-0 213076-75-6
                                                    216296-73-0
220500-43-6 226540-81-4, DNA (human gene P38IP cDNA)
                                                     227447-51-0
228685-95-8, DNA (human gene PIF1 cDNA) 241463-12-7
                                                     253570-31-9, DNA
(human gene FIR cDNA)
                      256189-00-1
                                   256630-24-7, DNA (human clone
ADKA01901 cDNA)
                 259479-03-3
                              261330-04-5, DNA (human clone LCHN cDNA)
            268185-97-3
                                       274670-41-6
266667-92-9
                         273904-51-1
                                                     280739-08-4
283089-44-1 288708-52-1, DNA (human reticulon 4a) 292553-67-4, DNA
(human clone HRC10233 cDNA)
                            292555-59-0, DNA (human clone HSI07791 cDNA)
292558-35-1
            292564-53-5, DNA (human clone LNG09301 cDNA) 312679-19-9,
DNA (human DC44 cDNA)
                     326661-72-7 326664-67-9
                                                 326673-49-8
            329305-57-9 336774-53-9 336774-78-8
326682-96-6
                                                     344977-30-6
346015-95-0, DNA (human clone IMAGE: 3544244 cDNA)
                                                 346026-13-9
350730-14-2
            354192-22-6 355890-95-8
                                       361976-35-4, DNA (human gene
                         364650-10-2
                                       366408-13-1 366422-30-2
MDM2 cDNA)
            362583-35-5
                         366429-37-0, DNA (human clone PLACE5000058
366425-45-8 366426-57-5
       366431-18-7, DNA (human clone PROST2003563 cDNA)
                                                        366434-69-7,
DNA (human clone TESTI1000131 cDNA) 366435-27-0, DNA (human clone
                   366437-44-7, DNA (human clone TESTI2007951 cDNA)
TESTI2001099 cDNA)
366442-40-2, DNA (human clone STM06043 cDNA) 375317-70-7 375323-40-3,
                                    378180-53-1
DNA (human clone IMAGE: 4500659 cDNA)
                                                   381471-54-1, DNA
(Hepatitis B virus gene OG23) 381982-42-9, GenBank AF456479
381987-16-2
             384432-32-0 384455-81-6
                                       384515-64-4
                                                     384569-79-3, DNA
(human gene APRF cDNA) 384599-49-9 384749-58-0 384976-50-5
385263-69-4 385727-26-4, DNA (human gene FBX29 cDNA)
                                                     385733-36-8
             389180-82-9 389184-31-0 389184-37-6
386194-13-4
                                                      389185-71-1,
GenBank M30496 389203-01-4, DNA (human binding protein cDNA)
```

ΙT

ΙT

ΙT

ΙT

```
390129-38-1, DNA (human cell line U937 gene
390095-19-9
             390125-31-2
G16 cDNA)
         390136-69-3, DNA (human gene G7b cDNA) 390250-30-3
390259-86-6
             390329-02-9, DNA (human clone PLACE1005876 cDNA)
390330-80-0, DNA (human clone PLACE2000216 cDNA) 390333-13-8
390632-01-6 390636-37-0, DNA (human clone HEMBB1002600 cDNA)
391532-75-5 391542-33-9, DNA (human PLC alfa cDNA) 391542-59-9
391552-32-2 391812-63-8 391831-71-3 391831-89-3, DNA (human gene
HTP-1 cDNA) 391837-44-8, DNA (human myosin I beta cDNA)
                                                         391849-15-3
392039-63-3 392049-86-4 392053-57-5 392059-27-7 392065-27-9
392074-84-9 392079-85-5, DNA (human gene RBBP2H1 cDNA) 392084-92-3
392093-04-8 392111-57-8 398399-18-3, DNA (human clone IMAGE:3508235
       398425-79-1, GenBank M15841 407526-89-0, DNA (human gene TPM3
cDNA)
cDNA)
       411873-71-7, DNA (human clone IMAGE:4339438 cDNA) 417979-99-8
             423687-63-2, DNA (human pseudogene Uox exon 8) 424470-24-6
418524-58-0
427276-40-2
             427276-44-6 438080-29-6 438080-63-8 439658-66-9
439774-65-9, DNA (human clone DKFZp451C066 cDNA) 439778-78-6, DNA (human
clone DKFZp686I1727 cDNA) 439779-47-2 439779-78-9 439781-74-5
439787-71-0, DNA (human clone DKFZp667K0520 cDNA) 440393-98-6
441606-54-8, DNA (human clone KIDNE2008403 cDNA) 441626-81-9, DNA (human
clone TRACH2015243 cDNA) 441628-70-2, DNA (human clone ADRGL2006124
cDNA) 441633-37-0, DNA (human clone BRAMY2010441 cDNA) 441642-14-4,
DNA (human clone D9OST2001433 cDNA) 441642-50-8, DNA (human clone
FCBBF1000053 cDNA) 441646-38-4, DNA (human clone HCHON2003642 cDNA)
441646-90-8, DNA (human clone HEART2006195 cDNA) 441650-05-1
441654-43-9, DNA (human clone PEBLM2006049 cDNA) 441655-85-2, DNA (human
clone PROST2017617 cDNA) 441657-18-7, DNA (human clone SMINT2003386
       441658-14-6, DNA (human clone SMINT2016313 cDNA) 441664-41-1,
DNA (human clone TESTI2034718 cDNA) 441665-98-1, DNA (human clone
TESTI2046786 cDNA) 441668-54-8, DNA (human clone TRACH2005210 cDNA)
441669-68-7, DNA (human clone UTERU2001024 cDNA) 444477-92-3
450510-87-9 453089-64-0, DNA (human clone PLACE1005539 cDNA)
453090-79-4, DNA (human clone THYRO1001457 cDNA) 453091-04-8
455220-38-9, DNA (human clone IMAGE:5263531 cDNA)
                                                456953-20-1, DNA
(human clone IMAGE:5241630 cDNA) 456954-22-6, DNA (human clone
IMAGE:5288990 cDNA) 492991-19-2
                                 493096-18-7, DNA (human clone
                    493356-90-4, DNA (human clone IMAGE:4400215 cDNA)
IMAGE: 5787152 cDNA)
                         494455-40-2
            494365-08-1
                                        494509-13-6, DNA (human clone
494346-55-3
IMAGE:5277710 cDNA) 494509-88-5 495663-69-9
                                               495690-84-1, DNA (human
clone IMAGE: 4820027 cDNA)
                         496323-48-9, DNA (human clone CS0DF038Y005
       496401-61-7 496417-48-2, DNA (human clone CS0DF007YN24 cDNA)
503763-48-2
             503986-53-6
                          505903-25-3
                                        514986-90-4
                                                      520897-62-5
520900-32-7
             520902-26-5
                           528328-40-7
                                        537435-71-5, DNA (human clone
DKFZp779B0244 cDNA)
                    552534-13-1 556761-35-4 577611-74-6
577612-50-1, DNA (human clone DKFZp686010247 cDNA) 577668-65-6, DNA
(human clone DKFZp686K02111 cDNA)
                                 577675-09-3, DNA (human clone
DKFZp686N2252 cDNA) 577678-62-7, DNA (human clone DKFZp686I16170 cDNA)
577679-80-2, DNA (human clone DKFZp686C20269 cDNA) 577679-94-8, DNA
(human clone DKFZp686K17155 cDNA) 577680-64-9 577683-33-1, DNA (human
                          577686-80-7 581048-25-1
clone DKFZp686A06190 cDNA)
                                                       582931-34-8, DNA
(human clone TLIVE2007016 cDNA) 582934-76-7, DNA (human clone
                   582935-07-7, DNA (human clone TESTI4014553 cDNA)
SYNOV4009298 cDNA)
582935-98-6, DNA (human clone ASTRO1000009 cDNA) 582954-59-4, DNA (human
                          582957-67-3, DNA (human clone BRAWH3004530
clone BRACE3002508 cDNA)
       582958-06-3, DNA (human clone BRCAN2002562 cDNA)
                                                        582964-77-0
cDNA)
582965-11-5
             582967-69-9, DNA (human clone PLACE6015211 cDNA)
582968-81-8, DNA (human clone SPLEN2016480 cDNA) 582972-11-0, DNA (human
clone TESTI4006407 cDNA) 582972-75-6, DNA (human clone TESTI4009457
       582979-35-9, DNA (human clone TRACH3008902 cDNA) 582981-36-0,
cDNA)
DNA (human clone UTERU3005205 cDNA) 582986-75-2, DNA (human clone
BRAMY3015549 cDNA) 582987-73-3, DNA (human clone BRAWH3011623 cDNA)
582990-54-3, DNA (human clone BRCAN2006051 cDNA) 583000-39-9, DNA (human
```

clone PLACE7000266 cDNA) 583004-17-5, DNA (human clone TESTI4010979 cDNA) 583879-62-3, GenBank AY225123 626095-42-9 633183-54-7, DNA (human FP291 cDNA) RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

ΙΤ

(nucleotide sequence; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases) 635266-00-1 638122-93-7 633234-90-9, DNA (human LP4947 cDNA) 645887-63-4, GenBank AY288946 645888-06-8, GenBank AY288979 663533-87-7, DNA (human unknown cDNA) 664946-03-6 668088-69-5, DNA (human clone IMAGE:30343220 cDNA) 673849-79-1, DNA (human clone IMAGE:5193590 cDNA) 680961-30-2, DNA (human clone CTONG2004000 cDNA) 680965-75-7, DNA (human clone TESTI4029528 cDNA) 686696-63-9 689699-30-7 695137-68-9 700666-63-3 700734-94-7 716907-04-9, DNA (human clone CSOCAP003YE18 cDNA) 716907-58-3, DNA (human clone CS0DI002YD21 cDNA) 716918-63-7, DNA (human clone CS0DI086YE21 cDNA) 716923-06-7, DNA (human clone CS0DI063YH06 cDNA) 716924-53-7, DNA (human clone CS0DI085YB07 cDNA) 716926-59-9, DNA (human clone CS0DI076YG17 716926-73-7, DNA (human clone CS0DC026YC15 cDNA) 716931-74-7, DNA (human clone CS0DF037YF09 cDNA) 716937-10-9, DNA (human clone CS0DI031YC12 cDNA) 716938-18-0, DNA (human clone CS0DI011YP01 cDNA) 716952-87-3, DNA (human clone CS0DI045YB05 cDNA) 716957-76-5, DNA (human clone CS0DF005YK21 cDNA) 716959-00-1, DNA (human clone CS0DK001YM17 716963-73-4, DNA (human clone CS0DF005YM18 cDNA) 716965-60-5, DNA (human clone CS0DI044YL08 cDNA) 716967-17-8, DNA (human clone CS0DD007YL12 cDNA) 716967-57-6, DNA (human clone CS0DH004YL21 cDNA) 716970-46-6, DNA (human clone CS0DI066YB16 cDNA) 716973-09-0, DNA (human clone CS0DI022YG21 cDNA) 716975-10-9, DNA (human clone CL0BA005ZG04 cDNA) 716979-70-3, DNA (human clone CS0DC001YH18 cDNA) 716983-78-7. DNA (human clone CS0DI084YG07 cDNA) 716993-15-6, DNA (human clone CS0DF036YG02 cDNA) 716994-30-8, DNA (human clone CS0DK008YI13 cDNA) 717004-61-0, DNA (human clone CS0DM011YK19 cDNA) 717007-19-7, DNA (human clone CS0DI053YB05 cDNA) 717018-01-4, DNA (human clone CS0DI057YM10 717025-51-9, DNA (human clone CS0DE006YB21 cDNA) 717028-42-7, DNA (human clone CS0DF006YB20 cDNA) 717028-86-9, DNA (human clone CL0BA006ZC10 cDNA) 717029-38-4, DNA (human clone CS0DB001YD10 cDNA) 717035-20-6, DNA (human clone CS0DL006YG09 cDNA) 717035-58-0, DNA (human clone CS0DJ005YD11 cDNA) 717035-87-5, DNA (human clone CS0DC017YA10 717042-47-2, DNA (human clone CS0DA010YE20 cDNA) DNA (human clone CS0DH001YN15 cDNA) 717053-08-2, DNA (human clone CS0DF018YJ11 cDNA) 717053-16-2, DNA (human clone CS0DI027YE21 cDNA) 717054-62-1, DNA (human clone CS0DI036YF07 cDNA) 717059-74-0, DNA (human clone CS0DC005YH06 cDNA) 717064-83-0, DNA (human clone CS0DF032YB12 cDNA) 717071-34-6, DNA (human clone CS0DF018YK19 cDNA) 717073-42-2, DNA (human clone CS0DI010YH14 cDNA) 717077-18-4, DNA (human clone CS0DL011YN12 cDNA) 717077-35-5, DNA (human clone CS0DK007YF11 cDNA) 717080-53-0, DNA (human clone CS0DB001YA17 cDNA) 717081-00-0, DNA (human clone CS0DI031YE19 cDNA) 717085-18-2, DNA (human clone CS0DM007YI10 717086-07-2, DNA (human clone CS0DD007YD16 cDNA) 717613-14-4, cDNA) DNA (human clone CS0DI034YG17 cDNA) 717614-74-9, DNA (human clone 717615-19-5, DNA (human clone CS0DI020Y004 cDNA) CS0DJ015YL04 cDNA) 717617-67-9, DNA (human clone CS0DF028Y007 cDNA) 717619-51-7, DNA (human 717622-23-6, DNA (human clone CS0DI059YF19 clone CS0DI016YM08 cDNA) 717623-43-3, DNA (human clone CS0CAP007YI09 cDNA) 717624-10-7, DNA (human clone CL0BA012ZA08 cDNA) 717627-50-4, DNA (human clone CS0DI060YJ19 cDNA) 717632-37-6, DNA (human clone CS0DJ002YN19 cDNA) 717632-77-4, DNA (human clone CS0DI019YI14 cDNA) 717644-46-7, DNA (human clone CS0DB004Y023 cDNA) 717650-67-4, DNA (human clone CS0DI013YH09 717653-98-0, DNA (human clone CS0DG007YD04 cDNA) 717658-48-5, DNA (human clone CS0DF008YL18 cDNA) 717661-22-8, DNA (human clone CS0DE002YP03 cDNA) 717670-75-2, DNA (human clone CS0DJ001YD15 cDNA)

```
717679-39-5, DNA (human clone CL0BA009ZC04 cDNA) 717680-82-5, DNA (human
clone CS0DB008YA09 cDNA)
                          717682-06-9, DNA (human clone CS0DC007YC01
       717685-75-1, DNA (human clone CS0DC017YN21 cDNA) 717686-17-4,
cDNA)
DNA (human clone CS0DI077YN15 cDNA) 717691-81-1, DNA (human clone
CS0DC004YN01 cDNA) 717693-04-4, DNA (human clone CS0DE003YE04 cDNA)
717695-93-7, DNA (human clone CS0DC023YC13 cDNA) 717704-82-0, DNA (human
clone CS0DF011YP12 cDNA)
                         717711-45-0, DNA (human clone CS0DI081YB23
       717717-03-8, DNA (human clone CS0DK012YC18 cDNA)
                                                         717719-05-6,
DNA (human clone CS0DC014YC18 cDNA) 717732-34-8, DNA (human clone
CS0DI056YJ24 cDNA) 717734-75-3, DNA (human clone CS0DL011YM05 cDNA)
717735-42-7, DNA (human clone CS0DC003YK02 cDNA) 717741-89-4, DNA (human
clone CS0DL004YL07 cDNA)
                         717747-53-0, DNA (human clone CS0DB006YN23
       717752-64-2, DNA (human clone CS0DJ009YD01 cDNA) 717752-98-2,
DNA (human clone CS0DI044YP06 cDNA) 717755-07-2, DNA (human clone
CS0DJ006YC05 cDNA) 717755-58-3, DNA (human clone CS0DF022YL07 cDNA)
717756-80-4, DNA (human clone CS0DI019YM04 cDNA)
                                                 717758-31-1, DNA (human
clone CS0DH006YI09 cDNA) 717771-77-2, DNA (human clone CS0DB002YC13
       717775-74-1, DNA (human clone CLOBB019ZH12 cDNA)
                                                        717786-50-0,
DNA (human clone CS0DI036YF21 cDNA) 717794-26-8, DNA (human clone
CS0DF010YL22 cDNA) 717795-17-0, DNA (human clone CS0DF002YP14 cDNA)
717796-45-7, DNA (human clone CSODF034YK23 cDNA) 717798-79-3, DNA (human
clone CS0DE009YF20 cDNA) 721296-60-2, GenBank AY044853
                                                         757860-59-6
770642-77-8 838051-94-8, DNA (human clone DKFZp686M208 cDNA)
838052-91-8, DNA (human clone DKFZp686G0883 cDNA)
                                                838053-45-5, DNA
(human clone DKFZp686P12164 cDNA)
                                 929579-52-2
                                               929579-54-4
929579-56-6 929579-58-8
                           929579-60-2, GenBank AY954500
                                                         929579-61-3
929579-63-5
             929579-65-7
                           929579-67-9
                                       929579-69-1
                                                     929579-71-5
                                       929579-79-3
                          929579-77-1
929579-73-7 929579-75-9
                                                      929579-81-7
929579-83-9
            929579-85-1
                          929579-87-3
                                        929579-89-5
                                                      929579-91-9, DNA
(human gene SMAP2 cDNA) 929579-93-1 929579-97-5 929579-99-7
929580-00-7 929580-02-9, DNA (human clone IMAGE:30529503 cDNA)
            929580-05-2 929871-85-2, GenBank F87463
929580-03-0
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
   (nucleotide sequence; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
929739-88-8 929739-89-9
                          929739-90-2 929739-91-3 929739-92-4
929739-93-5 929739-94-6
                         929739-95-7 929739-96-8 929739-97-9
929739-98-0 929739-99-1
                         929740-00-1 929740-01-2 929740-02-3
929740-03-4 929740-04-5
                         929740-05-6 929740-06-7 929740-07-8
929740-08-9 929740-09-0
                         929740-10-3 929740-11-4 929740-12-5
929740-13-6 929740-14-7
                         929740-15-8 929740-16-9 929740-17-0
929740-18-1 929740-19-2
                          929740-20-5
                                       929740-21-6
                                                      929740-22-7
929740-23-8 929740-24-9 929740-25-0 929740-26-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (siRNA; double-stranded RNAs and their use for downregulating genes and
   treating cardiovascular diseases)
9002-02-2, Succinate dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (subunit B, iron sulfur; double-stranded RNAs and their use for
   downregulating genes and treating cardiovascular diseases)
140879-24-9, 26S Proteasome
                           172522-01-9, AMP-activated protein kinase
362479-32-1, Protein phosphatase 1 362674-81-5, Protein phosphatase 2
364367-46-4, Protein phosphatase 4
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (subunits; double-stranded RNAs and their use for downregulating genes
   and treating cardiovascular diseases)
9013-05-2, Phosphatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (tensin-like C1 domain containing; double-stranded RNAs and their use for
```

ΤТ

TΤ

ΙT

ΙT

downregulating genes and treating cardiovascular diseases)

IT 104645-76-3, Phosphatidylinositol-4-phosphate 5-kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(type II, alpha; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

IT 9001-86-9, Phospholipase C

RL: BSU (Biological study, unclassified); BIOL (Biological study) (  $\alpha$  and  $\gamma$ 1; double-stranded RNAs and their use for

downregulating genes and treating cardiovascular diseases)

IT 9026-30-6, Poly(A) polymerase

RL: BSU (Biological study, unclassified); BIOL (Biological study) ( $\alpha$ ; double-stranded RNAs and their use for downregulating genes and treating cardiovascular diseases)

L32 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, Phosphoinositide 3-kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*
ACCESSION NUMBER: 2007:220269 CAPLUS

DOCUMENT NUMBER: 146:295955

TITLE: Preparation of pyrazine derivatives, particularly

N-[3-(oxyphenylamino)quinoxalin-2-yl] sulfonamides, as

PI3K inhibitors

INVENTOR(S): Gaillard, Pascale; Quattropani, Anna; Pomel, Vincent;

Rueckle, Thomas; Klicic, Jasna; Church, Dennis

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.

Antilles

SOURCE: PCT Int. Appl., 170pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE			
WO 2007023186	O 2007023186 A1 20070301 WO 2006-EP65688					
W: AE, AG, A	AL, AM, AT, AU, AZ,	BA, BB, BG, BR, BW, BY,	BZ, CA, CH,			
CN, CO, C	CR, CU, CZ, DE, DK,	DM, DZ, EC, EE, EG, ES,	FI, GB, GD,			
GE, GH, G	GM, HN, HR, HU, ID,	IL, IN, IS, JP, KE, KG,	KM, KN, KP,			
KR, KZ, L	LA, LC, LK, LR, LS,	LT, LU, LV, LY, MA, MD,	MG, MK, MN,			
MW, MX, M	MY, MZ, NA, NG, NI,	NO, NZ, OM, PG, PH, PL,	PT, RO, RS,			
RU, SC, S	SD, SE, SG, SK, SL,	SM, SV, SY, TJ, TM, TN,	TR, TT, TZ,			
UA, UG, U	JS, UZ, VC, VN, ZA,	ZM, ZW				
RW: AT, BE, B	BG, CH, CY, CZ, DE,	DK, EE, ES, FI, FR, GB,	GR, HU, IE,			
IS, IT, L	LT, LU, LV, MC, NL,	PL, PT, RO, SE, SI, SK,	TR, BF, BJ,			
CF, CG, C	CI, CM, GA, GN, GQ,	GW, ML, MR, NE, SN, TD,	TG, BW, GH,			
GM, KE, L	LS, MW, MZ, NA, SD,	SL, SZ, TZ, UG, ZM, ZW,	AM, AZ, BY,			
KG, KZ, M	MD, RU, TJ, TM					
AU 2006283846	A1 20070301	AU 2006-283846	20060825			
CA 2618479	A1 20070301	CA 2006-2618479	20060825			
EP 1917252	A1 20080507	EP 2006-793019	20060825			
R: AT, BE, B	BG, CH, CY, CZ, DE,	DK, EE, ES, FI, FR, GB,	GR, HU, IE,			
IS, IT, L	LI, LT, LU, LV, MC,	NL, PL, PT, RO, SE, SI,	SK, TR, AL,			
BA, HR, M	MK, RS					
KR 2008049767	A 20080604	KR 2008-707158	20080325			

MARPAT 146:295955 OTHER SOURCE(S):

AN 2007:220269 CAPLUS

DN 146:295955

EDEntered STN: 01 Mar 2007

Preparation of pyrazine derivatives, particularly N-[3-ΤI (oxyphenylamino)quinoxalin-2-yl|sulfonamides, as PI3K inhibitors

Gaillard, Pascale; Quattropani, Anna; Pomel, Vincent; Rueckle, Thomas; ΙN Klicic, Jasna; Church, Dennis

PΑ Applied Research Systems Ars Holding N.V., Neth. Antilles

SO PCT Int. Appl., 170pp. CODEN: PIXXD2

DT Patent

English LA

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1, 63

FAN.	CNT	1																
		CENT				KIN		DATE									ATE	
ΡI		2007																
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚM,	KN,	KP,
						LC,			•									
			MW,	MX,	MY,	${ m MZ}$ ,	NΑ,	NG,	NΙ,	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,
			RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ΤJ,	TM,	TN,	TR,	TT,	TZ,
			•	•	•	UΖ,	•	•	•	•								
		RW:				CH,	•								•	•		
			•	•	•	LU,	•	•	•	•	•	•	•	•	•	•	•	•
						CM,	•								•	•		
						MW,			SD,	SL,	SZ,	TZ,	UG,	ZM,	ΖW,	AM,	AΖ,	BY,
	70 5 7	2006				RU,			0201		י זיג	000	2020	1.0		2	0000	005
		2006.																
		2618																
	LP	1917.																
		K:	•	•	•	CH, LT,	•	•	•	•	•	•	•	•	•	•	•	•
			•	HR,			ш∪,	۷,	MC,	мь,	PЦ,	rı,	RO,	or,	SI,	or,	IK,	AL,
	KB	2008	,	,				2008	N6N4		KR 2	nna_	7071	5.8		2	กกลก	325
PRAT		2005						2005			1111 2	000	7071	50		4	0000	J
11/1/11		2005																
		2006																
CLAS									0020									
		NO.		CLA	SS	PATE	NT F	AMIL	Y CL	ASSI	FICA'	TION	COD	ES				
WO 2007023186 IPCI					C07D			- ,				-	•					

[I,A]; C07D0401-00 [I,C\*]; C07D0403-12 [I,A]; C07D0403-00 [I,C\*]; C07D0405-12 [I,A]; C07D0405-00 [I,C\*]; C07D0409-12 [I,A]; C07D0409-00 [I,C\*]; C07D0417-12 [I,A]; C07D0417-00 [I,C\*]; A61K0031-498

[I,A]; A61P0035-00 [I,A]

IPCR C07D0241-00 [I,C]; C07D0241-44 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0405-00 [I,C]; C07D0405-12 [I,A]; C07D0409-00 [I,C]; C07D0409-12 [I,A]; C07D0417-00 [I,C]; C07D0417-12 [I,A]

ECLA C07D241/44; C07D401/12; C07D403/12; C07D405/12;

C07D409/12; C07D413/12; C07D417/12 AU 2006283846 IPCI C07D0241-00 [I,C]; C07D0241-44 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C]; C07D0403-12 [I,A]; C07D0405-00 [I,C]; C07D0405-12 [I,A]; C07D0409-00 [I,C]; C07D0409-12 [I,A]; C07D0417-00 [I,C]; C07D0417-12 [I,A] **ECLA** C07D241/44; C07D401/12; C07D403/12; C07D405/12; C07D409/12; C07D413/12; C07D417/12 CA 2618479 IPCI A61K0031-498 [I,A]; A61P0035-00 [I,A]; C07D0241-44 [I,A]; C07D0241-00 [I,C\*]; C07D0401-12 [I,A]; C07D0401-00 [I,C\*]; C07D0403-12 [I,A]; C07D0403-00 [I,C\*]; C07D0405-12 [I,A]; C07D0405-00 [I,C\*]; C07D0409-12 [I,A]; C07D0409-00 [I,C\*]; C07D0417-12 [I,A]; C07D0417-00 [I,C\*] EP 1917252 IPCI C07D0241-44 [I,A]; C07D0241-00 [I,C\*]; C07D0401-12 [I,A]; C07D0401-00 [I,C\*]; C07D0403-12 [I,A]; C07D0403-00 [I,C\*]; C07D0405-12 [I,A]; C07D0405-00 [I,C\*]; C07D0409-12 [I,A]; C07D0409-00 [I,C\*]; C07D0417-12 [I,A]; C07D0417-00 [I,C\*]; A61K0031-498 [I,A]; A61P0035-00 [I,A] C07D0241-44 [I,A]; C07D0241-00 [I,C\*]; C07D0405-12 KR 2008049767 IPCI [I,A]; C07D0405-00 [I,C\*]; A61K0031-498 [I,A]; A61P0035-00 [I,A]

OS MARPAT 146:295955 GI

$$\begin{bmatrix} \mathbb{R}^{1} \end{bmatrix}_{n} \xrightarrow{B}_{\mathbb{R}}^{\mathbb{R}^{2}} \mathbb{R}^{3}$$

$$\begin{bmatrix} \mathbb{R}^{1} \end{bmatrix}_{n} \xrightarrow{\mathbb{R}^{2}} \mathbb{R}^{4}$$

$$\mathbb{R}^{2} \xrightarrow{\mathbb{R}^{3}} \mathbb{R}^{4}$$

$$\mathbb{R}^{1} \xrightarrow{\mathbb{R}^{4}} \mathbb{R}^{4}$$

$$\mathbb{R}^{2} \xrightarrow{\mathbb{R}^{4}} \mathbb{R}^{4}$$

$$\mathbb{R}^{4} \xrightarrow{\mathbb{R}^{4}} \mathbb{R}^{4}$$

$$\mathbb{R}^{4} \xrightarrow{\mathbb{R}^{4}} \mathbb{R}^{4}$$

$$\mathbb{R}^{4} \xrightarrow{\mathbb{R}^{4}} \mathbb{R}^{4}$$

AB Title compds. I [A, B, D, E = independently C, N, such that the ring R is an aromatic ring; R1 = H, halo, NO2, alk(en/yn)yl; R2 = H, alk(en/yn)yl; R3 = H, halo, alk(en/yn)yl, alkoxy, aryl, heteroaryl; R4 = alk(en/yn)yl, aryl, heteroaryl, arylalkenyl, cycloalkylalkyl, etc.; n = 0-4; and their geometrical isomers, their optically active forms as enantiomers,

ΙI

diastereomers, tautomers, racemates, and their pharmaceutically acceptable salts] were prepared as phosphoinositide 3-kinase (PI3K) inhibitors for use as a drug. Thus, treatment of 2,3-dichloroquinoxaline with ammonium carbonate in DMF, amination of the chloride with 2,5-dimethoxyaniline, and reaction of the amine 1-methylimidazole-4-sulfonyl chloride gave quinoxaline II. II inhibited PI3K induced-lipid phosphorylation with IC50 = 0.08  $\mu\text{M}$ . II inhibited IgM-induced Akt phosphorylation with IC50 = 0.03  $\mu\text{M}$ . Selected I inhibited stem cell factor-induced PKB/Akt phosphorylation in mast cells with IC50 ranging from 0.09  $\mu\text{M}$  to 1.22  $\mu\text{M}$ . I are useful for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

- ST pyrazine quinoxaline oxyphenylamino sulfonamide prepn phosphoinositide kinase PIK3K inhibitor; pyridopyrazine pyrazine quinoxaline prepn PIK3K inhibitor
- IT Nervous system, disease

(Huntington's chorea; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sarcoma

(Kaposi's; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease

(airway inflammation; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease

(atrophy, skeletal; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(bacterial, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(bacterial, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(bacterial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Nervous system, disease

(degeneration; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Erythrocyte

(disease, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sperm motility

(diseases; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood vessel, disease

(endothelium injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung

(epithelium, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood, disease

(erythrocyte, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Kidney, disease

(fibrosis, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation

Kidney, disease

(glomerulonephritis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease

(hypertrophy; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Brain, disease

(infection; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease

Reperfusion

(injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Neoplasm

(metastasis, invasion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Hypertrophy

(muscular; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation

Pancreas, disease

(pancreatitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Skin, disease

(passive cutaneous anaphylaxis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation

Lung, disease

(pneumonitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Allergy

Allergy inhibitors

Alzheimer's disease

Anaphylaxis

Angiogenesis

Angiogenesis inhibitors

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiasthmatics

Antibacterial agents

Antifibrotic agents

Antihypertensives

Antirheumatic agents

Antitumor agents

Antiviral agents

Asthma

Atherosclerosis

Autoimmune disease

B cell (lymphocyte)

Bone marrow

Cardiac hypertrophy

Cardiovascular agents

Cardiovascular system, disease

Central nervous system agents

Encephalitis Fibrosis Glomerulosclerosis Heart, disease Human Hypertension Immunomodulators Immunosuppressants Inflammation Inflammatory bowel disease Ischemia Kidney, disease Mast cell Melanoma Meningitis Multiple organ failure Multiple sclerosis Neoplasm Neuroprotective agents Pharmaceutical carriers Pharmaceutical excipients Platelet activation Platelet aggregation Platelet aggregation inhibitors Prophylaxis Psoriasis Rheumatoid arthritis Sepsis Stroke Thrombolytics Thrombosis Transplant and Transplantation Transplant rejection Vasoconstriction Vasodilators (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Epithelium (pulmonary, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) (pulmonary; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Leukocyte (recruitment in cancer tissue; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Fibrosis (renal, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Injury (reperfusion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Lupus erythematosus (systemic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Central nervous system, disease (trauma; preparation of pyrazine derivs. as PI3K inhibitors useful in

(vascular endothelial; preparation of pyrazine derivs. as PI3K inhibitors

treatment and prophylaxis of diseases)

useful in treatment and prophylaxis of diseases)

ΙT

ΙT

ΙT

ΤТ

ΙT

ΙT

ΙT

ΙT

Injury

ΤТ Endothelium (vascular, disease, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) ΙT (viral, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) ΙT Infection (viral, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) ΙT Infection (viral; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) ΙΤ 328039-48-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2yl]benzenesulfonamide 331723-61-6P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 371958-49-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide372090-78-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-372091-52-6P, N-[3-[(2,5yl]benzenesulfonamide Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 424804-76-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2yl]benzenesulfonamide 432007-91-5P, 4-Bromo-N-[3-[(3methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide N-[3-[(3,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl]-4fluorobenzenesulfonamide 585560-01-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide 713083-87-5P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2vllbenzenesulfonamide 714245-33-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714257-01-9P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2vl]benzensulfonamide 714282-93-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide 714916-66-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-714917-87-0P, 4-Fluoro-N-[3-[(3fluorobenzenesulfonamide methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 714932-70-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide 714932-98-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-843630-52-4P, N-[3-[(3,5methoxybenzenesulfonamide Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928139-93-9P, 4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic 928139-97-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2yl]amino]sulfonyl]benzoic acid 928140-00-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(hydroxymethyl)pyridine-3sulfonamide 928140-31-2P, Methyl 3-[[[3-[(2,5dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-928140-32-3P, Methyl 3-[[[3-[(3,5carboxylate dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-928140-36-7P, 3-Cyano-N-[3-[(3,5carboxylate dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-38-9P, Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2y1]amino]sulfony1]benzoate 928140-39-0P, Methy1 3-[[[3-[(3,5dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-43-6P, 4-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-928140-50-5P, Methyl 4-[[[3-[(2,5yl]benzenesulfonamide dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate 928140-51-6P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2yl]amino]sulfonyl]benzoate 928140-52-7P, Methyl 4-[[[3-[(2,5dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate 928140-53-8P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-928140-71-0P, N-[3-[(2,5yl]amino]sulfonyl]butanoate Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide

928140-73-2P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-

```
yl]benzenesulfonamide
                       928140-75-4P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide
                                                           928140-77-6P.
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide
928140-79-8P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-
yl]methanesulfonamide
                       928140-83-4P, 4-Bromo-N-[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                           928140-85-6P,
N-[3-[(2,5-Dimethoxyphenyl)]amino]quinoxalin-2-yl]-4-
(trifluoromethyl)Benzenesulfonamide 928140-87-8P, N-[3-[(3,5-
Dimethoxyphenyl)amino|quinoxalin-2-vl]-4-iodobenzenesulfonamide
928140-90-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
iodobenzenesulfonamide 928140-92-5P, 4,5-Dichloro-N-[3-[(2,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide
928140-95-8P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide
                      928140-96-9P, Methyl 3-[4-[[[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoate
928140-98-1P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-
1,3-dimethyl-1H-pyrazole-4-sulfonamide 928141-00-8P,
5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-
pyrazole-4-sulfonamide 928141-04-2P, 5-Bromo-N-[3-[(3,5-
\verb|dimethoxyphenyl|| amino|| quinoxalin-2-yl|| thiophene-2-sulfonamide
928141-06-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-
yl]benzenesulfonamide
                      928141-11-1P, N-[7-Chloro-3-[(3,5-
                                                         928141-13-3P,
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
Methyl 5-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-
4-methylthiophene-2-carboxylate
                                928141-14-4P, 5-[[[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-
2-carboxylic acid methyl ester 928141-15-5P, 5-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-
2-carboxylic acid methyl ester 928141-18-8P, 2-Chloro-N-[3-[(2,5-
dimethoxyphenyl)amino|quinoxalin-2-yl]-4-fluorobenzenesulfonamide
928141-20-2P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
                          928141-22-4P, N-[3-[(3,5-
fluorobenzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
928141-24-6P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide
                          928141-26-8P, 3-Cyano-N-[3-[(2,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
928141-28-0P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]pyridine-3-sulfonamide
                           928141-30-4P, N-[3-[(3,5-
Dimethoxyphenyl) amino] quinoxalin-2-yl]-6-(dimethylamino) pyridine-3-
              928141-32-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
sulfonamide
yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide
                                                       928141-35-9P,
N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-
cyanobenzenesulfonamide
                         928141-37-1P, N-[3-[(2-Chloro-5-
methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
                                                           928141-39-3P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-
sulfonamide
             928141-42-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
                                   928141-47-3P,
yl]-6-methylpyridine-3-sulfonamide
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-
                          928141-51-9P, N-[3-[(2,5-
methylbenzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
928141-53-1P, 4-Cyano-N-[3-[(5-methoxy-2-methylphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide
                      928141-56-4P, N-[3-[(5-Methoxy-2-
methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
928141-58-6P, N-[3-[(2-Chloro-5-methoxyphenyl)] amino]quinoxalin-2-yl]-6-
methylpyridine-3-sulfonamide
                              928141-59-7P, Methyl 5-[[[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-2-
carboxylate
             928141-62-2P, N-[3-[(3,5-Dimethoxyphenyl)] amino]quinoxalin-2-
                                                   928141-75-7P,
yl]-3-[(morpholin-4-yl)carbonyl]benzenesulfonamide
5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]pyridine-
                   928141-78-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxa
2-carboxylic acid
\lim_{t\to\infty} -2-y1 -4-[(4-methylpiperazin-1-y1)methyl]benzenesulfonamide
```

```
928141-81-5P, 4-(Aminomethyl)-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-
                        928141-84-8P, 3-(Aminomethyl)-N-[3-[(3,5-
2-v1|benzenesulfonamide
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                          928141-88-2P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-
                             928141-90-6P, N-[3-[(3,5-
yl)methyl]benzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)carbonyl]benzenesulfonamide 928141-91-7P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
v1) methyl benzenesulfonamide 928141-93-9P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesul
          928141-95-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-
3-[(dimethylamino)methyl]benzenesulfonamide 928142-00-1P,
4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-
(dimethylamino)propyl]benzamide
                               928142-02-3P, 3-[[[3-[(3,5-
(dimethylamino)propyl]benzamide 928142-07-8P, N-[3-[(3,5-
Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide
928142-12-5P, 5-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-
2-yl]thiophene-2-sulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
   (drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful
   in treatment and prophylaxis of diseases)
714244-38-9P, 3-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide 714924-49-9P, 3-Chloro-N-[3-[(2,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
N-[3-[(3,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-3-
methylsulfonylbenzenesulfonamide 928140-03-8P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide
928140-04-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-
(morpholin-4-yl)pyridine-3-sulfonamide
                                        928140-07-2P,
N-[3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]phenyl]acetamide 928140-08-3P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamid
   928140-09-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-
(methylsulfonyl) benzenesulfonamide 928140-10-7P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,3-dihydro-1,4-benzodioxine-6-
sulfonamide
             928140-11-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
vl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide
                                                    928140-12-9P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide
928140-13-0P, 2-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
                       928140-14-1P, 3-Cyano-N-[3-[(2,5-
yl]benzenesulfonamide
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-15-2P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
                          928140-16-3P, N-[3-[(2,5-
methoxybenzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide
928140-17-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-
                          928140-18-5P, N-[3-[(3,5-
fluorobenzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide
928140-19-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
(methylsulfonyl) benzenesulfonamide 928140-20-9P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-
yl)sulfonyl]benzenesulfonamide
                                928140-21-0P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(methylsulfonyl)benzenesulfonamid
   928140-22-1P, N-[3-[(2,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-2,1,3-
benzothiadiazole-4-sulfonamide
                               928140-23-2P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide
928140-24-3P, N-[3-[(3,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-2,1,3-
                             928140-25-4P, N-[3-[(2,5-
benzoxadiazole-4-sulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide
```

ΙT

```
928140-26-5P, N-[3-[(3,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl]-1-(pyridin-
2-yl)methanesulfonamide 928140-27-6P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide
928140-29-8P, N-[3-[(3,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-1-(pyridin-
3-y1) methanesulfonamide 928140-30-1P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-1,2-dimethyl-1H-imidazole-5-
sulfonamide
             928140-33-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
y1]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide
928140-34-5P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methyl-2-
oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide
                                                  928140-35-6P,
2-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
                      928140-37-8P, N-[3-[(3,5-
vl]benzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide
928140-40-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
fluorobenzenesulfonamide 928140-41-4P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide
928140-42-5P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide 928140-44-7P, 2-Chloro-N-[3-[(2,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928140-45-8P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide
928140-46-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-
sulfonamide
             928140-47-0P, N-[3-[[5-Methoxy-2-(1H-pyrrol-1-
yl)phenyl]amino]quinoxalin-2-yl]benzenesulfonamide 928140-48-1P,
N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
928140-49-2P, N-[3-[(5-Methoxy-2-methylphenyl)] amino]quinoxalin-2-
yl]benzenesulfonamide 928140-55-0P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-56-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
methylbenzenesulfonamide potassium salt
                                        928140-59-4P,
4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzensulfonamide potassium salt 928140-60-7P, 4-Fluoro-N-[3-[(3-
methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-61-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide potassium salt
                                         928140-62-9P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
methoxybenzenesulfonamide potassium salt
                                          928140-63-0P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
methylbenzenesulfonamide potassium salt
                                         928140-64-1P,
4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
vl]benzenesulfonamide potassium salt
                                      928140-65-2P, 4-Chloro-N-[3-[(3-
methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-66-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
vl]benzenesulfonamide potassium salt
                                      928140-67-4P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
potassium salt
                 928140-68-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-
2-yl]benzenesulfonamide potassium salt 928140-69-6P,
N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium
       928140-70-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
salt
yl]pyridine-3-sulfonamide potassium salt
                                          928140-72-1P,
4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
                                      928140-74-3P, N-[3-[(3,5-
yl]benzenesulfonamide potassium salt
Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt
928140-76-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]methanesulfonamide potassium salt
                                      928140-78-7P, N-[3-[(3-
Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt
928140-80-1P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt
                                     928140-81-2P, 4-Bromo-N-[3-[(3-
methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-82-3P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt 928140-84-5P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonami
```

```
de potassium salt
                   928140-86-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxa
lin-2-yl]-4-iodobenzenesulfonamide potassium salt 928140-88-9P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide
                928140-91-4P, 4,5-Dichloro-N-[3-[(2,5-
potassium salt
dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium
       928140-93-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-
2-yl]benzenesulfonamide potassium salt 928140-94-7P,
4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
vl]benzenesulfonamide potassium salt 928140-97-0P, 5-Chloro-N-[3-[(2,5-1)]]
dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-
sulfonamide potassium salt
                           928140-99-2P, 5-Chloro-N-[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-
sulfonamide potassium salt 928141-01-9P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide
potassium salt 928141-02-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
2-y1]-3-methylbenzenesulfonamide potassium salt 928141-03-1P,
5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-
sulfonamide potassium salt 928141-05-3P, N-[3-[(3,5-
Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide
                928141-07-5P, N-[3-[(2,5-Dimethoxyphenyl)]amino]pyrido[2,3-
potassium salt
b]pyrazin-2-yl]benzenesulfonamide 928141-08-6P, N-[2-[(2,5-
Dimethoxyphenyl)amino]pyrido[3,4-b]pyrazin-3-yl]benzenesulfonamide
928141-09-7P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
vl]benzenesulfonamide potassium salt
                                      928141-12-2P
                                                     928141-16-6P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide
                 928141-17-7P, 2-Chloro-N-[3-[(2,5-
potassium salt
dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
potassium salt 928141-19-9P, 2-Chloro-N-[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
potassium salt 928141-21-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
2-yl]pyridine-3-sulfonamide potassium salt 928141-23-5P,
3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide potassium salt 928141-25-7P,
3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
                                        928141-27-9P,
fluorobenzenesulfonamide potassium salt
6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-
sulfonamide potassium salt
                            928141-29-1P, N-[3-[(3,5-
Dimethoxyphenyl) amino] quinoxalin-2-yl]-6-(dimethylamino) pyridine-3-
sulfonamide potassium salt
                            928141-31-5P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-
                             928141-33-7P, N-[3-[(5-Methoxy-2-
3-sulfonamide hydrochloride
methylphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
                                                            928141-34-8P,
N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]-4-
cyanobenzenesulfonamide potassium salt
                                         928141-36-0P,
N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-
                            928141-38-2P, N-[3-[(3,5-
sulfonamide potassium salt
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide
                 928141-40-6P
                               928141-41-7P, N-[3-[(3,5-
potassium salt
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
                 928141-44-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
potassium salt
2-yl]-4-fluoro-2-methylbenzenesulfonamide potassium salt
                                                          928141-49-5P,
N-[3-[(2,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-6-methylpyridine-3-
sulfonamide potassium salt
                            928141-55-3P, N-[3-[(5-Methoxy-2-
methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
                 928141-57-5P, N-[3-[(2-Chloro-5-
potassium salt
methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
potassium salt
                 928141-60-0P, N-[3-[(2-Bromo-5-
methoxyphenyl) amino] quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide
928141-61-1P, N-[3-[(3,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-3-
[(morpholin-4-yl)carbonyl]benzenesulfonamide potassium salt
928141-63-3P, 3-[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
```

```
yl]sulfamoyl]benzoic acid
                          928141-65-5P, 4-[[[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid
928141-66-6P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]butanoic acid 928141-67-7P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid
928141-68-8P, 3-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]thiophene-2-carboxylic acid
                                               928141-69-9P,
3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
vl]amino|sulfonyl]thiophene-2-carboxylic acid
                                               928141-70-2P,
3-[4-[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]phenyl]propanoic acid
                                        928141-71-3P,
5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-
methylthiophene-2-carboxylic acid 928141-72-4P, 5-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-
carboxylic acid 928141-73-5P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxa
lin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium
      928141-74-6P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt
928141-76-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
[(morpholin-4-yl)methyl]benzenesulfonamide 928141-77-9P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-
yl)methyl]benzenesulfonamide dihydrochloride
                                              928141-80-4P
928141-82-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
(hydroxymethyl) benzenesulfonamide 928141-83-7P, 3-(Aminomethyl)-N-[3-
[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
              928141-85-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
hvdrochloride
2-yl]-4-(hydroxymethyl)benzenesulfonamide 928141-87-1P,
N-[3-[(3,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl]-4-[(morpholin-4-
yl)methyl]benzenesulfonamide hydrochloride 928141-89-3P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)methyl]benzenesulfonamide dihydrochloride 928141-92-8P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
[(dimethylamino)methyl]benzenesulfonamide hydrochloride
                                                         928141-94-0P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
[(dimethylamino)methyl]benzenesulfonamide hydrochloride
                                                         928141-96-2P,
4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]benzamide sodium salt
                                         928141-97-3P,
4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]benzamide sodium salt
                                         928141-98-4P,
4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-(3-
methoxypropyl)benzamide
                         928141-99-5P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-
(dimethylamino)propyl]benzamide hydrochloride
                                               928142-01-2P
928142-03-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]-N,N-dimethylpyridine-2-carboxamide 928142-04-5P,
N-[3-[(3,5-Dimethoxyphenyl)]] amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)carbonyl]benzenesulfonamide potassium salt
                                              928142-05-6P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(morpholin-4-
yl)carbonyl]pyridine-3-sulfonamide
                                   928142-06-7P, N-[3-[(3,5-
Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide
potassium salt
                 928142-08-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
2-yl]-6-[(4-methylpiperazin-1-yl)methyl]pyridine-3-sulfonamide
              928142-14-7P, N-[6-Chloro-3-[(3,5-
928142-09-0P
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                          928142-15-8P,
N-[3-[[(2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]amino]quinoxalin-2-
yl]benzenesulfonamide 928142-16-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]-6-
nitroquinoxalin-2-yl]benzenesulfonamide
                                         928142-17-0P,
5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-
methyl-1H-pyrrole-2-carboxylic acid 928142-18-1P, 5-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-
2-carboxylic acid 928142-19-2P, 4-[[[3-[(3,5-
```

```
928142-20-5P, 4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-
    yl]amino]sulfonyl]benzamide
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
        (drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful
        in treatment and prophylaxis of diseases)
    98-10-2P, Benzenesulfonamide 636-76-0P, 3-(Aminosulfonyl)benzoic acid
ΙΤ
    825-86-5P, 4-Iodobenzenesulfonamide 1565-17-9P, 4-
    Acetylbenzenesulfonamide 1899-94-1P, 3-Methylbenzenesulfonamide
    2067-84-7P, 1,4-Dihydropyrido[2,3-b]pyrazine-2,3-dione 2922-45-4P,
    3-Pyridinesulfonamide 4029-41-8P, N-(3-Chloroquinoxalin-2-yl)-4-
    methylbenzenesulfonamide 4029-43-0P, 4-Bromo-N-(3-chloroquinoxalin-2-
    yl)benzenesulfonamide 6339-87-3P, 2-Thiophenesulfonamide 6684-39-5P,
    6-Chloropyridine-3-sulfonyl chloride 22808-73-7P, Methyl
    4-(aminosulfonyl)benzoate 24243-71-8P, 1-Propanesulfonamide
    25710-18-3P, 2,3-Dichloropyrido[2,3-b]pyrazine 32947-34-5P, Methyl
    5-(aminosulfonyl)pyridine-2-carboxylate 34082-13-8P,
    6-Methylpyridine-3-sulfonamide 34117-90-3P, 3-Chloroquinoxalin-2-amine
    35251-84-4P, 1,4-Dihydropyrido[3,4-b]pyrazine-2,3-dione 35251-99-1P,
    2,3-Dichloropyrido[3,4-b]pyrazine 40741-46-6P, 6-Chloropyridine-3-
    sulfonamide 53595-65-6P, 5-Bromothiophene-2-sulfonamide 59777-67-2P,
    Methyl 3-(aminosulfonyl)benzoate 63555-50-0P, Methyl
    3-(chlorosulfonyl)benzoate 69156-30-5P, 2-Chloro-4-
    fluorobenzenesulfonamide 88398-46-3P, 5-Chloro-1,3-dimethyl-1H-pyrazole-
    4-sulfonamide 165058-49-1P, N-(3-Methoxyphenyl)quinoxaline-2,3-diamine
    166271-34-7P, N-(3-Chloro-2-quinoxalinyl)benzenesulfonamide
    199590-78-8P, 6-(Dimethylamino)pyridine-3-sulfonamide
                                                           256353-34-1P,
    4,5-Dichlorothiophene-2-sulfonamide 478264-00-5P, 6-Methylpyridine-3-
                        488744-02-1P, N-(3-Chloroquinoxalin-2-yl)-4-
    sulfonyl chloride
                               522628-95-1P, 4-Chloro-N-(3-chloroquinoxalin-2-
    fluorobenzenesulfonamide
                           565172-05-6P, N-(3-Chloroquinoxalin-2-yl)-3-
    yl)benzenesulfonamide
    methylbenzenesulfonamide 743444-94-2P, 3-Chloro-N-(3-chloroquinoxalin-2-
    yl)benzenesulfonamide 847985-15-3P, 2-Chloro-N-(3-chloroquinoxalin-2-
    yl)benzenesulfonamide 848052-87-9P, N-(3-Chloroquinoxalin-2-yl)thiophene-
    2-sulfonamide
                    856955-32-3P, 6-Methoxypyridine-3-sulfonamide
    859491-30-8P, 5-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-
    2-sulfonamide
                   883057-32-7P, 5-(Aminosulfonyl)-1-methyl-1H-pyrrole-2-
    carboxylic acid methyl ester
                                  928139-26-8P, N-(3,5-
                                             928139-27-9P,
    Dimethoxyphenyl)quinoxaline-2,3-diamine
    N-(2,5-Dimethoxyphenyl) quinoxaline-2,3-diamine
                                                     928139-28-0P, Methyl
    3-[4-(aminosulfonyl)phenyl]propanoate 928139-29-1P, Methyl
    5-(aminosulfonyl)-4-methylthiophene-2-carboxylate
                                                       928139-30-4P,
    3-Cyano-4-fluorobenzenesulfonamide
                                        928139-31-5P,
                                         928139-32-6P, 6-Cyanopyridine-3-
    6-Cyanopyridine-3-sulfonyl chloride
                  928139-33-7P, 3-[(Morpholin-4-yl)carbonyl]benzenesulfonamide
    sulfonamide
    928139-34-8P, 6-[(3-Methoxypropyl)amino]pyridine-3-sulfonamide
    928139-35-9P, N-(3-Chloroquinoxalin-2-yl)-3-fluorobenzenesulfonamide
    928139-36-0P, N-(3-Chloroquinoxalin-2-yl)propane-1-sulfonamide
    928139-37-1P, Methyl 4-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]butanoate
    928139-39-3P, Methyl 4-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]benzoate
    928139-44-0P, N-(3-Chloroquinoxalin-2-yl)-4-methoxybenzenesulfonamide
    928139-48-4P, N-(3-Chloroquinoxalin-2-yl)pyridine-3-sulfonamide
    928139-50-8P, N-(3-Chloroquinoxalin-2-yl)-4-cyanobenzenesulfonamide
    928139-52-0P, N-(3-Chloroquinoxalin-2-yl)methanesulfonamide
    928139-54-2P, N-(3-Chloroquinoxalin-2-yl)-4-(trifluoromethyl) benzenesulfon
    amide
            928139-56-4P, N-(3-Chloroquinoxalin-2-yl)-4-iodobenzenesulfonamide
    928139-58-6P, 4,5-Dichloro-N-(3-chloroquinoxalin-2-yl)thiophene-2-
                  928139-60-0P, 5-Chloro-N-(3-chloroquinoxalin-2-yl)-1,3-
    sulfonamide
    dimethyl-1H-pyrazole-4-sulfonamide 928139-62-2P, 4-Acetyl-N-(3-
```

Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide

```
chloroquinoxalin-2-yl)benzenesulfonamide 928139-63-3P, Methyl
3-[4-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]phenyl]propanoate
928139-64-4P, 5-Bromo-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide
928139-66-6P, N-(3,6-Dichloroquinoxalin-2-yl)benzenesulfonamide
928139-67-7P, Methyl 5-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]-4-
methylthiophene-2-carboxylate 928139-70-2P, 5-[[(3-Chloroquinoxalin-2-
yl)amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester
928139-72-4P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)-4-
fluorobenzenesulfonamide
                         928139-74-6P, N-(3-Chloroguinoxalin-2-vl)-5-
[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide
928139-76-8P, N-(3-Chloroquinoxalin-2-yl)-3-cyano-4-
                         928139-78-0P, 6-Chloro-N-(3-chloroquinoxalin-2-
fluorobenzenesulfonamide
yl)pyridine-3-sulfonamide 928139-79-1P, N-(3-Chloroquinoxalin-2-yl)-6-
(dimethylamino)pyridine-3-sulfonamide 928139-81-5P, N-(3-
Chloroquinoxalin-2-yl)-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide
928139-83-7P, N-(3-Chloroquinoxalin-2-yl)-6-methoxypyridine-3-sulfonamide
928139-85-9P, N-(3-Chloroquinoxalin-2-yl)-6-methylpyridine-3-sulfonamide
928139-87-1P, Methyl 5-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]pyridine-
2-carboxylate 928139-88-2P, N-(3-Chloroquinoxalin-2-yl)-3-[(morpholin-4-
yl)carbonyl]benzenesulfonamide 928139-89-3P, N-(3-Chloroquinoxalin-2-yl)-
1-methyl-1H-imidazole-4-sulfonamide
                                    928139-90-6P, N-(2-Chloropyrido[3,4-
                                   928139-91-7P, N-(3-Chloropyrido[2,3-
b]pyrazin-3-yl)benzenesulfonamide
                                   928139-92-8P, N-[3-[(3,5-
b]pyrazin-2-yl)benzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-
yl)carbonyl]benzenesulfonamide 928139-94-0P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-
yl)carbonyl]benzenesulfonamide 928139-95-1P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N, N-
dimethylbenzamide
                  928139-96-2P, 3-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-
                  928139-98-4P, 6-(Chloromethyl)-N-[3-[(3,5-
dimethylbenzamide
dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
928140-01-6P, Methyl 5-[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928142-21-6P,
N-(5-Methoxy-2-methylphenyl)quinoxaline-2,3-diamine
                                                     928142-22-7P,
N-[5-Methoxy-2-(pyrrol-1-yl)phenyl]quinoxaline-2,3-diamine
                                                            928142-23-8P,
N-(5-Methoxy-2-chlorophenyl)quinoxaline-2,3-diamine
                                                     928142-24-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
   (intermediate; preparation of pyrazine derivs. as PI3K inhibitors useful in
   treatment and prophylaxis of diseases)
115926-52-8, Phosphoinositide 3-kinase 148640-14-6, Akt kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (preparation of pyrazine derivs. as PI3K inhibitors useful in
  treatment and prophylaxis of diseases)
928142-13-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
   (preparation of pyrazine derivs. as PI3K inhibitors useful in
   treatment and prophylaxis of diseases)
54-96-6, 3, 4-Diaminopyridine
                              70-55-3, p-Toluenesulfonamide
                         98-61-3, Pipsyl chloride
                                                     98-64-6,
Benzenesulfonyl chloride
4-Chlorobenzenesulfonamide 102-56-7, 2, 5-Dimethoxyaniline 109-01-3,
                   109-55-7, N,N-Dimethyl-1,3-propanediamine
1-Methylpiperazine
4-(Aminosulfonyl) benzoic acid 402-46-0, 4-Fluorobenzenesulfonamide
452-58-4, 2,3-Diaminopyridine
                               536-90-3, m-Anisidine
                                                       701-34-8,
4-Bromobenzenesulfonamide 830-43-3, 4-(Trifluoromethyl)benzenesulfonamid
    1129-26-6, 4-Methoxybenzenesulfonamide
                                            1524-40-9,
3-Fluorobenzenesulfonamide 1788-10-9, 4-Acetylbenzensulfonyl chloride
```

ΙT

ΤТ

ΙT

```
1899-93-0, m-Toluenesulfonyl chloride 2213-63-0, 2,3-Dichloroquinoxaline 2401-24-3, 2-Chloro-5-methoxyaniline 2905-21-7, 2-Fluorobenzenesulfonyl
     chloride 2958-87-4, 2,3,6-Trichloroquinoxaline 3119-02-6,
     4-Cyanobenzenesulfonamide 3430-14-6, 3-Amino-6-methylpyridine
     4025-64-3, 3-(Chlorosulfonyl)benzoic acid 4808-69-9,
     6-Methylpyridine-3-sulfonic acid 5332-73-0, 3-Methoxypropylamine
     5335-40-0, 3-(Methylsulfonyl) benzenesulfonyl chloride 5350-93-6,
     5-Amino-2-chloropyridine 6961-82-6, 2-Chlorobenzenesulfonamide
     10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1,
     1-Propanesulfonyl chloride 10272-07-8, 3,5-Dimethoxyaniline
     16133-25-8, 3-Pyridinesulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl
              17260-71-8, 3-Chlorobenzenesulfonamide 23905-46-6,
     3-Acetylaminobenzenesulfonyl chloride 50868-72-9, 5-Methoxy-2-
                   51175-71-4, 3-Thiophenesulfonyl chloride 55338-73-3,
     methylaniline
     5-Amino-2-cyanopyridine 55854-46-1, 5-Bromothiophene-2-sulfonyl chloride
     56542-67-7, 3-Cyanobenzenesulfonyl chloride 59194-26-2,
     5-Methoxy-2-(1H-pyrrol-1-yl)aniline 59337-92-7, Methyl
     3-(chlorosulfonyl)thiophene-2-carboxylate 59557-92-5,
     2-Bromo-5-methoxyaniline 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl
               73713-79-8 82964-91-8, 4-(Methylsulfonyl)benzenesulfonyl
     chloride
              85958-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride
     chloride
     88398-93-0, 5-Chloro-1,3-dimethylpyrazole-4-sulfonyl chloride
     89265-35-0, 2-(Methylsulfonyl) benzenesulfonyl chloride 111124-90-4,
     1-Methyl-1H-imidazole-4-sulfonamide 114322-14-4, 2,1,3-Benzoxadiazole-4-
     sulfonyl chloride
                        126714-85-0, 2,3-Dichlorothiophene-5-sulfonyl chloride
     137049-00-4, 1-Methylimidazole-4-sulfonyl chloride 165669-32-9,
     4-[(Pyrrolidin-1-yl)sulfonyl]benzenesulfonyl chloride 175476-51-4,
     Methyl 4-(aminosulfonyl)butanoate 306936-62-9, 5-(Aminosulfonyl)-1-
     methyl-1H-pyrrole-2-carboxylic acid 312300-42-8, 6-Methoxypyridine-3-
     sulfonyl chloride 332361-07-6, 5-[(1,3-Dioxo-1,3-dihydroisoindol-2-
     yl)methyl]thiophene-2-sulfonyl chloride 337508-68-6
                                                             351003-23-1,
                                                374537-95-8, Methyl
     4-Fluoro-3-cyanobenzenesulfonyl chloride
     3-(4-chlorosulfonylphenyl)propionate
                                           423768-46-1, Methyl
     5-(chlorosulfonyl)-4-methyl-2-thiophenecarboxylate
                                                         847744-22-3,
     N-(3-Chloroquinoxalin-2-y1)-4-fluoro-2-methylbenzenesulfonamide
     849351-92-4, 1,2-Dimethyl-1H-imidazole-5-sulfonyl chloride
                                                                  878682-97-4,
     3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonyl chloride
     882564-09-2
                   928140-28-7
                                928141-10-0, N-(3,7-Dichloroquinoxalin-2-
     yl)benzenesulfonamide
                            928142-10-3, N-[3-[(3,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-5-[(1,3-dioxo-1,3-dihydro-2H-
     \verb|isoindol-2-y1|| \verb|methy1|| \verb|thiophene-2-sulfonamide||
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of pyrazine derivs. as PI3K inhibitors useful in
        treatment and prophylaxis of diseases)
RE.CNT 3
              THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
(1) Anon; Ambinter Stock Screening Collection 2005
(2) Anon; DATABASE CHEMCATS 2005
(3) Icos Corporation; WO 03035075 A 2003
    ANSWER 7 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
     98-59-9, 4-Methylphenylsulfonyl chloride
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (starting material; preparation of pyrrolopyridine derivs. as protein kinase
        inhibitors useful in treatment of diseases)
```

RE


L32

98-59-9 CAPLUS

Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)

ΙT

RN CN



ACCESSION NUMBER: 2007:11341 CAPLUS

DOCUMENT NUMBER: 146:121941

TITLE: Pyrrolo[2,3-b]pyridine derivatives as protein kinase

inhibitors and their preparation, pharmaceutical

compositions and use in the treatment of

diseases

INVENTOR(S): Ibrahim, Prabha N.; Artis, Dean R.; Bremer, Ryan;

Habets, Gaston; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Zuckerman, Rebecca; West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu,

Hongyao; Shi, Shenghua

PATENT ASSIGNEE(S): Plexxikon, Inc., USA SOURCE: PCT Int. Appl., 631 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PA	PATENT NO.			KIND DATE			APPLICATION NO.				DATE						
WO	WO 2007002433						WO 2006-US24524				20060621						
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	KP,
		KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,
		MW,	MX,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	RU,
		SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,
		US,	UZ,	VC,	VN,	ZA,	ZM,	ZW									
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG,	BW,	GH,
		GM,	ΚE,	LS,	MW,	ΜZ,	NΑ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,
		KG,	KΖ,	MD,	RU,	ТJ,	TM										
AU	2006	2619	93		A1		2007	0104	i	AU 2	006-	26199	93		2	0060	521
CA	2613	015			A1		2007	0104	(	CA 20	006-	2613	015		2	0060	521
EP	1893	612			A1		2008	0305	]	EP 20	006-	7738	61		2	0060	621
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
		IS,	ΙΤ,	LI,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	YU
PRIORIT	RIORITY APPLN. INFO.:						US 2005-692960P				P 20050622						
									US 2005-731528P				I	2	0051	028	
									Ī	WO 20	006-1	JS24.	524	I	W 2	0060	521

OTHER SOURCE(S): MARPAT 146:121941

AN 2007:11341 CAPLUS

DN 146:121941

ED Entered STN: 04 Jan 2007

TI Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Ibrahim, Prabha N.; Artis, Dean R.; Bremer, Ryan; Habets, Gaston; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang;

Zuckerman, Rebecca; West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu, Hongyao; Shi, Shenghua

PΑ

Plexxikon, Inc., USA PCT Int. Appl., 631 pp. SO

CODEN: PIXXD2

DT Patent

English LA

28-2 (Heterocyclic Compounds (More Than One Hetero Atom)) CC

Section cross-reference(s): 1, 63

FAN	.CN	Т 3

PATENT NO.		KIND	DATE	APPLICATION NO.	
PI WO 20070024 W: AE, CN, GE, KR, MW, SC, US, RW: AT, IS, CF, GM,	AG, AL, CO, CR, GH, GM, KZ, LA, MX, MZ, SD, SE, UZ, VC, BE, BG, IT, LT, CG, CI, KE, LS,	CU, CZ, HN, HR, LC, LK, NA, NG, SG, SK, VN, ZA, CH, CY, LU, LV, CM, GA, MW, MZ,	20070104 , AU, AZ, , DE, DK, , HU, ID, , LR, LS, , NI, NO, , SL, SM, , ZM, ZW , CZ, DE, , MC, NL, , GN, GQ, , NA, SD,	WO 2006-US24524 BA, BB, BG, BR, BW DM, DZ, EC, EE, EG IL, IN, IS, JP, KE LT, LU, LV, LY, MA NZ, OM, PG, PH, PL SY, TJ, TM, TN, TR  DK, EE, ES, FI, FR PL, PT, RO, SE, SI GW, ML, MR, NE, SN SL, SZ, TZ, UG, ZM	, BY, BZ, CA, CH, , ES, FI, GB, GD, , KG, KM, KN, KP, , MD, MG, MK, MN, , PT, RO, RS, RU, , TT, TZ, UA, UG, , GB, GR, HU, IE, , SK, TR, BF, BJ, , TD, TG, BW, GH,
AU 20062619 CA 2613015 EP 1893612 R: AT, IS, PRAI US 2005-692 US 2005-731 WO 2006-US2 CLASS	BE, BG, IT, LI, 960P 528P 4524	A1 A1 CH, CY, LT, LU, P P	20070104 20070104 20080305 CZ, DE, LV, MC, 20050622 20051028 20060621	AU 2006-261993 CA 2006-2613015 EP 2006-773861 DK, EE, ES, FI, FR NL, PL, PT, RO, SE	20060621 20060621 , GB, GR, HU, IE,
WO 2007002433				; C07D0471-00 [I,C	
AU 2006261993	IPCR ECLA IPCI	[I,A]; (A61P003SC07D047; [I,C]; A61P003SC07C037; C07C047; C07C047; A61P003SC1,A] C07D047; A61P003SC1,A] C07D047;	C07C0049- 5-00 [I,A 1-00 [I,C A61K0031- 5-00 [I,A /62; C07C /67C+47/5 /575; C073 1-00 [I,C A61K0031- 5-00 [I,A	517 [I,A]; C07C0049 ] ]; C07D0471-04 [I,A 435 [I,A]; A61P0035 ]; C07C0049-00 [I,C 039/27; C07C045/00+ 75; C07C045/71+47/5 D209/08; C07D471/04 ]; C07D0471-04 [I,A 435 [I,A]; A61P0035 ]; C07C0049-00 [I,C	-00 [I,C*];  ]; A61K0031-435 -00 [I,C]; ]; C07C0049-517  47/565; 75; C07C047/565; +221B+209B; M07D .]; A61K0031-435 -00 [I,C]; ]; C07C0049-517  .]; A61K0031-435
CA 2613015	ECLA	A61P003! [I,A] C07C037, C07C045, C07C047, A61K003! [I,A];	5-00 [I,A /62; C07C /67C+47/5 /575; C07: 1-435 [I,:	435 [I,A]; A61P0035 ]; C07C0049-00 [I,C 039/27; C07C045/00+ 75; C07C045/71+47/5 D209/08; C07D471/04 A]; A61P0035-00 [I, 00 [I,C*]; C07D0471	]; C07C0049-517 47/565; 75; C07C047/565; +221B+209B; M07D A]; C07C0049-517

TPCR C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 EP 1893612 IPCI C07D0471-04 [I,A]; C07D0471-00 [I,C\*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C\*]; A61P0035-00 [I,A] **IPCR** C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]ECLA C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D MARPAT 146:121941 OS

GΙ

AΒ Compds. of formula I which are active on protein kinases are described, as well as methods of using such compds. to treat diseases and conditions associated with aberrant activity of protein kinases. Compds. of formula I wherein Q is (un) substituted aryl, (un) substituted indole, (un) substituted heteroaryl, etc.; A is O, S, (un) substituted methylene, NH and derivs., CO, CS, SO and SO2; R4 - R6 is H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted alkynyl, (un) substituted (hetero) cycloalkyl, and (un) substituted (hetero) aryl; and their pharmaceutically acceptable salts, prodrugs, tautomers, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino) benzoate, which underwent hydrogenation to give the corresponding benzoic acid, which underwent chlorination, to give the corresponding acid chloride, which underwent reaction with 5-bromo-7-azaindole to give compound II. All the invention compds. were evaluated for their protein kinase inhibitory activity. Several of the tested compds. exhibited good protein kinase inhibitory activity against several kinases.

ST pyrrolopyridine prepn protein kinase inhibitory activity

ΙT Diabetes mellitus

> (-associated renal complication, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

ΙT Diabetes mellitus

> (-associated renal hypertrophy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

ΤТ Inflammation

(CNS, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Disease, animal (Costello, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Inflammatory bowel disease ΙT (Crohn's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Bone, disease ΙT Teratogenesis (Crouzon craniofacial dysostosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT EphA receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphA1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT EphA receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphA2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT EphB receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphB2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) EphB receptors TΤ RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphB4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Intestine, disease (Hirschsprung's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Nervous system, disease ΙT (Huntington's chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (Jackson-Weiss, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (MEN2, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Gene, animal RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (MEN2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (Noonan syndrome, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TΤ Disease, animal (Pfeiffer's, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Granulomatous disease (Wegener's granulomatosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

Antibodies and Immunoglobulins ТТ RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (X-linked infantile hypogammaglobulinemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (acrocephalosyndactylia type I, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Pain ΤТ Respiratory distress syndrome (acute, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Retinal disease (age-related macular degeneration, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TΤ Allergy Inflammation Nose, disease (allergic rhinitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Antiarteriosclerotics (antiatherosclerotics; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Neuroglia, neoplasm (astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Dermatitis (atopic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TТ Autoimmune disease Inflammation Thyroid gland, disease (autoimmune thyroiditis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Infection (bacterial, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Prostate gland, disease (benign hyperplasia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Hyperplasia (benign prostatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Bronchi, disease Inflammation (bronchitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TΤ Lung, neoplasm Mammary gland, neoplasm Pancreas, neoplasm (carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Disease, animal (cardio-faciocutaneous, treatment of; preparation of

pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia

(cerebrovascular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hypoxia

(chemotherapy-induced, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease

(chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease

(chronic obstructive pulmonary disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain

(chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, neoplasm

(colon, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

Intestine, neoplasm

(colon, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neoplasm

(complications, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders

(dementia, multi-infarct, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders

(dementia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Skin, disease

(dermal scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease

(diabetic retinopathy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, disease

(endometriosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, neoplasm

(endometrium, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(faciocutaneoskeletal, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease

(failure, chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of

diseases)

IT Reproductive system

(female, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease

(fibrosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease

(fracture, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene ALK5; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(genetic, developmental, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm

(glioblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(glomerulonephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant and Transplantation

(graft-vs.-host reaction, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury

(head and neck, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia

(hepatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(hepatocellular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, neoplasm

(hepatoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lymphoma

(histiocytic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sexual disorders

(impotence, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(in situ, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Helicobacter pylori pylori

Influenza virus

(infection, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain

(inflammatory pain, treatment of; preparation of pyrrolopyridine

derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Head and Neck, disease

Reperfusion

Spinal cord, disease

(injury, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease

(insulin-dependent diabetes mellitus, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus

(insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(interstitial nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, disease

(ischemia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Myoma

Sarcoma

(leiomyosarcoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(leopard, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(lupus nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Edema

(lympho-, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(mammary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Metabolic disorders

(metabolic syndrome X, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, neoplasm

(metastasis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Blood vessel, disease

(microangiopathy, thrombotic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Headache

(migraine, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone formation

(mineralization, diseases, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Oviduct

(neoplasm, adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Astrocyte

(neoplasm, astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Schwann cell

(neoplasm, schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease

(nephrosclerosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(neural crest, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nerve, neoplasm

(neuroblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain

(neuropathic pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus

(non-insulin-dependent, treatment of; preparation of
pyrrolopyridine derivs. as protein kinase inhibitors useful in
treatment of diseases)

IT Lung, neoplasm

(non-small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sarcoma

(of neuro-ectodermal origin, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant rejection

(organ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(oviduct adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(pancreatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Pancreas, disease

(pancreatitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease

(polycystic, treatment of; preparation of pyrrolopyridine derivs.

```
as protein kinase inhibitors useful in treatment of diseases)
ΤТ
    Allergy inhibitors
    Analgesics
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-infective agents
     Anti-inflammatory agents
    Anti-ischemic agents
     Antiarthritics
     Antiasthmatics
     Antibacterial agents
     Antidiabetic agents
     Antifibrotic agents
     Antimigraine agents
    Antiobesity agents
     Antiosteoporotic agents
     Antiparkinsonian agents
     Antipyretics
     Antirheumatic agents
     Antitumor agents
     Antiviral agents
     Canidae
     Cardiovascular agents
     Combination chemotherapy
     Human
     Immunostimulants
     Immunosuppressants
     Lipolysis
     Nervous system agents
     Pharmaceutical carriers
     Prodrugs
     Respiratory system agents
     Thrombolytics
     Transplant and Transplantation
        (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful
        in treatment of diseases)
ΤТ
     c-Kit (protein)
     neu (receptor)
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful
        in treatment of diseases)
ΤТ
    Carcinoma
        (pulmonary non-small-cell, treatment of; preparation of
        pyrrolopyridine derivs. as protein kinase inhibitors useful in
        treatment of diseases)
ΤТ
    Carcinoma
        (pulmonary small-cell, treatment of; preparation of
        pyrrolopyridine derivs. as protein kinase inhibitors useful in
        treatment of diseases)
ΙΤ
    Carcinoma
     Fibrosis
        (pulmonary, treatment of; preparation of pyrrolopyridine derivs.
        as protein kinase inhibitors useful in treatment of diseases)
     Kidney, neoplasm
ΤТ
        (renal cell carcinoma, treatment of; preparation of
        pyrrolopyridine derivs. as protein kinase inhibitors useful in
        treatment of diseases)
ΙT
     Carcinoma
        (renal cell, treatment of; preparation of pyrrolopyridine derivs.
        as protein kinase inhibitors useful in treatment of diseases)
ΤТ
     Injury
```

(reperfusion, treatment of; preparation of pyrrolopyridine derivs.
as protein kinase inhibitors useful in treatment of diseases)
Nervous system, neoplasm
 (schwannoma, treatment of; preparation of pyrrolopyridine derivs.
 as protein kinase inhibitors useful in treatment of diseases)

IT Immunodeficiency

(severe combined, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, neoplasm

(small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury

ΤТ

(spinal cord, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(squamous cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Digestive tract, neoplasm

(stroma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lupus erythematosus

(systemic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(tissue scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Acute lymphocytic leukemia Acute myeloid leukemia Aging, animal

Allergy

Alopecia

Alzheimer's disease

Amyotrophic lateral sclerosis

Asthma

Atherosclerosis

Bladder, neoplasm

Bone, disease

Bone, neoplasm

Brain, neoplasm

Cardiac hypertrophy

Cardiovascular system, disease

Central nervous system, neoplasm

Chronic lymphocytic leukemia

Chronic myeloid leukemia

Diabetic nephropathy

Digestive tract, neoplasm

Emphysema

Endocrine system, disease

Eosinophilia

Fever and Hyperthermia

Fibrosis

Graves' disease

Hair, disease

Heart failure

Hepatic steatosis Hepatitis Hyperglycemia Immunodeficiency Infection Inflammation Inflammatory bowel disease Intestine, disease Ischemia Kidney, disease Leukemia Liver, neoplasm Lung, disease Lung, neoplasm Lymphoma Mammary gland, neoplasm Mastocytoma Mastocytosis Melanoma Multiple myeloma Multiple sclerosis Mutation Myasthenia gravis Myelodysplastic syndromes Neoplasm Neurofibromatosis 1 Neuroglia, neoplasm Non-Hodgkin lymphoma Obesity Osteoarthritis Osteoporosis Ovary, neoplasm Pancreas, neoplasm Parkinson's disease Prostate gland, disease Prostate gland, neoplasm Psoriasis Rheumatoid arthritis Sarcoma Scleroderma Sepsis Sjogren syndrome Skeleton, disease Skin, disease Skin, neoplasm Stroke Systemic mastocytosis Testis, neoplasm Thrombosis Thyroid gland, neoplasm Tuberous sclerosis Vascular restenosis

(treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Necrosis

(tubular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Angiogenesis

(tumor, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Fibroblast growth factor receptors

```
(type 1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
     Fibroblast growth factor receptors
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΙT
     Fibroblast growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 3; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΤТ
     Fibroblast growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΤТ
     Inflammatory bowel disease
        (ulcerative colitis, treatment of; preparation of pyrrolopyridine
        derivs. as protein kinase inhibitors useful in treatment of
        diseases)
ΤT
     Colitis
        (ulcerative, treatment of; preparation of pyrrolopyridine derivs.
        as protein kinase inhibitors useful in treatment of diseases)
ΙT
     Infection
        (viral, treatment of; preparation of pyrrolopyridine derivs. as
        protein kinase inhibitors useful in treatment of diseases)
     Platelet-derived growth factor receptors
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha; preparation of pyrrolopyridine derivs. as protein kinase
        inhibitors useful in treatment of diseases)
     Platelet-derived growth factor receptors
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\beta; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
TΤ
     142805-58-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΙT
     50-99-7, D-Glucose, biological studies
     RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
     unclassified); BIOL (Biological study)
        (blood; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΙT
     858118-20-4P
                   918504-27-5P
                                  918506-28-2P
                                                  918506-62-4P
                                                                 918507-15-0P
     918507-82-1P
                   918507-83-2P
                                  918507-84-3P
                                                  918507-86-5P
                                                                 918507-89-8P
     918508-05-1P
                   918508-18-6P
                                 918508-21-1P
                                                  918508-33-5P
                                                                 918509-12-3P
     918509-57-6P
                                  918509-59-8P 918510-12-0P
                   918509-58-7P
                                                                 918510-89-1P
     918510-93-7P
                  918510-98-2P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate and intermediate; preparation of pyrrolopyridine derivs. as
        protein kinase inhibitors useful in treatment of diseases)
ΙΤ
     4649-09-6P
                 55052-24-9P 55052-28-3P
                                             74420-15-8P
                                                            183208-35-7P
     611204-98-9P
                   611205-38-0P
                                   757978-25-9P
                                                  849067-96-5P
                                                                 849068-05-9P
     858116-85-5P
                   858118-15-7P
                                   866319-00-8P
                                                  866546-07-8P
                                                                 918504-28-6P
                                   918504-32-2P
                                                  918504-33-3P
     918504-29-7P
                   918504-31-1P
                                                                 918504-36-6P
     918504-37-7P
                   918504-38-8P
                                  918504-39-9P
                                                  918505-66-5P
                                                                 918505-72-3P
     918506-47-5P
                  918506-48-6P
                                  918506-97-5P
                                                 918507-50-3P
                                                                 918507-53-6P
     918507-54-7P 918507-55-8P 918507-56-9P 918507-67-2P
                                                                 918510-14-2P
     918510-28-8P 918510-95-9P 918511-92-9P 918512-43-3P
                                                                918514-97-3P
     918516-12-8P 918516-27-5P 918517-04-1P 918519-14-9P 918519-37-6P
```

RL: BSU (Biological study, unclassified); BIOL (Biological study)

918519-69-4P 918520-82-8P 918521-31-0P 918522-25-5P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT 23612-48-8P 23616-63-9P 27663-72-5P 27663-73-6P 65623-46-3P 74420-00-1P, 1H-Pyrrolo[2,3-b]pyridin-4-amine 116168-44-6P 122379-64-0P 145934-58-3P 151098-60-1P 161225-76-9P 183208-54-0P 226085-70-7P 344327-11-3P, 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile 344454-28-0P 348640-06-2P 348640-54-0P 351438-96-5P 351439-00-4P 351439-01-5P 394223-03-1P 460053-58-1P 479552-75-5P 611204-94-5P 611205-04-0P 611205-10-8P 611205-12-0P 611205-16-4P 611205-18-6P 611205-34-6P 633303-87-4P 633303-90-9P 675840-52-5P 754214-42-1P 850014-39-0P 850014-40-3P 858116-61-7P 858116-65-1P 858116-60-6P 858116-73-1P 858116-74-2P 858116-68-4P 858116-69-5P 858116-70-8P 858116-76-4P 858116-75-3P 858116-77-5P 858116-78-6P 858116-82-2P 858116-87-7P 858116-90-2P 858116-91-3P 858116-89-9P 858116-93-5P 858116-97-9P 858116-98-0P 858117-01-8P 858117-07-4P 858116-99-1P 858117-12-1P 858117-13-2P 858117-14-3P 858117-15-4P 858117-16-5P 858117-19-8P 858117-20-1P 858117-21-2P 858117-22-3P 858117-23-4P 858117-24-5P 858117-25-6P 858117-26-7P 858117-27-8P 858117-28-9P 858117-29-0P 858117-30-3P 858117-33-6P 858117-34-7P 858117-35-8P 858117-36-9P 858117-37-0P 858117-38-1P 858117-39-2P 858117-40-5P 858117-41-6P 858117-42-7P 858117-43-8P 858117-44-9P 858117-45-0P 858117-47-2P 858117-48-3P 858117-46-1P 858117-49-4P 858117-50-7P 858117-52-9P 858117-51-8P 858117-53-0P 858117-54-1P 858117-55-2P 858117-56-3P 858117-57-4P 858117-58-5P 858117-59-6P 858117-60-9P 858117-61-0P 858117-63-2P 858117-62-1P 858117-64-3P 858117-65-4P 858117-66-5P 858117-67-6P 858117-68-7P 858117-69-8P 858117-70-1P 858117-71-2P 858117-72-3P 858117-73-4P 858117-74-5P 858117-76-7P 858117-77-8P 858117-78-9P 858117-79-0P 858117-80-3P 858117-81-4P 858117-82-5P 858117-83-6P 858117-84-7P 858117-85-8P 858117-86-9P 858117-87-0P 858117-88-1P 858117-89-2P 858117-90-5P 858117-91-6P 858117-93-8P 858117-95-0P 858117-92-7P 858117-94-9P 858117-96-1P 858117-97-2P 858117-98-3P 858117-99-4P 858118-00-0P 858118-01-1P 858118-02-2P 858118-03-3P 858118-04-4P 858118-05-5P 858118-06-6P 858118-07-7P 858118-08-8P 858118-09-9P 858118-10-2P 858118-11-3P 858118-12-4P 858118-13-5P 858118-14-6P 858118-17-9P 858118-18-0P 858118-19-1P 858118-21-5P 858118-23-7P 858118-22-6P 858118-24-8P 858118-25-9P 858118-26-0P 858118-27-1P 858118-28-2P 858118-29-3P 858118-30-6P 858118-31-7P 858118-32-8P 858118-33-9P 858118-34-0P 858118-35-1P 858118-36-2P 858118-37-3P 858118-38-4P 858118-39-5P 858118-40-8P 858118-41-9P 858118-42-0P 858118-43-1P 858118-44-2P 858118-45-3P 858118-46-4P 858118-47-5P 858118-48-6P 858118-49-7P 858118-50-0P 858118-54-4P 858118-51-1P 858118-52-2P 858118-53-3P 858118-55-5P 858118-56-6P 858118-57-7P 858118-59-9P 858118-58-8P 858118-61-3P 858118-63-5P 858118-60-2P 858118-62-4P 858118-64-6P 858118-65-7P 858118-66-8P 858118-67-9P 858118-68-0P 858118-69-1P 858118-70-4P 858118-71-5P 858118-72-6P 858118-73-7P 858118-74-8P 858118-75-9P 858118-76-0P 858118-77-1P 858118-78-2P 858118-79-3P 858118-80-6P 858118-81-7P 858118-82-8P 858118-83-9P 858118-84-0P 858118-85-1P 858118-86-2P 858118-87-3P 858118-88-4P 858118-89-5P 858118-90-8P 858118-91-9P 858118-92-0P 858118-93-1P 858118-94-2P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) 858118-98-6P ΙT 858118-95-3P 858118-96-4P 858118-97-5P 858118-99-7P

858119-02-5P

858119-03-6P

858119-04-7P

858119-00-3P

858119-01-4P

```
858119-05-8P
               858119-06-9P
                               858119-07-0P
                                              858119-08-1P
                                                              858119-09-2P
858119-10-5P
               858119-11-6P
                               858119-12-7P
                                              858119-13-8P
                                                              858119-14-9P
858119-15-0P
               858119-16-1P
                               858119-17-2P
                                              858119-18-3P
                                                              858119-19-4P
858119-20-7P
               858119-21-8P
                               858119-22-9P
                                              858119-23-0P
                                                              858119-24-1P
                               858119-27-4P
                                                              858119-29-6P
858119-25-2P
               858119-26-3P
                                              858119-28-5P
858119-30-9P
               858119-31-0P
                               858119-32-1P
                                              858119-33-2P
                                                              858119-34-3P
858119-35-4P
               858119-36-5P
                               858119-37-6P
                                              858119-38-7P
                                                              858119-39-8P
866545-86-0P
               866545-87-1P
                               873786-06-2P
                                              873786-08-4P
                                                              873786-10-8P
873786-11-9P
               873786-12-0P
                               873786-16-4P
                                              873786-17-5P
                                                              873786-19-7P
880770-36-5P
               880770-84-3P
                               880770-85-4P
                                              880770-86-5P
                                                              880771-30-2P
               880771-32-4P
                               880771-34-6P
                                              880771-35-7P
                                                              916172-49-1P
880771-31-3P
916173-07-4P
               916173-12-1P
                               916173-13-2P
                                              916173-16-5P
                                                              916173-34-7P
916174-24-8P
               916174-48-6P
                               916174-49-7P
                                              918504-30-0P
                                                              918504-34-4P
918504-35-5P
               918504-40-2P
                               918504-41-3P
                                              918504-42-4P
                                                              918504-43-5P
918504-44-6P
               918504-45-7P
                               918504-46-8P
                                              918504-47-9P
                                                              918504-48-0P
               918504-50-4P
                                              918504-52-6P
                                                              918504-53-7P
918504-49-1P
                               918504-51-5P
918504-54-8P
                                              918504-57-1P
                                                              918504-58-2P
               918504-55-9P
                               918504-56-0P
918504-59-3P
                               918504-61-7P
                                              918504-62-8P
                                                              918504-63-9P
               918504-60-6P
               918504-65-1P
                                              918504-67-3P
918504-64-0P
                               918504-66-2P
                                                              918504-68-4P
               918504-70-8P
                               918504-71-9P
                                              918504-72-0P
                                                              918504-73-1P
918504-69-5P
918504-74-2P
               918504-75-3P
                               918504-76-4P
                                              918504-77-5P
                                                              918504-78-6P
918504-79-7P
               918504-80-0P
                               918504-81-1P
                                              918504-82-2P
                                                              918504-83-3P
918504-84-4P
               918504-85-5P
                               918504-86-6P
                                              918504-87-7P
                                                              918504-88-8P
918504-89-9P
               918504-90-2P
                               918504-91-3P
                                              918504-92-4P
                                                              918504-93-5P
918504-94-6P
               918504-95-7P
                               918504-96-8P
                                              918504-97-9P
                                                              918504-98-0P
                                              918505-02-9P
918504-99-1P
               918505-00-7P
                               918505-01-8P
                                                              918505-03-0P
                               918505-07-4P
918505-04-1P
               918505-05-2P
                                              918505-08-5P
                                                              918505-09-6P
918505-10-9P
               918505-11-0P
                               918505-12-1P
                                              918505-13-2P
                                                              918505-14-3P
918505-15-4P
               918505-16-5P
                               918505-17-6P
                                              918505-18-7P
                                                              918505-19-8P
                               918505-22-3P
                                                              918505-24-5P
918505-20-1P
               918505-21-2P
                                              918505-23-4P
918505-25-6P
                               918505-27-8P
                                                              918505-29-0P
               918505-26-7P
                                              918505-28-9P
918505-30-3P
               918505-31-4P
                               918505-32-5P
                                              918505-33-6P
                                                              918505-34-7P
918505-35-8P
               918505-36-9P
                               918505-37-0P
                                              918505-38-1P
                                                              918505-39-2P
918505-40-5P
               918505-41-6P
                               918505-42-7P
                                              918505-43-8P
                                                              918505-44-9P
918505-45-0P
               918505-46-1P
                               918505-47-2P
                                              918505-48-3P
                                                              918505-49-4P
918505-50-7P
               918505-51-8P
                               918505-52-9P
                                              918505-53-0P
                                                              918505-54-1P
918505-55-2P
               918505-56-3P
                               918505-57-4P
                                              918505-58-5P
                                                              918505-59-6P
918505-60-9P
               918505-61-0P
                               918505-62-1P
                                              918505-63-2P
                                                              918505-64-3P
918505-65-4P
               918505-67-6P
                               918505-68-7P
                                              918505-69-8P
                                                              918505-70-1P
918505-71-2P
               918505-73-4P
                               918505-74-5P
                                              918505-75-6P
                                                              918505-76-7P
               918505-78-9P
                               918505-79-0P
918505-77-8P
                                              918505-80-3P
                                                              918505-81-4P
918505-82-5P
               918505-83-6P
                               918505-84-7P
                                              918505-85-8P
                                                              918505-86-9P
918505-87-0P
               918505-88-1P
                               918505-89-2P
                                              918505-90-5P
                                                              918505-91-6P
918505-92-7P
               918505-93-8P
                               918505-94-9P
                                              918505-95-0P
                                                              918505-96-1P
                               918505-99-4P
                                              918506-00-0P
918505-97-2P
               918505-98-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
```

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

```
ΙT
     918506-01-1P
                    918506-02-2P
                                    918506-03-3P
                                                    918506-04-4P
                                                                   918506-05-5P
     918506-06-6P
                    918506-07-7P
                                    918506-08-8P
                                                    918506-09-9P
                                                                   918506-10-2P
     918506-11-3P
                    918506-12-4P
                                    918506-13-5P
                                                    918506-14-6P
                                                                   918506-15-7P
     918506-16-8P
                    918506-17-9P
                                    918506-18-0P
                                                    918506-19-1P
                                                                   918506-20-4P
                                    918506-23-7P
     918506-21-5P
                    918506-22-6P
                                                    918506-24-8P
                                                                   918506-25-9P
     918506-26-0P
                    918506-27-1P
                                    918506-29-3P
                                                    918506-30-6P
                                                                   918506-31-7P
     918506-32-8P
                    918506-33-9P
                                    918506-34-0P
                                                    918506-35-1P
                                                                   918506-36-2P
     918506-37-3P
                    918506-38-4P
                                    918506-39-5P
                                                    918506-40-8P
                                                                   918506-41-9P
     918506-42-0P
                    918506-43-1P
                                    918506-44-2P
                                                    918506-45-3P
                                                                   918506-46-4P
     918506-49-7P
                    918506-50-0P
                                    918506-51-1P
                                                    918506-52-2P
                                                                   918506-53-3P
     918506-54-4P
                    918506-55-5P
                                    918506-56-6P
                                                    918506-57-7P
                                                                   918506-58-8P
```

(Uses)

```
918506-65-7P
               918506-66-8P
                              918506-67-9P
                                             918506-68-0P
                                                             918506-69-1P
918506-70-4P
               918506-71-5P
                              918506-72-6P
                                             918506-73-7P
                                                            918506-74-8P
918506-75-9P
               918506-76-0P
                              918506-77-1P
                                             918506-78-2P
                                                            918506-79-3P
               918506-81-7P
                                             918506-83-9P
                                                            918506-84-0P
918506-80-6P
                              918506-82-8P
918506-85-1P
               918506-86-2P
                              918506-87-3P
                                             918506-88-4P
                                                            918506-89-5P
918506-90-8P
               918506-91-9P
                              918506-92-0P
                                             918506-93-1P
                                                            918506-94-2P
918506-95-3P
               918506-96-4P
                              918506-98-6P
                                             918506-99-7P
                                                            918507-00-3P
918507-01-4P
               918507-02-5P
                              918507-03-6P
                                             918507-04-7P
                                                            918507-05-8P
918507-06-9P
               918507-07-0P
                              918507-08-1P
                                             918507-09-2P
                                                            918507-10-5P
918507-11-6P
               918507-12-7P
                              918507-13-8P
                                             918507-14-9P
                                                            918507-16-1P
               918507-18-3P
                              918507-19-4P
                                             918507-20-7P
918507-17-2P
                                                            918507-21-8P
918507-22-9P
               918507-23-0P
                              918507-24-1P
                                             918507-25-2P
                                                            918507-26-3P
918507-27-4P
               918507-28-5P
                              918507-29-6P
                                             918507-30-9P
                                                            918507-31-0P
918507-32-1P
               918507-33-2P
                              918507-34-3P
                                             918507-35-4P
                                                            918507-36-5P
               918507-38-7P
                              918507-40-1P
918507-37-6P
                                             918507-47-8P
                                                            918507-49-0P
               918507-52-5P
                              918507-57-0P
                                             918507-58-1P
                                                            918507-59-2P
918507-51-4P
918507-60-5P
               918507-61-6P
                              918507-62-7P
                                             918507-63-8P
                                                            918507-64-9P
               918507-66-1P
                                             918507-70-7P
                                                            918507-71-8P
918507-65-0P
                              918507-68-3P
918507-72-9P
               918507-73-0P
                              918507-74-1P
                                             918507-75-2P
                                                            918507-76-3P
918507-77-4P
               918507-78-5P
                              918507-79-6P
                                             918507-80-9P
                                                            918507-81-0P
918507-85-4P
               918507-87-6P
                              918507-88-7P
                                             918507-90-1P
                                                             918507-91-2P
918507-92-3P
               918507-93-4P
                              918507-94-5P
                                             918507-95-6P
                                                             918507-96-7P
918507-97-8P
               918507-98-9P
                              918507-99-0P
                                             918508-00-6P
                                                             918508-01-7P
                                                             918508-07-3P
918508-02-8P
               918508-03-9P
                              918508-04-0P
                                             918508-06-2P
918508-08-4P
               918508-09-5P
                              918508-10-8P
                                             918508-11-9P
                                                             918508-12-0P
918508-13-1P
               918508-14-2P
                              918508-15-3P
                                             918508-16-4P
                                                            918508-17-5P
918508-19-7P
               918508-20-0P
                              918508-22-2P
                                             918508-23-3P
                                                            918508-24-4P
918508-25-5P
               918508-26-6P
                              918508-27-7P
                                             918508-28-8P
                                                            918508-29-9P
                              918508-32-4P
                                             918508-34-6P
                                                            918508-35-7P
918508-30-2P
               918508-31-3P
918508-36-8P
               918508-37-9P
                              918508-38-0P
                                             918508-39-1P
                                                            918508-40-4P
918508-41-5P
               918508-42-6P
                              918508-43-7P
                                             918508-44-8P
                                                            918508-45-9P
918508-46-0P
               918508-47-1P
                            918508-48-2P
                                             918508-49-3P
                                                            918508-50-6P
918508-51-7P
               918508-52-8P
                            918508-53-9P
                                             918508-54-0P
                                                            918508-55-1P
918508-56-2P
               918508-57-3P
                              918508-58-4P
                                             918508-59-5P
                                                            918508-60-8P
918508-61-9P
               918508-62-0P
                              918508-63-1P
                                             918508-64-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
   (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
   inhibitors useful in treatment of diseases)
918508-65-3P
               918508-66-4P
                              918508-67-5P
                                             918508-68-6P
                                                            918508-69-7P
918508-70-0P
               918508-71-1P
                              918508-72-2P
                                             918508-73-3P
                                                            918508-74-4P
918508-75-5P
               918508-76-6P
                              918508-77-7P
                                             918508-78-8P
                                                            918508-79-9P
918508-80-2P
               918508-81-3P
                              918508-82-4P
                                             918508-83-5P
                                                            918508-84-6P
918508-85-7P
               918508-86-8P
                              918508-87-9P
                                                            918508-89-1P
                                             918508-88-0P
                              918508-92-6P
                                             918508-93-7P
               918508-91-5P
                                                            918508-94-8P
918508-90-4P
918508-95-9P
               918508-96-0P
                              918508-97-1P
                                             918508-98-2P
                                                            918508-99-3P
918509-00-9P
               918509-01-0P
                              918509-02-1P
                                             918509-03-2P
                                                            918509-04-3P
918509-05-4P
               918509-06-5P
                              918509-07-6P
                                             918509-08-7P
                                                             918509-09-8P
918509-10-1P
               918509-11-2P
                              918509-13-4P
                                             918509-14-5P
                                                             918509-15-6P
918509-16-7P
               918509-17-8P
                              918509-18-9P
                                             918509-19-0P
                                                             918509-20-3P
918509-21-4P
               918509-22-5P
                              918509-23-6P
                                             918509-24-7P
                                                             918509-25-8P
918509-26-9P
               918509-27-0P
                              918509-28-1P
                                             918509-29-2P
                                                             918509-30-5P
918509-31-6P
               918509-32-7P
                              918509-33-8P
                                             918509-34-9P
                                                             918509-35-0P
```

918509-38-3P

918509-43-0P

918509-48-5P

918509-53-2P

918509-61-2P

918509-66-7P 918509-67-8P

918509-39-4P

918509-44-1P

918509-49-6P

918509-54-3P

918509-62-3P

918509-40-7P

918509-45-2P

918509-50-9P

918509-55-4P

918509-63-4P

918509-68-9P

918506-61-3P

918506-63-5P

918506-64-6P

918506-59-9P

ΙT

918509-36-1P

918509-41-8P

918509-46-3P

918509-51-0P

918509-56-5P

918509-64-5P 918509-65-6P

918509-37-2P

918509-42-9P

918509-47-4P

918509-52-1P

918509-60-1P

918506-60-2P

```
918509-69-0P
              918509-70-3P
                             918509-71-4P
                                            918509-72-5P
                                                           918509-73-6P
918509-74-7P
              918509-75-8P
                             918509-76-9P
                                            918509-77-0P
                                                           918509-78-1P
918509-79-2P
             918509-80-5P
                             918509-81-6P
                                            918509-82-7P
                                                           918509-83-8P
918509-84-9P
              918509-85-0P
                             918509-86-1P
                                            918509-87-2P
                                                           918509-88-3P
918509-89-4P
              918509-90-7P
                             918509-91-8P
                                            918509-92-9P
                                                           918509-93-0P
918509-94-1P
              918509-95-2P
                             918509-96-3P
                                            918509-97-4P
                                                           918509-98-5P
918509-99-6P
              918510-00-6P
                             918510-01-7P
                                            918510-02-8P
                                                           918510-03-9P
918510-04-0P
              918510-05-1P
                             918510-06-2P
                                            918510-07-3P
                                                           918510-08-4P
918510-09-5P
              918510-10-8P
                             918510-11-9P
                                            918510-13-1P
                                                           918510-15-3P
918510-16-4P
              918510-17-5P
                             918510-18-6P
                                            918510-19-7P
                                                           918510-20-0P
918510-21-1P
              918510-22-2P
                             918510-23-3P
                                            918510-24-4P
                                                           918510-25-5P
              918510-27-7P
                                            918510-30-2P
918510-26-6P
                             918510-29-9P
                                                           918510-31-3P
918510-32-4P
              918510-33-5P
                             918510-34-6P
                                            918510-36-8P
                                                           918510-38-0P
918510-40-4P
              918510-41-5P
                             918510-42-6P
                                            918510-44-8P
                                                           918510-46-0P
              918510-50-6P
918510-48-2P
                             918510-52-8P
                                            918510-53-9P
                                                           918510-54-0P
              918510-56-2P
                             918510-57-3P
                                            918510-58-4P
918510-55-1P
                                                           918510-59-5P
918510-60-8P
              918510-61-9P
                             918510-62-0P
                                            918510-63-1P
                                                           918510-64-2P
918510-65-3P
              918510-66-4P
                             918510-67-5P
                                                           918510-69-7P
                                            918510-68-6P
918510-70-0P
              918510-71-1P
                             918510-72-2P
                                            918510-73-3P
                                                           918510-74-4P
918510-75-5P
              918510-76-6P
                             918510-77-7P
                                            918510-78-8P
                                                           918510-79-9P
918510-80-2P
              918510-81-3P
                             918510-82-4P
                                            918510-83-5P
                                                           918510-84-6P
918510-85-7P
              918510-86-8P
                             918510-87-9P
                                            918510-88-0P
                                                           918510-90-4P
918510-91-5P
              918510-92-6P
                             918510-94-8P
                                            918510-96-0P
                                                           918510-97-1P
918510-99-3P
              918511-00-9P
                             918511-01-0P
                                            918511-02-1P
                                                           918511-03-2P
918511-04-3P
              918511-05-4P
                             918511-06-5P
                                            918511-07-6P
                                                           918511-08-7P
918511-09-8P
              918511-10-1P
                             918511-11-2P
                                            918511-12-3P
                                                           918511-13-4P
918511-14-5P
              918511-15-6P
                             918511-16-7P
                                           918511-17-8P
```

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

ΙT

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

```
918511-21-4P
918511-18-9P 918511-19-0P 918511-20-3P
                                                          918511-22-5P
918511-23-6P
            918511-24-7P
                           918511-25-8P
                                           918511-26-9P
                                                          918511-27-0P
918511-28-1P 918511-29-2P 918511-30-5P
                                           918511-31-6P
                                                          918511-32-7P
918511-33-8P 918511-34-9P 918511-35-0P 918511-36-1P
                                                          918511-37-2P
918511-38-3P 918511-39-4P
                             918511-40-7P 918511-41-8P
                                                          918511-42-9P
918511-43-0P
              918511-44-1P
                             918511-45-2P 918511-46-3P
                                                          918511-47-4P
918511-48-5P
              918511-49-6P
                             918511-50-9P 918511-51-0P
                                                          918511-52-1P
918511-53-2P 918511-54-3P
                             918511-55-4P 918511-56-5P
                                                          918511-57-6P
918511-58-7P
              918511-59-8P
                             918511-60-1P 918511-61-2P
                                                          918511-62-3P
918511-63-4P
              918511-64-5P
                             918511-65-6P 918511-66-7P
                                                          918511-67-8P
918511-68-9P
              918511-69-0P
                             918511-70-3P 918511-71-4P
                                                          918511-72-5P
                             918511-75-8P
918511-73-6P
              918511-74-7P
                                           918511-76-9P
                                                          918511-77-0P
918511-78-1P
              918511-79-2P
                             918511-80-5P
                                           918511-81-6P
                                                          918511-82-7P
918511-83-8P
              918511-84-9P
                             918511-85-0P
                                           918511-86-1P
                                                          918511-87-2P
918511-88-3P
                                           918511-91-8P
                             918511-90-7P
                                                          918511-93-0P
              918511-89-4P
918511-94-1P
              918511-95-2P
                             918511-96-3P
                                           918511-97-4P
                                                          918511-98-5P
                                                          918512-04-6P
918511-99-6P
              918512-00-2P
                             918512-01-3P
                                           918512-03-5P
918512-05-7P
              918512-06-8P
                             918512-07-9P
                                           918512-08-0P
                                                          918512-09-1P
918512-10-4P
              918512-11-5P
                             918512-12-6P
                                           918512-13-7P
                                                          918512-14-8P
918512-15-9P
              918512-16-0P
                             918512-17-1P
                                           918512-18-2P
                                                          918512-19-3P
918512-20-6P
              918512-21-7P
                             918512-22-8P
                                           918512-23-9P
                                                          918512-24-0P
918512-25-1P
              918512-26-2P
                             918512-27-3P
                                                          918512-29-5P
                                           918512-28-4P
918512-30-8P
                             918512-32-0P
              918512-31-9P
                                           918512-33-1P
                                                          918512-34-2P
918512-35-3P
              918512-36-4P
                             918512-37-5P
                                           918512-38-6P
                                                          918512-39-7P
918512-40-0P
              918512-41-1P
                             918512-42-2P
                                           918512-44-4P
                                                          918512-45-5P
918512-46-6P
              918512-47-7P
                             918512-48-8P
                                           918512-49-9P
                                                          918512-50-2P
918512-51-3P
              918512-52-4P
                             918512-53-5P
                                           918512-54-6P
                                                          918512-55-7P
              918512-57-9P
918512-56-8P
                             918512-58-0P 918512-59-1P
                                                          918512-60-4P
918512-61-5P 918512-62-6P
                            918512-63-7P 918512-64-8P
                                                         918512-65-9P
```

```
918512-66-0P
               918512-67-1P
                               918512-68-2P
                                              918512-69-3P
                                                              918512-70-6P
918512-71-7P
               918512-72-8P
                               918512-73-9P
                                              918512-74-0P
                                                              918512-75-1P
918512-76-2P
               918512-77-3P
                                              918512-79-5P
                                                              918512-80-8P
                               918512-78-4P
918512-81-9P
               918512-82-0P
                               918512-83-1P
                                              918512-84-2P
                                                              918512-85-3P
               918512-87-5P
                                                              918512-90-0P
918512-86-4P
                               918512-88-6P
                                              918512-89-7P
918512-91-1P
               918512-92-2P
                               918512-93-3P
                                              918512-94-4P
                                                              918512-95-5P
918512-96-6P
               918512-97-7P
                               918512-98-8P
                                              918512-99-9P
                                                              918513-00-5P
918513-01-6P
               918513-02-7P
                               918513-03-8P
                                              918513-04-9P
                                                              918513-05-0P
918513-06-1P
               918513-07-2P
                               918513-08-3P
                                              918513-09-4P
                                                              918513-10-7P
               918513-12-9P
                               918513-13-0P
                                              918513-14-1P
                                                              918513-15-2P
918513-11-8P
                                              918513-19-6P
                                                              918513-20-9P
918513-16-3P
               918513-17-4P
                               918513-18-5P
918513-21-0P
               918513-22-1P
                               918513-23-2P
                                              918513-24-3P
                                                              918513-25-4P
918513-26-5P
               918513-27-6P
                               918513-28-7P
                                              918513-29-8P
                                                              918513-30-1P
918513-31-2P
               918513-32-3P
                               918513-33-4P
                                              918513-34-5P
                                                              918513-35-6P
918513-36-7P
               918513-37-8P
                               918513-38-9P
                                              918513-39-0P
                                                              918513-40-3P
918513-41-4P
               918513-42-5P
                               918513-43-6P
                                              918513-44-7P
                                                              918513-45-8P
918513-46-9P
               918513-47-0P
                               918513-48-1P
                                              918513-49-2P
                                                              918513-50-5P
918513-51-6P
               918513-52-7P
                               918513-53-8P
                                              918513-54-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
```

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

```
inhibitors useful in treatment of diseases)
ΙT
     918513-55-0P
                    918513-56-1P
                                    918513-57-2P
                                                    918513-58-3P
                                                                   918513-59-4P
     918513-60-7P
                                                    918513-63-0P
                                                                   918513-64-1P
                    918513-61-8P
                                    918513-62-9P
     918513-65-2P
                    918513-66-3P
                                    918513-67-4P
                                                    918513-68-5P
                                                                   918513-69-6P
     918513-70-9P
                    918513-71-0P
                                    918513-72-1P
                                                    918513-73-2P
                                                                   918513-74-3P
     918513-75-4P
                    918513-76-5P
                                    918513-77-6P
                                                    918513-78-7P
                                                                   918513-79-8P
     918513-80-1P
                    918513-81-2P
                                    918513-82-3P
                                                    918513-83-4P
                                                                   918513-84-5P
     918513-85-6P
                    918513-86-7P
                                                                   918513-89-0P
                                    918513-87-8P
                                                    918513-88-9P
                                                                   918513-94-7P
     918513-90-3P
                    918513-91-4P
                                    918513-92-5P
                                                    918513-93-6P
     918513-95-8P
                    918513-96-9P
                                    918513-97-0P
                                                    918513-98-1P
                                                                   918513-99-2P
     918514-00-8P
                    918514-01-9P
                                    918514-02-0P
                                                    918514-03-1P
                                                                   918514-04-2P
     918514-05-3P
                    918514-06-4P
                                    918514-07-5P
                                                    918514-08-6P
                                                                   918514-09-7P
     918514-10-0P
                    918514-11-1P
                                    918514-12-2P
                                                    918514-13-3P
                                                                   918514-14-4P
     918514-15-5P
                    918514-16-6P
                                    918514-17-7P
                                                    918514-18-8P
                                                                   918514-19-9P
     918514-20-2P
                    918514-21-3P
                                    918514-22-4P
                                                    918514-23-5P
                                                                   918514-24-6P
     918514-25-7P
                    918514-26-8P
                                    918514-27-9P
                                                    918514-28-0P
                                                                   918514-29-1P
     918514-30-4P
                    918514-31-5P
                                    918514-32-6P
                                                    918514-33-7P
                                                                   918514-34-8P
                    918514-36-0P
                                    918514-37-1P
                                                    918514-38-2P
     918514-35-9P
                                                                   918514-39-3P
     918514-40-6P
                    918514-41-7P
                                    918514-42-8P
                                                    918514-43-9P
                                                                   918514-44-0P
     918514-45-1P
                    918514-46-2P
                                    918514-47-3P
                                                    918514-48-4P
                                                                   918514-49-5P
     918514-50-8P
                    918514-51-9P
                                    918514-52-0P
                                                    918514-53-1P
                                                                   918514-54-2P
                                    918514-57-5P
     918514-55-3P
                    918514-56-4P
                                                    918514-58-6P
                                                                   918514-59-7P
                    918514-61-1P
     918514-60-0P
                                    918514-62-2P
                                                    918514-63-3P
                                                                   918514-64-4P
                    918514-66-6P
                                    918514-67-7P
                                                                   918514-69-9P
     918514-65-5P
                                                    918514-68-8P
     918514-70-2P
                    918514-71-3P
                                    918514-72-4P
                                                    918514-73-5P
                                                                   918514-74-6P
     918514-75-7P
                    918514-76-8P
                                    918514-77-9P
                                                    918514-78-0P
                                                                   918514-79-1P
     918514-80-4P
                    918514-81-5P
                                    918514-82-6P
                                                    918514-83-7P
                                                                   918514-84-8P
     918514-85-9P
                    918514-86-0P
                                    918514-87-1P
                                                    918514-88-2P
                                                                   918514-89-3P
     918514-90-6P
                    918514-91-7P
                                    918514-92-8P
                                                    918514-93-9P
                                                                   918514-94-0P
     918514-95-1P
                    918514-96-2P
                                    918514-98-4P
                                                    918514-99-5P
                                                                    918515-00-1P
     918515-01-2P
                    918515-02-3P
                                    918515-03-4P
                                                    918515-04-5P
                                                                    918515-05-6P
                    918515-07-8P
     918515-06-7P
                                    918515-08-9P
                                                    918515-09-0P
                                                                    918515-10-3P
     918515-11-4P
                    918515-12-5P
                                    918515-13-6P
                                                    918515-14-7P
                                                                    918515-15-8P
     918515-16-9P
                    918515-17-0P
                                    918515-18-1P
                                                    918515-19-2P
                                                                    918515-20-5P
     918515-21-6P
                    918515-22-7P
                                    918515-23-8P
                                                    918515-24-9P
                                                                   918515-25-0P
     918515-26-1P
                                    918515-28-3P
                    918515-27-2P
                                                    918515-29-4P
                                                                   918515-30-7P
     918515-31-8P
                    918515-32-9P
                                    918515-33-0P
                                                                   918515-35-2P
                                                    918515-34-1P
     918515-36-3P
                    918515-37-4P
                                    918515-38-5P
                                                    918515-39-6P
                                                                   918515-40-9P
                    918515-42-1P
                                                    918515-44-3P
     918515-41-0P
                                    918515-43-2P
                                                                   918515-45-4P
```

```
918515-46-5P
               918515-47-6P
                               918515-48-7P
                                              918515-49-8P
                                                              918515-50-1P
918515-51-2P
               918515-52-3P
                               918515-53-4P
                                              918515-54-5P
                                                              918515-55-6P
918515-56-7P
               918515-57-8P
                               918515-58-9P
                                              918515-59-0P
                                                              918515-60-3P
918515-61-4P
               918515-62-5P
                               918515-63-6P
                                              918515-64-7P
                                                              918515-65-8P
               918515-67-0P
                                              918515-69-2P
                                                              918515-70-5P
918515-66-9P
                               918515-68-1P
               918515-72-7P
918515-71-6P
                               918515-73-8P
                                              918515-74-9P
                                                              918515-75-0P
918515-76-1P
               918515-77-2P
                              918515-78-3P
                                              918515-79-4P
                                                              918515-80-7P
918515-81-8P
               918515-82-9P
                               918515-83-0P
                                              918515-84-1P
                                                              918515-85-2P
918515-86-3P
               918515-87-4P
                               918515-88-5P
                                              918515-89-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
   inhibitors useful in treatment of diseases)
918515-90-9P
                              918515-92-1P
                                              918515-93-2P
                                                              918515-94-3P
               918515-91-0P
                                              918515-98-7P
                                                              918515-99-8P
918515-95-4P
               918515-96-5P
                               918515-97-6P
918516-00-4P
               918516-01-5P
                               918516-02-6P
                                              918516-03-7P
                                                              918516-04-8P
918516-05-9P
               918516-06-0P
                               918516-07-1P
                                              918516-08-2P
                                                              918516-09-3P
               918516-11-7P
                                              918516-14-0P
918516-10-6P
                               918516-13-9P
                                                              918516-15-1P
918516-16-2P
               918516-17-3P
                               918516-18-4P
                                              918516-19-5P
                                                              918516-20-8P
918516-21-9P
               918516-22-0P
                               918516-23-1P
                                              918516-24-2P
                                                              918516-25-3P
918516-26-4P
               918516-28-6P
                               918516-29-7P
                                              918516-30-0P
                                                              918516-31-1P
918516-32-2P
               918516-33-3P
                               918516-34-4P
                                              918516-35-5P
                                                              918516-36-6P
918516-37-7P
               918516-38-8P
                               918516-39-9P
                                              918516-40-2P
                                                              918516-41-3P
918516-42-4P
               918516-43-5P
                               918516-44-6P
                                              918516-45-7P
                                                              918516-46-8P
918516-47-9P
               918516-48-0P
                               918516-49-1P
                                              918516-50-4P
                                                              918516-51-5P
918516-52-6P
               918516-53-7P
                               918516-54-8P
                                              918516-55-9P
                                                              918516-56-0P
918516-57-1P
               918516-58-2P
                               918516-59-3P
                                              918516-60-6P
                                                              918516-61-7P
918516-62-8P
               918516-63-9P
                              918516-64-0P
                                              918516-65-1P
                                                              918516-66-2P
918516-67-3P
               918516-68-4P
                              918516-69-5P
                                              918516-70-8P
                                                             918516-71-9P
                                              918516-75-3P
918516-72-0P
               918516-73-1P
                              918516-74-2P
                                                             918516-76-4P
                              918516-79-7P
918516-77-5P
               918516-78-6P
                                              918516-80-0P
                                                             918516-81-1P
918516-82-2P
                              918516-84-4P
               918516-83-3P
                                              918516-85-5P
                                                             918516-86-6P
918516-87-7P
               918516-88-8P
                              918516-89-9P
                                              918516-90-2P
                                                             918516-91-3P
918516-92-4P
                              918516-94-6P
                                              918516-95-7P
                                                             918516-96-8P
               918516-93-5P
918516-97-9P
               918516-98-0P
                              918516-99-1P
                                              918517-00-7P
                                                              918517-01-8P
918517-02-9P
               918517-06-3P
                               918517-08-5P
                                              918517-10-9P
                                                              918517-12-1P
918517-14-3P
               918517-16-5P
                               918517-18-7P
                                              918517-20-1P
                                                              918517-22-3P
918517-24-5P
               918517-26-7P
                               918517-28-9P
                                              918517-29-0P
                                                              918517-31-4P
918517-33-6P
               918517-35-8P
                               918517-37-0P
                                              918517-39-2P
                                                              918517-41-6P
918517-43-8P
               918517-45-0P
                               918517-47-2P
                                              918517-49-4P
                                                              918517-51-8P
918517-53-0P
               918517-55-2P
                               918517-57-4P
                                              918517-59-6P
                                                              918517-61-0P
918517-63-2P
               918517-65-4P
                               918517-67-6P
                                              918517-71-2P
                                                              918517-73-4P
918517-75-6P
               918517-77-8P
                               918517-79-0P
                                              918517-82-5P
                                                              918517-84-7P
918517-86-9P
               918517-88-1P
                               918517-90-5P
                                              918517-92-7P
                                                              918517-94-9P
               918517-98-3P
918517-96-1P
                                              918518-02-2P
                                                              918518-04-4P
                               918518-00-0P
918518-07-7P
                                              918518-16-8P
               918518-09-9P
                                                              918518-19-1P
                               918518-14-6P
918518-21-5P
               918518-23-7P
                               918518-25-9P
                                              918518-27-1P
                                                              918518-30-6P
                                                              918518-45-3P
918518-32-8P
               918518-34-0P
                               918518-39-5P
                                              918518-42-0P
918518-48-6P
               918518-50-0P
                               918518-53-3P
                                              918518-55-5P
                                                              918518-57-7P
918518-59-9P
               918518-61-3P
                               918518-63-5P
                                              918518-65-7P
                                                              918518-67-9P
918518-69-1P
               918518-71-5P
                               918518-73-7P
                                              918518-75-9P
                                                              918518-77-1P
918518-78-2P
               918518-80-6P
                               918518-82-8P
                                              918518-84-0P
                                                              918518-85-1P
918518-86-2P
               918518-87-3P
                               918518-88-4P
                                              918518-90-8P
                                                              918518-92-0P
918518-93-1P
               918518-96-4P
                                              918519-01-4P
                               918518-98-6P
                                                              918519-04-7P
918519-05-8P
               918519-06-9P
                               918519-26-3P
                                              918519-32-1P
                                                              918519-33-2P
918519-35-4P
               918519-40-1P
                               918519-42-3P
                                              918519-44-5P
                                                              918519-46-7P
918519-47-8P
               918519-48-9P
                               918519-50-3P
                                              918519-51-4P
                                                              918519-52-5P
918519-53-6P
               918519-54-7P
                               918519-55-8P
                                              918519-56-9P
                                                              918519-57-0P
918519-58-1P
               918519-59-2P
                               918519-60-5P
                                              918519-61-6P
                                                              918519-62-7P
918519-63-8P
               918519-64-9P
                              918519-65-0P
                                              918519-66-1P
```

ΙT

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

```
918519-71-8P
ΙT
     918519-67-2P
                    918519-68-3P
                                    918519-70-7P
                                                                   918519-72-9P
     918519-73-0P
                    918519-74-1P
                                    918519-75-2P
                                                   918519-76-3P
                                                                   918519-77-4P
     918519-79-6P
                    918519-80-9P
                                    918519-81-0P
                                                   918519-82-1P
                                                                   918519-83-2P
     918519-84-3P
                    918519-85-4P
                                    918519-86-5P
                                                   918519-87-6P
                                                                   918519-88-7P
                    918519-90-1P
                                    918519-91-2P
                                                   918519-92-3P
                                                                   918519-93-4P
     918519-89-8P
                                                   918519-97-8P
     918519-94-5P
                    918519-95-6P
                                    918519-96-7P
                                                                   918519-98-9P
     918519-99-0P
                    918520-00-0P
                                    918520-01-1P
                                                   918520-02-2P
                                                                   918520-03-3P
     918520-04-4P
                    918520-05-5P
                                    918520-06-6P
                                                   918520-07-7P
                                                                   918520-08-8P
     918520-09-9P
                    918520-10-2P
                                    918520-11-3P
                                                   918520-12-4P
                                                                   918520-13-5P
     918520-14-6P
                    918520-15-7P
                                    918520-16-8P
                                                   918520-17-9P
                                                                   918520-18-0P
                                                   918520-22-6P
                                                                   918520-23-7P
     918520-19-1P
                    918520-20-4P
                                    918520-21-5P
                                                   918520-27-1P
     918520-24-8P
                    918520-25-9P
                                    918520-26-0P
                                                                   918520-28-2P
     918520-29-3P
                    918520-30-6P
                                    918520-31-7P
                                                   918520-32-8P
                                                                   918520-33-9P
                                                   918520-37-3P
     918520-34-0P
                    918520-35-1P
                                    918520-36-2P
                                                                   918520-38-4P
                                                   918520-42-0P
     918520-39-5P
                    918520-40-8P
                                    918520-41-9P
                                                                   918520-43-1P
     918520-44-2P
                    918520-45-3P
                                    918520-46-4P
                                                   918520-47-5P
                                                                   918520-48-6P
     918520-49-7P
                    918520-50-0P
                                    918520-51-1P
                                                   918520-52-2P
                                                                   918520-53-3P
     918520-54-4P
                    918520-55-5P
                                    918520-56-6P
                                                   918520-57-7P
                                                                   918520-58-8P
     918520-59-9P
                    918520-60-2P
                                    918520-61-3P
                                                   918520-62-4P
                                                                   918520-63-5P
     918520-64-6P
                    918520-65-7P
                                                   918520-67-9P
                                                                   918520-68-0P
                                    918520-66-8P
     918520-69-1P
                    918520-70-4P
                                    918520-71-5P
                                                   918520-72-6P
                                                                   918520-73-7P
                                                   918520-77-1P
     918520-74-8P
                    918520-75-9P
                                    918520-76-0P
                                                                   918520-78-2P
     918520-79-3P
                    918520-80-6P
                                    918520-81-7P
                                                   918520-83-9P
                                                                   918520-84-0P
     918520-85-1P
                    918520-86-2P
                                    918520-87-3P
                                                   918520-88-4P
                                                                   918520-89-5P
                                                                  918520-94-2P
     918520-90-8P
                    918520-91-9P
                                    918520-92-0P
                                                   918520-93-1P
     918520-95-3P
                    918520-96-4P
                                                                  918520-99-7P
                                    918520-97-5P
                                                   918520-98-6P
     918521-00-3P
                    918521-01-4P
                                    918521-02-5P
                                                   918521-03-6P
                                                                  918521-04-7P
                    918521-06-9P
     918521-05-8P
                                    918521-07-0P
                                                   918521-08-1P
                                                                  918521-09-2P
     918521-10-5P
                    918521-11-6P
                                    918521-12-7P
                                                   918521-13-8P
                                                                  918521-14-9P
                                                                  918521-19-4P
     918521-15-0P
                    918521-16-1P
                                    918521-17-2P
                                                   918521-18-3P
     918521-20-7P
                    918521-21-8P
                                    918521-22-9P
                                                   918521-23-0P
                                                                  918521-24-1P
     918521-25-2P
                    918521-26-3P
                                    918521-27-4P
                                                   918521-28-5P
                                                                  918521-29-6P
     918521-30-9P
                    918521-32-1P
                                    918521-33-2P
                                                   918521-34-3P
                                                                  918521-35-4P
     918521-36-5P
                    918521-37-6P
                                    918521-38-7P
                                                   918521-39-8P
                                                                  918521-40-1P
                    918521-42-3P
                                    918521-43-4P
     918521-41-2P
                                                   918521-44-5P
                                                                  918521-45-6P
     918521-46-7P
                    918521-47-8P
                                    918521-48-9P
                                                   918521-49-0P
                                                                  918521-50-3P
     918521-51-4P
                    918521-52-5P
                                    918521-53-6P
                                                   918521-54-7P
                                                                  918521-55-8P
     918521-56-9P
                    918521-57-0P
                                    918521-58-1P
                                                   918521-59-2P
                                                                  918521-60-5P
     918521-61-6P
                                                   918521-64-9P
                                                                  918521-65-0P
                    918521-62-7P
                                    918521-63-8P
     918521-66-1P
                    918521-67-2P
                                    918521-68-3P
                                                   918521-69-4P
                                                                   918521-70-7P
     918521-71-8P
                    918521-72-9P
                                    918521-73-0P
                                                   918521-74-1P
                                                                   918521-75-2P
     918521-76-3P
                    918521-77-4P
                                    918521-78-5P
                                                   918521-79-6P
                                                                   918521-80-9P
     918521-81-0P
                    918521-82-1P
                                    918521-83-2P
                                                   918521-84-3P
                                                                   918521-85-4P
     918521-86-5P
                                                                   918521-90-1P
                    918521-87-6P
                                    918521-88-7P
                                                   918521-89-8P
     918521-91-2P
                    918521-92-3P
                                    918521-93-4P
                                                   918521-94-5P
                                                                   918521-95-6P
     918521-96-7P
                    918521-97-8P
                                    918521-98-9P
                                                   918521-99-0P
                                                                   918522-00-6P
     918522-01-7P
                    918522-02-8P
                                    918522-03-9P
                                                   918522-04-0P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
```

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

```
ΙT
    918522-05-1P
                    918522-06-2P
                                   918522-07-3P
                                                  918522-08-4P
                                                                  918522-09-5P
                    918522-11-9P
                                   918522-12-0P
                                                  918522-13-1P
                                                                  918522-14-2P
    918522-10-8P
    918522-15-3P
                    918522-16-4P
                                   918522-17-5P
                                                  918522-18-6P
                                                                  918522-19-7P
    918522-20-0P
                    918522-21-1P
                                  918522-22-2P
                                                  918522-23-3P
                                                                  918522-24-4P
```

(Uses)

```
918522-26-6P
            918522-27-7P
                           918522-28-8P
                                         918522-29-9P
                                                       918522-30-2P
918522-31-3P
             918522-32-4P
                           918522-33-5P
                                        918522-34-6P
                                                       918522-35-7P
918522-36-8P 918522-37-9P
                           918522-38-0P 918522-39-1P
                                                       918522-40-4P
918522-41-5P 918522-43-7P
                           918522-45-9P 918522-46-0P
                                                       918522-48-2P
918522-49-3P 918522-51-7P
                           918522-53-9P 918522-55-1P 918522-56-2P
918522-57-3P 918522-59-5P 918522-61-9P 918522-63-1P 918522-65-3P
918522-67-5P 918522-69-7P
                           918522-71-1P 918522-73-3P 918522-75-5P
918522-77-7P 918522-79-9P 918522-81-3P 918522-83-5P 918522-85-7P
918522-87-9P 918522-89-1P 918522-91-5P 918522-93-7P 918522-95-9P
918522-97-1P 918522-99-3P
                           918523-01-0P 918523-02-1P 918523-03-2P
918523-05-4P 918523-06-5P
                           918523-07-6P 918523-08-7P 918523-09-8P
                           918523-12-3P 918523-13-4P 918523-14-5P
918523-10-1P
             918523-11-2P
918523-15-6P
             918523-16-7P
                           918523-17-8P 918523-18-9P 918523-19-0P
918523-20-3P
             918523-21-4P
                           918523-22-5P 918523-23-6P 918523-24-7P
918523-25-8P
             918523-26-9P
                          918523-27-0P 918523-28-1P 918523-29-2P
                           918523-32-7P
                                         918523-33-8P
918523-30-5P
             918523-31-6P
                                                      918523-34-9P
918523-35-0P
             918523-36-1P
                           918523-37-2P
                                         918523-38-3P
                                                      918523-39-4P
918523-40-7P
            918523-41-8P
                           918523-42-9P 918523-43-0P
                                                       918523-50-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
```

(drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

7440-70-2, Calcium, biological studies

ΙT

ΙT

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(hypercalcemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

```
824-52-2P
          5654-92-2P 39255-23-7P 56741-33-4P
                                                70205-04-8P
76588-84-6P
             79418-72-7P
                          79418-77-2P 112434-18-1P 132303-32-3P
143468-13-7P
             152434-86-1P
                           152434-87-2P
                                        152434-88-3P 183208-36-8P
                           443124-79-6P
208986-50-9P
            269072-20-0P
                                          486424-36-6P
                                                       849409-81-0P
            858116-59-3P
849409-82-1P
                          858116-66-2P 858116-86-6P 858117-08-5P
901238-24-2P 902458-30-4P 913983-25-2P 918523-44-1P 918523-45-2P
918523-46-3P 918523-47-4P 918523-48-5P 918523-49-6P 918523-51-0P
918523-52-1P 918523-53-2P 918523-54-3P 918523-55-4P 918523-56-5P
918523-57-6P 918523-58-7P 918523-59-8P 918523-60-1P 918523-61-2P
918523-62-3P 918523-63-4P 918523-64-5P 918523-65-6P 918523-66-7P
918523-67-8P 918523-68-9P 918523-69-0P 918523-70-3P
                                                       918523-71-4P
918523-72-5P 918523-73-6P 918523-74-7P 918523-75-8P 918523-76-9P
918523-77-0P 918523-78-1P 918523-79-2P 918523-80-5P 918523-81-6P
918523-82-7P 918523-83-8P 918523-84-9P 918523-85-0P 918523-86-1P
918523-87-2P 918523-88-3P 918523-89-4P 918523-90-7P 918523-91-8P
918523-92-9P 918523-93-0P 918523-94-1P 918523-95-2P 918523-96-3P
                            918523-99-6P 918524-00-2P 918524-01-3P
918523-97-4P 918523-98-5P
                            918524-04-6P 918524-05-7P
918524-02-4P
              918524-03-5P
                                                        918524-06-8P
              918524-08-0P
                            918524-09-1P 918524-10-4P
918524-07-9P
                                                        918524-11-5P
                            918524-14-8P
918524-12-6P
              918524-13-7P
                                          918524-15-9P
                                                        918524-16-0P
918524-17-1P
                            918524-19-3P 918524-20-6P
                                                        918524-21-7P
              918524-18-2P
918524-22-8P
              918524-23-9P
                            918524-24-0P
                                          918524-25-1P
                                                        918524-26-2P
918524-27-3P
              918524-28-4P
                            918524-29-5P
                                          918524-30-8P
                                                        918524-31-9P
918524-32-0P
              918524-33-1P
                            918524-34-2P
                                          918524-35-3P
                                                        918524-36-4P
918524-37-5P
              918524-38-6P
                            918524-39-7P
                                          918524-40-0P
                                                        918524-41-1P
918524-42-2P
              918524-43-3P
                            918524-44-4P
                                          918524-45-5P
                                                        918524-46-6P
                                          918524-50-2P
918524-47-7P
              918524-48-8P
                            918524-49-9P
                                                        918524-51-3P
918524-52-4P
              918524-53-5P
                            918524-54-6P
                                          918524-55-7P
                                                        918524-56-8P
918524-57-9P
             918524-58-0P
                            918524-59-1P
                                          918524-60-4P
                                                        918524-61-5P
918524-62-6P
```

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolopyridine derivs. as protein kinase

inhibitors useful in treatment of diseases) 7782-44-7, Oxygen, biological studies ΤТ RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) 98037-52-6, Abl protein kinase 103843-29-4, ΙT 79079-06-4, EGFR kinase 108891-60-7 111694-09-8 114051-78-4, LCK kinase IGF1R kinase 136396-12-8 137632-03-2, Met kinase 137632-06-5, Csk kinase 137632-08-7, Erk2 kinase 137632-09-8, Erbb2 kinase 138359-29-2, c-KIT 138674-26-7, Protein kinase Syk 139691-76-2, c-Raf-1 141349-86-2, Cdk2 kinase 141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes protein kinase 141350-03-0, Flt1 kinase 141436-78-4, Protein kinase C $\beta$  144114-16-9, Fak kinase 144376-45-4, Pim1 kinase 144638-77-7, Flt4 kinase 144697-16-5, B-Raf kinase 145539-86-2, HCK kinase 146279-92-7, Ret kinase 146838-30-4, 147014-96-8, CDK5 kinase 147014-97-9, CDK4 kinase MAPKAPK2 147230-71-5, Flt3 kinase 148047-29-4, Tie 2 kinase 148047-34-1, Protein kinase Zap70 148640-14-6, Akt 1 kinase 149147-12-6, Btk kinase 150027-21-7 150316-14-6, Mitogen-activated protein kinase kinase 2 150977-45-0, Kdr kinase 151662-26-9, Itk kinase 152478-56-3, Jak1 kinase 152478-57-4, Jak2 kinase 152743-99-2, Her4 kinase 152787-58-1, Protein kinase TrkA 154907-65-0, CHK1 kinase 157482-36-5, Jak3 kinase 165245-96-5, p38 Kinase 165245-99-8, rolo like kinase 166433-56-3, Anaplastic lymphoma kinase 170780-46-8, Pyk2 kinase 165245-96-5, p38 Kinase 165245-99-8, Polo like kinase 1 176023-60-2, Akt2 kinase 182238-33-1, Gene Ron protein kinase 182938-07-4, Protein kinase ROCK1 182938-08-5, Protein kinase ROCK2 191359-13-4, Mnk1 kinase 191808-15-8, 3-Phosphoinositide dependent protein kinase-1 205265-41-4, Akt3 kinase 250649-03-7, Protein kinase MLK1 270086-00-5, Pim3 kinase 289898-51-7, Jnk1 kinase 289899-93-0, Jnk2 kinase 291756-39-3, Jnk3 kinase 303014-92-8, CDK6 kinase 362517-43-9, IKK- $\beta$  kinase 370088-29-2, Mitogen-activated protein kinase kinase kinase 4 372092-80-3 420790-04-1, Pim2 kinase 428817-87-2, Irak4 kinase 443900-95-6, Glycogen synthase kinase  $3\beta$ 458560-40-2, Protein kinase Stk6 553648-93-4, Glycogen synthase kinase RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT 9004-10-8, Insulin, biological studies RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (resistance; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) 62-53-3, Aniline, reactions 83-38-5, 2,6-Dichlorobenzaldehyde ΙT 2-Chlorobenzylamine 90-04-0, 2-Methoxyaniline 94-99-5, 95-51-2, 2-Chloroaniline 96-32-2, Methyl 2,4-Dichlorobenzyl chloride bromoacetate 96-33-3, Methyl acrylate 98-09-9, Benzenesulfonyl 98-16-8, 3-Trifluoromethylaniline 98-18-0, chloride 3-Aminobenzenesulfonamide 98-31-7, 3,4-Dichlorophenylsulfonyl chloride 98-59-9, 4-Methylphenylsulfonyl chloride 98-60-2, 4-Chlorophenylsulfonyl chloride 98-68-0, 4-Methoxybenzenesulfonyl 98-80-6, Phenylboronic acid 99-61-6, 3-Nitrobenzaldehyde chloride 99-98-9, 4-Dimethylaminoaniline 100-07-2, 4-Methoxybenzoic acid chloride 100-37-8, 2-(Diethylamino)ethanol 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-55-0, 3-Pyridinemethanol 100-61-8, N-Methylaniline, reactions 100-81-2, 3-Methylbenzylamine 103-71-9, Phenyl isocyanate, reactions 104-12-1, 4-Chlorophenyl isocyanate 104-84-7, 4-Methylbenzylamine 104-86-9, 4-Chlorobenzylamine 104-94-9, 4-Methoxyaniline 106-41-2, 4-Bromophenol 106-47-8, 4-Chloroaniline, reactions 106-49-0, 4-Methylaniline, reactions 107-10-8,

```
1-Propanamine, reactions 108-42-9, 3-Chloroaniline 108-91-8,
Aminocyclohexane, reactions 109-01-3 109-73-9, 1-Butanamine, reactions
109-86-4, 2-Methoxyethanol 110-68-9, N-Methyl-1-butanamine 110-91-8,
Morpholine, reactions 111-36-4, Butyl isocyanate 121-32-4,
3-Ethoxy-4-hydroxybenzaldehyde 121-33-5, 4-Hydroxy-3-methoxybenzaldehyde
121-51-7, 3-Nitrobenzenesulfonyl chloride 121-60-8, 4-
(Acetylamino) benzenesulfonyl chloride 123-08-0, 4-Hydroxybenzaldehyde
133-59-5, 2-Methylbenzenesulfonyl chloride 139-59-3, 4-Phenoxyaniline
140-75-0, 4-Fluorobenzylamine 271-63-6, 7-Azaindole 303-38-8,
2,3-Dihydroxybenzoic acid 327-78-6, 4-Chloro-3-trifluoromethylphenyl
isocyanate 349-88-2, 4-Fluorophenylsulfonyl chloride 367-25-9,
2,4-Difluoroaniline 367-27-1, 2,4-Difluorophenol 371-40-4,
4-Fluoroaniline 399-95-1, 2-Fluoro-4-hydroxyaniline 404-71-7,
3-Fluorophenyl isocyanate 405-05-0, 3-Fluoro-4-hydroxybenzaldehyde
437-81-0, 2,6-Difluorobenzaldehyde 445-05-6, 5-Fluoro-2-
methylbenzenesulfonyl chloride 445-26-1, 1-(2-Fluorophenyl)ethanol
446-31-1, 4-Amino-2-fluorobenzoic acid 446-51-5, 2-Fluorobenzyl alcohol 454-89-7, 3-Trifluoromethylbenzaldehyde 459-59-6, N-Methyl-4-
fluoroaniline 461-82-5, 4-Trifluoromethoxyaniline 462-08-8,
3-Aminopyridine 501-30-4 501-53-1, Benzyl chloroformate 536-90-3, 3-Methoxyaniline 582-33-2, Ethyl 3-aminobenzoate 586-95-8,
4-Pyridinemethanol 586-98-1, 2-Pyridinemethanol
                                                    589-87-7,
1-Bromo-4-iodobenzene 603-80-5, 3-Hydroxy-2-methylbenzoic acid
614-68-6, 2-Methylphenyl isocyanate 621-29-4, 3-Methylphenyl isocyanate
621-59-0, 3-Hydroxy-4-methoxybenzaldehyde 622-40-2, N-(2-
Hydroxyethyl)morpholine 622-58-2, 4-Methylphenyl isocyanate
                                                                 622-95-7.
4-Chlorobenzyl bromide
                       623-24-5, 1,4-Bis(bromomethyl)benzene 626-43-7,
3,5-Dichloroaniline 626-58-4, 4-Methylpiperidine 656-42-8,
3,4-(Difluoromethylenedioxy)benzaldehyde 696-44-6
                                                     701-27-9,
3-Fluorobenzenesulfonyl chloride 701-34-8, 4-Bromobenzenesulfonamide
766-00-7, 2-Cyclopentylethanol 766-80-3, 3-Chlorobenzyl bromide
767-05-5, 3-Cyclopentylpropanol 768-35-4, 3-Fluorophenylboronic acid
777-44-6, 3-Trifluoromethylbenzenesulfonyl chloride
                                                     824-94-2,
4-Methoxybenzyl chloride 932-96-7, N-Methyl-4-chloroaniline
                                                                 1003-03-8,
                   1072-67-9, 3-Amino-5-methylisoxazole
                                                           1074-86-8,
Aminocyclopentane
4-Indolecarboxaldehyde 1122-71-0, 6-Methylpyridine-2-methanol
1123-56-4, 2,6-Dimethylbenzaldehyde 1138-56-3, 4-Butoxyphenylsulfonyl
         1195-45-5, 4-Fluorophenyl isocyanate 1423-26-3,
3-Trifluoromethylphenylboronic acid 1483-28-9, 2,5-
Dimethoxybenzenesulfonyl chloride
                                    1535-73-5, 3-Trifluoromethoxyaniline
1548-13-6, 4-Trifluoromethylphenyl isocyanate 1679-18-1,
4-Chlorophenylboronic acid 1692-15-5, Pyridin-4-ylboronic acid
1692-25-7, Pyridin-3-ylboronic acid 1765-93-1, 4-Fluorophenylboronic
       1777-82-8, 2,4-Dichlorobenzyl alcohol
acid
                                              1899-93-0,
3-Methylbenzenesulfonyl chloride 1978-37-6, N-Methyl-3-fluoroaniline
                                     2038-03-1, N-(2-Aminoethyl)morpholine
1996-41-4, 2-Chloro-4-fluorophenol
2124-55-2, 4-Indolecarboxylic acid
                                     2359-60-6, 4-(Piperidin-1-yl) aniline
2386-60-9, 1-Butanesulfonyl chloride
                                      2393-23-9, 4-Methoxybenzylamine
2420-16-8, 3-Chloro-4-hydroxybenzaldehyde
                                           2426-87-1,
4-Benzyloxy-3-methoxybenzaldehyde
                                   2516-47-4, Cyclopropylmethylamine
2524-67-6, 4-(Morpholin-4-yL) aniline
                                      2688-84-8, 2-Phenoxyaniline
2713-31-7, 2,5-Difluorophenol 2740-83-2, 3-Trifluoromethylbenzylamine
2836-04-6, 3-Dimethylaminoaniline
                                    2905-21-7, 2-Fluorobenzenesulfonyl
chloride 2909-38-8, 3-Chlorophenyl isocyanate 2987-49-7,
2-Methylsulfonylaniline
                         2991-42-6, 4-Trifluoromethylphenylsulfonyl
          3048-01-9, 2-Trifluoromethylbenzylamine
                                                     3173-56-6, Benzyl
chloride
isocyanate
             3218-02-8, Cyclohexanemethanamine 3300-51-4,
4-Trifluoromethylbenzylamine
                             3355-28-0, 1-Bromo-2-butyne
                                                            3445-11-2,
N-(2-Hydroxyethyl)pyrrolidin-2-one 3586-12-7, 3-Phenoxyaniline 3587-60-8, Benzyloxymethyl chloride 3731-51-9, Pyridine-2-methylamine
3731-52-0, 3-Pyridinemethanamine 3954-13-0, Pentyl isocyanate
```

```
4152-90-3, 3-Chlorobenzylamine 4393-16-2, 4-Methylsulfonylbenzylamine
4441-30-9, N-(3-Hydroxypropyl)morpholine 4595-59-9, 5-Bromopyrimidine
5071-96-5, 3-Methoxybenzylamine 5180-79-0 5345-54-0,
3-Chloro-4-methoxyaniline 5369-19-7, 3-tert-Butylaniline
                                                             5416-93-3,
4-Methoxyphenyl isocyanate 5470-49-5, 4-Methylsulfonylaniline
5585-33-1, 2-Morpholinoaniline
                                5720-07-0, 4-Methoxyphenylboronic acid
5779-95-3, 3,5-Dimethylbenzaldehyde 5961-59-1, N-Methyl-4-methoxyaniline
6165-68-0, Thiophene-2-boronic acid 6482-24-2, 1-Bromo-2-methoxyethane
7006-52-2, N-Methyl-3-chloroaniline 7304-32-7, 2-Fluoro-5-nitrobenzoic
     10130-74-2, 3-Methoxyphenylsulfonyl chloride 10147-36-1,
1-Propanesulfonyl chloride 10147-37-2, 2-Propanesulfonyl chloride
10203-08-4, 3,5-Dichlorobenzaldehyde 10272-07-8, 3,5-Dimethoxyaniline
10365-98-7, 3-Methoxyphenylboronic acid 10541-83-0, 4-Methylaminobenzoic
     13358-73-1, Dibutyl carbamoyl chloride 13360-63-9,
N-Ethyl-1-butanamine 13918-92-8, 2,4-Difluorobenzenesulfonyl chloride
13952-84-6, 2-Butanamine 14318-66-2, N-Methyl-3-methoxyaniline
15268-31-2, 3-Isocyanatopyridine 15854-87-2, 4-Iodopyridine
16315-59-6, 4-Dimethylaminophenyl isocyanate 16629-19-9,
2-Thiophenesulfonyl chloride \bar{1}6712-\bar{69}-9, 4-Ethylphenylsulfonyl chloride
17334-08-6, 1-Methylimidazole-2-methanol 18278-34-7,
4-Hydroxy-2-methoxybenzaldehyde 18908-07-1, 3-Methoxyphenyl isocyanate
20012-63-9, 2-Benzyloxyaniline 20443-98-5, 2,6-Dichlorobenzyl bromide
20984-81-0, 3-(Diethylamino)pyrrolidine 21626-70-0 22184-97-0
23095-31-0, 3,4-Dimethoxyphenylsulfonyl chloride 23616-57-1 26153-38-8, 3,5-Dihydroxybenzaldehyde 27086-19-7, Dipropylcarbamoyl chloride 28439-86-3, 4-Butoxyphenyl isocyanate 28611-39-4,
4-Dimethylaminophenylboronic acid 29668-44-8, 3,4-
Ethylenedioxybenzaldehyde 30418-59-8, 3-Aminophenylboronic acid
35216-39-8, 3-Methylsulfonylaniline 35856-62-3, 1-Piperidinesulfonyl
chloride 37045-73-1 37527-66-5, 3,4-Dimethoxyphenyl isocyanate
38041-19-9, 4-Amino-tetrahydropyran 38070-73-4 39893-50-0,
3-Chloro-4-trifluoromethylphenyl isocyanate 39989-43-0,
3,5-Dichlorobenzylamine 40750-59-2, N-Methyl-3,4-dichloroaniline
41419-59-4, N-Methyl-4-trifluoromethoxyaniline 41483-74-3 41838-46-4,
4-Amino-1-methylpiperidine 42170-95-6, 2-Methoxyethyl isocyanate
42601-04-7, 3,4-Difluorophenyl isocyanate 49584-26-1,
4-Cyanophenylsulfonyl chloride 50382-32-6, 2,4-Dimethylthiazole-5-
methanol 50528-86-4, 2-Chloro-5-trifluoromethylphenyl isocyanate
51175-71-4, 3-Thiophenesulfonyl chloride
                                          51488-22-3,
2-Chloro-4-trifluoromethylphenyl isocyanate
                                              52130-17-3,
3-Amino-2-methylbenzoic acid
                              52771-21-8, 3-Trifluoromethoxybenzaldehyde
53104-95-3, 4-Hydroxy-3-trifluoromethoxybenzaldehyde
                                                      54751-01-8,
4-Bromomethylpyridine 54997-90-9, 4-Isopropylbenzenesulfonyl chloride
56456-47-4, 2,4-Difluorobenzylalcohol
                                       56456-49-6, 4-Chloro-2-
fluorobenzyl alcohol 56542-67-7, 3-Cyanobenzenesulfonyl chloride
56962-11-9, 2-Chloro-4-hydroxybenzaldehyde 57012-20-1 57678-46-3,
3-Dimethylaminobenzylamine 57946-56-2, 4-Chloro-2-fluoroaniline
61424-26-8, 3-Benzylaniline 61672-75-1, Isoxazol-3-yl isocyanate
63503-60-6, 3-Chlorophenylboronic acid 63624-28-2
                                                     63758-12-3
69360-26-5, 2-Cyanobenzenesulfonyl chloride 69816-05-3
                                                           70067-45-7
71189-18-9
             71916-82-0, 4-Chloro-2-fluorobenzyl bromide
                                                           71924-62-4
72975-46-3
RL: RCT (Reactant); RACT (Reactant or reagent)
   (starting material; preparation of pyrrolopyridine derivs. as protein kinase
   inhibitors useful in treatment of diseases)
78887-39-5, 3-(Acetylamino)phenylboronic acid
                                                79418-78-3,
3-Fluoro-4-hydroxy-5-methoxybenzaldehyde
                                           80466-80-4 85345-76-2,
3-Chloro-2-fluorobenzoyl chloride
                                   85684-61-3, 3-
                                           89599-01-9,
Difluoromethoxybenzaldehyde
                              86718-08-3
3-Bromobenzenesulfonamide 90001-64-2, Benzothiophene-2-sulfonyl chloride
90260-13-2, 3-Fluoro-4-methylbenzenesulfonyl chloride 93071-75-1,
```

```
3-Trifluoromethoxybenzylamine 93919-56-3, 4-Trifluoromethoxybenzylamine
97272-04-3, 2,5-Dimethylthiophene-3-sulfonyl chloride 98437-24-2,
2-Benzofuranboronic acid 103438-86-4 103438-88-6, 2-Fluoro-3-
methoxybenzaldehyde
                    104451-70-9, 2,3,6-Trifluorobenzaldehyde
108679-71-6, 3-Amino-2-chlorobenzoic acid 109299-78-7,
Pyrimidine-5-boronic acid
                          119895-68-0
                                        123088-59-5,
4-(Aminocarbonyl)phenylboronic acid 126747-14-6, 4-Cyanophenylboronic
      128796-39-4, 4-Trifluoromethylphenylboronic acid
                                                       137049-02-6
137654-20-7, 2-Fluoro-3-methoxybenzoic acid 138564-16-6,
N-Methyl-2, 4-difluoroaniline 148355-75-3, 3-
(Methylsulfonylamino)phenylboronic acid 151411-98-2,
2,4,6-Trifluorobenzyl bromide 151858-64-9, 5-(2-Pyridinyl)thiophene-2-
sulfonyl chloride 153912-60-8, 1,5-Dimethyl-1H-pyrazole-3-methanol
156545-07-2, 3,5-Difluorophenylboronic acid 163105-89-3,
2-Methoxypyridin-5-ylboronic acid 166964-26-7, 2,5-Dimethylfuran-3-
                  167678-46-8, Acetic acid 3-chlorocarbonyl-2-
sulfonyl chloride
methylphenyl ester 168899-43-2 175205-64-8, 2-
Trifluoromethoxybenzylamine 179113-90-7, 3-Trifluoromethoxyphenylboronic
      180200-86-6 181124-40-3, 6-Benzothiazolesulfonyl chloride
188815-30-7, 3-Fluoro-5-trifluoromethylbenzaldehyde 190774-52-8,
2-Fluoro-3-trifluoromethylphenyl isocyanate
                                           197239-49-9,
2-Fluoro-4-trifluoromethylbenzyl alcohol
                                        208186-84-9,
2-Chloro-4-fluorobenzyl alcohol 210532-25-5, 3,5-Difluorobenzenesulfonyl
         216144-91-1 252928-74-8
                                     306936-35-6 321309-40-4
chloride
337508-66-4, 4-(Oxazol-5-yl)benzenesulfonyl chloride
                                                    351003-34-4,
4-Difluoromethoxybenzenesulfonyl chloride 351422-73-6,
                                                373384-18-0,
3-(Aminocarbonyl)phenylboronic acid 364794-80-9
3-(Methylsulfonyl)phenylboronic acid
                                    380430-52-4
                                                  386704-04-7
388088-73-1
            389621-84-5
                          405520-68-5
                                       423151-49-9
                                                      445264-61-9
485799-04-0 532967-21-8, 2,6-Difluoro-4-hydroxybenzaldehyde
551930-53-1 628692-15-9 690632-68-9 701269-22-9 754214-56-7
761446-44-0 785785-59-3
                                        852227-95-3
                         852180-61-1
                                                      858116-95-7
909501-40-2 911210-53-2, 4-Cyano-3,5-dimethylphenylboronic acid
918524-63-7 \qquad 918524-64-8 \qquad 918524-65-9 \qquad 918524-66-0 \qquad 918524-67-1
918524-68-2 918524-69-3 918524-70-6 918524-71-7 918524-72-8
918524-73-9 918524-74-0 918524-75-1 918524-76-2 918524-77-3
918524-78-4 918524-80-8 918524-83-1 918524-85-3 918524-86-4
918524-87-5 918524-88-6 918524-89-7 918524-90-0 918524-91-1
918524-92-2 918524-93-3 918524-94-4 918524-95-5 918524-96-6
918524-97-7 918524-98-8 918524-99-9
                                      918525-00-5 918525-01-6
                         918525-04-9
918525-02-7 918525-03-8
RL: RCT (Reactant); RACT (Reactant or reagent)
   (starting material; preparation of pyrrolopyridine derivs. as protein kinase
   inhibitors useful in treatment of diseases)
             918724-53-5
                                        918724-55-7
918724-49-9
                          918724-54-6
                                                      918724-56-8
918724-57-9
             918724-58-0
                          918724-59-1
                                        918724-61-5 918724-62-6
918724-63-7
RL: PRP (Properties)
   (unclaimed nucleotide sequence; pyrrolo[2,3-b]pyridine derivs. as
  protein kinase inhibitors and their preparation, pharmaceutical compns. and
  use in the treatment of diseases)
             918724-64-8
918724-60-4
RL: PRP (Properties)
   (unclaimed protein sequence; pyrrolo[2,3-b]pyridine derivs. as protein
  kinase inhibitors and their preparation, pharmaceutical compns. and use in
  the treatment of diseases)
918724-35-3
             918724-36-4
                          918724-37-5
                                        918724-38-6
                                                      918724-39-7
918724-40-0
             918724-41-1
                           918724-42-2
                                        918724-43-3
                                                      918724-44-4
                                        918724-48-8
918724-45-5 918724-46-6
                         918724-47-7
                                                      918724-50-2
918724-51-3 918724-52-4
                         918724-65-9 918724-66-0
                                                      918724-67-1
918724-68-2 918724-69-3
                         918724-70-6 918724-71-7 918724-72-8
```

ΤТ

ΙT

```
918724-73-9
           918724-74-0
                       918724-75-1 918724-76-2 918724-77-3
918724-78-4 918724-79-5
                       918724-80-8 918724-81-9 918724-82-0
918724-83-1 918724-84-2
                       918724-85-3 918724-86-4 918724-87-5
918724-88-6 918724-89-7
                       918724-90-0 918724-91-1 918724-92-2
918724-93-3 918724-94-4
                       918724-95-5 918724-96-6 918724-97-7
918724-98-8 918724-99-9 918725-00-5 918725-01-6 918725-02-7
918725-03-8 918725-04-9 918725-05-0 918725-06-1 918725-07-2
918725-08-3 918725-09-4 918725-10-7 918725-11-8 918725-12-9
918725-13-0 918725-14-1 918725-15-2 918725-16-3 918725-17-4
918725-18-5 918725-19-6 918725-20-9 918725-21-0 918725-22-1
918725-23-2 918725-24-3 918725-25-4 918725-26-5 918725-27-6
918725-28-7 918725-29-8 918725-30-1 918725-31-2 918725-32-3
918725-33-4 918725-34-5
                       918725-35-6 918725-36-7 918725-37-8
918725-38-9 918725-39-0 918725-40-3 918725-41-4 918725-42-5
918725-43-6 918725-44-7
                       918725-45-8 918725-46-9 918725-47-0
918725-48-1 918725-49-2
                       918725-50-5 918725-51-6 918725-52-7
918725-53-8 918725-54-9
                       918725-55-0 918725-56-1 918725-57-2
918725-58-3
```

RL: PRP (Properties)

(unclaimed sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase inhibitors and their preparation, pharmaceutical compns. and use in the treatment of diseases)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

(1) Aadal, N; WO 2004016610 A 2004 CAPLUS

- (2) Barton; TETRAHEDRON 1987, V43(2), P323 CAPLUS
- (3) Bayer Aq; DE 2413258 A1 1975 CAPLUS
- (4) Curtin; J MED CHEM 1998, V41, P74 CAPLUS
- (5) Heacock; J AM CHEM SOC 1960, V82, P3460 CAPLUS
- (6) Langham; J AM CHEM SOC 1941, V63, P545 CAPLUS
- (7) Normington, J; US 2234705 A 1941 CAPLUS
- (8) Pierce; J AM CHEM SOC 1942, V64, P1691
- L32 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
- IT 98-59-9, 4-Methylbenzenesulfonyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

RN 98-59-9 CAPLUS

CN Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)

ACCESSION NUMBER: 2007:11300 CAPLUS

DOCUMENT NUMBER: 146:142627

TITLE: Pyrrolo[2,3-b]pyridine derivatives as protein kinase

inhibitors and their preparation, pharmaceutical

compositions and use in the treatment of

diseases

INVENTOR(S): Ibrahim, Prahbha N.; Artis, Dean R.; Bremer, Ryan;

Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho,

Hanna; Gillette, Samuel J.; Wu, Guoxiam; Zhu, Hongyao;

Shi, Shenghua

PATENT ASSIGNEE(S): Plexxikon, Inc., USA SOURCE: PCT Int. Appl., 291 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PA	PATENT NO.						KIND DATE				ICAT		DATE				
WC	WO 2007002325			A1 20070104				WO 2	006-	JS24	20060621						
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	ΒA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,	KP,
		KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,
		MW,	MX,	MZ,	NA,	NG,	NΙ,	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	RU,
		SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,
		US,	UΖ,	VC,	VN,	ZA,	ZM,	ZW									
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
		IS,	ΙT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ΒJ,
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	G₩,	ML,	MR,	ΝE,	SN,	TD,	ΤG,	BW,	GH,
		GM,	KΕ,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	AΖ,	BY,
		KG,	KΖ,	MD,	RU,	ΤJ,	$^{\mathrm{TM}}$										
KF	KR 2008030619						2008	0404	KR 2008-701659						20080121		
PRIORIT	PRIORITY APPLN. INFO.:								US 2005-692960P					P 2005062			622
									US 2005-731528P						P 20051028		
						WO 2	006-1	JS24.	361	1	W 2	0060	621				

OTHER SOURCE(S): MARPAT 146:142627

AN 2007:11300 CAPLUS

DN 146:142627

ED Entered STN: 04 Jan 2007

- TI Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
- IN Ibrahim, Prahbha N.; Artis, Dean R.; Bremer, Ryan; Mamo, Shumeye; Nespi, Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Tsai, James; Hirth, Klaus-Peter; Bollag, Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxiam; Zhu, Hongyao; Shi, Shenghua
- PA Plexxikon, Inc., USA
- SO PCT Int. Appl., 291 pp.

CODEN: PIXXD2

- DT Patent
- LA English
- CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
   Section cross-reference(s): 1, 63

FAN.CNT 3

	PATENT NO.					D	DATE		-	APPL	ICAT		DATE				
ΡI	WO 2007002325			A1		2007	0104	WO 2006-US24361						20060621			
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,	KP,
		KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,
		MW,	MX,	MZ,	ΝA,	NG,	NΙ,	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	RU,
		SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,
		US,	UZ,	VC,	VN,	ZA,	ZM,	ZW									
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ΒJ,
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG,	BW,	GH,
		GM,	ΚE,	LS,	MW,	MΖ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,

KG, KZ, MD, RU, TJ, TM KR 2008030619 20080404 KR 2008-701659 20080121 Α PRAI US 2005-692960P Р 20050622 Р US 2005-731528P 20051028 WO 2006-US24361 ΤΑΤ 20060621 CLASS PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES WO 2007002325 IPCI C07D0471-04 [I,A]; C07D0471-00 [I,C\*]; A61K0031-435 [I,A]; C07C0049-517 [I,A]; C07C0049-00 [I,C\*]; A61P0035-00 [I,A] **IPCR** C07D0471-00 [I,C]; C07D0471-04 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0049-00 [I,C]; C07C0049-517 [I,A]ECLA C07C037/62; C07C039/27; C07C045/00+47/565; C07C045/67C+47/575; C07C045/71+47/575; C07C047/565; C07C047/575; C07D209/08; C07D471/04+221B+209B; M07D KR 2008030619 IPCI C07D0471-04 [I,A]; C07D0471-00 [I,C\*]; A61K0031-435 [I,A]OS MARPAT 146:142627 GΙ

AΒ Compds. of formula I which are active on protein kinases are described, as well as methods of using such compds. to treat diseases and conditions associated with aberrant activity of protein kinases. Compds. of formula I wherein Q is (un)substituted (hetero)aryl, and (un)substituted indole; A is O, S, (un) substituted methylene, NH and derivs., CO, CS, SO and SO2; R4 - R6 are independently H, halo, (un) substituted lower alkyl, (un) substituted lower alkenyl, (un) substituted lower alkynyl, (un) substituted (hetero) cycloalkyl, (un) substituted (hetero) aryl, etc.; and their pharmaceutically acceptable salts, prodrugs, tautomer, and isomers thereof, are claimed. Example compound II was prepared by carboxylation of 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl 3-amino-2,6-difluorobenzoate underwent sulfonylation with propane-1-sulfonyl chloride to give benzyl 2,6-difluoro-3-(propylsulfonylamino) benzoate, which underwent hydrolysis to give the corresponding benzoic acid, which underwent chlorination and coupling with 5-bromo-7-azaindole to give compound II. All the invention compds. were evaluated for their protein kinase inhibitory activity. Several of the invention compds. exhibited good inhibitory activity against various protein kinases.

ST pyrrolopyridine prepn protein kinase inhibitor

IT Diabetes mellitus

(-associated renal complication, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

Diabetes mellitus ΤТ (-associated renal hypertrophy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Inflammation ΤТ (CNS, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT (Costello, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Inflammatory bowel disease ΤТ (Crohn's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Bone, disease Teratogenesis (Crouzon craniofacial dysostosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤT EphA receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphAl; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT EphA receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphA2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT EphB receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphB2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙΤ EphB receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (EphB4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤT Intestine, disease (Hirschsprung's disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Nervous system, disease (Huntington's chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Disease, animal ΙT (Jackson-Weiss, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (MEN2, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Gene, animal RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (MEN2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (Noonan syndrome, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Disease, animal

(Pfeiffer's, treatment of; preparation of pyrrolopyridine derivs.

as protein kinase inhibitors useful in treatment of diseases) ΤТ Granulomatous disease (Wegener's granulomatosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Antibodies and Immunoglobulins IT RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study) (X-linked infantile hypogammaglobulinemia; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Disease, animal (acrocephalosyndactylia type I, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Pain Respiratory distress syndrome (acute, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤT Retinal disease (age-related macular degeneration, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Allergy Inflammation Nose, disease (allergic rhinitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Antiarteriosclerotics (antiatherosclerotics; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TΤ Neuroglia, neoplasm (astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TΤ Dermatitis (atopic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Autoimmune disease Inflammation Thyroid gland, disease (autoimmune thyroiditis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Infection ΤТ (bacterial, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Prostate gland, disease (benign hyperplasia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Hyperplasia (benign prostatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Bronchi, disease ΤТ Inflammation (bronchitis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Lung, neoplasm ΤТ

Mammary gland, neoplasm

Pancreas, neoplasm

(carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(cardio-faciocutaneous, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia

(cerebrovascular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Hypoxia

(chemotherapy-induced, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Nervous system, disease

(chorea, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease

(chronic obstructive pulmonary disease, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pain

(chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Intestine, neoplasm

(colon, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

Intestine, neoplasm

(colon, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neoplasm

(complications, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders

(dementia, multi-infarct, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Mental and behavioral disorders

(dementia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Skin, disease

(dermal scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Retinal disease

(diabetic retinopathy, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, disease

(endometriosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Uterus, neoplasm

(endometrium, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(faciocutaneoskeletal, treatment of; preparation of

pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Kidney, disease

(failure, chronic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Reproductive system

(female, carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lung, disease

(fibrosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, disease

(fracture, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (gene ALK5; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(genetic, developmental, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Neuroglia, neoplasm

(glioblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(glomerulonephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Transplant and Transplantation

(graft-vs.-host reaction, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Injury

(head and neck, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Ischemia

(hepatic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(hepatocellular, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, neoplasm

(hepatoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Lymphoma

(histiocytic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Sexual disorders

(impotence, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(in situ, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Helicobacter pylori pylori

Influenza virus

(infection, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Pair

(inflammatory pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Head and Neck, disease

Reperfusion

Spinal cord, disease

(injury, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Autoimmune disease

(insulin-dependent diabetes mellitus, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Diabetes mellitus

(insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(interstitial nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Liver, disease

(ischemia, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Myoma

Sarcoma

(leiomyosarcoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Disease, animal

(leopard, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Inflammation

Kidney, disease

(lupus nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Edema

(lympho-, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Carcinoma

(mammary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Metabolic disorders

(metabolic syndrome X, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Bone, neoplasm

(metastasis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Blood vessel, disease

(microangiopathy, thrombotic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)

IT Headache

(migraine, treatment of; preparation of pyrrolopyridine derivs. as

protein kinase inhibitors useful in treatment of diseases) ΤТ Bone formation (mineralization, diseases, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Oviduct (neoplasm, adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Astrocyte (neoplasm, astrocytoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Schwann cell (neoplasm, schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Inflammation Kidney, disease (nephritis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙΤ Kidney, disease (nephrosclerosis, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (neural crest, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Nerve, neoplasm (neuroblastoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TΤ Pain (neuropathic pain, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Diabetes mellitus (non-insulin-dependent, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Lung, neoplasm (non-small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Sarcoma (of neuro-ectodermal origin, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Transplant rejection (organ; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT (oviduct adenocarcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Carcinoma (pancreatic, treatment of; preparation of pyrrolopyridine derivs.

as protein kinase inhibitors useful in treatment of diseases)

ΤТ

Inflammation
Pancreas, disease

derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Kidney, disease (polycystic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Allergy inhibitors Analgesics Angiogenesis inhibitors Anti-Alzheimer's agents Anti-infective agents Anti-inflammatory agents Anti-ischemic agents Antiarthritics Antiasthmatics Antibacterial agents Antidiabetic agents Antifibrotic agents Antimigraine agents Antiobesity agents Antiosteoporotic agents Antiparkinsonian agents Antipyretics Antirheumatic agents Antitumor agents Antiviral agents Canidae Cardiovascular agents Combination chemotherapy Human Immunostimulants Immunosuppressants Lipolysis Nervous system agents Pharmaceutical carriers Prodrugs Respiratory system agents Thrombolytics Transplant and Transplantation (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT c-Kit (protein) neu (receptor) RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΤТ Carcinoma (pulmonary non-small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Carcinoma (pulmonary small-cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Carcinoma Fibrosis (pulmonary, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) Kidney, neoplasm ΙT (renal cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in

(pancreatitis, treatment of; preparation of pyrrolopyridine

treatment of diseases) ТТ Carcinoma (renal cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) TΤ Injury (reperfusion, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Nervous system, neoplasm (schwannoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT T lymphocyte (selective defect of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Immunodeficiency (severe combined, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Lung, neoplasm (small-cell carcinoma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙΤ Injury (spinal cord, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Carcinoma (squamous cell, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Digestive tract, neoplasm (stroma, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙΤ Lupus erythematosus (systemic, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Disease, animal (tissue scarring, treatment of; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases) ΙT Acute lymphocytic leukemia Acute myeloid leukemia Aging, animal Allergy Alopecia Alzheimer's disease Amyotrophic lateral sclerosis Asthma Atherosclerosis Bladder, neoplasm Bone, disease Bone, neoplasm Brain, neoplasm Cardiac hypertrophy Cardiovascular system, disease Central nervous system, neoplasm Chronic lymphocytic leukemia Chronic myeloid leukemia Diabetic nephropathy Digestive tract, neoplasm Emphysema

Endocrine system, disease

Eosinophilia

```
Fever and Hyperthermia
Fibrosis
Graves' disease
Hair, disease
  Heart failure
Hepatic steatosis
Hepatitis
Hyperglycemia
Immunodeficiency
Infection
Inflammation
Inflammatory bowel disease
Intestine, disease
  Ischemia
Kidney, disease
Leukemia
Liver, neoplasm
Lung, disease
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Mastocytoma
Mastocytosis
Melanoma
Multiple myeloma
Multiple sclerosis
Mutation
Myasthenia gravis
Myelodysplastic syndromes
Neoplasm
Neurofibromatosis 1
Neuroglia, neoplasm
Non-Hodgkin lymphoma
Obesity
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Parkinson's disease
Prostate gland, disease
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Sarcoma
Scleroderma
Sepsis
Sjogren syndrome
Skeleton, disease
Skin, disease
Skin, neoplasm
Stroke
Systemic mastocytosis
Testis, neoplasm
Thrombosis
Thyroid gland, neoplasm
Tuberous sclerosis
Vascular restenosis
   (treatment of; preparation of pyrrolopyridine derivs. as protein
   kinase inhibitors useful in treatment of diseases)
Necrosis
   (tubular, treatment of; preparation of pyrrolopyridine derivs. as
```

```
protein kinase inhibitors useful in treatment of diseases)
ΤТ
     Angiogenesis
        (tumor, treatment of; preparation of pyrrolopyridine derivs. as
        protein kinase inhibitors useful in treatment of diseases)
     Fibroblast growth factor receptors
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΙΤ
     Fibroblast growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 2; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΙΤ
     Fibroblast growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 3; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
     Fibroblast growth factor receptors
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (type 4; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΤТ
     Inflammatory bowel disease
        (ulcerative colitis, treatment of; preparation of pyrrolopyridine
        derivs. as protein kinase inhibitors useful in treatment of
        diseases)
ΙT
    Colitis
        (ulcerative, treatment of; preparation of pyrrolopyridine derivs.
        as protein kinase inhibitors useful in treatment of diseases)
ΙT
     Infection
        (viral, treatment of; preparation of pyrrolopyridine derivs. as
        protein kinase inhibitors useful in treatment of diseases)
ΙT
     Platelet-derived growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (a; preparation of pyrrolopyridine derivs. as protein kinase
        inhibitors useful in treatment of diseases)
ΙT
     Platelet-derived growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\beta; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΙT
     142805-58-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (1; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
ΙT
     50-99-7, D-Glucose, biological studies
     RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
     unclassified); BIOL (Biological study)
        (blood; preparation of pyrrolopyridine derivs. as protein kinase inhibitors
        useful in treatment of diseases)
                  918506-28-2P
                                                  918507-82-1P
     918504-27-5P
                                  918507-15-0P
ΙT
                                                                  918507-83-2P
                    918507-88-7P
                                                  918508-21-1P
     918507-84-3P
                                   918508-05-1P
                                                                  918508-33-5P
                                 918509-58-7P
     918509-12-3P
                    918509-57-6P
                                                  918509-59-8P
                                                                  918510-89-1P
     918511-00-9P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate and intermediate; preparation of pyrrolopyridine derivs. as
        protein kinase inhibitors useful in treatment of diseases)
ΙT
     918504-32-2P
                    918504-33-3P
                                   918504-39-9P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
```

```
inhibitors useful in treatment of diseases)
ΤТ
     918504-31-1P
                    918504-34-4P
                                   918504-35-5P
                                                   918504-40-2P
                                                                  918504-41-3P
                                                   918504-62-8P
     918504-42-4P
                    918504-43-5P
                                   918504-61-7P
                                                                  918504-63-9P
     918504-64-0P
                    918504-65-1P
                                   918504-66-2P
                                                   918504-67-3P
                                                                  918504-68-4P
                    918504-70-8P
                                   918504-71-9P
                                                   918504-72-0P
     918504-69-5P
                                                                  918504-75-3P
                    918504-77-5P
     918504-76-4P
                                   918504-78-6P
                                                   918504-79-7P
                                                                  918504-80-0P
     918504-81-1P
                    918504-82-2P
                                   918504-83-3P
                                                   918504-84-4P
                                                                  918504-85-5P
     918504-86-6P
                    918504-87-7P
                                   918504-88-8P
                                                   918504-89-9P
                                                                  918504-90-2P
     918504-91-3P
                    918504-92-4P
                                   918504-93-5P
                                                   918504-94-6P
                                                                  918504-95-7P
     918504-96-8P
                    918504-97-9P
                                   918505-58-5P
                                                   918505-61-0P
                                                                  918505-62-1P
                    918505-69-8P
                                   918505-70-1P
                                                   918505-71-2P
                                                                  918505-73-4P
     918505-63-2P
                                                   918505-77-8P
     918505-74-5P
                    918505-75-6P
                                   918505-76-7P
                                                                  918505-78-9P
     918505-79-0P
                    918505-80-3P
                                   918505-81-4P
                                                   918505-82-5P
                                                                  918505-83-6P
     918505-84-7P
                    918505-85-8P
                                   918505-86-9P
                                                   918505-87-0P
                                                                  918505-88-1P
     918505-90-5P
                    918505-91-6P
                                   918505-92-7P
                                                   918505-93-8P
                                                                  918505-94-9P
                    918505-96-1P
                                   918505-97-2P
                                                                  918505-99-4P
     918505-95-0P
                                                   918505-98-3P
                    918506-01-1P
     918506-00-0P
                                   918506-02-2P
                                                   918506-03-3P
                                                                  918506-04-4P
     918506-05-5P
                    918506-06-6P
                                   918506-07-7P
                                                                  918506-09-9P
                                                   918506-08-8P
                    918506-11-3P
                                                   918506-13-5P
     918506-10-2P
                                   918506-12-4P
                                                                  918506-14-6P
     918506-15-7P
                    918506-16-8P
                                   918506-17-9P
                                                   918506-18-0P
                                                                  918506-19-1P
     918506-20-4P
                    918506-21-5P
                                   918506-26-0P
                                                   918506-27-1P
                                                                  918506-29-3P
     918506-35-1P
                    918506-36-2P
                                   918506-37-3P
                                                   918506-38-4P
                                                                  918506-39-5P
     918506-40-8P
                    918506-42-0P
                                   918506-43-1P
                                                   918506-44-2P
                                                                  918506-45-3P
     918506-49-7P
                    918506-50-0P
                                   918506-51-1P
                                                   918506-52-2P
                                                                  918506-53-3P
     918506-54-4P
                    918506-55-5P
                                   918506-56-6P
                                                   918506-57-7P
                                                                  918506-58-8P
     918506-59-9P
                    918506-60-2P
                                   918506-61-3P
                                                   918506-62-4P
                                                                  918506-63-5P
                                                   918506-67-9P
     918506-64-6P
                    918506-65-7P
                                   918506-66-8P
                                                                  918506-68-0P
     918506-70-4P
                    918506-71-5P
                                   918506-72-6P
                                                   918506-73-7P
                                                                  918506-74-8P
     918506-75-9P
                    918506-76-0P
                                   918506-77-1P
                                                   918506-78-2P
                                                                  918506-79-3P
                                                                  918506-84-0P
     918506-80-6P
                    918506-81-7P
                                   918506-82-8P
                                                   918506-83-9P
                    918506-86-2P
     918506-85-1P
                                   918506-87-3P
                                                   918506-88-4P
                                                                  918506-89-5P
     918506-90-8P
                    918506-92-0P
                                   918506-93-1P
                                                   918506-94-2P
                                                                  918506-95-3P
     918506-96-4P
                    918506-97-5P
                                   918506-98-6P
                                                   918506-99-7P
                                                                  918507-00-3P
     918507-01-4P
                    918507-02-5P
                                   918507-03-6P
                                                   918507-04-7P
                                                                  918507-05-8P
     918507-06-9P
                    918507-07-0P
                                   918507-08-1P
                                                   918507-09-2P
                                                                  918507-10-5P
     918507-11-6P
                    918507-12-7P
                                   918507-13-8P
                                                   918507-14-9P
                                                                  918507-16-1P
     918507-17-2P
                    918507-20-7P
                                   918507-21-8P
                                                   918507-22-9P
                                                                  918507-23-0P
     918507-24-1P
                    918507-28-5P
                                   918507-29-6P
                                                   918507-30-9P
                                                                  918507-31-0P
     918507-32-1P
                    918507-33-2P
                                   918507-34-3P
                                                   918507-38-7P
                                                                  918507-40-1P
     918507-47-8P
                    918507-49-0P
                                   918507-51-4P
                                                   918507-57-0P
                                                                  918507-58-1P
                    918507-60-5P
     918507-59-2P
                                   918507-61-6P
                                                   918507-62-7P
                                                                  918507-63-8P
     918507-64-9P
                    918507-65-0P
                                   918507-66-1P
                                                   918507-67-2P
                                                                  918507-68-3P
     918507-78-5P
                    918507-79-6P
                                   918507-85-4P
                                                   918507-86-5P
                                                                  918507-87-6P
     918507-89-8P
                    918507-90-1P
                                                                  918507-93-4P
                                   918507-91-2P
                                                   918507-92-3P
     918507-94-5P
                    918507-95-6P
                                   918507-96-7P
                                                                  918507-98-9P
                                                   918507-97-8P
                                   918508-01-7P
     918507-99-0P
                                                   918508-02-8P
                                                                  918508-03-9P
                    918508-00-6P
                                   918508-07-3P
     918508-04-0P
                                                   918508-08-4P
                                                                  918508-09-5P
                    918508-06-2P
     918508-10-8P
                    918508-11-9P
                                   918508-12-0P
                                                   918508-13-1P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
        inhibitors useful in treatment of diseases)
ΙT
                                                   918508-17-5P
                                                                  918508-18-6P
     918508-14-2P
                    918508-15-3P
                                   918508-16-4P
     918508-19-7P
                    918508-20-0P
                                   918508-22-2P
                                                   918508-23-3P
                                                                  918508-25-5P
     918508-26-6P
                    918508-27-7P
                                   918508-28-8P
                                                   918508-29-9P
                                                                  918508-30-2P
     918508-31-3P
                    918508-32-4P
                                   918508-34-6P
                                                   918508-35-7P
                                                                  918508-36-8P
     918508-37-9P
                    918508-38-0P
                                   918508-39-1P
                                                   918508-40-4P
                                                                  918508-41-5P
     918508-42-6P
                    918508-43-7P
                                   918508-44-8P
                                                   918508-45-9P
                                                                  918508-46-0P
     918508-47-1P
                    918508-48-2P
                                   918508-49-3P
                                                   918508-50-6P
                                                                  918508-51-7P
```

918508-54-0P

918508-55-1P

918508-56-2P

918508-52-8P

918508-53-9P

```
918508-57-3P
              918508-58-4P
                             918508-59-5P
                                             918508-60-8P
                                                            918508-61-9P
                                             918508-65-3P
918508-62-0P
              918508-63-1P
                             918508-64-2P
                                                            918508-66-4P
918508-67-5P
              918508-68-6P
                             918508-69-7P
                                            918508-70-0P
                                                            918508-71-1P
                                             918508-75-5P
918508-72-2P
              918508-73-3P
                             918508-74-4P
                                                            918508-76-6P
918508-77-7P
              918508-78-8P
                             918508-79-9P
                                            918508-80-2P
                                                            918508-81-3P
              918508-83-5P
                                            918508-85-7P
918508-82-4P
                             918508-84-6P
                                                           918508-86-8P
918508-87-9P
              918508-88-0P
                             918508-89-1P
                                             918508-90-4P
                                                           918508-91-5P
918508-92-6P
              918508-93-7P
                             918508-94-8P 918508-95-9P
                                                           918508-96-0P
918508-97-1P
              918508-98-2P
                             918508-99-3P
                                             918509-00-9P
                                                           918509-01-0P
918509-02-1P
              918509-03-2P
                              918509-04-3P
                                             918509-05-4P
                                                           918509-06-5P
918509-07-6P
              918509-08-7P
                              918509-09-8P
                                             918509-10-1P
                                                           918509-11-2P
              918509-14-5P
918509-13-4P
                              918509-15-6P
                                             918509-16-7P
                                                           918509-17-8P
918509-18-9P
              918509-19-0P
                              918509-20-3P
                                             918509-21-4P
                                                            918509-22-5P
918509-23-6P
              918509-24-7P
                             918509-25-8P
                                             918509-26-9P
                                                           918509-27-0P
918509-28-1P
              918509-29-2P
                             918509-30-5P
                                             918509-31-6P
                                                           918509-32-7P
              918509-34-9P
                                             918509-36-1P
918509-33-8P
                             918509-35-0P
                                                           918509-37-2P
                                             918509-42-9P
918509-38-3P
              918509-39-4P
                             918509-41-8P
                                                           918509-43-0P
                                             918509-47-4P
918509-44-1P
              918509-45-2P
                             918509-46-3P
                                                           918509-48-5P
              918509-50-9P
                             918509-51-0P
                                             918509-52-1P
918509-49-6P
                                                           918509-53-2P
              918509-55-4P
                             918509-56-5P
                                             918509-60-1P
918509-54-3P
                                                            918509-61-2P
918509-62-3P
              918509-63-4P
                             918509-64-5P
                                             918509-65-6P
                                                            918509-66-7P
918509-67-8P
              918509-68-9P
                              918509-69-0P
                                             918509-70-3P
                                                            918509-71-4P
918509-72-5P
              918509-73-6P
                              918509-74-7P
                                             918509-75-8P
                                                            918509-76-9P
918509-77-0P
              918509-78-1P
                              918509-79-2P
                                             918509-80-5P
                                                            918509-81-6P
918509-82-7P
              918509-83-8P
                              918509-84-9P
                                             918509-85-0P
                                                            918509-86-1P
918509-87-2P
              918509-88-3P
                              918509-89-4P
                                             918509-90-7P
                                                            918509-91-8P
              918509-93-0P
918509-92-9P
                             918509-94-1P
                                             918509-95-2P
                                                            918509-96-3P
918509-97-4P
              918509-98-5P
                             918509-99-6P
                                             918510-00-6P
                                                           918510-01-7P
918510-02-8P
              918510-03-9P
                             918510-04-0P
                                            918510-05-1P
                                                           918510-06-2P
918510-07-3P
              918510-08-4P
                             918510-09-5P
                                            918510-10-8P
                                                           918510-11-9P
918510-90-4P
                                                           918511-33-8P
              918510-91-5P
                                            918511-01-0P
                             918510-92-6P
                                                           918511-94-1P
918511-34-9P
             918511-35-0P
                             918511-36-1P
                                            918511-89-4P
918512-65-9P
             918513-93-6P
                                           918516-21-9P
                             918515-13-6P
                                                           918516-54-8P
918517-29-0P
             918517-39-2P
                             918517-41-6P 918518-09-9P
                                                           918519-06-9P
918520-58-8P
             918520-62-4P
                             918520-75-9P 918520-76-0P
                                                           918520-85-1P
918521-03-6P
             918521-04-7P
                             918521-05-8P
                                           918521-06-9P
                                                           918521-09-2P
918521-38-7P
              918521-56-9P
                             918521-57-0P 918521-58-1P
                                                           918521-59-2P
918521-68-3P
              918521-73-0P
                             918521-74-1P
                                             918521-87-6P
                                                            918521-92-3P
918521-93-4P
              918521-94-5P
                             918521-95-6P
                                            918521-99-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
   inhibitors useful in treatment of diseases)
                             918522-27-7P
                                             918522-83-5P
                                                            918522-97-1P
918522-00-6P
              918522-24-4P
918803-06-2P
              918803-08-4P
                              918803-09-5P
                                             918803-10-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase
   inhibitors useful in treatment of diseases)
7440-70-2, Calcium, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
unclassified); BIOL (Biological study)
   (hypercalcemia; preparation of pyrrolopyridine derivs. as protein kinase
   inhibitors useful in treatment of diseases)
918517-04-1P
               918520-82-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
   (intermediate, drug candidate; preparation of pyrrolopyridine derivs. as
```

ΤТ

TΤ

```
824-52-2P 4649-09-6P 39255-23-7P 79418-72-7P 112434-18-1P
ΤТ
    152434-86-1P
                  152434-87-2P
                                 183208-36-8P
                                                208986-50-9P
                                                               269072-20-0P
    443124-79-6P
                   486424-36-6P, 4-Bromo-2,5-difluorophenol 611204-98-9P
    611205-38-0P 849067-96-5P 849068-05-9P 849409-81-0P 849409-82-1P
    858116-66-2P 858116-85-5P
                                858116-86-6P 858117-08-5P 866319-00-8P
    866546-07-8P 901238-24-2P 913983-25-2P 918507-52-5P 918511-92-9P
    918516-27-5P 918519-14-9P 918519-37-6P 918522-25-5P 918523-44-1P
    918523-45-2P 918523-46-3P 918523-47-4P 918523-48-5P 918523-49-6P
    918523-51-0P 918523-52-1P 918523-53-2P 918523-54-3P 918523-56-5P
    918523-57-6P 918523-58-7P 918523-59-8P 918523-60-1P 918523-61-2P
    918523-62-3P 918523-63-4P 918523-64-5P 918523-65-6P 918523-66-7P
    918523-67-8P 918523-68-9P 918523-70-3P 918523-71-4P 918523-72-5P
    918523-73-6P 918523-76-9P 918523-77-0P 918523-78-1P 918523-79-2P
    918523-80-5P 918523-81-6P 918523-82-7P 918523-83-8P 918523-84-9P
    918523-85-0P 918523-86-1P 918523-87-2P 918523-88-3P 918523-89-4P
    918523-90-7P 918523-91-8P 918523-92-9P 918523-93-0P 918523-94-1P
    918523-95-2P 918523-96-3P 918523-98-5P 918523-99-6P 918524-01-3P
    918524-02-4P 918524-03-5P 918524-04-6P 918524-05-7P 918524-06-8P
    918524-07-9P 918524-08-0P
                                918524-09-1P 918524-11-5P 918524-12-6P
                 918524-14-8P
                                918524-15-9P 918524-16-0P
                                                             918524-17-1P
    918524-13-7P
                 918524-19-3P
                                               918524-21-7P
                                                              918524-22-8P
    918524-18-2P
                                  918524-20-6P
                                                              918524-27-3P
    918524-23-9P
                   918524-24-0P
                                  918524-25-1P
                                                918524-26-2P
                                918524-32-0P
                                                              918524-37-5P
    918524-28-4P
                   918524-31-9P
                                                918524-33-1P
    918524-44-4P
                   918524-45-5P
                                  918524-46-6P
                                                918524-50-2P
                                                               918524-52-4P
                   918524-54-6P
    918524-53-5P
                                  918524-55-7P
                                                918524-56-8P
                                                               918524-57-9P
    918524-58-0P
                   918524-59-1P
                                 918524-60-4P
                                               918524-61-5P
                                                               918524-62-6P
    918803-34-6P
                  918803-35-7P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of pyrrolopyridine derivs. as protein kinase
       inhibitors useful in treatment of diseases)
ΙT
    7782-44-7, Oxygen, biological studies
    RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
    unclassified); BIOL (Biological study)
        (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful
       in treatment of diseases)
ΙT
    79079-06-4, EGFR kinase 98037-52-6, Abl protein kinase 103843-29-4,
    IGF1R kinase
                 108891-60-7 111694-09-8 114051-78-4, LCK kinase
    136396-12-8
                 137632-03-2, Met kinase 137632-06-5, Csk kinase
    137632-08-7, Erk2 kinase 138359-29-2, c-KIT kinase 138674-26-7,
    Protein kinase Syk 139691-76-2, c-Raf-1 141349-86-2, Cdk2 kinase
    141349-87-3, Fyn kinase 141349-89-5, Src kinase 141349-91-9, Yes
    protein kinase 141350-03-0, Flt1 kinase 141436-78-4, Protein kinase
         144114-16-9, Fak kinase 144376-45-4, Pim1 kinase
    144638-77-7, Flt4 kinase 144697-16-5, B-Raf kinase 145539-86-2, HCK
            146279-92-7, Ret kinase
                                      146838-30-4, MAPKAPK2 147014-96-8,
    CDK5 kinase 147014-97-9, CDK4 kinase 147230-71-5, Flt3 kinase
    148047-29-4, Tie 2 kinase 148047-34-1, Protein kinase Zap70 148640-14-6, Akt 1 kinase 149147-12-6, Btk kinase 150027-21-7
    150316-14-6, Mitogen-activated protein kinase kinase 2 150977-45-0, Kdr
           151662-26-9, Itk kinase 152478-56-3, Jak1 kinase 152478-57-4,
    kinase
    Jak2 kinase 152743-99-2, Her4 kinase 152787-58-1, Protein kinase TrkA 154907-65-0, CHK1 kinase 157482-36-5, Jak3 kinase 165245-96-5, p38
             165245-99-8, Polo like kinase 1 166433-56-3, Anaplastic
    Kinase
    lymphoma kinase 170780-46-8, Pyk2 kinase 176023-60-2, Akt2 kinase
    182238-33-1, Gene Ron protein kinase 182938-07-4, Protein kinase ROCK1
    182938-08-5, Protein kinase ROCK2 191359-13-4, Mnk1 kinase
    191808-15-8, 3-Phosphoinositide dependent protein kinase-1 205265-41-4,
    Akt3 kinase 250649-03-7, Protein kinase MLK1 270086-00-5, Pim3 kinase
    289898-51-7, Jnk1 kinase 289899-93-0, Jnk2 kinase 291756-39-3, Jnk3
```

protein kinase inhibitors useful in treatment of diseases)

```
303014-92-8, CDK6 kinase 362517-43-9, IKK-\beta kinase
    kinase
    370088-29-2, Mitogen-activated protein kinase kinase kinase 4
                 420790-04-1, Pim2 kinase 428817-87-2, Irak4 kinase
    372092-80-3
    443900-95-6, Glycogen synthase kinase 3\beta
                                              458560-40-2, Protein
    kinase Stk6
                 553648-93-4, Glycogen synthase kinase 3\alpha
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful
        in treatment of diseases)
                                        13358-73-1
ΙΤ
    348-62-9, 4-Chloro-2-fluorophenol
    RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful
        in treatment of diseases)
ΙΤ
    9004-10-8, Insulin, biological studies
    RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
    unclassified); BIOL (Biological study)
        (resistance; preparation of pyrrolopyridine derivs. as protein kinase
        inhibitors useful in treatment of diseases)
    918505-72-3P
                  918511-37-2P
ΤТ
    RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
    preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (starting material, drug candidate; preparation of pyrrolopyridine derivs.
        as protein kinase inhibitors useful in treatment of diseases)
    56741-33-4P 70205-04-8P 79418-77-2P 918523-55-4P 918523-69-0P
ΙT
    918523-74-7P 918523-75-8P
                                  918523-97-4P
                                                 918524-00-2P 918524-30-8P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (starting material, intermediate; preparation of pyrrolopyridine derivs. as
       protein kinase inhibitors useful in treatment of diseases)
    62-53-3, Aniline, reactions 94-99-5, 2,4-Dichlorobenzyl chloride
ΤТ
    96-33-3, Methyl acrylate 98-09-9, Benzenesulfonyl chloride
    3,4-Dichlorobenzenesulfonyl chloride 98-59-9,
    4-Methylbenzenesulfonyl chloride
                                      98-60-2, 4-Chlorobenzenesulfonyl
    chloride
               98-68-0, 4-Methoxybenzenesulfonyl chloride 98-80-6,
    Phenylboronic acid 99-61-6, 3-Nitrobenzaldehyde 100-37-8,
    2-(Diethylamino)ethanol 100-39-0, Benzyl bromide
                                                        100-46-9,
    Benzylamine, reactions 100-55-0, 3-Pyridinemethanol 103-71-9, Phenyl
    isocyanate, reactions 104-12-1, 4-Chlorophenyl isocyanate 106-41-2,
     4-Bromophenol
                   107-10-8, 1-Propanamine, reactions
                                                        109-01-3 109-73-9,
    1-Butanamine, reactions 109-85-3, 2-Methoxyethylamine
                                                             109-86-4,
    2-Methoxyethanol 110-68-9, N-Methylbutanamine 110-91-8, Morpholine,
    reactions 111-36-4, Butyl isocyanate 120-83-2, 2,4-Dichlorophenol
    121-32-4, 3-Ethoxy-4-hydroxybenzaldehyde 121-33-5, 4-Hydroxy-3-
    methoxybenzaldehyde 121-60-8, 4-(Acetylamino)phenylsulfonyl chloride
    123-08-0, 4-Hydroxybenzaldehyde
                                     133-59-5, 2-Methylbenzenesulfonyl
    chloride 140-75-0, 4-Fluorobenzylamine 271-63-6, 7-Azaindole
    327-78-6, 4-Chloro-3-trifluoromethylphenyl isocyanate 329-01-1,
    3-Trifluoromethylphenyl isocyanate 349-88-2, 4-Fluorobenzenesulfonyl
    chloride 367-25-9, 2,4-Difluoroaniline 367-27-1, 2,4-Difluorophenol
    371-40-4, 4-Fluoroaniline 402-49-3, 1-Bromomethyl-4- (trifluoromethyl)benzene 404-71-7, 3-Fluorophenyl isocyanate
                                    444-30-4, 2-(Trifluoromethyl)phenol
    3-Fluoro-4-hydroxybenzaldehyde
    445-05-6, 5-Fluoro-2-methylbenzenesulfonyl chloride
                                                          445-26-1,
    1-(2-Fluorophenyl) ethanol 446-51-5, 2-Fluorobenzyl alcohol 501-30-4
    501-53-1, Benzyl chloroformate 541-41-3, Ethyl chloroformate
                            586-95-8, 4-Pyridinemethanol
    Ethyl 3-aminobenzoate
                                                           586-98-1,
    2-Pyridinemethanol 603-80-5, 3-Hydroxy-2-methylbenzoic acid
                                                                    614-68-6,
    2-Methylphenyl isocyanate 621-29-4, 3-Methylphenyl isocyanate
    622-40-2, N-(2-Hydroxyethyl)morpholine 622-58-2, 4-Methylphenyl
                 622-95-7 623-24-5, 1,4-Bis(bromomethyl)benzene
    isocyanate
    4-Methylpiperidine 701-27-9, 3-Fluorobenzenesulfonyl chloride
```

```
701-34-8, 4-Bromobenzenesulfonamide 766-00-7, 2-Cyclopentylethanol
766-80-3, 3-Chlorobenzyl bromide 767-05-5, 3-Cyclopentylpropanol
768-35-4, 3-Fluorophenylboronic acid 777-44-6, 3-
Trifluoromethylphenylsulfonyl chloride 824-94-2, 4-Methoxybenzyl
          1003-03-8, Aminocyclopentane 1074-86-8, Indole-4-
chloride
                1122-71-0, 6-Methylpyridine-2-methanol
                                                         1138-56-3,
carboxaldehyde
4-Butoxybenzenesulfonyl chloride 1195-45-5, 4-Fluorophenylisocyanate
1483-28-9, 2,5-Dimethoxybenzenesulfonyl chloride 1548-13-6,
4-Trifluoromethylphenyl isocyanate 1679-18-1, 4-Chlorophenylboronic acid
1692-15-5, Pyridine-4-boronic acid 1692-25-7, Pyridine-3-boronic acid
1765-93-1, 4-Fluorophenylboronic acid 1777-82-8, 2,4-Dichlorobenzyl
alcohol 1899-93-0, 3-Methylbenzenesulfonyl chloride 1996-41-4,
2-Chloro-4-fluorophenol 2038-03-1, N-(2-Aminoethyl)morpholine
2124-55-2, Indole-4-carboxylic acid 2386-60-9, Butanesulfonyl chloride
2420-16-8, 3-Chloro-4-hydroxybenzaldehyde 2426-87-1,
4-Benzyloxy-3-methoxybenzaldehyde 2516-47-4, Cyclopropylmethylamine
2713-31-7, 2,5-Difluorophenol 2905-21-7, 2-Fluorobenzenesulfonyl
chloride 2909-38-8, 3-Chlorophenyl isocyanate 2991-42-6,
4-Trifluoromethylbenzenesulfonyl chloride 3173-56-6, Benzyl isocyanate
3391-10-4, 1-(4-Chlorophenyl)ethanol 3445-11-2, N-(2-
Hydroxyethyl)pyrrolidin-2-one 3954-13-0, Pentyl isocyanate 4441-30-9,
N-(3-Hydroxypropyl)morpholine 4595-59-9, 5-Bromopyrimidine
                                                              4747-71-1,
Isocyanatocyclopentane 4857-04-9, 2-Chloromethyl-1H-benzimidazole
5180-79-0, 3-Isocyanatobenzovl chloride <math>5345-54-0, 3-Chloro-4-
methoxyaniline 5416-93-3, 4-Methoxyphenyl isocyanate
4-Methoxyphenylboronic acid 6482-24-2, 1-Bromo-2-methoxyethane
7304-32-7, 2-Fluoro-5-nitrobenzoic acid 10130-74-2, 3-
Methoxybenzenesulfonyl chloride 10147-36-1, 1-Propanesulfonyl chloride
10147-37-2, 2-Propanesulfonyl chloride 10365-98-7, 3-Methoxyphenylboronic acid 13360-63-9, N-Ethylbutanamine
                                                            13918-92-8,
2,4-Difluorobenzenesulfonyl chloride 13952-84-6, 2-Butanamine
15268-31-2, Pyridin-3-yl isocyanate 15854-87-2, 4-Iodopyridine
16315-59-6, 4-Dimethylaminophenyl isocyanate 16629-19-9,
2-Thiophenesulfonyl chloride 16712-69-9, 4-Ethylbenzenesulfonyl chloride
17334-08-6, 1-Methylimidazole-2-methanol 17739-45-6,
2-(2-Bromoethoxy)tetrahydropyran 18278-34-7, 4-Hydroxy-2-
methoxybenzaldehyde 18908-07-1, 3-Methoxyphenyl isocyanate
                                                               19463-48-0,
3-Chloro-4-hydroxy-5-methoxybenzaldehyde 20443-98-5, 2,6-Dichlorobenzyl
          20984-81-0, 3-(Diethylamino)pyrrolidine 23095-31-0,
3,4-Dimethoxybenzenesulfonyl chloride 23616-57-1, 3-Iodo-7-azaindole
24677-78-9, 2,3-Dihydroxybenzaldehyde 27086-19-7, Dipropyl carbamoyl
chloride
          28439-86-3, 4-Butoxyphenyl isocyanate 28611-39-4,
4-Dimethylaminophenylboronic acid 35856-62-3, 1-Piperidinesulfonyl
chloride 37527-66-5, 3,4-Dimethoxyphenyl isocyanate 38070-73-4
39893-50-0, 3-Chloro-4-trifluoromethylphenyl isocyanate 42170-95-6,
2-Methoxyethyl isocyanate 42601-04-7, 3,4-Difluorophenyl isocyanate
49584-26-1, 4-Cyanophenylsulfonyl chloride 50382-32-6,
2,4-Dimethylthiazole-5-methanol 50528-86-4, 2-Chloro-5-
trifluoromethylphenyl isocyanate 50824-04-9, 4-Bromo-2-
(trifluoromethyl)phenol 51175-71-4, 3-Thiophenesulfonyl chloride
51488-22-3, 2-Chloro-4-trifluoromethylphenyl isocyanate
                                                          52130-17-3,
3-Amino-2-methylbenzoic acid 53104-95-3, 4-Hydroxy-3-
                                54751-01-8, 4-Bromomethylpyridine
(trifluoromethoxy) benzaldehyde
54997-90-9, 4-Isopropylbenzenesulfonyl chloride
                                                 55052-28-3,
4-Chloro-7-azaindole 56456-47-4, 2,4-Difluorobenzyl alcohol
56456-49-6, 4-Chloro-2-fluorobenzyl alcohol 56542-67-7, 3-Cyanobenzenesulfonyl chloride 56962-11-9, 2-Chloro-4-hydroxybenzaldehyde 57012-20-1 57946-56-2, 4-Chloro-2-fluoroaniline
61672-75-1
           63503-60-6, 3-Chlorophenylboronic acid 63624-28-2,
2,4-Dimethoxybenzenesulfonyl chloride 63758-12-3 69360-26-5,
2-Cyanobenzenesulfonyl chloride 69816-05-3 70067-45-7 71189-18-9
```

```
71916-82-0, 4-Chloro-2-fluorobenzyl bromide 71924-62-4 72975-46-3
    79418-78-3, 3-Fluoro-4-hydroxy-5-methoxybenzaldehyde
                                                        80466-80-4
    86718-08-3
               89599-01-9, 3-Bromobenzenesulfonamide 90001-64-2,
    Benzothiophene-2-sulfonyl chloride
                                        90260-13-2, 3-Fluoro-4-
    methylbenzenesulfonyl chloride 97272-04-3, 2,5-Dimethylthiophene-3-
                       108679-71-6, 3-Amino-2-chlorobenzoic acid
    sulfonvl chloride
    123088-59-5, 4-Aminocarbonylphenylboronic acid 128796-39-4,
                                                      151411-98-2,
    4-Trifluoromethylphenylboronic acid
                                         137049-02-6
    2,4,6-Trifluorobenzyl bromide 151858-64-9
                                               152434-88-3 153912-60-8,
    1,5-Dimethylpyrazole-3-methanol 163105-89-3, 2-Methoxypyridine-5-boronic
          166964-26-7, 2,5-Dimethylfuran-3-sulfonyl chloride 168899-43-2
    179113-90-7, 3-Trifluoromethoxyphenylboronic acid
                                                     180200-86-6
    181124-40-3, 6-Benzothiazolesulfonyl chloride 183208-35-7,
    5-Bromo-7-azaindole 190774-52-8, 2-Fluoro-3-trifluoromethylphenyl
    isocyanate 197239-49-9, 2-Fluoro-4-trifluoromethylbenzyl alcohol
    208186-84-9, 2-Chloro-4-fluorobenzyl alcohol 210532-25-5,
    3,5-Difluorobenzenesulfonyl chloride 306936-35-6 321309-40-4
    337508-66-4 351003-34-4, 4-Difluoromethoxybenzenesulfonyl chloride
    351422-73-6, 3-Aminocarbonylphenylboronic acid 364794-80-9
    373384-18-0, 3-(Methylsulfonyl)phenylboronic acid 380430-52-4
    386704-04-7
                 388088-73-1
                               389621-84-5
                                            405520-68-5
                                                           423151-49-9
    445264-61-9
                  485799-04-0
                               551930-53-1
                                             628692-15-9
                                                           690632-68-9
    754214-56-7
                  757978-25-9
                               761446-44-0
                                             785785-59-3
                                                          852180-61-1
    852227-95-3
                  858116-95-7
                               909501-40-2
                                             911210-53-2,
                                           918519-69-4
    4-Cyano-3,5-dimethylphenylboronic acid
                                                         918523-07-6
    918524-34-2 918524-63-7 918524-64-8
                                             918524-65-9
                                                          918524-70-6
                               918524-73-9
    918524-71-7
                  918524-72-8
                                             918524-74-0
                                                          918524-75-1
                               918524-78-4
    918524-76-2 918524-77-3
                                            918524-83-1
                                                          918524-85-3
    918524-86-4
                918524-87-5
                               918524-88-6
    RL: RCT (Reactant); RACT (Reactant or reagent)
       (starting material; preparation of pyrrolopyridine derivs. as protein kinase
       inhibitors useful in treatment of diseases)
    918524-89-7 918524-90-0
                                           918524-92-2
                                                          918524-93-3,
                              918524-91-1
    4-Benzyloxy-2,6-difluorobenzaldehyde 918524-94-4 918524-95-5
    918524-96-6 918524-97-7
                               918524-99-9
                                             918525-00-5
                                                         918525-01-6
    918525-03-8
                  918525-04-9
                               918803-36-8
                                             918803-37-9
                                                          918803-38-0
    RL: RCT (Reactant); RACT (Reactant or reagent)
       (starting material; preparation of pyrrolopyridine derivs. as protein kinase
       inhibitors useful in treatment of diseases)
    918919-61-6 918919-62-7
                               918919-63-8
                                           918919-64-9
                                                         918919-65-0
    918919-66-1 918919-67-2
                               918919-68-3 918919-69-4 918919-70-7
    918919-71-8 918919-72-9
                              918919-73-0 918919-74-1 918919-75-2
    918919-76-3 918919-77-4
                              918919-78-5 918919-79-6 918919-80-9
    918919-81-0 918919-82-1
                               918919-83-2
                                           918919-84-3 918919-85-4
                               918919-88-7
    918919-86-5 918919-87-6
                                           918919-89-8 918919-90-1
    918919-91-2 918919-92-3
                                           918919-94-5 918919-95-6
                               918919-93-4
    918919-96-7 918919-97-8
                               918919-98-9
                                           918919-99-0 918920-00-0
    918920-01-1 918920-02-2
                                           918920-04-4
                                                         918920-05-5
                               918920-03-3
                918920-07-7
                                            918920-09-9
    918920-06-6
                               918920-08-8
                                                         918920-10-2
    918920-11-3
                 918920-12-4
                               918920-13-5
                                             918920-14-6
                                                          918920-15-7
    918920-16-8
                  918920-17-9
                               918920-18-0
                                             918920-19-1
                                                          918920-20-4
    918920-21-5
                  918920-22-6
                               918920-23-7
                                             918920-24-8
                                                          918920-25-9
    918920-26-0
                  918920-27-1
                               918920-28-2
                                             918920-29-3
                                                          918920-30-6
    918920-31-7
                  918920-32-8
                               918920-33-9
    RL: PRP (Properties)
        (unclaimed sequence; pyrrolo[2,3-b]pyridine derivs. as protein kinase
       inhibitors and their preparation, pharmaceutical compns. and use in the
       treatment of diseases)
RE.CNT 8
             THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

(1) Aadal, N; WO 2004016610 A 2004 CAPLUS

ΙT

ΙT

RE

```
(2) Barton; TETRAHEDRON 1987, V43(2), P323 CAPLUS
```

- (3) Bayer Ag; DE 2413258 A1 1975 CAPLUS
- (4) Curtin; J MED CHEM 1998, V41, P74 CAPLUS
- (5) Heacock; J AM CHEM SOC 1960, V82, P3460 CAPLUS
- (6) Langham; J AM CHEM SOC 1941, V63, P545 CAPLUS
- (7) Normington, J; US 2234705 A 1941 CAPLUS
- (8) Pierce; J AM CHEM SOC 1942, V64, P1691

## L32 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)

RN 115926-52-8 CAPLUS

CN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME)

## \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

ACCESSION NUMBER: 2006:1252615 CAPLUS

DOCUMENT NUMBER: 146:7952

TITLE: Preparation of 4,5'-bithiazole and

4-(oxazol-5-yl)thiazole derivatives as

phosphoinositide-3 kinase inhibitors with therapeutic

uses

INVENTOR(S): Quattropani, Anna; Dorbais, Jerome; Covini, David;

Desforges, Gwenaelle; Rueckle, Thomas

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N. V., Neth.

Antilles

SOURCE: PCT Int. Appl., 149pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT 1	NO.		KIND DATE				APPLICATION NO.						DATE				
WO 2006:				A1 20061130			WO 2006-EP62595										
₩:	AE, AG	, AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
	CN, CO	, CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
	GE, GH	, GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚM,	KN,	KP,	KR,		
	KZ, LC	, LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,		
	MZ, NA	, NG,	NΙ,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,		
	SG, SK	, SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,		
	VN, YU	, ZA,	ZM,	ZW													
RW:	AT, BE	, BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	IE,		
	IS, IT	, LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,		
	CF, CG	, CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG,	BW,	GH,		
	GM, KE	, LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	BY,		
	KG, KZ	, MD,	RU,	ΤJ,	$^{\mathrm{TM}}$												
AU 20062	AU 2006251159					1130	AU 2006-251159										
CA 26073	385		A1		2006	1130	CA 2006-2607385						20060524				
EP 18885	546		A1	20080220			EP 2006-777240										
R:	AT, BE	, BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	IE,		
	IS, IT	, LI,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	AL,		
	BA, HR	, MK,	ΥU														
MX 2007	А	20080215				MX 2007-14883						20071126					
NO 2007		20071219				NO 2007-6557						20071219					
	KR 2008015119					A 20080218				KR 2007-729932							
IORITY APPI	ORITY APPLN. INFO.:								EP 2005-104394					A 20050524			
						US 2			-			0050					
						WO 2	006-:	EP62	595	1	W 2	0060	524				

```
MARPAT 146:7952
OTHER SOURCE(S):
    2006:1252615 CAPLUS
AN
DN
     146:7952
     Entered STN: 01 Dec 2006
ED
TΙ
     Preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivatives as
     phosphoinositide-3 kinase inhibitors with therapeutic uses
IN
     Quattropani, Anna; Dorbais, Jerome; Covini, David; Desforges, Gwenaelle;
     Rueckle, Thomas
PA
     Applied Research Systems Ars Holding N. V., Neth. Antilles
     PCT Int. Appl., 149pp.
SO
     CODEN: PIXXD2
DT
     Patent
     English
LA
CC
     28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
     Section cross-reference(s): 1
FAN.CNT 1
                                             APPLICATION NO.
     PATENT NO.
                         KIND DATE
                                                                       DATE
                         ____
                                               ______
     WO 2006125805
                          A1 20061130 WO 2006-EP62595
                                                                      20060524
PΙ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
              VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
              CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
              GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM
     AU 2006251159 A1 20061130
                                              AU 2006-251159
                                                                       20060524
                                            CA 2006-251139
CA 2006-2607385
EP 2006-777240
     CA 2607385
                           A1
                                  20061130
                                                                       20060524
                                 20080220
                                            EP 2006-777240
     EP 1888546
                           Α1
                                                                        20060524
         R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
              BA, HR, MK, YU
                                                                      20071126
     MX 200714883 A
                                20080215
                                              MX 2007-14883
     NO 2007006557
                          Α
                                20071219
                                              NO 2007-6557
                                                                       20071219
NO 2007006557 A 20071219

KR 2008015119 A 20080218

PRAI EP 2005-104394 A 20050524

US 2005-686270P P 20050601

WO 2006-EP62595 W 20060524
                                              KR 2007-729932
                                                                       20071221
CLASS
             CLASS PATENT FAMILY CLASSIFICATION CODES
 PATENT NO.
 _____
 WO 2006125805 IPCI
                         C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56
                         [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A];
                         C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00
                          [I,C*]; C07D0493-08 [I,A]; C07D0493-00 [I,C*];
                         A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454
                          [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A];
                          A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377
                          [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A];
                         A61P0009-00 [I,A]; A61P0025-00 [I,A]
                         C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                  IPCR
                          [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C];
                         A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454
                         [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];
                         A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375
                          [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];
```

```
A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00
                       [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
                       C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00
                       [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C];
                       C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
                ECLA
                       C07D277/46; C07D277/48; C07D417/14;
                       C07D491/10+317B+221B; C07D498/04+317C+265C
AU 2006251159
                IPCI
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                       [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C];
                       A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454
                       [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];
                       A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375
                       [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];
                       A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00
                       [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
                       C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00
                       [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C];
                       C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
                IPCR
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                       [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C];
                       A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454
                       [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];
                       A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375
                       [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];
                       A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00
                       [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
                       C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00
                       [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C];
                       C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
                ECLA
                       C07D277/46; C07D277/48; C07D417/14;
                       C07D491/10+317B+221B; C07D498/04+317C+265C
CA 2607385
                IPCI
                       A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A];
                       A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377
                       [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A];
                       A61P0009-00 [I,A]; A61P0025-00 [I,A]; C07D0277-46
                       [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A];
                       C07D0277-00 [I,C*]; C07D0417-14 [I,A]; C07D0417-00
                       [I,C*]; C07D0491-10 [I,A]; C07D0491-00 [I,C*];
                       C07D0493-08 [I,A]; C07D0493-00 [I,C*]
                IPCR
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                       [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C];
                       A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454
                       [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];
                       A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375
                       [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C];
                       A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00
                       [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
                       C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00
                       [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C];
                       C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A]
EP 1888546
                IPCI
                       C07D0277-46 [I,A]; C07D0277-48 [I,A]; C07D0277-56
                       [I,A]; C07D0277-00 [I,C*]; C07D0417-14 [I,A];
                       C07D0417-00 [I,C*]; C07D0491-10 [I,A]; C07D0491-00
                       [I,C*]; C07D0493-08 [I,A]; C07D0493-00 [I,C*];
                       A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-496 [I,A];
                       A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-5377
                       [I,A]; A61K0031-5375 [I,C*]; A61K0031-553 [I,A];
                       A61P0009-00 [I,A]; A61P0025-00 [I,A]
                IPCR
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
```

[I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C]; A61K0031-433 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]; C07D0491-00 [I,C]; C07D0491-10 [I,A]; C07D0493-00 [I,C]; C07D0493-08 [I,A] C07D0277-46 [I,A]; A61K0031-427 [I,A]; A61K0031-433 [I,A]; A61K0031-454 [I,A]; A61K0031-4523 [I,C\*]; A61K0031-496 [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C\*]; A61K0031-553 [I,A]; A61P0025-00 [I,A]; A61P0009-00 [I,A]; C07D0277-48 [I,A]; C07D0277-56 [I,A]; C07D0277-00 [I,C\*]; C07D0417-14 [I,A]; C07D0417-00 [I,C\*]; C07D0491-10 [I,A]; C07D0491-00 [I,C\*]; C07D0493-08 [I,A]; C07D0493-00 [I,C\*] C07D0277-00 [I,C]; C07D0277-46 [I,A] C07D0277-00 [I,C]; C07D0277-46 [I,A] C07D277/46; C07D277/48; C07D417/14; C07D491/10+317B+221B; C07D498/04+317C+265C C07D0417-04 [I,A]; C07D0417-14 [I,A]; C07D0417-00 [I,C\*]; C07D0491-10 [I,A]; C07D0491-00 [I,C\*]

MARPAT 146:7952

MX 200714883

NO 2007006557

KR 2008015119

OS GI IPCI

IPCI

IPCR

ECLA

IPCI

AΒ The present invention is related to thiazole derivs. (shown as I; variables defined below; e.g. Et 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3thiazole-2-carboxylate) as well as geometrical isomers, optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries (no data). Although the methods of preparation are not claimed, prepns. and/or characterization data for .apprx.80 examples of I are included. For example, Et 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate was prepared in 46 % yield by cyclizing N-[5-(bromoacetyl)-4-methyl-1,3thiazol-2-yl]acetamide (preparation given) with Et thiooxamate in dioxane. For I: R1 = -C(0)R5, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl C1-C6-alkyl, heteroaryl C1-C6-alkyl, C3-C8 cycloalkyl C1-C6-alkyl and heterocycloalkyl C1-C6-alkyl; R2 = H, halogen, C1-C6-alkyl, C2-C6-alkenyl and C2-C6-alkynyl; R3 = H, halogen, C1-C6-alkyl, C2-C6-alkenyl and C2-C6-alkynyl; R4 = -C(0)R6, aryl, heteroaryl, heterocycloalkyl and C3-C8cycloalkyl; R5 = H, hydroxy, alkoxy, amino, aryl, heteroaryl, C3-C8 cycloalkyl and heterocycloalkyl; R6 = H, C1-C6-alkyl, C2-C6-alkenyl,

```
C2-C6-alkynyl, aryl C1-C6-alkyl, heteroaryl C1-C6-alkyl and amino; X = S
     and O. IC50 values for inhibition of PI3K\gamma-induced lipid and/or
     PI3K-induced Akt/PKB phosphorylation are tabulated for 12 examples of I.
    thiazole deriv prepn PI3 kinase inhibitor therapeutic use; bithiazole
ST
     oxazolylthiazole prepn PI3 kinase inhibitor therapeutic use
     Nervous system, disease
ΙT
        (Huntington's chorea; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
ΙT
     Sarcoma
        (Kaposi's; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
     Enzymes, biological studies
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (PI3 kinase \gamma, inhibitors; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
ΙT
     Fibrosis
        (anaphylactic shock; preparation of 4,5'-bithiazole and 4-(oxazol-5-
        yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)
ΤТ
     Antiarteriosclerotics
        (antiatherosclerotics; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
ΙT
     Muscle, disease
        (atrophy; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs.
        as PI3 kinase inhibitors with therapeutic uses)
ΙT
     Infection
        (bacterial; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
     Lung, disease
ΙT
        (chronic obstructive pulmonary disease; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
     Nervous system, disease
ΙT
        (degeneration; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
     Nervous system agents
        (degenerative; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
     Ervthrocvte
        (disease, deficiency; preparation of 4,5'-bithiazole and
        4-(oxazol-5-vl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
ΤТ
     Lung, disease
        (endothelial and epithelial injuries; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
TΤ
     Blood, disease
        (erythrocyte, deficiency; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
ΙT
     Kidney, disease
        (fibrosis, progressive; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
ΙT
     Inflammation
     Kidney, disease
        (glomerulonephritis; preparation of 4,5'-bithiazole and 4-(oxazol-5-
        yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
    Muscle, disease
```

```
(hypertrophy; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
ΤТ
     Brain, disease
        (infection; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
     Lung, disease
ΙT
     Reperfusion
        (injury; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs.
        as PI3 kinase inhibitors with therapeutic uses)
ΙT
        (metastasis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
     Hypertrophy
        (muscular; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
     Heart, disease
        (myocyte dysfunction; preparation of 4,5'-bithiazole and
        4-(oxazol-5-yl)thiazole derivs. as PI3 kinase inhibitors with
        therapeutic uses)
ΙT
     Inflammation
     Lung, disease
        (pneumonitis; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
        derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
    Allergy
     Allergy inhibitors
     Alzheimer's disease
     Angiogenesis
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiasthmatics
    Antibacterial agents
    Antifibrotic agents
     Antihypertensives
    Antirheumatic agents
    Antitumor agents
    Antiviral agents
    Asthma
    Atherosclerosis
     Autoimmune disease
     Cardiac hypertrophy
     Cardiovascular agents
     Cardiovascular system, disease
     Encephalitis
    Glomerulosclerosis
     Human
     Hypertension
     Immunomodulators
     Inflammation
     Inflammatory bowel disease
       Ischemia
     Kidney, disease
     Melanoma
     Meningitis
    Multiple sclerosis
     Neoplasm
     Platelet aggregation
     Platelet aggregation inhibitors
     Psoriasis
     Respiratory system, disease
```

```
Rheumatoid arthritis
      Sepsis
      Stroke
      Thrombolytics
      Thrombosis
      Transplant and Transplantation
      Transplant rejection
      Vasoconstriction
          (preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3
         kinase inhibitors with therapeutic uses)
ΙT
          (pulmonary; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
         derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
      Fibrosis
          (renal, progressive; preparation of 4,5'-bithiazole and 4-(oxazol-5-
         yl)thiazole derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
      Injury
          (reperfusion; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
         derivs. as PI3 kinase inhibitors with therapeutic uses)
ΤТ
      Lupus erythematosus
          (systemic; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
         derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
      Central nervous system, disease
          (trauma; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs.
         as PI3 kinase inhibitors with therapeutic uses)
      Infection
ΙT
         (viral; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs.
         as PI3 kinase inhibitors with therapeutic uses)
ΙT
      915702-31-7P, Ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-
      carboxylate 915702-33-9P, N-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-
      thiazol-2'-yl]acetamide 915702-34-0P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-
      1,3-thiazole-2-carboxylic acid 915702-64-6P, 5-[[[2'-(Acetylamino)-4'-
      methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid
      915702-68-0P, 2'-(Acetylamino)-4'-methyl-N-[4-(1H-tetrazol-5-yl)phenyl]-
      4,5'-bi-1,3-thiazole-2-carboxamide
                                                 915702-70-4P, N-[4'-Methyl-2-[(2H-
      tetrazol-5-yl)methyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide
                                                                             915702-74-8P,
      1-[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
      yl]carbonyl]piperidine-4-carboxylic acid
                                                        915702-88-4P,
      2'-(Acetylamino)-N-(1H-1,2,3-benzotriazol-5-yl)-4'-methyl-4,5'-bi-1,3-
      thiazole-2-carboxamide
                                   915702-92-0P, 4-[[[2'-(Acetylamino)-4'-methyl-
      4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-hydroxybenzoic acid
      915702-94-2P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
      yl]carbonyl]amino]-2-fluorobenzoic acid
                                                      915702-96-4P,
      2'-(Acetylamino)-N-[3-(5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-
      4,5'-bi-1,3-thiazole-2-carboxamide 915702-98-6P, 2'-(Acetylamino)-N-[4-
      (5-hydroxy-1,3,4-oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-yl)phenyl
      carboxamide 915703-28-5P, tert-Butyl 4-[[2-(cyanomethyl)-4'-methyl-4,5'-
      bi-1,3-thiazol-2'-yl]amino]-4-oxobutanoate 915703-29-6P, Methyl
      5-[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-5-
      oxopentanoate
      RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
      preparation); THU (Therapeutic use); BIOL (Biological study); PREP
      (Preparation); RACT (Reactant or reagent); USES (Uses)
          (drug candidate; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
         derivs. as PI3 kinase inhibitors with therapeutic uses)
ΙT
      915702-32-8P, 2'-(Acetylamino)-N-allyl-4'-methyl-4,5'-bi-1,3-thiazole-2-
      carboxamide
                      915702-35-1P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-
      thiazole-2-carboxylic acid potassium salt
                                                         915702-36-2P,
      2'-(Acetylamino)-N-(2-methoxyethyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-
                      915702-37-3P, 2'-(Acetylamino)-4'-methyl-N-(tetrahydrofuran-
      carboxamide
```

Respiratory system agents

```
2-ylmethyl)-4,5'-bi-1,3-thiazole-2-carboxamide 915702-38-4P,
2'-(Acetylamino)-N-[2-(dimethylamino)ethyl]-4'-methyl-4,5'-bi-1,3-thiazole-
2-carboxamide
               915702-39-5P, N-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-
4,5'-bi-1,3-thiazol-2'-yl] acetamide 915702-40-8P, N-[4'-Methyl-2-[(4-1)]
methylpiperazin-1-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide
915702-41-9P, N-[4'-Methyl-2-[(4-methylpiperazin-1-yl)carbonyl]-4,5'-bi-
1,3-thiazol-2'-yl]acetamide mono(trifluoroacetate) 915702-42-0P,
2'-(Acetylamino)-N-[3-(dimethylamino)propyl]-4'-methyl-4,5'-bi-1,3-
thiazole-2-carboxamide 915702-43-1P, 2'-(Acetylamino)-N-[3-
(dimethylamino)propyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide
mono(trifluoroacetate) 915702-44-2P, 2'-(Acetylamino)-N-(2-hydroxyethyl)-
4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-45-3P,
2'-(Acetylamino)-N-(2-cyanoethyl)-4'-methyl-4,5'-bi-1,3-thiazole-2-
carboxamide 915702-46-4P, 2'-(Acetylamino)-4'-methyl-N-(1H-tetrazol-5-
yl)-4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-48-6P,
4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
yl]carbonyl]amino]benzoic acid potassium salt 915702-49-7P,
3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
yl]carbonyl]amino]benzoic acid potassium salt 915702-50-0P,
2'-(Acetylamino)-4'-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-4,5'-bi-1,3-
thiazole-2-carboxamide potassium salt 915702-51-1P, 2'-(Acetylamino)-N-
benzyl-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-52-2P,
2'-(Acetylamino)-4'-methyl-N-propyl-4,5'-bi-1,3-thiazole-2-carboxamide
915702-53-3P, 2'-(Acetylamino)-4'-methyl-N-[4-(1H-tetrazol-5-yl)phenyl]-
4,5'-bi-1,3-thiazole-2-carboxamide potassium salt 915702-56-6P,
3-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-
hydroxybenzoic acid potassium salt 915702-58-8P, 1-[[2'-(Acetylamino)-4'-
methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]piperidine-3-carboxylic acid
915702-60-2P, 5-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
yl]carbonyl]amino]-2-hydroxybenzoic acid potassium salt
                                                       915702-66-8P,
N-[4'-Methyl-2-[(2H-tetrazol-5-yl)methyl]-4,5'-bi-1,3-thiazol-2'-
yl]acetamide potassium salt
                             915702-72-6P, 1-[[2'-(Acetylamino)-4'-methyl-
4,5'-bi-1,3-thiazol-2-yl]carbonyl]piperidine-4-carboxylic acid potassium
      915702-76-0P, 2'-(Acetylamino)-N-[3-(5-amino-1,3,4-thiadiazol-2-
yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915702-78-2P,
N-[2-[(3-Hydroxypiperidin-1-y1)carbony1]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
yl]acetamide 915702-80-6P, N-[2-[[4-(Hydroxymethyl)piperidin-1-
yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide
N-[2-[4-(2-Hydroxyethyl)piperidin-1-yl]carbonyl]-4'-methyl-4,5'-bi-1,3-
thiazol-2'-yl]acetamide 915702-84-0P, N-[2-[(4-Hydroxypiperidin-1-
yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide
                                                           915702-86-2P,
2'-(Acetylamino)-N-(1H-1,2,3-benzotriazol-5-yl)-4'-methyl-4,5'-bi-1,3-
thiazole-2-carboxamide potassium salt
                                       915702-90-8P, 4-[[[2'-
(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-
hydroxybenzoic acid potassium salt 915702-93-1P, 4-[[2'-(Acetylamino)-
4'-methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]-2-fluorobenzoic acid
               915702-95-3P, 2'-(Acetylamino)-N-[3-(5-hydroxy-1,3,4-
potassium salt
oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide
                915702-97-5P, 2'-(Acetylamino)-N-[4-(5-hydroxy-1,3,4-
potassium salt
oxadiazol-2-yl)phenyl]-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide
potassium salt
               915702-99-7P, N-[2-(Hydroxymethyl)-4'-methyl-4,5'-bi-1,3-
                        915703-00-3P, 1-(2-Methoxyethyl)-3-[4'-methyl-2-
thiazol-2'-yl]acetamide
[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]urea
                                                          915703-02-5P,
Ethyl N-[[4'-methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-
yl]amino]carbonyl]-β-alaninate
                               915703-03-6P, N-[2-[(1,4-Dioxa-8-
azaspiro[4.5]decan-8-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
yl]acetamide
              915703-04-7P, 2'-(Acetylamino)-N-(2,3-dihydroxypropyl)-4'-
methyl-4,5'-bi-1,3-thiazole-2-carboxamide 915703-05-8P,
1-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]urea
915703-06-9P, N-[4'-Methyl-2-[(3-oxopiperazin-1-yl)carbonyl]-4,5'-bi-1,3-
thiazol-2'-yl]acetamide 915703-07-0P, N-[4'-Methyl-2-[(4-oxopiperidin-1-
```

```
yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]acetamide
                                                                                                                                                   915703-08-1P,
N-[2-[(3-Hydroxypyrrolidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-thiazol-2'-bi-1,3-
                                           915703-09-2P, 2'-(Acetylamino)-4'-methyl-N-(2-propyn-1-yl)-
yl]acetamide
4,5'-bi-1,3-thiazole-2-carboxamide
                                                                                                        915703-10-5P, N-[2-[(4-
Acetylpiperazin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
                                           915703-11-6P, N, N-Dimethyl-N'-[[[4'-methyl-2-[(morpholin-4-
vllacetamide
yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]qlycinamide
915703-12-7P, N-[[[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-
thiazol-2'-yl]amino|carbonyl]-\beta-alanine 915703-13-8P,
N-[2-[(4-Fluoropiperidin-1-yl)carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
                                           915703-14-9P, N-[2-[[(1S,5S,7S)-7-(Hydroxymethyl)-6,8-dioxa-
yl]acetamide
3-azabicyclo[3.2.1]oct-3-yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-
yl]acetamide
                                           915703-15-0P, Ethyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-
1,3-thiazol-2'-yl]amino]carbonyl]-\beta-alaninate 915703-17-2P,
N-[2-[(1R,5R,7R)-7-(Hydroxymethyl)-6,8-dioxa-3-azabicyclo[3.2.1]oct-3-
yl]carbonyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-19-4P,
tert-Butyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-
                                                                                          915703-20-7P, [4'-Methyl-2'-
yl]amino]carbonyl]-\beta-alaninate
[(pyrazin-2-yl)amino]-4,5'-bi-1,3-thiazol-2-yl]acetonitrile
915703-22-9P, Ethyl 4'-methyl-2'-[(pyrazin-2-yl)amino]-4,5'-bi-1,3-
thiazole-2-carboxylate 915703-23-0P, [4'-Methyl-2'-[(1H-pyrazol-3-
yl)amino]-4,5'-bi-1,3-thiazol-2-yl]acetonitrile 915703-25-2P,
N-[4'-Methyl-2-[2-(morpholin-4-yl)-2-oxoethyl]-4,5'-bi-1,3-thiazol-2'-
yl]acetamide 915703-27-4P 915703-30-9P, Methyl 6-[[2-(cyanomethyl)-4'-
methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-6-oxohexanoate 915703-31-0P,
2'-(Acetylamino)-N,N,4'-trimethyl-4,5'-bi-1,3-thiazole-2-carboxamide
915703-32-1P, 2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-
carboxamide 915703-33-2P, 4-[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-
thiazol-2'-yl]amino]-4-oxobutanoic acid 915703-34-3P,
5-[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]-5-
oxopentanoic acid 915703-35-4P, tert-Butyl N-[[[2-(cyanomethyl)-4'-
methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]glycinate
                                                                                                                                                                             915703-36-5P,
tert-Butyl 4-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-
yl]amino]carbonyl]amino]butanoate 915703-37-6P, N'-[[[2-(Cyanomethyl)-4'-
methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N,N-dimethylglycinamide
915703-38-7P, tert-Butyl N-[[[4'-methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-
bi-1,3-thiazol-2'-yl]amino]carbonyl]-\beta-alaninate 915703-39-8P,
1-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3-yl]-3-[3
(morpholin-4-yl)-2-oxoethyl]urea
                                                                                                 915703-40-1P, 1-[2-(Cyanomethyl)-4'-
methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-(morpholin-4-yl)-2-oxoethyl]urea
915703-41-2P, Methyl N-[[[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-
yl]amino]carbonyl]-\beta-alaninate 915703-42-3P, N'-[[[2-(Cyanomethyl)-
4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N,N-diisopropyl-\beta-
alaninamide 915703-43-4P, N'-[[[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-
thiazol-2'-yl]amino]carbonyl]-N-(2-hydroxy-1,1-dimethylethyl)-\beta-
                                    915703-44-5P, N-(tert-Butyl)-N'-[[[2-(cyanomethyl)-4'-methyl-
alaninamide
4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-\beta-alaninamide
915703-45-6P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-
(2,2-dimethyl-1,3-thiazolidin-3-yl)-3-oxopropyl]urea 915703-46-7P,
1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-dimethyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[3-(4,4-
1,3-oxazolidin-3-yl)-3-oxopropyl]urea 915703-47-8P, N'-[[[2-
(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]amino]carbonyl]-N-(2,2-dimethylpropyl)glycinamide 915703-50-3P, 1-[3-(Azocan-1-yl)-3-oxopropyl]-
3-[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]urea
915703-52-5P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-3-[2-
                                                                                                                            915703-54-7P,
(1-isopropyl-1H-imidazol-4-yl)ethyl]urea
imidazol-4-yl)ethyl]urea
                                                                         915703-55-8P, 1-[2-(5-tert-Butyl-1,2,4-
oxadiazol-3-yl)ethyl]-3-[2-(cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4,5'-bi-1,3-thiazol-2'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-methyl-4'-
yl]urea 915703-56-9P, 1-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-
2'-y1]-3-[2-(5-isopropyl-1,2,4-oxadiazol-3-y1)ethy1]urea 915703-57-0P,
```

```
N-[4'-Methyl-2-[[5-(1-methylpiperidin-4-yl)-1,2,4-oxadiazol-3-yl]methyl]-
4,5'-bi-1,3-thiazol-2'-yl]acetamide 915703-58-1P, 2'-(Acetylamino)-4'-
methyl-N-(1H-tetrazol-5-yl)-4,5'-bi-1,3-thiazole-2-carboxamide
915703-59-2P, 4-[[[2'-(Acetylamino)-4'-methyl-4,5'-bi-1,3-thiazol-2-
yl]carbonyl]amino]benzoic acid 915703-60-5P, 3-[[[2'-(Acetylamino)-4'-
methyl-4,5'-bi-1,3-thiazol-2-yl]carbonyl]amino]benzoic acid
915703-61-6P, 2'-(Acetylamino)-4'-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-
4,5'-bi-1,3-thiazole-2-carboxamide 915703-62-7P, 3-[[[2'-(Acetylamino)-
4'-methyl-4,5'-bi-1,3-thiazol-2-yl|carbonyl|amino|-2-hydroxybenzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
   derivs. as PI3 kinase inhibitors with therapeutic uses)
115926-52-8, PI3 kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors; preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole
   derivs. as PI3 kinase inhibitors with therapeutic uses)
51-45-6, 2-(1H-Imidazol-4-yl)ethanamine, reactions 62-23-7,
4-Nitrobenzoic acid 75-30-9, 2-Iodopropane 75-64-9, tert-Butylamine,
          96-97-9, 2-Hydroxy-5-nitrobenzoic acid 97-72-3, Isobutyric
reactions
            99-05-8, 3-Aminobenzoic acid 100-46-9, Benzylamine,
anhydride
           107-10-8, N-Propylamine, reactions
reactions
                                               107-11-9, Allylamine
107-95-9, \beta-Alanine 108-00-9, 2-Dimethylaminoethylamine
                                                            108-18-9,
Diisopropylamine 109-01-3, 1-Methylpiperazine
                                                 109-55-7,
N,N-Dimethyl-1,3-propanediamine 109-85-3, 2-Methoxyethylamine 110-91-8, Morpholine, reactions 121-92-6, 3-Nitrobenzoic acid
124-68-5, 2-Amino-2-methyl-1-propanol 133-10-8, Sodium p-aminosalicylate
150-13-0, 4-Aminobenzoic acid 151-18-8, N-(2-Cyanoethyl)amine
177-11-7, 1,4-Dioxa-8-azaspiro[4.5]decane 446-31-1, 4-Amino-2-
fluorobenzoic acid
                    498-94-2, Isonipecotic acid 498-95-3, Nipecotic
      501-53-1, Benzyl chloroformate 570-23-0, 3-Aminosalicylic acid
acid
622-26-4, 4-Piperidineethanol 627-91-8 1121-92-2, Heptamethylenimine
          1694-29-7, 3-Chloro-2,4-pentanedione 1820-80-0,
1501-27-5
3-Aminopyrazole
                2237-30-1, 3-Aminobenzonitrile
                                                   2450 - 71 - 7,
Propargylamine
                 3196-73-4 3282-30-2, Trimethylacetyl chloride
3303-84-2, N-Boc-\beta-alanine 3325-11-9, 5-Aminobenzotriazole
4418-61-5, 5-Aminotetrazole 4530-20-5, Boc-glycine 4795-29-3,
Tetrahydrofurfurylamine 5049-61-6, 2-Aminopyrazine 5100-34-5, Ethyl
3-isocyanatopropionate
                         5382-16-1, 4-Hydroxypiperidine
                                                          5625-67-2,
Piperazin-2-one
                 5813-64-9, Neopentylamine 6456-74-2
                                                          6457-49-4,
4-(Hydroxymethyl)piperidine 6859-99-0, 3-Hydroxypiperidine
                                                              7357-70-2,
2-Cyanothioacetamide
                      13794-28-0, Ethyl 2-isocyanatopropionate
13889-98-0, 1-Acetylpiperazine
                               15026-17-2, Succinic acid mono-tert-butyl
       16982-21-1, Ethyl thiooxamate
                                      19351-18-9, 2,2-
Dimethylthiazolidine 22195-47-7, 2,2-Dimethyl-1,3-dioxolane-4-
             30748-47-1, 5-Acetyl-2-amino-4-methylthiazole
                                                              40499-83-0,
methanamine
                41979-39-9, 4-Piperidone hydrochloride 51200-87-4,
3-Pyrrolidinol
4,4-Dimethyloxazolidine 53588-95-7, tert-Butyl N-(2-cyanoethyl)carbamate
56414-96-1, 2-Amino-1-(morpholin-4-yl) ethanone
                                               58620-93-2,
\beta-Alanine tert-butyl ester hydrochloride
                                          58640-01-0, tert-Butyl
4-aminobutanoate hydrochloride 68947-43-3, N-Methyl-4-
piperidinecarboxylic acid
                            72410-06-1, 2-Thiocarbamoylacetamide
                                        78197-27-0, 4-Fluoropiperidine
73732-51-1, 5-(3-Aminophenyl)tetrazole
200634-33-9, Glycine dimethylamide acetate
                                             250137-96-3,
((1S, 5S, 7S) - 6, 8 - Dioxa - 3 - azabicyclo[3.2.1] oct - 7 - yl) methanol
                                                             915702-54-4,
4-(2H-Tetrazol-5-yl)aniline hydrochloride 915703-18-3,
((1R,5R,7R)-6,8-Dioxa-3-azabicyclo[3.2.1]oct-7-yl)methanol
                                                             915703-26-3,
3-(Morpholin-4-yl)-3-thioxopropionamide
RL: RCT (Reactant); RACT (Reactant or reagent)
   (preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3
```

ΙT

```
kinase inhibitors with therapeutic uses)
       618-94-0P, 3-Nitrobenzohydrazide 618-95-1P, Methyl 3-nitrobenzoate
ΤТ
                                                          636-97-5P, 4-Nitrobenzohydrazide
       619-50-1P, Methyl 4-nitrobenzoate
       6935-15-5P, 4-[[(Benzyloxy)carbonyl]amino]-2-hydroxybenzoic acid
                                                                                               31437-04-4P.
       14509-66-1P, 7,8-Dihydroimidazo[1,5-c]pyrimidin-5(6H)-one
       N-[[(Pyrazin-2-yl)amino]carbonothioyl]benzamide
                                                                                31437-05-5P,
       1-(Pyrazin-2-yl)thiourea
                                               32519-74-7P, N-[5-(Bromoacetyl)-4-methyl-1,3-
       thiazol-2-yl]acetamide 32519-75-8P, N-[5-(Bromoacetyl)-4-methyl-1,3-
       thiazol-2-yl]acetamide hydrobromide 34683-41-5P, N-[[(1H-Pyrazol-3-
       yl) amino] carbonothioyl] benzamide 39884-12-3P, N-(5-Acetyl-4-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-methyl-1,3-m
       thiazol-2-yl)acetamide 41125-77-3P, 5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-
                                                                              83725-80-8P,
              71274-46-9P, N,N-Diisopropyl-\beta-alaninamide
       5-(3-Nitropheny1)-1,3,4-oxadiazol-2-ol 94284-80-7P, 1-(2-Amino-4-methyl-
       1,3-thiazol-5-yl)-2-bromoethanone hydrobromide 98804-62-7P,
       7-(N-Cbz-amino)-2,2-dimethyl-4H-1,3-benzodioxin-4-one 113118-47-1P,
       5-(4-Aminophenyl)-1,3,4-oxadiazol-2-ol 115082-05-8P,
       5-(3-Aminophenyl)-1,3,4-oxadiazol-2-ol 209467-48-1P,
                                                   299171-15-6P, (2'-Amino-4'-methyl-4,5'-
       N-(tert-Butyl)-\beta-alaninamide
       bi-1,3-thiazol-2-yl)acetonitrile 299441-33-1P, 5-(3-Aminophenyl)-1,3,4-
       thiadiazol-2-amine 479408-49-6P, 2-(1-Ethyl-1H-imidazol-4-yl)ethanamine
       479408-51-0P, 2-(1-Isopropyl-1H-imidazol-4-yl)ethanamine 758715-91-2P,
       1-(1H-Pyrazol-3-yl)thiourea 842137-44-4P, 7-Amino-2,2-dimethyl-4H-1,3-
                                  842137-46-6P, 6-Amino-2,2-dimethyl-4H-1,3-benzodioxin-
       benzodioxin-4-one
                   847789-44-0P, N'-(tert-Butoxycarbonyl)-N-(tert-butyl)-\beta-
       alaninamide 915702-00-0P, 2-Bromo-1-[4-methyl-2-[(pyrazin-2-yl)amino]-
       1,3-thiazol-5-yl]ethanone hydrobromide 915702-01-1P,
       1-[4-Methyl-2-[(pyrazin-2-yl)amino]-1,3-thiazol-5-yl]ethanone
       hydrochloride
                             915702-02-2P, N-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-N-
       (pyrazin-2-yl)acetamide 915702-03-3P, 1-[2-[(1-Acetyl-1H-pyrazol-3-
       y1) amino] -4-methyl-1, 3-thiazol-5-y1] -2-bromoethanone hydrobromide
       915702-04-4P, 1-[4-Methyl-2-[(1H-pyrazol-3-yl)amino]-1,3-thiazol-5-
       yl]ethanone 915702-05-5P, N-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-N-(1-
       acetyl-1H-pyrazol-3-yl)acetamide 915702-06-6P,
       N-[2-(Cyanomethyl)-4'-methyl-4,5'-bi-1,3-thiazol-2'-yl]-1H-imidazole-1-
                          915702-07-7P, N-[4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-
       carboxamide
       bi-1,3-thiazol-2'-yl]-1H-imidazole-1-carboxamide 915702-08-8P, Ethyl
       2'-amino-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate
                                                                                         915702-10-2P,
       4'-Methyl-2-[(morpholin-4-yl)carbonyl]-4,5'-bi-1,3-thiazol-2'-amine
       mono(trifluoroacetate)
                                           915702-11-3P, 6-[Hydroxy(oxido)amino]-2,2-
       dimethyl-4H-1,3-benzodioxin-4-one 915702-14-6P, N3-(tert-Butoxycarbonyl)-
       N1, N1-diisopropyl-\beta-alaninamide 915702-15-7P, N1-(2-Hydroxy-1,1-
       dimethylethyl)-\beta-alaninamide
                                                   915702-16-8P, N3-(tert-Butoxycarbonyl)-
       N1-(2-hydroxy-1,1-dimethylethyl)-\beta-alaninamide
                                                                              915702-17-9P,
       3-(2,2-Dimethyl-1,3-thiazolidin-3-yl)-3-oxopropan-1-amine 915702-18-0P,
       tert-Butyl [3-(2,2-dimethyl-1,3-thiazolidin-3-yl)-3-oxopropyl]carbamate
       915702-19-1P, 3-(4,4-Dimethyl-1,3-oxazolidin-3-yl)-3-oxopropan-1-amine
       915702-20-4P, tert-Butyl [3-(4,4-dimethyl-1,3-oxazolidin-3-yl)-3-
       oxopropyl]carbamate 915702-21-5P, N-(2,2-Dimethylpropyl)glycinamide
       915702-22-6P, tert-Butyl [2-[(2,2-dimethylpropyl)amino]-2-
       oxoethyl]carbamate 915702-23-7P, 3-(Azocan-1-yl)-3-oxopropan-1-amine
       915702-24-8P, tert-Butyl [3-(azocan-1-y1)-3-oxopropyl] carbamate
       915702-25-9P, 2-Isopropyl-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-
                           915702-26-0P, 2-Ethyl-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-
       2-ium iodide
       c]pyrimidin-2-ium bromide
                                               915702-27-1P, 2-(5-tert-Butyl-1,2,4-oxadiazol-
                                915702-28-2P, tert-Butyl [2-(5-tert-butyl-1,2,4-
       3-yl)ethanamine
       oxadiazol-3-yl)ethyl]carbamate 915702-29-3P, 2-(5-Isopropyl-1,2,4-
       oxadiazol-3-yl)ethanamine
                                              915702-30-6P, tert-Butyl [2-(5-isopropyl-1,2,4-
       oxadiazol-3-yl)ethyl]carbamate 915702-47-5P, 2'-Acetylamino-4'-methyl-
       4,5'-bithiazole-2-carbonyl chloride 915702-62-4P, 2'-(Acetylamino)-N-
       (2,2-dimethyl-4-oxo-4H-1,3-benzodioxin-6-yl)-4'-methyl-4,5'-bi-1,3-benzodioxin-6-yl)\\
       thiazole-2-carboxamide 915702-91-9P, 2'-(Acetylamino)-N-(2,2-dimethyl-4-
```

oxo-4H-1,3-benzodioxin-7-yl)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxamide915703-01-4P, Ethyl 2'-amino-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate 915703-21-8P, 2-Bromo-1-[4-methyl-2-[(pyrazin-2monohydrobromide yl)amino]-1,3-thiazol-5-yl]ethanone 915703-24-1P, 1-[2-[(1-Acetyl-1Hpyrazol-3-yl) amino]-4-methyl-1,3-thiazol-5-yl]-2-bromoethanone 915710-94-0P, tert-Butyl [(3E)-3-amino-3-(hydroxyimino)propyl]carbamate 915710-95-1P, tert-Butyl [(3Z)-3-amino-3-[[(2,2-amino-3)-2]]dimethylpropanoyl)oxy]imino]propyl]carbamate 915710-96-2P, N-[2-[(2E)-2-Amino-2-(hydroxyimino)ethyl]-4'-methyl-4,5'-bi-1,3-thiazol-2'yl]acetamide RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of 4,5'-bithiazole and 4-(oxazol-5-yl)thiazole derivs. as PI3

kinase inhibitors with therapeutic uses)

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 6 RE

- (1) Agouron Pharmaceuticals Inc; WO 0075120 A 2000 CAPLUS
- (2) Bloomfield, G; WO 2004078754 A 2004 CAPLUS
- (3) Bruce, I; WO 03072557 A 2003 CAPLUS
- (4) Bruce, I; WO 2004096797 A 2004 CAPLUS
- (5) Fujisawa Pharmaceutical Co Ltd; EP 0117082 A 1984 CAPLUS
- (6) Sawhney, S; INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE 1976, V14B(7), P552 CAPLUS
- L32 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN IT 115926-52-8, Phosphoinositide-3-kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

115926-52-8 CAPLUS RN

Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME) CN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

91-56-5, Isatin ΙT

> RL: RCT (Reactant); RACT (Reactant or reagent) (starting material; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

RN 91-56-5 CAPLUS

CN 1H-Indole-2,3-dione (CA INDEX NAME)

ACCESSION NUMBER: 2005:1335074 CAPLUS

DOCUMENT NUMBER: 144:69859

Indoles, pteridines, pyridopyrazines, and TITLE: benzotriazines as vasculostatic agents, their

preparation, pharmaceutical compositions and use in

therapy

Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; INVENTOR(S):

Noronha, Glenn; Hood, John D.; Dneprovskaia, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning

Targegen, Inc., USA PATENT ASSIGNEE(S):

SOURCE: U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S.

Ser. No. 679,209.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE		
US 20050282814	A1	20051222	US 2005-105845		20050413		
US 20040167198 US 7208493	A1 B2	20040826 20070424	US 2003-679209		20031002		
ZA 2005002328	A	20060927	ZA 2005-2328		20050318		
US 20070208019 PRIORITY APPLN. INFO.:	A1	20070906	US 2007-653190 US 2002-415981P	Р	20070111 20021003		
			US 2003-440234P	P	20030114		
			US 2003-443752P US 2003-463818P	P P	20030129 20030417		
			US 2003-466983P	P	20030430		
			US 2003-479295P US 2003-679209	P 70.2	20030617 20031002		
OTHER SOURCE(S):	CASRE	ACT 144:69859		AZ	20031002		

CASREACT 144:69859; MARPAT 144:69859

AN 2005:1335074 CAPLUS

144:69859 DN

Entered STN: 23 Dec 2005 ED

TΙ Indoles, pteridines, pyridopyrazines, and benzotriazines as vasculostatic agents, their preparation, pharmaceutical compositions and use in therapy

Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood, ΙN John D.; Dneprovskaia, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning

PΑ Targegen, Inc., USA

SO U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 679,209. CODEN: USXXCO

DT Patent

English LA

IC ICM A61K031-525 ICS A61K031-724

INCL 514251000; 514058000

28-17 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1, 63

FAN CNT 2

FAI	N.CNI Z									
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE					
PΙ	US 20050282814	A1	20051222	US 2005-105845	20050413					
	US 20040167198	A1	20040826	US 2003-679209	20031002					
	US 7208493	В2	20070424							
	ZA 2005002328	A	20060927	ZA 2005-2328	20050318					
	US 20070208019	A1	20070906	US 2007-653190	20070111					
PRA	AI US 2002-415981P	P	20021003							
	US 2003-440234P	P	20030114							
	US 2003-443752P	P	20030129							
	US 2003-463818P	P	20030417							
	US 2003-466983P	P	20030430							
	US 2003-479295P	P	20030617							
	US 2003-679209	A2	20031002							
CLP	ASS									
PI	ATENT NO. CLASS	PATENT	FAMILY CLAS	SIFICATION CODES						

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES \_\_\_\_\_

US 20050282814 ICM A61K031-525 ICS A61K031-724

INCL 514251000; 514058000

IPCI A61K0031-525 [ICM, 7]; A61K0031-519 [ICM, 7, C\*];

```
A61K0031-724 [ICS, 7]; A61K0031-716 [ICS, 7, C*]
                IPCR
                       A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
                       [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
                       A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02
                       [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
                       C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
                       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
                       C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
                       [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
                       [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
                       C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                NCL
                       514/251.000; 514/058.000
US 20040167198
                IPCI
                       A61K0031-4985 [I,A]; C07D0471-02 [I,A]; C07D0471-00
                       [I,C*]
                IPCR
                       A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
                       [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
                       A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02
                       [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
                       C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
                       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
                       C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
                       [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
                       [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
                       C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                NCL
                       514/414.000; 514/415.000; 548/465.000; 548/511.000;
                       514/249.000; 544/256.000
                       A61K [N,S]; C07D [N,S]
ZA 2005002328
                TPCT
US 20070208019 IPCI
                       A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-525
                       [I,A]; A61K0031-519 [I,C*]; A61K0039-395 [I,A];
                       A61K0031-704 [I,A]; A61K0031-7028 [I,C*]; A61K0031-7048
                       [I,A]; A61K0031-7042 [I,C*]; A61K0031-337 [I,A];
                       A61K0031-404 [I,A]; A61K0031-403 [I,C*]
                IPCR
                       A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-337
                       [I,C]; A61K0031-337 [I,A]; A61K0031-403 [I,C];
                       A61K0031-404 [I,A]; A61K0031-519 [I,C]; A61K0031-525
                       [I,A]; A61K0031-7028 [I,C]; A61K0031-704 [I,A];
                       A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0039-395
                       [I,C]; A61K0039-395 [I,A]
                       514/234.500; 424/155.100; 424/649.000; 514/027.000;
                NCL
                       514/034.000; 514/251.000; 514/414.000; 514/449.000;
                       514/492.000
    CASREACT 144:69859; MARPAT 144:69859
```

OS

GΙ

$$(R^1)_m \xrightarrow{W}^B \xrightarrow{A} (R^2)_n$$

AΒ The invention relates to nitrogen heterocyclic compds. of formula I, which are useful for treating disorders associated with compromised vasculostasis. In compds. I, each of A, B, W, X, Y, and Z is independently selected from C, C(O), N, and NR3, where R3 is H or (un) substituted alkyl; each R1 is independently halo, OR4, N(R4)2, or SR4, where R4 is H, lower alkyl, aryl, heteroaryl, etc.; each R2 is independently halo, OR5, N(R5)2, SR5, OPO3H2, (un)substituted alkyl, (un) substituted aryl, (un) substituted heteroaryl, where R5 is H, lower alkyl, aryl, heteroaryl, etc.; and each of m and n is independently an integer from 1 to 4. The invention also relates to the preparation of I, pharmaceutical compns, comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of a variety of disorders including stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like. Cyclocondensation of 3,3'-dihydroxybenzil with 2,4,5,6-tetraaminopyrimidine sulfate results in the formation of diaminopteridine II. Compound II expresses an IC50 value of 83 nM in an assay for the inhibition of the human  $p120\gamma$  subunit of PI3 kinase and results in 65% reduction of myocardial infarction in rats.

ΙI

ST indolyl phenyl carboxamide prepn vasculostatic; pteridine prepn vasculostatic; pyridopyrazine prepn vasculostatic; quinazoline prepn vasculostatic; benzotriazine prepn vasculostatic

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HER2; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Respiratory distress syndrome

(acute; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Respiratory distress syndrome

(adult; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

IT Antibiotics

ΙT

(anthracycline; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) Cytotoxic agents

(antimetabolites; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis)

ΤТ Disease, animal (arthropathy; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) Disease, animal IΤ (associated with compromised vasculostasis; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙΤ Antibiotics (bleomycin-type; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΤТ Muscle, disease (cancer; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Drug delivery systems (carriers; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Intestine, neoplasm (colon; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT RL: BSU (Biological study, unclassified); BIOL (Biological study) (crosslinking agents; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Joint, anatomical (disease; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Heart, disease (failure; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Heart, disease (infarction; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) Drug delivery systems ΙT (injections; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Reperfusion (injury; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) Capillary vessel, disease ΤТ (leakage syndrome; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Eye, disease (macula, degeneration; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΤТ Lung, neoplasm (metastasis; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) TΤ Antibiotics (mitomycin-type; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Blood vessel (permeability; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) TΤ Biological transport (permeation, vascular; preparation of vasculostatic agents and use for treatment of disorders associated with compromised vasculostasis) ΙT Alkylating agents, biological Angiogenesis Angiogenesis inhibitors Anti-inflammatory agents

```
Anti-ischemic agents
     Antiarthritics
     Antitumor agents
     Arthritis
     Autoimmune disease
     Bladder, neoplasm
     Bone, neoplasm
     Brain, neoplasm
     Burn
     Cardiovascular agents
     Combination chemotherapy
     Digestive tract, neoplasm
     Edema
     Human
     Immunomodulators
     Inflammation
     Kidney, neoplasm
     Leukemia
     Liver, neoplasm
     Lung, neoplasm
     Lymphoma
     Mammary gland, neoplasm
    Melanoma
    Microtubule
     Neoplasm
     Ovary, neoplasm
     Prostate gland, neoplasm
     Skin, neoplasm
     Spleen
     T cell (lymphocyte)
     Transplant rejection
        (preparation of vasculostatic agents and use for treatment of
        disorders associated with compromised vasculostasis)
ΤТ
    Growth factor receptors
     Growth factors, animal
     Integrins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (preparation of vasculostatic agents and use for treatment of
        disorders associated with compromised vasculostasis)
ΙT
     Interleukin 2
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (preparation of vasculostatic agents and use for treatment of
        disorders associated with compromised vasculostasis)
ΤТ
     Injury
        (reperfusion; preparation of vasculostatic agents and use for
        treatment of disorders associated with compromised vasculostasis)
ΙT
     Eye, disease
        (retinopathy, vitreo-; preparation of vasculostatic agents and use for
        treatment of disorders associated with compromised vasculostasis)
ΙT
        (retinopathy; preparation of vasculostatic agents and use for
        treatment of disorders associated with compromised vasculostasis)
ΤТ
     Brain, disease
        (stroke; preparation of vasculostatic agents and use for treatment
        of disorders associated with compromised vasculostasis)
     Drug interactions
ΙT
        (synergistic; preparation of vasculostatic agents and use for
        treatment of disorders associated with compromised vasculostasis)
     Antibodies and Immunoglobulins
ΤТ
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
```

```
(Biological study); USES (Uses)
        (therapeutic; preparation of vasculostatic agents and use for
        treatment of disorders associated with compromised vasculostasis)
ΙT
     Cardiovascular agents
        (vasculostatics; preparation of vasculostatic agents and use for
        treatment of disorders associated with compromised vasculostasis)
ΙT
     Alkaloids, biological studies
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (vinca; preparation of vasculostatic agents and use for treatment
        of disorders associated with compromised vasculostasis)
ΙT
        (vitreous humor, vitreoretinal disease; preparation of vasculostatic agents
        and use for treatment of disorders associated with compromised
        vasculostasis)
     677297-15-3P, N-[2-(1H-Indol-2-yl)-phenyl]-2-(2-methoxyphenyl)acetamide
ΤТ
     677297-25-5P, N-[2-(1H-Indol-2-yl)-phenyl]phthalamic acid 677297-30-2P,
     6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine 677297-48-2P,
     4-(4-Aminopteridin-7-yl)-phenol 677297-51-7P, 6,7-Bis(3-
     hydroxyphenyl)pteridine-2,4,-diamine
                                          677297-58-4P, 6,7-Bis(3-
     hydroxyphenyl)pteridin-4-ylamine 677297-61-9P, 6,7-Bis(4-
     hydroxyphenyl)pteridin-4-ylamine sulfate 677297-63-1P,
     6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine dihydrochloride
     677297-65-3P, 6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine
     677297-75-5P
                  677297-77-7P 677297-90-4P, 7-(2,6-
     Dimethylphenyl)benzo[1,2,4]triazin-3-ylamine 677298-01-0P,
     N-(7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)-phenylamine 677298-27-0P,
     6-Bromo-3-(3-hydroxypropionyl)-3H-quinazolin-4-one
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate; preparation of vasculostatic agents and use for
        treatment of disorders associated with compromised vasculostasis)
                  102704-20-1P, N-[2-(1H-Indol-2-yl)-phenyl]-2-phenylacetamide
TТ
     14892-98-9P
                                              278799-97-6P,
     128076-13-1P, 6-Phenylpteridin-4-ylamine
     6-(Benzylaminomethyl)-2,4-pteridinediamine 677297-11-9P,
     2-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl] acetamide
                                                                677297-12-0P,
     4-Hydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide
                                                       677297-13-1P,
     3,4-Dihydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide
                                                           677297-14-2P,
     2-Hydroxy-N-[2-(1H-indol-2-yl)-phenyl]benzamide
                                                     677297-16-4P,
     2-(2-Hydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl] acetamide
     2-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-2-yl)-phenyl]acetamide
     677297-18-6P, 2-[1,3-Benzodioxol-5-yl]-N-[2-(1H-indol-2-yl)-phenyl]-
     acetamide
                 677297-19-7P, N-[2-(1H-Indol-2-yl)-phenyl]-3-
                         677297-20-0P, 3-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-
     phenylpropionamide
                              677297-21-1P, N-[2-(1H-Indol-2-yl)-phenyl]-3-(2-
     yl)-phenyl]propionamide
     methoxyphenyl)propionamide 677297-22-2P, 3-(3,4-Dihydroxyphenyl)-N-[2-
     (1H-indol-2-yl)-phenyl]propionamide 677297-23-3P, 2-(4-Hydroxyphenoxy)-N-
                                          677297-26-6P, 2-[2-(1H-Indol-2-yl)-
     [2-(1H-indol-2-yl)-phenyl]acetamide
     phenylcarbamoyl]nicotinic acid 677297-27-7P, 3,4,5-Trihydroxy-N-[2-(1H-
     indol-2-yl)-phenyl]benzamide
                                  677297-28-8P 677297-29-9P,
     6,7-Bis-(4-hydroxyphenyl)pteridin-4-yl-(3-(morpholin-4-yl)propyl)amine
                    677297-31-3P, Acetic acid 4-[7-(4-acetoxyphenyl)-4-
     hydrochloride
     aminopteridin-6-yl]-phenyl ester
                                       677297-32-4P, Acetic acid
     4-[2-(4-acetoxyphenyl)-6-aminopyrido[2,3-b]pyrazin-3-yl]-phenyl ester
     677297-35-7P, (3,4-Dimethoxyphenyl)-(6-phenylpteridin-4-yl)-amine
     677297-36-8P, (3-Chloro-4,6-dimethoxyphenyl)-(6-phenylpteridin-4-yl)-amine
     677297-37-9P, (3-Hydroxy-4-methoxyphenyl)-(6-phenylpteridin-4-yl)-amine
     677297-38-0P, (4-Hydroxyphenyl)-(6-phenylpteridin-4-yl)-amine
     677297-39-1P, (2,5-Dimethyl-4-hydroxyphenyl)-(6-phenylpteridin-4-yl)-amine
     677297-40-4P, 2-Hydroxy-5-(6-phenylpteridin-4-ylamino)benzenesulfonic acid
```

```
677297-41-5P, 2-Diethylaminomethyl-4-(6-phenylpteridin-4-ylamino)phenol
677297-44-8P, Benzyl-(6-phenylpteridin-4-yl)-amine 677297-45-9P,
4-[(6-Phenylpteridin-4-ylamino)methyl]benzene-1,2-diol
                                                              677297-46-0P,
Indan-2-yl-(6-phenylpteridin-4-yl)-amine 677297-47-1P,
2-(3,4-Dimethoxyphenyl)ethyl]-(6-phenylpteridin-4-yl)-amine
677297-49-3P, 4-(4-Benzylaminopteridin-7-yl)-phenol 677297-53-9P,
6-Pyridin-2-yl-7-pyridin-3-ylpteridin-4-amine sulfate
                                                             677297-54-0P,
6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diol
                                                    677297-55-1P,
6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrochloride
677297-56-2P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine
methanesulfonate 677297-57-3P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-
diamine dihydrobromide 677297-59-5P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-
ylamine hydrochloride 677297-60-8P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-
ylamine methanesulfonate 677297-62-0P, 6,7-Bis(3,4-
dihydroxyphenyl)pteridine-2,4-diamine 677297-64-2P, 6,7-Bis(3,4-
dihydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-66-4P,
6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine methanesulfonate
677297-67-5P, 4-(2,4-Diaminopteridin-6-yl)phenol 677297-68-6P,
2,3-Diphenylpyrido[3,4-b]pyrazin-8-ylamine hydrochloride 677297-69-7P,
2,3-Bis(4-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride
677297-70-0P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine
hydrochloride
               677297-71-1P, 2,3-Bis(3-hydroxyphenyl)pyrido[3,4-b]pyrazin-
8-ylamine hydrochloride 677297-72-2P, 2,3-Bis(3-hydroxyphenyl)pyrido[2,3-
b]pyrazin-6-ylamine dihydrochloride 677297-73-3P, 2,3-Bis(4-
hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride
              677297-78-8P 677297-79-9P, 4-(4-Aminopteridin-7-yl)-
677297-76-6P
benzene-1,2-diol
                   677297-80-2P, 4-(2,4-Diaminopteridin-7-yl)-benzene-1,2-
       677297-81-3P, 4-(2,4-Diaminopteridin-7-yl)-phenol 677297-82-4P,
4-[2-(6-Phenylpteridin-4-ylamino)ethyl]benzene-1,2-diol 677297-83-5P,
2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride
677297-84-6P, 2,3-Bis(3-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride
677297-85-7P, 2,3-Bis(4-hydroxyphenyl)quinoxalin-6-ylamine dihydrochloride
677297-86-8P, 2,3-Bis(3,4-dihydroxyphenyl)quinoxalin-6-ylamine
dihydrochloride
                 677297-89-1P, [7-(1,3-Benzodioxol-5-
yl)benzo[1,2,4]triazin-3-yl]amine 677297-91-5P, 7-(4-
Phenoxyphenyl)benzo[1,2,4]triazin-3-ylamine 677297-92-6P,
7-(2,6-Dimethoxyphenyl)benzo[1,2,4]triazin-3-ylamine 677297-93-7P,
7-(4-tert-Butylphenyl)benzo[1,2,4]triazin-3-ylamine 677297-94-8P,
7-(2-Trifluoromethylphenyl)benzo[1,2,4]triazin-3-ylamine
                                                               677297-95-9P,
7-Biphenyl-4-ylbenzo[1,2,4]triazin-3-ylamine
                                                 677297-96-0P,
7-Benzofuran-2-ylbenzo[1,2,4]triazin-3-ylamine
                                                     677297-97-1P,
7-Dibenzofuran-4-ylbenzo[1,2,4]triazin-3-ylamine 677297-98-2P,
7-Naphthalen-1-ylbenzo[1,2,4]triazin-3-ylamine
                                                     677297-99-3P,
3-(3-Aminobenzo[1,2,4]triazin-7-yl)-phenol
                                               677298-00-9P,
N-[7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]-phenylamine
677298-02-1P, (7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)-[3-(4-
methylpiperazin-1-yl)-propyl]amine 677298-03-2P, N-[5-Methyl-7-(2,4,6-
trimethylphenyl)benzo[1,2,4]triazin-3-yl]-phenylamine 677298-04-3P,
N-[7-(2-Fluoro-6-methoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-
phenylamine 677298-05-4P, N-[7-(2,6-Dimethoxyphenyl)-5-
                                                677298-06-5P,
methylbenzo[1,2,4]triazin-3-yl]-phenylamine
N-[7-(2,6-Dimethylphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-phenylamine
677298-07-6P, 7-Naphthalen-2-ylbenzo[1,2,4]triazin-3-ylamine-1-oxide <math>677298-08-7P, 2-[(2,4-Diaminopteridin-6-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)amino]-3-(4-ylmethyl)aminopteridin-6-ylmethyl)aminopteridin-6-ylmethyl)aminopteridin-6-ylmethyl)aminopteridin-6-ylmethyl)aminopteridin-6-ylmethyl
hydroxyphenyl)propionic acid tert-butyl ester
                                                   677298-09-8P,
6-[[(Pyridin-2-ylmethyl)amino]methyl]-2,4-pteridinediamine
                                                                  677298-10-1P,
6-[[(Naphthalen-1-ylmethyl)amino]methyl]-2,4-pteridinediamine
677298-11-2P, 6-[[(Adamantan-1-ylmethyl)amino]methyl]-2,4-pteridinediamine
677298-13-4P, 6-[2,2-Dimethylpropylamino)methyl]-2,4-pteridinediamine
677298-14-5P, 6-[[2-(3,4-Dimethoxyphenyl)ethylamino]methyl]-2,4-
pteridinediamine 677298-15-6P, 6-[[2-(3,4-Dihydroxyphenyl)ethylamino]met
```

```
677298-16-7P, 4-[2-[Di(2,4-diaminopteridin-6-
hyl]-2,4-pteridinediamine
ylmethyl)amino]ethyl]benzene-1,2-diol 677298-17-8P 677298-18-9P,
3-(4-tert-Butoxyphenyl)-2-[(2,4-diaminopteridin-6-ylmethyl)amino]propionic
acid tert-butyl ester 677298-19-0P, 1-[[[Bis-(2,4-Diaminopteridin-6-
ylmethyl)]-amino]methyl]naphthalene 677298-20-3P, 6-(2,6-Dimethylphenyl)-
3H-quinazolin-4-one 677298-21-4P, 6-(2,6-Dimethoxyphenyl)-3H-quinazolin-
4-one
       677298-22-5P, 6-(2-Chloro-6-methoxyphenyl)-3H-quinazolin-4-one
677298-23-6P, 6-(2,4,6-Trimethylphenyl)-3H-quinazolin-4-one
677298-24-7P, 6-(Naphthalen-1-yl)-3H-quinazolin-4-one 677298-25-8P,
6-(Naphthalen-2-yl)-3H-quinazolin-4-one
                                         677298-26-9P,
6-(4-Phenoxyphenyl)-3H-quinazolin-4-one
                                       677298-28-1P,
6-(2,6-Dimethylphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one
677298-29-2P, 6-(2-Chloro-6-methoxyphenyl)-3-(3-hydroxypropionyl)-3H-
quinazolin-4-one 677298-31-6P, 8-Bromo-4-[3-(4-methylpiperazin-1yl)-
propylamino]-6-nitroquinazolin-2-ol 677298-32-7P, (6,7-Diphenylpteridin-
4-yl)-[3-(4-methylpiperazin-1-yl)-propyl]amine 677298-33-8P
             871590-51-1P, (S)-2-Acetylamino-3-(4-hydroxyphenyl)-N-[2-
677298-34-9P
                                    871590-52-2P, 5-(6-Phenylpteridin-4-
(1H-indol-2-yl)-phenyl]propionamide
ylamino)quinolin-8-ol hydrochloride
                                     871590-53-3P, 6-((3,4-
Dimethoxybenzylamino)methyl)-2,4-pteridinediamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of vasculostatic agents and use for
   treatment of disorders associated with compromised vasculostasis)
6298-38-0P, 7-Bromobenzo[1,2,4]triazin-3-ylamine-1-oxide 32084-59-6P,
6-Bromo-3H-quinazolin-4-one 52853-40-4P, 6-Bromomethyl-2,4-
pteridinediamine hydrobromide
                              59368-16-0P, 6-Bromomethyl-2,4-
pteridinediamine 677297-74-4P
                                677297-87-9P
                                                677297-88-0P,
[7-(1,3-Benzodioxol-5-yl)-1-oxo-benzo[1,2,4]triazin-3-yl]amine
677298-30-5P, 4-Amino-8-bromo-6-nitroquinazolin-2-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
   (intermediate; preparation of vasculostatic agents and use for
   treatment of disorders associated with compromised vasculostasis)
115926-52-8, Phosphoinositide-3-kinase 127464-60-2, VEGF
141349-89-5, Src kinase
                        141349-91-9, Yes kinase
                                                  143180-75-0
144114-16-9, Protein tyrosine kinase 2
                                       148640-14-6, Akt kinase
372092-80-3, Protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (preparation of vasculostatic agents and use for treatment of
  disorders associated with compromised vasculostasis)
50-76-0, Dactinomycin
                       59-05-2, Methotrexate
                                               64-86-8, Colchicine
                       1605-68-1, Taxane
477-30-5, Demecolcine
                                          7585-39-9, \beta-Cyclodextrin
12619-70-4, Cyclodextrin
                          15663-27-1, Cisplatin
                                                  20830-81-3,
              23214-92-8, Doxorubicin
                                       33069-62-4, Taxol
                                                           33419-42-0,
Daunorubicin
          41575-94-4, Carboplatin 42077-25-8, Adriamycin-14-octanoate
Etoposide
            56420-45-2, Epirubicin
                                    58957-92-9, Idarubicin
                                                             59367-03-2,
50935-04-1
                        64161-91-7, Adriamycin-14-naphthaleneacetate
Adriamycin-14-benzoate
65271-80-9, Mitoxantrone
                          79466-09-4, 13-Deoxydaunorubicin 84325-15-5,
11-Deoxydaunorubicin 114977-28-5, Taxotere
                                             154447-36-6, LY294002
                          183319-69-9, OSI-774 194615-04-8, Captisol
180288-69-1, Trastuzumab
216974-75-3, Bevacizumab
                          677298-35-0, 6,7-Bis-(3-hydroxyphenyl)pteridine-
                     892553-42-3, Vitaxin
2,4-diamine sulfate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (preparation of vasculostatic agents and use for treatment of
  disorders associated with compromised vasculostasis)
77-92-9, Citric acid, biological studies 1404-00-8, Mitomycin
11056-06-7, Bleomycin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
```

ΙT

TΤ

ΙT

ΙT

```
(preparation of vasculostatic agents and use for treatment of
       disorders associated with compromised vasculostasis)
ΤТ
    51-61-6, 2-(3,4-Dihydroxyphenyl)ethylamine, reactions 62-31-7,
                                                                   69-72-7,
    3-Hydroxytyramine hydrochloride 62-53-3, Aniline, reactions
    Salicylic acid, reactions 85-44-9, Phthalic anhydride 91-56-5,
            93-25-4, 2-Methoxyphenylacetic acid 97-50-7,
    Isatin
     (3-Chloro-4,6-dimethoxyphenyl)amine 99-50-3, 3,4-Dihydroxybenzoic acid
    99-96-7, 4-Hydroxybenzoic acid, reactions 100-46-9, Benzylamine,
    reactions 102-32-9, 3,4-Dihydroxyphenylacetic acid 103-82-2,
    Phenylacetic acid, reactions 118-31-0, 1-Aminomethylnaphthalene
    118-70-7, 4,5,6-Triaminopyrimidine 120-20-7, 2-(3,4-
    Dimethoxyphenyl)ethylamine 123-00-2, N-(3-Aminopropyl)morpholine
    123-30-8, (4-Hydroxyphenyl)amine 134-81-6, Benzil 149-91-7, Gallic
    acid, reactions 156-38-7, 4-Hydroxyphenylacetic acid 501-52-0,
    Hydrocinnamic acid 501-97-3, 3-(4-Hydroxyphenyl)propionic acid
    537-55-3, N-Acetyl-L-tyrosine 615-47-4 635-85-8, 2-(3,4-
    Dimethoxyphenyl)ethylamine hydrochloride 699-98-9, 2,3-
    Pyridinedicarboxylic anhydride 814-68-6, Acryloyl chloride
                                                                 875-51-4,
    4-Bromo-2-nitrophenylamine 1004-74-6, 2,4,5,6-Tetraaminopyrimidine
    1078-61-1, 3,4-Dihydroxyhydrocinnamic acid 1124-40-9,
    3,4-Dihydroxybenzylamine hydrochloride 1423-27-4, 2-Trifluoromethyl
    phenylboronic acid 1687-53-2, (3-Hydroxy-4-methoxyphenyl)amine
    1878-84-8, (4-Hydroxyphenoxy) acetic acid 2835-04-3, 2-Hydroxy-5-
    aminobenzenesulfonic acid 2861-28-1, 3,4-(Methylenedioxy)phenylacetic
          2975-41-9, Indan-2-ylamine 3096-71-7, (2,5-Dimethyl-4-
    hydroxyphenyl)amine 3731-51-9, 2-(Aminomethyl)pyridine 4572-03-6,
    3-(4-Methylpiperazin-1-yl)-propylamine 5122-94-1, 4-Biphenylboronic acid
    5763-61-1, 3,4-Dimethoxybenzylamine 5794-88-7, 2-Amino-5-Bromobenzoic
          5813-64-9, 2,2-Dimethylpropylamine 5980-97-2,
    2,4,6-Trimethylphenylboronic acid 5993-91-9, 2-Aminomethylbenzimidazole
    dihydrochloride 6309-15-5, 3,3',4,4'-Tetrahydroxybenzil 6315-89-5,
     (3,4-Dimethoxyphenyl)amine 6342-77-4, 3-(2-Methoxyphenyl)propionic acid
    13207-66-4, 5-(Amino)quinolin-8-ol 13922-41-3, 1-Naphthylboronic acid
    16290-26-9, 3,4-Dihydroxybenzylamine hydrobromide 17601-94-4,
    2-Amino-3-bromo-5-nitrobenzonitrile
                                        17768-41-1, 1-Aminomethyl adamantane
    20284-90-6, 2,3,6-Triaminopyridine dihydrochloride
                                                      21454-19-3
    23112-96-1, 2,6-Dimethoxyphenylboronic acid
                                                 24645-80-5,
     4-Hydroxyphenylglyoxal
                            24850-02-0, 6,7-Diphenylpteridin-4-ylamine
    29477-55-2, 3,4-Dihydroxyphenylglyoxal 32316-92-0, 2-Naphthylboronic
          32566-01-1, 2-(2-Aminophenyl)indole 33288-79-8,
    4,4'-Dihydroxybenzil
                         37491-68-2, 4-[(Amino)methyl]benzene-1,2-diol
    42965-55-9, 5,6-Diamino-2,4-dihydroxypyrimidine sulfate 49647-58-7,
    2,4,5,6-Tetraaminopyrimidine sulfate 49721-45-1, 4,5,6-
    Triaminopyrimidine sulfate 51067-38-0, 4-Phenoxyphenylboronic acid
    51387-92-9, 2-Diethylaminomethyl-4-(amino)phenol 63192-57-4,
    3,3'-Dihydroxybenzil 76145-91-0, (2,4-DiaminoPteridin-6-yl)-methanol
    hydrobromide 77712-97-1, 3,4,5-Triaminopyridine hydrochloride
    77811-44-0, 4-Bromo-2-methyl-6-nitrophenylamine 78495-63-3,
    2-Fluoro-6-methoxyphenylboronic acid 87199-18-6, 3-Hydroxyphenylboronic
          88878-78-8, 2-Amino-3-(4-hydroxyphenyl)propionic acid tert-butyl
    acid
            94839-07-3, 3,4-(Methylenedioxy)phenylboronic acid 95195-43-0,
                  98437-24-2, 2-Benzofuranboronic acid 100124-06-9,
    2,3'-Pyridil
    4-Dibenzofuranboronic acid 100379-00-8, 2,6-Dimethylphenylboronic acid
    123324-71-0, 4-tert-Butylphenylboronic acid 385370-80-9,
    2-Chloro-6-methoxyphenylboronic acid 545390-26-9, 2-Amino-3-(4-tert-
    butoxyphenyl)propionic acid tert-butyl ester hydrochloride 677297-33-5,
    2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine
                                                            677297-34-6,
    N'-(3-Cyano-5-phenylpyrazin-2-yl)-N, N-dimethylformamidine
    RL: RCT (Reactant); RACT (Reactant or reagent)
        (starting material; preparation of vasculostatic agents and use for
       treatment of disorders associated with compromised vasculostasis)
```

L32 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN ΤТ 115926-52-8 RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks)) 115926-52-8 CAPLUS RN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME) CN \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* ACCESSION NUMBER: 2005:673279 CAPLUS DOCUMENT NUMBER: 143:172865 TITLE: Preparation of thiazole derivatives as modulators of the phosphoinositide 3-kinases (PI3Ks) Quattropani, Anna; Rueckle, Thomas; Schwarz, Matthias; INVENTOR(S): Dorbais, Jerome; Sauer, Wolfgang; Cleva, Christophe; Desforges, Gwenaelle PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N. V., Neth. Antilles SOURCE: PCT Int. Appl., 212 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.					KIND DATE			APPL	ICAT	DATE							
WO		0684	44		A2		2005	0728		WO 2	005-		20050111				
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
											JP,						
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MΖ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ТJ,	TM,	TN,	TR,	ΤΤ,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MΖ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	ΙΤ,	LT,	LU,	MC,	NL,	PL,	PT,
		RO,	SE,	SI,	SK,	TR,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,
		MR,	NE,	SN,	TD,	ΤG											
AU	2005	2052											_	20050111			
						.1 20050728											
	1709									EP 2	005-		2	0050	111		
EP	1709	019			B1 20070808												
	R:		•	,	•		,		•		ΙT,	•	,	•		,	•
				,		FI,	RO,	MK,	CY,	AL,	TR,	ВG,	CZ,	EE,	HU,	PL,	SK,
			HR,	,													
_	1926										005-						
	2005		-				2007						20050111				
JP	JP 2007517835				T		2007				006-						
	AT 369349				T		2007				005-			0050			
	ES 2287896						2007				005-			0050			
	IN 2006DN03731						2007				006-				2		
	2006							0914			006-					0060	
	2006				А		2006	1012			006-					0060	
IORIT	Y APP	LN.	TNF.O	.:							004-						
ned c	OLID CE	/C) -			C7\ C1		т 1/	2.17		-	005-		-		w 2	0050	T T T
HER S	CADI	KEAU	т 14	J:⊥/.	∠00J	, MA	LEAL	T43	· 1 / Z	000							

ΑN 2005:673279 CAPLUS

DN 143:172865

```
ED Entered STN: 29 Jul 2005
```

- TI Preparation of thiazole derivatives as modulators of the phosphoinositide 3-kinases (PI3Ks)
- IN Quattropani, Anna; Rueckle, Thomas; Schwarz, Matthias; Dorbais, Jerome; Sauer, Wolfgang; Cleva, Christophe; Desforges, Gwenaelle
- PA Applied Research Systems ARS Holding N. V., Neth. Antilles
- SO PCT Int. Appl., 212 pp.
- CODEN: PIXXD2
- DT Patent
- LA English
- IC ICM C07D277-46
- CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
   Section cross-reference(s): 1, 63

FAN	.CNT	1

FAN.							KIND DATE					LICAT	DATE						
PI WO 200506844 WO 200506844				44	44						WO 2005-EP50102								
		₩:	CN, GE, LK, NO,	CO, GH, LR, NZ,	CR, GM, LS, OM,	CU, HR, LT, PG,	CZ, HU, LU, PH,	DE, ID, LV, PL,	DK, IL, MA, PT,	DM, IN, MD, RO,	DZ IS MG RU	B, BG, E, EC, S, JP, G, MK, J, SC,	EE, KE, MN, SD,	EG, KG, MW, SE,	ES, KP, MX, SG,	FI, KR, MZ, SK,	GB, KZ, NA, SL,	GD, LC, NI, SY,	
		R₩:	BW, AZ, EE, RO,	GH, BY, ES, SE,	GM, KG, FI, SI,	KE, KZ, FR,	LS, MD, GB, TR,	MW, RU, GR,	MZ, TJ, HU,	NA, TM, IE,	SD AT IS	S, UZ, S, SL, S, BE, S, IT, G, CI,	SZ, BG, LT,	TZ, CH, LU,	UG, CY, MC,	ZM, CZ, NL,	ZW, DE, PL,	AM, DK, PT,	
	CA EP	U 2005205201 A 2551415 P 1709019 P 1709019				A1 2005 A1 2005 A2 2006			0050728 0050728 0061011 0070808			2005- 2005- 2005-	-2551						
		R:	ΙE,	SI,	LT,	LV,						R, IT,							
PRAI CLAS	BR JP AT ES IN MX NO EP WO	BA, HR, IS, N 1926121 R 2005006749 P 2007517835 T 369349 S 2287896 N 2006DN03731 X 2006PA07934 O 2006003606 P 2004-100083 O 2005-EP50102				A A T T T3 A	A 20070307 CN 2005-80006639 A 20070522 BR 2005-6749 T 20070705 JP 2006-548315 T 20070815 AT 2005-701490 T3 20071216 ES 2005-701490 A 20070420 IN 2006-DN3731 A 20060914 MX 2006-PA7934 A 20061012 NO 2006-3606 A 20040112								20050111 20050111 20050111 20050111 20050111 20060629 20060711 20060809				
PATENT NO. CLASS																			
WO 2005068444		ICM IPC IPC	I	C07D C07D	7D277-46 7D0277-46 [ICM,7]; C07D0277-00 [ICM,7,C*] 7D0277-00 [I,C*]; C07D0277-46 [I,A]; C07D0417-00 ,C*]; C07D0417-14 [I,A]														
ECLA						C07D C07D	417/ 417/	14+2	77B+: 77B+:	277E 277E	3+20 3+21	·277B+ )7; C( .3; C( '7B	7D41	7/14	+277				
AU	2005	52052	01	IPC		C07D	0277	7-00	[I,C	*];	C07	'D041	7-00	[I,C	*];	C07D	0277	-46	
CA						A61K	[I,A]; C07D0417-14 [I,A] A61K0031-427 [I,A]; C07D0277-46 [I,A]; C07D0277-00												

[I,C\*]; C07D0417-14 [I,A]; C07D0417-00 [I,C\*]

```
C07D277/46; C07D417/14+277B+263B+207;
                ECLA
                       C07D417/14+277B+277B+207; C07D417/14+277B+277B+211;
                       C07D417/14+277B+277B+213; C07D417/14+307+277B+277B;
                       C07D417/14+307B+277B+277B
EP 1709019
                IPCI
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                       [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C];
                       C07D0417-14 [I,A]
                IPCR
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                       [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C];
                       C07D0417-14 [I,A]
CN 1926121
                IPCI
                       C07D0277-46 [I,A]; C07D0277-00 [I,C*]; C07D0417-14
                       [I,A]; C07D0417-00 [I,C*]; A61K0031-427 [I,A]
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; C07D0417-00
                IPCR
                       [I,C*]; C07D0417-14 [I,A]
                ECLA
                       C07D277/46; C07D417/14+277B+263B+207;
                       C07D417/14+277B+277B+207; C07D417/14+277B+277B+211;
                       C07D417/14+277B+277B+213; C07D417/14+307+277B+277B;
                       C07D417/14+307B+277B+277B
                       C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
BR 2005006749
                IPCI
                       [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C];
                       C07D0417-14 [I,A]
                ECLA
                       C07D277/46; C07D417/14+277B+263B+207;
                       C07D417/14+277B+277B+207; C07D417/14+277B+277B+211;
                       C07D417/14+277B+277B+213; C07D417/14+307+277B+277B;
                       C07D417/14+307B+277B+277B
                       C07D0277-20 [I,A]; C07D0277-46 [I,A]; C07D0417-14
JP 2007517835
                IPCI
                       [I,A]; C07D0417-00 [I,C*]; C07D0277-48 [I,A];
                       C07D0277-00 [I,C*]; A61K0031-427 [I,A]; A61K0031-454
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-496 [I,A]; A61K0031-5377
                       [I,A]; A61K0031-5375 [I,C*]; A61K0031-433 [I,A];
                       A61K0031-4709 [I,A]; A61P0025-28 [I,A]; A61P0025-14
                       [I,A]; A61P0025-00 [I,A]; A61P0043-00 [I,A];
                       A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0017-06
                       [I,A]; A61P0017-00 [I,C*]; A61P0019-02 [I,A];
                       A61P0019-00 [I,C*]; A61P0037-02 [I,A]; A61P0001-04
                       [I,A]; A61P0001-00 [I,C*]; A61P0011-00 [I,A];
                       A61P0007-02 [I,A]; A61P0007-00 [I,C*]; A61P0031-00
                       [I,A]; A61P0029-00 [I,A]; A61P0009-12 [I,A];
                       A61P0009-08 [I,A]; A61P0037-08 [I,A]; A61P0011-06
                       [I,A]; A61P0021-02 [I,A]; A61P0021-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0031-04 [I,A]; A61P0031-12
                       [I,A]; A61P0037-06 [I,A]; A61P0037-00 [I,C*];
                       A61P0013-12 [I,A]; A61P0013-00 [I,C*]; A61P0015-08
                       [I,A]; A61P0015-00 [I,C*]
                       C07D0277-00 [I,C]; C07D0277-20 [I,A]; A61K0031-427
                IPCR
                       [I,C]; A61K0031-427 [I,A]; A61K0031-433 [I,C];
                       A61K0031-433 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439
                       [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A];
                       A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-5375 [I,C];
                       A61K0031-5377 [I,A]; A61P0001-00 [I,C]; A61P0001-04
                       [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A];
                       A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0009-08
                       [I,A]; A61P0009-10 [I,A]; A61P0009-12 [I,A];
                       A61P0011-00 [I,C]; A61P0011-00 [I,A]; A61P0011-06
                       [I,A]; A61P0013-00 [I,C]; A61P0013-12 [I,A];
                       A61P0015-00 [I,C]; A61P0015-08 [I,A]; A61P0017-00
                       [I,C]; A61P0017-06 [I,A]; A61P0019-00 [I,C];
                       A61P0019-02 [I,A]; A61P0021-00 [I,C]; A61P0021-02
                       [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
```

```
A61P0025-14 [I,A]; A61P0025-28 [I,A]; A61P0029-00
                        [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C];
                        A61P0031-00 [I,A]; A61P0031-04 [I,A]; A61P0031-12
                        [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
                        A61P0037-00 [I,C]; A61P0037-02 [I,A]; A61P0037-06
                        [I,A]; A61P0037-08 [I,A]; A61P0043-00 [I,C];
                        A61P0043-00 [I,A]; C07D0277-46 [I,A]; C07D0277-48
                        [I,A]; C07D0417-00 [I,C]; C07D0417-14 [I,A]
                 ECLA
                        C07D277/46; C07D417/14+277B+263B+207;
                        C07D417/14+277B+277B+207; C07D417/14+277B+277B+211;
                        C07D417/14+277B+277B+213; C07D417/14+307+277B+277B;
                        C07D417/14+307B+277B+277B
                 FTERM 4C033/AD04; 4C033/AD07; 4C033/AD15; 4C033/AD16;
                        4C033/AD17; 4C033/AD20; 4C063/AA03; 4C063/BB02;
                        4C063/BB07; 4C063/BB09; 4C063/CC62; 4C063/CC67;
                        4C063/CC73; 4C063/CC76; 4C063/CC94; 4C063/DD03;
                        4C063/DD04; 4C063/DD10; 4C063/DD12; 4C063/DD14;
                        4C063/DD47; 4C063/DD51; 4C063/DD52; 4C063/DD58;
                        4C063/DD62; 4C063/EE01; 4C086/AA01; 4C086/AA02;
                        4C086/AA03; 4C086/BC82; 4C086/GA02; 4C086/GA04;
                        4C086/GA07; 4C086/GA08; 4C086/GA09; 4C086/GA10;
                        4C086/GA12; 4C086/MA01; 4C086/MA02; 4C086/MA04;
                        4C086/MA05; 4C086/NA14; 4C086/NA15; 4C086/ZA02;
                        4C086/ZA16; 4C086/ZA22; 4C086/ZA23; 4C086/ZA36;
                        4C086/ZA39; 4C086/ZA42; 4C086/ZA45; 4C086/ZA54;
                        4C086/ZA59; 4C086/ZA66; 4C086/ZA81; 4C086/ZA89;
                        4C086/ZA96; 4C086/ZB05; 4C086/ZB08; 4C086/ZB11;
                        4C086/ZB13; 4C086/ZB15; 4C086/ZB21; 4C086/ZB26;
                        4C086/ZB32; 4C086/ZB33; 4C086/ZB35; 4C086/ZC19;
                        4C086/ZC20
AT 369349
                 IPCI
                        C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                        [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C];
                        C07D0417-14 [I,A]
                 IPCR
                        C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                        [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C];
                        C07D0417-14 [I,A]
                 ECLA
                        C07D277/46; C07D417/14+277B+263B+207;
                        C07D417/14+277B+277B+207; C07D417/14+277B+277B+211;
                        C07D417/14+277B+277B+213; C07D417/14+307+277B+277B;
                        C07D417/14+307B+277B+277B
 ES 2287896
                 IPCI
                        C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                        [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C];
                        C07D0417-14 [I,A]
                 IPCR
                        C07D0277-00 [I,C]; C07D0277-46 [I,A]; A61K0031-427
                        [I,C]; A61K0031-427 [I,A]; C07D0417-00 [I,C];
                        C07D0417-14 [I,A]
                        C07D277/46; C07D417/14+277B+263B+207;
                 ECLA
                        C07D417/14+277B+277B+207; C07D417/14+277B+277B+211;
                        C07D417/14+277B+277B+213; C07D417/14+307+277B+277B;
                        C07D417/14+307B+277B+277B
 IN 2006DN03731
                 IPCI
                        C07D0277-46 [ICM, 7]; C07D0277-00 [ICM, 7, C*]
MX 2006PA07934
                 IPCI
                        A61K0031-427 [ICM,7]; C07D0277-46 [ICS,7]; C07D0277-00
                        [ICS, 7, C*]; C07D0417-14 [ICS, 7]; C07D0417-00 [ICS, 7, C*]
 NO 2006003606
                 IPCI
                        C07D0277-00 [I,C]; C07D0277-46 [I,A]
                 IPCR
                        C07D0277-00 [I,C]; C07D0277-46 [I,A]; C07D0417-00
                        [I,C*]; C07D0417-14 [I,A]
                 ECLA
                        C07D277/46; C07D417/14+277B+263B+207;
                        C07D417/14+277B+277B+207; C07D417/14+277B+277B+211;
                        C07D417/14+277B+277B+213; C07D417/14+307+277B+277B;
                        C07D417/14+307B+277B+277B
OS
```

$$R^{4}$$
 $N$ 
 $R^{2}$ 
 $N$ 
 $R^{2}$ 
 $N$ 
 $R^{2}$ 
 $N$ 
 $R^{3}$ 
 $N$ 
 $R^{1}$ 

AB The title compds. I [R1 = NR5R6; R2, R3, R5 = H, alkyl, alkenyl, alkynyl; R4 = H, alkyl, alkenyl, alkynyl, NR8R9 (wherein R8, R9 = H, alkyl, alkenyl, etc.); R6 = alkyl, aryl, heteroaryl, etc.], useful in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 3- [(aminocarbonothioyl)amino]benzoic acid with N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide (preparation given) afforded II.HBr which showed IC50 of 10 nM against PI3Kγ.

ST thiazole prepn phosphoinositide 3 kinase PI3K gamma modulator

Ι

ΙI

IT Nervous system, disease

(Huntington's chorea, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Sarcoma

(Kaposi's, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle, disease

(atrophy, treating or preventing skeletal muscle atrophy; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Infection

(bacterial, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Muscle

(cardiac, treating or preventing cardiac myocyte dysfunction; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Hypertrophy

(cardiac, treating or preventing; preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))

IT Lung, disease

```
(chronic obstructive pulmonary disease, treating or
        preventing; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
     Nervous system, disease
        (degeneration, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Kidney, disease
        (fibrosis, treating or preventing progressive renal fibrosis;
        preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
     Inflammation
ΤТ
     Kidney, disease
        (glomerulonephritis, treating or preventing; preparation of
        thiazole derivs. as modulators of the phosphoinositide 3-kinases
        (PI3Ks))
ΤТ
     Kidney, disease
        (glomerulosclerosis, treating or preventing; preparation of
        thiazole derivs. as modulators of the phosphoinositide 3-kinases
        (PI3Ks))
     Muscle, disease
ΤT
        (hypertrophy, treating or preventing skeletal muscle
        atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
     Heart, disease
ΙT
        (hypertrophy, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Brain, disease
        (infection, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΤТ
     Intestine, disease
        (inflammatory, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
TT
     Lung, disease
     Reperfusion
        (injury, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
        (metastasis, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Hypertrophy
        (muscular, treating or preventing skeletal muscle
        atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
    Heart.
        (myocardium, treating or preventing cardiac myocyte
        dysfunction; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
     Inflammation
ΙT
     Lung, disease
        (pneumonitis, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
TΤ
     Allergy inhibitors
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiasthmatics
     Antibacterial agents
     Anticoagulants
     Antihypertensives
     Antirheumatic agents
```

```
Antitumor agents
     Antiviral agents
     Cardiovascular agents
     Human
     Immunosuppressants
     Platelet aggregation inhibitors
        (preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
ΙΤ
     Injury
        (pulmonary, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Fibrosis
        (renal, treating or preventing progressive renal fibrosis;
        preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
ΙT
     Injury
        (reperfusion, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
TΤ
     Brain, disease
        (stroke, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Lupus erythematosus
        (systemic, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Central nervous system, disease
        (trauma, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Leukocyte
        (treating or preventing leukocyte recruitment in cancer
        tissue; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
     Allergy
ΤТ
     Alzheimer's disease
     Anaphylaxis
     Angiogenesis
     Asthma
     Atherosclerosis
     Autoimmune disease
     Cardiovascular system, disease
     Encephalitis
     Fibrosis
     Hypertension
     Inflammation
       Ischemia
     Kidney, disease
     Melanoma
     Meningitis
     Multiple sclerosis
     Neoplasm
     Platelet aggregation
     Psoriasis
     Rheumatoid arthritis
     Sepsis
     Thrombosis
     Transplant and Transplantation
     Transplant rejection
     Vasoconstriction
        (treating or preventing; preparation of thiazole derivs. as
        modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Infection
        (viral, treating or preventing; preparation of thiazole derivs. as
```

modulators of the phosphoinositide 3-kinases (PI3Ks)) ΤТ 115926-52-8 RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks)) 860619-39-2P 860619-58-5P 860619-75-6P 860620-37-7P ΙT 860619-22-3P 860620-38-8P 860620-39-9P 860620-40-2P 860620-42-4P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks)) ΙΤ 32558-17-1P 307343-36-8P 315704-54-2P 315705-71-6P 315705-72-7P 315705-74-9P 315705-75-0P 315705-76-1P 315705-77-2P 315705-78-3P 315705-79-4P 315705-80-7P 315705-81-8P 315705-82-9P 315705-83-0P 315705-87-4P 315705-90-9P 315705-91-0P 315705-92-1P 315705-86-3P 315705-94-3P 315705-95-4P 333746-52-4P 333746-55-7P 333746-64-8P 412919-76-7P 333746-84-2P 421580-61-2P 428836-20-8P 443747-65-7P 860619-23-4P 472980-88-4P 860619-24-5P 860619-25-6P 860619-26-7P 860619-27-8P 860619-28-9P 860619-30-3P 860619-29-0P 860619-31-4P 860619-32-5P 860619-33-6P 860619-34-7P 860619-35-8P 860619-36-9P 860619-37-0P 860619-38-1P 860619-40-5P 860619-41-6P 860619-42-7P 860619-43-8P 860619-44-9P 860619-45-0P 860619-46-1P 860619-47-2P 860619-48-3P 860619-49-4P 860619-50-7P 860619-51-8P 860619-52-9P 860619-53-0P 860619-54-1P 860619-55-2P 860619-56-3P 860619-57-4P 860619-59-6P 860619-60-9P 860619-61-0P 860619-62-1P 860619-63-2P 860619-67-6P 860619-64-3P 860619-65-4P 860619-66-5P 860619-68-7P 860619-69-8P 860619-70-1P 860619-71-2P 860619-72-3P 860619-73-4P 860619-74-5P 860619-76-7P 860619-77-8P 860619-78-9P 860619-79-0P 860619-80-3P 860619-84-7P 860619-81-4P 860619-82-5P 860619-83-6P 860619-85-8P 860619-86-9P 860619-87-0P 860619-89-2P 860619-88-1P 860619-90-5P 860619-91-6P 860619-92-7P 860619-93-8P 860619-94-9P 860619-95-0P 860619-96-1P 860619-98-3P 860620-00-4P 860620-02-6P 860620-03-7P 860620-04-8P 860620-05-9P 860620-06-0P 860620-07-1P 860620-08-2P 860620-09-3P 860620-10-6P 860620-11-7P 860620-12-8P 860620-13-9P 860620-14-0P 860620-15-1P 860620-16-2P 860620-17-3P 860620-18-4P 860620-19-5P 860620-20-8P 860620-21-9P 860620-22-0P 860620-23-1P 860620-24-2P 860620-25-3P 860620-26-4P 860620-27-5P 860620-28-6P 860620-29-7P 860620-30-0P 860620-31-1P 860620-32-2P 860620-33-3P 860620-34-4P 860620-35-5P 860620-36-6P 860620-41-3P 860620-43-5P 860620-44-6P 860620-45-7P 860620-46-8P 860620-47-9P 860620-48-0P 860620-49-1P 860620-50-4P 860620-51-5P 860620-52-6P 860620-53-7P 860620-70-8P 860620-75-3P 860620-76-4P 860620-77-5P 860620-87-7P 860620-78-6P 860620-83-3P 860620-84-4P 860620-86-6P 860620-88-8P 860620-89-9P 860621-18-7P 860621-19-8P 860621-20-1P 860621-21-2P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of thiazole derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks)) ΙT 79-19-6, Thiosemicarbazide 103-85-5, N-Phenylthiourea 107-95-9, 109-57-9, N-Allylthiourea 109-94-4, Ethyl formate β-Alanine 121-92-6, 3-Nitrobenzoic acid 123-54-6, 2,4-Pentanedione, reactions 621-83-0, N-Benzylthiourea 367-57-7, 1,1,1-Trifluoropentane-2,4-dione 709-72-8 1516-33-2, N-Isobutylthiourea 1516-37-6, N-(2-1520-26-9 1520-27-0, N-(4-2237-30-1, 3-Aminobenzonitrile Methoxyphenyl)thiourea Hydroxyphenyl)thiourea 2293-07-4, 2295-31-0, 2,4-Thiazolidinedione N-(4-Methoxyphenyl)thiourea 3394-05-6, N-(3-Hydroxyphenyl)thiourea 3460-55-7, N-(4-Cyanophenyl)thiourea 3696-22-8, N-(4-Nitrophenyl)thiourea 3696-23-9,

```
N-(4-Chlorophenyl)thiourea 4947-89-1, N-(3-Chlorophenyl)thiourea
5055-72-1, N-Cyclohexylthiourea 5100-34-5, Ethyl 3-isocyanatopropionate
5344-82-1, N-(2-Chlorophenyl)thiourea 5657-42-1 6814-99-9,
N-(sec-Butyl)thiourea 6815-00-5, N-(2-Phenylethyl)thiourea
                        7366-56-5 14294-09-8, 1-
N-(tert-Butyl)thiourea
Piperidinecarbothioamide 14294-10-1, 4-Morpholinecarbothioamide
14294-11-2, N-Pyridin-2-ylthiourea 20602-45-3
                                                 25343-29-7,
N-(2,2-Dimethylpropyl)thiourea 25433-09-4 29146-81-4 30162-37-9,
N-Pyridin-3-ylthiourea 30162-39-1 30381-21-6, N-(2-Cyanoethyl)thiourea
30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 33860-28-5,
4-Methylpiperazine-1-carbothioamide 37014-08-7 37182-75-5
40398-36-5, 1-Pyrrolidinecarbothioamide 51039-84-0
55130-40-0 56541-14-1, N-Cyclopropylthiourea 61451-94-3,
N-(2,3-Dihydro-1H-inden-2-yl)thiourea 63467-61-8, N-(2,2-yl)
Diethoxyethyl)thiourea 66892-01-1 66892-25-9, N-(Tetrahydrofuran-2-
ylmethyl)thiourea
                   72806-58-7 73161-70-3, N-(Pyridin-3-
                   73434-75-0, N-(2-Hydroxy-2-phenylethyl)thiourea
ylmethyl)thiourea
74764-61-7 86114-63-8 99115-47-6 102353-42-4, N-(2-
Methoxyethyl)thiourea 102936-57-2, N-Cyclopentylthiourea
                                                           111538-46-6,
N-(3-(Morpholin-4-yl)propyl)thiourea 122641-10-5, N-(2-(Morpholin-4-yl)propyl)
vl)ethvl)thiourea
                  125117-97-7, N-(6-Chloropyridin-3-yl)thiourea
             171874-49-0, N-[2-(2-Hydroxyethyl)phenyl]thiourea
140899-50-9
                          206761-87-7, N-(2-(Piperidin-1-
179927-28-7
             196809-80-0
vl)ethvl)thiourea
                  227932-43-6
                                237385-80-7, N-[3-
(Hydroxymethyl)phenyl]thiourea
                               282715-65-5, N-(Pyridin-4-
vlmethvl)thiourea 342626-46-4
                                420130-44-5, N-(6-Methoxypyridin-3-
            473706-96-6
                          473706-97-7 500865-55-4 572889-33-9,
yl)thiourea
N-Cyclobutylthiourea 618913-44-3, N-(Cyclopropylmethyl)thiourea
659741-74-9
            659741-75-0
                           763887-70-3
                                       850164-09-9,
N-(3-Cyanophenyl)thiourea 859786-81-5
                                       860615-45-8,
N-(Benzofuran-5-yl)thiourea 860617-18-1, N-(2-Chloropyridin-4-
            860620-65-1 860620-66-2 860620-67-3 860620-68-4,
yl)thiourea
3-Hydroxypyrrolidine-1-carbothioamide 860620-69-5, N-(2-Fluoropyridin-3-
yl)thiourea 860620-71-9, N-(3,3-Diethoxypropyl)thiourea 860620-72-0,
N-(2-Chloropyridin-3-y1)thiourea 860620-73-1, N-[3-(1,3-0xazol-5-x)]
yl)phenyl]thiourea 860620-74-2, N-[3-(1H-Tetrazol-5-yl)phenyl]thiourea
860620-79-7, N-[3-(5-Hydroxy-1,3,4-oxadiazol-2-yl)phenyl]thiourea
860620-80-0, N-[3-(5-Amino-1,3,4-thiadiazol-2-yl)phenyl]thiourea
860620-91-3
            860620-92-4, N-[4-(2-Hydroxyethyl)phenyl]thiourea
860620-93-5, N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]thiourea
860620-95-7
            860620-96-8
                          860620-97-9
                                       860620-98-0
                                                      860620-99-1
860621-00-7 860621-01-8
                          860621-02-9 860621-03-0 860621-04-1
860621-05-2, N-(4-Hydroxybutyl)thiourea 860621-06-3 860621-07-4
860621-08-5
            860621-09-6 860621-10-9
                                         860621-11-0 860621-12-1
860621-13-2
                                       860621-16-5 860621-17-6
            860621-14-3
                           860621-15-4
RL: RCT (Reactant); RACT (Reactant or reagent)
   (preparation of thiazole derivs. as modulators of the phosphoinositide
   3-kinases (PI3Ks))
618-95-1P, Methyl 3-nitrobenzoate
                                 926-59-0P 3043-28-5P,
3-Bromo-2,4-pentanedione 4138-35-6P, Methyl 3-aminopropanoate
14062-34-1P
             32519-72-5P
                           32519-75-8P
                                         39884-12-3P 53159-71-0P,
1-(2-Amino-1,3-thiazol-5-yl) ethanone 83725-80-8P, 5-(3-Nitrophenyl)-
1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P, Ethyl
5-acetyl-2-amino-1,3-thiazole-4-carboxylate
                                           115082-05-8P
                                                           167405-28-9P,
1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-yl]ethanone 191399-17-4P,
1-(2-Amino-4-methyl-1,3-oxazol-5-yl)ethanone 299441-33-1P,
5-(3-Aminophenyl)-1,3,4-thiadiazol-2-amine 440087-89-8P 696629-98-860615-87-8P 860620-54-8P 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-
                                                         696629-98-8P
oxazol-2-yl)acetamide 860620-56-0P
                                    860620-57-1P, N-(5-Acetyl-1,3-
thiazol-2-yl)acetamide 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-
(trifluoromethyl)-1,3-thiazol-2-yl)acetamide 860620-60-6P
```

ΤТ

860620-61-7P, Ethyl 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate 860620-62-8P 860620-63-9P 860620-64-0P, N-[3-(5-Amino-[1,3,4]thiadiazol-2-yl)phenyl]-2,2,2-trifluoro-acetamide 860620-81-1P 860620-82-2P 860620-85-5P 860620-90-2P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of thiazole derivs. as modulators of the phosphoinositide

L32 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

ΙT 115926-52-8, PI3 kinase

3-kinases (PI3Ks))

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; VEGF receptor inhibitor combination with other agents for therapeutic use)

115926-52-8 CAPLUS RN

Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME) CN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* ACCESSION NUMBER: 2005:283364 CAPLUS

DOCUMENT NUMBER: 142:349102

TITLE: Combinations of a VEGF receptor inhibitor with other

agents for therapeutic use

Bold, Guido; Brueggen, Josef Bernhard; Huang, Jerry INVENTOR(S):

Min-Jian; Kinder, Frederick Ray; Lane, Heidi; Latour, Elisabeth Jeanne; Manley, Paul William; Wood, Jeanette

Mariorie

Novartis Ag, Switz.; Novartis Pharma GmbH PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA.	PATENT NO.					KIND DATE				APPI	LICAT		DATE				
	2005027973 2005027973								WO 2	2004-1		20040923					
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,
		SN,	TD,	ΤG													
AU	2004	2736	19		A1 20050331				AU 2	2004-		20040923					
CA	2539	230			A1 20050331			CA 2004-2539230						20040923			
EP	1667	721			A2 20060614			EP 2004-765555						20040923			
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	FΙ,	RO,	CY,	TR,	BG,	CZ,	EE,	HU,	PL,	SK				
	1856				Α		2006	1101		CN 2	2004-	8002	7535		20040923		
	R 2004014604										2004-		_			0040	
JP	JP 2007505939				Τ		2007	0315		JP 2	2006-	5273	55		20040923		
	2006		-		Α		2006	0605		MX 2	2006-1	PA31	64		20060320		320
IORIT	Y APP	LN.	INFO	.:						US 2	2003-	5052	55P		P 2	0030	923
										WO 2	2004-1	EP10	701	1	₩ 2	0040	923
HER SOURCE(S):				MAR]	PAT	142:	3491	02									

OTHER SOURCE(S): MARPAT 142:349102

```
2005:283364 CAPLUS
ΑN
DN
     142:349102
ΕD
     Entered STN: 01 Apr 2005
TΙ
     Combinations of a VEGF receptor inhibitor with other agents for
      therapeutic use
      Bold, Guido; Brueggen, Josef Bernhard; Huang, Jerry Min-Jian; Kinder,
ΙN
      Frederick Ray; Lane, Heidi; Latour, Elisabeth Jeanne; Manley, Paul
      William; Wood, Jeanette Marjorie
PA
      Novartis Aq, Switz.; Novartis Pharma GmbH
      PCT Int. Appl., 52 pp.
SO
      CODEN: PIXXD2
DT
      Patent
     English
LA
TC
      ICM A61K045-06
      ICS A61P035-00; A61P027-00; A61P009-00; A61P003-00
CC
      1-12 (Pharmacology)
FAN.CNT 1
      PATENT NO.
                           KIND DATE
                                                APPLICATION NO.
                           ____
                                                 _____

      WO 2005027973
      A2 20050331

      WO 2005027973
      A3 20050909

                                                                           20040923
                                                WO 2004-EP10701
PΙ
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
          NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
               SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
               SN, TD, TG
                                               AU 2004-273619
      AU 2004273619
                                    20050331
                                                                            20040923
                             Α1
     CA 2539230
                                               CA 2004-2539230
                             A1
                                    20050331
                                                                            20040923
      EP 1667721
                             A2
                                   20060614
                                               EP 2004-765555
                                                                            20040923
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
      CN 1856326
                    A
                                  20061101 CN 2004-80027535
                                                                           20040923
      BR 2004014604
                                   20061107
                                                BR 2004-14604
                                                                           20040923
                            Α
BR 2004014604 A 20061107
JP 2007505939 T 20070315
MX 2006PA03164 A 20060605
PRAI US 2003-505255P P 20030923
WO 2004-EP10701 W 20040923
                                   20070315
                                                 JP 2006-527355
                                                                           20040923
                                                 MX 2006-PA3164
                                                                            20060320
CLASS
 PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
 _____
                          ______
                 ICM
 WO 2005027973
                           A61K045-06
                           A61P035-00; A61P027-00; A61P009-00; A61P003-00
                   ICS
                           A61K0045-06 [ICM, 7]; A61K0045-00 [ICM, 7, C*];
                   IPCI
                           A61P0035-00 [ICS, 7]; A61P0027-00 [ICS, 7]; A61P0009-00
                           [ICS, 7]; A61P0003-00 [ICS, 7]
                           A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00
                   IPCR
                           [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*];
                           A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00
                           [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
                           A61K045/06
                   ECLA
 AU 2004273619
                   IPCI
                           A61K0045-00 [I,C]; A61P0003-00 [I,C]; A61P0009-00
                           [I,C]; A61P0027-00 [I,C]; A61P0035-00 [I,C];
                           A61K0045-06 [I,A]; A61P0003-00 [I,A]; A61P0009-00
                           [I,A]; A61P0027-00 [I,A]; A61P0035-00 [I,A]
                   IPCR
                           A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00
```

```
[I,C]; A61P0003-00 [I,A]; A61P0009-00 [I,C];
                       A61P0009-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00
                       [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]
CA 2539230
                IPCI
                       A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61P0003-00
                       [I,A]; A61P0009-00 [I,A]; A61P0027-00 [I,A];
                       A61P0035-00 [I,A]
                       A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00
                IPCR
                       [I,C]; A61P0003-00 [I,A]; A61P0009-00 [I,C];
                       A61P0009-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00
                       [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]
                ECLA
                       A61K045/06
EP 1667721
                IPCI
                       A61K0045-06 [ICM, 7]; A61K0045-00 [ICM, 7, C*];
                       A61P0035-00 [ICS,7]; A61P0027-00 [ICS,7]; A61P0009-00
                       [ICS, 7]; A61P0003-00 [ICS, 7]
                IPCR
                       A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00
                       [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*];
                       A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00
                       [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
                ECLA
                       A61K045/06
CN 1856326
                IPCI
                       A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61P0035-00
                       [I,A]; A61P0027-00 [I,A]; A61P0009-00 [I,A];
                       A61P0003-00 [I,A]
                       A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0003-00
                IPCR
                       [I,C*]; A61P0003-00 [I,A]; A61P0009-00 [I,C*];
                       A61P0009-00 [I,A]; A61P0027-00 [I,C*]; A61P0027-00
                       [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]
                       A61K045/06
                ECLA
BR 2004014604
                IPCI
                       A61K0045-06 [ICS, 7]; A61K0045-00 [ICS, 7, C*];
                       A61P0003-00 [ICS,7]; A61P0009-00 [ICS,7]; A61P0027-00
                       [ICS, 7]; A61P0035-00 [ICS, 7]
                IPCR
                       A61K0045-00 [I,C*]; A61P0003-00 [I,C*]; A61P0009-00
                       [I,C*]; A61P0027-00 [I,C*]; A61P0035-00 [I,C*];
                       A61K0045-06 [I,A]; A61P0003-00 [I,A]; A61P0009-00
                       [I,A]; A61P0027-00 [I,A]; A61P0035-00 [I,A]
                ECLA
                       A61K045/06
JP 2007505939
                IPCI
                       A61K0045-06 [I,A]; A61K0045-00 [I,C*]; A61K0031-502
                       [I,A]; A61P0017-06 [I,A]; A61P0009-10 [I,A];
                       A61P0015-00 [I,A]; A61P0001-04 [I,A]; A61P0019-02
                       [I,A]; A61P0019-00 [I,C*]; A61P0029-00 [I,A];
                       A61P0035-00 [I,A]; A61P0009-14 [I,A]; A61P0009-00
                       [I,C*]; A61P0027-02 [I,A]; A61P0003-10 [I,A];
                       A61P0003-00 [I,C*]; A61P0027-06 [I,A]; A61P0041-00
                       [I,A]; A61P0027-10 [I,A]; A61P0027-00 [I,C*];
                       A61P0013-12 [I,A]; A61P0013-00 [I,C*]; A61P0007-02
                       [I,A]; A61P0007-00 [I,C*]; A61P0037-06 [I,A];
                       A61P0037-00 [I,C*]; A61P0001-16 [I,A]; A61P0001-00
                       [I,C*]; A61P0025-00 [I,A]; A61P0017-00 [I,A];
                       A61P0017-02 [I,A]; A61P0011-06 [I,A]; A61P0011-00
                       [I,A]; A61P0043-00 [I,A]; C07D0401-06 [N,A];
                       C07D0401-00 [N,C*]
                IPCR
                       A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61K0031-502
                       [I,C]; A61K0031-502 [I,A]; A61P0001-00 [I,C];
                       A61P0001-04 [I,A]; A61P0001-16 [I,A]; A61P0003-00
                       [I,C]; A61P0003-00 [I,A]; A61P0003-10 [I,A];
                       A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0009-00
                       [I,C]; A61P0009-00 [I,A]; A61P0009-10 [I,A];
                       A61P0009-14 [I,A]; A61P0011-00 [I,C]; A61P0011-00
                       [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C];
                       A61P0013-12 [I,A]; A61P0015-00 [I,C]; A61P0015-00
                       [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A];
                       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
```

```
[I,C]; A61P0019-02 [I,A]; A61P0025-00 [I,C];
                        A61P0025-00 [I,A]; A61P0027-00 [I,C]; A61P0027-00
                        [I,A]; A61P0027-02 [I,A]; A61P0027-06 [I,A];
                        A61P0027-10 [I,A]; A61P0029-00 [I,C]; A61P0029-00
                        [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
                        A61P0037-00 [I,C]; A61P0037-06 [I,A]; A61P0041-00
                        [I,C]; A61P0041-00 [I,A]; A61P0043-00 [I,C];
                        A61P0043-00 [I,A]; C07D0401-00 [N,C]; C07D0401-06 [N,A]
                 FTERM 4C063/AA01; 4C063/BB03; 4C063/CC28; 4C063/DD12;
                        4C063/EE01; 4C084/AA19; 4C084/AA20; 4C084/MA02;
                        4C084/NA05; 4C084/NA14; 4C084/ZA011; 4C084/ZA331;
                        4C084/ZA361; 4C084/ZA441; 4C084/ZA451; 4C084/ZA541;
                        4C084/ZA591; 4C084/ZA661; 4C084/ZA681; 4C084/ZA751;
                        4C084/ZA811; 4C084/ZA891; 4C084/ZA961; 4C084/ZB071;
                        4C084/ZB081; 4C084/ZB111; 4C084/ZB151; 4C084/ZB261;
                        4C084/ZC021; 4C084/ZC351; 4C084/ZC751; 4C086/AA01;
                        4C086/AA02; 4C086/BC41; 4C086/MA02; 4C086/MA04;
                        4C086/NA05; 4C086/NA14; 4C086/ZA01; 4C086/ZA33;
                        4C086/ZA36; 4C086/ZA44; 4C086/ZA45; 4C086/ZA54;
                        4C086/ZA59; 4C086/ZA66; 4C086/ZA68; 4C086/ZA75;
                        4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB07;
                        4C086/ZB08; 4C086/ZB11; 4C086/ZB15; 4C086/ZB26;
                        4C086/ZC02; 4C086/ZC35; 4C086/ZC75
MX 2006PA03164 IPCI
                        A61K0045-06 [ICM, 7]; A61K0045-00 [ICM, 7, C*];
                        A61P0027-00 [ICS, 7]; A61P0003-00 [ICS, 7]; A61P0035-00
                        [ICS, 7]; A61P0009-00 [ICS, 7]
                        A61K045/06
                 ECLA
OS
    MARPAT 142:349102
AΒ
     The invention discloses a combination therapy for treating
     patients suffering from diseases characterized by cell proliferation and
     infiltration of inflammatory cells, coronary diseases, hypertension, renal
     diseases, diabetes, or ocular diseases and conditions. The patient is
     treated with a combination of a VEGF inhibitor compound and one or more
     second therapeutic agents selected from angiostatic steroids,
     photosensitizers, implants containing corticosteroids, AT1 receptor
     antagonists, ACE inhibitors, cyclooxygenase inhibitors, IGF-IR inhibitors,
     mTOR kinase inhibitors, somatostatin receptor antagonists, P13K
     inhibitors, Raf kinase inhibitors, PKC inhibitors; xiii. integrin
     antagonists, endogenous anti-angiogenic mols., and PEDF (pigment
     epithelium-derived factor) and analogs.
ST
     VEGF receptor inhibitor combination therapeutic; cell proliferation
     inflammatory cell infiltration VEGF receptor inhibitor combination;
     coronary renal disease hypertension VEGF receptor inhibitor combination
     therapeutic; diabetes eye disease VEGF receptor inhibitor combination
     therapeutic
ΤТ
    Inflammation
        (Crohn's disease; VEGF receptor inhibitor combination with other agents
        for therapeutic use)
ΙT
     Intestine, disease
        (Crohn's; VEGF receptor inhibitor combination with other agents for
        therapeutic use)
TΤ
     Angiogenesis inhibitors
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiarteriosclerotics
     Antiarthritics
     Antiasthmatics
     Anticoaqulants
     Antidiabetic agents
     Antiglaucoma agents
     Antihypertensives
```

Antirheumatic agents Antitumor agents Arteriosclerosis Arthritis Asthma Cardiovascular agents Cell proliferation Cirrhosis Combination chemotherapy Cytotoxic agents Diabetes mellitus Drug delivery systems Eye, disease Fibrosis Gastrointestinal agents Heart, disease Human Hypertension Immunosuppressants Inflammation Kidney, disease Nervous system agents Photosensitizers, pharmaceutical Prophylaxis Rheumatoid arthritis Thrombosis Transplant rejection Wound Wound healing promoters (VEGF receptor inhibitor combination with other agents for therapeutic Vascular endothelial growth factor receptors ТТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (VEGF receptor inhibitor combination with other agents for therapeutic TΤ Corticosteroids, biological studies RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (VEGF receptor inhibitor combination with other agents for therapeutic use) ΙT Aging, animal (age spots; VEGF receptor inhibitor combination with other agents for therapeutic use) ΙT Blood vessel, neoplasm (angiofibroma; VEGF receptor inhibitor combination with other agents for therapeutic use) ΤТ Steroids, biological studies RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (angiostatic; VEGF receptor inhibitor combination with other agents for therapeutic use) ΙT Angiotensin AT1 receptors Integrins Somatostatin receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; VEGF receptor inhibitor combination with other agents for therapeutic use) ΙT Blood vessel (artificial; VEGF receptor inhibitor combination with other agents for therapeutic use) Bronchi, disease ΤТ

Inflammation

(chronic bronchitis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Dermatitis

(contact; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Transplant and Transplantation

(cornea, after-effects; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye

(cornea, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eve

(cornea, transplant, after-effects; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease

(cystoid macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease

(diabetic macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease

(diabetic nephropathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease

(diabetic retinopathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Uterus, disease

(endometriosis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Inflammation

Kidney, disease

(glomerulonephritis; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease

(glomerulus; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, neoplasm

(hemangioma; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Drug delivery systems

(implants, corticosteroid-containing; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Insulin-like growth factor I receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Nerve, disease

(injury; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye

(iris, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Ischemia

(ischemic retinopathy; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Transplant and Transplantation

(kidney; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease

(macula, senile degeneration; VEGF receptor inhibitor combination with

other agents for therapeutic use)

IT Eye, disease

(macular edema; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Medical goods

(mech. devices for holding vessels open; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney

(mesangium, proliferative disease; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, disease

(microangiopathy, thrombotic microangiopathic syndrome; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vision disorders

(myopia, pathol.; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Glaucoma (disease)

(neovascular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiogenesis

(neovascularization, ocular; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angiogenesis

(neovascularization, retinal; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney, disease

(nephrosclerosis, malignant; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Injury

(neuronal; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Vein, disease

(occlusion, central vein occlusion; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Blood vessel, disease

(occlusion, re-occlusion after balloon catheter treatment; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Histoplasma capsulatum

IT Disease, animal

(proliferative; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Angioplasty

(re-occlusion after; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Artery, disease

(restenosis, stent-induced; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease

(retina, neovascularization; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease

(retinopathy, ischemic; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Eye, disease

(retrolental fibroplasia; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Wound healing

(scar-free; VEGF receptor inhibitor combination with other agents for

therapeutic use)

IT Medical goods

(stents, restenosis induced by; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT Kidney

(transplant; VEGF receptor inhibitor combination with other agents for therapeutic use)

IT 127464-60-2, VEGF 386705-49-3, Vascular endothelial growth factor receptor kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (VEGF receptor inhibitor combination with other agents for therapeutic use)

IT 50-02-2, Dexamethasone 124-94-7, Triamcinolone 807-38-5, Fluocinolone 7753-60-8, Anecortave 83150-76-9, Octreotide 86541-75-5, Benazepril 129497-78-5, BPD-MA 137862-53-4, Valsartan 159351-69-6, Everolimus 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 197980-93-1, Pigment epithelium-derived factor 197980-93-1D, Pigment epithelium-derived factor, analogs 212141-54-3 220991-20-8, Lumiracoxib 396091-73-9, SOM230

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(VEGF receptor inhibitor combination with other agents for therapeutic use)

IT 9015-82-1 39391-18-9, Cyclooxygenase 103843-29-4, IGF-1 receptor
 tyrosine kinase 115926-52-8, PI3 kinase 139691-76-2, Raf
 kinase 141436-78-4, Protein kinase C 171715-28-9, MTOR kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; VEGF receptor inhibitor combination with other agents for
 therapeutic use)

L32 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 39755-95-8, 5-Methoxy isatin

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

RN 39755-95-8 CAPLUS

CN 1H-Indole-2,3-dione, 5-methoxy- (CA INDEX NAME)

ACCESSION NUMBER: 2005:238947 CAPLUS

DOCUMENT NUMBER: 142:316831

TITLE: Preparation of amides of pyrazolamines and anilines as

well as analogs as cytokine inhibitors for the

treatment of inflammatory diseases

INVENTOR(S): Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet,

Nancy G. J.; Ernst, Justin; Montalban, Antonio G.;

Kahl, Jeffrey D.; Larson, Christopher; Miller,

Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah,

Eddine; Sullivan, Robert; Wang, Zhijun

PATENT ASSIGNEE(S): Kemia, Inc., USA

SOURCE: PCT Int. Appl., 316 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

```
APPLICATION NO.
     PATENT NO.
                          KIND DATE
                                                                            DATE
                                                _____
                           ----
     _____
                                                                           _____
     WO 2005023761 A2 20050317 WO 2005023761 A3 20050714
                                               WO 2004-US29372
                                                                           20040910
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
              SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
              SN, TD, TG
     AU 2004270733
                                    20050317
                                                 AU 2004-270733
                             Α1
                                                                            20040910
     CA 2538820
                             Α1
                                    20050317
                                                 CA 2004-2538820
                                                                            20040910
                                               US 2004-939324
EP 2004-809707
                                 20050519
20060621
     US 20050107399
                             Α1
                                                                            20040910
     EP 1670787
                             Α2
                                                                            20040910
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
                                 20061107
                                               BR 2004-14313
                                                                       20040910
     BR 2004014313 A
     CN 1878769 A 20061213
JP 2007505127 T 20070308
KR 2007020370 A 20070221
MX 2006PA02853 A 20060614
IN 2006KN00791 A 20080215
                                               CN 2004-80033055
JP 2006-526272
KR 2006-705055
                                                                            20040910
                                                                            20040910
                                                                            20060310
                                               KR 2006-705055 20060310

MX 2006-PA2853 20060313

IN 2006-KN791 20060331

US 2003-502569P P 20030911

US 2003-531234P P 20031218

US 2004-575704P P 20040528

US 2004-585012P P 20040702
PRIORITY APPLN. INFO.:
                                                  WO 2004-US29372 W 20040910
OTHER SOURCE(S):
                            CASREACT 142:316831; MARPAT 142:316831
     2005:238947 CAPLUS
DN
     142:316831
ΕD
     Entered STN: 18 Mar 2005
     Preparation of amides of pyrazolamines and anilines as well as analogs as
     cytokine inhibitors for the treatment of inflammatory diseases
     Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet, Nancy G. J.; Ernst,
ΤN
     Justin; Montalban, Antonio G.; Kahl, Jeffrey D.; Larson, Christopher;
     Miller, Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah, Eddine;
     Sullivan, Robert; Wang, Zhijun
PA
     Kemia, Inc., USA
     PCT Int. Appl., 316 pp.
SO
     CODEN: PIXXD2
DT
     Patent
     English
LA
IC
     ICM C07D
     28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
     Section cross-reference(s): 1, 63
FAN.CNT 1
     PATENT NO.
                           KIND
                                   DATE
                                                APPLICATION NO.
                                                 _____

      WO 2005023761
      A2
      20050317

      WO 2005023761
      A3
      20050714

                                                 WO 2004-US29372
                                                                            20040910
PΙ
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
```

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

```
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004270733
                         Α1
                               20050317
                                          AU 2004-270733
                                                                  20040910
     CA 2538820
                               20050317
                                          CA 2004-2538820
                        A1
     US 20050107399
                              20050519 US 2004-939324
                        A1
                                                                 20040910
                              20060621 EP 2004-809707
     EP 1670787
                        A2
                                                                  20040910
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
                             20061107 BR 2004-14313
     BR 2004014313 A
                                                                 20040910
                       A
T
                               20061213
                                          CN 2004-80033055
     CN 1878769
                                                                 20040910
     JP 2007505127
                              20070308
                                           JP 2006-526272
                                                                 20040910
     KR 2007020370
                       А
                              20070221
                                          KR 2006-705055
                                                                 20060310
     MX 2006PA02853
                        Α
                              20060614
                                          MX 2006-PA2853
                                                                 20060313
                        A
P
     IN 2006KN00791
                               20080215
                                          IN 2006-KN791
                                                                 20060331
PRAI US 2003-502569P
                               20030911
                        Р
     US 2003-531234P
                               20031218
                        P
P
     US 2004-575704P
                               20040528
    US 2004-585012P
WO 2004-US29372
                               20040702
                        W
                               20040910
CLASS
               CLASS PATENT FAMILY CLASSIFICATION CODES
 PATENT NO.
 WO 2005023761
               ICM
                       C07D
                IPCI
                       C07D [ICM, 7]
                 IPCR
                       A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S];
                       C07D0403-00 [I,C*]; C07D0403-12 [I,A]
                       C07D0403-00 [I,C*]; A61K0031-416 [I,C*]; C07D0403-12
 AU 2004270733
                IPCI
                       [I,A]; A61K0031-416 [I,A]
                       C07D0403-00 [I,C*]; C07D0403-12 [I,A]; A61K0031-416
                 IPCR
                       [I,C*]; A61K0031-416 [I,A]; C07D [I,S]
 CA 2538820
                 IPCI
                       A61K0031-416 [I,A]; C07D0403-12 [I,A]; C07D0403-00
                       [I,C*]
                 IPCR
                       C07D0403-00 [I,C]; C07D0403-12 [I,A]; A61K0031-416
                       [I,C]; A61K0031-416 [I,A]; C07D [I,S]
 US 20050107399
                IPCI
                       A61K0031-4965 [ICM, 7]
                 IPCR
                       A61K0031-4965 [I,C*]; A61K0031-4965 [I,A]
                 NCL
                       514/255.060; 514/356.000; 514/617.000
 EP 1670787
                 IPCI
                       C07D0403-12 [ICM, 7]; C07D0403-00 [ICM, 7, C^*];
                       A61K0031-416 [ICS, 7]
                       A61K0031-416 [I,C*]; A61K0031-416 [I,A]; C07D [I,S];
                 IPCR
                       C07D0403-00 [I,C*]; C07D0403-12 [I,A]
                       C07D0403-12 [ICS, 7]; C07D0403-00 [ICS, 7, C*];
 BR 2004014313
                 IPCI
                       A61K0031-416 [ICS, 7]
                       A61K0031-416 [I,C*]; C07D0403-00 [I,C*]; A61K0031-416
                 IPCR
                       [I,A]; C07D0403-12 [I,A]
 CN 1878769
                 IPCI
                       C07D0403-12 [I,A]; C07D0403-00 [I,C*]; A61K0031-416
                       [I,A]
                       C07D0403-00 [I,C]; C07D0403-12 [I,A]
                 IPCR
                       C07D0207-40 [I,A]; C07D0207-00 [I,C*]; C07D0231-38
 JP 2007505127
                IPCI
                       [I,A]; C07D0231-00 [I,C*]; C07D0239-47 [I,A];
                       C07D0239-00 [I,C*]; C07D0249-12 [I,A]; C07D0249-00
                       [I,C*]; C07D0253-06 [I,A]; C07D0253-00 [I,C*];
                       C07D0295-08 [I,A]; C07D0295-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0471-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0487-00 [I,C*]; A61K0031-415 [I,A]; A61K0031-437
```

```
[I,A]; A61K0031-4353 [I,C*]; A61K0031-5375 [I,A];
       A61K0031-5377 [I,A]; A61P0001-02 [I,A]; A61P0001-04
       [I,A]; A61P0001-14 [I,A]; A61P0001-18 [I,A];
       A61P0001-00 [I,C*]; A61P0003-00 [I,A]; A61P0003-04
       [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
       A61P0005-48 [I,A]; A61P0005-00 [I,C*]; A61P0007-00
       [I,A]; A61P0007-02 [I,A]; A61P0009-00 [I,A];
       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0009-14
       [I,A]; A61P0011-00 [I,A]; A61P0011-02 [I,A];
      A61P0011-06 [I,A]; A61P0011-10 [I,A]; A61P0013-02
       [I,A]; A61P0013-12 [I,A]; A61P0013-00 [I,C*];
      A61P0015-00 [I,A]; A61P0017-00 [I,A]; A61P0017-02
       [I,A]; A61P0017-06 [I,A]; A61P0017-10 [I,A];
      A61P0019-02 [I,A]; A61P0019-06 [I,A]; A61P0019-10
       [I,A]; A61P0019-00 [I,C*]; A61P0021-00 [I,A];
       A61P0025-00 [I,A]; A61P0025-04 [I,A]; A61P0025-08
       [I,A]; A61P0025-14 [I,A]; A61P0025-16 [I,A];
       A61P0025-18 [I,A]; A61P0025-22 [I,A]; A61P0025-24
       [I,A]; A61P0025-28 [I,A]; A61P0025-30 [I,A];
       A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0027-14
       [I,A]; A61P0027-00 [I,C*]; A61P0029-00 [I,A];
       A61P0031-04 [I,A]; A61P0031-08 [I,A]; A61P0031-12
       [I,A]; A61P0031-18 [I,A]; A61P0031-00 [I,C*];
       A61P0033-06 [I,A]; A61P0033-00 [I,C*]; A61P0035-00
       [I,A]; A61P0037-00 [I,A]; A61P0037-02 [I,A];
       A61P0039-00 [I,A]; A61P0043-00 [I,A]
IPCR
      C07D0207-00 [I,C]; C07D0207-40 [I,A]; A61K0031-415
       [I,C]; A61K0031-415 [I,A]; A61K0031-416 [I,C^*];
       A61K0031-416 [I,A]; A61K0031-4353 [I,C]; A61K0031-437
       [I,A]; A61K0031-5375 [I,C]; A61K0031-5375 [I,A];
       A61K0031-5377 [I,A]; A61P0001-00 [I,C]; A61P0001-02
       [I,A]; A61P0001-04 [I,A]; A61P0001-14 [I,A];
      A61P0001-18 [I,A]; A61P0003-00 [I,C]; A61P0003-00
       [I,A]; A61P0003-04 [I,A]; A61P0003-06 [I,A];
       A61P0003-10 [I,A]; A61P0005-00 [I,C]; A61P0005-48
       [I,A]; A61P0007-00 [I,C]; A61P0007-00 [I,A];
       A61P0007-02 [I,A]; A61P0009-00 [I,C]; A61P0009-00
       [I,A]; A61P0009-04 [I,A]; A61P0009-10 [I,A];
      A61P0009-14 [I,A]; A61P0011-00 [I,C]; A61P0011-00
       [I,A]; A61P0011-02 [I,A]; A61P0011-06 [I,A];
      A61P0011-10 [I,A]; A61P0013-00 [I,C]; A61P0013-02
       [I,A]; A61P0013-12 [I,A]; A61P0015-00 [I,C];
      A61P0015-00 [I,A]; A61P0017-00 [I,C]; A61P0017-00
       [I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A];
      A61P0017-10 [I,A]; A61P0019-00 [I,C]; A61P0019-02
       [I,A]; A61P0019-06 [I,A]; A61P0019-10 [I,A];
       A61P0021-00 [I,C]; A61P0021-00 [I,A]; A61P0025-00
       [I,C]; A61P0025-00 [I,A]; A61P0025-04 [I,A];
       A61P0025-08 [I,A]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-18 [I,A]; A61P0025-22 [I,A];
       A61P0025-24 [I,A]; A61P0025-28 [I,A]; A61P0025-30
       [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A];
       A61P0027-06 [I,A]; A61P0027-14 [I,A]; A61P0029-00
       [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C];
       A61P0031-04 [I,A]; A61P0031-08 [I,A]; A61P0031-12
       [I,A]; A61P0031-18 [I,A]; A61P0033-00 [I,C];
       A61P0033-06 [I,A]; A61P0035-00 [I,C]; A61P0035-00
       [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A];
       A61P0037-02 [I,A]; A61P0039-00 [I,C]; A61P0039-00
       [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D
       [I,S]; C07D0231-00 [I,C]; C07D0231-38 [I,A];
```

```
C07D0239-00 [I,C]; C07D0239-47 [I,A]; C07D0249-00
                        [I,C]; C07D0249-12 [I,A]; C07D0253-00 [I,C];
                        C07D0253-06 [I,A]; C07D0295-00 [I,C]; C07D0295-08
                        [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A];
                        C07D0471-00 [I,C]; C07D0471-04 [I,A]; C07D0487-00
                        [I,C]; C07D0487-04 [I,A]
                       4C050/AA01; 4C050/BB05; 4C050/CC05; 4C050/EE04;
                 FTERM
                        4C050/FF02; 4C050/FF05; 4C050/GG01; 4C050/HH04;
                        4C065/AA04; 4C065/BB06; 4C065/CC01; 4C065/DD03;
                        4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK09;
                        4C065/LL04; 4C065/PP03; 4C065/PP04; 4C069/AC32;
                        4C069/BB08; 4C069/BB16; 4C086/AA01; 4C086/AA02;
                        4C086/AA03; 4C086/BC36; 4C086/BC73; 4C086/CB03;
                        4C086/CB05; 4C086/GA07; 4C086/GA12; 4C086/MA01;
                        4C086/MA04; 4C086/NA14; 4C086/ZA02; 4C086/ZA06;
                        4C086/ZA08; 4C086/ZA12; 4C086/ZA16; 4C086/ZA18;
                        4C086/ZA21; 4C086/ZA22; 4C086/ZA29; 4C086/ZA33;
                        4C086/ZA34; 4C086/ZA36; 4C086/ZA44; 4C086/ZA45;
                        4C086/ZA51; 4C086/ZA54; 4C086/ZA59; 4C086/ZA63;
                        4C086/ZA66; 4C086/ZA68; 4C086/ZA69; 4C086/ZA70;
                        4C086/ZA75; 4C086/ZA81; 4C086/ZA89; 4C086/ZA94;
                        4C086/ZA96; 4C086/ZA97; 4C086/ZB01; 4C086/ZB07;
                        4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB21;
                        4C086/ZB26; 4C086/ZB33; 4C086/ZB35; 4C086/ZB37;
                        4C086/ZC01; 4C086/ZC31; 4C086/ZC33; 4C086/ZC35;
                        4C086/ZC37; 4C086/ZC39; 4C086/ZC41; 4C086/ZC54;
                        4C086/ZC55
                        A61K0031-416 [I,A]; C07D0403-12 [I,A]; C07D0403-00
 KR 2007020370
                 IPCI
                        [I,C*]; A61K0031-4965 [I,A]
MX 2006PA02853
                 IPCI
                        A61K0031-416 [ICM, 7]; C07D0403-12 [ICS, 7]; C07D0403-00
                        [ICS, 7, C*]
                        C07D0403-12 [ICM, 7]; C07D0403-00 [ICM, 7, C*];
 IN 2006KN00791
                 IPCI
                        A61K0031-416 [ICS, 7]
     CASREACT 142:316831; MARPAT 142:316831
OS
GΙ
```

AB Title compds., such as I and II (four Markush structures are claimed), wherein X = C(0), C(S) or CH2; G = (un) substituted carbocyclyl or heterocyclyl; Ar = indazolyl, indolyl, pyrazolyl, alkyl, etc.; L = covalent bond or (un) substituted carbon chain; Q = H, (un) substituted amino, cycloalkyl, heterocyclyl, alkoxy or sulfonyl; with some limitations and exclusions, and stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, were prepared as cytokine inhibitors. For instance, cyclization of p-tolylhydrazine hydrochloride with 4,4-dimethyl-3-oxopentanenitrile to the corresponding pyrazolamine

(92% yield) followed by EDC-mediated coupling with indazole-3-carboxylic acid gave indazolopyrazole III (40% yield). I were found to have activity in the TNFa ELISA assay, with some compds. having IC50 < 10  $\mu$ M. Therefore, I and their pharmaceutical compns. are useful in preventing or treating conditions mediated by cytokines, such as arthritis and inflammatory diseases.

ST pyrazolamine aniline amide prepn cytokine TNF inhibitor antiinflammatory agent

IT AIDS (disease)

(AIDS dementia complex, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Mental and behavioral disorders

(AIDS dementia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lymph node, disease

(Castleman's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation

(Crohn's disease, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Intestine, disease

(Crohn's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Selectins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (E-, compns. comprising of inhibitors of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease

(Gilles de la Tourette syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nervous system, disease

(Guillain-Barre syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nervous system, disease

(Huntington's chorea, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease

(MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Muscle, disease

(MERRF (myoclonic epilepsy associated with ragged-red muscle fibers), treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Arthritis

(Reiter's syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Brain, disease

(Rett syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Anti-infective agents

(SARS; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Pain

(acute, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Respiratory distress syndrome

(adult, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Allergy

Eye, disease Inflammation

(allergic conjunctivitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Allergy

Inflammation

Nose, disease

(allergic rhinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Transplant rejection

(allotransplant; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nervous system, disease

(amyotrophic lateral sclerosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Nervous system agents

(amyotrophic lateral sclerosis; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Artery, disease

Inflammation

(arteritis, Takayasu, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Disease, animal

(arthropathy, bursitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Animal tissue

(artificial, phantom, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Infection

(aseptic meningitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Meningitis

(aseptic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Dermatitis

(atopic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Meningitis

(bacterial, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Bronchi, disease

Inflammation

(bronchitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Medical goods

(cannulas; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Ischemia

(cardiac, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Heart, disease

(cardiomyopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Inflammation

(carditis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

IT Lung, disease

(chronic obstructive pulmonary disease, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Inflammation Lung, disease (chronic pneumonitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) (chronic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Headache (cluster, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Intestine, neoplasm (colon, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Adhesion, biological (compns. comprising of inhibitors; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Angiogenesis inhibitors Anticoagulants Cytotoxic agents Immunomodulators Immunosuppressants (compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) CTLA-4 (antigen) Glucocorticoids Interleukin 1 receptor antagonist LFA-1 (antigen) Macrolides RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Dermatitis (contact, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Artery, disease (coronary, occlusion, acute, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Artery, disease (coronary, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) (cutaneous, varicose ulcers, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Heart, disease (decreased cardiac output, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Muscle, disease (degeneration, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Nerve, disease (demyelination, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Mental and behavioral disorders (depression, treatment of; preparation of amides of pyrazolamines

and anilines as well as analogs as cytokine inhibitors)

ΙT

ΙT

ΙT

ΙT

ΤТ

ΤT

ΤT

ΙT

ΙT

ΙT

ΤТ

TΤ

TΤ

TΤ

ΙT

TΤ

Kidney, disease

(diabetic nephropathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Eye, disease (diabetic retinopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Lung, disease (diminished lung compliance, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Toxins RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (diphtheria, DAB389, compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Joint, anatomical (disease, bursitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Viscera (disease, pain, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Tendon (disease, tendinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Tendon (disease, tenosynovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Platelet (blood) (disease, thrombocytopenia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Blood coagulation disorders (disseminated intravascular coagulation, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Thrombosis TΤ (during pregnancy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Lung, disease (embolism, massive, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Lung, disease (embolism, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Uterus, disease (endometriosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Heart, disease Kidney, disease (failure, chronic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Heart, disease (failure, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Muscle, disease (fibromyalgia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤT Kidney, disease (fibrosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Meningitis (fulminant meningococcemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Inflammation

Kidney, disease (glomerulonephritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Transplant and Transplantation ΙT (graft-vs.-host reaction; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Brain, disease (hepatic encephalopathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Eye, disease ΙT (hereditary optic atrophy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Inborn errors of metabolism (homocysteinuria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Metabolic disorders (hydroxybutyric aminoaciduria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Inborn errors of metabolism ΤT (hyperhomocysteinuria, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Metabolic disorders (hyperprolinemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Mucus (hypersecretion, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Heart, disease (infarction, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Arthritis ТТ (infectious, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Respiratory system, disease ΙT (inflammation, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Intestine, disease (inflammatory, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Tumor necrosis factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Eye, disease (injury, laser induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Reperfusion Spinal cord, disease (injury, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Spinal column, disease ΙT (intervertebral disk syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Intestine, disease (irritable bowel syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Heart, disease (ischemia, treatment of; preparation of amides of

pyrazolamines and anilines as well as analogs as cytokine inhibitors)

Brain, disease ΤТ (lead, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Infection (leishmaniasis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Headache (migraine, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Heart, disease ΙT Inflammation (myocarditis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Skin, disease (necrosis, hemorrhagic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Nerve, disease Pain (neuralgia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Inflammation Nerve, disease (neuritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Nerve, disease (neuropathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Lymphoma (nodular, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Lymphoma (non-Hodgkin's, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Inflammation (non-articular, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Metabolic disorders (nonketotic hyperglycinemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Anti-inflammatory agents (nonsteroidal, compns. comprising of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Artery, disease (occlusion, acute peripheral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Injury ΙT (ocular, laser induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT (osteo-traumatic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Inflammation ΤТ Pancreas, disease (pancreatitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Eye, disease (periretinal proliferation, trauma-induced, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

ΤТ Nerve, disease (polyneuropathy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Allergy inhibitors Analgesics Anti-AIDS agents Anti-Alzheimer's agents Anti-inflammatory agents Antiarthritics Antiasthmatics Anticonvulsants Antidepressants Antidiabetic agents Antiglaucoma agents Antimalarials Antimigraine agents Antiobesity agents Antiparkinsonian agents Antipsychotics Antirheumatic agents Antitumor agents Anxiolytics Drug tolerance Fibrinolytics Hematopoietic precursor cell Human Parturition Rheumatoid arthritis Surgerv Vascular resistance (preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Arthritis TΤ (psoriatic arthritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Embolism (pulmonary, massive, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤT (pulmonary, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Nervous system, disease (reflex sympathetic dystrophy, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Fibrosis (renal, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Injury (reperfusion, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Bone, disease (resorption, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Inflammation (respiratory tract, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Artery, disease (restenosis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Cardiovascular agents

(restenosis; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Eye, disease (retinal ischemia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Ischemia (retinal, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Disease, animal (sciatica, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Necrosis (skin, hemorrhagic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Injury (spinal cord, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Nervous system, disease (spinocerebellar ataxia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙΤ Arthritis (spondylarthritis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Inflammation Spinal column, disease (spondylitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Brain, disease ΙT (stroke, acute thrombotic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Brain, disease (stroke, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Arthritis ΙT Synovial membrane, disease (synovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Lupus erythematosus (systemic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Inflammation (tendinitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Inflammation (tenosynovitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Blood, disease (thrombocytopenia, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Shock (circulatory collapse) (toxic shock syndrome, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Central nervous system, disease ΤТ Injury (trauma, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Arthritis (traumatic, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

Hepatitis C virus

TΤ

Human immunodeficiency virus (treatment of infection from; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT AIDS (disease) Acne Acute myeloid leukemia Alcoholism Alzheimer's disease Aneurysm Angiogenesis Anorexia Anxiety Asthma Atherosclerosis Blood coagulation Bulimia Cachexia Convulsion Diabetes insipidus Diabetes mellitus Drug dependence Drug resistance Eczema Emphysema Endotoxemia Epilepsy Familial hypercholesterolemia Fibrinolytic disorders Glaucoma (disease) Gout Hypercholesterolemia Hypotension Infection Leprosy Leukocytopenia Lung, neoplasm Lyme disease Malaria Mammary gland, neoplasm Multiple myeloma Multiple sclerosis Musculoskeletal diseases Myelodysplastic syndromes Neoplasm Obesity Osteoarthritis Osteoporosis Pain Parkinson's disease Prostate gland, neoplasm Psoriasis Rubella Schizophrenia Seizures Sepsis Silicosis Thrombosis Thrombus Wernicke-Korsakoff syndrome (treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

Skin, disease ΤТ (ulcer, varicose ulcers, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Inflammation Intestine, disease (ulcerative colitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Eye, disease Inflammation (uveitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΤТ Heart, disease (valve, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Blood vessel, disease Inflammation (vasculitis, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) TΤ Liver, disease (venoocclusive, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Thrombosis (venous, axillary, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Thrombosis (venous, massive iliofemoral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) ΙT Thrombosis (venous, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Disease, animal ΙT (visceral pain, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Pain ΙT (visceral, treatment of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) Interferons ΙT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  $(\alpha, \text{ compns. comprising of; preparation of amides of pyrazolamines and}$ anilines as well as analogs as cytokine inhibitors) ΙT 80449-02-1 RL: BSU (Biological study, unclassified); BIOL (Biological study) (compns. comprising of inhibitors of; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) 127464-60-2, VEGF ΤТ RL: BSU (Biological study, unclassified); BIOL (Biological study) (compns. comprising of inhibitors; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-35-1, Thalidomide ΙT 50 - 78 - 2, Aspirin 52-67-5, D-Penicillamine 53-86-1, Indomethacin 54-21-7, 58-32-2, Dipyridamole 59-05-2, Methotrexate Sodium salicylate 61-68-7, Mefenamic acid 67-73-2, Fluocinolone acetonide Vitamin D3 76-25-5, Triamcinolone acetonide 77-86-1, Tromethamine 80-08-0, Dapsone 83-43-2, Methylprednisolone 89-57-6, 5-ASA Coumarin 103-90-2, Acetaminophen 118-42-3, Hydroxychloroquine 127-07-1, Hydroxyurea 154-42-7, 6-Thioguanine 305-03-3, Chlorambucil 356-12-7, Fluocinonide 378-44-9, Betamethasone 446-86-6, Azathioprine 552-94-3, Salsalate 599-79-1, Sulfasalazine 2016-36-6, Choline salicylate 2607-06-9, Diflucortolone 3615-24-5, Ramifenazone

```
9002-01-1, Streptokinase 9005-49-6, Heparin, biological studies
     9039-53-6, Urokinase 10118-90-8, Minocycline
                                                      12244-57-4, Gold sodium
     thiomalate 14484-47-0, Deflazacort 15307-86-5, Diclofenac
     15687-27-1, Ibuprofen 18917-89-0, Magnesium salicylate
                                                                 21256-18-8,
               22071-15-4, Ketoprofen 22204-53-1, Naproxen
                                                                  22494-42-4,
     Diflunisal
                  23187-87-3, Choline magnesium salicylate
                                                             26171-23-3,
     Tolmetin 31441-78-8, Mercaptopurine
                                             31842-01-0, Indoprofen
     32222-06-3, 1\alpha, 25-Dihydroxyvitamin D3 33005-95-7, Tiaprofenic acid
     33069-62-4, Taxol
                        34031-32-8, Auranofin
                                                34597-40-5, Fenoprofen calcium
     36322-90-4, Piroxicam 38194-50-2, Sulindac 41340-25-4, Etodolac
                            51333-22-3, Budesonide 51803-78-2, Nimesulide
     42924-53-8, Nabumetone
     53123-88-9, Sirolimus 53716-49-7, Carprofen 54063-32-0, Clobetasone
     55142-85-3, Ticlopidine 57333-96-7, Tacalcitol
                                                        59865-13-3,
     Cyclosporine A 63798-73-2, Cyclosporine 70374-27-5, Lomoxicam
     70374-39-9, Lornoxicam
                            71125-38-7, Meloxicam
                                                     74103-06-3, Ketorolac
                              80937-31-1, Flosulide 82657-92-9, Pro-UK
     75706-12-6, Leflunomide
     87653-67-6, Aggrenox 90566-53-3, Fluticasone 98651-66-2, Halobetasol
     103370-86-1, Parathyroid hormone-related peptide 103909-75-7,
     Maxacalcitol 104987-11-3, Tacrolimus 104987-12-4, Ascomycin
     105102-22-5, Mometasone 105913-11-9, Plasminogen activator 106362-32-7, Peptide T 112965-21-6, Calcipotriol 113665-84-2,
     Clopidogrel 128794-94-5, Mycophenolate mofetil 137071-32-0,
                  143090-92-0, Anakinra
                                           143653-53-6, Abciximab
     Pimecrolimus
     144494-65-5, Aggrestat 145155-23-3, Interferon beta-1B 152923-56-3,
                  162011-90-7, Rofecoxib 169590-42-5, Celecoxib
     Daclizumab
     170277-31-3, Infliximab 173146-27-5, DAB389 IL-2
                                                         179045-86-4,
     Basiliximab 181695-72-7, Valdecoxib 185243-69-0, Etanercept 188627-80-7, Integrilin 202409-33-4, Etoricoxib 214745-43-4,
     Efalizumab 222535-22-0, Alefacept 331731-18-1, Adalimumab
     679809-58-6, Enoxaparin sodium
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (compns. comprising of; preparation of amides of pyrazolamines and anilines
        as well as analogs as cytokine inhibitors)
ΙT
     9029-38-3, Sulfite oxidase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (deficiency, treatment of; preparation of amides of pyrazolamines
        and anilines as well as analogs as cytokine inhibitors)
     848144-15-0P
                    848144-45-6P
                                   848144-49-0P
                                                  848144-84-3P
                    848145-02-8P
                                   848150-50-5P
     848145-00-6P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (inhibitor; preparation of amides of pyrazolamines and anilines as well as
        analogs as cytokine inhibitors)
ΤТ
     105438-50-4P
                    763089-51-6P
                                                  848144-09-2P
                                   848144-05-8P
                                                                  848144-12-7P
     848144-14-9P
                                                  848144-31-0P
                    848144-21-8P
                                                                  848144-32-1P
                                   848144-26-3P
     848144-34-3P
                    848144-35-4P
                                   848144-39-8P
                                                  848144-42-3P
                                                                  848144-47-8P
                                                  848144-77-4P
     848144-48-9P
                    848144-50-3P
                                   848144-64-9P
                                                                  848144-78-5P
     848144-89-8P
                    848144-90-1P
                                   848144-91-2P
                                                  848144-92-3P
                                                                  848144-94-5P
     848144-96-7P
                    848144-98-9P
                                   848145-01-7P
                                                  848145-05-1P
                                                                  848145-07-3P
     848145-08-4P
                    848145-09-5P
                                   848145-10-8P
                                                  848145-11-9P
                                                                  848145-12-0P
     848145-13-1P
                    848145-14-2P
                                   848145-15-3P
                                                  848145-16-4P
                                                                  848145-17-5P
                                   848145-20-0P
     848145-18-6P
                    848145-19-7P
                                                  848145-21-1P
                                                                  848145-22-2P
     848145-23-3P
                    848145-24-4P
                                   848145-25-5P
                                                  848145-26-6P
                                                                  848145-27-7P
     848145-28-8P
                    848145-29-9P
                                   848145-30-2P
                                                  848145-31-3P
                                                                  848145-32-4P
     848145-33-5P
                   848145-34-6P
                                   848145-35-7P
                                                  848145-36-8P
                                                                  848145-37-9P
     848145-38-0P
                   848145-39-1P
                                   848145-40-4P
                                                  848145-41-5P
                                                                  848145-42-6P
     848145-43-7P
                   848145-44-8P
                                   848145-45-9P
                                                  848145-46-0P
                                                                  848145-47-1P
     848145-48-2P 848145-49-3P
                                   848145-50-6P 848145-51-7P
                                                                  848145-52-8P
     848145-53-9P 848145-54-0P
                                   848145-55-1P 848145-56-2P
                                                                 848145-57-3P
```

5104-49-4, Flurbiprofen 6385-02-0, Meclofenamate sodium 6493-05-6

```
848145-58-4P
               848145-59-5P
                              848145-60-8P
                                              848145-61-9P
                                                             848145-62-0P
848145-63-1P
               848145-64-2P
                              848145-65-3P
                                              848145-66-4P
                                                             848145-67-5P
848145-68-6P
               848145-69-7P
                              848145-71-1P
                                              848145-72-2P
                                                             848145-73-3P
848145-74-4P
               848145-75-5P
                              848145-76-6P
                                              848145-77-7P
                                                             848145-78-8P
848145-79-9P
               848145-80-2P
                              848145-81-3P
                                              848145-82-4P
                                                             848145-83-5P
848145-84-6P
               848145-85-7P
                              848145-86-8P
                                              848145-87-9P
                                                             848145-88-0P
848145-89-1P
               848145-90-4P
                              848145-91-5P
                                              848145-92-6P
                                                             848145-93-7P
848145-94-8P
               848145-95-9P
                              848145-96-0P
                                              848145-97-1P
                                                             848145-98-2P
848145-99-3P
               848146-00-9P
                              848146-01-0P
                                              848146-02-1P
                                                             848146-03-2P
848146-04-3P
               848146-05-4P
                              848146-06-5P
                                              848146-07-6P
                                                             848146-08-7P
               848146-10-1P
                                              848146-12-3P
848146-09-8P
                              848146-11-2P
                                                             848146-13-4P
                                              848146-17-8P
848146-14-5P
               848146-15-6P
                              848146-16-7P
                                                             848146-18-9P
848146-19-0P
               848146-20-3P
                              848146-21-4P
                                              848146-22-5P
                                                             848146-23-6P
848146-24-7P
               848146-25-8P
                              848146-26-9P
                                              848146-27-0P
                                                             848146-28-1P
848146-29-2P
               848146-30-5P
                              848146-31-6P
                                              848146-32-7P
                                                             848146-33-8P
                                              848146-37-2P
848146-34-9P
               848146-35-0P
                              848146-36-1P
                                                             848146-38-3P
848146-39-4P
               848146-40-7P
                              848146-41-8P
                                              848146-42-9P
                                                             848146-43-0P
                                              848146-47-4P
                                                             848146-48-5P
848146-44-1P
               848146-45-2P
                              848146-46-3P
                                              848146-52-1P
                                                             848146-53-2P
848146-49-6P
               848146-50-9P
                              848146-51-0P
848146-54-3P
                                              848146-57-6P
               848146-55-4P
                              848146-56-5P
                                                             848146-58-7P
848146-59-8P
               848146-60-1P
                              848146-61-2P
                                              848146-62-3P
                                                             848146-63-4P
848146-64-5P
               848146-65-6P
                              848146-66-7P
                                              848146-67-8P
                                                             848146-68-9P
848146-69-0P
               848146-70-3P
                              848146-71-4P
                                              848146-72-5P
                                                             848146-73-6P
848146-75-8P
               848146-77-0P
                              848146-79-2P
                                              848146-81-6P
                                                             848146-82-7P
                                                             848146-87-2P
848146-83-8P
               848146-84-9P
                              848146-85-0P
                                              848146-86-1P
848146-88-3P
               848146-89-4P
                              848146-90-7P
                                              848146-91-8P
                                                             848146-92-9P
848146-93-0P
               848146-94-1P
                              848146-95-2P
                                              848146-96-3P
                                                             848146-97-4P
848146-98-5P
               848146-99-6P
                              848147-00-2P
                                              848147-01-3P
                                                             848147-02-4P
848147-03-5P
               848147-04-6P
                              848147-05-7P
                                              848147-06-8P
                                                             848147-07-9P
848147-08-0P
               848147-09-1P
                              848147-10-4P
                                              848147-11-5P
                                                             848147-12-6P
848147-13-7P
               848147-14-8P
                              848147-15-9P
                                             848147-16-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
```

(Uses)
(inhibitor; preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

ΤТ

```
848147-17-1P
             848147-18-2P
                              848147-19-3P
                                             848147-20-6P
                                                            848147-21-7P
848147-22-8P
               848147-23-9P
                              848147-24-0P
                                             848147-25-1P
                                                            848147-26-2P
848147-27-3P
               848147-28-4P
                              848147-29-5P
                                             848147-30-8P
                                                            848147-31-9P
848147-32-0P
               848147-33-1P
                              848147-34-2P 848147-35-3P
                                                            848147-36-4P
848147-37-5P
               848147-38-6P
                              848147-39-7P 848147-40-0P
                                                            848147-41-1P
848147-42-2P 848147-43-3P
                              848147-44-4P 848147-45-5P
                                                           848147-46-6P
848147-47-7P 848147-48-8P
                              848147-49-9P 848147-50-2P
                                                            848147-51-3P
848147-52-4P
               848147-53-5P
                              848147-54-6P
                                           848147-55-7P
                                                            848147-56-8P
                                                            848147-61-5P
848147-57-9P
               848147-58-0P
                              848147-59-1P
                                             848147-60-4P
848147-62-6P
               848147-63-7P
                              848147-64-8P
                                             848147-65-9P
                                                            848147-66-0P
               848147-68-2P
                                             848147-70-6P
848147-67-1P
                              848147-69-3P
                                                            848147-71-7P
848147-72-8P
                                                            848147-76-2P
               848147-73-9P
                              848147-74-0P
                                             848147-75-1P
848147-77-3P
               848147-78-4P
                              848147-79-5P
                                                            848147-81-9P
                                             848147-80-8P
848147-82-0P
               848147-83-1P
                              848147-84-2P
                                             848147-85-3P
                                                            848147-86-4P
848147-87-5P
               848147-88-6P
                              848147-89-7P
                                             848147-90-0P
                                                            848147-91-1P
848147-92-2P
               848147-93-3P
                              848147-94-4P
                                             848147-95-5P
                                                            848147-96-6P
848147-97-7P
               848147-99-9P
                              848148-00-5P
                                             848148-01-6P
                                                            848148-02-7P
848148-03-8P
               848148-04-9P
                                                            848148-07-2P
                              848148-05-0P
                                             848148-06-1P
848148-08-3P
               848148-09-4P
                              848148-10-7P
                                             848148-11-8P
                                                            848148-12-9P
848148-13-0P
               848148-14-1P
                              848148-15-2P
                                             848148-16-3P
                                                            848148-17-4P
848148-18-5P
               848148-19-6P
                              848148-20-9P
                                             848148-21-0P
                                                            848148-22-1P
848148-23-2P
               848148-24-3P
                              848148-25-4P
                                             848148-26-5P
                                                            848148-27-6P
848148-28-7P
               848148-29-8P
                              848148-30-1P
                                             848148-31-2P
                                                            848148-32-3P
848148-33-4P
               848148-34-5P
                              848148-35-6P
                                             848148-36-7P
                                                            848148-37-8P
848148-38-9P
             848148-39-0P
                             848148-40-3P
                                            848148-41-4P
                                                           848148-42-5P
```

```
848148-53-8P
                  848148-54-9P
                                 848148-55-0P
                                               848148-56-1P
                                                              848148-57-2P
    848148-58-3P
                 848148-59-4P
                                 848148-60-7P 848148-61-8P
                                                              848148-62-9P
    848148-63-0P
                 848148-64-1P
                                 848148-65-2P 848148-66-3P
                                                              848148-67-4P
                                 848148-70-9P 848148-71-0P
    848148-68-5P 848148-69-6P
                                                              848148-72-1P
    848148-73-2P 848148-74-3P
                                 848148-75-4P 848148-76-5P
                                                              848148-77-6P
    848148-78-7P 848148-79-8P
                                 848148-80-1P 848148-81-2P
                                                              848148-82-3P
    848148-83-4P 848148-84-5P
                                 848148-85-6P 848148-86-7P
                                                              848148-87-8P
    848148-88-9P 848148-89-0P
                                 848148-91-4P 848148-92-5P
                                                              848148-93-6P
    848148-94-7P 848148-95-8P
                                 848148-96-9P 848148-97-0P
                                                              848148-98-1P
    848148-99-2P 848149-00-8P
                                 848149-01-9P 848149-02-0P
                                                              848149-03-1P
    848149-04-2P 848149-05-3P
                                 848149-06-4P 848149-07-5P
                                                              848149-08-6P
    848149-09-7P
                 848149-10-0P
                                 848149-11-1P
                                              848149-12-2P
                                                              848149-13-3P
    848149-14-4P
                 848149-15-5P
                                 848149-16-6P
                                              848149-17-7P
                                                              848149-18-8P
    848149-19-9P
                   848149-20-2P
                                                848149-22-4P
                                 848149-21-3P
                                                              848149-23-5P
                   848149-25-7P
                                                848149-27-9P
    848149-24-6P
                                 848149-26-8P
                                                              848149-28-0P
                                 848149-31-5P
                                                848149-32-6P
    848149-29-1P
                   848149-30-4P
                                                              848149-33-7P
    848149-34-8P
                   848149-35-9P
                                 848149-36-0P
                                                848149-37-1P
                                                              848149-38-2P
    848149-39-3P
                                 848149-42-8P
                                                848149-44-0P
                                                              848149-46-2P
                   848149-40-6P
    848149-48-4P
                   848149-50-8P
                                 848149-51-9P
                                                848149-52-0P
                                                              848149-53-1P
    848149-55-3P
                   848149-56-4P
                                 848149-57-5P
                                               848149-58-6P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (inhibitor; preparation of amides of pyrazolamines and anilines as well as
       analogs as cytokine inhibitors)
ΙT
    848149-59-7P
                 848149-60-0P
                                848149-61-1P
                                                848149-62-2P
                                                              848149-63-3P
    848149-64-4P
                  848149-65-5P
                                 848149-66-6P
                                                848149-67-7P
                                                              848149-68-8P
    848149-69-9P
                  848149-70-2P
                                 848149-71-3P
                                               848149-72-4P
                                                              848149-73-5P
                                                              848149-78-0P
    848149-74-6P
                 848149-75-7P
                                 848149-76-8P
                                               848149-77-9P
    848149-79-1P 848149-80-4P
                                 848149-81-5P 848149-82-6P
                                                              848149-83-7P
                                                              848149-88-2P
    848149-84-8P 848149-85-9P
                                848149-86-0P 848149-87-1P
    848149-89-3P 848149-90-6P
                                848149-91-7P 848149-92-8P
                                                              848149-93-9P
    848149-94-0P 848149-95-1P 848149-96-2P 848149-97-3P
                                                              848149-98-4P
    848149-99-5P 848150-00-5P 848150-01-6P 848150-02-7P
                                                              848150-03-8P
    848150-04-9P 848150-05-0P 848150-06-1P 848150-07-2P
                                                              848150-08-3P
    848150-09-4P 848150-10-7P 848150-11-8P 848150-12-9P
                                                              848150-13-0P
    848150-14-1P 848150-15-2P
                                848150-16-3P 848150-17-4P
                                                              848150-18-5P
    848150-19-6P 848150-20-9P 848150-21-0P 848150-22-1P
                                                              848150-23-2P
    848150-24-3P 848150-25-4P 848150-26-5P 848150-27-6P
                                                              848150-28-7P
    848150-29-8P 848150-30-1P 848150-31-2P 848150-32-3P 848150-33-4P
    848150-34-5P
                 848150-35-6P
                                848150-36-7P
                                              848150-37-8P
                                                             848150-38-9P
    848150-39-0P
                   848150-40-3P
                                 848150-41-4P
                                                848150-42-5P
                                                             848150-43-6P
                   848150-45-8P
                                 848150-46-9P
    848150-44-7P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (inhibitor; preparation of amides of pyrazolamines and anilines as well as
       analogs as cytokine inhibitors)
ΙT
    848150-47-0P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (inhibitor; preparation of amides of pyrazolamines and anilines as well as
       analogs as cytokine inhibitors)
ΙT
    9004-10-8, Insulin, biological studies
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
       (insulinitis; preparation of amides of pyrazolamines and anilines as well as
       analogs as cytokine inhibitors)
                                           848144-76-3P 848144-86-5P
ΤТ
    3993-78-0P, 4-Chloro-2-pyrimidinamine
    RL: BYP (Byproduct); PREP (Preparation)
```

848148-45-8P

848148-50-5P

848148-46-9P

848148-51-6P

848148-47-0P

848148-52-7P

848148-43-6P

848148-48-1P

848148-44-7P

848148-49-2P

(preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) 90-11-9, 1-Bromonaphthalene 90-15-3, ΤТ 62-53-3, Aniline, reactions 98-09-9, Benzenesulfonyl chloride 98-27-1, 1-Naphthalenol 4-tert-Butyl-2-methylphenol 98-54-4, 4-tert-Butylphenol 106-49-0, (p-Methylphenyl)amine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 134-32-7, 1-Naphthylamine 135-19-3, 2-Hydroxynaphthalene, reactions 444-30-4, 2-Trifluoromethylphenol 637-60-5, p-Tolylhydrazine hydrochloride 765-30-0, Cyclopropylamine 1774-47-6, Trimethylsulfoxonium iodide 2534-77-2, exo-2-Bromonorbornane 2605-67-6 3240-94-6, 4-(2-Chloroethyl) morpholine 3279-07-0, 4-tert-Butyl-2-nitrophenol 3647-69-6, N-(2-Chloroethyl)morpholine hydrochloride 3934-20-1, 2,4-Dichloropyrimidine 4114-31-2, Ethyl hydrazinecarboxylate 4498-67-3, Indazole-3-carboxylic acid 5369-19-7, 3-tert-Butylaniline 5720-05-8, (p-Methylphenyl)boronic acid 5781-53-3, Methyl chloroglyoxylate 7677-24-9, Trimethylsilyl cyanide 7770-45-8, 4-Hydroxy-1-naphthaldehyde 16013-85-7, 2,6-Dichloro-3-nitropyridine 16640-68-9, (Triphenylphosphoranylidene)acetonitrile 23056-36-2, 2-Chloro-4-nitropyridine 23894-12-4, 6-Amino-1-naphthalenol 26867-21-0 36082-50-5, 5-Bromo-2,4-dichloropyrimidine 39755-95-8, 5-Methoxy isatin 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 73469-54-2, 5-tert-Butyl-2-methoxybenzoic acid 74124-79-1 82560-12-1, 83405-70-3 (5-tert-Butyl-1H-pyrazol-3-yl)amine 88139-91-7, (5-Bromopyridin-2-yl)methanol 118430-73-2 175137-04-9 285984-25-0 285984-50-1 306937-27-9, 3-tert-Butylphenylhydrazine hydrochloride 473269-70-4, 5-tert-Butyl-2-methoxybenzene-1,3-diamine 317806-90-9 848144-33-2 848144-81-0, 2,6-Dichloro-3-nitropyrimidine 725686-47-5 848144-88-7 848144-99-0 855304-89-1 929011-97-2 RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) 98-28-2P, 4-tert-Butyl-2-chlorophenol 7461-50-9P, 2-Chloro-4-ΙΤ 14593-28-3P, 4-tert-Butyl-2-chloro-6-nitrophenol pyrimidinamine 18215-94-6P, [2-(Morpholin-4-yl)pyrimidin-4-yl]amine 20294-44-4P, 4-tert-Butyl-2-methyl-6-nitrophenol 21660-76-4P, N-Naphthalen-1yloxalamic acid 26867-13-0P 32569-82-7P 33353-61-6P 33353-66-1P 35980-77-9P, [2-(Morpholin-4-yl)pyridin-4-yl]amine 55304-16-0P 57477-80-2P, 4-tert-Butyl-2-trifluoromethylphenol 90417-53-1P, 5-Methoxy-1H-indazole-3-carboxylic acid 157130-34-2P 294851-95-9P, 4-(5-Bromopyridin-2-ylmethyl)morpholine 294851-97-1P 404010-35-1P, N-(3-Amino-5-tert-butyl-2-methoxyphenyl)methanesulfonamide 848144-06-9P 848144-07-0P 848144-08-1P 848144-10-5P 848144-11-6P 848144-13-8P 848144-16-1P 848144-17-2P 848144-18-3P 848144-19-4P 848144-20-7P 848144-22-9P 848144-23-0P 848144-24-1P 848144-25-2P 848144-27-4P, 4-(4-Nitropyridin-2-yl)morpholine 848144-28-5P 848144-29-6P 848144-30-9P 848144-36-5P 848144-37-6P 848144-38-7P 848144-40-1P 848144-41-2P 848144-44-5P 848144-43-4P 848144-46-7P 848144-51-4P 848144-56-9P 848144-59-2P 848144-52-5P 848144-54-7P 848144-68-3P 848144-69-4P 848144-70-7P 848144-61-6P 848144-71-8P, 848144-73-0P 6-(Boc-amino)naphthalen-1-ol 848144-72-9P 848144-74-1P 848144-75-2P 848144-79-6P 848144-80-9P 848144-82-1P 848144-83-2P 848144-87-6P 848144-93-4P 848144-95-6P 848144-97-8P 848145-03-9P 848145-04-0P 848145-06-2P 848150-48-1P 848150-49-2P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors) L32 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN ΙΤ 115926-52-8, PI3 kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors) 115926-52-8 CAPLUS RN Kinase (phosphorylating), phosphatidylinositol 3- (CA INDEX NAME) CN \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* ACCESSION NUMBER: 2005:120737 CAPLUS DOCUMENT NUMBER: 142:219270 TITLE: Preparation of 2-imino-4-(thio)oxo-5polycyclovinylazolines as PI3 kinase inhibitors INVENTOR(S): Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini, PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. SOURCE: PCT Int. Appl., 72 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE \_\_\_\_ \_\_\_\_\_ \_\_\_\_\_ 20050210 WO 2004-EP51625 20040727 WO 2005011686 A1 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2004260836 20050210 AU 2004-260836 20040727 Α1 CA 2531140 Α1 20050210 CA 2004-2531140 20040727 EP 2004-766335 EP 1648452 Α1 20060426 20040727 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR JP 2007500171 Τ 20070111 JP 2006-521581 20040727 US 2004-565976 US 20070021447 Α1 20070125 20040727 NO 2006000573 Α 20060203 NO 2006-573 20060203 EP 2003-102313 PRIORITY APPLN. INFO.: A 20030728 WO 2004-EP51625 W 20040727 CASREACT 142:219270; MARPAT 142:219270 OTHER SOURCE(S): 2005:120737 CAPLUS ΑN 142:219270 DN Entered STN: 11 Feb 2005 ΕD TΙ Preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors Rueckle, Thomas; Shaw, Jeffrey; Church, Denis; Covini, David INPAApplied Research Systems Ars Holding N.V., Neth. SO PCT Int. Appl., 72 pp. CODEN: PIXXD2 DT Patent English LA IC ICM A61K031-427 ICS A61P037-00; A61P029-00; C07D417-06; C07D417-14

28-7 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

CC

FAN.CNT 1

```
PATENT NO.
                   KIND DATE APPLICATION NO. DATE
    WO 2005011686 A1 20050210 WO 2004-EP51625 20040727
PΤ
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    AU 2004260836
                         A1
                               20050210
                                          AU 2004-260836
                                                                  20040727
    CA 2531140
                               20050210
                                         CA 2004-2531140
                         A1
                                                                  20040727
    EP 1648452
                         A1
                               20060426 EP 2004-766335
                                                                  20040727
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
                             20070111 JP 2006-521581 20040727
20070125 US 2004-565976 20040727
    JP 2007500171
                        T
    US 20070021447
                         Α1
                                          NO 2006-573
    NO 2006000573
                        Α
                              20060203
                                                                 20060203
PRAI EP 2003-102313
                         Α
                               20030728
    WO 2004-EP51625
                         W
                               20040727
CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
                ICM
WO 2005011686
                       A61K031-427
                ICS
                       A61P037-00; A61P029-00; C07D417-06; C07D417-14
                IPCI
                       A61K0031-427 [ICM, 7]; A61P0037-00 [ICS, 7]; A61P0029-00
                       [ICS, 7]; C07D0417-06 [ICS, 7]; C07D0417-14 [ICS, 7];
                       C07D0417-00 [ICS, 7, C*]
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0037-00
                IPCR
                       [I,C*]; A61P0037-00 [I,A]; C07D0417-00 [I,C*];
                       C07D0417-06 [I,A]; C07D0417-14 [I,A]
                ECLA
                       C07D417/06+277B+215; C07D417/06+277B+239;
                       C07D417/06+277B+241; C07D417/06+317+277B;
                       C07D417/14+317+277B+213; C07D417/14+317+277B+215;
                       C07D417/14+317+277B+231; C07D417/14+333B+277B+215;
                       C07D417/14+333B+317+277B
AU 2004260836
                IPCI
                       A61K0031-427 [I,C]; A61P0029-00 [I,C]; A61P0037-00
                       [I,C]; C07D0417-00 [I,C]; A61K0031-427 [I,A];
                       A61P0029-00 [I,A]; A61P0037-00 [I,A]; C07D0417-06
                       [I,A]; C07D0417-14 [I,A]
                       A61K0031-427 [I,A]; A61K0031-427 [I,C]; A61P0029-00
                IPCR
                        [I,C]; A61P0029-00 [I,A]; A61P0037-00 [I,C];
                       A61P0037-00 [I,A]; C07D0417-00 [I,C]; C07D0417-06
                        [I,A]; C07D0417-14 [I,A]
CA 2531140
                       A61K0031-427 [I,A]; A61P0029-00 [I,A]; A61P0037-00
                IPCI
                        [I,A]; C07D0417-06 [I,A]; C07D0417-14 [I,A];
                       C07D0417-00 [I,C*]
                       A61K0031-427 [I,A]; A61K0031-427 [I,C]; A61P0029-00
                IPCR
                       [I,C]; A61P0029-00 [I,A]; A61P0037-00 [I,C];
                       A61P0037-00 [I,A]; C07D0417-00 [I,C]; C07D0417-06
                       [I,A]; C07D0417-14 [I,A]
                ECLA
                       C07D417/06+277B+215; C07D417/06+277B+239;
                       C07D417/06+277B+241; C07D417/06+317+277B;
                       C07D417/14+317+277B+213; C07D417/14+317+277B+215;
                       C07D417/14+317+277B+231; C07D417/14+333B+277B+215;
                       C07D417/14+333B+317+277B
EP 1648452
                IPCI A61K0031-427 [ICM,7]; A61P0037-00 [ICS,7]; A61P0029-00
```

```
[ICS, 7]; C07D0417-06 [ICS, 7]; C07D0417-14 [ICS, 7];
                        C07D0417-00 [ICS, 7, C*]
                 IPCI
 JP 2007500171
                        C07D0417-06 [I,A]; A61K0031-427 [I,A]; C07D0417-14
                        [I,A]; C07D0417-00 [I,C*]; A61K0031-4439 [I,A];
                        A61K0031-4427 [I,C*]; A61K0031-4709 [I,A]; A61K0031-498
                        [I,A]; A61K0031-517 [I,A]; A61P0037-06 [I,A];
                        A61P0037-00 [I,C*]; A61P0029-00 [I,A]; A61P0009-00
                        [I,A]; A61P0025-00 [I,A]; A61P0007-02 [I,A];
                        A61P0007-00 [I,C*]; A61P0035-00 [I,A]; A61P0011-00
                        [I,A]; C07B0061-00 [N,A]
                 IPCR
                        C07D0417-00 [I,C]; C07D0417-06 [I,A]; A61K0031-427
                        [I,C]; A61K0031-427 [I,A]; A61K0031-4427 [I,C];
                        A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709
                        [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A];
                        A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61P0007-00
                        [I,C]; A61P0007-02 [I,A]; A61P0009-00 [I,C];
                        A61P0009-00 [I,A]; A61P0011-00 [I,C]; A61P0011-00
                        [I,A]; A61P0025-00 [I,C]; A61P0025-00 [I,A];
                        A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00
                        [I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C];
                        A61P0037-00 [I,A]; A61P0037-06 [I,A]; C07B0061-00
                        [N,C]; C07B0061-00 [N,A]; C07D0417-14 [I,A]
                 FTERM
                        4C063/AA01; 4C063/AA03; 4C063/BB03; 4C063/BB08;
                        4C063/CC81; 4C063/CC92; 4C063/DD14; 4C063/DD31;
                        4C063/DD34; 4C063/DD62; 4C063/EE01; 4C086/AA01;
                        4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC82;
                        4C086/GA02; 4C086/GA04; 4C086/GA07; 4C086/GA08;
                        4C086/GA10; 4C086/MA01; 4C086/MA04; 4C086/NA14;
                        4C086/ZA02; 4C086/ZA36; 4C086/ZA54; 4C086/ZA59;
                        4C086/ZB08; 4C086/ZB11; 4C086/ZB26; 4H039/CA80;
                        4H039/CD20
 US 20070021447 IPCI
                        A61K0031-517 [I,A]; A61K0031-4709 [I,A]; A61K0031-427
                        [I,A]; A61K0031-422 [I,A]; A61K0031-4178 [I,A];
                        A61K0031-4164 [I,C*]; C07D0417-02 [I,A]; C07D0417-00
                        [I,C*]; C07D0413-02 [I,A]; C07D0413-00 [I,C*]
                 NCL
                        514/266.230; 514/317.000; 514/369.000; 514/376.000;
                        514/388.000; 544/284.000; 546/159.000; 548/181.000;
                        548/225.000; 548/311.100
                        C07D417/06+277B+215; C07D417/06+277B+239;
                 ECLA
                        C07D417/06+277B+241; C07D417/06+317+277B;
                        C07D417/14+317+277B+213; C07D417/14+317+277B+215;
                        C07D417/14+317+277B+231; C07D417/14+333B+277B+215;
                        C07D417/14+333B+317+277B
 NO 2006000573
                 IPCI
                        C07D0413-00 [I,C]; A61K0031-427 [I,C]; C07D0413-06
                        [I,A]; A61K0031-427 [I,A]
                 IPCR
                        C07D0413-00 [I,C]; C07D0413-06 [I,A]; A61K0031-427
                        [I,C]; A61K0031-427 [I,A]; A61P0029-00 [I,C*];
                        A61P0029-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-00
                        [I,A]; C07D0417-00 [I,C*]; C07D0417-06 [I,A];
                        C07D0417-14 [I,A]
                 ECLA
                        C07D417/06+277B+215; C07D417/06+277B+239;
                        C07D417/06+277B+241; C07D417/06+317+277B;
                        C07D417/14+317+277B+213; C07D417/14+317+277B+215;
                        C07D417/14+317+277B+231; C07D417/14+333B+277B+215;
                        C07D417/14+333B+317+277B
OS
     CASREACT 142:219270; MARPAT 142:219270
```

Τ

AB The title compds. I [A = 5-8 membered heterocyclic or carbocyclic group which may be fused with an aryl, heteroaryl, cycloalkyl or heterocycloalkyl; X = S, O, NR3, Y = S, O; R1 = H, CN, CO2H, acyl, etc.; R2 = H, halo, acyl, NH2, etc.; G = alkoxy, alkyl, CN, etc.; R3 = H, alkyl; with provisos], useful in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries, were prepared and formulated. Thus, reacting 5-benzo[1,3]dioxol-5-ylmethylene-2-iminothiazolidin-4-one (preparation given) with 2-chlorobenzenesulfonyl chloride afforded 17% II. The tested compds. I showed IC50 of < 10  $\mu$ M with regard to PI3K $\gamma$ .

ST iminothioxopolycyclovinylazoline prepn PI3 kinase inhibitor; thiazolidine benzodioxolylmethylene quinoxalinylmethylene quinolinylmethylene prepn PI3 kinase inhibitor

IT Nervous system, disease

(Huntington's chorea, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT Sarcoma

(Kaposi's, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT Muscle, disease

(atrophy, treating skeletal muscle atrophy/hypertrophy; preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT Muscle

(cardiac, treating cardiac myocyte dysfunction; preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT Hypertrophy

(cardiac, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT Lung, disease

(chronic obstructive pulmonary disease, treating; preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT Nervous system, disease

(degeneration, treating; preparation of 2-imino-4-(thio)oxo-5-

```
polycyclovinylazolines as PI3 kinase inhibitors)
ΤТ
     Kidney, disease
        (fibrosis, treating progressive renal fibrosis; preparation of
        2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)
     Inflammation
ΤТ
     Kidney, disease
        (glomerulonephritis, treating; preparation of 2-imino-4-(thio)oxo-
        5-polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Kidney, disease
        (glomerulosclerosis, treating; preparation of 2-imino-4-(thio)oxo-
        5-polycyclovinylazolines as PI3 kinase inhibitors)
ΤТ
     Muscle, disease
        (hypertrophy, treating skeletal muscle atrophy/hypertrophy;
        preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase
        inhibitors)
ΙT
     Heart, disease
        (hypertrophy, treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Intestine, disease
        (inflammatory, treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΙΤ
     Lung, disease
     Reperfusion
        (injury, treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Leukocyte
        (leukocyte recruitment in cancer tissue; preparation of 2-imino-4-(thio)oxo-
        5-polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Neoplasm
        (metastasis, treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ТТ
     Hypertrophy
        (muscular, treating skeletal muscle atrophy/hypertrophy;
        preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase
        inhibitors)
TΤ
    Heart.
        (myocardium, treating cardiac myocyte dysfunction; preparation of
        2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Inflammation
     Lung, disease
        (pneumonitis, treatment; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Allergy inhibitors
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiasthmatics
     Anticoaqulants
     Antihypertensives
     Antirheumatic agents
     Antitumor agents
     Cardiovascular agents
     Human
     Immunomodulators
     Immunosuppressants
     Nervous system agents
     Platelet aggregation inhibitors
        (preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase
        inhibitors)
ΤТ
     Injury
```

```
(pulmonary, treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΤТ
     Fibrosis
        (renal, treating progressive renal fibrosis; preparation of
        2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
        (reperfusion, treating; preparation of 2-imino-4-(thio) oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Brain, disease
        (stroke, treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΤТ
     Lupus erythematosus
        (systemic, treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Central nervous system, disease
        (trauma, treating CNS trauma; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
ΤТ
     Brain, disease
     Encephalitis
     Meningitis
        (treating brain infection/inflammation; preparation of
        2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)
ΙT
     Alleray
     Alzheimer's disease
     Anaphylaxis
     Angiogenesis
     Asthma
     Atherosclerosis
     Autoimmune disease
     Cardiovascular system, disease
     Hypertension
     Inflammation
       Ischemia
     Kidney, disease
     Melanoma
     Multiple sclerosis
     Neoplasm
     Platelet aggregation
     Psoriasis
     Rheumatoid arthritis
     Sepsis
     Thrombosis
     Transplant rejection
        (treating; preparation of 2-imino-4-(thio)oxo-5-
        polycyclovinylazolines as PI3 kinase inhibitors)
     115926-52-8, PI3 kinase
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase
        inhibitors)
ΙΤ
     843641-13-4P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase
        inhibitors)
     176529-68-3P
                    326093-91-8P
                                   419552-35-5P
                                                  843641-09-8P
                                                                  843641-10-1P
     843641-11-2P
                    843641-12-3P
                                   843641-14-5P
                                                  843641-15-6P
                                                                  843641-16-7P
     843641-17-8P
                  843641-18-9P
                                  843641-19-0P
                                                  843641-20-3P
                                                                  843641-21-4P
     843641-22-5P
                   843641-23-6P
                                  843641-24-7P
                                                  843641-25-8P
                                                                  843641-26-9P
     843641-27-0P
                    843641-28-1P
                                   843641-29-2P
                                                  843641-30-5P
                                                                  888948-67-2P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
```

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT 100-46-9, Benzylamine, reactions 120-57-0, Piperonal 656-42-8,

2,2-Difluoro-1,3-benzodioxole-5-carboxaldehyde 2688-90-6,

[1,1'-Biphenyl]-2-sulfonyl chloride 2905-23-9, 2-Chlorobenzenesulfonyl

chloride 3113-71-1, 3-Methyl-4-nitrobenzoic acid 4113-04-6,

6-Quinolinecarboxaldehyde 130345-50-5, 6-Quinoxalinecarboxaldehyde 412311-41-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

IT 4315-09-7P 28824-66-0P 33890-03-8P 33986-75-3P 152536-17-9P

152536-21-5P 300829-97-4P 304645-61-2P 648449-05-2P 648449-06-3P

648449-09-6P 648449-81-4P 648450-30-0P 719286-35-8P 843641-32-7P

843641-33-8P 843641-34-9P 843641-35-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-imino-4-(thio)oxo-5-polycyclovinylazolines as PI3 kinase inhibitors)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

- (1) Fujimoto Pharmaceutical Co Ltd; EP 0697410 A 1996 CAPLUS
- (2) Roue, N; TETRAHEDRON 1999, V55(51), P14729 CAPLUS
- L32 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
- IT 91-56-5, Isatin

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of vasculostatic agents and methods of use)

RN 91-56-5 CAPLUS

CN 1H-Indole-2, 3-dione (CA INDEX NAME)

ACCESSION NUMBER: 2004:308364 CAPLUS

DOCUMENT NUMBER: 140:321386

TITLE: Preparation of vasculostatic agents and methods of use

INVENTOR(S): Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor;
Noronha, Glenn; Hood, John D.; Dneprovskaia, Elena;
Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning

PATENT ASSIGNEE(S): Targegen, Inc., USA SOURCE: PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030635	A2	20040415	WO 2003-US31721	20031002
WO 2004030635	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

```
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
              LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
              OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
              TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
              FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2500727
                             Α1
                                    20040415
                                                CA 2003-2500727
     AU 2003282726
                                    20040423
                                                 AU 2003-282726
                             Α1
     EP 1549614
                             A2
                                    20050706
                                                 EP 2003-774610
                                                                            20031002
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                                BR 2003-15053
     BR 2003015053
                            Α
                                    20050809
                                                                            20031002
     CN 1720224
                             Α
                                    20060111
                                                 CN 2003-80104711
                                                                            20031002
     JP 2006515317
                            Τ
                                    20060525
                                                 JP 2005-500378
                                                                            20031002
                                   20070316
                                                 IN 2005-DN1020
     IN 2005DN01020
                                                                            20050316
                            Α
     ZA 2005002328
                                    20060927
                                                 ZA 2005-2328
                            Α
                                                                            20050318
                            Α
                                    20050722
                                                 MX 2005-PA3477
     MX 2005PA03477
                                                                            20050401
PRIORITY APPLN. INFO.:
                                                 US 2002-415981P
                                                                           20021003
                                                                        Ρ
                                                  US 2003-440234P
                                                                        Ρ
                                                                           20030114
                                                  US 2003-443752P
                                                                        Ρ
                                                                            20030129
                                                  US 2003-463818P
                                                                        Ρ
                                                                            20030417
                                                  US 2003-466983P
                                                                        Ρ
                                                                            20030430
                                                  US 2003-479295P
                                                                        Ρ
                                                                            20030617
                                                  WO 2003-US31721
                                                                      W 20031002
OTHER SOURCE(S):
                            MARPAT 140:321386
ΑN
     2004:308364 CAPLUS
DN
     140:321386
     Entered STN: 15 Apr 2004
ED
ΤI
     Preparation of vasculostatic agents and methods of use
     Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood,
ΙN
     John D.; Dneprovskaia, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao,
     Ningning
PA
     Targegen, Inc., USA
SO
     PCT Int. Appl., 230 pp.
     CODEN: PIXXD2
\mathsf{DT}
     Patent
     English
LA
IC
     28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
CC
     Section cross-reference(s): 1, 63
FAN.CNT 2
     PATENT NO.
                            KIND
                                    DATE
                                                APPLICATION NO.
                                                                            DATE
                            ____
                                    _____
                            A2
                                    20040415
                                                WO 2003-US31721
PΙ
     WO 2004030635
                                                                            20031002
                            A3
     WO 2004030635
                                    20040812
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
              GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
         OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2500727
                             A1
                                    20040415
                                               CA 2003-2500727
                                                                            20031002
     AU 2003282726
                             Α1
                                    20040423
                                                 AU 2003-282726
                                                                            20031002
                                    20050706
                                               EP 2003-774610
     EP 1549614
                            Α2
                                                                            20031002
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

```
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                               20050809 BR 2003-15053
    BR 2003015053 A
                                                                 20031002
    CN 1720224
                        Α
                               20060111
                                           CN 2003-80104711
                                                                 20031002
                        Τ
    JP 2006515317
                               20060525
                                           JP 2005-500378
                                                                 20031002
                       A
                              20070316
    IN 2005DN01020
                                          IN 2005-DN1020
                                                                 20050316
                       A
    ZA 2005002328
                              20060927
                                          ZA 2005-2328
                                                                 20050318
    MX 2005PA03477
                       Α
                              20050722
                                          MX 2005-PA3477
                                                                 20050401
                       P
PRAI US 2002-415981P
                              20021003
                       Ρ
    US 2003-440234P
                              20030114
    US 2003-443752P
                        Р
                              20030129
                        Ρ
    US 2003-463818P
                              20030417
                        Р
    US 2003-466983P
                              20030430
    US 2003-479295P
                        Р
                              20030617
    WO 2003-US31721
                        W
                              20031002
CLASS
                CLASS PATENT FAMILY CLASSIFICATION CODES
PATENT NO.
                ____
                ICM
WO 2004030635
                       A61K
                IPCI
                       A61K [ICM]
                IPCR
                       A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
                       [I,C^*]; A61K0031-525 [I,A]; A61K0031-716 [I,C^*];
                       A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02 [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
                       C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
                       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
                       C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
                       [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
                       [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
                       C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                       C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90;
                ECLA
                       C07D239/95; C07D241/42; C07D253/08C; C07D401/12;
                       C07D403/12; C07D405/04; C07D405/12;
                       C07D471/04+241B+221B; C07D487/04+241B+239B;
                       C07D519/00+487/00+487/00; M07D; M07D
CA 2500727
                IPCI
                       C07D0209-04 [ICM, 7]; C07D0209-00 [ICM, 7, C*];
                       A61K0031-404 [ICS, 7]; A61K0031-403 [ICS, 7, C*];
                       A61K0031-495 [ICS, 7]
                IPCR
                       A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
                       [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
                       A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02
                       [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
                       C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
                       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
                       C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
                       [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
                       [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
                       C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90;
                       C07D239/95; C07D241/42; C07D253/08C; C07D401/12;
                       C07D403/12; C07D405/04; C07D405/12;
                       C07D471/04+241B+221B; C07D487/04+241B+239B;
                       C07D519/00+487/00+487/00
AU 2003282726
                IPCI
                       C07D0209-04 [ICM, 7]; C07D0209-00 [ICM, 7, C*];
                       A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*];
                       A61K0031-495 [ICS, 7]
```

```
TPCR
                       A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
                       [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
                       A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02
                       [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
                       C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
                       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
                       C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
                       [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
                       [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
                       C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
EP 1549614
                IPCI
                       C07D0209-04 [ICM, 7]; C07D0209-00 [ICM, 7, C*];
                       A61K0031-404 [ICS,7]; A61K0031-403 [ICS,7,C*];
                       A61K0031-495 [ICS,7]
                       C07D0209-00 [I,C]; C07D0209-14 [I,A]; A61K0031-403
                IPCR
                       [I,C]; A61K0031-404 [I,A]; A61K0031-405 [I,A];
                       A61K0031-495 [I,C]; A61K0031-495 [I,A]; A61K0031-519
                       [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
                       A61K0031-724 [I,A]; A61P0035-00 [I,C]; A61P0035-00
                       [I,A]; C07D0209-02 [I,A]; C07D0209-04 [I,A];
                       C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
                       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
                       C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
                       [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
                       [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
                       C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                       C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90;
                ECLA
                       C07D239/95; C07D241/42; C07D253/08C; C07D401/12;
                       C07D403/12; C07D405/04; C07D405/12;
                       C07D471/04+241B+221B; C07D487/04+241B+239B;
                       C07D519/00+487/00+487/00; M07D; M07D
BR 2003015053
                IPCI
                       C07D0209-04 [ICM, 7]; C07D0209-00 [ICM, 7, C*];
                       A61K0031-404 [ICS, 7]; A61K0031-403 [ICS, 7, C*];
                       A61K0031-495 [ICS, 7]
                IPCR
                       A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-519
                       [I,C*]; A61K0031-525 [I,A]; A61K0031-716 [I,C*];
                       A61K0031-724 [I,A]; C07D0209-00 [I,C*]; C07D0209-02
                       [I,A]; C07D0209-04 [I,A]; C07D0209-14 [I,A];
                       C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
                       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
                       C07D0241-00 [I,C*]; C07D0241-42 [I,A]; C07D0253-00
                       [I,C*]; C07D0253-10 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-12
                       [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A];
                       C07D0405-12 [I,A]; C07D0471-00 [I,C*]; C07D0471-04
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D209/14; C07D209/48D5A2; C07D239/88; C07D239/90;
                       C07D239/95; C07D241/42; C07D253/08C; C07D401/12;
                       C07D403/12; C07D405/04; C07D405/12;
                       C07D471/04+241B+221B; C07D487/04+241B+239B;
                       C07D519/00+487/00+487/00
CN 1720224
                IPCI
                       C07D0209-04 [I,A]; C07D0209-00 [I,C*]; A61K0031-404
                       [I,A]; A61K0031-403 [I,C*]; A61K0031-495 [I,A]
                IPCR
                       C07D0209-00 [I,C]; C07D0209-04 [I,A]
JP 2006515317
                IPCI
                       C07D0209-14 [I,A]; A61K0031-404 [I,A]; A61K0031-403
```

```
[I,C*]; C07D0209-48 [I,A]; C07D0209-00 [I,C*];
      A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; C07D0475-08
       [I,A]; C07D0519-00 [I,A]; C07D0471-04 [I,A];
       C07D0471-00 [I,C*]; A61K0031-4985 [I,A]; C07D0253-08
       [I,A]; C07D0253-00 [I,C*]; A61K0031-53 [I,A];
       C07D0487-04 [I,A]; C07D0487-00 [I,C*]; C07D0475-02
       [I,A]; C07D0475-06 [I,A]; C07D0475-00 [I,C*];
       A61K0031-519 [I,A]; C07D0241-44 [I,A]; C07D0241-00
       [I,C*]; A61K0031-498 [I,A]; A61P0009-00 [I,A];
      A61P0009-10 [I,A]; A61P0035-00 [I,A]; A61P0019-02
       [I,A]; A61P0019-00 [I,C*]; A61P0027-02 [I,A];
      A61P0027-00 [I,C*]; A61P0037-06 [I,A]; A61P0037-00
       [I,C*]; A61P0029-00 [I,A]; A61P0017-02 [I,A];
      A61P0017-00 [I,C*]; A61P0011-00 [I,A]; A61P0043-00
       [I,A]; A61K0031-704 [I,A]; A61K0031-7028 [I,C*];
       A61K0031-337 [I,A]; A61K0038-00 [I,A]; A61K0039-395
       [I,A]; A61K0031-661 [I,A]; C07D0405-04 [I,A];
       A61J0001-05 [I,A]; A61J0003-00 [I,A]; A61K0031-5377
       [I,A]; A61K0031-5375 [I,C*]; C07D0405-12 [I,A];
       C07D0405-00 [I,C*]
IPCR
       C07D0209-00 [I,C]; C07D0209-14 [I,A]; A61J0001-05
       [I,C]; A61J0001-05 [I,A]; A61J0003-00 [I,C];
       A61J0003-00 [I,A]; A61K0031-337 [I,C]; A61K0031-337
       [I,A]; A61K0031-403 [I,C]; A61K0031-404 [I,A];
       A61K0031-405 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439
       [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A];
       A61K0031-4985 [I,C]; A61K0031-4985 [I,A]; A61K0031-519
       [I,C]; A61K0031-519 [I,A]; A61K0031-525 [I,A];
       A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-5375
       [I,C]; A61K0031-5377 [I,A]; A61K0031-661 [I,C];
      A61K0031-661 [I,A]; A61K0031-7028 [I,C]; A61K0031-704
       [I,A]; A61K0031-716 [I,C*]; A61K0031-724 [I,A];
      A61K0038-00 [I,C]; A61K0038-00 [I,A]; A61K0039-395
       [I,C]; A61K0039-395 [I,A]; A61P0009-00 [I,C];
      A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0011-00
       [I,C]; A61P0011-00 [I,A]; A61P0017-00 [I,C];
      A61P0017-02 [I,A]; A61P0019-00 [I,C]; A61P0019-02
       [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A];
      A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00
       [I,C]; A61P0035-00 [I,A]; A61P0037-00 [I,C];
      A61P0037-06 [I,A]; A61P0043-00 [I,C]; A61P0043-00
       [I,A]; C07D0209-02 [I,A]; C07D0209-04 [I,A];
      C07D0209-48 [I,A]; C07D0239-00 [I,C*]; C07D0239-88
       [I,A]; C07D0239-90 [I,A]; C07D0239-95 [I,A];
      C07D0241-00 [I,C]; C07D0241-42 [I,A]; C07D0241-44
       [I,A]; C07D0253-00 [I,C]; C07D0253-08 [I,A];
       C07D0253-10 [I,A]; C07D0401-00 [I,C*]; C07D0401-12
       [I,A]; C07D0403-00 [I,C*]; C07D0403-12 [I,A];
       C07D0405-00 [I,C]; C07D0405-04 [I,A]; C07D0405-12
       [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A];
       C07D0475-00 [I,C]; C07D0475-02 [I,A]; C07D0475-06
       [I,A]; C07D0475-08 [I,A]; C07D0487-00 [I,C];
       C07D0487-04 [I,A]; C07D0519-00 [I,C]; C07D0519-00 [I,A]
FTERM 4C050/AA01; 4C050/BB08; 4C050/CC12; 4C050/EE04;
       4C050/FF05; 4C050/GG04; 4C050/HH01; 4C063/AA01;
       4C063/BB01; 4C063/BB09; 4C063/CC12; 4C063/CC76;
       4C063/CC81; 4C063/DD06; 4C063/DD44; 4C063/EE01;
       4C065/AA04; 4C065/BB12; 4C065/CC01; 4C065/DD03;
       4C065/EE02; 4C065/HH01; 4C065/JJ07; 4C065/KK04;
       4C065/LL01; 4C065/PP03; 4C072/MM02; 4C084/AA02;
       4C084/BA44; 4C084/DB52; 4C084/MA02; 4C084/NA05;
```

```
4C084/NA14; 4C084/ZA331; 4C084/ZA332; 4C084/ZA361;
                        4C084/ZA362; 4C084/ZA891; 4C084/ZA892; 4C084/ZA961;
                        4C084/ZA962; 4C084/ZB081; 4C084/ZB082; 4C084/ZB111;
                        4C084/ZB112; 4C084/ZB261; 4C084/ZB262; 4C084/ZC751;
                        4C085/AA13; 4C085/EE03; 4C086/AA01; 4C086/AA02;
                        4C086/AA03; 4C086/BA02; 4C086/BC13; 4C086/BC17;
                        4C086/BC52; 4C086/BC64; 4C086/CB09; 4C086/CB14;
                        4C086/DA34; 4C086/EA10; 4C086/GA02; 4C086/GA07;
                        4C086/GA08; 4C086/MA01; 4C086/MA02; 4C086/MA04;
                        4C086/NA05; 4C086/NA14; 4C086/ZA33; 4C086/ZA36;
                        4C086/ZA89; 4C086/ZA96; 4C086/ZB08; 4C086/ZB11;
                        4C086/ZB26; 4C086/ZC75; 4C204/BB01; 4C204/CB03;
                        4C204/CB04; 4C204/DB03; 4C204/DB30; 4C204/EB02;
                        4C204/EB03; 4C204/FB01; 4C204/FB16; 4C204/GB01
                        C07D0209-04 [ICM, 7]; C07D0209-00 [ICM, 7, C*]
 IN 2005DN01020 IPCI
 ZA 2005002328
                 IPCI
                        A61K [N,S]; C07D [N,S]
 MX 2005PA03477 IPCI
                        A61K [ICM, 7]; A61K0031-404 [ICS, 7]; A61K0031-403
                        [ICS, 7, C*]; A61K0031-495 [ICS, 7]; C07D0209-04 [ICS, 7];
                        C07D0209-00 [ICS,7,C*]
OS
    MARPAT 140:321386
```

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

GΙ

AΒ Compds. (2 Markush structures shown as I and II; others are described in the claims and disclosure; variables defined below; e.g. III and IV) and methods are provided for treating disorders associated with compromised vasculostasis. Invention methods and compns. are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like. Although the methods of preparation are not claimed, many example prepns. are included. For example, III was prepared (75 %) from 2-(2-aminophenyl)indole and 4-hydroxyphenylacetic acid. Various expts. are described that show the use of the claimed compds. along with chemotherapeutic agents for cancer treatment. The claimed compds. also show inhibition of vascular leak induced by interleukin 2. Inhibition of VEGF-induced edema, reduction of myocardial infarction and inhibition of c-Src and Yes kinases were demonstrated for some of the claimed compds. For I: each R0 = -H, -COOH, -OR', -SO3H, wherein R' is - H or lower alkyl, or when x = 2, each R0 is taken together to form a 1,3-dioxolyl ring, or each R0 = (un) substituted alkyl, (un) substituted alkenyl, (un) substituted alkynyl, (un) substituted cycloalkyl, (un) substituted heterocyclic, (un) substituted aryl, (un) substituted heteroaryl, (un) substituted alkylaryl, (un) substituted arylalkyl, (un) substituted arylalkenyl, (un) substituted arylalkynyl, halogen, amino, amido, nitro, or thioalkyl. R1 and R2 = H, (un) substituted alkyl, (un) substituted alkenyl, (un) substituted alkynyl, (un) substituted cycloalkyl, (un) substituted heterocyclic, (un) substituted aryl, (un) substituted heteroaryl, (un) substituted alkylaryl, (un) substituted arylalkyl, (un) substituted arylalkenyl, (un) substituted arylalkynyl; G is NH, O, S, or (CR'')p, wherein R'' is -H, lower alkyl, or acetamido, and wherein p = 0-3; Ar is aryl or heteroaryl, and x and y =1-4. For II: Z1-Z6 = C, -C:O, N, or NRa, wherein Ra is -H, (un) substituted alkyl, wherein said substituents are halogen, hydroxy, oxo, or amino; each X = halogen, -ORb, -NRb2, or -SRb, wherein Rb is -H

```
lower alkyl, -(CH2)2NHEt, -(CH2)3morpholin-1-yl, -(CH2)3-(N-
methylpiperazin-1-yl), aryl, heteroaryl, -(NH-NH-Rc), -(N:N-NH-Rc),
wherein Rc is H or lower alkyl. Each Y = -ORd, -NRd2, -SRd, or -OPO3H2
wherein Rd is H, lower alkyl, aryl, heteroaryl, -(CH2)2NHEt,
-(CH2)3morpholin-1-yl, or (CH2)3-(N-methylpiperazin-1-yl); or each Y =
(un) substituted alkyl, (un) substituted aryl, (un) substituted heteroaryl,
or halogen, wherein said substituents = halogen, -ORe, -NRe2, -SRe,
-P(O)(OH)2, wherein Re is -H, lower alkyl, aryl, or heteroaryl; or each Y
= CH2qlycinyl, CH2NHethoxy, CH2NHCH2alkyl, CH2NHCH2t-Bu, CH2NHCH2aryl,
CH2NHCH2substituted aryl, CH2NHCH2heteroaryl, CH2NHCH2substituted
heteroaryl; or when n is 2, each Y is taken together to form a fused aromatic
or heteroarom. ring system; and m and n = 1 to 4, wherein when Z1, Z3, Z5,
and Z6 are each N, X is NH2, and m = n = 2, Y is not Ph or
4-hydroxyphenyl.
indolylphenyl carboxamide prepn vasculostatic agent compn; pteridine prepn
vasculostatic agent compn; quinoxaline prepn vasculostatic agent compn;
quinazoline prepn vasculostatic agent compn; benzotriazine prepn
vasculostatic agent compn; vasculostasis treatment fused
nitrogen heterocycle prepn
Respiratory distress syndrome
   (acute; preparation of vasculostatic agents and methods of use)
Respiratory distress syndrome
   (adult; preparation of vasculostatic agents and methods of use)
Alkylation
   (agents, codrugs for cancer; preparation of vasculostatic agents and methods
   of use)
Antibiotics
   (anthracycline, codrugs for cancer; preparation of vasculostatic agents and
   methods of use)
Antitumor agents
   (antifolates, codrugs; preparation of vasculostatic agents and methods of
   use)
Cytotoxic agents
   (antimetabolites, codrugs for cancer; preparation of vasculostatic agents
   and methods of use)
Disease, animal
   (arthropathy; preparation of vasculostatic agents and methods of use)
Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
   (binding to HER2 protein, growth factors or growth factor receptors, or
   integrin receptors; codrugs; preparation of vasculostatic agents and methods
   of use)
Antibiotics
   (bleomycin- and mitomycin-type, codrugs for cancer; preparation of
   vasculostatic agents and methods of use)
Interleukin 2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
   (codrug; preparation of vasculostatic agents and methods of use)
Taxanes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
   (codrugs for cancer; preparation of vasculostatic agents and methods of use)
Intestine, neoplasm
   (colon; preparation of vasculostatic agents and methods of use)
Joint, anatomical
   (disease; preparation of vasculostatic agents and methods of use)
Heart, disease
   (failure; preparation of vasculostatic agents and methods of use)
Crosslinking agents
   (for DNA, as codrugs for cancer; preparation of vasculostatic agents and
   methods of use)
Heart, disease
```

ST

ΙT

ΙΤ

ΙT

ΙT

ΤТ

TΤ

ΙT

ΙT

ΙT

ΤТ

ΤТ

ΙT

ΙΤ

ΙΤ

ΤТ

ΙT

```
(infarction; preparation of vasculostatic agents and methods of use)
ΤТ
    Microtubule
        (inhibitors, codrugs for cancer; preparation of vasculostatic agents and
        methods of use)
     Reperfusion
ΤТ
        (injury; preparation of vasculostatic agents and methods of use)
ΙT
     Capillary vessel, disease
        (leakage syndrome; preparation of vasculostatic agents and methods of use)
ΙΤ
     Eve, disease
        (macula, degeneration; preparation of vasculostatic agents and methods of
     Angiogenesis inhibitors
ΤТ
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiarthritics
     Antitumor agents
     Arthritis
     Autoimmune disease
     Bladder, neoplasm
     Blood vessel, disease
     Bone, neoplasm
     Brain, neoplasm
     Burn
     Cardiovascular agents
     Digestive tract, neoplasm
     Diuretics
     Drug delivery systems
     Edema
     Human
     Immunomodulators
     Inflammation
       Ischemia
     Kidney, neoplasm
     Leukemia
     Liver, neoplasm
     Lung, neoplasm
     Lymphoma
     Mammary gland, neoplasm
     Myoma
     Neoplasm
     Ovary, neoplasm
     Packaging materials
     Prostate gland, neoplasm
     Skin, neoplasm
     Transplant rejection
        (preparation of vasculostatic agents and methods of use)
ΙT
     Injury
        (reperfusion; preparation of vasculostatic agents and methods of use)
ΤТ
     Eve, disease
        (retinopathy; preparation of vasculostatic agents and methods of use)
ΙT
     Brain, disease
        (stroke; preparation of vasculostatic agents and methods of use)
     Alkaloids, biological studies
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (vinca, codrugs for cancer; preparation of vasculostatic agents and methods
        of use)
     Eye, disease
ΙT
        (vitreoretinal; preparation of vasculostatic agents and methods of use)
     180288-69-1, Trastuzumab
                                183319-69-9, OSI-774
                                                        216974-75-3, Bevacizumab
ΤТ
     892553-42-3, Vitaxin
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
```

```
(codrug for cancer; preparation of vasculostatic agents and methods of use)
ΤТ
       50-76-0, Dactinomycin
                                         59-05-2, Methotrexate 64-86-8, Colchicine
       477-30-5, Demecolcine
                                           15663-27-1, Cisplatin
                                                                               20830-81-3, Daunorubicin
       23214-92-8, Doxorubicin
                                              33069-62-4, Taxol 33419-42-0, Etoposide
       39472-31-6, Carminomycin 41575-94-4, Carboplatin
                                                                                    42077-25-8,
       Adriamycin-14-octanoate 56420-45-2, Epirubicin
                                                                                   58957-92-9, Idarubicin
       59367-03-2, Adriamycin-14-benzoate 64161-91-7, Adriamycin-14-
       naphthaleneacetate
                                      65271-80-9, Mitoxantrone
                                                                              79466-09-4,
       13-Deoxydaunorubicin
                                         84325-15-5, 11-Deoxydaunorubicin
                                                                                            114977-28-5,
       Docetaxel
       RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
            (codrugs for cancer; preparation of vasculostatic agents and methods of use)
ΙT
                          677297-15-3P, N-[2-(1H-Indol-2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-(2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl]-2-yl)phenyl[-2-yl]-2-yl)phenyl[-2-yl]-2-yl]-2-yl)phenyl[-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2-yl]-2
       methoxyphenyl)acetamide 677297-25-5P, N-[2-(1H-Indol-2-
       yl)phenyl]phthalamic acid 677297-30-2P, 6,7-Bis(4-hydroxyphenyl)pteridin-
                       677297-48-2P, 4-(4-Aminopteridin-7-yl)phenol 677297-51-7P,
       4-ylamine
       6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine
                                                                            677297-58-4P,
       6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine 677297-61-9P,
       6,7-Bis(4-hydroxyphenyl)pteridin-4-ylamine sulfate
                                                                                    677297-63-1P,
       6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diamine dihydrochloride
       677297-75-5P
                            677297-77-7P 677297-99-3P, 3-(3-Aminobenzo[1,2,4]triazin-
                            677298-01-0P, N-(7-Bromo-5-methylbenzo[1,2,4]triazin-3-
       7-yl)phenol
       yl)phenylamine
       RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
       preparation); THU (Therapeutic use); BIOL (Biological study); PREP
       (Preparation); RACT (Reactant or reagent); USES (Uses)
            (drug candidate; preparation of vasculostatic agents and methods of use)
       14892-98-9P, 6,7-Diphenylpteridine-2,4-diol 18181-93-6P,
       6,7-Diphenylpteridine-2,4-diamine
                                                            24863-39-6P, 6,7-Diphenylpteridin-4-ol
       32044-95-4P, 2,3-Diphenylquinoxalin-5-amine 73384-11-9P,
       7-Phenylpteridin-4-amine
                                               102554-55-2P, 2,3-Diphenylquinoxalin-5-ol
       102704-20-1P, N-[2-(1H-Indol-2-yl)phenyl]-2-phenylacetamide
       126988-00-9P, 3-Phenylquinoxalin-5-amine 128076-13-1P,
       (6-Phenylpteridin-4-yl) amine 278799-97-6P, 6-[(Benzylamino)methyl]-2,4-
                                   677297-11-9P, 2-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-
       pteridinediamine
       yl)phenyl]acetamide 677297-12-0P, 4-Hydroxy-N-[2-(1H-indol-2-
                                        677297-13-1P, 3,4-Dihydroxy-N-[2-(1H-indol-2-
       yl)phenyl]benzamide
       yl)phenyl]benzamide
                                        677297-14-2P, 2-Hydroxy-N-[2-(1H-indol-2-
       yl)phenyl]benzamide
                                        677297-16-4P, 2-(2-Hydroxyphenyl)-N-[2-(1H-indol-2-
                                        677297-17-5P, 2-(3,4-Dihydroxyphenyl)-N-[2-(1H-indol-
       yl)phenyl]acetamide
       2-y1) phenyl] acetamide 677297-18-6P, 2-(Benzodioxol-5-y1)-N-[2-(1H-indol-19-2)]
       2-yl)phenyl]acetamide
                                           677297-19-7P, N-[2-(1H-Indol-2-vl)phenvl]-3-
       phenylpropionamide
                                      677297-20-0P, 3-(4-Hydroxyphenyl)-N-[2-(1H-indol-2-
       yl)phenyl]propionamide
                                            677297-21-1P, N-[2-(1H-Indol-2-yl)phenyl]-3-(2-
                                                677297-22-2P, 3-(3,4-Dihydroxyphenyl)-N-[2-
       methoxyphenyl)propionamide
                                                            677297-23-3P, 2-(4-Hydroxyphenoxy)-N-
       (1H-indol-2-yl)phenyl]propionamide
                                                              677297-24-4P, 2-Acetylamino-3-(4-
       [2-(1H-indol-2-yl)phenyl]acetamide
       hydroxyphenyl)-N-[2-(1H-indol-2-yl)phenyl]propionamide 677297-26-6P,
       2-[[2-(1H-Indol-2-yl)phenyl]carbamoyl]nicotinic acid
                                                                                        677297-27-7P,
       3, 4, 5-Trihydroxy-N-[2-(1H-indol-2-yl)phenyl]benzamide
                                                                                         677297-28-8P,
       2-(2-Phthalimidophenyl)-1H-indole 677297-29-9P, [6,7-Bis(4-
       hydroxyphenyl)pteridin-4-yl][3-(morpholin-4-yl)propyl]amine hydrochloride
       677297-31-3P, Acetic acid 4-[7-(4-acetoxyphenyl)-4-aminopteridin-6-
                                677297-32-4P, Acetic acid 4-[2-(4-acetoxyphenyl)-6-
       yl]phenyl ester
       aminopyrido[2,3-b]pyrazin-3-yl]phenyl ester
                                                                          677297-35-7P,
                                                                                   677297-36-8P,
       (3,4-Dimethoxyphenyl)(6-phenylpteridin-4-yl)amine
       (3-Chloro-4,6-dimethoxyphenyl)(6-phenylpteridin-4-yl)amine
                                                                                                  677297-37-9P,
       (3-Hydroxy-4-methoxyphenyl)(6-phenylpteridin-4-yl)amine
                                                                                           677297-38-0P,
       (4-Hydroxyphenyl)(6-phenylpteridin-4-yl)amine 677297-39-1P,
       (2,5-Dimethyl-4-hydroxyphenyl)(6-phenylpteridin-4-yl)amine
                                                                                                677297-40-4P,
       2-Hydroxy-5-(6-phenylpteridin-4-ylamino)benzenesulfonic acid
```

```
677297-41-5P, 2-[(Diethylamino)methyl]-4-(6-phenylpteridin-4-
                 677297-42-6P, 5-(6-Phenylpteridin-4-ylamino)quinolin-8-ol
ylamino)phenol
dihydrochloride
                677297-44-8P, Benzyl (6-phenylpteridin-4-yl) amine
677297-45-9P, 4-[(6-Phenylpteridin-4-ylamino)methyl]benzene-1,2-diol
677297-46-0P, (Indan-2-yl)(6-phenylpteridin-4-yl)amine 677297-47-1P,
[2-(3,4-Dimethoxyphenyl)ethyl](6-phenylpteridin-4-yl)amine
                                                             677297-49-3P,
4-(4-Benzylaminopteridin-7-yl)phenol 677297-50-6P, 6,7-Bis(3-
hydroxyphenyl)pteridine-2,4-diamine monohydrochloride 677297-52-8P,
6-(Pvridin-2-vl)-7-(pvridin-3-vl) pteridin-4-amine 677297-53-9P,
6-(Pyridin-2-yl)-7-(pyridin-3-yl)pteridin-4-amine sulfate
6,7-Bis(3,4-dihydroxyphenyl)pteridine-2,4-diol 677297-55-1P,
6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine dihydrochloride
677297-56-2P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine
methanesulfonate 677297-57-3P, 6,7-Bis(3-hydroxyphenyl)pteridine-2,4-
diamine dihydrobromide 677297-59-5P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-
                      677297-60-8P, 6,7-Bis(3-hydroxyphenyl)pteridin-4-
ylamine hydrochloride
ylamine methanesulfonate 677297-62-0P, 6,7-Bis(3,4-
dihydroxyphenyl)pteridine-2,4-diamine 677297-64-2P, 6,7-Bis(3,4-
dihydroxyphenyl)pteridin-4-ylamine hydrochloride 677297-65-3P,
6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine 677297-66-4P,
6,7-Bis(3,4-dihydroxyphenyl)pteridin-4-ylamine methanesulfonate
677297-67-5P, 4-(2,4-Diaminopteridin-6-yl)phenol 677297-68-6P,
(2,3-Diphenylpyrido[3,4-b]pyrazin-8-yl)amine hydrochloride 677297-69-7P,
2,3-Bis(4-hydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine hydrochloride
677297-70-0P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-ylamine
              677297-71-1P, 2,3-Bis(3-hydroxyphenyl)pyrido[3,4-b]pyrazin-
hvdrochloride
8-ylamine hydrochloride 677297-72-2P, 2,3-Bis(3-hydroxyphenyl)pyrido[2,3-
b]pyrazin-6-ylamine dihydrochloride 677297-73-3P, 2,3-Bis(4-
hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine dihydrochloride
677297-76-6P
             677297-78-8P 677297-79-9P, 4-(4-Aminopteridin-7-
yl)benzene-1,2-diol 677297-80-2P, 4-(2,4-Diaminopteridin-7-yl)benzene-
1,2-diol 677297-81-3P, 4-(2,4-Diaminopteridin-7-yl)phenol
677297-82-4P, 4-[2-(6-Phenylpteridin-4-ylamino)ethyl]benzene-1,2-diol
677297-83-5P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine
dihydrochloride
                677297-84-6P, 2,3-Bis(3-hydroxyphenyl)quinoxalin-6-
ylamine dihydrochloride
                        677297-85-7P, 2,3-Bis(4-hydroxyphenyl)quinoxalin-
6-ylamine dihydrochloride
                           677297-86-8P, 2,3-Bis(3,4-
dihydroxyphenyl)quinoxalin-6-ylamine dihydrochloride
                                                      677297-94-8P,
[7-(2-Trifluoromethylphenyl)benzo[1,2,4]triazin-3-yl]amine
[7-(Naphthalen-1-yl)benzo[1,2,4]triazin-3-yl]amine 677298-00-9P,
N-[7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]phenylamine
677298-02-1P, (7-Bromo-5-methylbenzo[1,2,4]triazin-3-yl)[3-(4-
methylpiperazin-1-yl)propyl]amine
                                  677298-03-2P, N-[5-Methyl-7-(2,4,6-
trimethylphenyl)benzo[1,2,4]triazin-3-yl]phenylamine
                                                      677298-04-3P,
N-[7-(2-Fluoro-6-methoxyphenyl)-5-methylbenzo[1,2,4]triazin-3-
                677298-05-4P, N-[7-(2,6-Dimethoxyphenyl)-5-
yl]phenylamine
methylbenzo[1,2,4]triazin-3-yl]phenylamine 677298-06-5P,
\label{eq:n-problem} \texttt{N-[7-(2,6-Dimethylphenyl)-5-methylbenzo[1,2,4]triazin-3-yl]} \\ \texttt{phenylamine}
677298-08-7P, 2-[(2,4-Diaminopteridin-6-ylmethyl)amino]-3-(4-3)
hydroxyphenyl)propionic acid tert-butyl ester
                                               677298-09-8P,
                                                            677298-10-1P,
6-[[(Pyridin-2-ylmethyl)amino]methyl]-2,4-pteridinediamine
6-[[(Naphthalen-1-ylmethyl)amino]methyl]-2,4-pteridinediamine
677298-11-2P, 6-[[(Adamantan-1-ylmethyl)amino]methyl]-2,4-pteridinediamine
677298-12-3P, 6-[(3,4-Dimethoxybenzyl)amino]-2,4-pteridinediamine
677298-13-4P, 6-[(2,2-Dimethylpropylamino)methyl]-2,4-pteridinediamine
677298-14-5P, 6-[[[2-(3,4-Dimethoxyphenyl)ethyl]amino]methyl]-2,4-
pteridinediamine
                  677298-15-6P, 6-[[[2-(3,4-Dihydroxyphenyl)ethyl]amino]m
ethyl]-2,4-pteridinediamine
                             677298-16-7P, 4-[2-[Di(2,4-diaminopteridin-6-
ylmethyl)amino]ethyl]benzene-1,2-diol 677298-17-8P, 6-[[(3,4-
Dihydroxybenzyl)amino]methyl]-2,4-pteridinediamine 677298-18-9P,
3-(4-tert-Butoxyphenyl)-2-[[(2,4-diaminopteridin-6-
```

```
yl)methyl]amino]propionic acid tert-butyl ester 677298-19-0P,
1-[[Bis(2,4-diaminopteridin-6-ylmethyl)amino]methyl]naphthalene
677298-20-3P, 6-(2,6-Dimethylphenyl)-3H-quinazolin-4-one
                                                         677298-21-4P,
6-(2,6-Dimethoxyphenyl)-3H-quinazolin-4-one 677298-22-5P,
6-(2-Chloro-6-methoxyphenyl)-3H-quinazolin-4-one
                                                  677298-23-6P,
6-(2,4,6-Trimethylphenyl)-3H-quinazolin-4-one
                                               677298-24-7P,
6-(Naphthalen-1-yl)-3H-quinazolin-4-one
                                         677298-25-8P,
6-(Naphthalen-2-yl)-3H-quinazolin-4-one
                                         677298-26-9P,
6-(4-Phenoxyphenyl)-3H-quinazolin-4-one
                                         677298-28-1P,
6-(2,6-Dimethylphenyl)-3-(3-hydroxypropionyl)-3H-quinazolin-4-one
677298-29-2P, 6-(2-Chloro-6-methoxyphenyl)-3-(3-hydroxypropionyl)-3H-
quinazolin-4-one 677298-32-7P, (6,7-Diphenylpteridin-4-y1)[3-(4-y1)]
methylpiperazin-1-yl)propyl]amine 677298-33-8P 677298-34-9P,
3-[(Benzimidazol-2-ylmethyl)amino]-1H-indolin-2-one 677298-35-0P,
6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine sulfate 677298-36-1P,
4-(2,4-Diaminopteridin-6-yl)phenol sulfate 677298-37-2P,
6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diol
                                           677298-38-3P,
N-[2-(2,3-Dihydro-1H-indol-2-yl)phenyl]-2-hydroxybenzamide
                                                            677298-39-4P,
3-[[2-(1H-Indol-2-yl)phenyl]carbamoyl]pyridine-2-carboxylic acid
677298-40-7P, 6-[[(Naphthalen-2-ylmethyl)amino]methyl]pteridine-2,4-
diamine 677298-42-9P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[3,4-b]pyrazin-8-
        677298-46-3P, 3,4,5-Trihydroxy-N-(1H-indol-2-yl)benzamide
677298-47-4P, 6,7-Bis(pyridin-2-yl)pteridin-4-ylamine 677298-48-5P,
6,7-Bis(3-hydroxyphenyl)pteridin-2-amine
                                          677298-49-6P,
6,7-Bis(3-hydroxyphenyl)pteridin-4-ylamine hydrobromide
                                                         677298-50-9P,
2-Phenylquinoxalin-5-amine 677298-51-0P, 6-(Pyridin-2-yl)-7-(pyridin-3-
yl)pteridine-2,4-diol 677298-53-2P, 6-(Pyridin-3-yl)-7-(pyridin-2-
yl)pteridin-4-amine
                    677298-54-3P, 2,3-Bis(3,4-dihydroxyphenyl)pyrido[2,3-
b]pyrazin-6-ylamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of vasculostatic agents and methods of use)
677298-52-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
   (drug candidate; preparation of vasculostatic agents and methods of use)
143180-75-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors, codrugs for cancer; preparation of vasculostatic agents and
  methods of use)
372092-80-3, Protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors, codrugs; preparation of vasculostatic agents and methods of
                                              80449-02-1, Tyrosine kinase
9026-43-1, Serine kinase
                          9031-44-1, Kinase
                        141349-91-9, Yes kinase
141349-89-5, Src kinase
                                                   144697-17-6, c-Src
kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (inhibitors; preparation of vasculostatic agents and methods of use)
51-61-6, 2-(3,4-Dihydroxyphenyl) ethylamine, reactions 62-31-7,
3-Hydroxytyramine hydrochloride
                                 62-53-3, Aniline, reactions 69-72-7,
Salicylic acid, reactions
                           85-44-9, Phthalic anhydride 91-56-5,
        93-25-4, 2-Methoxyphenylacetic acid
Isatin
                                              99-50-3,
3,4-Dihydroxybenzoic acid 99-96-7, 4-Hydroxybenzoic acid, reactions
100-46-9, Benzylamine, reactions 102-32-9, 3,4-Dihydroxyphenylacetic
      103-82-2, Phenylacetic acid, reactions
                                              118-31-0,
acid
1-Aminomethylnaphthalene 123-00-2, N-(3-Aminopropyl)morpholine
134-81-6, Benzil 149-91-7, Gallic acid, reactions 156-38-7,
4-Hydroxyphenylacetic acid 501-52-0, Hydrocinnamic acid
                                                          501-97-3,
3-(4-Hydroxyphenyl) propionic acid 537-55-3, N-Acetyl-L-tyrosine
```

TТ

ΙT

ΙT

ΤТ

ΙΤ

```
615-47-4, 1,2,4-Benzenetriamine dihydrochloride 635-85-8,
2-(3,4-Dimethoxyphenyl)ethylamine hydrochloride 699-98-9,
2,3-Pyridinedicarboxylic anhydride 814-68-6, Acryloyl chloride
875-51-4, (4-Bromo-2-nitrophenyl)amine 1078-61-1, 3,4-
Dihydroxyhydrocinnamic acid 1124-40-9, (3,4-Dihydroxybenzyl)amine
              1423-27-4, 2-Trifluoromethylphenylboronic acid
hydrochloride
1878-84-8, (4-Hydroxyphenoxy) acetic acid 2861-28-1, 3,4-
(Methylenedioxy) phenylacetic acid 3731-51-9, 2-(Aminomethyl) pyridine
4572-03-6, 3-(4-Methylpiperazin-1-yl)propylamine 5122-94-1,
(4-Biphenyl)boronic acid
                         5763-61-1, 3,4-Dimethoxybenzylamine
5794-88-7, 2-Amino-5-Bromobenzoic acid 5813-64-9, 2,2-
Dimethylpropylamine 5980-97-2, 2,4,6-Trimethylphenylboronic acid
6309-15-5, 3,3',4,4'-Tetrahydroxybenzil 6342-77-4, 3-(2-
Methoxyphenyl)propionic acid 7757-21-3 13922-41-3, (1-Naphthyl)boronic
      16290-26-9, 3,4-Dihydroxybenzylamine hydrobromide 17601-94-4,
2-Amino-3-bromo-5-nitrobenzonitrile 17768-41-1, 1-Aminomethyladamantane
20284-90-6, 2,3,6-Triaminopyridine dihydrochloride 21454-19-3,
Bis[4-(1,2-dioxo-2-phenylethyl)phenyl] ether 23112-96-1,
2,6-Dimethoxyphenylboronic acid 24645-80-5, 4-Hydroxyphenylglyoxal
32316-92-0, (2-Naphthyl)boronic acid 32566-01-1, 2-(2-Aminophenyl)indole
33288-79-8, 4,4'-Dihydroxybenzil 42965-55-9, 5,6-Diamino-2,4-
                            49647-58-7, 2,4,5,6-Tetraaminopyrimidine
dihydroxypyrimidine sulfate
sulfate
        49721-45-1, 4,5,6-Triaminopyrimidine sulfate
                                                       51067-38-0,
4-Phenoxyphenylboronic acid 52853-40-4, 6-Bromomethyl-2, 4-
pteridinediamine hydrobromide 63192-57-4, 3,3'-Dihydroxybenzil
76145-91-0, (2,4-Diaminopteridin-6-yl)methanol hydrobromide 77712-97-1,
3,4,5-Triaminopyridine hydrochloride 77811-44-0, (4-Bromo-2-methyl-6-
nitrophenyl)amine
                  78495-63-3, 2-Fluoro-6-methoxyphenylboronic acid
87199-18-6, 3-Hydroxyphenylboronic acid 88878-78-8, 2-Amino-3-(4-
hydroxyphenyl)propionic acid tert-butyl ester 94839-07-3,
3,4-(Methylenedioxy)phenylboronic acid 95195-43-0, 2,3'-Pyridil
98437-24-2, 2-Benzofuranboronic acid 100124-06-9, 4-Dibenzofuranboronic
     100379-00-8, 2,6-Dimethylphenylboronic acid 123324-71-0,
4-tert-Butylphenylboronic acid
                                385370-80-9, 2-Chloro-6-
                           545390-26-9, 2-Amino-3-(4-tert-
methoxyphenylboronic acid
butoxyphenyl)propionic acid tert-butyl ester hydrochloride
                                                            677297-33-5,
2,3-Bis(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-ylamine
                                                       677297-34-6,
N'-(3-Cyano-5-phenylpyrazin-2-yl)-N, N-dimethylformamidine
RL: RCT (Reactant); RACT (Reactant or reagent)
   (preparation of vasculostatic agents and methods of use)
6298-38-0P, (7-Bromobenzo[1,2,4]triazin-3-yl)amine 1-oxide
                                                            32084-59-6P,
6-Bromo-3H-quinazolin-4-one 59368-16-0P, 6-Bromomethyl-2,4-
pteridinediamine
                  677297-74-4P
                                 677297-87-9P
                                                677297-88-0P,
[7-(Benzodioxol-5-yl)benzo[1,2,4]triazin-3-yl]amine 1-oxide
677297-89-1P, [7-(Benzodioxol-5-yl)benzo[1,2,4]triazin-3-yl]amine
677297-90-4P, [7-(2,6-Dimethylphenyl)benzo[1,2,4]triazin-3-yl]amine
677297-91-5P, [7-(4-Phenoxyphenyl)benzo[1,2,4]triazin-3-yl]amine
677297-92-6P, [7-(2,6-Dimethoxyphenyl)benzo[1,2,4]triazin-3-yl]amine
677297-93-7P, [7-(4-tert-Butylphenyl)benzo[1,2,4]triazin-3-yl]amine
677297-95-9P, [7-(Biphenyl-4-yl)benzo[1,2,4]triazin-3-yl]amine
677297-96-0P, \quad \hbox{$[7-(Benzofuran-2-yl)$ benzo} \\ \hbox{$[1,2,4]$ triazin-3-yl]$ amine}
677297-97-1P, [7-(Dibenzofuran-4-yl)benzo[1,2,4]triazin-3-yl]amine
677298-27-0P, 6-Bromo-3-(3-hydroxypropionyl)-3H-quinazolin-4-one
677298-30-5P, 4-Amino-8-bromo-6-nitroquinazolin-2-ol 677298-31-6P,
8-Bromo-4-[[3-(4-methylpiperazin-1-yl)propyl]amino]-6-nitroquinazolin-2-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
   (preparation of vasculostatic agents and methods of use)
677298-07-6P, [7-(Naphthalen-2-yl)benzo[1,2,4]triazin-3-yl]amine 1-oxide
RL: SPN (Synthetic preparation); PREP (Preparation)
   (preparation of vasculostatic agents and methods of use)
```

ΙΤ

ΙT

L32 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN

IT 1072-84-0, 4-Imidazolecarboxylic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral

infections, autoimmune diseases, and other conditions)

RN 1072-84-0 CAPLUS

CN 1H-Imidazole-5-carboxylic acid (CA INDEX NAME)

M CO<sub>2</sub>H

ACCESSION NUMBER: 2003:656582 CAPLUS

DOCUMENT NUMBER: 139:197371

TITLE: Preparation of substituted pyridinones as modulators

of p38 MAP kinase

INVENTOR(S): Devadas, Balekudru; Walker, John; Selness, Shaun R.;

Boehm, Terri L.; Durley, Richard C.; Devraj, Rajesh; Hickory, Brian S.; Rucker, Paul V.; Jerome, Kevin D.; Madsen, Heather M.; Alvira, Edgardo; Promo, Michele

A.; Blevis-Bal, Radhika M.; Marrufo, Laura D.;

Hitchcock, Jeff; Owen, Thomas; Naing, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang; Scott,

Ian L.; McGee, Kevin F.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA SOURCE: PCT Int. Appl., 1052 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 2003068230	A1 20030821	WO 2003-US4634	20030214
W: AE, AG, AL,	AM, AT, AU, AZ,	BA, BB, BG, BR, BY, BZ	, CA, CH, CN,
CO, CR, CU,	CZ, DE, DK, DM,	DZ, EC, EE, ES, FI, GB	, GD, GE, GH,
GM, HR, HU,	ID, IL, IN, IS,	JP, KE, KG, KP, KR, KZ	, LC, LK, LR,
LS, LT, LU,	LV, MA, MD, MG,	MK, MN, MW, MX, MZ, NO	, NZ, OM, PH,
PL, PT, RO,	RU, SC, SD, SE,	SG, SK, SL, TJ, TM, TN	, TR, TT, TZ,
UA, UG, US,	UZ, VC, VN, YU,	ZA, ZM, ZW	
RW: GH, GM, KE,	LS, MW, MZ, SD,	SL, SZ, TZ, UG, ZM, ZW	, AM, AZ, BY,
KG, KZ, MD,	RU, TJ, TM, AT,	BE, BG, CH, CY, CZ, DE	, DK, EE, ES,
		LU, MC, NL, PT, SE, SI	
		GQ, GW, ML, MR, NE, SN	
		CA 2003-2476012	
		AU 2003-217433	
		US 2003-367987	20030214
	B2 20060627		
		BR 2003-7631	
EP 1490064	A1 20041229	EP 2003-713478	20030214
· · · · ·	· · · · · · · · · · · · · · · · · · ·	GB, GR, IT, LI, LU, NL	
· · · · · · · · · · · · · · · · · · ·		CY, AL, TR, BG, CZ, EE	•
		CN 2003-808042	
		JP 2003-567412	
NZ 534395	A 20061027	NZ 2003-534395	20030214

```
IN 2004DN02150 A
                                                                       20040723
                                 20050401 IN 2004-DN2150
                                             MX 2004-PA7470
                                 20041110
     MX 2004PA07470
                          A
                                                                       20040802
                                              ZA 2004-6275
     ZA 2004006275
                          Α
                                                                       20040805
                                 20051004
                          A
                                20041109
     NO 2004003820
                                              NO 2004-3820
                                                                       20040913
                          A1 20060921
                                            US 2005-226556
     US 20060211694
                                                                       20050914
     US 20070088033
                          A1 20070419
                                             US 2006-531492
                                                                       20060913
                          A 20070201
A 20070209
     JP 2007023053
                                              JP 2006-263778
                                                                       20060928
     KR 2007017443
AU 2007202607
                                              KR 2007-701895
                                                                       20070125
                          A1 20070628
                                               AU 2007-202607
                                                                       20070607
                                                                 P 20020214
PRIORITY APPLN. INFO.:
                                               US 2002-357029P
                                               US 2002-436915P
                                                                  P 20021230
                                              AU 2003-217433 A3 20030214

JP 2003-567412 A3 20030214

US 2003-367987 A1 20030214

WO 2003-US4634 W 20030214

KR 2004-712622 A3 20040813

US 2005-226556 A3 20050914
OTHER SOURCE(S):
                          MARPAT 139:197371
     2003:656582 CAPLUS
ΑN
     139:197371
DΝ
     Entered STN: 22 Aug 2003
ED
ΤI
     Preparation of substituted pyridinones as modulators of p38 MAP kinase
     Devadas, Balekudru; Walker, John; Selness, Shaun R.; Boehm, Terri L.;
IN
     Durley, Richard C.; Devraj, Rajesh; Hickory, Brian S.; Rucker, Paul V.;
     Jerome, Kevin D.; Madsen, Heather M.; Alvira, Edgardo; Promo, Michele A.;
     Blevis-Bal, Radhika M.; Marrufo, Laura D.; Hitchcock, Jeff; Owen, Thomas;
     Naing, Win; Xing, Li; Shieh, Huey S.; Sambandam, Aruna; Liu, Shuang;
     Scott, Ian L.; McGee, Kevin F.
PA
     Pharmacia Corporation, USA
SO
     PCT Int. Appl., 1052 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LA
IC
     ICM A61K031-4412
     ICS A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70;
          C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10;
          C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79;
          C07D401-04; C07D405-04; C07D413-10; C07D215-22
     27-16 (Heterocyclic Compounds (One Hetero Atom))
     Section cross-reference(s): 1, 63
FAN.CNT 1
     PATENT NO.
                         KIND DATE
                                         APPLICATION NO. DATE
     WO 2003068230
                         A1 20030821 WO 2003-US4634 20030214
PΤ
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2476012
                                  20030821
                                            CA 2003-2476012
                                                                       20030214
                           Α1
                           Α1
                                  20030904
                                               AU 2003-217433
     AU 2003217433
                                                                       20030214
                          A1
     US 20040058964
                                 20040325
                                              US 2003-367987
                                                                       20030214
                          В2
                                20060627
     US 7067540
                     A 20041221 BR 2003-7631 20030214
A1 20041229 EP 2003-713478 20030214
     BR 2003007631
     EP 1490064
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

```
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                              20050727 CN 2003-808042
                  А
    CN 1646125
                                                               20030214
                       Τ
    JP 2005531501
                              20051020
                                         JP 2003-567412
                                                               20030214
    NZ 534395
                       Α
                              20061027
                                        NZ 2003-534395
                                                               20030214
                      A
    IN 2004DN02150
                             20050401
                                       IN 2004-DN2150
                                                               20040723
                      А
                             20041110
    MX 2004PA07470
                                        MX 2004-PA7470
                                                               20040802
    ZA 2004006275
                      A
                             20051004
                                        ZA 2004-6275
                                                               20040805
    NO 2004003820
                      A
                            20041109 NO 2004-3820
                                                               20040913
    US 20060211694
                      A1
                            20060921 US 2005-226556
                                                               20050914
                      A1
    US 20070088033
                             20070419 US 2006-531492
                                                               20060913
    JP 2007023053
                             20070201 JP 2006-263778
                       A
                                                               20060928
                      Α
                             20070209
                                        KR 2007-701895
    KR 2007017443
                                                               20070125
                      A1
P
    AU 2007202607
                             20070628
                                        AU 2007-202607
                                                               20070607
PRAI US 2002-357029P
                             20020214
                      P
    US 2002-436915P
                             20021230
                      A3
A3
A1
    AU 2003-217433
                             20030214
    JP 2003-567412
                             20030214
    US 2003-367987
                             20030214
                       W
    WO 2003-US4634
                             20030214
                       А3
    KR 2004-712622
                              20040813
                       АЗ
    US 2005-226556
                             20050914
CLASS
              CLASS PATENT FAMILY CLASSIFICATION CODES
PATENT NO.
               ____
                      _____
WO 2003068230
               ICM
                      A61K031-4412
                      A61P029-00; C07D213-69; C07D401-06; C07D409-06;
                ICS
                      C07D213-70; C07D213-64; C07D213-74; C07D405-06;
                      C07D213-84; C07D401-10; C07D405-12; C07D401-12;
                      C07D213-75; C07D401-14; C07D213-79; C07D401-04;
                      C07D405-04; C07D413-10; C07D215-22
                IPCI
                      A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-69
                      [ICS, 7]; C07D0401-06 [ICS, 7]; C07D0409-06 [ICS, 7];
                      C07D0213-70 [ICS, 7]; C07D0213-64 [ICS, 7]; C07D0213-74
                      [ICS, 7]; C07D0405-06 [ICS, 7]; C07D0213-84 [ICS, 7];
                      C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12
                      [ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14 [ICS,7];
                      C07D0213-79 [ICS,7]; C07D0401-04 [ICS,7]; C07D0401-00
                      [ICS, 7, C*]; C07D0405-04 [ICS, 7]; C07D0413-10 [ICS, 7];
                      C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
                      C07D0215-00 [ICS, 7, C*]; C07D0405-14 [ICS, 7];
                      C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7];
                      C07D0409-00 [ICS,7,C*]; C07D0213-85 [ICS,7];
                      C07D0213-00 [ICS, 7, C*]
                IPCR
                      A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                      A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
                      A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
                      A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
                       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
                      A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
                       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
                      A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
                       [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
                      A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
                       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
                      A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
                      [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
                      A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
                      [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
                      A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
                       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
```

```
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
                       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
                       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
                       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
                       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
                       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
                       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
                       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
                       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
                       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
                       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
                       C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
                       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
                       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
                       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
                       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
                       C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
                       [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
                       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
                       [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
                ECLA
                       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
                       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
                       C07D213/85; C07D215/22D; C07D401/04+213+211;
                       C07D401/04+239B+213; C07D401/04+231+213;
                       C07D401/06+213+211; C07D401/06+217+213;
                       C07D401/06+213+209C; C07D401/06+231+213;
                       C07D401/06+239B+213; C07D401/06+241B+213;
                       C07D401/10+213+211; C07D401/10+233+213;
                       C07D401/10+231+213; C07D401/12+213+207;
                       C07D401/12+233+213; C07D401/14+239B+213+211;
                       C07D405/04+307B+213; C07D405/06+307B+213;
                       C07D405/06+317+213; C07D405/12+307B+213;
                       C07D405/14+307B+307B+213; C07D409/06+333B+213;
                       C07D409/14+333B+333B+213; C07D413/10+261+213
CA 2476012
                IPCI
                       A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0401-04
                       [ICS, 7]; C07D0405-04 [ICS, 7]; C07D0401-06 [ICS, 7];
                       C07D0405-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0401-10
                       [ICS, 7]; C07D0413-10 [ICS, 7]; C07D0413-00 [ICS, 7, C*];
                       C07D0401-12 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-14
                       [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0405-14 [ICS,7];
                       C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7];
                       C07D0409-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
                       C07D0215-00 [ICS,7,C*]; C07D0213-64 [ICS,7];
                       C07D0213-69 [ICS,7]; C07D0213-70 [ICS,7]; C07D0213-74
                       [ICS, 7]; C07D0213-75 [ICS, 7]; C07D0213-79 [ICS, 7];
                       C07D0213-84 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00
                       [ICS, 7, C*]
                       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                IPCR
                       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
                       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
                       [I,C*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
                       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
                       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
                       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
                       [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
                       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
                       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
```

```
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
       C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
       C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
       [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
       [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
ECLA
       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
       C07D213/85; C07D215/22D; C07D401/04+213+211;
       C07D401/04+231+213; C07D401/04+239B+213;
       C07D401/06+213+209C; C07D401/06+213+211;
       C07D401/06+217+213; C07D401/06+231+213;
       C07D401/06+239B+213; C07D401/06+241B+213;
       C07D401/10+213+211; C07D401/10+231+213;
       C07D401/10+233+213; C07D401/12+213+207;
       C07D401/12+233+213; C07D401/14+239B+213+211;
       C07D405/04+307B+213; C07D405/06+307B+213;
       C07D405/06+317+213; C07D405/12+307B+213;
       C07D405/14+307B+307B+213; C07D409/06+333B+213;
       C07D409/14+333B+333B+213; C07D413/10+261+213
IPCI
       A61K0031-4412 [ICM, 7]; C07D0409-14 [ICS, 7]; C07D0213-85
       [ICS, 7]; A61P0029-00 [ICS, 7]; C07D0213-69 [ICS, 7];
       C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7]; C07D0409-00
       [ICS, 7, C*]; C07D0213-70 [ICS, 7]; C07D0213-64 [ICS, 7];
       C07D0213-74 [ICS,7]; C07D0405-06 [ICS,7]; C07D0213-84
       [ICS, 7]; C07D0401-10 [ICS, 7]; C07D0405-12 [ICS, 7];
       C07D0401-12 [ICS,7]; C07D0213-75 [ICS,7]; C07D0401-14
       [ICS, 7]; C07D0213-79 [ICS, 7]; C07D0213-00 [ICS, 7, C*];
       C07D0401-04 [ICS, 7]; C07D0401-00 [ICS, 7, C*];
       C07D0405-04 [ICS,7]; C07D0413-10 [ICS,7]; C07D0413-00
       [ICS, 7, C*]; C07D0215-22 [ICS, 7]; C07D0215-00
       [ICS, 7, C*]; C07D0405-14 [ICS, 7]; C07D0405-00 [ICS, 7, C*]
       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
IPCR
       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
```

AU 2003217433

```
[I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
[I,C^*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
[I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
[I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
[I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
[I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
[I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
[I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
[I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
[I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
[I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
[I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
[I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
[I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
[I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
[I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
[I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
A61K0031-44 [I,A]; C07D0213-02 [I,A]; C07D0213-00
[I,C*]; C07D0401-02 [I,A]; C07D0401-00 [I,C*]
A61P0029-00 [I,C*]; A61P0029-00 [I,A]; C07D0213-00
[I,C*]; C07D0213-64 [I,A]; C07D0213-69 [I,A];
C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75
[I,A]; C07D0213-79 [I,A]; C07D0213-84 [I,A];
C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22
[I,A]; C07D0401-00 [I,C*]; C07D0401-04 [I,A];
C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12
[I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C*];
C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12
[I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C*];
C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00
[I,C*]; C07D0413-10 [I,A]
514/340.000; 514/344.000; 514/345.000; 546/268.100;
546/288.000; 546/290.000; 514/348.000; 514/256.000;
514/336.000; 544/333.000; 546/283.400; 546/296.000
C07D213/64A; C07D401/14+239B+213+211;
C07D405/04+307B+213; C07D405/06+307B+213;
C07D405/06+317+213; C07D405/12+307B+213;
C07D405/14+307B+307B+213; C07D409/06+333B+213;
C07D409/14+333B+333B+213; C07D413/10+261+213;
C07D213/69B; C07D213/70D; C07D213/74B; C07D213/74C;
C07D213/75B8; C07D213/79E2; C07D213/84E; C07D213/85;
C07D215/22D; C07D401/04+213+211; C07D401/04+231+213;
C07D401/04+239B+213; C07D401/06+213+209C;
C07D401/06+217+213; C07D401/06+213+211;
```

C07D401/06+239B+213; C07D401/06+231+213;

US 20040058964

IPCI

IPCR

NCL

**ECLA** 

```
C07D401/06+241B+213; C07D401/10+213+211;
                       C07D401/10+231+213; C07D401/10+233+213;
                       C07D401/12+213+207; C07D401/12+233+213
                IPCI
BR 2003007631
                       A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-69
                       [ICS,7]; C07D0401-06 [ICS,7]; C07D0409-06 [ICS,7];
                       C07D0409-00 [ICS, 7, C*]; C07D0213-70 [ICS, 7];
                       C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-84
                       [ICS, 7]; C07D0405-06 [ICS, 7]; C07D0401-10 [ICS, 7];
                       C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75
                       [ICS, 7]; C07D0401-14 [ICS, 7]; C07D0213-79 [ICS, 7];
                       C07D0213-00 [ICS, 7, C*]; C07D0401-04 [ICS, 7];
                       C07D0401-00 [ICS, 7, C*]; C07D0405-04 [ICS, 7];
                       C07D0405-00 [ICS,7,C*]; C07D0413-10 [ICS,7];
                       C07D0413-00 [ICS, 7, C*]
                IPCR
                       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
                       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
                       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
                       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
                       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
                       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
                       [I,C^*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
                       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
                       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
                       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
                       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
                       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
                       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
                       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
                       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
                       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
                       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
                       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
                       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
                       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
                       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
                       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
                       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
                       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
                       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
                       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
                       C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
                       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
                       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
                       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
                       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
                       C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
                       [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
                       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
                       [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
                ECLA
                       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
                       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
                       C07D213/85; C07D215/22D; C07D401/04+213+211;
                       C07D401/04+231+213; C07D401/04+239B+213;
                       C07D401/06+213+209C; C07D401/06+213+211;
                       C07D401/06+217+213; C07D401/06+231+213;
                       C07D401/06+239B+213; C07D401/06+241B+213;
```

```
C07D401/10+213+211; C07D401/10+231+213;
       C07D401/10+233+213; C07D401/12+213+207;
       C07D401/12+233+213; C07D401/14+239B+213+211;
       C07D405/04+307B+213; C07D405/06+307B+213;
       C07D405/06+317+213; C07D405/12+307B+213;
       C07D405/14+307B+307B+213; C07D409/06+333B+213;
       C07D409/14+333B+333B+213; C07D413/10+261+213
IPCI
       A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-69
       [ICS, 7]; C07D0401-06 [ICS, 7]; C07D0409-06 [ICS, 7];
       C07D0409-00 [ICS,7,C*]; C07D0213-70 [ICS,7];
       C07D0213-64 [ICS,7]; C07D0213-74 [ICS,7]; C07D0405-06
       [ICS,7]; C07D0213-84 [ICS,7]; C07D0401-10 [ICS,7];
       C07D0405-12 [ICS,7]; C07D0401-12 [ICS,7]; C07D0213-75
       [ICS, 7]; C07D0401-14 [ICS, 7]; C07D0213-79 [ICS, 7];
       C07D0213-00 [ICS,7,C*]; C07D0401-04 [ICS,7];
       C07D0401-00 [ICS,7,C*]; C07D0405-04 [ICS,7];
       C07D0413-10 [ICS,7]; C07D0413-00 [ICS,7,C*];
       C07D0215-22 [ICS, 7]; C07D0215-00 [ICS, 7, C*];
       C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*]
IPCR
       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
       [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
       C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
       C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
       [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
       [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
ECLA
       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
```

EP 1490064

```
C07D213/85; C07D215/22D; C07D401/04+213+211;
       C07D401/04+231+213; C07D401/04+239B+213;
       C07D401/06+213+209C; C07D401/06+213+211;
       C07D401/06+217+213; C07D401/06+231+213;
       C07D401/06+239B+213; C07D401/06+241B+213;
       C07D401/10+213+211; C07D401/10+231+213;
       C07D401/10+233+213; C07D401/12+213+207;
       C07D401/12+233+213; C07D401/14+239B+213+211;
       C07D405/04+307B+213; C07D405/06+307B+213;
       C07D405/06+317+213; C07D405/12+307B+213;
       C07D405/14+307B+307B+213; C07D409/06+333B+213;
       C07D409/14+333B+333B+213; C07D413/10+261+213
IPCI
       A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-69
       [ICS, 7]; C07D0401-06 [ICS, 7]; C07D0409-06 [ICS, 7];
       C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74
       [ICS, 7]; C07D0405-06 [ICS, 7]; C07D0213-84 [ICS, 7];
       C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12
       [ICS, 7]; C07D0213-75 [ICS, 7]; C07D0401-14 [ICS, 7];
       C07D0213-79 [ICS,7]; C07D0401-04 [ICS,7]; C07D0401-00
       [ICS, 7, C*]; C07D0405-04 [ICS, 7]; C07D0413-10 [ICS, 7];
       C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
       C07D0215-00 [ICS,7,C*]; C07D0405-14 [ICS,7];
       C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7];
       C07D0409-00 [ICS, 7, C*]; C07D0213-85 [ICS, 7];
       C07D0213-00 [ICS,7,C*]
IPCR
       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
       [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
       C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
```

CN 1646125

```
C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
                        [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
                       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
                        [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
                ECLA
                       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
                       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
                       C07D213/85; C07D215/22D; C07D401/04+213+211;
                       C07D401/04+231+213; C07D401/04+239B+213;
                       C07D401/06+213+209C; C07D401/06+213+211;
                       C07D401/06+217+213; C07D401/06+231+213;
                       C07D401/06+239B+213; C07D401/06+241B+213;
                       C07D401/10+213+211; C07D401/10+231+213;
                       C07D401/10+233+213; C07D401/12+213+207;
                       C07D401/12+233+213; C07D401/14+239B+213+211;
                       C07D405/04+307B+213; C07D405/06+307B+213;
                       C07D405/06+317+213; C07D405/12+307B+213;
                       C07D405/14+307B+307B+213; C07D409/06+333B+213;
                       C07D409/14+333B+333B+213; C07D413/10+261+213
JP 2005531501
                       C07D0213-64 [ICM, 7]; A61K0031-4412 [ICS, 7];
                IPCI
                       A61K0031-4418 [ICS, 7]; A61K0031-4439 [ICS, 7];
                       A61K0031-444 [ICS, 7]; A61K0031-4427 [ICS, 7, C*];
                       A61K0031-4545 [ICS,7]; A61K0031-4523 [ICS,7,C*];
                       A61K0031-455 [ICS, 7]; A61K0031-4725 [ICS, 7];
                       A61K0031-472 [ICS, 7, C*]; A61K0031-496 [ICS, 7];
                       A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*];
                       A61K0031-506 [ICS, 7]; A61K0031-5377 [ICS, 7];
                       A61K0031-5375 [ICS,7,C*]; A61P0001-04 [ICS,7];
                       A61P0001-16 [ICS, 7]; A61P0001-00 [ICS, 7, C*];
                       A61P0003-10 [ICS, 7]; A61P0003-00 [ICS, 7, C*];
                       A61P0007-02 [ICS,7]; A61P0007-00 [ICS,7,C*];
                       A61P0009-04 [ICS,7]; A61P0009-10 [ICS,7]; A61P0009-00
                       [ICS, 7, C*]; A61P0011-00 [ICS, 7]; A61P0011-06 [ICS, 7];
                       A61P0013-12 [ICS, 7]; A61P0013-00 [ICS, 7, C*];
                       A61P0015-08 [ICS, 7]; A61P0015-00 [ICS, 7, C*];
                       A61P0017-02 [ICS,7]; A61P0017-06 [ICS,7]; A61P0017-00
                        [ICS, 7, C*]; A61P0019-02 [ICS, 7]; A61P0019-06 [ICS, 7];
                       A61P0019-08 [ICS, 7]; A61P0019-10 [ICS, 7]; A61P0019-00
                       [ICS, 7, C*]; A61P0025-00 [ICS, 7]; A61P0025-02 [ICS, 7];
                       A61P0025-04 [ICS, 7]; A61P0025-14 [ICS, 7]; A61P0025-16
                       [ICS, 7]; A61P0025-28 [ICS, 7]; A61P0027-02 [ICS, 7];
                       A61P0027-00 [ICS,7,C*]; A61P0029-00 [ICS,7];
                       A61P0031-04 [ICS, 7]; A61P0031-12 [ICS, 7]; A61P0031-18
                       [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0033-02 [ICS,7];
                       A61P0033-06 [ICS, 7]; A61P0033-00 [ICS, 7, C*];
                       A61P0035-00 [ICS, 7]; A61P0037-06 [ICS, 7]; A61P0037-00
                        [ICS, 7, C*]; A61P0043-00 [ICS, 7]; C07D0213-69 [ICS, 7];
                       C07D0213-70 [ICS,7]; C07D0213-74 [ICS,7]; C07D0213-75
                        [ICS, 7]; C07D0213-79 [ICS, 7]; C07D0213-80 [ICS, 7];
                       C07D0213-82 [ICS,7]; C07D0213-85 [ICS,7]; C07D0213-00
                        [ICS,7,C*]; C07D0215-22 [ICS,7]; C07D0215-00
                        [ICS, 7, C*]; C07D0401-04 [ICS, 7]; C07D0401-06 [ICS, 7];
                       C07D0401-10 [ICS,7]; C07D0401-12 [ICS,7]; C07D0401-14
                        [ICS, 7]; C07D0401-00 [ICS, 7, C*]; C07D0405-04 [ICS, 7];
                       C07D0405-12 [ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00
                        [ICS, 7, C*]; C07D0409-06 [ICS, 7]; C07D0409-14 [ICS, 7];
                       C07D0409-00 [ICS,7,C*]; C07D0413-10 [ICS,7];
                       C07D0413-00 [ICS,7,C*]
                IPCR
                       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
                        [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
```

```
A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
       [I,C^*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
       [I,C^*]; A61P0007-02 [I,A]; A61P0009-00 [I,C^*];
       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
       C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
       C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
       [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
       [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
FTERM
      4C031/EA15; 4C031/EA17; 4C055/AA03; 4C055/AA06;
       4C055/AA09; 4C055/AA10; 4C055/BA02; 4C055/BA42;
       4C055/CA01; 4C055/CA02; 4C055/CA39; 4C055/DA08;
       4C055/DA42; 4C055/DA47; 4C055/DA52; 4C055/DB01;
       4C055/DB04; 4C055/DB06; 4C055/DB08; 4C055/DB10;
       4C055/DB16; 4C055/FA03; 4C063/AA01; 4C063/AA03;
       4C063/BB01; 4C063/BB03; 4C063/BB04; 4C063/BB06;
       4C063/BB08; 4C063/BB09; 4C063/CC12; 4C063/CC15;
       4C063/CC22; 4C063/CC25; 4C063/CC29; 4C063/CC34;
       4C063/CC51; 4C063/CC71; 4C063/CC75; 4C063/CC92;
       4C063/DD03; 4C063/DD06; 4C063/DD10; 4C063/DD12;
       4C063/EE01; 4C086/AA01; 4C086/AA02; 4C086/AA03;
       4C086/BC17; 4C086/BC21; 4C086/BC30; 4C086/BC36;
       4C086/BC37; 4C086/BC38; 4C086/BC42; 4C086/BC47;
       4C086/BC48; 4C086/BC67; 4C086/BC73; 4C086/GA02;
       4C086/GA04; 4C086/GA07; 4C086/GA08; 4C086/GA09;
       4C086/GA12; 4C086/GA13; 4C086/MA01; 4C086/NA14;
       4C086/ZA02; 4C086/ZA08; 4C086/ZA33; 4C086/ZA36;
       4C086/ZA40; 4C086/ZA45; 4C086/ZA54; 4C086/ZA59;
       4C086/ZA66; 4C086/ZA68; 4C086/ZA75; 4C086/ZA81;
       4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB08;
       4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB26;
       4C086/ZB33; 4C086/ZB35; 4C086/ZB38; 4C086/ZC10;
       4C086/ZC11; 4C086/ZC31; 4C086/ZC35; 4C086/ZC55
```

```
[ICS, 7]; C07D0213-69 [ICS, 7]; C07D0213-70 [ICS, 7];
       C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79
       [ICS, 7]; C07D0213-84 [ICS, 7]; C07D0213-85 [ICS, 7];
       C07D0213-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
       C07D0215-00 [ICS, 7, C*]; C07D0401-04 [ICS, 7];
       C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12
       [ICS, 7]; C07D0401-14 [ICS, 7]; C07D0401-00 [ICS, 7, C*];
       C07D0405-04 [ICS,7]; C07D0405-06 [ICS,7]; C07D0405-12
       [ICS,7]; C07D0405-14 [ICS,7]; C07D0405-00 [ICS,7,C*];
       C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00
       [ICS, 7, C*]; C07D0413-10 [ICS, 7]; C07D0413-00 [ICS, 7, C*]
IPCR
       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
       [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
       C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
       C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
       [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
ECLA
       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
       C07D213/85; C07D215/22D; C07D401/04+213+211;
       C07D401/04+231+213; C07D401/04+239B+213;
       C07D401/06+213+209C; C07D401/06+213+211;
       C07D401/06+217+213; C07D401/06+231+213;
       C07D401/06+239B+213; C07D401/06+241B+213;
       C07D401/10+213+211; C07D401/10+231+213;
       C07D401/10+233+213; C07D401/12+213+207;
       C07D401/12+233+213; C07D401/14+239B+213+211;
```

```
C07D405/04+307B+213; C07D405/06+307B+213;
                       C07D405/06+317+213; C07D405/12+307B+213;
                       C07D405/14+307B+307B+213; C07D409/06+333B+213;
                       C07D409/14+333B+333B+213; C07D413/10+261+213
IN 2004DN02150 IPCI
                       A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-69
                       [ICS, 7]; C07D0401-06 [ICS, 7]; C07D0409-06 [ICS, 7];
                       C07D0213-70 [ICS,7]; C07D0213-64 [ICS,7]; C07D0213-74
                       [ICS, 7]; C07D0405-06 [ICS, 7]; C07D0213-84 [ICS, 7];
                       C07D0401-10 [ICS,7]; C07D0405-12 [ICS,7]; C07D0401-12
                       [ICS, 7]; C07D0213-75 [ICS, 7]; C07D0401-14 [ICS, 7];
                       C07D0213-79 [ICS,7]; C07D0401-04 [ICS,7]; C07D0401-00
                       [ICS, 7, C*]; C07D0405-04 [ICS, 7]; C07D0413-10 [ICS, 7];
                       C07D0413-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
                       C07D0215-00 [ICS,7,C*]; C07D0405-14 [ICS,7];
                       C07D0405-00 [ICS,7,C*]; C07D0409-14 [ICS,7];
                       C07D0409-00 [ICS,7,C*]; C07D0213-85 [ICS,7];
                       C07D0213-00 [ICS,7,C*]
                       A61K0031-4412 [ICM, 7]; A61P0029-00 [ICS, 7]; C07D0213-64
MX 2004PA07470 IPCI
                       [ICS, 7]; C07D0213-69 [ICS, 7]; C07D0213-70 [ICS, 7];
                       C07D0213-74 [ICS,7]; C07D0213-75 [ICS,7]; C07D0213-79
                       [ICS, 7]; C07D0213-84 [ICS, 7]; C07D0213-85 [ICS, 7];
                       C07D0213-00 [ICS,7,C*]; C07D0215-22 [ICS,7];
                       C07D0215-00 [ICS,7,C*]; C07D0401-04 [ICS,7];
                       C07D0401-06 [ICS,7]; C07D0401-10 [ICS,7]; C07D0401-12
                       [ICS, 7]; C07D0401-14 [ICS, 7]; C07D0401-00 [ICS, 7, C*];
                       C07D0405-04 [ICS,7]; C07D0405-06 [ICS,7]; C07D0405-12
                       [ICS, 7]; C07D0405-14 [ICS, 7]; C07D0405-00 [ICS, 7, C*];
                       C07D0409-06 [ICS,7]; C07D0409-14 [ICS,7]; C07D0409-00
                       [ICS, 7, C*]; C07D0413-10 [ICS, 7]; C07D0413-00 [ICS, 7, C*]
                IPCI
                       A61K [ICM, 7]; A61P [ICS, 7]; C07D [ICS, 7]
ZA 2004006275
                IPCI
NO 2004003820
                       C07D0213-64 [ICM, 7]; C07D0213-00 [ICM, 7, C*]
                       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                IPCR
                       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
                       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
                       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
                       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
                       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
                       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
                       [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
                       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
                       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
                       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
                       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
                       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
                       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
                       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
                       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
                       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
                       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
                       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
                       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
                       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
                       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
                       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
                       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
                       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
                       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0213-00 [I,C*]; C07D0213-64
                       [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A];
```

```
C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79
                       [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A];
                       C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00
                       [I,C*]; C07D0215-22 [I,A]; C07D0401-00 [I,C*];
                       C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10
                       [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A];
                       C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-06
                       [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A];
                       C07D0409-00 [I,C*]; C07D0409-06 [I,A]; C07D0409-14
                       [I,A]; C07D0413-00 [I,C*]; C07D0413-10 [I,A]
                ECLA
                       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
                       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
                       C07D213/85; C07D215/22D; C07D401/04+213+211;
                       C07D401/04+231+213; C07D401/04+239B+213;
                       C07D401/06+213+209C; C07D401/06+213+211;
                       C07D401/06+217+213; C07D401/06+231+213;
                       C07D401/06+239B+213; C07D401/06+241B+213;
                       C07D401/10+213+211; C07D401/10+231+213;
                       C07D401/10+233+213; C07D401/12+213+207;
                       C07D401/12+233+213; C07D401/14+239B+213+211;
                       C07D405/04+307B+213; C07D405/06+307B+213;
                       C07D405/06+317+213; C07D405/12+307B+213;
                       C07D405/14+307B+307B+213; C07D409/06+333B+213;
                       C07D409/14+333B+333B+213; C07D413/10+261+213
                       A61K0031-53 [I,A]; A61K0031-506 [I,A]; A61K0031-498
US 20060211694 IPCI
                       [I,A]; A61K0031-497 [I,A]; A61K0031-4965 [I,C*];
                       A61K0031-501 [I,A]; A61K0031-4439 [I,A]; A61K0031-4427
                       [I,C^*]; A61K0031-4747 [I,A]; A61K0031-4709 [I,A];
                       A61K0031-4412 [I,A]
                IPCR
                       A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-4412
                       [I,C]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C];
                       A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709
                       [I,A]; A61K0031-4747 [I,C]; A61K0031-4747 [I,A];
                       A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-498
                       [I,C]; A61K0031-498 [I,A]; A61K0031-501 [I,C];
                       A61K0031-501 [I,A]; A61K0031-506 [I,C]; A61K0031-506
                       [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A];
                       C07D0213-00 [I,C*]; C07D0213-64 [I,A]; C07D0213-69
                       [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A];
                       C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-84
                       [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C*];
                       C07D0215-22 [I,A]; C07D0401-00 [I,C*]; C07D0401-04
                       [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A];
                       C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00
                       [I,C*]; C07D0405-04 [I,A]; C07D0405-06 [I,A];
                       C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00
                       [I,C*]; C07D0409-06 [I,A]; C07D0409-14 [I,A];
                       C07D0413-00 [I,C*]; C07D0413-10 [I,A]
                       514/241.000; 514/252.030; 514/255.050; 514/256.000;
                NCL
                       514/307.000; 514/338.000; 514/340.000; 514/341.000;
                       514/344.000; 514/345.000; 544/209.000; 544/238.000;
                       544/333.000; 544/405.000; 546/015.000; 546/148.000;
                       546/256.000; 546/272.700; 546/275.400; 546/276.400;
                       546/284.400; 546/288.000; 546/290.000
                ECLA
                       C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
                       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
                       C07D213/85; C07D215/22D; C07D401/04+213+211;
                       C07D401/04+231+213; C07D401/04+239B+213;
                       C07D401/06+213+209C; C07D401/06+213+211;
                       C07D401/06+217+213; C07D401/06+231+213;
                       C07D401/06+239B+213; C07D401/06+241B+213;
```

```
C07D401/10+213+211; C07D401/10+231+213;
                       C07D401/10+233+213; C07D401/12+213+207;
                       C07D401/12+233+213; C07D401/14+239B+213+211;
                       C07D405/04+307B+213; C07D405/06+307B+213;
                       C07D405/06+317+213; C07D405/12+307B+213;
                       C07D405/14+307B+307B+213; C07D409/06+333B+213;
                       C07D409/14+333B+333B+213; C07D413/10+261+213
US 20070088033 IPCI
                       A61K0031-53 [I,A]; A61K0031-506 [I,A]; A61K0031-497
                       [I,A]; A61K0031-4965 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4545 [I,A];
                       A61K0031-4523 [I,C*]; A61K0031-4709 [I,A]; C07D0417-02
                       [I,A]; C07D0417-00 [I,C*]; C07D0403-02 [I,A];
                       C07D0403-00 [I,C*]; C07D0401-02 [I,A]; C07D0401-00
                       [I,C*]
                IPCR
                       A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-4427
                       [I,C]; A61K0031-4439 [I,A]; A61K0031-4523 [I,C];
                       A61K0031-4545 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709
                       [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A];
                       A61K0031-506 [I,C]; A61K0031-506 [I,A]; C07D0401-00
                       [I,C]; C07D0401-02 [I,A]; C07D0403-00 [I,C];
                       C07D0403-02 [I,A]; C07D0417-00 [I,C]; C07D0417-02 [I,A]
                NCL
                       514/241.000; 514/255.050; 514/256.000; 514/310.000;
                       514/314.000; 514/318.000; 514/340.000; 514/341.000;
                       544/209.000; 544/333.000; 544/405.000; 546/148.000;
                       546/169.000; 546/194.000; 546/268.400; 546/269.700;
                       546/272.700; 546/273.100; 546/275.100
JP 2007023053
                       C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0401-06
                IPCI
                       [I,A]; C07D0409-06 [I,A]; C07D0213-70 [I,A];
                       C07D0213-74 [I,A]; C07D0405-04 [I,A]; C07D0401-10
                       [I,A]; C07D0213-75 [I,A]; C07D0405-12 [I,A];
                       C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0401-00
                       [I,C*]; C07D0213-80 [I,A]; C07D0213-00 [I,C*];
                       C07D0405-06 [I,A]; C07D0405-14 [I,A]; C07D0405-00
                       [I,C*]; C07D0409-14 [I,A]; C07D0409-00 [I,C*];
                       A61K0031-4412 [I,A]; A61K0031-4545 [I,A]; A61K0031-4535
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4418 [I,A];
                       A61K0031-4725 [I,A]; A61K0031-472 [I,C*]; A61K0031-4439
                       [I,A]; A61K0031-443 [I,A]; A61K0031-5377 [I,A];
                       A61K0031-5375 [I,C*]; A61K0031-497 [I,A]; A61K0031-4965
                       [I,C*]; A61K0031-506 [I,A]; A61K0031-444 [I,A];
                       A61K0031-4427 [I,A]; A61K0031-4436 [I,A]; A61P0043-00
                       [I,A]; A61P0029-00 [I,A]; A61P0019-02 [I,A];
                       A61P0019-06 [I,A]; A61P0037-02 [I,A]; A61P0025-00
                       [I,A]; A61P0037-08 [I,A]; A61P0037-00 [I,C*];
                       A61P0011-00 [I,A]; A61P0035-00 [I,A]; A61P0011-06
                       [I,A]; A61P0009-10 [I,A]; A61P0007-02 [I,A];
                       A61P0007-00 [I,C*]; A61P0009-04 [I,A]; A61P0009-12
                       [I,A]; A61P0009-00 [I,C*]; A61P0013-12 [I,A];
                       A61P0013-00 [I,C*]; A61P0017-02 [I,A]; A61P0001-16
                       [I,A]; A61P0001-04 [I,A]; A61P0027-02 [I,A];
                       A61P0027-06 [I,A]; A61P0027-00 [I,C*]; A61P0001-02
                       [I,A]; A61P0001-00 [I,C*]; A61P0003-10 [I,A];
                       A61P0003-00 [I,C*]; A61P0017-00 [I,A]; A61P0017-06
                       [I,A]; A61P0031-04 [I,A]; A61P0031-12 [I,A];
                       A61P0033-06 [I,A]; A61P0033-00 [I,C*]; A61P0031-18
                       [I,A]; A61P0031-22 [I,A]; A61P0031-16 [I,A];
                       A61P0031-00 [I,C*]; A61P0019-10 [I,A]; A61P0015-08
                       [I,A]; A61P0015-00 [I,C*]; A61P0019-08 [I,A];
                       A61P0019-00 [I,C*]; A61P0035-02 [I,A]; A61P0025-28
                       [I,A]; A61P0025-16 [I,A]; A61P0025-14 [I,A];
                       A61P0021-04 [I,A]; A61P0021-00 [I,C*]; A61P0025-02
```

```
IPCR
      C07D0213-00 [I,C]; C07D0213-64 [I,A]; A61K0031-4412
       [I,C]; A61K0031-4412 [I,A]; A61K0031-4418 [I,C];
      A61K0031-4418 [I,A]; A61K0031-4427 [I,C]; A61K0031-4427
       [I,A]; A61K0031-443 [I,A]; A61K0031-4436 [I,A];
       A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523
       [I,C]; A61K0031-4535 [I,A]; A61K0031-4545 [I,A];
       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
       [I,C]; A61K0031-4725 [I,A]; A61K0031-496 [I,C*];
      A61K0031-496 [I,A]; A61K0031-4965 [I,C]; A61K0031-497
       [I,A]; A61K0031-506 [I,C]; A61K0031-506 [I,A];
      A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61P0001-00
       [I,C]; A61P0001-02 [I,A]; A61P0001-04 [I,A];
      A61P0001-16 [I,A]; A61P0003-00 [I,C]; A61P0003-10
       [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A];
       A61P0009-00 [I,C]; A61P0009-04 [I,A]; A61P0009-10
       [I,A]; A61P0009-12 [I,A]; A61P0011-00 [I,C];
       A61P0011-00 [I,A]; A61P0011-06 [I,A]; A61P0013-00
       [I,C]; A61P0013-12 [I,A]; A61P0015-00 [I,C];
       A61P0015-08 [I,A]; A61P0017-00 [I,C]; A61P0017-00
       [I,A]; A61P0017-02 [I,A]; A61P0017-06 [I,A];
       A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0019-06
       [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A];
       A61P0021-00 [I,C]; A61P0021-04 [I,A]; A61P0025-00
       [I,C]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C];
       A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0029-00
       [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C];
      A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0031-16
       [I,A]; A61P0031-18 [I,A]; A61P0031-22 [I,A];
      A61P0033-00 [I,C]; A61P0033-02 [I,A]; A61P0033-06
       [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
      A61P0035-02 [I,A]; A61P0037-00 [I,C]; A61P0037-02
       [I,A]; A61P0037-06 [I,A]; A61P0037-08 [I,A];
      A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0213-69
       [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A];
      C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80
       [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A];
      C07D0213-85 [I,A]; C07D0215-00 [I,C*]; C07D0215-22
       [I,A]; C07D0401-00 [I,C]; C07D0401-04 [I,A];
      C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12
       [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C];
      C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12
       [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C];
      C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00
       [I,C]; C07D0413-10 [I,A]
ECLA
      C07D213/64A; C07D213/69B; C07D213/70D; C07D213/74B;
       C07D213/74C; C07D213/75B8; C07D213/79E2; C07D213/84E;
       C07D213/85; C07D215/22D; C07D401/04+213+211;
       C07D401/04+231+213; C07D401/04+239B+213;
       C07D401/06+213+209C; C07D401/06+213+211;
       C07D401/06+217+213; C07D401/06+231+213;
       C07D401/06+239B+213; C07D401/06+241B+213;
       C07D401/10+213+211; C07D401/10+231+213;
       C07D401/10+233+213; C07D401/12+213+207;
       C07D401/12+233+213; C07D401/14+239B+213+211;
       C07D405/04+307B+213; C07D405/06+307B+213;
       C07D405/06+317+213; C07D405/12+307B+213;
       C07D405/14+307B+307B+213; C07D409/06+333B+213;
       C07D409/14+333B+333B+213; C07D413/10+261+213
```

[I,A]; C07D0413-10 [I,A]; C07D0413-00 [I,C\*]

```
4C055/AA13; 4C055/BA01; 4C055/BA02; 4C055/BA03;
                       4C055/BA05; 4C055/BA06; 4C055/BA16; 4C055/BA25;
                       4C055/BA27; 4C055/BA42; 4C055/BA50; 4C055/BB02;
                       4C055/BB08; 4C055/CA01; 4C055/CA02; 4C055/CA05;
                       4C055/CA06; 4C055/CA13; 4C055/CA25; 4C055/CA39;
                       4C055/CA57; 4C055/CA59; 4C055/DA01; 4C055/DA05;
                       4C055/DA06; 4C055/DA22; 4C055/DA25; 4C055/DA47;
                       4C055/DA53; 4C055/DB01; 4C055/DB02; 4C055/DB07;
                       4C055/EA01; 4C063/AA01; 4C063/AA03; 4C063/BB02;
                       4C063/BB05; 4C063/BB06; 4C063/BB07; 4C063/BB08;
                       4C063/BB09; 4C063/CC12; 4C063/CC15; 4C063/CC22;
                       4C063/CC25; 4C063/CC29; 4C063/CC34; 4C063/CC73;
                       4C063/CC75; 4C063/CC92; 4C063/DD03; 4C063/DD06;
                       4C063/DD10; 4C063/DD12; 4C063/EE01; 4C086/AA01;
                       4C086/AA02; 4C086/AA03; 4C086/BC17; 4C086/BC21;
                       4C086/BC28; 4C086/BC30; 4C086/BC37; 4C086/BC38;
                       4C086/BC39; 4C086/BC42; 4C086/BC48; 4C086/BC50;
                       4C086/BC73; 4C086/GA02; 4C086/GA04; 4C086/GA07;
                       4C086/GA08; 4C086/MA01; 4C086/MA04; 4C086/NA14;
                       4C086/ZA01; 4C086/ZA02; 4C086/ZA07; 4C086/ZA08;
                       4C086/ZA15; 4C086/ZA16; 4C086/ZA18; 4C086/ZA20;
                       4C086/ZA33; 4C086/ZA34; 4C086/ZA36; 4C086/ZA37;
                       4C086/ZA40; 4C086/ZA45; 4C086/ZA53; 4C086/ZA59;
                       4C086/ZA67; 4C086/ZA68; 4C086/ZA75; 4C086/ZA81;
                       4C086/ZA89; 4C086/ZA94; 4C086/ZA96; 4C086/ZA97;
                       4C086/ZB05; 4C086/ZB07; 4C086/ZB11; 4C086/ZB13;
                       4C086/ZB15; 4C086/ZB26; 4C086/ZB27; 4C086/ZB33;
                       4C086/ZB35; 4C086/ZB38; 4C086/ZC02; 4C086/ZC54;
                       4C086/ZC55
KR 2007017443
                IPCI
                       A61K0031-4412 [I,A]; A61P0029-00 [I,A]; C07D0401-06
                       [I,A]; C07D0401-00 [I,C*]
                       A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
AU 2007202607
                IPCI
                       A61K0031-4418 [I,C*]; A61K0031-4418 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444
                       [I,A]; A61K0031-4523 [I,C*]; A61K0031-4545 [I,A];
                       A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-472
                       [I,C^*]; A61K0031-4725 [I,A]; A61K0031-496 [I,C^*];
                       A61K0031-496 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
                       [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
                       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0001-00
                       [I,C*]; A61P0001-04 [I,A]; A61P0001-16 [I,A];
                       A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0007-00
                       [I,C*]; A61P0007-02 [I,A]; A61P0009-00 [I,C*];
                       A61P0009-04 [I,A]; A61P0009-10 [I,A]; A61P0011-00
                       [I,C*]; A61P0011-00 [I,A]; A61P0011-06 [I,A];
                       A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00
                       [I,C*]; A61P0015-08 [I,A]; A61P0017-00 [I,C*];
                       A61P0017-02 [I,A]; A61P0017-06 [I,A]; A61P0019-00
                       [I,C*]; A61P0019-02 [I,A]; A61P0019-06 [I,A];
                       A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0025-00
                       [I,C*]; A61P0025-00 [I,A]; A61P0025-02 [I,A];
                       A61P0025-04 [I,A]; A61P0025-14 [I,A]; A61P0025-16
                       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
                       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
                       [I,A]; A61P0031-00 [I,C*]; A61P0031-04 [I,A];
                       A61P0031-12 [I,A]; A61P0031-18 [I,A]; A61P0033-00
                       [I,C*]; A61P0033-02 [I,A]; A61P0033-06 [I,A];
                       A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00
                       [I,C*]; A61P0037-06 [I,A]; A61P0043-00 [I,C*];
```

FTERM 4C055/AA01; 4C055/AA03; 4C055/AA04; 4C055/AA05;

4C055/AA06; 4C055/AA09; 4C055/AA10; 4C055/AA12;

A61P0043-00 [I,A]; C07D0213-00 [I,C\*]; C07D0213-64 [I,A]; C07D0213-69 [I,A]; C07D0213-70 [I,A]; C07D0213-74 [I,A]; C07D0213-75 [I,A]; C07D0213-79 [I,A]; C07D0213-80 [I,A]; C07D0213-82 [I,A]; C07D0213-84 [I,A]; C07D0213-85 [I,A]; C07D0215-00 [I,C\*]; C07D0215-22 [I,A]; C07D0401-00 [I,C\*]; C07D0401-04 [I,A]; C07D0401-06 [I,A]; C07D0401-10 [I,A]; C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0405-00 [I,C\*]; C07D0405-04 [I,A]; C07D0405-06 [I,A]; C07D0405-12 [I,A]; C07D0405-14 [I,A]; C07D0409-00 [I,C\*]; C07D0409-06 [I,A]; C07D0409-14 [I,A]; C07D0413-00 [I,C\*]; C07D0413-10 [I,A]

OS MARPAT 139:197371

GΙ

$$\mathbb{R}^2$$
 $\mathbb{R}^3$ 
 $\mathbb{R}^4$ 
 $\mathbb{R}^4$ 
 $\mathbb{R}^5$ 
 $\mathbb{R}^5$ 
 $\mathbb{R}^2$ 
 $\mathbb{R}^3$ 
 $\mathbb$ 

Disclosed are title compds. I [wherein R1 = H, halo, NO2, CHO, CN, CO2H, AΒ or (un)substituted (halo)alkyl, (aryl)alkoxy, aryl(alkyl), alkenyl, (aryl)alkynyl, (aryl)alkanoyl, alkoxyalkyl, or haloalkoxy; R2 = H, OH, halo, NR8R9, CO2R, or (un) substituted OSO2-alkyl, OSO2-aryl, arylalkoxy, aryloxy(alkyl), arylthio(alkoxy), arylalkynyl, alkoxy(alkoxy), alkyl, alkynyl, OCONH(CH2)n-aryl, OCON(alkyl)(CH2)n-aryl, dialkylamino, (hetero)aryl(alkyl), arylalkenyl, or heterocycloalkyl(alkyl); R3 = H, halo, alkenyl, NR6R7, NR6R7-alkyl, alkyl, or (un)substituted (aryl)alkoxycarbonyl, aryloxycarbonyl, arylalkyl, OCONH(CH2)n-aryl, arylalkoxy, OCON(alkyl)(CH2)n-aryl, aryloxy, arylthio, or (aryl)thioalkoxy; R4 = H or (un)substituted alkyl; R5 = H, aryl, aryl(thio)alkyl, NH2, alkoxycarbonyl, alkynyl, SO2-alkyl, (hetero)cycloalkyl(alkyl), heteroaryl, or (un)substituted alkyl, alkoxy(alkyl), or alkenyl; R6 and R7 = independently H, OH, or (un) substituted (aryl) alkyl, alkoxy(alkyl), alkanoyl(alkyl), arylalkoxy, SO2-alkyl, (aryl)alkoxycarbonyl, heteroarylalkyl, or arylalkanoyl; or NR6R7 = (un)substituted (thio)morpholinyl, pyrrolidinyl, piperidinyl, pyrrolidinyl, or piperazinyl; R8 = independently H or (un)substituted (aryl)alkyl or (aryl)alkanoyl; R9 = H or (un)substituted (aryl)alkyl, (aryl)alkanoyl, cycloalkyl(alkyl), alkenyl, heteroaryl, (alkyl)aminoalkyl, SO2Ph, or aryl; R = independently H or (un) substituted alkyl; n = 0-6; and pharmaceutically acceptable salts thereof]. These compds. are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity, such as inflammation, ischemia, viral infections, and autoimmune diseases (no data). Pharmaceutical compns. containing I, methods of preparing them, and methods of treatment using the compds. are also disclosed. For example, reaction of 4-benzyloxy-2(1H)-pyridone with EtBr in the presence of K2CO3 in DMF gave II. The latter inhibited MKK6-activated human p38lphakinase phosphorylation of a biotinylated substrate or human  $p38\alpha\text{-induced phosphorylation of EGFRP}$  (epidermal growth factor receptor peptide) with an IC50 in the range of 1  $\mu M$  to 25  $\mu M.$ ST pyridone p38 MAP kinase inhibitor antiinflammatory antiviral antiischemic

immunomodulator

ΤТ AIDS (disease) (-related complex, cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Lymphoma ΙT (B-cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT (Crohn's disease; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Intestine, disease ΙT (Crohn's; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Nervous system, disease (Huntington's chorea; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Carcinoma (adenocarcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Respiratory distress syndrome (adult; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Transplant rejection (allotransplant; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Nervous system, disease (amyotrophic lateral sclerosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Blood vessel, neoplasm (angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Bone (avascular necrosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Necrosis (avascular, bone; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT (bacterial; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Skin, neoplasm ΙT (basal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions,

ischemia, viral infections, autoimmune diseases, and other

conditions)

ΤТ Carcinoma (basal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) AIDS (disease) ΤТ Human herpesvirus Pneumonia (cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Heart, disease ΤТ (cardiomyopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Edema Ischemia (cerebral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤT Uterus, neoplasm (cervix; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Inflammation Lung, disease (chronic pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Intestine, neoplasm (colon; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Intestine, neoplasm (colorectal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Transplant rejection ΙT (corneal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Kidney, disease (diabetic nephropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Eye, disease (diabetic retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Brain, disease (edema; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Uterus, disease (endometriosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

ΙΤ

(epidermal growth factor-binding; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Heart, disease (failure; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Ulcer (gastric; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Inflammation Stomach, disease (gastritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Transplant and Transplantation (graft-vs.-host reaction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Blood vessel, neoplasm (hemangioma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Heart, disease (infarction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Intestine, disease (inflammatory; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Eye, disease Reperfusion Spinal cord, disease (injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Intestine, disease (irritable bowel syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Brain, disease (ischemia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Rheumatoid arthritis (juvenile; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Neoplasm (metastasis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Pharvnx

(nasopharynx, angiofibroma; preparation of pyridinones as modulators of p38

MAP kinase for treatment of inflammatory conditions,

TΤ

ΙΤ

ΙT

ΙT

ΙT

ΙT

ΙT

ΙT

ΙT

ΤТ

ΙT

ΤT

ΙT

```
ischemia, viral infections, autoimmune diseases, and other
        conditions)
ΤТ
    Lip
        (neoplasm; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Glaucoma (disease)
        (neovascular; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
    Angiogenesis
        (neovascularization, eye; preparation of pyridinones as modulators of p38
        MAP kinase for treatment of inflammatory conditions,
        ischemia, viral infections, autoimmune diseases, and other
        conditions)
ΤТ
     Angiogenesis
        (neovascularization, retinal; preparation of pyridinones as modulators of
        p38 MAP kinase for treatment of inflammatory conditions,
        ischemia, viral infections, autoimmune diseases, and other
        conditions)
ΙT
     Eye, disease
        (neovascularization; preparation of pyridinones as modulators of p38 MAP
        kinase for treatment of inflammatory conditions,
        ischemia, viral infections, autoimmune diseases, and other
        conditions)
     Inflammation
ΤТ
    Kidney, disease
        (nephritis; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Inflammation
        (neurogenic; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
IT
     Nerve, disease
        (neuropathy; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
        (ocular; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Eye, disease
        (photophobia; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΤТ
     Inflammation
     Lung, disease
        (pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
TΤ
    Alzheimer's disease
     Analgesics
     Angiogenesis
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiarteriosclerotics
     Antiarthritics
```

Antiasthmatics

Antibacterial agents

Anticoagulants

Antidiabetic agents

Antimalarials

Antiparkinsonian agents

Antipyretics

Antirheumatic agents

Antitumor agents

Antiulcer agents

Antiviral agents

Arteriosclerosis

Arthritis

Asthma

Autoimmune disease

Bladder, neoplasm

Bone, neoplasm

Bone resorption

Bone resorption inhibitors

Brain, neoplasm

Burn

Cachexia

Carcinoma

Cardiovascular agents

Cardiovascular system, disease

Dermatitis

Diabetes insipidus

Diabetes mellitus

Digestive tract, disease

Digestive tract, neoplasm

Drug delivery systems

Eczema

Esophagus, neoplasm

Eye, disease

Fever and Hyperthermia

Gastrointestinal agents

Gout

Granulation tissue

Human

Immunomodulators

Inflammation

Influenza

Ischemia

Keloid

Leukemia

Lip

Liver, disease

Liver, neoplasm

Lung, disease

Lung, neoplasm

Lymphoma

Malaria

Mammary gland, neoplasm

Meningitis

Mouth, neoplasm

Multiple sclerosis

Neoplasm

Nervous system agents

Osteoarthritis

Osteoporosis

Ovary, neoplasm

Pain

Pancreas, neoplasm Parkinson's disease Phosphorylation, biological Prostate gland, neoplasm Psoriasis Reproduction disorders Rheumatoid arthritis Sepsis Silicosis Skin, disease Skin, neoplasm Solid phase synthesis Stomach, neoplasm Thrombosis (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Tumor necrosis factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Sarcoidosis (pulmonary; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Kidney, neoplasm (renal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Carcinoma (renal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Heart Kidney (reperfusion injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Injury (reperfusion; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Eye, disease (retina, neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Eye, disease (retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Eye, disease (retrolental fibroplasia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

(sarcoidosis; preparation of pyridinones as modulators of p38 MAP kinase for

ТТ

ΙT

TΤ

ΤТ

TΤ

ΙT

ΤТ

ΙT

TΤ

ΙΤ

Lung, disease

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Shock (circulatory collapse) (septic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Intestine, neoplasm (small; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Injury (spinal cord; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Spinal column, disease (spondyloarthropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤT Brain, disease (stroke; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Lupus erythematosus (systemic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Shock (circulatory collapse) (toxic shock syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Brain, disease (trauma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Stomach, disease (ulcer; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Inflammation Intestine, disease (ulcerative colitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Eye, disease Inflammation (uveitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Infection (viral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Central nervous system, disease (with inflammatory or apoptotic component; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) 329-59-9P, Methyl 4-fluoro-3-nitrobenzoate 369-26-6P, Methyl TΤ

```
3-amino-4-fluorobenzoate 874-97-5P, 3-Hydroxymethylbenzonitrile
3446-91-1P, 4-Bromomethyl-N, N-dimethylbenzenesulfonamide
4-Hydroxy-6-methyl-2(1H)-pyridone
                                  13737-35-4P, (2-
Bromomethylphenyl)acetic acid 13737-37-6P, Methyl (2-
Bromomethylphenyl)acetate 19858-50-5P, [2-(Methylthio)pyrimidin-5-
             21317-88-4P, 1-Allyl-4-hydroxy-6-methylpyridin-2(1H)-one
yl]methanol
21642-98-8P, 4-Methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile
24812-90-6P, Methyl 3-amino-4-methoxybenzoate
                                              26576-93-2P,
3-Chloro-4-hydroxy-6-methyl-1H-pyridin-2-one
                                               33524-79-7P,
1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one
                                             38275-41-1P, Methyl
2-(methylthio)pyrimidine-5-carboxylate 39204-47-2P, 2-
                     41110-34-3P, Ethyl 5-methylpyrazine-2-carboxylate
Chloromethylpyrazine
49668-89-5P
            49668-90-8P, Methyl 6-(chloromethyl)nicotinate
68432-92-8P, Methyl 3-cyanomethylbenzoate 76518-57-5P,
Isoquinolin-5-ylmethanol 104317-94-4P, 3-Amino-4-chlorobenzyl alcohol
119887-89-7P, 3-Acetyl-1-(2-chlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-19887-89-7P
      121669-69-0P, 4-Methylpyrazole-1-carboxylic acid tert-butyl ester
123226-36-8P, (3-Bromomethylphenyl)acetonitrile 135645-63-5P,
4-(Bromomethyl)-2-(methylthio)pyrimidine 140215-42-5P, Ethyl
(3-bromomethylphenyl)acetate 171670-20-5P, Methyl 3-bromomethyl-2-fluorobenzoate 177665-49-5P, (3-Hydroxymethylphenyl)acetonitrile
185629-32-7P, Methyl 4-amino-3-fluorobenzoate 186551-69-9P,
3-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester
3-Methylpyrazole-1-carboxylic acid tert-butyl ester
                                                      217661-27-3P,
2-(Bromomethyl)-5-fluorobenzonitrile 220364-34-1P, [3-
(Bromomethyl)benzyl]carbamic acid tert-butyl ester 220798-39-0P
226070-69-5P, [3-(Hydroxymethyl)benzyl]carbamic acid tert-butyl ester
227609-86-1P, (3-Amino-4-fluorophenyl) methanol 391957-11-2P,
3-[(tert-Butyldimethylsilyloxy)methyl]benzylamine 530144-72-0P,
4-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester
                                                            586373-04-8P,
1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate
586373-18-4P, 1-Benzyl-3-bromo-4-hydroxypyridin-2(1H)-one 586373-21-9P,
1-Benzyl-3-bromo-4-(phenylethynyl)pyridin-2(1H)-one 586373-24-2P,
3-Acetyl-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586373-25-3P, 1-(2,6-Dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586373-26-4P, 4-(Benzyloxy)-1-(2,6-dichlorophenyl)-6-methylpyridin-2(1H)-
      586373-29-7P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl
N-methyl-N-phenylcarbamate
                            586373-31-1P, 4-(Benzyloxy)-1-(3-
fluorobenzyl)-3-iodopyridin-2(1H)-one
                                       586373-32-2P, 4-(Benzyloxy)-1-(3-
fluorobenzyl)-3-[(trimethylsilyl)ethynyl]pyridin-2(1H)-one
                                                             586373-34-4P,
1-(3-Fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586373-35-5P,
4-(Benzylamino)-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                      586373-37-7P.
4-[(4-Fluorobenzyl)oxy]pyridine-1-oxide
                                          586373-38-8P,
4-[(4-Fluorobenzyl)oxy]pyridine-2(1H)-one
                                            586373-39-9P,
3-Bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one
                                                   586373-51-5P.
3-[(tert-Butyldimethylsilyloxy)methyl]benzonitrile
                                                     586373-57-1P,
4-[(2,4-Difluorobenzyl)oxy]pyridine-1-oxide
                                             586373-58-2P,
4-[(2,4-Difluorobenzyl)oxy]pyridin-2(1H)-one
                                             586373-59-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-60-6P,
3-Bromo-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-
      586373-67-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
586373-68-4P, 3-Chloro-1-(4-chloromethylbenzyl)-4-[(2,4-
difluorobenzyl)oxy]-1H-pyridin-2-one
                                      586373-70-8P, 1-Chloromethyl-3-
(methanesulfonyl)benzene 586373-73-1P, Methyl 4-[[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate
5-Bromomethylisoquinoline hydrobromide
                                        586373-79-7P,
[5-(Carboxymethyl)indol-1-yl]carbamic acid tert-butyl ester
586373-80-0P, [5-Hydroxymethylindol-1-yl]carbamic acid tert-butyl ester
586373-81-1P, [5-Bromomethylindol-1-yl]carbamic acid tert-butyl ester
586373-82-2P, [5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]indol-1-yl]carbamic acid tert-butyl ester 586373-93-5P,
```

```
4-[(2,4-Difluorobenzyl)oxy]-1-(2,4-difluorobenzyl)-1H-pyridin-2-one
586374-02-9P, 3-Bromo-1-(3-bromomethyl-2-fluorobenzyl)-4-[(2,4-bromomethyl-2-fluorobenzyl)]
difluorobenzyl)oxy]-1H-pyridin-2-one 586374-04-1P, Methyl
                                                      586374-07-4P, 3-Bromo-1-(3-fluorobenzyl)-4-
2-fluoro-3-methylbenzoate
hydroxypyridin-2(1H)-one 586374-12-1P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-
fluorobenzyl)-1H-pyridin-2-one
                                                              586374-29-0P, Methyl [2-[[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetate
586374-37-0P, 1-(3-Fluorobenzyl)-4-methoxy-2-oxo-1, 2-dihydropyridine-3-
carbonitrile
                          586374-38-1P, 1-(3-Fluorobenzyl)-4-hydroxy-2-oxo-1,2-
dihydropyridine-3-carbonitrile 586374-40-5P, Methyl 1-cyclohexyl-4-
hydroxy-2,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate
586374-41-6P, 1-Cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-
dihydropyridine-3-carboxylic acid 586374-42-7P, 1-Cyclohexyl-4-hydroxy-
3,6-dimethyl-1H-pyridin-2-one 586374-44-9P, 4-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-
carboxylic acid tert-butyl ester 586374-45-0P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-09-9P,
4-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]benzonitrile
                                                                                                        586375-14-6P,
1-(4-Cyanophenyl)-4-hydroxy-2(1H)-pyridinone 586375-15-7P,
4-[4-[(2,4-Difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]benzonitrile
yl]benzoate 586375-18-0P, 4-Hydroxy-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586375-19-1P, 1-[3-(Hydroxymethyl)phenyl]-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-21-5P, Methyl
4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate
                                                                                                           586375-22-6P,
Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                        586375-29-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
vllbenzoate
methyl-2-oxo-2H-pyridin-1-yl] methyl] benzaldehyde 586375-31-7P,
                                                                                                                586375-35-1P,
1-(4-Methoxybenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one
4-Hydroxy-4-methylpiperidine hydrochloride 586375-72-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586375-93-1P
                            586375-98-6P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-
                             586376-00-3P, Methyl 3-[3-bromo-4-[(2,4-
1-yl)benzoate
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
586376-21-8P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl]benzoate
                                                           586376-24-1P, 1-[3-(Chloromethyl)phenyl]-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                       586376-25-2P,
1-[3-(Aminomethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                       586376-34-3P 586376-39-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-[3-
[(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one
                                                                                                                    586376-52-5P,
3,4-Dibromo-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                                                                  586376-56-9P,
4-Azido-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                                                                          586376-58-1P,
4-Amino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one hydrochloride
586376-62-7P, 1-(4-Bromo-2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-
                       586376-74-1P, 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-
(2, 4, 6-trifluorophenyl)pyridin-2(1H)-one
                                                                                    586376-80-9P,
4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-
methylpyridin-2(1H)-one 586376-91-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-
difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-95-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-
methylpyridin-2(1H)-one
                                                 586376-99-0P, 1-(2,6-Difluorophenyl)-4-[[4-
fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one
586377-01-7P, 1-(2,6-Difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586377-08-4P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-
                                586377-09-5P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-
methylbenzoate
methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoate
                                                                                                586377-10-8P,
3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-incomplex and the second contract of the second
                                        586377-11-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
methylbenzoic acid
6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid 586377-32-4P,
3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-1-yl]-2-oxo-2H-pyridin-
methylbenzoic acid 586377-38-0P, tert-Butyl [4-[3-chloro-4-[(2,4-
```

```
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]carbamate
586377-40-4P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]-3,5-difluorobenzyl](methyl)carbamate 586377-41-5P,
tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-
3,5-difluorobenzyl](cyclopropylmethyl)carbamate
                                                                        586377-43-7P,
4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-
difluorobenzamide 586377-45-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-
2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile 586377-46-0P,
4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-
hydroxybenzonitrile potassium salt 586377-58-4P, 1-(3-Fluorobenzyl)-4-
                                                    586377-59-5P, 3-Bromo-1-(3-
hydroxy-6-methylpyridin-2(1H)-one
fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586377-60-8P,
3-Bromo-1-(3-fluorobenzyl)-6-methyl-2-oxo-1, 2-dihydropyridin-4-yl
trifluoromethanesulfonate 586377-61-9P, 3-Bromo-1-(3-fluorobenzyl)-6-
methyl-4-(phenylethynyl)pyridin-2(1H)-one 586377-66-4P,
1-(2,6-Dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
3-Bromo-1-(2,6-dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586377-72-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-
               586377-76-6P, 4-Hydroxy-1-(2-methoxy-6-methylphenyl)-6-
din-2(1H)-one 586377-77-7P, 3-Bromo-4-hydroxy-1-(2-methoxy-6-
2(1H)-one
methylpyridin-2(1H)-one
methylphenyl)-6-methylpyridin-2(1H)-one 586377-79-9P,
3,5-Dichloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-
yl)benzenesulfonamide 586377-81-3P, 3-Bromo-1-(2,6-difluorophenyl)-4-
hydroxy-6-methylpyridin-2(1H)-one 586377-84-6P, 3,5-Difluoro-N,N-
dimethylbenzene-1,2-diamine 586377-85-7P, 1-[2-(Dimethylamino)-4,6-
difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586377-86-8P,
3-Bromo-1-[2-(dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-
2(1H)-one
               586378-01-0P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4-
hydroxy-6-methylpyridin-2(1H)-one
                                                   586378-02-1P, 1-[(4-Amino-2-
methylpyrimidin-5-yl)methyl]-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one
586378-06-5P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-
hydroxy-6-methylpyridin-2(1H)-one 586378-26-9P, 4-Hydroxy-6-methyl-1-[(5-
methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-27-0P,
3-Bromo-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-
         586378-30-5P, Ethyl 5-(bromomethyl)pyrazine-2-carboxylate
586378-34-9P, 3-Bromo-1-[[5-(chloromethyl)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyl]-4-[(2,4-1)pyrazin-2-yl]methyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyllmethyl
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-40-7P,
5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrazine-2-carboxylic acid
                                                         586378-50-9P, 1-(3-Fluorobenzyl)-4-
hydroxy-3-iodopyridin-2(1H)-one
                                                  586378-55-4P, 4-Amino-1-(3-
fluorobenzyl)pyridin-2(1H)-one
                                                 586378-56-5P, 4-Fluoro-N-[1-(3-
fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzamide
                                                                                   586378-58-7P,
3-Chloro-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586378-60-1P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-
                 586378-64-5P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-4-
2(1H)-one
                                         586378-66-7P, 3-Bromo-4-hydroxy-6-methyl-1-
ylmethyl)pyridin-2(1H)-one
                                                         586378-68-9P, 3-Bromo-4-hydroxy-6-
(pyridin-3-ylmethyl)pyridin-2(1H)-one
methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one
                                                                        586378-69-0P
586378-84-9P, 3-Bromo-6-methyl-2-oxo-1-[(pyridin-3-yl)methyl]-1,2-
dihydropyridin-4-yl trifluoromethanesulfonate 586378-85-0P,
3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-[(pyridin-3-
                                           586378-88-3P, 3-Chloro-4-hydroxy-6-methyl-1-
vl)methyl]pyridin-2(1H)-one
(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-99-6P, 3-Chloro-4-hydroxy-6-
methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one
                                                                                        586379-10-4P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrazine-2-carboxylic acid 586379-14-8P, 1-Allyl-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                     586379-16-0P,
1-Allyl-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one
                                                                                  586379-19-3P,
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one
586379-26-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-
dihydropyridine-2-carboxaldehyde 586379-27-3P, 4-[(2,4-
```

```
Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-
            586379-36-4P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-
                                 586379-37-5P, Methyl 4-(3-bromo-4-hydroxy-6-methyl-2-oxo-
methylbenzoate
                                                                    586379-43-3P, 1-(4-Bromo-2-
2H-pyridin-1-yl)-3-methylbenzoate
methylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
                                                                                                    586379-44-4P,
1-(4-Bromo-2-methylphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
2(1H)-one
                       586379-45-5P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-methyl-1-0)oxyl-1-(2-met
4-vinylphenyl)pyridin-2(1H)-one 586379-48-8P, Methyl
4-chloro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate
586379-49-9P, Methyl 4-chloro-3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl] benzoate 586379-52-4P, 4-Hydroxy-1-[5-
(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one
4-[(2,4-Difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-
methylpyridin-2(1H)-one 586379-55-7P, 1-[2-Chloro-5-
(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one
                                                                                                                        586379-56-8P,
1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586379-58-0P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzaldehyde
586379-61-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-
methylbenzoate
                               586379-62-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-63-7P,
3-[4-[(2,4-Difluorobenzy1)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
methylbenzoic acid 586379-64-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
6-\text{methyl}-2-\text{oxo}-2\text{H}-\text{pyridin}-1-\text{yl}]-4-\text{methyl}benzoic acid 586379-70-6P,
Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                            586379-73-9P, Methyl 3-chloro-4-(4-hydroxy-6-methyl-
vll-4-methvlbenzoate
2-oxo-2H-pyridin-1-yl)benzoate 586379-74-0P, Methyl 3-chloro-4-[4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
586379-77-3P, 4-[(2,4-Difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-
                       586379-82-0P, 4-[(2,4-Difluorobenzyl)amino]-6-methyl-1-
2(1H)-one
(pyridin-4-ylmethyl)pyridin-2(1H)-one
                                                                             586379-86-4P, 4-[(2,4-
Difluorobenzyl) amino] -1-(2,6-\text{difluorophenyl})-6-\text{methylpyridin}-2(1H)-\text{one}
586379-89-7P, 3-[(4-Hydroxy-6-methyl-2-oxo-2H-pyridin-1-
yl)methyl]benzonitrile
                                                586379-90-0P, 3-[[4-[(2,4-Difluorobenzyl)amino]-6-
methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
                                                                                                   586379-94-4P,
1-[2-Fluoro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one
586379-95-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2-fluoro-5-
(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one
                                                                                                    586379-97-7P, Methyl
4-fluoro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate
586379-98-8P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-fluorobenzoate
                                                               586379-99-9P, Methyl 3-[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate
586380-12-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-
2H-pyridin-1-yl]-4-fluorobenzoate
                                                                       586380-14-5P, Methyl
3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methoxybenzoate
586380-15-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-methoxybenzoate 586380-16-7P, Methyl
3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
                                 586380-20-3P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methoxybenzoate
methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide 586380-49-6P
586380-51-0P, 4-[(2,4-Difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyridin-2-
vl]methyl]-6-methylpyridin-2(1H)-one 586380-53-2P
                                                                                                        586380-54-3P,
6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]nicotinic acid
                                                    586380-58-7P, 4-Hydroxy-6-methyl-1-[2-
(trifluoromethyl)phenyl]pyridin-2(1H)-one
                                                                                      586380-59-8P,
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-
                       586380-65-6P, 4-(Benzyloxy)-1-(2,6-difluorophenyl)-6-
2(1H)-one
methylpyridin-2(1H)-one
                                                 586380-83-8P
                                                                               586380-84-9P
                                                                                                             586380-85-0P
586380-88-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2-oxo-2H-methyl-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-
pyridin-1-yl]-3-chlorobenzoic acid 586380-90-7P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
```

```
586381-05-7P, Methyl 3-fluoro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-
       yl)benzoate 586381-06-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-
       2-oxo-2H-pyridin-1-yl]-3-fluorobenzoate 586381-12-6P,
       1-[4-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
       difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]amino]-2-
       oxoethyl] acetate 586381-16-0P
, tert-Butyl [4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-
       1-yl]methyl]phenyl]carbamate 586381-33-1P, 4-Bromomethyl-N-(2-
       hydroxyethyl)benzenesulfonamide 586381-36-4P, 4-Bromomethyl-N-(2-hydroxy-
       2-methylpropyl) benzenesulfonamide 586381-39-7P, 3-[[3-Chloro-4-[(2,4-1)]]
       difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-
       carboxylic acid tert-butyl ester 586381-41-1P, [5-[[3-Chloro-4-[(2,4-
       \verb|difluorobenzyl| oxy| -6 - methyl -2 - oxo -2 H - pyridin -1 -yl| methyl| indol-1 -yl| methyl| meth
       yl]carbamic acid tert-butyl ester 586381-42-2P, 3-Chloro-4-[(2,4-
       difluorobenzyl)oxy]-6-methyl-1-(1H-indol-5-ylmethyl)-1H-pyridin-2-one
       586381-44-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-
       pyridin-1-yl]methyl]-3,3-dibromo-1H-indol-2-one
                                                                                586381-53-5P
       586381-55-7P, 4-Hydroxy-1-(1H-indazol-5-yl)-6-methylpyridin-2(1H)-one
       586381-57-9P, 4-Hydroxy-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one
       586381-59-1P, Methyl 3-[4-[(2-cyano-4-fluorobenzyl)oxy]-6-methyl-2-oxo-2H-
       pyridin-1-y1]-4-methylbenzoate 586381-61-5P, Methyl 3-[4-[[2-
       (aminomethy1)-4-fluorobenzy1]oxy]-6-methy1-2-oxo-2H-pyridin-1-y1]-4-
       methylbenzoate trifluoroacetate 586381-62-6P
                                                                              586381-63-7P,
       3-[4-[4-Fluoro-2-[((methoxycarbonyl)amino]methyl]benzyl]oxy]-6-methyl-2-
       oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-64-8P,
       3-[3-Bromo-4-[[4-fluoro-2-[[(methoxycarbonyl)amino]methyl]benzyl]oxy]-6-
       methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid 586381-72-8P, Methyl
       3-[4-[[2-[[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-
       oxo-2H-pyridin-1-y1]-4-methylbenzoate 586381-73-9P, 3-[4-[[2-
       [[(Ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-
       pyridin-1-yl]-4-methylbenzoic acid 586381-74-0P, 3-[3-Bromo-4-[[2-
       \hbox{\tt [[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-linearity.}\\
       pyridin-1-yl]-4-methylbenzoic acid 586381-76-2P, Methyl
       3-[4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-
       methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-77-3P,
       3-[4-[[2-[[(Cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-
       methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
                                                                                      586381-79-5P, Ethyl
       (5-fluoro-2-methylphenoxy) acetate
                                                            586381-80-8P, Ethyl
       [2-(bromomethyl)-5-fluorophenoxy]acetate
                                                                      586381-81-9P, Ethyl
       [2-[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
       yl]oxy]methyl]-5-fluorophenoxy]acetate 586381-82-0P,
       [2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
       yl]oxy]methyl]-5-fluorophenoxy]acetic acid 586381-84-2P,
       3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-oxopropyl acetate
       RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
       (Reactant or reagent)
            (intermediate; preparation of pyridinones as modulators of p38 MAP kinase
            for treatment of inflammatory conditions, ischemia,
       viral infections, autoimmune diseases, and other conditions) 586381-85-3P, Methyl 3-[6-[(acetyloxy)methyl]-4-hydroxy-2-oxo-2H-pyridin-1-
ΙT
       yl]-4-methylbenzoate
                                       586381-86-4P, Methyl 3-[6-[(acetyloxy)methyl]-3-
       bromo-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate
                                                                                             586381-93-3P,
       (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                      586381-96-6P, 2-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
       yl]-2-butenoic acid
       6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzoic acid
       586382-03-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-
       methylpyridin-2(1H)-one
                                             586382-08-3P, 1-[4-(Aminomethyl)benzyl]-3-chloro-
       4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                           586382-14-1P,
       [1-[3-(Aminocarbonyl)phenyl]-4-hydroxy-6-oxo-1,6-dihydropyridin-2-
       yl]methyl acetate 586382-15-2P, [1-[3-(Aminocarbonyl)phenyl]-4-[(2,4-
```

```
difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate
586382-17-4P, 5-(Chloromethyl)-2-(methylthio)pyrimidine
                                                                                        586382-19-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylthio)pyrimidin-5-
yl]methyl]pyridin-2(1H)-one trifluoroacetate 586382-21-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-
(methylsulfonyl)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate
586382-26-5P, Ethyl 3-[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl]-4-methylphenyl]-3-oxopropanoate
                                                                                    586382-30-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]quinolin-2(1H)-one
                                                                                    586382-31-2P,
Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-
                             586382-33-4P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
yl]methyl]benzoate
6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoic acid
                                                                                    586382-35-6P,
Methyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-furoate
586382-36-7P, Methyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-fine the second of th
2H-pyridin-1-y1]-2-furoate 586382-37-8P, 5-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoic acid
586382-39-0P, Dimethyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-
                         586382-40-3P, Dimethyl 5-(3-bromo-4-hydroxy-6-methyl-2-
yl)isophthalate
oxo-2H-pyridin-1-yl)isophthalate 586382-41-4P, Dimethyl
5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
vllisophthalate
                         586382-42-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]isophthalic acid 586382-48-1P, tert-Butyl
[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
                                     586382-50-5P, 2-[[3-[3-Bromo-4-[(2,4-
fluorophenyl]carbamate
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-
2-oxoethyl acetate 586382-52-7P, 2-[[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-
1,1-dimethyl-2-oxoethyl acetate 586382-54-9P, 4-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
     (intermediate; preparation of pyridinones as modulators of p38 MAP kinase
    for treatment of inflammatory conditions, ischemia,
    viral infections, autoimmune diseases, and other conditions)
586375-79-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (p38 kinase inhibitor; hydrochloride)
586379-66-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-
[(methylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one
586380-87-2P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-3-chlorobenzamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical
process); PYP (Physical process); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC
(Process); USES (Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
586414-48-4P
                       586414-49-5P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
108379-95-9P
                       571168-92-8P, 1-Benzyl-4-(benzyloxy)-3-iodopyridin-2(1H)-
```

ΙT

ΤТ

ΤТ

```
586372-64-7P, 4-(Benzyloxy)-1-(4-methylbenzyl)pyridin-2(1H)-one
one
586372-72-7P, 4-(Benzyloxy)-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one
586372-76-1P, 4-(Benzyloxy)-3-bromopyridin-2(1H)-one
586372-77-2P, 4-(Benzyloxy)-1-[4-(benzyloxy)benzyl]-3-bromopyridin-2(1H)-
           586372-81-8P, 4-(Benzyloxy)-1-[(4-cyanophenyl)methyl]pyridin-2(1H)-
one
           586372-82-9P
                                        586372-87-4P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-
2(1H)-one hydrobromide
                                                586373-00-4P, 1-Benzyl-4-(benzyloxy)-6-
methylpyridin-2(1H)-one
                                               586373-03-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                                                586373-06-0P, 1-Benzyl-4-[(2,6-
dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-14-0P, 1-Benzyl-4-
(benzyloxy)-3-vinylpyridin-2(1H)-one 586373-20-8P, 1-Benzyl-3-bromo-2-
oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate
                                                                                                          586373-50-4P
586373-55-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[2-
(hydroxymethyl)benzyl]pyridin-2(1H)-one 586373-64-0P,
[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]carbamic acid tert-butyl ester 586373-75-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(isoquinolin-5-yl)methyl]-1H-
pyridin-2-one trifluoroacetate 586373-78-6P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-(1H-indol-5-ylmethyl)-1H-pyridin-2-one
586373-84-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-
indol-5-yl)methyl]pyridin-2(1H)-one
                                                                        586373-95-7P, 2-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
586373-97-9P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-final content of the second of the secon
pyridin-1-yl]methyl]benzoate 586374-03-0P, Methyl 3-[[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzoate
586374-06-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl
fluorobenzyl)pyridin-2(1H)-one
                                                             586374-28-9P, 2-[2-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide
586374-30-3P, Ethyl [3-[[3-Bromo-4-[(2,4-difluorobenzyl)]]-2-oxo-2H-
pyridin-1-yl]methyl]phenyl]acetate
                                                                     586374-34-7P, 4-[(2,4-
Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-
                             586374-39-2P, 1-Cyclohexyl-4-[(2,4-difluorobenzyl)oxy]-3,6-
carbonitrile
dimethylpyridin-2(1H)-one
                                                      586374-46-1P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-
2H-pyridin-1-yl]methyl]benzonitrile
                                                                         586374-47-2P, 2-[[4-(Benzyloxy)-3-
bromo-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
                                                                                                 586374-55-2P,
4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl] benzonitrile
586374-59-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]benzonitrile
                                                                  586374-61-0P, 3-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
586374-62-1P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]benzonitrile
                                                                    586374-63-2P, 4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide
586374-65-4P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
                                                                        586374-70-1P, 3-Bromo-1-[4-
oxo-2H-pyridin-1-yl]methyl]benzoate
(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586374-72-3P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-80-3P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzoic acid 586375-08-8P, Methyl 4-[4-(benzyloxy)-3-bromo-2-
oxo-2H-pyridin-1-yl]benzoate
                                                            586375-10-2P, 4-[4-(Benzyloxy)-3-bromo-2-
oxo-2H-pyridin-1-yl]benzoic acid
                                                                    586375-20-4P, Methyl
4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                           586375-23-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
yl]benzoate
methyl-2-oxo-2H-pyridin-1-yl]benzoic acid
                                                                                    586375-25-9P,
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzoic acid
                                               586375-26-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
1-[4-(hydroxymethyl)benzyl]-6-methylpyridin-2(1H)-one
                                                                                                           586375-30-6P,
4-[(2,4-Difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-methylpyridin-2(1H)-one
586375-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-
methylpyridin-2(1H)-one 586375-66-8P, 3-Bromo-4-[(2,4-
```

```
difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinylcarbonyl)phenyl]pyridin-
                                                                                             586375-71-5P, Methyl 4-[[3-chloro-4-[(2,4-
2(1H)-one hydrochloride
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate
586375-97-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]benzoic acid 586375-99-7P, Methyl 3-[4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
586376-20-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]benzoic acid 586376-23-0P, 1-[3-(Aminomethyl)phenyl]-3-
bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586376-64-9P, 1-(4-Bromo-2,6-difluorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586376-66-1P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one
586376-70-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]-6-methyl-1-(2,4,
trifluorophenyl)pyridin-2(1H)-one 586377-36-8P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile
586377-37-9P, 1-[4-(Aminomethyl)-2,6-difluorophenyl]-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difl
difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride 586377-80-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-
                                        586377-82-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
2(1H)-one
difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one 586377-88-0P,
2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
y1]oxy]methy1]-5-fluorobenzonitrile 586377-90-4P, 4-[[2-(Aminomethy1)-4-
fluorobenzyl]oxy]-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one
                                                                   586377-96-0P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-3-
trifluoroacetate
chloro-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate
586378-00-9P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
586378-03-2P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride
586378-05-4P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-((2,4-methylpyrimidin-5-yl)methylpyrimidin-5-[(2,4-methylpyrimidin-5-yl]-3-((2,4-methylpyrimidin
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
586378-12-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-
(methylthio)pyrimidin-4-yl]methyl]pyridin-2(1H)-one
                                                                                                                                                                                                           586378-13-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-
(methylsulfonyl)pyrimidin-4-yl]methyl]pyridin-2(1H)-one
                                                                                                                                                                                                                        586378-15-6P,
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrimidine-2-carbonitrile trifluoroacetate 586378-29-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-
yl]methyl]-6-methylpyridin-2(1H)-one
                                                                                                                                                  586378-31-6P, Ethyl
5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrazine-2-carboxylate
                                                                                                                                 586378-38-3P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-
yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate
586378-49-6P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-iodopyridin-
                                            586379-02-4P, Ethyl 5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate
                                                                                                                                                                                                                                      586379-25-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
                                                                                                                               586379-30-8P, 5-Bromo-4-[(2,4-
(hydroxymethyl)pyridin-2(1H)-one
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-
carboxaldehyde 586379-42-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one
                                                                                                                                                                                                  586379-51-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-
methylpyridin-2(1H)-one
                                                                                              586379-72-8P, Methyl 4-[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoate
586379-96-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-final content of the content of the
                                                                                                                                       586380-11-2P, 3-[3-Bromo-4-[(2,4-
pyridin-1-yl]-4-fluorobenzoic acid
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid
586380-13-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-met
pyridin-1-yl]-4-methoxybenzoic acid 586380-19-0P, 1-[5-(Aminomethyl)-2-
fluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-
                                                                      586380-26-9P, 2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-
one hydrochloride
```

```
methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile
586380-60-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
methyl-5-vinylpyridin-2(1H)-one 586380-61-2P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxyethyl)-6-
methylpyridin-2(1H)-one 586380-62-3P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(hydroxymethyl)-6-
methylpyridin-2(1H)-one 586380-63-4P, 5-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-
dihydropyridine-3-carboxaldehyde
                                                   586380-64-5P, 4-(Benzyloxy)-3-bromo-1-
(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586380-67-8P,
5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-
1,6-dihydropyridine-3-carboxaldehyde oxime 586380-73-6P,
4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-
         586380-75-8P, Ethyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-1,2'-bipyridine-5'-carboxylate 586380-82-7P 586381-04-6P,
Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
y1]-3-fluorobenzoate 586381-07-9P, 4-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoic acid
586381-08-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]benzamide 586381-15-9P, 1-(4-Aminobenzyl)-3-bromo-4-
[(2, 4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-40-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2,3-dihydro-1H-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-indol-5-ind
yl)methyl]-1H-pyridin-2-one
                                          586381-58-0P, Methyl [2-[[[3-bromo-6-methyl-
1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate
                                                            586381-78-4P,
3-[3-Bromo-4-[[2-[[[(cyclopropylamino)carbonyl]amino]methyl]-4-
\verb|fluorobenzyl| oxy| -6 - \verb|methyl-2-oxo-2H-pyridin-\bar{1}-yl| -4 - \verb|methy\bar{1}| benzoic acid| \\
586381-89-7P
                     586381-94-4P, Methyl 5-[[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoate
586381-95-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-(hydroxymethyl)-N-methylbenzamide 586382-02-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-
methylpyridin-2(1H)-one 586382-04-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2,6-difluorophenyl]-6-
methylpyridin-2(1H)-one 586382-05-0P, 4-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-
difluorobenzaldehyde 586382-16-3P 586382-46-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[4-(1-hydroxy-1-methylethyl)phenyl]-6-methylpyridin-
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
4241-21-8P, 2-0xo-6-phenethyl-1,2-dihydropyridine-3-carbonitrile
39883-43-7P, 6-0xo-1, 6-dihydro-[2,3'] bipyridinyl-5-carbonitrile
43083-13-2P, 2-0xo-6-phenyl-1,2-dihydropyridine-3-carbonitrile
53179-13-8P, 5-Methyl-1-phenyl-1H-pyridin-2-one
                                                                        54923-34-1P,
4-\text{Benzyloxy}-3-\text{methyl}-1\text{H-pyridin}-2-\text{one} 56304-43-9P, 6-0xo-1,6-dihydro-
[2,3'] bipyridinyl-5-carboxylic acid 123100-43-6P, 1-(2-Bromobenzyl)-3-
[(2-bromobenzy1)oxy]pyridin-2(1H)-one 242472-06-6P, 5-[[4-(3-bromobenzy1)oxy]
Chlorophenyl)piperazin-1-yl]carbonyl]-1-(3,4-dichlorobenzyl)-1H-pyridin-2-
         242472-09-9P, N-Allyl-2-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-
yl)carbonyl]hydrazinecarbothioamide 338774-98-4P, N-[5-Acetyl-1-(4-
338782-59-5P, 1-(3,4-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(2,4-difluorophenyl)amide 338978-39-5P
                                                                                           338981-04-7P,
1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
N-(3-dimethylaminopropyl) amide 338981-05-8P, 1-(2,6-Dichlorobenzyl)-6-
```

ΤТ

```
oxo-1,6-dihydropyridine-3-carboxylic acid N-(2-dimethylaminoethyl)amide
339008-61-6P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(2,4-difluorophenyl)amide 339008-62-7P,
1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
N-(4-\text{chlorophenyl}) amide 339008-63-8P, 1-(2,6-\text{Dichlorobenzyl})-6-\text{oxo}-1,6-
dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide
339008-64-9P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(4-trifluoromethoxyphenyl)amide 339008-65-0P,
1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
             339008-68-3P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-
dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide
339009-09-5P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(2,4-difluorophenyl)amide 339023-89-1P,
5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic
acid N-(3-trifluoromethylphenyl)amide 339023-98-2P, 5-Chloro-1-(2,6-
dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide
             400087-49-2P, Methyl 5-chloro-1-(4-chlorobenzyl)-6-oxo-1,6-
339024-00-9P
dihydropyridine-3-carboxylate 4\overline{7}7852-96-3P, 1-Benzyl-5-[5-[(3,4-
dichlorobenzyl)sulfanyl]-[1,3,4]oxadiazol-2-yl]-1H-pyridin-2-one
477858-09-6P, 1-(4-Chlorobenzyl)-5-[3-(4-chlorophenyl)-[1,2,4] oxadiazol-5-
yl]-1H-pyridin-2-one 477864-11-2P, N'-[[(1-Benzyl-6-oxo-1,6-
dihydropyridin-3-yl)carbonyl]oxy]pyridine-4-carboximidamide
478065-97-3P, 1-Benzyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid
N-[2-(morpholin-4-yl)ethyl] amide 478066-00-1P, 1-(2,6-Dichlorobenzyl)-6-
oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylbenzyl)amide
478247-73-3P, 3-Benzyl-4-hydroxy-1-(2-phenylethyl)pyridin-2(1H)-one
565156-95-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[[2-
(hydroxymethyl)benzyl]oxy]pyridazin-3(2H)-one
                                              565157-26-8P,
4-Bromo-2-(2,6-dichlorophenyl)-5-[(2,4-difluorobenzyl)oxy]pyridazin-3(2H)-
      586372-66-9P, 4-(Benzyloxy)-3-bromo-1-(4-methylbenzyl)pyridin-2(1H)-
one
      586372-68-1P, 4-(Benzyloxy)-1-[(4-bromophenyl)methyl]pyridin-2(1H)-
one
      586372-69-2P, 4-(Benzyloxy)-3-bromo-1-[(4-bromophenyl)methyl]pyridin-
one
           586372-70-5P, 4-(Benzyloxy)-1-[(4-chlorophenyl)methyl]pyridin-
2(1H)-one
           586372-71-6P, 4-(Benzyloxy)-3-bromo-1-[(4-
2(1H)-one
chlorophenyl)methyl]pyridin-2(1H)-one 586372-74-9P, 4-(Benzyloxy)-1-[(2-
fluorophenyl)methyl]pyridin-2(1H)-one 586372-75-0P, 4-(Benzyloxy)-3-
                                                  586372-78-3P,
bromo-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one
4-(Benzyloxy)-1-[[4-(methoxycarbonyl)phenyl]methyl]pyridin-2(1H)-one
586372-79-4P, 4-(Benzyloxy)-3-bromo-1-[[4-(methoxycarbonyl)phenyl]methyl]p
vridin-2(1H)-one
                  586372-80-7P, 4-(Benzyloxy)-3-bromo-1-[(4-
carboxyphenyl)methyl]pyridin-2(1H)-one
                                        586372-83-0P,
4-(Benzyloxy)-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one
586372-84-1P, 4-(Benzyloxy)-3-bromo-1-[(4-tert-butylphenyl)methyl]pyridin-
2(1H)-one
           586372-85-2P, 4-(Benzyloxy)-3-bromo-1-ethylpyridin-2(1H)-one
586372-86-3P, 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one
586372-88-5P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-2(1H)-one
586372-89-6P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]-N'-
                               586372-90-9P, 4-(Benzyloxy)-3-bromo-1-
hydroxybenzenecarboximidamide
(piperidin-4-ylmethyl)pyridin-2(1H)-one hydrochloride
                                                      586372-91-0P,
4-(Benzyloxy)-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one
586372-92-1P, 4-(Benzyloxy)-3-bromo-1-[4-(trifluoromethyl)benzyl]pyridin-
2(1H)-one
           586372-93-2P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-
ylmethyl)pyridin-2(1H)-one hydrochloride
                                         586372-94-3P,
4-(Benzyloxy)-3-bromo-1-[2-(thien-3-yl)ethyl]pyridin-2(1H)-one
586372-95-4P, 4-(Benzyloxy)-3-bromo-1-[2-(thien-2-yl)ethyl]pyridin-2(1H)-
      586372-96-5P, 4-(Benzyloxy)-3-bromo-1-[3-
one
(trifluoromethyl)benzyl]pyridin-2(1H)-one 586372-97-6P,
4-(Benzyloxy)-3-bromo-1-[2-(trifluoromethyl)benzyl]pyridin-2(1H)-one
586372-99-8P, 4-(Benzyloxy)-3-bromo-1-[4-
(trifluoromethoxy)benzyl]pyridin-2(1H)-one 586373-01-5P,
```

```
1-Benzyl-4-(benzyloxy)-3-bromo-6-methylpyridin-2(1H)-one
                                                                                                                     586373-02-6P.
1-Benzyl-4-(benzyloxy)-3,5-dibromo-6-methylpyridin-2(1H)-one
586373-05-9P, 1-Benzyl-3-bromo-4-[(3-chlorobenzyl)oxy]-6-methylpyridin-
                       586373-07-1P, 1-Benzyl-3-bromo-4-[(2,6-
2(1H)-one
dichlorobenzyl)oxy]pyridin-2(1H)-one
                                                                             586373-08-2P, 1-Benzyl-4-[(2-
chlorobenzyl)oxy]pyridin-2(1H)-one 586373-09-3P, 1-Benzyl-3-bromo-4-[(2-
chlorobenzyl)oxy]pyridin-2(1H)-one
                                                                     586373-10-6P, 1-Benzyl-3-bromo-4-[(4-
                                                                     586373-11-7P, 1-Benzyl-4-[(3-
methylbenzyl)oxy]pyridin-2(1H)-one
chlorobenzyl)oxy|pyridin-2(1H)-one
                                                                         586373-12-8P,
1-Benzyl-4-(benzylthio)-3-bromopyridin-2(1H)-one
                                                                                                     586373-13-9P,
1-Benzyl-3-bromo-4-[[2-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one
586373-15-1P, 1-Benzyl-4-(benzyloxy)-3-ethylpyridin-2(1H)-one
586373-16-2P, 3-Acetyl-4-(benzyloxy)-1-(2-chlorophenyl)-6-methylpyridin-
2(1H)-one
                    586373-17-3P, 1-Benzyl-3-bromo-4-(2-phenylethyl)pyridin-2(1H)-
            586373-22-0P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(2-
one
phenylethyl)pyridin-2(1H)-one
                                                            586373-23-1P, 4-(Benzyloxy)-3-bromo-1-(2,6-
dichlorophenyl)-6-methylpyridin-2(1H)-one 586373-27-5P,
3-Bromo-1-(3-fluorobenzyl)-4-(2-phenylethyl)pyridin-2(1H)-one
586373-28-6P, 1-Benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl
N-methyl-N-phenylcarbamate 586373-30-0P, 4-(Benzyloxy)-3-ethynyl-1-(3-
fluorobenzyl)pyridin-2(1H)-one 586373-33-3P, 4-(Benzylamino)-3-bromo-1-
(3-fluorobenzyl)pyridin-2(1H)-one
                                                                      586373-36-6P, 3-Bromo-1-
(cyclopropylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
586373-40-2P, 3-Bromo-1-[(pyridin-4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-yl)methyl]-4-[(4-
fluorobenzyl)oxy]pyridin-2(1H)-one 586373-41-3P, 3-Bromo-1-[(pyridin-3-
yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-42-4P,
3-Bromo-1-(4-tert-butylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
586373-43-5P, 3-Bromo-1-(3-trifluoromethylbenzyl)-4-[(4-
fluorobenzyl)oxy]pyridin-2(1H)-one 586373-44-6P, 3-Bromo-1-[(biphenyl-2-
yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586373-45-7P,
3-Bromo-1-(4-methoxybenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
                             586373-47-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[4-
586373-46-8P
(trifluoromethyl)benzyl]pyridin-2(1H)-one
                                                                                      586373-48-0P,
3-Bromo-1-[(biphenyl-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
586373-49-1P, 3-Bromo-1-(cyclohexylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-
2(1H)-one
                       586373-52-6P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(4-
fluorobenzyl)oxy]pyridin-2(1H)-one
                                                                        586373-53-7P, 1-(3-Aminomethylbenzyl)-
3-bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one trifluoroacetate
                       586373-54-8P, Methyl 2-[[3-bromo-4-[(4-fluorobenzyl)oxy]-2-oxo-
2H-pyridin-1-yl]methyl]benzoate
                                                                   586373-56-0P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[4-[(dimethylamino)methyl]benzyl]-1H-pyridin-2-one
586373-61-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-
[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one
                                                                                                     586373-62-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(dimethylaminomethyl)benzyl]-1H-
                               586373-63-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-
pyridin-2-one
[(methylamino)methyl]benzyl]-1H-pyridin-2-one
                                                                                               586373-65-1P,
1-[(3-Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-
            586373-66-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-
one
[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one
                                                                                                    586373-69-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(methanesulfonyl)benzyl]-1H-
pyridin-2-one
                               586373-71-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-
(methanesulfonyl)benzyl]-1H-pyridin-2-one
                                                                                       586373-72-0P,
4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]benzamide
                                           586373-77-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
[(1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one
586373-83-3P, 1-[(1-Acetyl-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-chloro-4-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-
difluorobenzyl)oxy]pyridin-2(1H)-one
                                                                            586373-85-5P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
586373-86-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-4-
ylmethyl)pyridin-2(1H)-one 586373-87-7P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[(pyridin-2-yl)methyl]-1H-pyridine-2-one
```

```
586373-88-8P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(2,4-
difluorobenzyl)oxy]pyridin-2(1H)-one 586373-89-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(3-methoxybenzyl)pyridin-2(1H)-one 586373-90-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(benzodioxol-5-yl)methyl]pyridine-
                 586373-91-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-
2(1H)-one
fluorobenzyl)pyridin-2(1H)-one
                                               586373-92-4P, 3-Bromo-1-(2,4-
difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
586373-94-6P, [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
vl]methyl]phenyl]acetonitrile 586373-96-8P, 1-[2-(Aminomethyl)benzyl]-3-
bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-98-0P, Methyl
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]benzoate 586373-99-1P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-00-7P,
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]benzamide 586374-01-8P, 1-(3-Aminomethyl-2-fluorobenzyl)-3-
bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-05-2P,
3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-
fluorobenzamide 586374-08-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2,3,4-
trifluorobenzyl)oxy]-1H-pyridin-2-one 586374-10-9P 586374-11-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one
586374-13-2P, 3-Bromo-4-[(3-chlorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-
                586374-14-3P, 3-Bromo-4-[(3,4-difluorobenzyl)oxy]-1-(3-
fluorobenzyl) pyridin-2(1H) -one 586374-15-4P, 3-Bromo-1-(3-fluorobenzyl) -
4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
                                                              586374-16-5P,
3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)oxy]pyridin-2(1H)-one
586374-18-7P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methoxybenzyl)oxy]pyridin-
               586374-19-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-tert-
2(1H)-one
butylbenzyl)oxy]-1H-pyridin-2-one
                                                    586374-20-1P, 3-Bromo-1-(3-
fluorobenzyl)-4-[(3-methylbenzyl)oxy]pyridin-2(1H)-one
                                                                                  586374-21-2P,
3-Bromo-1-(3-fluorobenzyl)-4-[[4-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-
        586374-22-3P
                             586374-23-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2-
methylbenzyl)oxy]pyridin-2(1H)-one 586374-24-5P
                                                                            586374-25-6P,
3-Bromo-1-(3-fluorobenzyl)-4-[(4-methoxybenzyl)oxy]pyridin-2(1H)-one
586374-27-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[[2-
(hydroxymethyl)benzyl]oxy]pyridin-2(1H)-one
                                                                   586374-31-4P,
2-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]phenyl]acetamide
                                        586374-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-
(3-fluorobenzyl)-3-methylpyridin-2(1H)-one 586374-33-6P,
4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-iodo-1H-pyridin-2-one
586374-43-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-
                                            586374-48-3P, 1-[4-(Aminomethyl)benzyl]-4-
4-ylmethyl)-1H-pyridin-2-one
(benzyloxy)-3-bromopyridin-2(1H)-one
                                                        586374-49-4P, 1-[3-
(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one
586374-50-7P, 1-[2-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(1H)-1-2-(
         586374-51-8P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
                                586374-52-9P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-
yl]methyl]benzamide
                                              586374-53-0P, 2-[[4-(Benzyloxy)-3-bromo-2-
pyridin-1-yl]methyl]benzamide
oxo-2H-pyridin-1-yl]methyl]benzamide
                                                       586374-54-1P, Methyl
3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzoate
586374-56-3P, 2-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile
586374-57-4P, [4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
                                                                  586374-64-3P, Methyl
yl]methyl]phenyl]acetic acid 586374-58-5P
4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzoate
                            586374-66-5P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-67-6P,
2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzamide
                               586374-68-7P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                               586374-69-8P,
3-Bromo-1-[3-(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586374-71-2P, 1-[4-(Aminomethyl)benzyl]-3-bromo-
4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-73-4P,
```

```
1-[3-[(Morpholin-4-y1)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                         586374-74-5P, 1-[3-[(Dimethylamino)methyl]benzyl
]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586374-75-6P, 1-[3-[(Isopropylamino)methyl]benzyl]-3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                              586374-76-7P,
1-[3-[(Piperidin-1-y1)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                         586374-77-8P, 1-[3-[[(2-
Hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
                         586374-78-9P, 1-[3-[[Bis(2-
methylpyridin-2(1H)-one
hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586374-79-0P, 1-[3-[(Piperazin-1-
y1)methy1]benzy1]-3-bromo-4-[(2,4-difluorobenzy1)oxy]-6-methylpyridin-
2(1H)-one
           586374-81-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
[3-[(acetylamino)methyl]benzyl]pyridin-2(1H)-one
                                                  586374-82-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(methoxycarbonylamino)methyl]benzyl]pyridin-2(1H)-one
                                                        586374-83-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(methylsulfonylamino)methyl]benzyl]pyridin-2(1H)-one
                                                       586374-84-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-
hydroxyacetylamino)methyl]benzyl]pyridin-2(1H)-one
                                                    586374-85-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(aminocarbonylamino)methyl]benzyl]pyridin-2(1H)-one
                                                      586374-86-9P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(isopropylamino)methyl]benzyl]pyridin-2(1H)-one
                                                  586374-87-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholin-4-
vl)methyl]benzyl]pyridin-2(1H)-one 586374-88-1P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)methyl]benzyl]pyridin-
2(1H)-one
            586374-89-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
[4-[(piperidin-1-yl)methyl]benzyl]pyridin-2(1H)-one
                                                     586374-90-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-methyl-1)oxy]]]
hydroxyethyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-91-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-difluorobenzyl)oxy]]
hydroxyethyl)amino]methyl]benzyl]pyridin-2(1H)-one
                                                    586374-92-7P,
yl)methyl]benzyl]pyridin-2(1H)-one
                                    586374-93-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
                                                          586374-94-9P,
[[(methoxycarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(acetylamino)methyl]benzyl]pyridin-2(1H)-one 586374-95-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[[(methylsulfonyl)amino]methyl]benzyl]pyridin-2(1H)-one
                                                         586374-96-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[[(aminocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one
                                                        586374-97-2P.
4-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzoyl]piperazine-1-carboxamide
                                            586374-99-4P,
N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-2-methoxyacetamide
                                      586375-00-0P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methoxycarbonyl)methyl]carbonyl]ami
                                    586375-01-1P, 3-Bromo-4-[(2,4-
no]methyl]benzyl]pyridin-2(1H)-one
difluorobenzyl)oxy]-6-methyl-1-[4-[[[(1-hydroxy-1-
                                                            586375-02-2P
methylethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
586375-03-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[[[(aminomethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
hydrochloride
               586375-04-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[4-[[[(hydroxymethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
586375-05-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-browner]
[[[[(acetylamino)methyl]carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
586375-06-6P, 1-[4-[(4-Acetylpiperazin-1-yl)carbonyl]benzyl]-3-bromo-4-
[(2, 4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-07-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[4-
(methylsulfonyl)piperazin-1-yl]carbonyl]benzyl]pyridin-2(1H)-one
```

```
586375-11-3P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzamide
         586375-12-4P, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-
                      586375-13-5P, Methyl 4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
         one
                                                                 586375-17-9P, 3-Bromo-4-[(2,4-
         2H-pyridin-1-yl]benzoate
         difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one
         586375-24-8P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-(trifluoromethyl)pyridin-
         2(1H)-one
                                  586375-27-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-4)]
         hydroxy-1-methylethyl)benzyl]-6-methylpyridin-2(1H)-one
                                                                                                                                586375-28-2P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(methylamino)methyl]benzyl]pyridin-2(1H)-one
                                                                                                         586375-33-9P,
          3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-hydroxybenzyl)-6-methylpyridin-
                                  586375-34-0P
                                                               586375-36-2P, 4-[[3-Bromo-4-[(2,4-
         difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-
         methylpropyl)benzamide 586375-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
         1-[4-[(4-hydroxypiperidin-1-y1)carbony1]benzy1]-6-methylpyridin-2(1H)-one
         586375-38-4P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
         pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586375-39-5P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(piperazino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                           586375-40-8P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[(2-methyl-1)oxy]]]
         aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                      586375-41-9P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl]oxy]-6-methyl-1-[4-[(3-4-difluorobenzyl]oxy]-6-methyl
          aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                         586375-42-0P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                  586375-43-1P,
          3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(methylamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                586375-44-2P,
          3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                     586375-45-3P,
          3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(morpholino)carbonyl]benzyl]pyridin-2(1H)-one 586375-46-4P,
          3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-
         hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                           586375-47-5P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(cyclopentylamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                           586375-48-6P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          [(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                      586375-49-7P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(1-
         pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one 586375-50-0P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-interval)oxy]]
         methylpiperazinyl)carbonyl]benzyl]pyridin-2(1H)-one
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[2-
          (dimethylamino)ethyl]amino]carbonyl]benzyl]pyridin-2(1H)-one
         586375-52-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[4-4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[4-4-4-[(4-4-difluorobenzyl]oxy]-6-methyl-1-[
         methoxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                                         586375-53-3P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-hydroxyethyl)-N-(2-hydroxyethyl)]]
         methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-54-4P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[N-(2-methoxyethyl)-N-(2-methoxyethyl)]]
         methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-55-5P,
          4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
          (2-hydroxyethyl)benzamide
                                                                   586375-56-6P
, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
          (piperazinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride
                                                                                                                                    586375-57-7P,
         N-(2-Aminoethyl)-4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
         pyridin-1-yl]benzamide hydrochloride
                                                                                         586375-58-8P, N-(3-Aminopropyl)-4-
         [3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                                                   586375-59-9P, 3-Bromo-4-[(2,4-
         yl]benzamide hydrochloride
         difluorobenzyl)oxy]-6-methyl-1-[4-[(hydroxyamino)carbonyl]phenyl]pyridin-
         2(1H)-one hydrochloride
                                                              586375-60-2P, 3-Bromo-4-[(2,4-
         difluorobenzyl)oxy]-6-methyl-1-[4-[(methylamino)carbonyl]phenyl]pyridin-
         2(1H)-one hydrochloride 586375-61-3P, 3-Bromo-4-[(2,4-
```

```
586375-62-4P, 3-Bromo-4-[(2,4-
               2(1H)-one hydrochloride
               difluorobenzyl)oxy]-6-methyl-1-[4-(morpholinocarbonyl)phenyl]pyridin-2(1H)-
                                                                           586375-63-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
               one hydrochloride
               methyl-1-[4-[[bis(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
                                                               586375-64-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
               hydrochloride
               1-[4-(piperidinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride
               586375-65-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
               [(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
               586375-67-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
               pyridin-1-yl]benzamide 586375-68-0P, 4-(Benzyloxy)-3-bromo-1-[4-
               (morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one
                                                                                                                                                                         586375-69-1P,
               4-(Benzyloxy)-3-bromo-1-[4-(piperazin-1-ylcarbonyl)phenyl]pyridin-2(1H)-
               one hydrochloride
                                                                           586375-70-4P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-
               pyridin-1-yl]-N-hydroxybenzamide 586375-73-7P, 3-[[3-Bromo-4-[(2,4-
               difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-
                                                                  586375-74-8P 586375-75-9P, 3-Bromo-4-[(2,4-
               methylbenzamide
               difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-aminoethyl)amino]carbonyl]benzyl]py
               ridin-2(1H)-one hydrochloride 586375-76-0P, 3-Bromo-4-[(2,4-
               difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-aminopropyl)amino]carbonyl]benzyl]p
               yridin-2(1H)-one hydrochloride
               RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
                (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
                (Uses)
                         (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
                        kinase for treatment of inflammatory conditions,
                        ischemia, viral infections, autoimmune diseases, and other
                        conditions)
ΙT
               586375-77-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[
                [(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
               586375-78-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                [(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
               586375-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                (morpholinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-81-7P,
               3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy]]-6-methyl-1-[[3-[[(2-methyl-1)oxy
               hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
               586375-82-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[bis(2-4)]oxy]-6-methyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]oxyl-1-[3-1]ox
               hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
               586375-83-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                (piperidinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride
                                                                                                                                                                                                     586375-84-0P,
               3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                [(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
               586375-85-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(1-4)]
               pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride
               586375-86-2P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
               pyridin-1-yl]methyl]benzyl]-2-methoxyacetamide
                                                                                                                                                                     586375-87-3P
                                                           586375-89-5P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
               586375-88-4P
               methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide
                                                               586375-90-8P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
               hydrochloride
               methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxy-2-methylpropanamide
               586375-91-9P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
               pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide
               586375-92-0P, N'-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-
               2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea
                                                                                                                                                                     586375-94-2P,
               3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                [[(piperazinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride
               586375-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[
               [[[(methylamino)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
                                                            586375-96-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
               hydrochloride
               1-[3-[[(morpholinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one
               hydrochloride 586376-01-4P, Ethyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-
```

difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)carbonyl]phenyl]pyridin-

```
586376-02-5P.
6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
                                                                                               586376-03-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylbenzamide
methyl-1-[3-[(piperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-04-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-m
aminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-05-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-
aminopropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-06-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-07-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[
[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-08-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[3-bromo-4-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-methyl-1-[(3,4-difluorobenzyl)oxy]-6-m
[(morpholino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-09-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-difluorobenzyl)oxy]-6-methyl-1-[(3-di
hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-10-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [(piperidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-11-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-12-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [(pyrrolidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-13-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy
methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-14-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]]-6-methyl-1-[[(2-4-difluorobenzyl]oxy]]-6-methyl-1-[[(2-4-difluorobenzyl]oxy]-6-methyl-1-[[(2-4-difluorobenzyl]oxy]]-6-methyl-1-[[(2-4-difluorobenzyl]oxy]-6-methyl-1-[[(2-4-difluorobenzyl]oxy]-6-methyl-1-[[(2
dimethylaminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-15-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl]oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl]oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl]oxy]-6-methyl-1-[3-[(3-4-difluorobe
methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-16-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-
dimethylaminoethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                 586376-17-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
hydrochloride
1-[3-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                 586376-18-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
hydrochloride
1-[3-[N-(2-methoxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
hydrochloride
                                                                              586376-19-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]benzamide
                                                                                                                                                                                                                    586376-22-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-
methylpyridin-2(1H)-one
                                                                                                                                          586376-26-3P, N-[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
vl|benzyl|methanesulfonamide
                                                                                                                                                               586376-27-4P, N-[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]acetamide
586376-28-5P
                                                                                586376-29-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-methoxyacetamide
                                                                                                                                                                                                                                                                                                                       586376-30-9P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-2-acetoxyacetamide hydrochloride
                                                                                                                                                                                                                                               586376-31-0P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-2-aminoacetamide hydrochloride 586376-32-1P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-2-hydroxyacetamide hydrochloride 586376-33-2P,
N'-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-N,N-dimethylurea 586376-35-4P, N-[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N'-methylurea
586376-36-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
 [[(morpholinocarbonyl)amino]methyl]phenyl]pyridin-2(1H)-one
586376-37-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-final content of the second cont
pyridin-1-yl]benzyl]urea 586376-38-7P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-
2(1H)-one
                                                                586376-41-2P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
yl]benzyl]acetamide 586376-44-5P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-
pyridin-1-yl]benzyl]-2-hydroxyacetamide
                                                                                                                                                                                                                               586376-45-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(morpholin-4-
```

```
yl)ethyl]pyridin-2(1H)-one
                                                                                                                586376-47-8P, Ethyl 3-[4-(benzyloxy)-3-bromo-
2-oxo-2H-pyridin-1-yl]propanoate 586376-48-9P, Methyl
3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate
                                                                                                                                                                                                                                         586376-50-3P,
N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,6-
                                                                             586376-60-5P, 3-Bromo-1-(4-bromo-2,6-difluorophenyl)-4-
difluorobenzamide
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                                                                                                                                586376-68-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-
trifluorophenyl)pyridin-2(1H)-one 586376-72-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxyl-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-
                                              586376-76-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-
yl)phenyl]-6-methylpyridin-2(1H)-one 586376-82-1P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-
methylpyridin-2(1H)-one 586376-83-2P, 3-Chloro-4-[(2,4-
\verb|difluorobenzyl| oxy| -1 - [2,6 - \verb|difluoro-4-(4-methylpiperazin-1-yl)| phenyl| -6 - [2,6 - [2,6 - [2,6]]| phenyl| -6 - [2,6]| phenyl|
methylpyridin-2(1H)-one 586376-87-6P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-
methylpyridin-2(1H)-one 586376-89-8P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]pheny
1]-6-methylpyridin-2(1H)-one 586376-90-1P, 3-Bromo-1-(3,5-dibromo-2,6-
difluoro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                                         586376-93-4P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
2(1H)-one
methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorophenoxy]acetamide
586376-97-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(2-4)]-1-[2,6-difluoro-4-(2-4)]-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluoro-4-(2-4)]-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenz
hydroxyethoxy)phenyl]-6-methylpyridin-2(1H)-one 586376-98-9P,
3-Bromo-1-(2,6-difluorophenyl)-4-[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-
methylpyridin-2(1H)-one
                                                                                                   586377-04-0P, 3-Chloro-1-(2,6-difluorophenyl)-4-
[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one
586377-06-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-2-methyl-N-[2-(morpholin-4-yl)ethyl]benzamide
586377-13-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[3-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-methyl-1-[(4-4)]oxy]-6-
methoxyethyl)amino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one
586377-15-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(dimethylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-17-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(2-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[3-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methyl-1-[(3-methyl-1)oxy]-6-methy
hydroxyethyl)amino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one
586377-18-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl-1-[3-[N-(2-hydroxyethyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-methyl)-N-(3-meth
methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-21-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1]oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1]oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1]oxy]-6-methyl-1-[3-[(4-methylpipera
yl)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-23-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)-2-
methylphenyl]pyridin-2(1H)-one 586377-24-4P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[3-[[N-(2-methoxyethyl)-N-
                                                                                                                                                                                                                         586377-26-6P,
methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(aminocarbonyl)-2-
                                                                                                                           586377-28-8P, 3-Bromo-4-[(2,4-
methylphenyl]pyridin-2(1H)-one
difluorobenzyl)oxy]-1-[3-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-
                                              586377-30-2P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-2-methylbenzamide
                                                                                                                                                                                                                                                  586377-33-5P
586377-34-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-N-(2-hydroxyethyl)-2-methylbenzamide
                                                                                                                                                                                                             586377-35-7P,
3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
                                                                  586377-39-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
methylbenzamide
[2,6-difluoro-4-[(methylamino)methyl]phenyl]pyridin-2(1H)-one
hydrochloride
                                                         586377-42-6P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]-3,5-difluoro-N,N-dimethylbenzamide 586377-44-8P,
4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-
methoxybenzonitrile 586377-47-1P, N-[4-[3-Chloro-4-[(2,4-
```

```
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]urea
586377-48-2P, 2-[[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
1-y1]-3,5-difluorobenzyl]amino]-1,1-dimethyl-2-oxoethyl acetate
586377-49-3P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
1-y1]-3,5-difluorobenzyl]acetamide 586377-50-6P, N-[4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-
methoxyacetamide 586377-51-7P, N-[4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-furamide
586377-52-8P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
1-yl]-3,5-difluorobenzyl]-1H-imidazole-4-carboxamide 586377-53-9P
586377-54-0P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
1-y1]-3,5-difluorobenzy1]-3-hydroxy-3-methylbutanamide 586377-55-1P,
N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-
difluorobenzyl]-1-hydroxycyclopropanecarboxamide 586377-56-2P,
N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-
difluorobenzyl]-2-hydroxy-2-methylpropanamide 586377-57-3P,
4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-
                                586377-62-0P, 3-Bromo-1-(3-fluorobenzyl)-4-(1-
difluorobenzonitrile
phenylethoxy)pyridin-2(1H)-one 586377-63-1P, 3-Bromo-1-(3-fluorobenzyl)-
4-[(E)-2-(4-fluorophenyl)ethenyl]pyridin-2(1H)-one
                                                                            586377-64-2P,
4-(Benzyloxy)-3-bromo-1-[(6-fluoropyridin-3-yl)methyl]pyridin-2(1H)-one
586377-65-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-
methylpyridin-2(1H)-one 586377-68-6P, 3-Bromo-1-(2,6-dimethylphenyl)-4-
[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-69-7P,
3-Bromo-1-(2,6-dimethylphenyl)-6-methyl-4-[(2,4,6-dimethylphenyl)]
trifluorobenzyl)oxy]pyridin-2(1H)-one 586377-70-0P, 3-Bromo-4-[(2,6-
difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one
586377-71-1P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586377-73-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-74-4P,
3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,6-difluorobenzyl)oxy]-6-methylpyridin-
                 586377-75-5P, 3-Bromo-4-[(2,4-difluorobenzyl))oxy]-1-(2-methoxy-
2(1H)-one
6-methylphenyl)-6-methylpyridin-2(1H)-one
                                                               586377-78-8P,
4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-
dichlorobenzenesulfonamide
                                          586377-83-5P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-
methylpyridin-2(1H)-one 586377-87-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2,4-difluoro-6-[(2-hydroxyethyl)(methyl)amino]pheny
1]-6-methylpyridin-2(1H)-one
                                             586377-91-5P, N-[2-[[[3-Bromo-1-(2,6-
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzvllurea
                             586377-92-6P, Methyl [2-[[[3-bromo-1-(2,6-
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]carbamate 586377-93-7P, N-[2-[[[3-Bromo-1-(2,6-1)]]]
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]-2-hydroxyacetamide 586377-94-8P, Ethyl
[2-[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-97-1P, Isobutyl
[2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-98-2P, Cyclopropylmethyl
[2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate
                                                            586378-07-6P,
1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl]-4-[(2,4-methylpyrimidin-5-yl]-4-[(2,4-methylpyrimid
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride
586378-09-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-
ylmethyl)-6-methylpyridin-2(1H)-one trifluoroacetate
                                                                                 586378-11-2P
                      586378-19-0P, Methyl 4-[[3-bromo-4-[(2,4-
586378-17-8P
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-
carboxylate trifluoroacetate 586378-21-4P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[(2-hydroxypyrimidin-4-yl)methyl]-6-methylpyridin-
2(1H)-one trifluoroacetate 586378-23-6P, 4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-
```

```
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidin-2-
                                                              586378-25-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
           yl]methylcarbamate
           methyl-1-[(5-methylpyrazin-2-yl)methyl] pyridin-2(1H)-one
                                                                                                                                                            586378-28-1P,
           3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyrazin-2-ylmethyl)pyridin-
                                       586378-33-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
           [(dimethylamino)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
           trifluoroacetate
                                                         586378-36-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
           [[(2-hydroxyethyl)(methyl)amino]methyl]pyrazin-2-yl]methyl]-6-
           methylpyridin-2(1H)-one trifluoroacetate 586378-37-2P,
           3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-
           yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one
                                                                                                                                       586378-41-8P,
           5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
           yl]methyl]-N-(2-hydroxyethyl)-N-methylpyrazine-2-carboxamide
           586378-42-9P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
           pyridin-1-yl]methyl]-N-(2,3-dihydroxypropyl)pyrazine-2-carboxamide
           586378-43-0P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
           pyridin-1-yl]methyl]-N-(2-hydroxyethyl)pyrazine-2-carboxamide
           586378-44-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
            (methoxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
           586378-45-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(2-
           methoxyethoxy)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
           586378-46-3P, Carbamic acid [5-[[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-
           methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl ester
           586378-48-5P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one
           586378-51-0P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-methylpyridin-
                                        586378-52-1P, 1-Benzyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
           2(1H)-one
           methylpyridin-2(1H)-one
                                                                        586378-54-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-
           oxo-1,2-dihydropyridin-4-yl]-4-fluorobenzamide
                                                                                                                                586378-57-6P,
           3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
           methylpyridin-2(1H)-one 586378-59-8P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-
           fluorobenzyl)amino]-6-methylpyridin-2(1H)-one
                                                                                                                                586378-61-2P,
           3-Bromo-1-(cyclopropylmethyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                                        586378-63-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
           2(1H)-one
            (pyridin-4-ylmethyl)pyridin-2(1H)-one
                                                                                                          586378-65-6P, 3-Bromo-4-[(2,4-
           difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
           586378-67-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-2-
           ylmethyl)pyridin-2(1H)-one
                                                                                  586378-70-3P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-
           6-methyl-1-[(pyridin-4-yl)methyl]pyridin-2(1H)-one
                                                                                                                                            586378-71-4P
, 3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-4-
           yl)methyl]pyridin-2(1H)-one
                                                                                 586378-72-5P, 3-Bromo-4-[(2,6-
           difluorobenzyl)oxy]-6-methyl-1-[(pyridin-4-yl)methyl]pyridin-2(1H)-one
           586378-73-6P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-
           yl)methyl]pyridin-2(1H)-one
                                                                                   586378-74-7P, 3-Bromo-4-[(2,4,6-
           trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-75-8P, 3-Bromo-4-[(2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-fluor
           trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-77-0P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)oxy]-6-methyl-1-
            [(pyridin-3-yl)methyl]pyridin-2(1H)-one
                                                                                                                586378-78-1P,
           3-Bromo-4-[(2-chloro-4-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-
                                                                                    586378-79-2P, 3-Bromo-4-[(2,6-
           vl)methyl]pyridin-2(1H)-one
           difluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-80-5P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-fluor
           yl)methyl]pyridin-2(1H)-one
                                                                                     586378-81-6P, 3-Bromo-4-[(2,4,6-
           trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-yl)methyl]pyridin-2(1H)-one
           586378-82-7P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6-methyl-1-[(pyridin-1)oxy]-6
           2-y1) methyl]pyridin-2(1H)-one 586378-83-8P, 3-Bromo-4-[2-(4-
           fluorophenyl)ethyl]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-86-1P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-[(pyridin-4-
           y1) methy1] pyridin-2(1H) - one 586378-87-2P, 3-Chloro-4-[(2,4-
```

586378-24-7P, Methyl [4-[[3-bromo-4-[(2,4-

carboxamide trifluoroacetate

```
difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
586378-91-8P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-
4-[(2,4,6-trifluorobenzyl)oxy]pyridin-2(1H)-one trifluoroacetate
(methylamino)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate
586378-95-2P
                                  586378-97-4P
                                                                       586378-98-5P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-
              586379-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-
[(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one
trifluoroacetate
                                           586379-03-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
[[5-(hydroxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
586379-04-6P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N,N-dimethylpyrazine-2-carboxamide 586379-05-7P,
5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-methylpyrazine-2-carboxamide 586379-06-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(1-hydroxy-1-methylethyl)pyrazin-
2-yl]methyl]-6-methylpyridin-2(1H)-one 586379-07-9P,
5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-(2-methoxyethyl)pyrazine-2-carboxamide 586379-08-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-(morpholin-4-
ylcarbonyl)pyrazin-2-yl]methyl]pyridin-2(1H)-one 586379-09-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(4-hydroxypiperidin-1-
y1) carbony1]pyrazin-2-y1]methy1]-6-methy1pyridin-2(1H)-one 586379-11-5P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-(3-hydroxy-2,2-dimethylpropyl)pyrazine-2-carboxamide
586379-12-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2,2,2-trifluoroethyl)pyrazine-2-carboxamide
586379-13-7P, 1-Allyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                          586379-15-9P, 1-Allyl-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
2(1H)-one
methylpyridin-2(1H)-one 586379-17-1P, Methyl (2E)-4-[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenoate
586379-18-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-prop-2-
ynylpyridin-2(1H)-one 586379-21-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-
(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-23-9P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-
ylmethyl) pyridin-2(1H)-one 586379-24-0P, 3-Bromo-4-[(2,4-4)]
difluorobenzyl)oxy]-6-[(dimethylamino)methyl]-1-(pyridin-3-
ylmethyl)pyridin-2(1H)-one
                                                                      586379-29-5P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-
              586379-31-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586379-32-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(morpholin-4-
ylmethyl)pyridin-2(1H)-one
                                                                      586379-33-1P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[[(2-
methoxyethyl)amino]methyl]pyridin-2(1H)-one
                                                                                                              586379-34-2P,
5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-
dihydropyridine-2-carboxylic acid 586379-35-3P, Methyl
4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
                                         586379-38-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylbenzoate
methyl-1-(2-methyl-4-carboxyphenyl) pyridin-2(1H)-one 586379-39-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-
(hydroxymethyl)phenyl]pyridin-2(1H)-one
                                                                                                   586379-40-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methy
methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                                                   586379-41-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-
[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                                          586379-46-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2-indiploxed for a context of the context of th
methylphenyl]-6-methylpyridin-2(1H)-one
                                                                                                   586379-47-7P, Methyl
3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-incomposition and the second contract of the second contract o
                                         586379-50-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
chlorobenzoate
methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoic acid 586379-54-6P,
```

```
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-
6-methylpyridin-2(1H)-one 586379-57-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[5-[(dimethylamino)methyl]-2-methylphenyl]-6-
                                                                                                                                     586379-59-1P, 3-Bromo-4-[(2,4-
methylpyridin-2(1H)-one hydrochloride
difluorobenzyl)oxy]-1-[5-[(isopropylamino)methyl]-2-methylphenyl]-6-
methylpyridin-2(1H)-one hydrochloride 586379-60-4P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-
                                                          586379-65-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-
methylbenzamide
[[(2-methoxyethyl)amino]carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-
                     586379-67-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-
[(dimethylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one
586379-68-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-
(morpholinocarbonyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one
586379-69-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1-hydroxy-1-
methylethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-71-7P,
Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]-4-methylbenzoate 586379-76-2P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-
1-(3-fluorobenzyl)pyridin-2(1H)-one 586379-78-4P, 3-Bromo-1-(3-
\verb|fluorobenzyl| -4-[[3-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one|\\
586379-79-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-fluoro-2-
(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one
                                                                                                                                                                        586379-80-8P,
3-Bromo-4-[(4-chloro-2-fluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-
                     586379-81-9P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-
(pyridin-4-ylmethyl) pyridin-2(1H)-one 586379-83-1P, 3-Bromo-4-[(2,4-
difluorobenzyl)amino]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
586379-85-3P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-
6-methylpyridin-2(1H)-one trifluoroacetate 586379-87-5P,
3-Chloro-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-
methylpyridin-2(1H)-one 586379-88-6P, 3-[[3-Chloro-4-[(2,4-
difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
586379-91-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]benzonitrile 586379-93-3P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-
2(1H)-one trifluoroacetate 586380-00-9P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-
methylbenzamide
                                                           586380-01-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-1-[2-fluoro-5-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one
586380-02-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-03-2P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(4-difluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzy
methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
(morpholinocarbonyl)phenyl]pyridin-2(1H)-one
                                                                                                                                                                586380-05-4P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-fluoro-5-[(2-flu
methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                                                                                                               586380-06-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-fluorobenzyl)oxy]]-6-methyl-1-[2-fluorobenzyl]oxy]-6-methyl-1-[2-fluorobenzyl]oxy
hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
586380-07-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[[(3-hydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                                                                                                                                586380-08-7P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2,3-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2,3-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2,3-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(3,3-difluorobenzyl)oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluorobenzyl]oxy]-6-methyl-1-[3-fluor
dihydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                                                                                                                    586380-09-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[(2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[2-fluoro-5-[](2-hydroxy-1)oxy]-6-methyl-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hydroxy-1)oxy-1-[](2-hy
1,1-dimethylethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-10-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
(piperazinocarbonyl)phenyl]pyridin-2(1H)-one
                                                                                                                                                             586380-17-8P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-incomplex of the second context of 
methoxy-N-methylbenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
           (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
```

kinase for treatment of inflammatory conditions,
ischemia, viral infections, autoimmune diseases, and other
conditions)

ΙT 586380-18-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)]-6-methyl-2-oxo-2Hpyridin-1-yl]-4-methoxy-N, N-dimethylbenzamide 586380-21-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4fluoro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide 586380-22-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(acetylamino)methyl]phenyl]pyridin-2(1H)-one 586380-23-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methoxyacetylamino)methyl]phenyl]pyridin-2(1H)-one 586380-24-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(methylsulfonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-25-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(aminocarbonylamino)methyl]phenyl]pyridin-2(1H)-one 586380-27-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[(methoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-28-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(trifluoromethy1)carbony1]amino]methy1]benzy1]oxy]pyridin-2(1H)-one 586380-29-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[(isopropoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-30-5P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(ethylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-31-6P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tetrahydrofuran-3-yloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-586380-32-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[(propoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-33-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(allyloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-34-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(propargyloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-35-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(tert-butoxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-36-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[[(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-37-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[(propylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-38-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[(ethylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(isopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-40-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methoxymethyl)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-41-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(methylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one 586380-42-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[[N-methyl-N-(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-586380-43-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-2(1H)-one fluoro-2-[[[(cyclopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-586380-44-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-2(1H)-one fluoro-2-[[[[(2,2,2-trifluoroethyl)amino]carbonyl]amino]methyl]benzyl]oxy] 586380-45-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 4-[[4-fluoro-2-[[[((cyclopropylmethyl)amino]carbonyl]amino]methyl]benzyl]o 586380-46-3P, 3-Chloro-1-(2,6-difluorophenyl)-6xy]pyridin-2(1H)-one methyl-4-[[4-fluoro-2-[[[(2,2-dimethylpropylamino)carbonyl]amino]methyl]be nzyl]oxy]pyridin-2(1H)-one 586380-47-4P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-[[[(dimethylamino)carbonyl]amino]methyl]benzyl]oxy ]pyridin-2(1H)-one 586380-48-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-586380-50-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one

```
586380-52-1P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylnicotinamide
586380-55-4P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2-hydroxyethyl)nicotinamide
                                                                               586380-56-5P,
6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N,N-dimethylnicotinamide
                                                     586380-57-6P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-
         586380-66-7P, Carbamic acid [5-bromo-4-[(2,4-difluorobenzyl)]]
(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridin-3-yl]methyl ester
586380-68-9P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-
methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile 586380-69-0P,
4-(Benzyloxy)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-
         586380-70-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
difluorophenyl)-6-methyl-5-(oxiran-2-yl)pyridin-2(1H)-one 586380-71-4P,
4-(Benzylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-
                586380-72-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
2(1H)-one
difluorophenyl)-6-methyl-5-((E)-2-phenylethenyl)pyridin-2(1H)-one
586380-74-7P, 4-(Allylamino)-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-
               586380-76-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-5'-(1-
2(1H)-one
hydroxy-1-methylethyl)-6-methyl-2H-1,2'-bipyridin-2-one 586380-77-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(furyl-2-ylmethyl)-6-methylpyridin-
                 586380-78-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
2(1H)-one
(thien-2-ylmethyl) pyridin-2(1H)-one 586380-79-2P, 3-Bromo-1-(2,6-
difluorophenyl)-4-(furyl-2-ylmethoxy)-6-methylpyridin-2(1H)-one
586380-80-5P, 3-Bromo-1-[2-fluoro-6-(furyl-3-ylmethoxy)phenyl]-4-(furyl-3-
ylmethoxy)-6-methylpyridin-2(1H)-one 586380-81-6P, 3-Bromo-1-[2-fluoro-6-
(thien-3-ylmethoxy)phenyl]-6-methyl-4-(thien-3-ylmethoxy)pyridin-2(1H)-one
586380-86-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-(1-hydroxy-1-methylethyl)-N-methylbenzamide
586380-89-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-methylbenzamide
                                               586380-91-8P
                                                                       586380-92-9P,
N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-
4-fluorobenzyl] propanamide 586380-93-0P, N-[3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-N',N'-
                   586380-94-1P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
dimethylurea
methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxyacetamide
586380-95-2P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-fluorobenzyl]-2-hydroxy-2-methylpropanamide
                                                                                          586380-96-3P
586380-97-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-fluorobenzamide
                                                 586380-98-5P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-
methylbenzamide
                          586380-99-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N, N-dimethylbenzamide
586381-00-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-[(4-
methylpiperazin-1-yl)carbonyl]phenyl]-6-methylpyridin-2(1H)-one
586381-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586381-02-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methy
hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
586381-03-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[[(2-hydroxy-2-methylpropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
586381-09-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N, N-dimethylbenzamide
                                                                 586381-10-4P,
4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzamide
                                                                           586381-11-5P,
N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-2-hydroxyacetamide
                                              586381-14-8P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide
586381-17-1P, 1-(3-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
                                     586381-18-2P, N-[4-[[3-Bromo-4-[(2,4-
methylpyridin-2(1H)-one
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide
```

```
586381-19-3P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]phenyl]-2-hydroxyacetamide
                                                                                                                                           586381-20-6P,
N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]phenyl]-2-acetoxyacetamide
                                                                                                              586381-21-7P
                                                                                                                                                        586381-22-8P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
v_1]methyl]phenyl]acetamide 586381-23-9P, N-[4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-
                                 586381-24-0P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl|methyl|benzyl|-N'-(2-hydroxy-2-
methylpropyl)urea 586381-25-1P, N-[4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]piperidine-1-carboxamide
                                                                                                                              586381-26-2P,
N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]morpholine-4-carboxamide 586381-27-3P,
N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]piperazine-1-carboxamide hydrochloride 586381-28-4P,
N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-N'-(2-hydroxyethyl)urea 586381-29-5P,
N'-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-N,N-dimethylurea 586381-30-8P, N-[4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-4-
hydroxypiperidine-1-carboxamide 586381-31-9P, 4-[[3-Bromo-4-[(2,4-
difluorobenzy1)oxy]-6-methy1-2-oxo-2H-pyridin-1-y1]methy1]-N,N-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weighty1-weight
dimethylbenzenesulfonamide 586381-32-0P, 4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-methyl)oxyl-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-methyl-2-oxo-2H-pyridin-1-yl)methyl]-N-(2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2H-pyridin-1-yl)methyl-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-wall-2-oxo-2-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-
methylpropyl)benzenesulfonamide 586381-38-6P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one
586381-43-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-y1]methy1]-1,3-dihydroindol-2-one 586381-45-5P,
N-[[5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrazin-2-yl]methyl]-N-methylmethanesulfonamide 586381-46-6P,
Methyl [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-
1-yl]methyl]pyrazin-2-yl]methyl(methyl)carbamate
                                                                                                                                                 586381-47-7P
586381-48-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)pyrazine-2-carboxamide
586381-50-2P, 1-[(5-Aminopyrazin-2-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-bromo-4-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4-yl)methyl]-3-[(2,4
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
1,2,4-triazin-6-yl)methyl]pyridin-2(1H)-one trifluoroacetate
586381-54-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)-6-
methylpyridin-2(1H)-one 586381-56-8P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one
586381-65-9P, Methyl [2-[[[3-bromo-1-[5-[[(2-hydroxyethyl)amino]carbonyl]-
2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]carbamate 586381-66-0P, Methyl [2-[[[3-bromo-1-[5-[[(2-
hydroxy-2-methylpropyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-
dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate
                                                                                                                                                                          586381-67-1P,
Methyl [2-[[[3-bromo-1-[5-[[(2-methoxyethyl)amino]carbonyl]-2-
methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]carbamate 586381-68-2P, O-Methyl [2-[[[1-[5-(aminocarbonyl)-
2-methylphenyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-
5-fluorobenzyl]carbamate 586381-69-3P, N-[2-[[[3-Chloro-1-(2,6-
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]-N'-phenylurea 586381-70-6P, (Thien-3-yl)methyl
 [2-[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-4-nethyl-2-oxo-1,2-dihydropyridin-
yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-71-7P, Ethyl
[2-[[3-bromo-6-methyl-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-browned]
1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate
                                         586381-83-1P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-
586381-75-1P
```

```
[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate
586381-87-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-
oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
                                                               586381-88-6P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-
1-y1]-N-(2-hydroxyethy1)-4-methylbenzamide 586381-90-0P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-
[1-y1]-4-methylbenzamide 586381-91-1P, [5-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-6-oxo-1,6-
dihydropyridin-2-yl]methyl acetate 586381-92-2P, (2E)-4-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-methyl-2-butenamide
586381-97-7P
                      586381-98-8P
                                            586381-99-9P
                                                                 586382-00-5P 586382-01-6P,
Carbamic acid 2-[3-bromo-4-[(2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-[(methylamino)carbonyl]benzyl ester 586382-06-1P,
Carbamic acid 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-difluorobenzyl)oxyl-6-methyl-2-oxo-2H-difluorobenzyl
pyridin-1-yl]-3,5-difluorobenzyl ester 586382-07-2P,
N-[4-[(3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-2-hydroxyacetamide 586382-09-4P, N-[4-[[3-Chloro-4-
[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-
hydroxycyclopropanecarboxamide 586382-10-7P, Carbamic acid
4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl ester 586382-11-8P, (S)-2-[[4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-1-
methyl-2-oxoethyl acetate 586382-12-9P, 2-[[4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-
1,1-dimethyl-2-oxoethyl acetate 586382-13-0P, [1-[3-
(Aminocarbonyl)phenyl]-5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxo-1,6-
dihydropyridin-2-yl]methyl acetate 586382-20-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-
yl]methyl]pyridin-2(1H)-one 586382-22-1P, Ethyl [2-[[[3-bromo-1-[5-[[(2-
hydroxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-
dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586382-24-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1H-imidazol-2-yl)-2-
methylphenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586382-25-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(5-hydroxy-1H-pyrazol-3-yl)-2-
methylphenyl]-6-methylpyridin-2(1H)-one
                                                            586382-27-6P 586382-28-7P
586382-29-8P, Methyl 4-[[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-
yl]methyl]benzoate
                              586382-32-3P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furamide
                                                                           586382-34-5P,
5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
                586382-38-9P, 1-[3,5-Bis(hydroxymethyl)phenyl]-3-bromo-4-[(2,4-
                                                                     586382-43-6P,
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
vl]isophthalamide
                            586382-44-7P, 1-[3,5-Bis(1-hydroxy-1-
methylethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                 586382-45-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-
2(1H)-one
(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one
                                                                           586382-47-0P,
1-(5-Amino-2-fluorophenyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one hydrochloride 586382-49-2P, N-[3-[3-Bromo-4-
[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-
                               586382-51-6P, N-[3-[3-Bromo-4-[(2,4-
2-hydroxyacetamide
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-
hydroxy-2-methylpropanamide 586382-53-8P, 4-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluoro-N,N-
dimethylbenzamide
                             586382-55-0P
                                                  586382-56-1P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
indol-5-yl]methyl]-6-methylpyridin-2(1H)-one
                                                                   586382-57-2P,
 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-(methoxyacetyl)-2,3-dihydro-1H-1]-1-[(1-
indol-5-yl]methyl]-6-methylpyridin-2(1H)-one 586382-58-3P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N,N-dimethylindoline-1-carboxamide 586382-59-4P
586382-60-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-1-[]]
```

```
2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                  586382-61-8P,
         5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-N,N-
         dimethylindoline-1-carboxamide
                                                                        586382-62-9P, 1-Benzyl-4-(benzyloxy)-3-
                                                        586382-63-0P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-
         bromopyridin-2(1H)-one
         fluorobenzyl)oxy]pyridin-2(1H)-one
                                                                                586382-64-1P, 4-(Benzyloxy)-3-bromo-1-
         (4-fluorobenzyl)pyridin-2(1H)-one 586382-65-2P, 4-(Benzyloxy)-3-bromo-1-
         [4-(methylthio)benzyl]pyridin-2(1H)-one
                                                                                            586382-66-3P,
         1-\text{Benzyl}-4-(\text{benzyloxy})-3-\text{chloropyridin}-2(1\text{H})-\text{one} 586382-67-4P,
         3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-fluorobenzyl)pyridin-2(1H)-one
         586382-68-5P, 1-Benzyl-3-bromo-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one
         586382-69-6P, 3-Bromo-1-(4-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-
                               586382-70-9P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-[2-
         (phenylthio)ethyl]pyridin-2(1H)-one 586382-71-0P, 3-Bromo-4-[(4-
         chlorobenzyl)oxy]-1-(2-phenylethyl)pyridin-2(1H)-one
                                                                                                                    586382-72-1P
         586382-73-2P, 1-Benzyl-2-oxo-4-phenoxy-1,2-dihydropyridine-3-
         carboxaldehyde 586382-74-3P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(
         methoxybenzyl)pyridin-2(1H)-one 586382-75-4P, 3-Bromo-4-[(4-
         fluorobenzyl)oxy]-1-(3-phenylpropyl)pyridin-2(1H)-one 586382-76-5P,
         1-Benzyl-4-(benzyloxy)-3-(hydroxymethyl)pyridin-2(1H)-one 586382-77-6P,
         3-Bromo-1-(4-methylbenzyl)-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-one
         586382-78-7P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-
                               586382-79-8P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-
         fluorobenzyl)oxy]pyridin-2(1H)-one 586382-80-1P, 5-Bromo-1-(2-chloro-6-
         fluorobenzyl)-3-methylpyridin-2(1H)-one
                                                                                          586382-81-2P,
         1-Benzyl-4-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
         586382-82-3P, 1-Benzyl-4-chloro-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
         586382-83-4P, 1-Benzyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-
         carboxaldehyde
                                          586382-84-5P, 1-Benzyl-4-(benzyloxy)-3-methylpyridin-
         2(1H)-one
                                586382-85-6P, 4-(Benzyloxy)-1-(4-fluorobenzyl)pyridin-2(1H)-
                     586382-86-7P, 1-Benzyl-4-(benzyloxy)-3,5-dibromopyridin-2(1H)-one
         one
         586382-87-8P, 1-Benzyl-3-bromo-4-(3-phenylpropyl)pyridin-2(1H)-one
         586382-88-9P, 1-Benzyl-3-methyl-4-(2-phenylethyl)pyridin-2(1H)-one
         586382-89-0P, 1-Benzyl-3-methyl-4-(3-phenylpropyl)pyridin-2(1H)-one
         586382-90-3P, 1-Benzyl-4-(benzylthio)-3-methylpyridin-2(1H)-one
         586382-91-4P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate
         586382-92-5P, 6-(Benzyloxy)-1-methyl-2-oxo-1, 2-dihydropyridine-3-
         carbonitrile
                                    586382-93-6P, 3-Benzoyl-6-(benzyloxy)-1-methylpyridin-2(1H)-
                     586382-94-7P, 3-Benzyl-6-(benzyloxy)-1-methylpyridin-2(1H)-one
         586382-95-8P, 1-Benzyl-4-(benzylthio)pyridin-2(1H)-one
         4-Amino-1-benzylpyridin-2(1H)-one
                                                                               586382-97-0P, 4-[(2,6-
         Dichlorobenzyl)oxy]pyridine-1-oxide
                                                                                    586382-98-1P, 3-Bromo-1-(3-
         fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586382-99-2P
         586383-00-8P, 1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-3-chloro-4-[(2,4-
         difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-01-9P,
         3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-
         2,3-dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-02-0P,
         3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,3-(N-methylglycyl)-2,
                                                                                         586383-03-1P
         dihydro-1H-indol-5-yl]pyridin-2(1H)-one
, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-dihydro-1H-
         indol-5-yl]-6-methylpyridin-2(1H)-one 586383-04-2P, 3-Chloro-4-[(2,4-
         difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-indol-
         5-y1]-6-methylpyridin-2(1H)-one 586383-05-3P, 5-[3-Chloro-4-[(2,4-1)]-6-methylpyridin-2(1H)-one
         difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]indoline-1-carboxamide
         586383-06-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-
         (methylsulfonyl)-2,3-dihydro-1H-indol-5-yl]pyridin-2(1H)-one
         586383-07-5P, 1-(1-Acetyl-1H-indol-5-yl)-3-chloro-4-[(2,4-
         difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                        586383-08-6P
         586383-09-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-
         methylpropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-10-0P,
         3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
         indol-5-yl]pyridin-2(1H)-one 586383-11-1P, 3-Chloro-4-[(2,4-
```

```
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-indol-5-yl]-6-
methylpyridin-2(1H)-one 586383-12-2P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6-indol-5-yl]-6
methylpyridin-2(1H)-one 586383-13-3P, 5-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-indole-1-
                                                                   586383-14-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-indol-5-yl]pyridin-2(1H)-one 586383-15-5P,
1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4
difluorobenzyl)oxyl-6-methylpyridin-2(1H)-one
                                                                                                                                                                                                                                                                      586383-16-6P
586383-17-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
586383-18-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzyl)oxy]-6-methyl-1-[2-(N-difluorobenzy
methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one
586383-20-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-d
hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
586383-21-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-
methylbutanoy1)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
586383-22-4P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide 586383-23-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-2,3-
dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-24-6P,
1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3-(2-yl)-3
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-25-7P
586383-26-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-
                                 586383-27-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-final content of the con
methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-yl] pyridin-2(1H)-one
586383-28-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-d
hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-
                                                           586383-29-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-d
2(1H)-one
hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-
methylpyridin-2(1H)-one
                                                                                                                                     586383-30-4P, 6-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-
dihydroisoquinoline-2(1H)-carboxamide 586383-31-5P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-
tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one
                                                                                                                                                                                                                                                       586383-32-6P,
1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-33-7P
586383-34-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-
                                 586383-35-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-
methylglycyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one
586383-36-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-
hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-
                                                                586383-37-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-d
hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-
methylpyridin-2(1H)-one 586383-38-2P, 7-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-
                                                                                                                                                                                                                  586383-39-3P, 3-Chloro-4-[(2,4-
dihydroisoguinoline-2(1H)-carboxamide
difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-
tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one
                                                                                                                                                                                                                                                           586383-40-6P,
1-(1-Acetyl-1H-benzimidazol-5-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                                                                                                                                             586383-41-7P 586383-42-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
                                                                                                                                                                                                                                                         586383-43-9P,
benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
benzimidazol-5-yl] pyridin-2(1H)-one
                                                                                                                                                                                                               586383-44-0P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-benzimidazol-5-yl]-6-
methylpyridin-2(1H)-one 586383-45-1P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-benzimidazol-5-
yl]-6-methylpyridin-2(1H)-one 586383-47-3P,
```

```
benzimidazole-1-carboxamide 586383-48-4P, 3-Chloro-4-[(2,4-4)]
            difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-1H-benzimidazol-5-
            yl]pyridin-2(1H)-one 586383-49-5P, 3-Chloro-1-(1,3-diacetyl-2,3-dihydro-
            1H-benzimidazol-5-yl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-
                           586383-50-8P
                                                               586383-51-9P, 1-[3-Acetyl-1-(2-hydroxy-2-
            methylpropanoy1)-2,3-dihydro-1H-benzimidazo1-5-y1]-3-chloro-4-[(2,4-
            difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-52-0P,
            1-[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-
            4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                                                                         586383-53-1P,
            1-[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-
            chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
            586383-54-2P, 1-[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
            benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                                          586383-55-3P, 3-Acetyl-5-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-
            2(1H)-one
            6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide
            RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
             (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
             (Uses)
                     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
                    kinase for treatment of inflammatory conditions,
                    ischemia, viral infections, autoimmune diseases, and other
                    conditions)
ΙT
            586383-56-4P
                                                  586383-57-5P
                                                                                       586383-58-6P
                                                                                                                             586383-59-7P
                                                                                                                                                                  586383-60-0P
            586383-61-1P
                                                 586383-62-2P
                                                                                       586383-63-3P
                                                                                                                             586383-64-4P,
            1-[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-
            yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
            586383-65-5P, 1-[1,3-Bis(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-methylpropanoyl)
            benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                                          586383-66-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-
            2(1H)-one
            hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-
            5-y1]-6-methylpyridin-2(1H)-one 586383-67-7P, 3-Chloro-4-[(2,4-
            difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(3-
            hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
                           586383-68-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-
            methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
            benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
                                                                                                                                 586383-69-9P,
            5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
            (2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-benzimidazole-1-carboxamide
            586383-70-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-
            methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-
            methylpyridin-2(1H)-one
                                                                         586383-71-3P, 1-[1-Acetyl-3-(N-methylglycyl)-2,3-
            dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
            methylpyridin-2(1H)-one
                                                                             586383-72-4P 586383-73-5P,
            3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-
            (N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
                           586383-74-6P, 1-[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-
            5-y1]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
            586383-75-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl]oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl]oxy]-1-[1-(3-4-d
            hydroxypropanoy1)-3-(N-methylglycy1)-2,3-dihydro-1H-benzimidazol-5-yl]-6-
                                                                          586383-76-8P, 3-Chloro-4-[(2,4-
            methylpyridin-2(1H)-one
            difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-
            2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
            586383-77-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
            pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-
                                               586383-78-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
            carboxamide
            1-[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidazol-5-(methylsulfonyl)-3,3-dihydro-1H-benzimidaz
            yl]pyridin-2(1H)-one
                                                                     586383-79-1P, 1-[1-Acetyl-3-(3-hydroxypropanoyl)-
            2, 3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2, 4-difluorobenzyl)oxy]-6-difluorobenzyl)oxyl-6-difluorobenzyl)oxyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difluorobenzyl-6-difl
                                                                             586383-80-4P
            methylpyridin-2(1H)-one
                                                                                                                586383-81-5P,
            3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-
```

5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-

```
(3-hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-
                                  586383-82-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-d
2(1H)-one
\label{localization} \verb|hydroxypropanoyl|) - 1 - (\verb|N-methylglycyl|) - 2, 3 - dihydro - 1 + benzimidazol - 5 - yl] - 6 - benzimidazol - 5 - yl] - 5 -
methylpyridin-2(1H)-one 586383-83-7P, 1-[1,3-Bis(3-hydroxypropanoy1)-2,3-
dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586383-84-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(3-
hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
                 586383-85-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-
2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-
carboxamide 586383-86-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-
hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-
methylpyridin-2(1H)-one
                                                                        586383-87-1P, 1-[1-Acetyl-3-(3-hydroxy-3-
methylbutanoy1)-2,3-dihydro-1H-benzimidazol-5-y1]-3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-88-2P
586383-89-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-
methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
benzimidazol-5-y1]-6-methylpyridin-2(1H)-one 586383-90-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-[3-(3-hydroxy-3-methylbutanoyl)]
(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
                 586383-91-7P, 1-[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                               586383-92-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide 586383-93-9P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-
2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
586383-94-0P, 3-Acetyl-6-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide
586383-95-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-
                                          586383-96-2P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
1-carboxamide
methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide 586383-97-3P, 6-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-
2,3-dihydro-1H-benzimidazole-1-carboxamide
                                                                                                                               586383-98-4P,
6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586383-99-5P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-1H-benzimidazole-1,3(2H)-dicarboxamide
                                                                                                                                                             586384-00-1P,
6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586384-01-2P, 1-[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
y1]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586384-02-3P
                                           586384-03-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-
hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-
                                                                                                 586384-04-5P, 3-Chloro-4-[(2,4-
5-yl]-6-methylpyridin-2(1H)-one
difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-
dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586384-05-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[-1-(3-hydroxypropanoyl)-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
                 586384-06-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy-3-[1-(3-hydroxy-3-1)oxy]-1-[1-(3-hydroxy-3-1)oxy-3-[1-(3-hydroxy-3-1)oxy-3-[1-(3-hydroxy-3-1)oxy-3-[1-(3-hydroxy-3-1)oxy-3-[1-(3-hydroxy-3-1)oxy-3-[1-(3-hydroxy-3-1)oxy-3-[1-(3-hydroxy-3-1)oxy
methylbutanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-
methylpyridin-2(1H)-one
                                                                         586384-07-8P, 5-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-
dihydro-1H-benzimidazole-1-carboxamide
                                                                                                                  586384-08-9P,
1-[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                                                                          586384-09-0P,
1-[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5-yl]-3-chloro-1H-benzimidazol-5
4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586384-10-3P,
1-(1-Acetyl-1H-pyrrol-3-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
```

```
methylpyridin-2(1H)-one
                         586384-11-4P
                                       586384-12-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
pyrrol-3-yl]-6-methylpyridin-2(1H)-one 586384-13-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
pyrrol-3-yl]pyridin-2(1H)-one 586384-14-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrrol-3-yl]-6-
methylpyridin-2(1H)-one 586384-15-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrrol-3-yl]-6-
methylpyridin-2(1H)-one 586384-16-9P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrrole-1-
carboxamide 586384-17-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one
                                                       586384-18-1P,
1-(1-Acetyl-1H-imidazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                        586384-19-2P 586384-20-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-individual (2,4-difluorobenzyl)oxy]
imidazol-4-yl]-6-methylpyridin-2(1H)-one
                                          586384-21-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
imidazol-4-yl]pyridin-2(1H)-one 586384-22-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-imidazol-4-yl]-6-
                        586384-23-8P, 3-Chloro-4-[(2,4-
methylpyridin-2(1H)-one
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-imidazol-4-yl]-6-
methylpyridin-2(1H)-one 586384-24-9P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-imidazole-1-
             586384-25-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
carboxamide
1-[1-(methylsulfonyl)-1H-imidazol-4-yl] pyridin-2(1H)-one
                                                          586384-26-1P,
1-(1-Acetyl-1H-pyrazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586384-27-2P 586384-28-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-29-4P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
pyrazol-4-yl]pyridin-2(1H)-one
                                586384-30-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrazol-4-yl]-6-
methylpyridin-2(1H)-one 586384-31-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrazol-4-yl]-6-
methylpyridin-2(1H)-one 586384-32-9P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrazole-1-
             586384-33-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-34-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-isoquinolin-7-yl-6-methylpyridin-
            586384-35-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
2(1H)-one
(isoquinolin-6-ylmethyl)pyridin-2(1H)-one
                                           586384-36-3P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-
dihydro-2H-indol-2-one
                        586384-37-4P, 1-[(1-Acetyl-2,3-dihydro-1H-indol-5-
y1)methy1]-3-chloro-4-[(2,4-difluorobenzy1)oxy]pyridin-2(1H)-one
586384-38-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one
586384-39-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-1]]
2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-40-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-
dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-41-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-
2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-42-1P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]indoline-1-carboxamide
                                 586384-43-2P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-
                             586384-44-3P, 3-Chloro-4-[(2,4-
yl]methyl]pyridin-2(1H)-one
difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-
one
      586384-45-4P, 1-[(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)methyl]-3-
chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586384-46-5P
586384-47-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one
```

```
586384-48-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1]]
2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                                    586384-49-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-2,3-
dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-50-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-
2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                                        586384-51-2P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-
dihydro-2H-isoindole-2-carboxamide 586384-52-3P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-
y1]methy1]pyridin-2(1H)-one 586384-53-4P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[(1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-
                            586384-54-5P, 1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-
y1)methy1]-3-chloro-4-[(2,4-difluorobenzy1)oxy]pyridin-2(1H)-one
                                    586384-56-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-
586384-55-6P
hydroxy-2-methylpropanoy1)-1,2,3,4-tetrahydroisoquinolin-6-
yl]methyl]pyridin-2(1H)-one 586384-57-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-
yl]methyl]pyridin-2(1H)-one 586384-58-9P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-
tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-59-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-
1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one
586384-60-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
vl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide
                                                                                                                                    586384-61-4P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-individual fonyl)]
tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-62-5P,
1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllameth
difluorobenzyl)oxy] pyridin-2(1H)-one 586384-63-6P 586384-64-7P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl)-1-[[2-(2-hydroxy-2-methylpropanoyl]-1-[2-(2-hydroxy-2-methylpropanoyl]-1-[[2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpropanoyl]-1-[-2-(2-hydroxy-2-methylpro
1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one
586384-65-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1]]
1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-66-9P
, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-hydroxypropanoyl)]
tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one 586384-67-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-
1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one
586384-68-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide
                                                                                                                                    586384-69-2P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-
tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                                   586384-70-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-benzimidazol-5-
yl)methyl]pyridin-2(1H)-one
                                                                      586384-71-6P, 1-[(1-Acetyl-2,3-dihydro-1H-
benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-
2(1H)-one
                             586384-72-7P 586384-73-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
                                                                                                         586384-74-9P,
benzimidazol-5-yl]methyl]pyridin-2(1H)-one
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-75-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-
dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-76-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-
2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                                                586384-77-2P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-
dihydro-1H-benzimidazole-1-carboxamide
                                                                                                586384-78-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                           586384-79-4P,
1-[(3-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-dihydro-1H-benzimidazol-5-yl)methyllagol-5-[(2,4-dihydro-1H-benzimidazol-5-yl)methyllagol-5-[(2,4-dihydro-1H-benzimidazol-5-yl)methyllagol-5-[(2,4-dihydro-1H-benzimidazol-5-yl)methyllagol-5-[(2,4-dihydro-1H-benzimidazol-5-yl)methyllagol-5-[(2,4-dihydro-1H-benzimidazol-5-yl)methyllagol-5-[(2,4-dihydro-1H-benzimidazol-5-yl)methyllagol-5-[(2,4-dihydro-1H-benzimidazol-5-[(2,4-dihydro-1H-benzimidazol-5-[(2,4-dihydro-1H-benzimidazol-5-[(2,4-dihydro-1H-benzimidazo
difluorobenzyl)oxy] pyridin-2(1H)-one 586384-80-7P, 3-Chloro-1-[(1,3-
diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-4-[(2,4-
difluorobenzyl)oxy] pyridin-2(1H)-one 586384-81-8P
                                                                                                                                    586384-82-9P,
1-[[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-
```

```
yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
     586384-83-0P, 1-[[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-
     5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
     586384-84-1P, 1-[[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-
     benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
                                                            586384-85-2P, 1-[[3-Acetyl-1-(3-hydroxy-3-
     pyridin-2(1H)-one
     methylbutanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
     difluorobenzyl)oxy]pyridin-2(1H)-one 586384-86-3P, 3-Acetyl-5-[[3-chloro-
     4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-
     benzimidazole-1-carboxamide 586384-87-4P, 1-[[3-Acetyl-1-
      (methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
     difluorobenzyl)oxy]pyridin-2(1H)-one
                                                                                                                   586384-88-5P
                                                                                                                                                                586384-89-6P
     586384-90-9P
                                                586384-91-0P
                                                                                         586384-92-1P
                                                                                                                                      586384-93-2P
                                                                                                                                                                                  586384-94-3P
                                                586384-96-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-
     586384-95-4P
     hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-
                                   586384-97-6P, 1-[[1-Acetyl-3-(2-hydroxy-2-methylpropanoy1)-2,3-
     2(1H)-one
     dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
                                                           586384-98-7P 586384-99-8P, 1-[[1,3-Bis(2-hydroxy-2-
     pyridin-2(1H)-one
     methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
     difluorobenzyl)oxy]pyridin-2(1H)-one 586385-00-4P, 3-Chloro-4-[(2,4-
     difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-
     2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                                                                               586385-01-5P,
     (3-hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
                       586385-02-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-
     3-methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
     benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-03-7P,
     5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
      (2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-benzimidazole-1-carboxamide
     586385-04-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hydroxy-2-hy
     methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
     v1] methyl] pyridin-2(1H)-one 586385-05-9P, 3-Chloro-4-[(2,4-
     difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
     yl]methyl]pyridin-2(1H)-one 586385-06-0P, 1-[[1-Acetyl-3-(N-
     methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
     difluorobenzyl)oxy]pyridin-2(1H)-one 586385-07-1P
                                                                                                                                                                 586385-08-2P,
     3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-
      (N-methylqlycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
     586385-09-3P, 1-[[1,3-Bis(N-methylqlycyl)-2,3-dihydro-1H-benzimidazol-5-
     yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
     586385-10-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]ox
     hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
     yl]methyl]pyridin-2(1H)-one
586385-11-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hydroxy-3-1)]-1-[1-(3-hy
     methylbutanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
                                                                                         586385-12-8P, 5-[[3-Chloro-4-[(2,4-
     yl]methyl]pyridin-2(1H)-one
     difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2,3-
     dihydro-1H-benzimidazole-1-carboxamide
                                                                                                                      586385-13-9P,
     3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(N-methylglycyl)-1-[3-(
      (methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
     hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
                       586385-15-1P, 1-[[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-
     benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
                                                           586385-16-2P
                                                                                                     586385-17-3P, 3-Chloro-4-[(2,4-
     pyridin-2(1H)-one
     difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(3-
     hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
     one
                       586385-18-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-
     hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
     yl]methyl]pyridin-2(1H)-one
                                                                                         586385-19-5P, 1-[[1,3-Bis(3-
     hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-
```

```
586385-20-8P.
[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-
(3-hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
         586385-21-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-
                   586385-22-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-
hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
v1] methyl] pyridin-2(1H)-one 586385-23-1P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-24-2P,
1-[[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
586385-25-3P
                   586385-26-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-
hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-27-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-
(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
586385-28-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-
methylbutanoy1)-1-(methylsulfony1)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]pyridin-2(1H)-one 586385-29-7P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-
methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
                                                                                       586385-30-0P,
1-[[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
586385-31-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-
methylbutanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-
y1]methy1]pyridin-2(1H)-one 586385-32-2P, 6-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-
benzimidazole-1-carboxamide
                                            586385-33-3P, 3-Acetyl-6-[[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-
                                            586385-34-4P, 6-[[3-Chloro-4-[(2,4-
benzimidazole-1-carboxamide
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-
methylpropanoy1)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-35-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-36-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-
carboxamide
                    586385-37-7P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl))]-2-oxo-
2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide
                                            586385-38-8P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1H-benzimidazole-1,3(2H)-
dicarboxamide
                       586385-39-9P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide
                                           586385-40-2P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
                                           586385-41-3P, 1-[[1-Acetyl-3-
yl]methyl]pyridin-2(1H)-one
(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
difluorobenzyl)oxy]pyridin-2(1H)-one 586385-42-4P
                                                                               586385-43-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
586385-44-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-
3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
         586385-45-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]oxy]-1-[1-(3-4)]ox
hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
                                           586385-46-8P, 3-Chloro-4-[(2,4-
yl]methyl]pyridin-2(1H)-one
difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-
2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                       586385-47-9P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-48-0P, 1-[[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
```

```
586385-49-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one
                                                                     586385-50-4P,
1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one
                                                                   586385-51-5P
586385-52-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-
         586385-53-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-1-(N-methylqlycyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-54-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-55-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-
         586385-56-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-57-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-[(3,4-difluorobenzyl)oxy]-2-[(3,4-difluorobenzyl)oxy]-2-[(3,4-difluorobenzyl)oxy]-2-[(3,4-difluorobenzyl)oxy]-2-[(3,4-diflu
yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-58-2P, 1-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-59-3P,
1,3-Diacetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one
                                                                    586385-60-6P
586385-61-7P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
benzimidazol-2-one 586385-62-8P, 3-Acetyl-5-[[3-chloro-4-[(2,4-4-4)]]]
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-
dihydro-2H-benzimidazol-2-one 586385-63-9P, 3-Acetyl-5-[[3-chloro-4-
[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-
hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
                                                                              586385-64-0P,
3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)]]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-
         586385-65-1P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
                   586385-66-2P, 3-Acetyl-5-[[3-chloro-4-[(2,4-
carboxamide
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(methylsulfonyl)-1,3-
dihydro-2H-benzimidazol-2-one
                                               586385-67-3P
                                                                      586385-68-4P
                                                                                            586385-69-5P
586385-70-8P
                     586385-71-9P
                                          586385-72-0P
                                                                586385-73-1P
                                                                                         586385-74-2P
586385-75-3P
                      586385-76-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
benzimidazol-2-one
                              586385-77-5P, 1-Acetyl-5-[[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-
methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
                                                                              586385-78-6P
586385-79-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-bis(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
                               586385-80-0P, 5-[[3-Chloro-4-[(2,4-
benzimidazol-2-one
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-
methylpropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
586385-81-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-1,3-
dihydro-2H-benzimidazol-2-one
                                             586385-82-2P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-
methylbutanoy1)-3-(2-hydroxy-2-methylpropanoy1)-1,3-dihydro-2H-
benzimidazol-2-one
                              586385-83-3P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-
methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-84-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
```

ΙΤ

```
yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-1,3-dihydro-
2H-benzimidazol-2-one 586385-85-5P, 6-[[3-Chloro-4-[(2,4-
dihydro-2H-benzimidazol-2-one 586385-86-6P,
1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)]]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-87-7P
              586385-88-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-(N-
methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-89-9P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-
bis(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
                                                       586385-90-2P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-
(3-hydroxypropanoy1)-3-(N-methylglycy1)-1,3-dihydro-2H-benzimidazol-2-one
586385-91-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
y1] methyl] -1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-1,3-dihydro-
2H-benzimidazol-2-one 586385-92-4P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-2-oxo-
2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-93-5P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(N-methylglycyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-94-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-95-7P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-
     586385-96-8P 586385-97-9P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-
methylpropanoy1)-3-(3-hydroxypropanoy1)-1,3-dihydro-2H-benzimidazol-2-one
586385-98-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(3-hydroxypropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-
                   586385-99-1P, 5-[[3-Chloro-4-[(2,4-
benzimidazol-2-one
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(3-
hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-00-7P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-
(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-
benzimidazol-2-one
                    586386-01-8P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2-
oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
                                               586386-02-9P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)]]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(3-hydroxypropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-03-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-
one
      586386-04-1P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-
benzimidazol-2-one
                    586386-05-2P
                                   586386-06-3P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-
methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
                    586386-07-4P, 5-[[3-Chloro-4-[(2,4-
benzimidazol-2-one
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-
methylbutanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-08-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-bis(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-
        586386-09-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-
benzimidazole-1-carboxamide
                             586386-10-9P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-
methylbutanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-11-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586386-12-1P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586386-13-2P
             586386-14-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
```

```
oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-
dihydro-1H-benzimidazole-1-carboxamide 586386-15-4P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(N-methylqlycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586386-16-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide
            586386-17-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-
1H-benzimidazole-1-carboxamide 586386-18-7P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-1H-benzimidazole-
1,3(2H)-dicarboxamide 586386-19-8P, 6-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2-oxo-
2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-20-1P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-
(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-21-2P,
1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
              586386-23-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
586386-22-3P
oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-
(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
                                                  586386-24-5P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-
(N-methylglycyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-25-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-
benzimidazol-2-one 586386-26-7P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-
methylbutanoy1)-3-(methylsulfony1)-1,3-dihydro-2H-benzimidazol-2-one
586386-27-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide
            586386-28-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
2H-pyridin-1-yl]methyl]-1,3-bis(methylsulfonyl)-1,3-dihydro-2H-
benzimidazol-2-one 586386-30-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-
fluorophenyl)ethynyl]-6-methylpyridin-2(1H)-one
                                               586386-31-4P,
3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzaldehyde
586386-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-
difluorophenyl]-6-methylpyridin-2(1H)-one
                                          586386-33-6P,
4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-
hydroxyethyl) (methyl) amino]phenyl]-6-methylpyridin-2(1H)-one
586386-34-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)-2-
methoxyphenyl]-6-methylpyridin-2(1H)-one
                                         586386-35-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-
yl)carbonyl]phenyl]pyridin-2(1H)-one
                                     586386-36-9P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-
(dimethylamino)ethyl]benzamide
                               586386-37-0P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-
                       586386-38-1P, 3-[3-Bromo-4-[(2,4-
methoxyethyl)benzamide
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-
(dimethylamino)ethyl]-N-methylbenzamide
                                       586386-39-2P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
(2-hydroxyethy1)-N-methy1benzamide 586386-40-5P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-N-
                586386-41-6P, 4-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-
methylbenzamide
oxo-2H-pyridin-1-yl]-3-methylbenzoic acid 586386-42-7P, Methyl
[2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-3,5-difluorobenzyl]carbamate 586386-43-8P,
ylcarbonyl)benzyl]-1H-pyridin-2-one
                                    586386-44-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(ethoxyamino)methyl]pyridin-
           586386-45-0P, N-(3-Aminopropyl)-4-[[3-bromo-4-[(2,4-
2(1H)-one
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide
               586386-46-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-
hydrochloride
```

```
indazol-5-ylmethyl)pyridin-2(1H)-one
                                                         586386-47-2P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-
methylpyridin-2(1H)-one hydrochloride 586386-48-3P, N-(2-Aminoethyl)-4-
[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
vl]methyl]benzamide hydrochloride 586386-49-4P, N-(2-Aminoethyl)-3-[3-
bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide
586386-50-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazin-
1-ylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride
                                                                              586386-51-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
[(dimethylamino)methyl]pyridin-2(1H)-one 586386-52-9P 586386-53-0P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
                            586386-54-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
isopropylbenzamide
methyl-1-[3-(morpholin-4-ylcarbonyl)benzyl]-1H-pyridin-2-one
586386-55-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N, N-bis(2-hydroxyethyl)benzamide 586386-56-3P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-hydroxybenzamide 586386-57-4P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(3-hydroxymethylbenzyl)-6-methyl-1H-pyridin-2-one
586386-58-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
(pyrrolidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-59-6P,
3-Bromo-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586386-60-9P, 3-Chloro-1-[2-chloro-5-
(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-
         586386-61-0P 586386-62-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide
586386-63-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586386-64-3P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N, N-dimethylbenzamide
                                                 586386-65-4P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide
586386-66-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-67-6P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                               586386-68-7P, 3-Bromo-4-[(2,4-
yl]methyl]-N-isopropylbenzamide
difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)phenyl]pyridin-
2(1H)-one
                 586386-69-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
[3-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one
                                                                              586386-70-1P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-
dimethylbenzamide
                             586386-71-2P, 4-(Benzylamino)-1-(3-fluorobenzyl)-6-
methyl-3-nitropyridin-2(1H)-one
                                                 586386-72-3P, tert-Butyl
4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]piperazine-1-
carboxylate
                    586386-73-4P, Ethyl [4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-
1-vl]acetate
                      586386-74-5P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-
dihydropyridin-4-yl]benzenesulfonamide
                                                            586386-75-6P,
N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-1-
                                       586386-76-7P, 3-Bromo-4-[(2,4-
phenylmethanesulfonamide
difluorophenyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                                                        586386-77-8P,
4-Anilino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-78-9P,
Methyl 4-[[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-
                            586386-79-0P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3,4,5-
vl]amino|benzoate
trimethoxyphenyl)amino]pyridin-2(1H)-one
                                                               586386-80-3P,
3-Bromo-1-(3-fluorobenzyl)-4-[4-(4-fluorophenyl)piperazin-1-yl]pyridin-
                 586386-82-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-methylpiperazin-
2(1H)-one
1-yl)pyridin-2(1H)-one trifluoroacetate
                                                              586386-83-6P,
N-[3-Bromo-1-(3-fluorobenzy1)-2-oxo-1,2-dihydropyridin-4-y1]-2,5-indin-4-y1]
                             586386-84-7P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-
difluorobenzamide
dihydropyridin-4-yl]-2,4-difluorobenzamide
                                                               586386-85-8P,
3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoic acid
586386-86-9P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihydropyridin-4-yl]-10-0x0-1,2-dihy
N'-(2,4-difluorophenyl)urea 586386-87-0P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-
2H-pyridin-1-yl]propanamide
                                            586386-88-1P, 4-(Benzyloxy)-3-bromo-1-[3-
```

```
(morpholin-4-yl)-3-oxopropyl]pyridin-2(1H)-one
                                                                          586386-89-2P.
N-(3-Aminopropy1)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
yl]propanamide hydrochloride
                                            586386-90-5P, 4-(Benzyloxy)-3-bromo-1-[3-
oxo-3-(piperazin-1-yl)propyl]pyridin-2(1H)-one hydrochloride
586386-91-6P, 4-(Benzyloxy)-3-bromo-1-[2-(morpholin-4-yl)ethyl]pyridin-
                 586386-92-7P, N-(2-Aminoethyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-
2H-pyridin-1-yl]propanamide hydrochloride
                                                                586386-93-8P,
[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]acetic
          586386-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one
                                                                         586386-95-0P,
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-
yl)methyl]pyridin-2(1H)-one 586386-96-1P, Methyl 3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridine-1-carboxylate
586386-97-2P, 1-Allyl-3-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586386-98-3P, 4-(Benzyloxy)-1-(2,2-
diethoxyethyl)pyridin-2(1H)-one 586386-99-4P 586387-00-0P
                    586387-02-2P, 4-(Benzyloxy)-1-(2-oxopropyl)pyridin-2(1H)-
586387-01-1P
         586387-03-3P, 5-[[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]-5-
methylimidazolidine-2,4-dione 586387-04-4P, Ethyl [4-(benzyloxy)-2-oxo-
2H-pyridin-1-yl]acetate 586387-05-5P, 2-[4-(Benzyloxy)-2-oxo-2H-pyridin-
1-y1] acetamide 586387-06-6P, 4-(Benzyloxy)-1-ethylpyridin-2(1H)-one
586387-07-7P, tert-Butyl 3-[[4-(benzyloxy)-2-oxo-2H-pyridin-1-
yl]methyl]piperidine-1-carboxylate 586387-08-8P, 1,3-Dibenzyl-4-hydroxy-
6-methylpyridin-2(1H)-one 586387-09-9P, 1-Benzyl-6-methyl-2-oxo-1,2-
dihydropyridin-4-yl methanesulfonate
                                                        586387-10-2P, 1-Benzyl-4-(naphthyl-
                                                586387-11-3P, 1-Benzyl-4-(benzylthio)-3,5-
1-ylmethoxy)pyridin-2(1H)-one
dibromopyridin-2(1H)-one 586387-12-4P, 1-Benzyl-3-[(benzylamino)methyl]-
4-(benzyloxy)pyridin-2(1H)-one 586387-13-5P, 1-Benzyl-4-(benzyloxy)-3-
[[(2-cyclohexylethyl)amino]methyl]pyridin-2(1H)-one
                                                                                586387-14-6P,
1-Benzyl-4-(benzylthio)-5-methylpyridin-2(1H)-one 586387-15-7P,
1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate
586387-16-8P, 1-Benzyl-3-bromo-6-methyl-4-[[2-
                                                                        586387-17-9P,
(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one
1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl
                                     586387-18-0P, 4-Phenoxy-1-[[2-
4-bromobenzenesulfonate
(trimethylsilyl)ethoxy]methyl]pyridin-2(1H)-one 586387-19-1P,
                                                       586387-20-4P
1-Benzyl-4-phenoxypyridin-2(1H)-one
                                                                               586387-21-5P,
3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one hydrochloride
586387-22-6P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-
         586387-23-7P, Benzyl (5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-
one
                   586387-24-8P, Methyl (2E)-4-[4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]-2-butenoate 586387-25-9P, tert-Butyl
4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-
carboxylate
                     586387-26-0P, 1-Benzyl-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-
         586387-27-1P, 2-[[[3-Bromo-2-oxo-1-(pyridin-3-ylmethyl)-1,2-
dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile
                                                                                  586387-28-2P,
tert-Butyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
yl]methyl]piperidine-1-carboxylate 586387-29-3P, 4-Benzyloxy-3-bromo-1-
                                                     586387-30-6P, tert-Butyl
(methanesulfonyl)-1H-pyridin-2-one
4-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]piperidine-1-carboxylate
586387-31-7P, 4-(Benzyloxy)-1-[4-(methylthio)benzyl]pyridin-2(1H)-one 586387-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2-methyl-4-
methylaminopyrimidin-5-yl)methyl]-1H-pyridin-2-one
                                                                                586387-33-9P,
4-(Benzyloxy)-1-[4-(methylsulfonyl)benzyl]pyridin-2(1H)-one
586387-34-0P, 4-Phenoxy-1H-pyridin-2-one
                                                                586387-35-1P,
4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-
         586387-36-2P, 1-(3-Fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one
586387-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[2-methyl-1-[
(methylthio)pyrimidin-4-yl]pyridin-2(1H)-one 586387-38-4P,
4-(Benzyloxy)-3-bromo-1-piperidin-4-ylpyridin-2(1H)-one hydrochloride
586387-39-5P, 4-Benzyloxy-1-difluoromethyl-1H-pyridin-2-one
```

```
586387-41-9P, 3-Bromo-6-methyl-1-(pyridin-3-ylmethyl)-4-[(pyridin-3-
           ylmethyl)amino]-1H-pyridin-2-one
                                                                                             586387-42-0P, 2-Chloro-N-[1-(2,6-
           dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-
           fluorobenzamide 586387-43-1P, N-[1-(2,6-Dichlorobenzy1)-6-oxo-5-
           trifluoromethyl-1,6-dihydropyridin-3-yl]-4-isopropoxybenzamide
           586387-44-2P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-methoxyphenyl)-1H-pyridin-2-
                          586387-45-3P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-isopropylphenyl)-1H-
           pyridin-2-one
                                               586387-46-4P, 3'-Bromo-1'-(3-fluorobenzyl)-6-methoxy-1'H-
           [3,4']bipyridinyl-2'-one 586387-47-5P, 4-Benzo[1,3]dioxol-5-yl-3-bromo-1-
           (3-fluorobenzyl)-1H-pyridin-2-one 586387-48-6P, 3-Bromo-1-(3-
           fluorobenzyl)-4-thiophen-3-yl-1H-pyridin-2-one 586387-49-7P,
           3-Bromo-1-(3-fluorobenzyl)-4-(3-trifluoromethylphenyl)-1H-pyridin-2-one
           586387-50-0P, 3-Bromo-1-(3-fluorobenzyl)-4-naphthalen-2-yl-1H-pyridin-2-
                          586387-51-1P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-fluorophenyl)-1H-
                                                  586387-52-2P, 1-Benzenesulfonyl-4-benzyloxy-3-bromo-1H-
           pyridin-2-one
                                                  586387-53-3P, 4-[3-Amino-1-(2,4-difluorophenyl)propoxy]-3-
           pyridin-2-one
           bromo-6-methyl-1-[(pyridin-3-yl)methyl]-1H-pyridin-2-one 586387-54-4P,
           2-[[[1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1,2-methyl-2-oxo-1
           dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile 586387-55-5P,
           1-(2-Chloro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1H-
                                                586387-56-6P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-
           pyridin-2-one
           methyl-5-vinyl-1H-pyridin-2-one 586387-57-7P
                                                                                                                              586387-58-8P,
           1-(2,6-Difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one
           586387-59-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-
           phenethyl-1H-pyridin-2-one 586387-60-2P, 1-(1H-Indazol-5-yl)-4-(1H-
           indazol-5-ylamino)-6-methylpyridin-2(1H)-one 586387-61-3P,
           5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-[2-(2,4-difluorobenzyl)oxy]
           difluorophenyl)ethyl]-6-oxo-1,6-dihydropyridine-3-carboxaldehyde
           586387-62-4P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)]0xy]-6-methyl-2-oxo-2H-
           pyridin-1-yl]pyrimidine-2-carbonitrile 586387-63-5P,
           3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-
           carboxylic acid 586387-64-6P, 3-Bromo-4-[(5-carboxypyridin-2-y1)oxy]-6-
           methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
                                                                                                                                                 586387-65-7P,
           3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6,6'-dimethyl-2-oxo-2H-
           [1,2']bipyridinyl-3'-carbonitrile
                                                                                                 586387-66-8P, 3-Bromo-4-[(2,4-
           difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
           methylamide 586387-67-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
           oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-hydroxyethyl)amide
           586387-68-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
           [1,2']bipyridinyl-5'-carboxylic acid N-(2-methoxyethyl)amide
           586387-69-1P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-(4-
                                                                                           586387-70-4P, 3-Bromo-4-[(2,4-
           methylbenzyl)-1H-pyridin-2-one
           difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxy-2-phenylethyl)-
           6-methylpyridin-2(1H)-one
                                                                              586387-71-5P, 3-Chloro-1-(4-fluorobenzyl)-4-
           [(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-72-6P,
           4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-
           yl]methyl]benzonitrile trifluoroacetate 586387-74-8P 586387-75-9P,
           methylbenzamide
                                                     586387-76-0P
, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(piperidin-1-
           vlcarbonv1)phenv1] pvridin-2(1H)-one 586387-77-1P, 4-[3-Bromo-4-[(2,4-
           difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide
           586387-78-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[2-(4-fluorophenyl)ethyl]-6-
                                                                         586387-79-3P, 4-[3-Bromo-4-[(2,4-
           methylpyridin-2(1H)-one
           difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-isopropylbenzamide
           586387-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl)oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluorobenzyl]oxy]-6-methyl-1-[4-difluo
           (pyrrolidin-1-ylcarbonyl)phenyl] pyridin-2(1H)-one
                                                                                                                                           586387-81-7P,
           4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N,N-1-2-0xo-2H-pyridin-1-yl]-N
           bis(2-hydroxyethyl)benzamide 586387-83-9P, 4-(Benzyloxy)-1-(piperidin-3-
           ylmethyl)pyridin-2(1H)-one trifluoroacetate 586387-84-0P,
```

586387-40-8P, 4-Benzyloxy-3-bromo-1-(2-chlorophenyl)-6-methyl-1H-pyridin-2-

```
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(morpholin-4-
ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-85-1P
                                                                                586387-86-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-
ylcarbonyl)phenyl]pyridin-2(1H)-one 586387-87-3P, 3-Bromo-1-(3-
fluorobenzyl)-4-[(3-fluorobenzyl)amino]pyridin-2(1H)-one 586387-88-4P
586387-89-5P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-
pyridin-1-yl]benzyl]-2-hydroxyacetamide 586387-90-8P,
1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
586387-91-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-N, N-dimethylbenzamide 586387-92-0P, 4-(Allylamino)-3-bromo-
1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one 586387-93-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-
1H-pyridin-2-one 586387-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[1-
(2-hydroxyacetyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methyl-1H-pyridin-2-
         586387-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-final content of the conten
pyrazol-3-ylmethyl)-1H-pyridin-2-one 586396-12-5P, 3-Chloro-1-[4-
[[(cyclopropylmethyl)amino]methyl]-2,6-difluorophenyl]-4-[(2,4-
difluorobenzyl)oxy] pyridin-2(1H)-one hydrochloride 586396-39-6P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-2-acetoxyacetamide 586396-68-1P 586397-52-6P
586397-63-9P
                     586397-73-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
165245-96-5, p38\alpha MAP kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
     (preparation of pyridinones as modulators of p38 MAP kinase for
    treatment of inflammatory conditions, ischemia, viral
    infections, autoimmune diseases, and other conditions)
586374-26-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
     (preparation of pyridinones as modulators of p38 MAP kinase for
    treatment of inflammatory conditions, ischemia, viral
    infections, autoimmune diseases, and other conditions)
56-37-1, Benzyltriethylammonium chloride
                                                                  75-31-0, Isopropylamine,
reactions
                  79-44-7, Dimethylcarbamyl chloride
                                                                           86-95-3,
4-Hydroxy-1,2-dihydroquinolin-2-one 87-62-7, 2,6-Dimethylaniline
88-17-5, 2-(Trifluoromethyl) aniline 95-02-3, 4-Amino-5-aminomethyl-2-
                           96-33-3, Methyl acrylate
                                                                    98-00-0, Furfuryl alcohol
methylpyrimidine
                                                                                99-27-4, Dimethyl
98-58-8, 4-Bromobenzenesulfonyl chloride
                                                                 98-79-3
5-aminoisophthalate 100-82-3, 3-Fluorobenzylamine
                                                                                 103-64-0,
\beta-Bromostyrene 103-71-9, Phenyl isocyanate, reactions
                                                                                         104-81-4,
                                    105-36-2, Ethyl bromoacetate 106-96-7,
4-Methylbenzyl bromide
Propargyl bromide 107-11-9, Allylamine 109-01-3, 1-Methylpiperazine 109-08-0, 2-Methylpyrazine 109-83-1, 2-(Methylamino)ethanol 109-85-3,
2-Methoxyethylamine 110-89-4, Piperidine, reactions
                                                                                      110-91-8,
Morpholine, reactions 140-75-0, 4-Fluorobenzylamine
                                                                                      140-88-5, Ethyl
                315-14-0, 2,4,6-Trifluoronitrobenzene
                                                                             315-31-1,
acrylate
2-Fluoro-3-methylbenzoic acid 363-81-5, 2,4,6-Trifluoroaniline
402-23-3, 3-Trifluoromethylbenzyl bromide 403-43-0, 4-Fluorobenzoyl
chloride
               405-99-2, 4-Fluorostyrene 452-85-7, 5-Fluoro-2-methylphenol
453-71-4, 4-Fluoro-3-nitrobenzoic acid 455-87-8, 4-Amino-3-fluorobenzoic
acid 456-41-7, 3-Fluorobenzyl bromide 459-46-1, 4-Fluorobenzyl bromide
459-56-3, 4-Fluorobenzyl alcohol 527-69-5, 2-Furoyl chloride
                                                                                                    536-74-3,
Phenylacetylene 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl
```

ΙT

ΙT

ΙT


```
chloroformate 582-33-2, Ethyl 3-aminobenzoate
                                                  585-71-7,
(1-Bromoethyl)benzene 594-61-6, 2-Hydroxyisobutyric acid 616-30-8,
3-Amino-1,2-propanediol 617-88-9, 2-(Chloromethyl)furan 619-45-4,
Methyl 4-aminobenzoate 625-45-6, Methoxyacetic acid
                                                         626-03-9,
2,4-Dihydroxypyridine 626-15-3, \alpha,\alpha'-Dibromo-m-xylene
674-82-8, Diketene 675-10-5, 4-Hydroxy-6-methyl-2H-pyran-2-one
765-50-4, 2-(Chloromethyl)thiophene 766-98-3, 4-Fluorophenylacetylene
867-44-7 873-63-2, 3-Chlorobenzyl alcohol 1011-65-0, Methyl
indole-5-carboxylate 1071-46-1, Monoethyl malonate 1072-84-0,
4-Imidazolecarboxylic acid 1117-71-1, Methyl 4-bromocrotonate
1121-76-2, 4-Chloropyridine 1-oxide 1124-33-0, 4-Nitropyridine N-oxide
1129-28-8, Methyl 3-bromomethylbenzoate 1194-02-1, 4-Fluorobenzonitrile
1453-58-3, 3-Methyl-1H-pyrazole 1465-76-5, 1-tert-Butyl-4-oxopiperidine 1877-77-6, 3-Aminobenzyl alcohol 2038-03-1, 4-(2-Aminoethyl)morpholine
2144-37-8 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl
4-(bromomethyl)benzoate 2486-74-0, 4-Amino-2-methylmethyl benzoate
2840-26-8, 3-Amino-4-methoxybenzoic acid 2854-16-2, 3-Amino-2-methyl-2-
propanol 3240-94-6, 4-(2-Chloroethyl)morpholine 3320-83-0,
2-Chlorophenyl isocyanate 3544-24-9, 3-Aminobenzamide 3731-51-9,
2-(Aminomethyl)pyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1, 4-(Aminomethyl)pyridine 3739-30-8, 2-Hydroxy-2-methylbutyric acid
4285-42-1, N-Methyl-N-phenylcarbamoyl chloride
                                                 4385-35-7,
Isochroman-3-one 4412-91-3, 3-Furylmethanol
                                                 4518-10-9, Methyl
3-aminobenzoate 4530-20-5, Boc-glycine 5345-27-7, 3- (Methylsulfonyl)benzoic acid 5382-16-1, 4-Hydroxypiperidine
3-aminobenzoate
                                                                 5394-63-8,
2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5470-70-2, Methyl 6-methylnicotinate
5509-65-9, 2,6-Difluoroaniline 5521-55-1, 5-Methylpyrazine-2-carboxylic
      5571-03-9, Methyl 2-methyl-5-pyrimidinecarboxylate 6482-24-2,
acid
2-Methoxyethyl bromide 6723-30-4, [(Tetrahydro-2H-pyranyl-2-yl)oxy]amine
7051-34-5, Cyclopropylmethyl bromide 7554-65-6, 4-Methyl-1H-pyrazole
7693-46-1, 4-Nitrophenyl chloroformate 10406-24-3, 3- (Aminomethyl)benzonitrile 13737-36-5, 4-(Bromomethyl)phenylacetic acid
13831-30-6, Acetoxyacetic acid 13831-31-7, Acetoxyacetyl chloride
14001-63-9, 4-Methyl-2-methylthiopyrimidine 15781-71-2, 2-Methylmalonic
acid bis(2,4,6-trichlorophenyl) ester 17201-43-3, \alpha-Bromo-p-
tolunitrile 17994-25-1, 1-Hydroxy-1-cyclopropanecarboxylic acid
18063-02-0, 2,6-Difluorobenzoyl chloride 18583-89-6, Methyl
3-amino-2-methylbenzoate 18595-18-1, Methyl 3-amino-4-methylbenzoate
19335-11-6, 5-Aminoindazole 20274-69-5, 4-Fluoro-3-nitrobenzyl alcohol
22115-41-9, \alpha-Bromo-o-tolunitrile
                                    22134-75-4
                                                  22600-30-2, Methyl
2-amino-5-furoate
                    23063-36-7, \alpha, \alpha-Dichloro-p-xylene
23915-07-3, 2,4-Difluorobenzyl bromide
                                         24424-99-5, Di-tert-butyl
dicarbonate 24964-64-5, 3-Cyanobenzaldehyde 25006-86-4,
2,6-Bis(bromomethyl)fluorobenzene 30533-50-7, 1-Amino-2-methyl-2-
                        36394-75-9, (S)-(-)-2-Acetoxypropionyl chloride
propanol hydrochloride
38870-89-2, 2-Methoxyacetyl chloride 39920-37-1, 2,6-Dichlorophenyl
            40061-55-0, m-Tolylacetic acid ethyl ester
                                                           40635-66-3,
isocyanate
2-Acetoxy-2-methylpropionyl chloride 40872-87-5, Methyl
3-amino-4-chlorobenzoate 49608-01-7, Ethyl 6-chloronicotinate
50628-37-0, 3,3-Dimethoxy-2-methoxycarbonylpropen-1-ol sodium salt
53937-02-3, 4-Benzyloxy-2(1H)-pyridone 55912-20-4, 3-Nitro-4-
chlorobenzyl alcohol 56456-47-4, 2,4-Difluorobenzyl alcohol
57260-71-6, N-(tert-Butyloxycarbonyl)piperazine 57791-63-6,
3-(Cyclohexylamino)-2-butenoic acid methyl ester
                                                   60728-41-8,
3-Amino-4-(methoxycarbonyl)benzoic acid 62558-08-1, 1,2-
Bis(hydroxymethyl)-4-fluorobenzene 66176-39-4, 4-
(Bromomethyl) benzenesulfonyl chloride 67567-26-4, 4-Bromo-2,6-
difluoroaniline 71637-34-8, Thien-3-ylmethanol 72235-52-0,
2,4-Difluorobenzylamine 77532-79-7, 5-Fluoro-2-methylbenzonitrile
80278-67-7, Isoquinoline-5-carboxaldehyde 81863-45-8,
3-Amino-4-methylbenzyl alcohol 84257-12-5, 5-(1-Hydroxy-3-oxobutylidene)-
```

```
2,2-dimethyl-1,3-dioxane-4,6-dione 105827-74-5, 5-Bromomethyl-2-
     fluoropyridine 114896-64-9, Methanesulfonic acid 2-(thiophen-3-yl)ethyl
            120100-15-4, Methyl 3-amino-2-chlorobenzoate
                                                          132664-85-8,
     5-Aminomethyl-2-methylpyrazine 134227-45-5, 3,4,5-Trifluorobenzonitrile
     135394-68-2
                 161975-39-9, 4-(Methanesulfonyloxymethyl)-1-piperidine-1-
     carboxylic acid tert-butyl ester 162166-99-6, 3-
     [(Methanesulfonyloxy)methyl]piperidine-1-carboxylic acid tert-butyl ester
     192369-91-8, 5-(Bromomethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
     586373-19-5, 1-Benzyl-4-hydroxypyridin-2(1H)-one 586374-17-6,
     1-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]-1H-pyridin-2-one
     586374-60-9, 3-Bromo-4-(2,4-difluorophenoxy)-6-methylpyridin-2(1H)-one
     586374-98-3, 3-Bromo-4-(2,4-difluorophenoxy)-6-methyl-1-[4-(piperazin-1-1)]
     ylcarbonyl)benzyl]pyridin-2(1H)-one 586376-42-3, 1-[4-
     (Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one hydrochloride
     586376-54-7, 3-Bromo-1-(3-fluorobenzyl)-2-oxo-1, 2-dihydropyridin-4-yl
     trifluoromethanesulfonate 586376-85-4, 4-[(2,4-Difluorobenzyl)oxy]-1-
     [2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-methylpyridin-2(1H)-one
     586378-53-2, 1-Benzyl-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one
     586378-62-3, 3-Bromo-1-(cyclopropylmethyl)-4-hydroxy-6-methylpyridin-2(1H)-
           586378-89-4, 4-Hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-1
     one
           586379-00-2, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-
     one
     [(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one 586379-20-6,
     4-[(2,4-Difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586379-22-8,
     4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
                 586378-47-4P 586381-34-2P
                                               586381-37-5P
     58804-19-6P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
RE.CNT
             THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
       11
(1) Anon; CHEM BER 1956, V89, P876
(2) Anon; COLLECT CZECH CHEM COMMUN 1993, V58(4), P947
(3) Anon; JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1 1986, P1289
(4) Anon; LIEBIGS ANN, RECL 1997, V8, P1777
(5) Crich, J; WO 0031063 A 2000 CAPLUS
(6) Dorn, C; US 3715358 A 1973
(7) Graham, P; US 3654291 A 1972 CAPLUS
(8) Margolin, S; WO 9710712 A 1997 CAPLUS
(9) Merck & Co Inc; GB 1289187 A 1972 CAPLUS
(10) Sandoz Ag; WO 8601815 A 1986 CAPLUS
(11) Witzel, B; US 3644626 A 1972 CAPLUS
L32 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
     84-11-7, Phenanthrene-9, 10-dione
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (therapeutics for chemokine-mediated diseases)
     84-11-7 CAPLUS
     9,10-Phenanthrenedione (CA INDEX NAME)
```

ΙT

ΙT

RN CN



2002:449493 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 137:15782

TITLE: Therapeutics for chemokine-mediated diseases

INVENTOR(S): Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan

PATENT ASSIGNEE(S): Chemokine Therapeutics Corporation, Can.

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO.						DATE			APPL	ICAT	ION :						
	WO 2002045702 WO 2002045702					A2 20020613				WO 2	001-	 CA17	20011205					
	W: AE, AG, AL,						BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,			
							DK,											
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TR,	TT,	TZ,	UA,	
		UG,	US,	UΖ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	BE,	CH,	
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	TR,	
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
CA	CA 2330350					A1 20020605				CA 2	000-	2330	350	20001205				
US	2003	0069	265		A1	A1 20030410				US 2	001-	7673	78	20010122				
US	US 6706767					B2 20040316												
AU	2002	0157	37		Α5		2002	0618	AU 2002-15737					20011205				
PRIORIT	RIORITY APPLN. INFO.:								CA 2000-2330350						A 2	A 20001205		
										US 2001-767378					A 20010122			
										WO 2	001-	CA17	48	W 20011205				
OTHER S	OTHER SOURCE(S):						137:	15782	2									

ΑN 2002:449493 CAPLUS

137:15782 DN

Entered STN: 14 Jun 2002 ΕD

ΤI Therapeutics for chemokine-mediated diseases

Saxena, Geeta; Tudan, Christopher R.; Salari, Hassan ΙN

Chemokine Therapeutics Corporation, Can. PA

PCT Int. Appl., 52 pp. SO

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

1-7 (Pharmacology)

FAN.CNT 1

	PAT	CENT	NO.			KIN	D	DATE			APPL	ICAT	D	DATE				
							_											
ΡI	WO	WO 2002045702					A2 20020613					001-	20011205					
	WO 2002045702					АЗ		20030103										
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	BZ,	CA,	CH,	CN,

```
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2330350
                         A1
                               20020605
                                         CA 2000-2330350 20001205
     US 20030069265
                        A1
                               20030410
                                           US 2001-767378
                                                                   20010122
     US 6706767
                        В2
                               20040316
     AU 2002015737
                        A5
                                           AU 2002-15737
                               20020618
                                                                   20011205
PRAI CA 2000-2330350
                        Α
                               20001205
     US 2001-767378
                        A
                               20010122
     WO 2001-CA1748
                        W
                              20011205
CLASS
               CLASS PATENT FAMILY CLASSIFICATION CODES
 PATENT NO.
 _____
 WO 2002045702
               ICM
                       A61K031-00
                 IPCI
                        A61K0031-00 [ICM, 7]
                 IPCR
                        A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01
                        [I,C^*]; A61K0031-015 [I,A]; A61K0031-11 [I,C^*];
                        A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122
                        [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A];
                        A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0009-00
                        [I,C*]; A61P0009-10 [I,A]; A61P0011-00 [I,C*];
                        A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06
                        [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A];
                        A61P0025-00 [I,C*]; A61P0025-28 [I,A]; A61P0029-00
                        [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*];
                        A61P0031-02 [I,A]; A61P0033-00 [I,C*]; A61P0033-06
                        [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]
                        A61K031/00+A; A61K031/015; A61K031/11; A61K031/122;
                 ECLA
                        A61K031/473
                        A61K0031-122 [ICM, 7]; A61K0031-015 [ICS, 7]; A61K0031-01
 CA 2330350
                 IPCI
                        [ICS, 7, C*]; A61P0019-02 [ICS, 7]; A61P0019-00
                        [ICS, 7, C*]; A61P0001-04 [ICS, 7]; A61P0001-00
                        [ICS, 7, C*]; A61P0011-06 [ICS, 7]; A61P0011-00
                        [ICS, 7, C*]; A61P0017-06 [ICS, 7]; A61P0017-00
                        [ICS, 7, C*]; A61P0037-06 [ICS, 7]; A61P0037-00
                        [ICS,7,C*]; A61P0009-10 [ICS,7]; A61P0009-00
                        [ICS, 7, C*]; A61K0031-11 [ICS, 7]; A61K0031-473 [ICS, 7];
                        A61K0031-66 [ICS, 7]; A61K0031-695 [ICS, 7]
                 IPCR
                       A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01
                        [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,C*];
                        A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122
                        [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]
                        A61K031/00+A; A61K031/015; A61K031/11; A61K031/122;
                 ECLA
                        A61K031/473
                        A61K0031-473 [ICM, 7]; A61K0031-122 [ICS, 7];
 US 20030069265
                IPCI
                        A61K0031-015 [ICS, 7]; A61K0031-01 [ICS, 7, C*]
                 IPCR
                        A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-01
                        [I,C*]; A61K0031-015 [I,A]; A61K0031-11 [I,A];
                        A61K0031-11 [I,C*]; A61K0031-122 [I,A]; A61K0031-122
                        [I,C*]; A61K0031-473 [I,A]; A61K0031-473 [I,C*]
                 NCL
                        514/290.000; 514/680.000; 514/765.000
                 ECLA
                        A61K031/00+A; A61K031/015; A61K031/11; A61K031/122;
                        A61K031/473
                       A61K0031-00 [ICM, 7]
 AU 2002015737
                 IPCI
                       A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-01
                 IPCR
                        [I,C^*]; A61K0031-015 [I,A]; A61K0031-11 [I,C^*];
```

```
A61K0031-11 [I,A]; A61K0031-122 [I,C*]; A61K0031-122
                   [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A];
                   A61P0001-00 [I,C*]; A61P0001-04 [I,A]; A61P0009-00
                   [I,C*]; A61P0009-10 [I,A]; A61P0011-00 [I,C*];
                   A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-06
                   [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A];
                   A61P0025-00 [I,C*]; A61P0025-28 [I,A]; A61P0029-00
                   [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*];
                   A61P0031-02 [I,A]; A61P0033-00 [I,C*]; A61P0033-06
                   [I,A]; A61P0037-00 [I,C*]; A61P0037-00 [I,A]
The invention provides therapeutic and biol. uses of chemokine
receptor-binding compds. (including chemokine receptor ligands such as
chemokine receptor agonists or antagonists), such as tricyclic
phenanthrene derivs., including uses in the treatment of disease
states mediated by chemokines or chemokine receptors. The relevant
chemokines may be e.g. monocyte chemoattractant protein-1 (MCP-1) or
interleukin-8 (IL-8), and the relevant chemokine receptors may be e.g.
corresponding chemokine receptors (CCR-2, CCR-4, CXCR-1, and CXCR-2).
invention also provides corresponding pharmaceutical compns. and
therapeutic methods. In one aspect, for example, the invention provides
for the use of phenanthrene-9,10-dione in the treatment of
multiple sclerosis.
chemokine mediated disease treatment chemokine receptor binding
compd; tricyclic phenanthrene deriv chemokine mediated disease
treatment; phenanthrenedione multiple sclerosis treatment
Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (CCR2; therapeutics for chemokine-mediated diseases)
Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (CCR4; therapeutics for chemokine-mediated diseases)
Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (CXCR1; therapeutics for chemokine-mediated diseases)
Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (CXCR2; therapeutics for chemokine-mediated diseases)
   (Crohn's disease; therapeutics for chemokine-mediated diseases)
Intestine, disease
   (Crohn's; therapeutics for chemokine-mediated diseases)
   (Gram-neq.; therapeutics for chemokine-mediated diseases)
   (activation; therapeutics for chemokine-mediated diseases)
   (acute; therapeutics for chemokine-mediated diseases)
Respiratory distress syndrome
   (adult; therapeutics for chemokine-mediated diseases)
Transplant rejection
   (allotransplant; therapeutics for chemokine-mediated diseases)
Antiarteriosclerotics
   (antiatherosclerotics; therapeutics for chemokine-mediated diseases)
   (atopic; therapeutics for chemokine-mediated diseases)
   (chronic obstructive pulmonary disease; therapeutics for
   chemokine-mediated diseases)
```

OS

AB

ST

ΙT

ΙT

ΙT

TΤ

ΙT

ΙT

ΙT

ΤТ

ΤТ

ΤТ

ΙT

ΙT

ΙT

ΙT

ΤТ

Inflammation

Sepsis

Neutrophil

Dermatitis

Lung, disease

Inflammation

Transplant rejection

Inflammation

MARPAT 137:15782

```
(chronic; therapeutics for chemokine-mediated diseases)
ΤТ
     Autoimmune disease
        (exptl. autoimmune encephalomyelitis; therapeutics for
        chemokine-mediated diseases)
     Encephalomyelitis
ΤТ
        (exptl. autoimmune; therapeutics for chemokine-mediated diseases)
ΙT
     Lung, disease
        (fibrosis, idiopathic; therapeutics for chemokine-mediated diseases)
ΙΤ
     Ischemia
        (focal; therapeutics for chemokine-mediated diseases)
ΙT
     Inflammation
     Kidney, disease
        (glomerulonephritis; therapeutics for chemokine-mediated diseases)
ΙT
     Transplant and Transplantation
        (graft-vs.-host reaction; therapeutics for chemokine-mediated diseases)
ΙΤ
     Intestine, disease
        (inflammatory; therapeutics for chemokine-mediated diseases)
ΙT
     Reperfusion
        (injury, cardiac and renal; therapeutics for chemokine-mediated
        diseases)
ΤТ
     Lung, disease
        (injury, mononuclear phagocyte-dependent; therapeutics for
        chemokine-mediated diseases)
ΙT
     Phagocyte
        (mononuclear, mononuclear phagocyte-dependent lung injury; therapeutics
        for chemokine-mediated diseases)
ΤT
     Cell activation
        (neutrophil; therapeutics for chemokine-mediated diseases)
ΙT
     Arthritis
        (pseudogout, acute; therapeutics for chemokine-mediated diseases)
ΙT
     Fibrosis
        (pulmonary, idiopathic; therapeutics for chemokine-mediated diseases)
TΤ
     Injury
        (pulmonary, mononuclear phagocyte-dependent; therapeutics for
        chemokine-mediated diseases)
TΤ
     Heart, disease
     Kidney, disease
        (reperfusion injury; therapeutics for chemokine-mediated diseases)
ΙT
        (reperfusion, cardiac and renal; therapeutics for chemokine-mediated
        diseases)
ΙT
     Artery, disease
        (restenosis; therapeutics for chemokine-mediated diseases)
ΤТ
     Shock (circulatory collapse)
        (septic; therapeutics for chemokine-mediated diseases)
     Brain, disease
ΤТ
        (stroke; therapeutics for chemokine-mediated diseases)
ΙT
     Multiple sclerosis
        (therapeutic agents; therapeutics for chemokine-mediated diseases)
     Alzheimer's disease
ΙT
     Angiogenesis
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiarthritics
     Antiasthmatics
     Anticoagulants
     Antimalarials
     Arthritis
     Asthma
```

```
Atherosclerosis
     Cardiovascular agents
     Drug delivery systems
     Gastrointestinal agents
     Gout
     Inflammation
     Malaria
    Multiple sclerosis
     Neutrophil
     Psoriasis
     Rheumatoid arthritis
     Sarcoidosis
     Thrombosis
        (therapeutics for chemokine-mediated diseases)
ΙT
    Chemokine receptors
     Chemokines
     Interleukin 8
     Monocyte chemoattractant protein-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (therapeutics for chemokine-mediated diseases)
ΙT
     Shock (circulatory collapse)
        (toxic shock syndrome; therapeutics for chemokine-mediated diseases)
ΙT
     Inflammation
     Intestine, disease
        (ulcerative colitis; therapeutics for chemokine-mediated diseases)
     Interleukin 8 receptors
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha; therapeutics for chemokine-mediated diseases)
ΙT
     Interleukin 8 receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\beta; therapeutics for chemokine-mediated diseases)
     7440-70-2, Calcium, biological studies 169592-56-7, Caspase 3
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (therapeutics for chemokine-mediated diseases)
     82-86-0, Acenaphthenequinone
                                   83-32-9, Acenaphthene 84-11-7,
ΙT
     Phenanthrene-9,10-dione
                               1015-89-0, 6(5H)-Phenanthridinone 4707-71-5,
     Phenanthrene-9-carboxaldehyde
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (therapeutics for chemokine-mediated diseases)
L32 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2008 ACS on STN
ΤТ
     98-59-9, p-Toluenesulfonyl chloride
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of novel multicyclic compds. and their amino acid derivs. as
        inhibitors of enzymes for treatment of diseases related to
        enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
        kinase)
     98-59-9 CAPLUS
RN
     Benzenesulfonyl chloride, 4-methyl- (CA INDEX NAME)
CN
```

ACCESSION NUMBER:

2001:833276 CAPLUS

DOCUMENT NUMBER: 135:371989

Preparation of novel multicyclic compounds and their TITLE:

amino acid derivatives as inhibitors of enzymes such

as poly(ADP-ribose) polymerase

INVENTOR(S): Ator, Mark A.; Bihovsky, Ron; Chatterjee, Sankar;

Dunn, Derek; Hudkins, Robert L.

PATENT ASSIGNEE(S): Cephalon, Inc., USA

SOURCE: PCT Int. Appl., 209 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE				
WO 2001085686 WO 2001085686	A2 20011115 A3 20020530		20010509				
CO, CR, CU HR, HU, ID LT, LU, LV	, AM, AT, AU, AZ, , CZ, DE, DK, DM, , IL, IN, IS, JP, , MA, MD, MG, MK,	BA, BB, BG, BR, BY, I DZ, EE, ES, FI, GB, G KE, KG, KP, KR, KZ, I MN, MW, MX, MZ, NO, I TJ, TM, TR, TT, TZ, U	GD, GE, GH, GM, LC, LK, LR, LS, NZ, PL, PI, RO,				
DE, DK, ES	, FI, FR, GB, GR,	SL, SZ, TZ, UG, ZW, Z IE, IT, LU, MC, NL, I GW, ML, MR, NE, SN, S	PT, SE, TR, BF,				
US 20020028815 US 7122679		US 2001-850858	20010508				
CA 2409758 EP 1294725 EP 1294725	A1 20011115 A2 20030326 B1 20060104	CA 2001-2409758 EP 2001-935215	20010509 20010509				
	, DE, DK, ES, FR, , LV, FI, RO, MK,	GB, GR, IT, LI, LU, I	NL, SE, MC, PT,				
BR 2001010993 HU 2003002385	A 20030624 A2 20031229	BR 2001-10993 HU 2003-2385					
JP 2004501097 NZ 522539	A3 20070328 T 20040115 A 20040528	NZ 2001-522539	20010509 20010509				
AT 315039 ES 2256238 EP 1754707 EP 1754707	T 20060215 T3 20060716 A2 20070221 A3 20070228	ES 2001-935215 EP 2005-76862	20010509 20010509 20010509				
	, CY, DE, DK, ES,	FI, FR, GB, GR, IE,	IT, LI, LU, MC,				
MX 2002PA10977 ZA 2002009065 NO 2002005376 NO 324256	A 20030714 A 20040209 A 20030108 B1 20070917	ZA 2002-9065 NO 2002-5376	20021107 20021107 20021108				
IN 2002CN01380 KR 832602 BG 107355 HK 1051369	A 20050311 B1 20080527 A 20030731 A1 20060504	IN 2002-CN1380 KR 2002-715062 BG 2002-107355	20021108 20021109 20021205 20030522				
PRIORITY APPLN. INFO.:	WIDDLE 405 0540		P 20000509 A 20010508 A3 20010509 W 20010509				

MARPAT 135:371989

OTHER SOURCE(S):
AN 2001:833276 CAPLUS

DN 135:371989

ED Entered STN: 16 Nov 2001

```
Preparation of novel multicyclic compounds and their amino acid
ΤI
     derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase
    Ator, Mark A.; Bihovsky, Ron; Chatterjee, Sankar; Dunn, Derek; Hudkins,
ΙN
     Robert L.
PA
     Cephalon, Inc., USA
     PCT Int. Appl., 209 pp.
SO
     CODEN: PIXXD2
DT
    Patent
    English
LA
    ICM C07D209-00
IC
     34-2 (Amino Acids, Peptides, and Proteins)
CC
     Section cross-reference(s): 1, 7, 28
```

FAN.CNT 2 PATENT NO.						KIN:	D		DATE										
ΡI		2001				A2		20011115				2001-US149							
	WO	2001				A3		2002											
		W:						AU,											
								DK,											
								IS,											
								MG,											
						SG,	SI,	SK,	SL,	TJ,	.T.I.	М,	TR,	TT,	TZ,	UA,	UG,	UΖ,	VN,
		DIT	•	ZA,		т. С	B AT.T	N A CZ	C D	ОТ	0.5	7	TT [7	110	F7 T-7	2	DE	OII	037
		RW:						MZ,											
								GB,										IK,	BF,
	TTC	2002			CG,	CI, A1	CM,		0307				, MR, NE, 2001-85085			ID,		0010500	500
		2002 7122		013		B2		2002			U.S	20	) U I —	0000	50		20010508		
		2409				B2 A1					$C^{\Lambda}$	20	0.01	2400	750		2	0010	500
		1294				A1 A2		2001		CA 2001-2				935215					
		1294				B1		2003		C.F	2(	) O T —	9332	13		۷	0010	309	
	ш	R:		BE	СН		DK	ES,		GB	GF	R	тт	T.T	T.IT	MT.	SE	МС	PТ
		11.												шт,	шо,	1111,	oш,	110,	,
	BR	2001010993			шт,	д <b>,</b> А	,		0624	CY, AL, TR BR 2001-10993							2	0010	509
					_			1229									20010509		
		J 2003002385				A2 A3		2007											
		2004501097				Т					JP	2.0	001-	5822	87		2.	0010	509
		522539				A		2004	0528		JP 2001-582287 NZ 2001-522539						20010509		
	ΑT	315039				T 2.0			0215		AT 2001-935215 ES 2001-935215 EP 2005-76862							0010	
	ES	2256	238			T3		2006	0716		ES	20	01-	9352	15		20010509		
	EP	1754	707			A2		20070221 20070228			ΕP	20	005-	7686	2		2	200105	
	EP	1754	707			А3													
		R:	ΑT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FF	R,	GB,	GR,	ΙE,	ΙΤ,	LI,	LU,	MC,
			NL,	PT,	SE,	TR													
	MX	2002	2002PA10977			A		20030714			MX	20	002-	PA10	977		2	0021	107
	ZA	2002	0090	65		А		2004	0209		ZA	20	002-	9065			2	0021	107
		2002		76		А		20030108 20070917 20050311 20080527		N	ИО	0 2002-		-5376 -CN1380			20021		1108
	ИО	3242	56			В1													
		2002		380								N 2002-						2002110	
		8326				В1								7150				0021	
		1073				А		2003		BG 2002-107355						20021205			
		1051				A1 P		2006			HK	20	003-	1036	39		2	0030	522
PRAI		2000				P		2000											
		2001				A A3		2001											
		2001						2001											
OT 7 C		2001	-081	4996		W		2001	0509										
CLAS		NIO		CT 7	C C	ים יח עום	יייוע	ידעותי	V CT	א כי כי ד	- E- T- /	~ 7\ -	ד ר אי	COD	EС				
		NO.						`AMIL				_A1							
		10856	86	ICM		C07D													
				TDC	т	007D	0.00	0.0	L T CIVI	71									

IPCI C07D0209-00 [ICM, 7]

```
IPCR
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
                       [I,C^*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C^*];
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                       [I,A]; A61K0031-4412 [I,C^*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                       [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                       [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
US 20020028815
               IPCI
                       C07D0209-56 [I,A]; C07D0209-00 [I,C*]; A61K0031-46
                       [I,A]
                IPCR
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
                       [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*];
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                       [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                       [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                       [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                       514/249.000; 514/290.000; 514/373.000; 514/411.000;
                NCL
                       544/234.000; 546/079.000; 548/207.000; 548/427.000;
                       548/418.000; 548/416.000; 548/417.000; 548/420.000
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                ECLA
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
CA 2409758
                IPCI
                       C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7, C*];
                       C07D0209-00 [ICS,7]; C07D0221-00 [ICS,7]; C07D0223-00
```

```
[ICS, 7]; C07D0243-00 [ICS, 7]; C07D0307-00 [ICS, 7];
       C07D0519-00 [ICS,7]; A61P0043-00 [ICS,7]; C07D0471-14
       [ICS, 7]; C07D0471-00 [ICS, 7, C*]; C07D0491-14 [ICS, 7];
       C07D0491-00 [ICS, 7, C*]; A61K0031-395 [ICS, 7]
IPCR
       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
       [I,C^*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C^*];
       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
       [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
       [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
       [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
ECLA
       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
       C07D487/04+235A+209A; C07D487/04+237A+209A;
       C07D487/04+239A+209A; C07D491/04+307A+209A;
       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
       C07D519/00+487/00+487/00
IPCI
       C07D0487-00 [I,C]; A61K0031-395 [I,C]; A61P0043-00
       [I,C]; C07D0471-00 [I,C]; C07D0491-00 [I,C];
       C07D0519-00 [I,C]; C07D0487-04 [I,A]; A61K0031-395
       [I,A]; A61P0043-00 [I,A]; C07D0471-14 [I,A];
       C07D0491-14 [I,A]; C07D0519-00 [I,A]
IPCR
       C07D0487-00 [I,C]; C07D0487-04 [I,A]; A61K0031-395
       [I,C]; A61K0031-395 [I,A]; A61K0031-407 [I,C*];
       A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41
       [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A];
       A61K0031-4196 [I,C*]; A61K0031-4196 [I,A]; A61K0031-427
       [I,C*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C*];
       A61K0031-4412 [I,A]; A61K0031-4427 [I,C*];
       A61K0031-4439 [I,A]; A61K0031-4453 [I,C*];
       A61K0031-4453 [I,A]; A61K0031-4965 [I,C*]; A61K0031-497
       [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A];
       A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61P0003-00
       [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*];
       A61P0009-10 [I,A]; A61P0015-00 [I,C*]; A61P0015-00
       [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A];
       A61P0025-00 [I,C*]; A61P0025-14 [I,A]; A61P0025-16
       [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
       A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00
       [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A];
       A61P0043-00 [I,C]; A61P0043-00 [I,A]; C07D0471-00
       [I,C]; C07D0471-14 [I,A]; C07D0491-00 [I,C];
       C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00
       [I,C*]; C07D0495-04 [I,A]; C07D0519-00 [I,C];
       C07D0519-00 [I,A]
ECLA
       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
       C07D487/04+235A+209A; C07D487/04+237A+209A;
```

EP 1294725

```
C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
BR 2001010993
                IPCI
                       C07D0209-00 [ICM, 7]
                IPCR
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
                       [I,C^*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C^*];
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                       [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                       [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                       [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                ECLA
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
                       C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7, C*]
HU 2003002385
                IPCI
                IPCR
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
                       [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*];
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                       [I,A]; A61K0031-4412 [I,C^*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                       [I,C^*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C^*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                       [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0487-00 [I,C*]; C07D0487-04
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                ECLA
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
JP 2004501097
                IPCI
                       C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C*];
                       A61K0031-407 [ICS, 7]; A61K0031-41 [ICS, 7];
                       A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C*];
                       A61K0031-4196 [ICS,7]; A61K0031-427 [ICS,7];
                       A61K0031-4412 [ICS, 7]; A61K0031-4439 [ICS, 7];
```


```
A61K0031-4427 [ICS,7,C*]; A61K0031-4453 [ICS,7];
                       A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*];
                       A61K0031-501 [ICS,7]; A61K0031-5377 [ICS,7];
                       A61K0031-5375 [ICS,7,C*]; A61P0003-10 [ICS,7];
                       A61P0003-00 [ICS, 7, C*]; A61P0009-10 [ICS, 7];
                       A61P0009-00 [ICS, 7, C*]; A61P0015-00 [ICS, 7];
                       A61P0017-06 [ICS, 7]; A61P0017-00 [ICS, 7, C*];
                       A61P0025-14 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-28
                        [ICS,7]; A61P0025-00 [ICS,7,C*]; A61P0027-02 [ICS,7];
                       A61P0027-00 [ICS, 7, C*]; A61P0029-00 [ICS, 7];
                       A61P0035-00 [ICS, 7]; A61P0043-00 [ICS, 7]
                IPCR
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
                       [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*];
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                        [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                        [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                        [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                        [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                        [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                        [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
                       4C050/AA01; 4C050/AA07; 4C050/AA08; 4C050/BB04;
                        4C050/CC04; 4C050/DD10; 4C050/EE02; 4C050/FF01;
                        4C050/FF02; 4C050/FF05; 4C050/FF10; 4C050/GG03;
                        4C050/HH03; 4C050/HH04; 4C086/AA01; 4C086/AA02;
                        4C086/AA03; 4C086/CB03; 4C086/NA14; 4C086/ZA02;
                        4C086/ZA15; 4C086/ZA16; 4C086/ZA33; 4C086/ZA36;
                        4C086/ZA81; 4C086/ZA89; 4C086/ZB11; 4C086/ZB15;
                        4C086/ZB21; 4C086/ZB26; 4C086/ZC02; 4C086/ZC35
                       C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7, C*];
NZ 522539
                IPCI
                       C07D0519-00 [ICS,7]; C07D0491-14 [ICS,7]; C07D0491-00
                        [ICS,7,C*]; C07D0471-14 [ICS,7]; C07D0471-00
                        [ICS, 7, C*]; A61K0031-395 [ICS, 7]; A61P0043-00 [ICS, 7]
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*];
                IPCR
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                        [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                       [I,C^*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C^*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                        [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
```

```
A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                        [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
AT 315039
                       C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*];
                IPCI
                       A61K0031-395 [ICS,7]; A61P0043-00 [ICS,7]; C07D0471-14
                        [ICS,7]; C07D0471-00 [ICS,7,C*]; C07D0491-14 [ICS,7];
                       C07D0491-00 [ICS,7,C*]; C07D0519-00 [ICS,7]
                IPCR
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
                        [I,C^*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C^*];
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                        [I,A]; A61K0031-4412 [I,C^*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                        [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                       [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
ES 2256238
                       C07D0487-04 [ICS, 4]; C07D0487-00 [ICS, 4, C*];
                IPCI
                       A61K0031-395 [ICS, 4]; C07D0471-14 [ICS, 4]; C07D0471-00
                        [ICS, 4, C*]; C07D0491-14 [ICS, 4]; C07D0491-00
                        [ICS, 4, C*]; C07D0519-00 [ICS, 4]; A61P0043-00 [ICS, 4]
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C*];
                IPCR
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                       [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                       [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
```

```
[I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
EP 1754707
                IPCI
                       C07D0487-04 [I,A]; C07D0487-00 [I,C*]; A61K0031-395
                       [I,A]; A61P0043-00 [I,A]; C07D0519-00 [I,A];
                       C07D0491-04 [I,A]; C07D0491-00 [I,C*]; C07D0495-04
                       [I,A]; C07D0495-00 [I,C*]; C07D0209-00 [N,A];
                       C07D0243-00 [N,A]; C07D0223-00 [N,A]; C07D0307-00
                       [N,A]; C07D0221-00 [N,A]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
MX 2002PA10977
                IPCI
                       C07D0209-00 [ICM,6]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
                       C07D491/14+307A+209A+209A; C07D495/04+333A+209A;
                       C07D519/00+487/00+487/00
ZA 2002009065
                IPCI
                       C07D [ICM, 7]
NO 2002005376
                IPCI
                       C07D0209-00 [ICM, 7]
                IPCR
                       A61K0031-407 [I,C*]; A61K0031-407 [I,A]; A61K0031-41
                       [I,C^*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C^*];
                       A61K0031-4178 [I,A]; A61K0031-4196 [I,C*];
                       A61K0031-4196 [I,A]; A61K0031-427 [I,C*]; A61K0031-427
                       [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A];
                       A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
                       A61K0031-4453 [I,C*]; A61K0031-4453 [I,A];
                       A61K0031-4965 [I,C*]; A61K0031-497 [I,A]; A61K0031-501
                       [I,C*]; A61K0031-501 [I,A]; A61K0031-5375 [I,C*];
                       A61K0031-5377 [I,A]; A61P0003-00 [I,C*]; A61P0003-10
                       [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
                       A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00
                       [I,C*]; A61P0017-06 [I,A]; A61P0025-00 [I,C*];
                       A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28
                       [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
                       A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0035-00
                       [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
                       A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-14
                       [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A];
                       C07D0491-00 [I,C*]; C07D0491-04 [I,A]; C07D0491-14
                       [I,A]; C07D0495-00 [I,C*]; C07D0495-04 [I,A];
                       C07D0519-00 [I,C*]; C07D0519-00 [I,A]
                ECLA
                       C07D471/14+221A+209A+209A; C07D487/04+209A+209A;
                       C07D487/04+235A+209A; C07D487/04+237A+209A;
                       C07D487/04+239A+209A; C07D491/04+307A+209A;
```

C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00 C07D0209-00 [ICM, 7] IN 2002CN01380 IPCI C07D0487-04 [I,A]; C07D0487-00 [I,C\*] KR 832602 IPCI BG 107355 IPCI C07D0487-04 [ICM, 7]; C07D0487-00 [ICM, 7, C\*]; A61K0031-395 [ICS,7]; A61P0043-00 [ICS,7]; C07D0519-00 [ICS, 7]; C07D0491-14 [ICS, 7]; C07D0491-00 [ICS, 7, C\*];C07D0471-14 [ICS,7]; C07D0471-00 [ICS,7,C\*] **IPCR** C07D0487-00 [I,C\*]; C07D0487-04 [I,A] **ECLA** C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00 HK 1051369 IPCI C07D [ICS, 7]; A61K [ICS, 7]; A61P [ICS, 7] **IPCR** A61K0031-407 [I,C\*]; A61K0031-407 [I,A]; A61K0031-41 [I,C\*]; A61K0031-41 [I,A]; A61K0031-4164 [I,C\*]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C\*]; A61K0031-4196 [I,A]; A61K0031-427 [I,C\*]; A61K0031-427 [I,A]; A61K0031-4412 [I,C\*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C\*]; A61K0031-4439 [I,A]; A61K0031-4453 [I,C\*]; A61K0031-4453 [I,A]; A61K0031-4965 [I,C\*]; A61K0031-497 [I,A]; A61K0031-501  $[I,C^*];$  A61K0031-501 [I,A]; A61K0031-5375  $[I,C^*];$ A61K0031-5377 [I,A]; A61P0003-00 [I,C\*]; A61P0003-10 [I,A]; A61P0009-00 [I,C\*]; A61P0009-10 [I,A]; A61P0015-00 [I,C\*]; A61P0015-00 [I,A]; A61P0017-00 [I,C\*]; A61P0017-06 [I,A]; A61P0025-00 [I,C\*]; A61P0025-14 [I,A]; A61P0025-16 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C\*]; A61P0027-02 [I,A]; A61P0029-00 [I,C\*]; A61P0029-00 [I,A]; A61P0035-00 [I,C\*]; A61P0035-00 [I,A]; A61P0043-00 [I,C\*]; A61P0043-00 [I,A]; C07D0471-00 [I,C\*]; C07D0471-14 [I,A]; C07D0487-00 [I,C\*]; C07D0487-04 [I,A]; C07D0491-00 [I,C\*]; C07D0491-04 [I,A]; C07D0491-14 [I,A]; C07D0495-00 [I,C\*]; C07D0495-04 [I,A]; C07D0519-00 [I,C\*]; C07D0519-00 [I,A] **ECLA** C07D471/14+221A+209A+209A; C07D487/04+209A+209A; C07D487/04+235A+209A; C07D487/04+237A+209A; C07D487/04+239A+209A; C07D491/04+307A+209A; C07D491/14+307A+209A+209A; C07D495/04+333A+209A; C07D519/00+487/00+487/00

OS MARPAT 135:371989 GI



AB The title compds. such as penta[a]pyrrolo[3,4-c]carbazole, hexano[a]pyrrolo[3,4-c]carbazole, pyrrolo[3,4-c]carbazole, and

furano[a-3,2]pyrrolo[3,4-c]carbazole derivs. [I; A, B = CO, CH(OR3), CH(SR3), CH2, CHR3, CHR3CHR4, CR3R4, COR3, N:CR3, SO, SO2 (wherein R3, R4 = H, optionally substituted lower alkyl or aryl); Y and Z, together with the carbon to which they are attached, form an (un)substituted mono- or bicyclic aryl or bicyclic heteroaryl, or C3-5 heteroaryl; E, F = lower alkyl or E and F, together with the carbon to which they are attached, form an (un)substituted C4-7 cycloalkyl, C3-6 heterocycloalkyl or heteroaryl, or an (un) substituted heterocycloalkyl endocyclically comprising at least one group G (wherein G = O, S, SO, SO2, NR2, NR2CO, NR2CONR3, NR2SO2, NR3SO2; R2 = H, optionally substituted lower alkyl or alkanoyl, CHO, acetyl, lower alkylsulfonyl, arylsulfonyl, an optionally protected amino acid)] are prepared These compds. are effective in the treatment of diseases or disease states related to the activity of enzymes such as poly(ADP-ribose) polymerase (PARP), vascular endothelial growth factor receptor kinase (VEGFR2 kinase), and MLK3 kinase (a member of the mixed lineage kinase family), including, for example, traumatic central nervous system injuries, neurodegenerative diseases (in particular Parkinson's, Huntington's, or Alzheimer's disease), inflammation, cerebral or cardiac ischemia, endotoxic shock, diabetes, or cellular proliferative disorders (in particular cancer, solid tumors, diabetic retinopathy, intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, or endometriosis). They also suppress the formation of blood vessels (angiogenesis) and prevent neuronal degradation associated with traumatic central nervous system injuries. Thus, 2H-1,3,4,5,6,7-hexahydrocyclopenta[a]pyrrolo[3,4-c]carbazole-1,3-dione

(II; R = H) (preparation given) was treated with NaH in DMF at room temperature for

30 min and condensed with a stirred mixture of Boc-Lys(Boc)-OH dicyclohexylamine salt, TBTU, N-Methylmorpholine, and DMF at room temperature for 1 h, followed by treatment of the product with 4 N HCl in dioxane to give II (R = H-Lys). II (R = H-Lys) showed IC50 of  $\mu g/mL$  against of 22 nM against PARP.

- ST clopentapyrrolocarbazole prepn inhibitor poly ADP ribose polymerase; PARP inhibitor multicyclic compd prepn; pyrrolocarbazole prepn inhibitor VEGFR2 kinase; furanopyrrolocarbazole prepn inhibitor VEGFR2 kinase; neurodegenerative disease treatment multicyclic compd prepn; inflammation treatment multicyclic compd prepn; ischemia treatment multicyclic compd prepn; MLK3 kinase inhibitor multicyclic compd prepn
- IT Nervous system

(Huntington's chorea; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system

(central, injury; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Nervous system

(degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,

and MLK3 kinase)

IT Eye, disease

(diabetic retinopathy; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Cell proliferation

(disorders; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Uterus, disease

(endometriosis; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease

(intraocular neovascular syndromes; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Brain, disease

Heart, disease

(ischemia; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease

(macula, degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Heterocyclic compounds

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nitrogen, aromatic; preparation of novel multicyclic compds. and their

amino

acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Alzheimer's disease

Angiogenesis inhibitors

Anti-inflammatory agents

Antidiabetic agents

Antitumor agents

Parkinson's disease

Psoriasis

Rheumatoid arthritis

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amino acids, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

```
ΙT
     Shock (circulatory collapse)
        (septic; preparation of novel multicyclic compds. and their amino acid
        derivs. as inhibitors of enzymes for treatment of diseases
        related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,
        and MLK3 kinase)
ΙT
     374069-00-8P
                    374069-03-1P
                                    374069-12-2P
                                                    374069-14-4P
                                                                   374069-19-9P
     374069-21-3P
                    374069-22-4P
                                    374069-23-5P
                                                    374069-25-7P
                                                                   374069-26-8P
     374069-31-5P
                    374069-33-7P
                                    374069-35-9P
                                                    374069-36-0P
                                                                   374069-43-9P
     374069-44-0P
                    374069-53-1P
                                    374069-62-2P
                                                    374069-75-7P
                                                                   374070-30-1P
     374070-33-4P
                    374070-38-9P
                                    374070-39-0P
                                                    374070-57-2P
                                                                   374070-59-4P
                    374070-73-2P
                                    374070-77-6P
                                                    374070-79-8P
                                                                   374070-80-1P
     374070-64-1P
     374070-83-4P
                    374070-95-8P
                                    374070-96-9P
                                                    374071-01-9P
                                                                   374071-12-2P
     374071-16-6P
                    374071-28-0P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
     (Reactant or reagent); USES (Uses)
        (preparation of novel multicyclic compds. and their amino acid derivs. as
        inhibitors of enzymes for treatment of diseases related to
        enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
        kinase)
ΙT
     154114-97-3P
                    374068-99-2P
                                    374069-01-9P
                                                    374069-02-0P
                                                                   374069-04-2P
     374069-05-3P
                    374069-06-4P
                                    374069-07-5P
                                                    374069-08-6P
                                                                   374069-09-7P
     374069-10-0P
                    374069-11-1P
                                    374069-13-3P
                                                    374069-15-5P
                                                                   374069-16-6P
     374069-17-7P
                    374069-18-8P
                                    374069-20-2P
                                                    374069-24-6P
                                                                   374069-27-9P
     374069-28-0P
                    374069-29-1P
                                    374069-30-4P
                                                    374069-32-6P
                                                                   374069-34-8P
     374069-37-1P
                    374069-38-2P
                                    374069-39-3P
                                                    374069-40-6P
                                                                   374069-41-7P
     374069-42-8P
                    374069-45-1P
                                    374069-46-2P
                                                    374069-47-3P
                                                                   374069-48-4P
     374069-49-5P
                    374069-50-8P
                                    374069-51-9P
                                                    374069-52-0P
                                                                   374069-54-2P
     374069-55-3P
                    374069-56-4P
                                    374069-57-5P
                                                    374069-58-6P
                                                                   374069-59-7P
     374069-60-0P
                    374069-61-1P
                                    374069-63-3P
                                                    374069-64-4P
                                                                   374069-65-5P
                    374069-67-7P
     374069-66-6P
                                    374069-68-8P
                                                    374069-69-9P
                                                                   374069-70-2P
     374069-71-3P
                    374069-72-4P
                                    374069-73-5P
                                                    374069-74-6P
                                                                   374069-76-8P
     374069-77-9P
                    374069-78-0P
                                    374069-79-1P
                                                                   374069-81-5P
                                                    374069-80-4P
     374069-82-6P
                    374069-83-7P
                                    374069-84-8P
                                                    374069-85-9P
                                                                   374069-87-1P
     374069-88-2P
                    374069-89-3P
                                    374069-90-6P
                                                    374069-91-7P
                                                                   374069-92-8P
     374069-93-9P
                    374069-94-0P
                                    374069-95-1P
                                                    374069-96-2P
                                                                   374069-97-3P
     374069-98-4P
                    374069-99-5P
                                    374070-00-5P
                                                    374070-01-6P
                                                                   374070-02-7P
     374070-03-8P
                    374070-04-9P
                                    374070-05-0P
                                                    374070-06-1P
                                                                   374070-07-2P
                    374070-09-4P
     374070-08-3P
                                    374070-10-7P
                                                    374070-11-8P
                                                                   374070-12-9P
     374070-13-0P
                    374070-14-1P
                                    374070-15-2P
                                                    374070-16-3P
                                                                   374070-17-4P
     374070-18-5P
                    374070-19-6P
                                    374070-20-9P
                                                    374070-21-0P
                                                                   374070-22-1P
     374070-23-2P
                    374070-24-3P
                                    374070-25-4P
                                                    374070-26-5P
                                                                   374070-27-6P
     374070-28-7P
                    374070-29-8P
                                    374070-31-2P
                                                    374070-32-3P
                                                                   374070-34-5P
     374070-35-6P
                    374070-36-7P
                                    374070-37-8P
                                                    374070-40-3P
                                                                   374070-41-4P
     374070-42-5P
                    374070-43-6P
                                    374070-44-7P
                                                    374070-45-8P
                                                                   374070-46-9P
     374070-47-0P
                                    374070-49-2P
                                                    374070-50-5P
                                                                   374070-51-6P
                    374070-48-1P
     374070-52-7P
                    374070-53-8P
                                    374070-54-9P
                                                    374070-55-0P
                                                                   374070-56-1P
                                                                   374070-65-2P
     374070-58-3P
                    374070-60-7P
                                    374070-62-9P
                                                    374070-63-0P
     374070-66-3P
                    374070-67-4P
                                    374070-68-5P
                                                    374070-69-6P
                                                                   374070-70-9P
     374070-71-0P
                    374070-72-1P
                                    374070-74-3P
                                                    374070-75-4P
                                                                   374070-76-5P
     374070-78-7P
                    374070-81-2P
                                    374070-82-3P
                                                    374070-84-5P
                                                                   374070-85-6P
     374070-86-7P
                    374070-87-8P
                                    374070-88-9P
                                                    374070-89-0P
                                                                   374070-90-3P
     374070-91-4P
                    374070-92-5P
                                    374070-93-6P
                                                    374070-94-7P
                                                                   374070-97-0P
     374070-98-1P
                    374070-99-2P
                                    374071-00-8P
                                                    374071-02-0P
                                                                   374071-03-1P
     374071-04-2P
                    374071-05-3P
                                    374071-06-4P
                                                    374071-07-5P
                                                                   374071-08-6P
     374071-09-7P
                    374071-10-0P
                                    374071-11-1P
                                                    374071-13-3P
                                                                   374071-14-4P
                                    374071-18-8P
     374071-15-5P
                    374071-17-7P
                                                    374071-19-9P
                                                                   374071-20-2P
```

374071-23-5P

374071-29-1P

374071-34-8P

374071-24-6P

374071-30-4P

374071-35-9P

374071-25-7P

374071-31-5P

374071-36-0P

374071-22-4P

374071-27-9P

374071-33-7P

374071-21-3P

374071-26-8P

374071-32-6P

```
374071-37-1P 374071-38-2P
                             374071-39-3P 374071-40-6P
                                                             374071-41-7P
                                                             374071-46-2P
374071-42-8P 374071-43-9P 374071-44-0P 374071-45-1P
374071-47-3P 374071-48-4P 374071-49-5P 374071-50-8P 374071-51-9P
374071-52-0P 374071-53-1P 374071-54-2P 374071-55-3P 374071-56-4P
374071-57-5P 374071-58-6P 374072-29-4P 374553-23-8P 374553-24-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
   (preparation of novel multicyclic compds. and their amino acid derivs. as
   inhibitors of enzymes for treatment of diseases related to
   enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
   kinase)
9055-67-8, Poly(ADP-ribose) polymerase 150977-45-0, VEGFR2 kinase
153190-46-6, MLK3 kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC
(Miscellaneous); BIOL (Biological study); PROC (Process)
   (preparation of novel multicyclic compds. and their amino acid derivs. as
   inhibitors of enzymes for treatment of diseases related to
   enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
   kinase)
50-00-0, Formaldehyde, reactions 60-34-4 62-55-5, Thioacetamide
62-56-6, Thiourea, reactions 64-19-7, Acetic acid, reactions 68-12-2,
DMF, reactions 74-88-4, Methyl iodide, reactions 75-36-5, Acetyl
chloride 79-03-8, Propionyl chloride 79-09-4, Propionic acid, reactions 79-30-1, Isobutyryl chloride 79-37-8, Oxalyl chloride
95-15-8, Benzothiophene 98-09-9, Phenylsulfonyl chloride 98-59-9
, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 105-36-2, Ethyl
bromoacetate 107-13-1, Acrylonitrile, reactions 107-92-6, Butyric
acid, reactions 108-00-9, N,N-Dimethylethylenediamine 108-12-3,
Isovaleryl chloride 108-30-5, Succinic anhydride, reactions
Glutaric anhydride 109-01-3, N-Methylpiperazine 109-86-4,
2-Methoxyethanol 109-89-7, Diethylamine, reactions 109-90-0, Ethyl
           109-97-7, Pyrrole 110-89-4, Piperidine, reactions
isocyanate
110-91-8, Morpholine, reactions 120-72-9, Indole, reactions 120-92-3,
               123-75-1, Pyrrolidine, reactions 124-63-0,
Cyclopentanone
Methanesulfonyl chloride 140-88-5, Ethyl acrylate 141-43-5,
Ethanolamine, reactions 141-75-3, Butyryl chloride 271-89-6,
             288-88-0, 1H-1,2,4-Triazole 399-52-0, 5-Fluoroindole
Benzofuran
541-59-3, Maleimide 544-92-3, Copper(I) cyanide 557-21-1, Zinc cyanide
591-08-2, N-Acetylthiourea 594-27-4, Tetramethyltin 598-21-0,
Bromoacetyl bromide
                     598-52-7, N-Methylthiourea 614-96-0,
5-Methylindole
                623-91-6, Diethyl fumarate
                                             630-08-0, Carbon monoxide,
reactions
           638-29-9, Valeryl chloride 690-76-6, 2-(tert-
Butoxycarbonyl)thioacetamide 762-42-5, Dimethyl acetylenedicarboxylate
933-67-5, 7-Methylindole 999-97-3, Hexamethyldisilazane 1121-92-2
1462-37-9, Benzyl 2-bromoethyl ether 1501-27-5, Glutaric acid monomethyl
        2038-03-1, 4-(2-Aminoethyl) morpholine 2114-02-5
                                                            2133-40-6,
L-Proline methyl ester hydrochloride 2812-46-6 3303-84-2,
N-tert-Butoxycarbonyl-\beta-alanine 3878-55-5, Succinic acid monomethyl
       4023-34-1, Cyclopropanecarbonyl chloride 4377-33-7, 2-Picolyl
ester
          4524-93-0, Cyclopentanecarbonyl chloride 4530-20-5,
N-tert-Butoxycarbonyl-glycine 4744-50-7, Furo[3,4-b]pyrazine-5,7-dione 5070-13-3, Bis(4-nitrophenyl) carbonate 5332-06-9, 4-Bromobutyronitrile
           5437-45-6, Benzyl bromoacetate
                                            5699-40-1, N-Acetylguanidine
6940-76-7, 1-Chloro-3-iodopropane
                                   6971-44-4, 4-(N-
Methylaminomethyl)pyridine 7148-07-4, 1-(Cyclopenten-1-yl)pyrrolidine 7531-52-4, L-Prolinamide 13154-24-0, Triisopropylsilyl chloride
15098-69-8 16503-22-3, N-Methylhistamine dihydrochloride 18107-18-1,
Trimethylsilyldiazomethane 19099-93-5, Benzyl 4-oxo-1-
piperidinecarboxylate 21035-59-6, 2-(N-Methylaminomethyl)pyridine
24424-99-5, Di-tert-butyl dicarbonate 40594-97-6 49548-40-5
```

ΙΤ

ΙT

```
53300-47-3, 2-(Methanesulfonyl)thioacetamide 53654-35-6, 2-Vinylindole
     54663-78-4, 2-(Tributylstannyl)thiophene 57260-71-6
                                                              57260-73-8,
     N-tert-Butoxycarbonylethylenediamine 57294-38-9, 4-(tert-
     Butoxycarbonylamino) butyric acid 76822-35-0
                                                     86864-60-0,
     (2-Bromoethoxy)-tert-butyldimethylsilane 89031-84-5,
                                                               118486-97-8,
     (3-Bromopropoxy)-tert-butyldimethylsilane 98518-10-6
                                           124252-41-1, 4-
     2-(Tributylstannyl)-1-methylpyrrole
     (Tributylstannyl)pyridine 133565-49-8
                                              136088-69-2
                                                              138585-09-8,
     p-(tert-Butyldimethylsilyloxy)benzyl chloride 155440-58-7,
     3-(Furan-3-yl)indole
                           175277-31-3, 2-(tert-Butanesulfonyl)thioacetamide
     175334-72-2, 5-Isoxazolecarbothioamide 374071-64-4, 5-
     (Triisopropylsilyloxy) -2-(1-hydroxycyclopentyl)indole
     5-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-67-7,
     5-(2-Ethoxyethoxy)-2-(1-hydroxycyclopentyl)indole 374071-68-8,
     5-[2-(Diethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-69-9,
     5-[2-(Dimethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-70-2,
     5-[2-Morpholinoethoxy]-2-(1-hydroxycyclopentyl)indole
                                                             374071-71-3,
     2-(tert-Butoxycarbonyloxy)thioacetamide
                                              374071-77-9,
     2-(2-Buten-2-yl)indole 374071-87-1 374071-90-6, 2-(3-Hepten-3-yl)indole 374071-91-7, 3-(Cyclohexen-1-yl)-1-methylindole 3740
                                                                    374071-92-8,
     2-(2,3-Dihydrofuran-4-yl)indole 374071-93-9 374071-94-0
                                                                    374071-96-2,
     6-Methoxy-2-(1-hydroxycyclopentyl)indole
                                                374071-97-3,
     4-Methoxy-2-(1-hydroxycyclopentyl)indole
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of novel multicyclic compds. and their amino acid derivs. as
        inhibitors of enzymes for treatment of diseases related to
        enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
        kinase)
     90971-74-7P, 3-(Cyclopenten-1-yl)-1-(triisopropylsilyl)pyrrole
     118959-02-7P, 2-(Cyclopenten-1-yl)benzofuran 374071-59-7P, 2-(1-Hydroxycyclopentyl)indole 374071-60-0P, 2-(1-Cyclopentenyl)indole
                   374071-62-2P 374071-63-3P 374071-65-5P 374071-72-4P
     374071-61-1P
     374071-73-5P
                    374071-74-6P
                                   374071-75-7P
                                                 374071-76-8P
                                                                  374071-78-0P
     374071-79-1P, 2-(Cyclopenten-1-yl)pyrrole 374071-80-4P,
     3-(Cyclopenten-1-yl)pyrrole
                                  374071-81-5P, 2-(Cyclopenten-1-yl)-1-
     (triisopropylsilyl)pyrrole
                                  374071-82-6P 374071-83-7P 374071-84-8P
     374071-85-9P, 1,6,7,8-Tetrahydrocyclopenta[g]indole-4,5-dicarboxylic acid
     374071-86-0P
                    374071-88-2P 374071-89-3P 374071-95-1P
                                                                  374071-98-4P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of novel multicyclic compds. and their amino acid derivs. as
        inhibitors of enzymes for treatment of diseases related to
        enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
        kinase)
L32 ANSWER 19 OF 19
                      EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights
     reserved on STN
                    1999036418 EMBASE
ACCESSION NUMBER:
TITLE:
                    Angiogenesis: Possibilities for therapeutic interventions.
AUTHOR:
                    Wynendaele, W.; Van Oosterom, A.T.; Pawinski, A.; De
                    Bruijn, E.A., Dr. (correspondence)
                    Laboratory of Experimental Oncology, Herestraat 49, B-3000
CORPORATE SOURCE:
                    Leuven, Belgium.
                    De Bruijn, E.A., Dr. (correspondence); Maes, R.A.
AUTHOR:
CORPORATE SOURCE:
                    Laboratory of Human Toxicology, Department of
                    Pharmaceutics, University of Utrecht, Sorbonnelaan 16, 3508
                    TB Utrecht, Netherlands.
AUTHOR:
                    De Bruijn, E.A., Dr. (correspondence)
CORPORATE SOURCE:
                    Patent Technology Lille France, P.O. Box 192, NL-4500 AD
                    Oostburg, Netherlands.
```

Pharmacy World and Science, (1998) Vol. 20, No. 6, pp.

ΙT

SOURCE:

225 - 235. Refs: 131

ISSN: 0928-1231 CODEN: PWSCED

COUNTRY: Netherlands

Journal; General Review; (Review) DOCUMENT TYPE:

FILE SEGMENT: 030 Clinical and Experimental Pharmacology

> 037 Drug Literature Index

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 18 Feb 1999

Last Updated on STN: 18 Feb 1999

1999036418 EMBASE

- ΤI Angiogenesis: Possibilities for therapeutic interventions.
- ΑU Wynendaele, W.; Van Oosterom, A.T.; Pawinski, A.; De Bruijn, E.A., Dr. (correspondence)
- CS Laboratory of Experimental Oncology, Herestraat 49, B-3000 Leuven, Belgium
- ΑU De Bruijn, E.A., Dr. (correspondence); Maes, R.A.
- Laboratory of Human Toxicology, Department of Pharmaceutics, University of CS Utrecht, Sorbonnelaan 16, 3508 TB Utrecht, Netherlands.
- ΑU De Bruijn, E.A., Dr. (correspondence)
- Patent Technology Lille France, P.O. Box 192, NL-4500 AD Oostburg, CS Netherlands.
- Pharmacy World and Science, (1998) Vol. 20, No. 6, pp. 225-235. SO Refs: 131

ISSN: 0928-1231 CODEN: PWSCED

- CY Netherlands
- DТ Journal; General Review; (Review)
- FS 030 Clinical and Experimental Pharmacology 037 Drug Literature Index
- LA English
- SL English
- ED Entered STN: 18 Feb 1999 Last Updated on STN: 18 Feb 1999
- AΒ Vascular proliferation normally occurs only during embryonic development, the female reproductive cycle and wound healing. Various pathological conditions such as diabetic retinopathy are characterized by persistent, uncontrolled angiogenesis. At the other hand, impaired development of new blood vessels has been found to be related with myocardial infarction. A series of anti-angiogenic drugs are currently included in experimental cancer treatment, whereas the failure of ulcers to heal may be limited by increased angiogenesis upon administration of growth factors. In the present review control mechanisms of the vasculature are summarized and therapeutic approaches discussed.
- Medical Descriptors: СТ

\*angiogenesis

cancer

cardiovascular disease diabetic retinopathy embryo development endothelium

heart infarction

ischemia

ovary cycle

review

ulcer healing

wound healing

СТ Drug Descriptors:

acidic fibroblast growth factor

alpha interferon

\*angiogenesis inhibitor

```
angiogenin
     angiostatin
     basic fibroblast growth factor
     genistein
     granulocyte colony stimulating factor
     *growth factor
     herbimycin a
     hyaluronic acid
     *interleukin 2
     interleukin 8
     lavendustin a
     oleanolic acid
     platelet derived endothelial cell growth factor
    prolactin
    proliferin
    roquinimex
     scatter factor
     *sialic acid derivative
     suramin
     thrombocyte factor 4
     thrombospondin 1
     tissue inhibitor of metalloproteinase 1
     tissue inhibitor of metalloproteinase 2
     tissue inhibitor of metalloproteinase 3
     transforming growth factor alpha
     transforming growth factor beta
     ursolic acid
     vasculotropin
RN
     (acidic fibroblast growth factor) 106096-92-8; (angiogenin) 97950-81-7;
     (angiostatin) 172642-30-7, 86090-08-6; (basic fibroblast growth factor)
     106096-93-9; (genistein) 446-72-0; (herbimycin A) 70563-58-5; (hyaluronic
     acid) 31799-91-4, 9004-61-9, 9067-32-7; (interleukin 2) 85898-30-2;
     (interleukin 8) 114308-91-7; (lavendustin A) 125697-92-9; (oleanolic acid)
     508-02-1; (prolactin) 12585-34-1, 50647-00-2, 9002-62-4; (proliferin)
     92769-12-5; (roquinimex) 84088-42-6; (scatter factor) 67256-21-7,
     72980-71-3; (suramin) 129-46-4, 145-63-1; (thrombocyte factor 4)
     37270-94-3, 69670-74-2; (thrombospondin 1) 343987-56-4; (tissue inhibitor
     of metalloproteinase 1) 140208-24-8; (tissue inhibitor of
     metalloproteinase 2) 124861-55-8; (tissue inhibitor of metalloproteinase
     3) 145809-21-8, 164781-40-2; (ursolic acid) 77-52-1; (vasculotropin)
     127464-60-2
=> d his
     (FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)
     FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008
                E US2007-599748/APPS
                E US2006-599748/APPS
              1 S E3
L1
                SEL RN L1
     FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008
L2
            162 S E1-E162
L3
             22 S L2 AND DIONE
L4
              0 S L2 AND PHENANTHROLINEDIONE
L_5
              2 S L2 AND PHENANTHROLINE
L6
              0 S "SUBSTITUTED PHENANTHROLINE"
```

angiogenic factor

```
FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON
     11 JUN 2008
         224329 S L2
T.7
         13877 S L3
Г8
T.9
            406 S L5
L10
         224329 S L7 OR L8 OR L9
L11
           3300 S 10 AND ANTIANGIOGENIC
L12
            56 S L11 AND ISCHEMIA
L13
             28 S L11 AND ("HEART DISEASE")
L14
             2 S L13 AND L12
L15
             7 S (L3 OR L5) AND ANTIANGIOGENIC
L16
            587 S "1,10-PHENANTHROLINE-5,6-DIONE"
L17
              4 S L16 AND PHENANTHRENE
     FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008
L18
                STR 27318-90-7
L19
              1 S L18 FAM SAM
                SET SMA OFF
                SET SMA ON
     FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008
     FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON
     11 JUN 2008
L20
           1303 S ("1,4-NAPHTHALENEDIONE?")
            129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L21
              0 S L21 AND ("HEART ATTACK")
L22
L23
              0 S L21 AND ("MYOCARDIAL INFARCTION")
L24
              4 S L21 AND ISCHEMIA
L25
              1 S L16 AND ("MYOCARDIAL INFARCTION")
L26
             0 S L16 AND ("ANGIOGENESIS INHIBITOR?")
           552 S L2 AND ("ANGIOGENESIS INHIBITOR?")
L27
L28
            24 S L3 AND ("ANGIOGENESIS INHIBITOR?")
L29
             2 S L5 AND ("ANGIOGENESIS INHIBITOR?")
L30
             53 S (L27 OR L28 OR L29) AND HEART
L31
             24 S L30 AND ISCHEMIA
L32
             19 S L31 AND (TREAT OR TREATING OR TREATMENT)
=> s 132 and ("5,6-dione")
L33
             0 L32 AND ("5,6-DIONE")
=> s 132 and ("1,10-phenanthrene")
L34
             0 L32 AND ("1,10-PHENANTHRENE")
=> s 132 and dione
             5 L32 AND DIONE
L35
=> dup rem 132 135
PROCESSING COMPLETED FOR L32
PROCESSING COMPLETED FOR L35
L36
             19 DUP REM L32 L35 (5 DUPLICATES REMOVED)
                ANSWERS '1-18' FROM FILE CAPLUS
                ANSWER '19' FROM FILE EMBASE
=> d scan 135
L35
      5 ANSWERS
                CAPLUS COPYRIGHT 2008 ACS on STN
IC
     ICM C07D277-46
CC
     28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
     Section cross-reference(s): 1, 63
ΤI
    Preparation of thiazole derivatives as modulators of the phosphoinositide
```

```
3-kinases (PI3Ks)
     thiazole prepn phosphoinositide 3 kinase PI3K gamma modulator
ST
     Nervous system, disease
ΤТ
        (Huntington's chorea, treating or preventing; preparation of
        thiazole derivs. as modulators of the phosphoinositide 3-kinases
        (PI3Ks))
ΙT
     Sarcoma
        (Kaposi's, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
     Antiarteriosclerotics
ΙT
        (antiatherosclerotics; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
     Muscle, disease
        (atrophy, treating or preventing skeletal muscle atrophy;
        preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
     Infection
ΙT
        (bacterial, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΤT
    Muscle
        (cardiac, treating or preventing cardiac myocyte dysfunction;
        preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
ΙT
     Hypertrophy
        (cardiac, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Lung, disease
        (chronic obstructive pulmonary disease, treating or
        preventing; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
     Nervous system, disease
        (degeneration, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
TТ
     Kidney, disease
        (fibrosis, treating or preventing progressive renal fibrosis;
        preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
ΙT
     Inflammation
     Kidney, disease
        (glomerulonephritis, treating or preventing; preparation of
        thiazole derivs. as modulators of the phosphoinositide 3-kinases
        (PI3Ks))
ΙT
     Kidney, disease
        (glomerulosclerosis, treating or preventing; preparation of
        thiazole derivs. as modulators of the phosphoinositide 3-kinases
        (PI3Ks))
ΤТ
     Muscle, disease
        (hypertrophy, treating or preventing skeletal muscle
        atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
     Heart, disease
        (hypertrophy, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΤТ
     Brain, disease
        (infection, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Intestine, disease
        (inflammatory, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΤТ
     Lung, disease
     Reperfusion
```

```
(injury, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
    Neoplasm
ΤТ
        (metastasis, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
IT
     Hypertrophy
        (muscular, treating or preventing skeletal muscle
        atrophy/hypertrophy; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
        (myocardium, treating or preventing cardiac myocyte
        dysfunction; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
     Inflammation
     Lung, disease
        (pneumonitis, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΤТ
    Allergy inhibitors
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiasthmatics
     Antibacterial agents
     Anticoaqulants
     Antihypertensives
     Antirheumatic agents
     Antitumor agents
    Antiviral agents
     Cardiovascular agents
     Human
     Immunosuppressants
     Platelet aggregation inhibitors
        (preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
TΤ
     Injury
        (pulmonary, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΤТ
        (renal, treating or preventing progressive renal fibrosis;
        preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
ΙT
     Injury
        (reperfusion, treating or preventing; preparation of thiazole
        derivs. as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΤТ
     Brain, disease
        (stroke, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
TΤ
     Lupus erythematosus
        (systemic, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
TΤ
     Central nervous system, disease
        (trauma, treating or preventing; preparation of thiazole derivs.
        as modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Leukocyte
        (treating or preventing leukocyte recruitment in cancer
        tissue; preparation of thiazole derivs. as modulators of the
        phosphoinositide 3-kinases (PI3Ks))
ΙT
     Allergy
     Alzheimer's disease
     Anaphylaxis
```

```
Asthma
     Atherosclerosis
     Autoimmune disease
     Cardiovascular system, disease
     Encephalitis
     Fibrosis
     Hypertension
     Inflammation
       Ischemia
     Kidney, disease
     Melanoma
     Meningitis
     Multiple sclerosis
     Neoplasm
     Platelet aggregation
     Psoriasis
     Rheumatoid arthritis
     Sepsis
     Thrombosis
     Transplant and Transplantation
     Transplant rejection
     Vasoconstriction
        (treating or preventing; preparation of thiazole derivs. as
        modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     Infection
        (viral, treating or preventing; preparation of thiazole derivs. as
        modulators of the phosphoinositide 3-kinases (PI3Ks))
ΙT
     115926-52-8
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
     860619-22-3P
                    860619-39-2P
                                   860619-58-5P
                                                  860619-75-6P
                                                                 860620-37-7P
TΤ
                    860620-39-9P
     860620-38-8P
                                   860620-40-2P
                                                  860620-42-4P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
ΙT
     32558-17-1P
                  307343-36-8P
                                  315704-54-2P
                                                 315705-71-6P
                                                                315705-72-7P
     315705-74-9P
                    315705-75-0P
                                   315705-76-1P
                                                  315705-77-2P
                                                                 315705-78-3P
     315705-79-4P
                    315705-80-7P
                                   315705-81-8P
                                                  315705-82-9P
                                                                 315705-83-0P
     315705-86-3P 315705-87-4P
                                   315705-90-9P
                                                  315705-91-0P
                                                                 315705-92-1P
     315705-94-3P
                    315705-95-4P
                                   333746-52-4P
                                                  333746-55-7P
                                                                 333746-64-8P
                  412919-76-7P
                                                428836-20-8P
                                                                 443747-65-7P
     333746-84-2P
                                   421580-61-2P
     472980-88-4P
                    860619-23-4P
                                   860619-24-5P
                                                  860619-25-6P
                                                                 860619-26-7P
                                   860619-29-0P
     860619-27-8P
                    860619-28-9P
                                                  860619-30-3P
                                                                 860619-31-4P
     860619-32-5P
                    860619-33-6P
                                   860619-34-7P
                                                  860619-35-8P
                                                                 860619-36-9P
     860619-37-0P
                    860619-38-1P
                                   860619-40-5P
                                                  860619-41-6P
                                                                 860619-42-7P
     860619-43-8P
                    860619-44-9P
                                   860619-45-0P
                                                  860619-46-1P
                                                                 860619-47-2P
     860619-48-3P
                    860619-49-4P
                                   860619-50-7P
                                                  860619-51-8P
                                                                 860619-52-9P
     860619-53-0P
                    860619-54-1P
                                   860619-55-2P
                                                  860619-56-3P
                                                                 860619-57-4P
     860619-59-6P
                    860619-60-9P
                                   860619-61-0P
                                                  860619-62-1P
                                                                 860619-63-2P
     860619-64-3P
                    860619-65-4P
                                   860619-66-5P
                                                  860619-67-6P
                                                                 860619-68-7P
     860619-69-8P
                    860619-70-1P
                                                  860619-72-3P
                                   860619-71-2P
                                                                 860619-73-4P
     860619-74-5P
                    860619-76-7P
                                   860619-77-8P
                                                  860619-78-9P
                                                                 860619-79-0P
     860619-80-3P
                    860619-81-4P
                                   860619-82-5P
                                                  860619-83-6P
                                                                 860619-84-7P
     860619-85-8P
                    860619-86-9P
                                   860619-87-0P
                                                  860619-88-1P
                                                                 860619-89-2P
     860619-90-5P
                    860619-91-6P
                                   860619-92-7P
                                                  860619-93-8P
                                                                 860619-94-9P
     860619-95-0P
                    860619-96-1P
                                   860619-98-3P
                                                  860620-00-4P
                                                                 860620-02-6P
     860620-03-7P
                   860620-04-8P
                                   860620-05-9P
                                                 860620-06-0P
                                                                 860620-07-1P
```

Angiogenesis

```
860620-15-1P
                                                          860620-17-3P
860620-13-9P
             860620-14-0P
                                           860620-16-2P
860620-18-4P 860620-19-5P
                             860620-20-8P 860620-21-9P
                                                          860620-22-0P
                                                          860620-27-5P
860620-23-1P 860620-24-2P
                             860620-25-3P 860620-26-4P
860620-28-6P 860620-29-7P
                             860620-30-0P 860620-31-1P
                                                          860620-32-2P
860620-33-3P 860620-34-4P
                            860620-35-5P 860620-36-6P
                                                          860620-41-3P
860620-43-5P 860620-44-6P
                            860620-45-7P 860620-46-8P
                                                          860620-47-9P
860620-48-0P 860620-49-1P
                            860620-50-4P 860620-51-5P
                                                         860620-52-6P
860620-53-7P 860620-70-8P
                             860620-75-3P 860620-76-4P
                                                          860620-77-5P
860620-78-6P
              860620-83-3P
                             860620-84-4P
                                           860620-86-6P
                                                          860620-87-7P
860620-88-8P 860620-89-9P
                             860621-18-7P
                                           860621-19-8P
                                                          860621-20-1P
860621-21-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (preparation of thiazole derivs. as modulators of the phosphoinositide
   3-kinases (PI3Ks))
79-19-6, Thiosemicarbazide 103-85-5, N-Phenylthiourea 107-95-9,
\beta-Alanine 109-57-9, N-Allylthiourea 109-9\overline{4}-4, Ethyl formate
121-92-6, 3-Nitrobenzoic acid 123-54-6, 2,4-Pentanedione, reactions
367-57-7, 1,1,1-Trifluoropentane-2,4-dione 621-83-0,
N-Benzylthiourea 709-72-8 1516-33-2, N-Isobutylthiourea
                            1520-26-9
N-(2-Methoxyphenyl)thiourea
                                       1520-27-0, N-(4-
Hydroxyphenyl)thiourea 2237-30-1, 3-Aminobenzonitrile
                                                       2293-07-4.
N-(4-Methoxyphenyl)thiourea 2295-31-0, 2,4-Thiazolidinedione
3394-05-6, N-(3-Hydroxyphenyl)thiourea 3460-55-7, N-(4-
                    3696-22-8, N-(4-Nitrophenyl)thiourea
Cyanophenyl)thiourea
                                                            3696-23-9.
N-(4-Chlorophenyl)thiourea 4947-89-1, N-(3-Chlorophenyl)thiourea
5055-72-1, N-Cyclohexylthiourea 5100-34-5, Ethyl 3-isocyanatopropionate
5344-82-1, N-(2-Chlorophenyl)thiourea 5657-42-1 6814-99-9,
N-(sec-Butyl)thiourea 6815-00-5, N-(2-Phenylethyl)thiourea
                      7366-56-5
                                  14294-09-8, 1-
N-(tert-Butyl)thiourea
Piperidinecarbothioamide 14294-10-1, 4-Morpholinecarbothioamide
14294-11-2, N-Pyridin-2-ylthiourea 20602-45-3 25343-29-7,
N-(2,2-Dimethylpropyl)thiourea 25433-09-4 29146-81-4 30162-37-9,
N-Pyridin-3-ylthiourea 30162-39-1 30381-21-6, N-(2-Cyanoethyl)thiourea
30748-47-1, 5-Acetyl-2-amino-4-methylthiazole 33860-28-5,
4-Methylpiperazine-1-carbothioamide 37014-08-7
                                               37182-75-5
40398-36-5, 1-Pyrrolidinecarbothioamide
                                        51039-84-0
                                                    52992-37-7
            56541-14-1, N-Cyclopropylthiourea 61451-94-3,
N-(2,3-Dihydro-1H-inden-2-yl)thiourea
                                      63467-61-8, N-(2,2-
Diethoxyethyl)thiourea
                       66892-01-1
                                    66892-25-9, N-(Tetrahydrofuran-2-
vlmethyl)thiourea
                   72806-58-7
                              73161-70-3, N-(Pyridin-3-
                   73434-75-0, N-(2-Hydroxy-2-phenylethyl)thiourea
ylmethyl)thiourea
74764-61-7
            86114-63-8
                         99115-47-6
                                     102353-42-4, N-(2-
                       102936-57-2, N-Cyclopentylthiourea
                                                           111538-46-6,
Methoxyethyl)thiourea
N-(3-(Morpholin-4-yl)propyl)thiourea 122641-10-5, N-(2-(Morpholin-4-yl)propyl)
                  125117-97-7, N-(6-Chloropyridin-3-yl)thiourea
yl)ethyl)thiourea
             171874-49-0, N-[2-(2-Hydroxyethyl)phenyl]thiourea
140899-50-9
179927-28-7
             196809-80-0
                         206761-87-7, N-(2-(Piperidin-1-
                   227932-43-6
yl)ethyl)thiourea
                                237385-80-7, N-[3-
(Hydroxymethyl)phenyl]thiourea
                                282715-65-5, N-(Pyridin-4-
ylmethyl)thiourea 342626-46-4
                               420130-44-5, N-(6-Methoxypyridin-3-
             473706-96-6
                         473706-97-7 500865-55-4
yl)thiourea
                                                     572889-33-9,
N-Cyclobutylthiourea
                     618913-44-3, N-(Cyclopropylmethyl)thiourea
            659741-75-0
                           763887-70-3
                                       850164-09-9,
659741-74-9
N-(3-Cyanophenyl)thiourea
                           859786-81-5
                                        860615-45-8,
N-(Benzofuran-5-yl)thiourea
                             860617-18-1, N-(2-Chloropyridin-4-
yl)thiourea 860620-65-1 860620-66-2 860620-67-3 860620-68-4,
3-Hydroxypyrrolidine-1-carbothioamide 860620-69-5, N-(2-Fluoropyridin-3-
yl)thiourea 860620-71-9, N-(3,3-Diethoxypropyl)thiourea 860620-72-0,
```

860620-10-6P

860620-11-7P

860620-12-8P

860620-08-2P

ΙT

860620-09-3P

```
N-(2-Chloropyridin-3-y1)thiourea 860620-73-1, N-[3-(1,3-0xazol-5-1)]
    yl)phenyl]thiourea 860620-74-2, N-[3-(1H-Tetrazol-5-yl)phenyl]thiourea
    860620-79-7, N-[3-(5-Hydroxy-1,3,4-oxadiazol-2-yl)phenyl]thiourea
    860620-80-0, N-[3-(5-Amino-1,3,4-thiadiazol-2-y1)phenyl]thiourea
    860620-91-3 860620-92-4, N-[4-(2-Hydroxyethyl)phenyl]thiourea
    860620-93-5, N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]thiourea
                                                                  860620-94-6
    860620-95-7 860620-96-8 860620-97-9
                                             860620-98-0 860620-99-1
    860621-00-7
                 860621-01-8
                                860621-02-9
                                              860621-03-0 860621-04-1
    860621-05-2, N-(4-Hydroxybutyl)thiourea 860621-06-3 860621-07-4
    860621-08-5
                 860621-09-6
                                860621-10-9
                                              860621-11-0 860621-12-1
    860621-13-2
                  860621-14-3
                                860621-15-4 860621-16-5 860621-17-6
    RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
ΙT
    618-95-1P, Methyl 3-nitrobenzoate 926-59-0P 3043-28-5P,
    3-Bromo-2,4-pentanedione
                               4138-35-6P, Methyl 3-aminopropanoate
    14062-34-1P 32519-72-5P 32519-75-8P 39884-12-3P 53159-71-0P,
    1-(2-Amino-1, 3-thiazol-5-yl) ethanone 83725-80-8P, 5-(3-Nitrophenyl)-
    1,3,4-oxadiazol-2-ol 87005-15-0P 94284-63-6P, Ethyl
    5-acetyl-2-amino-1,3-thiazole-4-carboxylate
                                                 115082-05-8P
                                                                 167405-28-9P,
    1-[2-Amino-4-(trifluoromethyl)-1,3-thiazol-5-yl] ethanone 191399-17-4P,
    1-(2-Amino-4-methyl-1, 3-oxazol-5-yl) ethanone 299441-33-1P,
    5-(3-Aminophenyl)-1,3,4-thiadiazol-2-amine 440087-89-8P
                                                               696629-98-8P
                                 860620-55-9P, N-(5-Acetyl-4-methyl-1,3-
    860615-87-8P
                  860620-54-8P
                                          860620-57-1P, N-(5-Acetyl-1,3-
    oxazol-2-yl)acetamide 860620-56-0P
    thiazol-2-yl)acetamide 860620-58-2P 860620-59-3P, N-[5-Acetyl-4-
     (trifluoromethyl)-1,3-thiazol-2-yl)acetamide 860620-60-6P
    860620-61-7P, Ethyl 5-acetyl-2-(acetylamino)-1,3-thiazole-4-carboxylate
                   860620-63-9P
                                 860620-64-0P, N-[3-(5-Amino-
    860620-62-8P
     [1,3,4]thiadiazol-2-yl)phenyl]-2,2,2-trifluoro-acetamide
                                                               860620-81-1P
                  860620-85-5P
    860620-82-2P
                                  860620-90-2P
    RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of thiazole derivs. as modulators of the phosphoinositide
        3-kinases (PI3Ks))
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5
     5 ANSWERS
L35
                CAPLUS COPYRIGHT 2008 ACS on STN
IC
    ICM A61K031-00
    1-7 (Pharmacology)
CC
ΤI
    Therapeutics for chemokine-mediated diseases
ST
    chemokine mediated disease treatment chemokine receptor binding
    compd; tricyclic phenanthrene deriv chemokine mediated disease
    treatment; phenanthrenedione multiple sclerosis treatment
ΤТ
    Chemokine receptors
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (CCR2; therapeutics for chemokine-mediated diseases)
ΤТ
    Chemokine receptors
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (CCR4; therapeutics for chemokine-mediated diseases)
TΤ
    Chemokine receptors
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (CXCR1; therapeutics for chemokine-mediated diseases)
TΤ
    Chemokine receptors
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (CXCR2; therapeutics for chemokine-mediated diseases)
ΙT
    Inflammation
        (Crohn's disease; therapeutics for chemokine-mediated diseases)
ΤТ
    Intestine, disease
        (Crohn's; therapeutics for chemokine-mediated diseases)
```

```
ТТ
     Sepsis
        (Gram-neg.; therapeutics for chemokine-mediated diseases)
ΤТ
     Neutrophil
        (activation; therapeutics for chemokine-mediated diseases)
ΤТ
     Inflammation
        (acute; therapeutics for chemokine-mediated diseases)
ΙT
     Respiratory distress syndrome
        (adult; therapeutics for chemokine-mediated diseases)
ΙΤ
     Transplant rejection
        (allotransplant; therapeutics for chemokine-mediated diseases)
ΙΤ
     Antiarteriosclerotics
        (antiatherosclerotics; therapeutics for chemokine-mediated diseases)
ΙΤ
     Dermatitis
        (atopic; therapeutics for chemokine-mediated diseases)
ΙT
     Lung, disease
        (chronic obstructive pulmonary disease; therapeutics for
        chemokine-mediated diseases)
ΙT
     Inflammation
     Transplant rejection
        (chronic; therapeutics for chemokine-mediated diseases)
ΤТ
     Autoimmune disease
        (exptl. autoimmune encephalomyelitis; therapeutics for
        chemokine-mediated diseases)
ΙT
     Encephalomyelitis
        (exptl. autoimmune; therapeutics for chemokine-mediated diseases)
ΙT
     Lung, disease
        (fibrosis, idiopathic; therapeutics for chemokine-mediated diseases)
ΙT
     Ischemia
        (focal; therapeutics for chemokine-mediated diseases)
ΙT
     Inflammation
     Kidney, disease
        (glomerulonephritis; therapeutics for chemokine-mediated diseases)
TΤ
     Transplant and Transplantation
        (graft-vs.-host reaction; therapeutics for chemokine-mediated diseases)
ΙT
     Intestine, disease
        (inflammatory; therapeutics for chemokine-mediated diseases)
ΙT
        (injury, cardiac and renal; therapeutics for chemokine-mediated
        diseases)
ΙT
     Lung, disease
        (injury, mononuclear phagocyte-dependent; therapeutics for
        chemokine-mediated diseases)
ΙT
     Phagocyte
        (mononuclear, mononuclear phagocyte-dependent lung injury; therapeutics
        for chemokine-mediated diseases)
ΤТ
     Cell activation
        (neutrophil; therapeutics for chemokine-mediated diseases)
ΙT
     Arthritis
        (pseudogout, acute; therapeutics for chemokine-mediated diseases)
ΙT
     Fibrosis
        (pulmonary, idiopathic; therapeutics for chemokine-mediated diseases)
ΙT
     Injury
        (pulmonary, mononuclear phagocyte-dependent; therapeutics for
        chemokine-mediated diseases)
ΙT
     Heart, disease
     Kidney, disease
        (reperfusion injury; therapeutics for chemokine-mediated diseases)
ΤТ
     Injury
        (reperfusion, cardiac and renal; therapeutics for chemokine-mediated
        diseases)
TΤ
     Artery, disease
```

```
(restenosis; therapeutics for chemokine-mediated diseases)
ΤТ
     Shock (circulatory collapse)
        (septic; therapeutics for chemokine-mediated diseases)
     Brain, disease
IΤ
        (stroke; therapeutics for chemokine-mediated diseases)
ΙT
     Multiple sclerosis
        (therapeutic agents; therapeutics for chemokine-mediated diseases)
ΙT
     Alzheimer's disease
     Angiogenesis
       Angiogenesis inhibitors
     Anti-Alzheimer's agents
     Anti-inflammatory agents
     Anti-ischemic agents
     Antiarthritics
     Antiasthmatics
     Anticoagulants
     Antimalarials
     Arthritis
     Asthma
     Atherosclerosis
     Cardiovascular agents
     Drug delivery systems
     Gastrointestinal agents
     Gout
     Inflammation
     Malaria
     Multiple sclerosis
     Neutrophil
     Psoriasis
     Rheumatoid arthritis
     Sarcoidosis
     Thrombosis
        (therapeutics for chemokine-mediated diseases)
TТ
     Chemokine receptors
     Chemokines
     Interleukin 8
     Monocyte chemoattractant protein-1
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (therapeutics for chemokine-mediated diseases)
ΙT
     Shock (circulatory collapse)
        (toxic shock syndrome; therapeutics for chemokine-mediated diseases)
ΙT
     Inflammation
     Intestine, disease
        (ulcerative colitis; therapeutics for chemokine-mediated diseases)
     Interleukin 8 receptors
ΤТ
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\alpha; therapeutics for chemokine-mediated diseases)
     Interleukin 8 receptors
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (\beta; therapeutics for chemokine-mediated diseases)
     7440-70-2, Calcium, biological studies 169592-56-7, Caspase 3
ΙT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (therapeutics for chemokine-mediated diseases)
     82-86-0, Acenaphthenequinone
                                   83-32-9, Acenaphthene 84-11-7,
ΤТ
     Phenanthrene-9,10-dione
                               1015-89-0, 6(5H)-Phenanthridinone
     4707-71-5, Phenanthrene-9-carboxaldehyde
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (therapeutics for chemokine-mediated diseases)
L35
      5 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
```

- CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1, 63
- TI Preparation of pyrazine derivatives, particularly N-[3- (oxyphenylamino)quinoxalin-2-yl]sulfonamides, as PI3K inhibitors
- ST pyrazine quinoxaline oxyphenylamino sulfonamide prepn phosphoinositide kinase PIK3K inhibitor; pyridopyrazine pyrazine quinoxaline prepn PIK3K inhibitor
- IT Nervous system, disease

(Huntington's chorea; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sarcoma

(Kaposi's; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease

(airway inflammation; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Antiarteriosclerotics

(antiatherosclerotics; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease

(atrophy, skeletal; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(bacterial, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(bacterial, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Infection

(bacterial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease

(chronic obstructive pulmonary disease; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Nervous system, disease

(degeneration; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Ervthrocvte

(disease, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Sperm motility

(diseases; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood vessel, disease

(endothelium injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung

(epithelium, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Blood, disease

(erythrocyte, deficiency; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Kidney, disease

(fibrosis, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation

Kidney, disease

(glomerulonephritis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Muscle, disease

(hypertrophy; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Brain, disease

(infection; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Lung, disease

Reperfusion

(injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Neoplasm

(metastasis, invasion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Hypertrophy

(muscular; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation

Pancreas, disease

(pancreatitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Skin, disease

(passive cutaneous anaphylaxis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Inflammation

Lung, disease

(pneumonitis; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases)

IT Allergy

Allergy inhibitors

Alzheimer's disease

Anaphylaxis

Angiogenesis

Angiogenesis inhibitors

Anti-Alzheimer's agents

Anti-inflammatory agents

Anti-ischemic agents

Antiasthmatics

Antibacterial agents

Antifibrotic agents

Antihypertensives

Antirheumatic agents

Antitumor agents

Antiviral agents

Asthma

Atherosclerosis

Autoimmune disease

B cell (lymphocyte)

Bone marrow

Cardiac hypertrophy

Cardiovascular agents

Cardiovascular system, disease

Central nervous system agents

Encephalitis

Fibrosis

Glomerulosclerosis

Heart, disease

Human

Hypertension

Immunomodulators

Immunosuppressants

Inflammation

Inflammatory bowel disease

Ischemia Kidney, disease Mast cell Melanoma Meningitis Multiple organ failure Multiple sclerosis Neoplasm Neuroprotective agents Pharmaceutical carriers Pharmaceutical excipients Platelet activation Platelet aggregation Platelet aggregation inhibitors Prophylaxis Psoriasis Rheumatoid arthritis Sepsis Stroke Thrombolytics Thrombosis Transplant and Transplantation Transplant rejection Vasoconstriction Vasodilators (preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Epithelium (pulmonary, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Injury (pulmonary; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Leukocyte (recruitment in cancer tissue; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Fibrosis (renal, progressive; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Injury (reperfusion; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Lupus erythematosus (systemic; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Central nervous system, disease (trauma; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Injury (vascular endothelial; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) Endothelium (vascular, disease, injury; preparation of pyrazine derivs. as PI3K inhibitors useful in treatment and prophylaxis of diseases) (viral, acute; preparation of pyrazine derivs. as PI3K inhibitors useful in

(viral, chronic; preparation of pyrazine derivs. as PI3K inhibitors useful

ΙT

ΙT

ΙT

ΙT

ΙT

ΙT

ΤТ

TΤ

TΤ

ΤT

ΙT

ΤТ

Infection

Infection

treatment and prophylaxis of diseases)

in treatment and prophylaxis of diseases)

```
(viral; preparation of pyrazine derivs. as PI3K inhibitors useful in
        treatment and prophylaxis of diseases)
ΤТ
    328039-48-1P, 4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
                           331723-61-6P, N-[3-[(3-
    yl]benzenesulfonamide
    Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 371958-49-5P,
    N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
    372090-78-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
                            372091-52-6P, N-[3-[(2,5-
    yl]benzenesulfonamide
    Dimethoxyphenyl)amino|quinoxalin-2-yl]-4-methylbenzenesulfonamide
     424804-76-2P, 4-Chloro-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-
    yl]benzenesulfonamide 432007-91-5P, 4-Bromo-N-[3-[(3-
    methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
    N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
    fluorobenzenesulfonamide 585560-01-6P, N-[3-[(3,5-
    Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide
    713083-87-5P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-
    yl]benzenesulfonamide 714245-33-7P, N-[3-[(3,5-
    Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide
    714257-01-9P, 4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
                          714282-93-6P, N-[3-[(2,5-
    yl]benzensulfonamide
    Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methylbenzenesulfonamide
    714916-66-2P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
    fluorobenzenesulfonamide 714917-87-0P, 4-Fluoro-N-[3-[(3-
    methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                            714932-70-4P,
    N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide
    714932-98-6P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
    methoxybenzenesulfonamide
                               843630-52-4P, N-[3-[(3,5-
    Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                               928139-93-9P,
     4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic
           928139-97-3P, 3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
    yl]amino]sulfonyl]benzoic acid
                                    928140-00-5P, N-[3-[(3,5-
    Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(hydroxymethyl)pyridine-3-
                 928140-31-2P, Methyl 3-[[[3-[(2,5-
    sulfonamide
    dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-
                 928140-32-3P, Methyl 3-[[[3-[(3,5-
    carboxylate
    dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]thiophene-2-
                  928140-36-7P, 3-Cyano-N-[3-[(3,5-
    dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                               928140-38-9P,
    Methyl 3-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
    yl]amino]sulfonyl]benzoate
                                 928140-39-0P, Methyl 3-[[[3-[(3,5-
    dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate
    928140-43-6P, 4-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
    yl]benzenesulfonamide
                            928140-50-5P, Methyl 4-[[[3-[(2,5-
    dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoate
    928140-51-6P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
                                928140-52-7P, Methyl 4-[[[3-[(2,5-
    yl]amino]sulfonyl]benzoate
    dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoate
    928140-53-8P, Methyl 4-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
                                  928140-71-0P, N-[3-[(2,5-
    vl]amino|sulfonvl]butanoate
    Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
    928140-73-2P, 4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
                            928140-75-4P, N-[3-[(3,5-
    yl]benzenesulfonamide
    Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide
                                                               928140-77-6P,
    N-[3-[(2,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl] methanesulfonamide
    928140-79-8P, N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-
                            928140-83-4P, 4-Bromo-N-[3-[(3,5-
    yl]methanesulfonamide
    dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                               928140-85-6P,
    N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
     (trifluoromethyl)Benzenesulfonamide 928140-87-8P, N-[3-[(3,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide
    928140-90-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
```

```
928140-92-5P, 4,5-Dichloro-N-[3-[(2,5-
iodobenzenesulfonamide
dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide
928140-95-8P, 4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
                       928140-96-9P, Methyl 3-[4-[[[3-[(3,5-
yl]benzenesulfonamide
dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]phenyl]propanoate
928140-98-1P, 5-Chloro-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-
1,3-dimethyl-1H-pyrazole-4-sulfonamide
                                        928141-00-8P,
5-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-
pyrazole-4-sulfonamide 928141-04-2P, 5-Bromo-N-[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide
928141-06-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-
yl]benzenesulfonamide 928141-11-1P, N-[7-Chloro-3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide 928141-13-3P,
Methyl 5-[[[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-
4-methylthiophene-2-carboxylate 928141-14-4P, 5-[[[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-
2-carboxylic acid methyl ester 928141-15-5P, 5-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-
2-carboxylic acid methyl ester 928141-18-8P, 2-Chloro-N-[3-[(2,5-
\verb|dimethoxyphenyl| amino] | quinoxalin-2-yl] - 4-fluor obenzene sulfonamide|
928141-20-2P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide
                         928141-22-4P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
928141-24-6P, 3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide 928141-26-8P, 3-Cyano-N-[3-[(2,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
928141-28-0P, 6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
vl]pvridine-3-sulfonamide
                           928141-30-4P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-
             928141-32-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
sulfonamide
yl]-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide 928141-35-9P,
N-[3-[(2-Chloro-5-methoxyphenyl) amino] quinoxalin-2-yl]-4-
cyanobenzenesulfonamide
                        928141-37-1P, N-[3-[(2-Chloro-5-
methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
                                                           928141-39-3P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-
sulfonamide
             928141-42-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]-6-methylpyridine-3-sulfonamide
                                   928141-47-3P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluoro-2-methylbenzenesulfonamide
928141-51-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-
methylpyridine-3-sulfonamide
                              928141-53-1P, 4-Cyano-N-[3-[(5-methoxy-2-
                                                       928141-56-4P,
methylphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-
             928141-58-6P, N-[3-[(2-Chloro-5-
methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
928141-59-7P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]pyridine-2-carboxylate
                                          928141-62-2P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(morpholin-4-
yl)carbonyl]benzenesulfonamide
                                928141-75-7P, 5-[[[3-[(3,5-
Dimethoxyphenyl)amino|quinoxalin-2-yl|amino|sulfonyl|pyridine-2-carboxylic
       928141-78-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
acid
[(4-methylpiperazin-1-yl)methyl]benzenesulfonamide
                                                    928141-81-5P,
4-(Aminomethyl)-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
                       928141-84-8P, 3-(Aminomethyl)-N-[3-[(3,5-
yl]benzenesulfonamide
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                           928141-88-2P,
N-[3-[(3,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl]-4-[(morpholin-4-
                              928141-90-6P, N-[3-[(3,5-
yl)methyl]benzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)carbonyl]benzenesulfonamide 928141-91-7P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)methyl]benzenesulfonamide 928141-93-9P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(dimethylamino)methyl]benzenesul
```

```
928141-95-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-
     fonamide
     3-[(dimethylamino)methyl]benzenesulfonamide 928142-00-1P,
     4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-
                                       928142-02-3P, 3-[[[3-[(3,5-
     (dimethylamino)propyl]benzamide
     Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-
     (dimethylamino) propyl] benzamide 928142-07-8P, N-[3-[(3,5-
     Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide
     928142-12-5P, 5-(Aminomethyl)-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-
     2-v1|thiophene-2-sulfonamide
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful
        in treatment and prophylaxis of diseases)
ΙT
     714244-38-9P, 3-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
                            714924-49-9P, 3-Chloro-N-[3-[(2,5-
     yl]benzenesulfonamide
     dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                                928140-02-7P,
     N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
     methylsulfonylbenzenesulfonamide 928140-03-8P, N-[3-[(3,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-3-sulfonamide
     928140-04-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-
     (morpholin-4-yl)pyridine-3-sulfonamide
                                              928140-07-2P,
     N-[3-[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
     v1]amino]sulfonyl]phenyl]acetamide 928140-08-3P, N-[3-[(2,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-(methylsulfonyl)benzenesulfonamid
         928140-09-4P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-
     (methylsulfonyl) benzenesulfonamide 928140-10-7P, N-[3-[(2,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,3-dihydro-1,4-benzodioxine-6-
     sulfonamide
                  928140-11-8P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
     yl]-4-[(pyrrolidin-1-yl)sulfonyl]benzenesulfonamide 928140-12-9P,
     N-[3-[(2,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]thiophene-3-sulfonamide
     928140-13-0P, 2-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
     yl]benzenesulfonamide
                            928140-14-1P, 3-Cyano-N-[3-[(2,5-
                                                                928140-15-2P,
     dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
     N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
     methoxybenzenesulfonamide
                                 928140-16-3P, N-[3-[(2,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide
     928140-17-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-
     fluorobenzenesulfonamide
                                928140-18-5P, N-[3-[(3,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-2-fluorobenzenesulfonamide
     928140-19-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
     (methylsulfonyl) benzenesulfonamide
                                         928140-20-9P, N-[3-[(3,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(pyrrolidin-1-
     yl)sulfonyl]benzenesulfonamide
                                     928140-21-0P, N-[3-[(2,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-(methylsulfonyl)benzenesulfonamid
         928140-22-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-
                                     928140-23-2P, N-[3-[(3,5-
     benzothiadiazole-4-sulfonamide
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide
     928140-24-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-2,1,3-
     benzoxadiazole-4-sulfonamide
                                    928140-25-4P, N-[3-[(2,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-2-yl)methanesulfonamide
     928140-26-5P, N-[3-[(3,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-1-(pyridin-
     2-yl)methanesulfonamide
                               928140-27-6P, N-[3-[(2,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-1-(pyridin-3-yl)methanesulfonamide
     928140-29-8P, N-[3-[(3,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl]-1-(pyridin-
                               928140-30-1P, N-[3-[(2,5-
     3-yl)methanesulfonamide
     \label{lem:decomposition} \mbox{Dimethoxyphenyl)amino]} \mbox{quinoxalin-2-yl]-1,2-dimethyl-1H-imidazole-5-}
                   928140-33-4P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
     sulfonamide
     yl]-3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide
     928140-34-5P, N-[3-[(3,5-Dimethoxyphenyl)] amino]quinoxalin-2-yl]-3-methyl-2-
     oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonamide 928140-35-6P,
```

```
2-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide 928140-37-8P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-methoxybenzenesulfonamide
928140-40-3P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
                          928140-41-4P, N-[3-[(3,5-
fluorobenzenesulfonamide
Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-fluorobenzenesulfonamide
928140-42-5P, 2-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
                      928140-44-7P, 2-Chloro-N-[3-[(2,5-
yl]benzenesulfonamide
dimethoxyphenyl)amino|quinoxalin-2-yl|benzenesulfonamide 928140-45-8P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-sulfonamide
928140-46-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]propane-1-
sulfonamide 928140-47-0P, N-[3-[[5-Methoxy-2-(1H-pyrrol-1-
yl)phenyl]amino]quinoxalin-2-yl]benzenesulfonamide 928140-48-1P,
N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
928140-49-2P, N-[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide
                      928140-55-0P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-56-1P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
methylbenzenesulfonamide potassium salt 928140-59-4P,
4-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzensulfonamide potassium salt 928140-60-7P, 4-Fluoro-N-[3-[(3-
methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-61-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide potassium salt
                                         928140-62-9P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
methoxybenzenesulfonamide potassium salt 928140-63-0P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
methylbenzenesulfonamide potassium salt
                                        928140-64-1P,
4-Bromo-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt 928140-65-2P, 4-Chloro-N-[3-[(3-
methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-66-3P, 4-Chloro-N-[3-[(2,5-dimethoxyphenyl)]amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt 928140-67-4P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
                928140-68-5P, N-[3-[(2,5-Dimethoxyphenyl)] amino] quinoxalin-
potassium salt
2-yl]benzenesulfonamide potassium salt
                                       928140-69-6P,
N-[3-[(3-Methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium
       928140-70-9P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]pyridine-3-sulfonamide potassium salt
                                          928140-72-1P,
4-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt
                                      928140-74-3P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt
928140-76-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]methanesulfonamide potassium salt
                                      928140-78-7P, N-[3-[(3-
Methoxyphenyl)amino]quinoxalin-2-yl]methanesulfonamide potassium salt
928140-80-1P, 4-Methoxy-N-[3-[(3-methoxyphenyl)amino]quinoxalin-2-
                                     928140-81-2P, 4-Bromo-N-[3-[(3-
yl]benzenesulfonamide potassium salt
methoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide potassium salt
928140-82-3P, 4-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt
                                      928140-84-5P, N-[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-(trifluoromethyl)Benzenesulfonami
                  928140-86-7P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxa
de potassium salt
lin-2-yl]-4-iodobenzenesulfonamide potassium salt
                                                   928140-88-9P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-iodobenzenesulfonamide
                 928140-91-4P, 4,5-Dichloro-N-[3-[(2,5-
potassium salt
dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide potassium
       928140-93-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-
salt.
2-yl]benzenesulfonamide potassium salt 928140-94-7P,
4-Acetyl-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt 928140-97-0P, 5-Chloro-N-[3-[(2,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-
```

```
sulfonamide potassium salt 928140-99-2P, 5-Chloro-N-[3-[(3,5-1)]]
dimethoxyphenyl)amino]quinoxalin-2-yl]-1,3-dimethyl-1H-pyrazole-4-
sulfonamide potassium salt 928141-01-9P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-methylbenzenesulfonamide
                928141-02-0P, N-[3-[(3,5-Dimethoxyphenyl)]amino]quinoxalin-
potassium salt
2-y1]-3-methylbenzenesulfonamide potassium salt
                                                928141-03-1P,
5-Bromo-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-
sulfonamide potassium salt 928141-05-3P, N-[3-[(3,5-
Dimethoxyphenyl)amino|pyrido[2,3-b]pyrazin-2-yl]benzenesulfonamide
potassium salt
                 928141-07-5P, N-[3-[(2,5-Dimethoxyphenyl)amino]pyrido[2,3-
b]pyrazin-2-yl]benzenesulfonamide 928141-08-6P, \overline{N}-[2-[(2,5-
Dimethoxyphenyl)amino]pyrido[3,4-b]pyrazin-3-yl]benzenesulfonamide
928141-09-7P, N-[7-Chloro-3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide potassium salt 928141-12-2P
                                                     928141-16-6P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]thiophene-2-sulfonamide
                928141-17-7P, 2-Chloro-N-[3-[(2,5-
potassium salt
dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
potassium salt 928141-19-9P, 2-Chloro-N-[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]-4-fluorobenzenesulfonamide
potassium salt 928141-21-3P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
2-yl]pyridine-3-sulfonamide potassium salt 928141-23-5P,
3-Cyano-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide potassium salt
                                        928141-25-7P,
3-Cyano-N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
fluorobenzenesulfonamide potassium salt 928141-27-9P,
6-Chloro-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-
sulfonamide potassium salt 928141-29-1P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-(dimethylamino)pyridine-3-
sulfonamide potassium salt 928141-31-5P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-[(3-methoxypropyl)amino]pyridine-
3-sulfonamide hydrochloride 928141-33-7P, N-[3-[(5-Methoxy-2-
methylphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide 928141-34-8P,
N-[3-[(2-Chloro-5-methoxyphenyl) amino]quinoxalin-2-yl]-4-
cyanobenzenesulfonamide potassium salt 928141-36-0P,
N-[3-[(2-Chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-
sulfonamide potassium salt
                            928141-38-2P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methoxypyridine-3-sulfonamide
potassium salt
                 928141-40-6P
                               928141-41-7P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
                 928141-44-0P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
potassium salt
2-yl]-4-fluoro-2-methylbenzenesulfonamide potassium salt
                                                          928141-49-5P,
N-[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-
sulfonamide potassium salt
                            928141-55-3P, N-[3-[(5-Methoxy-2-
methylphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
                 928141-57-5P, N-[3-[(2-Chloro-5-
potassium salt
methoxyphenyl)amino]quinoxalin-2-yl]-6-methylpyridine-3-sulfonamide
                928141-60-0P, N-[3-[(2-Bromo-5-
potassium salt
methoxyphenyl)amino]quinoxalin-2-yl]-1-methyl-1H-imidazole-4-sulfonamide
928141-61-1P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
[(morpholin-4-yl)carbonyl]benzenesulfonamide potassium salt
928141-63-3P, 3-[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]sulfamoyl]benzoic acid
                          928141-65-5P, 4-[[[3-[(2,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzoic acid
928141-66-6P, 4-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]butanoic acid
                                 928141-67-7P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]butanoic acid
928141-68-8P, 3-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]thiophene-2-carboxylic acid
                                               928141-69-9P,
3-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]thiophene-2-carboxylic acid 928141-70-2P,
3-[4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
```

```
928141-71-3P,
yl]amino]sulfonyl]phenyl]propanoic acid
5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-
methylthiophene-2-carboxylic acid 928141-72-4P, 5-[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-4-methylthiophene-2-
                928141-73-5P, 5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxa
carboxylic acid
lin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium
       928141-74-6P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid dipotassium salt
928141-76-8P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
[(morpholin-4-yl)methyl]benzenesulfonamide 928141-77-9P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-
yl)methyl]benzenesulfonamide dihydrochloride 928141-80-4P
928141-82-6P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-
(hydroxymethyl) benzenesulfonamide 928141-83-7P, 3-(Aminomethyl)-N-[3-
[(3,5-dimethoxyphenyl) amino] quinoxalin-2-yl] benzenesulfonamide
              928141-85-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
hydrochloride
2-yl]-4-(hydroxymethyl)benzenesulfonamide 928141-87-1P,
N-[3-[(3,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl]-4-[(morpholin-4-
yl)methyl]benzenesulfonamide hydrochloride 928141-89-3P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)methyl]benzenesulfonamide dihydrochloride 928141-92-8P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-
[(dimethylamino)methyl]benzenesulfonamide hydrochloride
                                                         928141-94-0P,
N-[3-[(3,5-Dimethoxyphenyl)]amino]quinoxalin-2-yl]-3-
[(dimethylamino)methyl]benzenesulfonamide hydrochloride
                                                         928141-96-2P,
4-[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
vl]amino]sulfonyl]benzamide sodium salt
                                        928141-97-3P,
4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-
                                        928141-98-4P,
yl]amino]sulfonyl]benzamide sodium salt
4-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-(3-
methoxypropyl)benzamide
                        928141-99-5P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N-[3-
                                              928142-01-2P
(dimethylamino)propyl]benzamide hydrochloride
928142-03-4P, 5-[[[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]-N,N-dimethylpyridine-2-carboxamide 928142-04-5P,
N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]-3-[(4-methylpiperazin-1-
yl)carbonyl]benzenesulfonamide potassium salt
                                               928142-05-6P,
N-[3-[(3,5-Dimethoxyphenyl)] amino] quinoxalin-2-yl]-6-[(morpholin-4-
yl)carbonyl]pyridine-3-sulfonamide
                                    928142-06-7P, N-[3-[(3,5-
Dimethoxyphenyl)amino]pyrido[2,3-b]pyrazin-2-yl]ethanesulfonamide
potassium salt
                 928142-08-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]quinoxalin-
2-yl]-6-[(4-methylpiperazin-1-yl)methyl]pyridine-3-sulfonamide
928142-09-0P
              928142-14-7P, N-[6-Chloro-3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]benzenesulfonamide
                                                           928142-15-8P,
N-[3-[[(2,3-Dihydro-1,4-benzodioxin-5-yl)methyl]amino]quinoxalin-2-
yl]benzenesulfonamide 928142-16-9P, N-[3-[(3,5-Dimethoxyphenyl)amino]-6-
                                        928142-17-0P,
nitroquinoxalin-2-yl]benzenesulfonamide
5-[[[3-[(2,5-Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-
                                    928142-18-1P, 5-[[[3-[(3,5-
methyl-1H-pyrrole-2-carboxylic acid
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-1-methyl-1H-pyrrole-
                  928142-19-2P, 4-[[[3-[(3,5-
2-carboxylic acid
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]benzamide
928142-20-5P, 4-[[[3-[(5-Methoxy-2-methylphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (drug candidate; preparation of pyrazine derivs. as PI3K inhibitors useful
   in treatment and prophylaxis of diseases)
                             636-76-0P, 3-(Aminosulfonyl)benzoic acid
98-10-2P, Benzenesulfonamide
```

825-86-5P, 4-Iodobenzenesulfonamide 1565-17-9P, 4-

ΤТ

```
Acetylbenzenesulfonamide 1899-94-1P, 3-Methylbenzenesulfonamide
2067-84-7P, 1,4-Dihydropyrido[2,3-b]pyrazine-2,3-dione
2922-45-4P, 3-Pyridinesulfonamide 4029-41-8P, N-(3-Chloroquinoxalin-2-1)
yl)-4-methylbenzenesulfonamide 4029-43-0P, 4-Bromo-N-(3-chloroquinoxalin-
2-yl)benzenesulfonamide 6339-87-3P, 2-Thiophenesulfonamide
                                                             6684-39-5P,
6-Chloropyridine-3-sulfonyl chloride 22808-73-7P, Methyl
4-(aminosulfonyl)benzoate 24243-71-8P, 1-Propanesulfonamide
25710-18-3P, 2,3-Dichloropyrido[2,3-b]pyrazine 32947-34-5P, Methyl
5-(aminosulfonyl)pyridine-2-carboxylate
                                        34082-13-8P,
6-Methylpyridine-3-sulfonamide 34117-90-3P, 3-Chloroquinoxalin-2-amine
35251-84-4P, 1,4-Dihydropyrido[3,4-b]pyrazine-2,3-dione
35251-99-1P, 2,3-Dichloropyrido[3,4-b]pyrazine 40741-46-6P,
6-Chloropyridine-3-sulfonamide 53595-65-6P, 5-Bromothiophene-2-
sulfonamide 59777-67-2P, Methyl 3-(aminosulfonyl)benzoate 63555-50-0P,
Methyl 3-(chlorosulfonyl)benzoate 69156-30-5P, 2-Chloro-4-
fluorobenzenesulfonamide 88398-46-3P, 5-Chloro-1,3-dimethyl-1H-pyrazole-
4-sulfonamide 165058-49-1P, N-(3-Methoxyphenyl)quinoxaline-2,3-diamine
166271-34-7P, N-(3-Chloro-2-quinoxalinyl)benzenesulfonamide
199590-78-8P, 6-(Dimethylamino)pyridine-3-sulfonamide 256353-34-1P,
4,5-Dichlorothiophene-2-sulfonamide
                                    478264-00-5P, 6-Methylpyridine-3-
sulfonyl chloride 488744-02-1P, N-(3-Chloroquinoxalin-2-yl)-4-
fluorobenzenesulfonamide
                         522628-95-1P, 4-Chloro-N-(3-chloroquinoxalin-2-
                      565172-05-6P, N-(3-Chloroquinoxalin-2-yl)-3-
yl)benzenesulfonamide
methylbenzenesulfonamide 743444-94-2P, 3-Chloro-N-(3-chloroquinoxalin-2-
yl) benzenesulfonamide 847985-15-3P, 2-Chloro-N-(3-chloroquinoxalin-2-
vl)benzenesulfonamide
                       848052-87-9P, N-(3-Chloroguinoxalin-2-yl)thiophene-
2-sulfonamide 856955-32-3P, 6-Methoxypyridine-3-sulfonamide
859491-30-8P, 5-[(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-
2-sulfonamide 883057-32-7P, 5-(Aminosulfonyl)-1-methyl-1H-pyrrole-2-
carboxylic acid methyl ester 928139-26-8P, N-(3,5-
Dimethoxyphenyl)quinoxaline-2,3-diamine
                                        928139-27-9P,
N-(2,5-Dimethoxyphenyl)quinoxaline-2,3-diamine 928139-28-0P, Methyl
3-[4-(aminosulfonyl)phenyl]propanoate 928139-29-1P, Methyl
5-(aminosulfonyl)-4-methylthiophene-2-carboxylate 928139-30-4P,
3-Cyano-4-fluorobenzenesulfonamide 928139-31-5P, 6-Cyanopyridine-3-
sulfonyl chloride
                  928139-32-6P, 6-Cyanopyridine-3-sulfonamide
928139-33-7P, 3-[(Morpholin-4-yl)carbonyl]benzenesulfonamide
928139-34-8P, 6-[(3-Methoxypropyl)amino]pyridine-3-sulfonamide
928139-35-9P, N-(3-Chloroquinoxalin-2-yl)-3-fluorobenzenesulfonamide
928139-36-0P, N-(3-Chloroquinoxalin-2-yl)propane-1-sulfonamide
928139-37-1P, Methyl 4-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]butanoate
928139-39-3P, Methyl 4-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]benzoate
928139-44-0P, N-(3-Chloroquinoxalin-2-yl)-4-methoxybenzenesulfonamide
928139-48-4P, N-(3-Chloroquinoxalin-2-yl)pyridine-3-sulfonamide
928139-50-8P, N-(3-Chloroquinoxalin-2-yl)-4-cyanobenzenesulfonamide
928139-52-0P, N-(3-Chloroquinoxalin-2-yl)methanesulfonamide
928139-54-2P, N-(3-Chloroquinoxalin-2-yl)-4-(trifluoromethyl) benzenesulfon
      928139-56-4P, N-(3-Chloroquinoxalin-2-yl)-4-iodobenzenesulfonamide
928139-58-6P, 4,5-Dichloro-N-(3-chloroquinoxalin-2-yl)thiophene-2-
             928139-60-0P, 5-Chloro-N-(3-chloroquinoxalin-2-yl)-1,3-
sulfonamide
dimethyl-1H-pyrazole-4-sulfonamide
                                   928139-62-2P, 4-Acetyl-N-(3-
chloroquinoxalin-2-yl)benzenesulfonamide
                                         928139-63-3P, Methyl
3-[4-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]phenyl]propanoate
928139-64-4P\text{, }5-Bromo-N-(3-chloroquinoxalin-2-yl)thiophene-2-sulfonamide
928139-66-6P, N-(3,6-Dichloroquinoxalin-2-y1) benzenesulfonamide
928139-67-7P, Methyl 5-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]-4-
methylthiophene-2-carboxylate 928139-70-2P, 5-[[(3-Chloroquinoxalin-2-
yl)amino]sulfonyl]-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester
928139-72-4P, 2-Chloro-N-(3-chloroquinoxalin-2-yl)-4-
fluorobenzenesulfonamide 928139-74-6P, N-(3-Chloroquinoxalin-2-y1)-5-
[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]thiophene-2-sulfonamide
```

```
928139-76-8P, N-(3-Chloroquinoxalin-2-yl)-3-cyano-4-
                          928139-78-0P, 6-Chloro-N-(3-chloroquinoxalin-2-
fluorobenzenesulfonamide
yl)pyridine-3-sulfonamide 928139-79-1P, N-(3-Chloroquinoxalin-2-yl)-6-
(dimethylamino)pyridine-3-sulfonamide 928139-81-5P, N-(3-
Chloroquinoxalin-2-yl)-6-[(3-methoxypropyl)amino]pyridine-3-sulfonamide
928139-83-7P, N-(3-Chloroquinoxalin-2-yl)-6-methoxypyridine-3-sulfonamide
928139-85-9P, N-(3-Chloroquinoxalin-2-yl)-6-methylpyridine-3-sulfonamide
928139-87-1P, Methyl 5-[[(3-chloroquinoxalin-2-yl)amino]sulfonyl]pyridine-
2-carboxylate 928139-88-2P, N-(3-Chloroquinoxalin-2-v1)-3-[(morpholin-4-
yl)carbonyl]benzenesulfonamide 928139-89-3P, N-(3-Chloroquinoxalin-2-yl)-
1-methyl-1H-imidazole-4-sulfonamide 928139-90-6P, N-(2-Chloropyrido[3,4-
b]pyrazin-3-yl)benzenesulfonamide
                                  928139-91-7P, N-(3-Chloropyrido[2,3-
b]pyrazin-2-yl)benzenesulfonamide 928139-92-8P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(4-methylpiperazin-1-
yl)carbonyl]benzenesulfonamide 928139-94-0P, N-[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]-4-[(morpholin-4-
yl)carbonyl]benzenesulfonamide 928139-95-1P, 4-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-
dimethylbenzamide 928139-96-2P, 3-[[[3-[(3,5-
Dimethoxyphenyl)amino]quinoxalin-2-yl]amino]sulfonyl]-N,N-
dimethylbenzamide 928139-98-4P, 6-(Chloromethyl)-N-[3-[(3,5-
dimethoxyphenyl)amino]quinoxalin-2-yl]pyridine-3-sulfonamide
928140-01-6P, Methyl 5-[[[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]amino]sulfonyl]-4-methylthiophene-2-carboxylate 928142-21-6P,
N-(5-Methoxy-2-methylphenyl)quinoxaline-2,3-diamine
                                                     928142-22-7P,
N-[5-Methoxy-2-(pyrrol-1-yl)phenyl]quinoxaline-2,3-diamine
                                                             928142-23-8P.
N-(5-Methoxy-2-chlorophenyl)quinoxaline-2,3-diamine
                                                     928142-24-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
   (intermediate; preparation of pyrazine derivs. as PI3K inhibitors useful in
   treatment and prophylaxis of diseases)
115926-52-8, Phosphoinositide 3-kinase 148640-14-6, Akt kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (preparation of pyrazine derivs. as PI3K inhibitors useful in
   treatment and prophylaxis of diseases)
928142-13-6P, 4-Acetyl-N-[3-[(3,5-dimethoxyphenyl)amino]quinoxalin-2-
yl]benzenesulfonamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
   (preparation of pyrazine derivs. as PI3K inhibitors useful in
   treatment and prophylaxis of diseases)
                               70-55-3, p-Toluenesulfonamide
54-96-6, 3, 4-Diaminopyridine
Benzenesulfonyl chloride
                          98-61-3, Pipsyl chloride
                                                      98-64-6,
4-Chlorobenzenesulfonamide 102-56-7, 2,5-Dimethoxyaniline 109-01-3,
                    109-55-7, N,N-Dimethyl-1,3-propanediamine
1-Methylpiperazine
                                                                 138-41-0,
4-(Aminosulfonyl)benzoic acid
                              402-46-0, 4-Fluorobenzenesulfonamide
452-58-4, 2,3-Diaminopyridine 536-90-3, m-Anisidine 701-34-8,
4-Bromobenzenesulfonamide 830-43-3, 4-(Trifluoromethyl)benzenesulfonamid
    1129-26-6, 4-Methoxybenzenesulfonamide <math>1524-40-9,
3-Fluorobenzenesulfonamide 1788-10-9, 4-Acetylbenzensulfonyl chloride
1899-93-0, m-Toluenesulfonyl chloride 2213-63-0, 2,3-Dichloroquinoxaline 2401-24-3, 2-Chloro-5-methoxyaniline 2905-21-7, 2-Fluorobenzenesulfonyl
           2958-87-4, 2,3,6-Trichloroquinoxaline
                                                   3119-02-6,
chloride
4-Cyanobenzenesulfonamide
                           3430-14-6, 3-Amino-6-methylpyridine
4025-64-3, 3-(Chlorosulfonyl)benzoic acid
                                           4808-69-9,
6-Methylpyridine-3-sulfonic acid
                                  5332-73-0, 3-Methoxypropylamine
5335-40-0, 3-(Methylsulfonyl)benzenesulfonyl chloride 5350-93-6,
5-Amino-2-chloropyridine 6961-82-6, 2-Chlorobenzenesulfonamide
10130-74-2, 3-Methoxybenzenesulfonyl chloride 10147-36-1,
1-Propanesulfonyl chloride 10272-07-8, 3,5-Dimethoxyaniline
```

ΙΤ

ΙT

ΙT

```
23905-46-6,
               17260-71-8, 3-Chlorobenzenesulfonamide
     chloride
     3-Acetylaminobenzenesulfonyl chloride 50868-72-9, 5-Methoxy-2-methylaniline 51175-71-4, 3-Thiophenesulfonyl chloride
     55338-73-3, 5-Amino-2-cyanopyridine 55854-46-1, 5-Bromothiophene-2-
     sulfonyl chloride
                        56542-67-7, 3-Cyanobenzenesulfonyl chloride
     59194-26-2, 5-Methoxy-2-(1H-pyrrol-1-yl)aniline 59337-92-7, Methyl
     3-(chlorosulfonyl)thiophene-2-carboxylate
                                                 59557-92-5,
     2-Bromo-5-methoxyaniline 63758-12-3 69360-26-5, 2-Cyanobenzenesulfonyl
                73713-79-8
                           82964-91-8, 4-(Methylsulfonyl)benzenesulfonyl
     chloride
               85958-57-2, 2-Chloro-4-fluorobenzenesulfonyl chloride
     chloride
     88398-93-0, 5-Chloro-1,3-dimethylpyrazole-4-sulfonyl chloride
     89265-35-0, 2-(Methylsulfonyl)benzenesulfonyl chloride 111124-90-4,
     1-Methyl-1H-imidazole-4-sulfonamide 114322-14-4, 2,1,3-Benzoxadiazole-4-
     sulfonyl chloride 126714-85-0, 2,3-Dichlorothiophene-5-sulfonyl chloride
     137049-00-4, 1-Methylimidazole-4-sulfonyl chloride 165669-32-9,
     4-[(Pyrrolidin-1-yl)sulfonyl]benzenesulfonyl chloride 175476-51-4,
     Methyl 4-(aminosulfonyl)butanoate 306936-62-9, 5-(Aminosulfonyl)-1-
     methyl-1H-pyrrole-2-carboxylic acid 312300-42-8, 6-Methoxypyridine-3-
     sulfonyl chloride 332361-07-6, 5-[(1,3-Dioxo-1,3-dihydroisoindol-2-
     yl)methyl]thiophene-2-sulfonyl chloride 337508-68-6 351003-23-1,
     4-Fluoro-3-cyanobenzenesulfonyl chloride 374537-95-8, Methyl
     3-(4-chlorosulfonylphenyl)propionate 423768-46-1, Methyl
     5-(chlorosulfonyl)-4-methyl-2-thiophenecarboxylate
                                                         847744-22-3,
     N-(3-Chloroquinoxalin-2-yl)-4-fluoro-2-methylbenzenesulfonamide
     849351-92-4, 1,2-Dimethyl-1H-imidazole-5-sulfonyl chloride
                                                                 878682-97-4.
     3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazole-6-sulfonyl chloride
     882564-09-2
                  928140-28-7 928141-10-0, N-(3,7-Dichloroquinoxalin-2-
     vl)benzenesulfonamide
                            928142-10-3, N-[3-[(3,5-
     Dimethoxyphenyl)amino]quinoxalin-2-yl]-5-[(1,3-dioxo-1,3-dihydro-2H-
     isoindol-2-yl)methyl]thiophene-2-sulfonamide
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of pyrazine derivs. as PI3K inhibitors useful in
        treatment and prophylaxis of diseases)
L35
      5 ANSWERS
                 CAPLUS COPYRIGHT 2008 ACS on STN
ΙC
     ICM A61K031-4412
     ICS A61P029-00; C07D213-69; C07D401-06; C07D409-06; C07D213-70;
          C07D213-64; C07D213-74; C07D405-06; C07D213-84; C07D401-10;
          C07D405-12; C07D401-12; C07D213-75; C07D401-14; C07D213-79;
          C07D401-04; C07D405-04; C07D413-10; C07D215-22
CC
     27-16 (Heterocyclic Compounds (One Hetero Atom))
     Section cross-reference(s): 1, 63
ΤI
     Preparation of substituted pyridinones as modulators of p38 MAP kinase
     pyridone p38 MAP kinase inhibitor antiinflammatory antiviral antiischemic
ST
     immunomodulator
     AIDS (disease)
ΤТ
        (-related complex, cachexia from; preparation of pyridinones as modulators
        of p38 MAP kinase for treatment of inflammatory conditions,
        ischemia, viral infections, autoimmune diseases, and other
        conditions)
ΙT
     Lymphoma
        (B-cell; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
     Inflammation
ΙT
        (Crohn's disease; preparation of pyridinones as modulators of p38 MAP kinase
        for treatment of inflammatory conditions, ischemia,
        viral infections, autoimmune diseases, and other conditions)
ΙΤ
     Intestine, disease
        (Crohn's; preparation of pyridinones as modulators of p38 MAP kinase for
```

16133-25-8, 3-Pyridinesulfonyl chloride 16629-19-9, 2-Thiophenesulfonyl

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nervous system, disease

(Huntington's chorea; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma

(adenocarcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Respiratory distress syndrome

(adult; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection

(allotransplant; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Nervous system, disease

(amyotrophic lateral sclerosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Blood vessel, neoplasm

(angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Bone

(avascular necrosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Necrosis

(avascular, bone; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Infection

(bacterial; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Skin, neoplasm

(basal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Carcinoma

(basal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral

infections, autoimmune diseases, and other conditions)

IT AIDS (disease)

Human herpesvirus

Pneumonia

(cachexia from; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease

(cardiomyopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Edema

Ischemia

(cerebral; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral  $\frac{1}{2}$ 

infections, autoimmune diseases, and other conditions)

IT Uterus, neoplasm

(cervix; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation

Lung, disease

(chronic pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm

(colon; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Intestine, neoplasm

(colorectal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Transplant rejection

(corneal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Kidney, disease

(diabetic nephropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Eye, disease

(diabetic retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Brain, disease

(edema; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Uterus, disease

(endometriosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (epidermal growth factor-binding; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Heart, disease

(failure; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Ulcer

(gastric; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions)

IT Inflammation

Stomach, disease

(gastritis; preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Transplant and Transplantation ΤТ (graft-vs.-host reaction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Blood vessel, neoplasm (hemangioma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Heart, disease (infarction; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Intestine, disease (inflammatory; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤT Eye, disease Reperfusion Spinal cord, disease (injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Intestine, disease (irritable bowel syndrome; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Brain, disease (ischemia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Rheumatoid arthritis (juvenile; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Neoplasm (metastasis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Pharynx (nasopharynx, angiofibroma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Lip (neoplasm; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Glaucoma (disease) (neovascular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Angiogenesis (neovascularization, eye; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other

conditions)

ТТ Angiogenesis (neovascularization, retinal; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Eve, disease (neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Inflammation Kidney, disease (nephritis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Inflammation (neurogenic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤT Nerve, disease (neuropathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Injury (ocular; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Eye, disease (photophobia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Inflammation Lung, disease (pneumonitis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Alzheimer's disease Analgesics Angiogenesis Angiogenesis inhibitors Anti-Alzheimer's agents Anti-inflammatory agents Anti-ischemic agents Antiarteriosclerotics Antiarthritics Antiasthmatics Antibacterial agents Anticoagulants Antidiabetic agents Antimalarials Antiparkinsonian agents Antipyretics Antirheumatic agents Antitumor agents Antiulcer agents Antiviral agents Arteriosclerosis Arthritis Asthma Autoimmune disease Bladder, neoplasm

Bone, neoplasm Bone resorption Bone resorption inhibitors Brain, neoplasm Burn Cachexia Carcinoma Cardiovascular agents Cardiovascular system, disease Dermatitis Diabetes insipidus Diabetes mellitus Digestive tract, disease Digestive tract, neoplasm Drug delivery systems Eczema Esophagus, neoplasm Eye, disease Fever and Hyperthermia Gastrointestinal agents Gout Granulation tissue Human Immunomodulators Inflammation Influenza Ischemia Keloid Leukemia Lip Liver, disease Liver, neoplasm Lung, disease Lung, neoplasm Lymphoma Malaria Mammary gland, neoplasm Meningitis Mouth, neoplasm Multiple sclerosis Neoplasm Nervous system agents Osteoarthritis Osteoporosis Ovary, neoplasm Pain Pancreas, neoplasm Parkinson's disease Phosphorylation, biological Prostate gland, neoplasm Psoriasis Reproduction disorders Rheumatoid arthritis Sepsis Silicosis Skin, disease Skin, neoplasm Solid phase synthesis Stomach, neoplasm

Thrombosis

(preparation of pyridinones as modulators of p38 MAP kinase for

treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Tumor necrosis factors RL: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Sarcoidosis (pulmonary; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Kidney, neoplasm (renal cell carcinoma; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) Carcinoma ΤТ (renal cell; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Heart Kidney (reperfusion injury; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Injury (reperfusion; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Eve, disease (retina, neovascularization; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Eye, disease (retinopathy; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Eve, disease (retrolental fibroplasia; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΤТ Lung, disease (sarcoidosis; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Shock (circulatory collapse) (septic; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Intestine, neoplasm (small; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) ΙT Injury (spinal cord; preparation of pyridinones as modulators of p38 MAP kinase for treatment of inflammatory conditions, ischemia, viral infections, autoimmune diseases, and other conditions) TΤ Spinal column, disease

```
kinase for treatment of inflammatory conditions,
        ischemia, viral infections, autoimmune diseases, and other
        conditions)
TΤ
     Brain, disease
        (stroke; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Lupus erythematosus
        (systemic; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Shock (circulatory collapse)
        (toxic shock syndrome; preparation of pyridinones as modulators of p38 MAP
        kinase for treatment of inflammatory conditions,
        ischemia, viral infections, autoimmune diseases, and other
        conditions)
ΤТ
     Brain, disease
        (trauma; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Stomach, disease
        (ulcer; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Inflammation
     Intestine, disease
        (ulcerative colitis; preparation of pyridinones as modulators of p38 MAP
        kinase for treatment of inflammatory conditions,
        ischemia, viral infections, autoimmune diseases, and other
        conditions)
ΙΤ
     Eye, disease
     Inflammation
        (uveitis; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
        (viral; preparation of pyridinones as modulators of p38 MAP kinase for
        treatment of inflammatory conditions, ischemia, viral
        infections, autoimmune diseases, and other conditions)
ΙT
     Central nervous system, disease
        (with inflammatory or apoptotic component; preparation of pyridinones as
        modulators of p38 MAP kinase for treatment of inflammatory
        conditions, ischemia, viral infections, autoimmune diseases,
        and other conditions)
ΤТ
     329-59-9P, Methyl 4-fluoro-3-nitrobenzoate 369-26-6P, Methyl
     3-amino-4-fluorobenzoate 874-97-5P, 3-Hydroxymethylbenzonitrile
     3446-91-1P, 4-Bromomethyl-N, N-dimethylbenzenesulfonamide 3749-51-7P,
                                       13737-35-4P, (2-
     4-Hydroxy-6-methyl-2(1H)-pyridone
     Bromomethylphenyl)acetic acid 13737-37-6P, Methyl (2-
     Bromomethylphenyl)acetate 19858-50-5P, [2-(Methylthio)pyrimidin-5-
                   21317-88-4P, 1-Allyl-4-hydroxy-6-methylpyridin-2(1H)-one
     vl]methanol
     21642-98-8P, 4-Methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile
     24812-90-6P, Methyl 3-amino-4-methoxybenzoate
                                                    26576-93-2P,
     3-Chloro-4-hydroxy-6-methyl-1H-pyridin-2-one
                                                    33524-79-7P,
     1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one
                                                    38275-41-1P, Methyl
     2-(methylthio)pyrimidine-5-carboxylate 39204-47-2P, 2-
     Chloromethylpyrazine
                           41110-34-3P, Ethyl 5-methylpyrazine-2-carboxylate
     49668-89-5P
                  49668-90-8P, Methyl 6-(chloromethyl)nicotinate
     68432-92-8P, Methyl 3-cyanomethylbenzoate
                                                76518-57-5P,
     Isoquinolin-5-ylmethanol 104317-94-4P, 3-Amino-4-chlorobenzyl alcohol
```

(spondyloarthropathy; preparation of pyridinones as modulators of p38 MAP

```
119887-89-7P, 3-Acetyl-1-(2-chlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-
      121669-69-0P, 4-Methylpyrazole-1-carboxylic acid tert-butyl ester
123226-36-8P, (3-Bromomethylphenyl)acetonitrile
                                                135645-63-5P,
4-(Bromomethyl)-2-(methylthio)pyrimidine
                                          140215-42-5P, Ethyl
(3-bromomethylphenyl)acetate 171670-20-5P, Methyl 3-bromomethyl-2-
               177665-49-5P, (3-Hydroxymethylphenyl)acetonitrile
fluorobenzoate
185629-32-7P, Methyl 4-amino-3-fluorobenzoate 186551-69-9P,
                                                            186551-70-2P,
3-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester
3-Methylpyrazole-1-carboxylic acid tert-butyl ester
                                                     217661-27-3P,
2-(Bromomethyl)-5-fluorobenzonitrile
                                     220364-34-1P, [3-
(Bromomethyl)benzyl]carbamic acid tert-butyl ester 220798-39-0P
226070-69-5P, [3-(Hydroxymethyl)benzyl]carbamic acid tert-butyl ester
227609-86-1P, (3-Amino-4-fluorophenyl) methanol 391957-11-2P,
3-[(tert-Butyldimethylsilyloxy)methyl]benzylamine 530144-72-0P,
4-(Bromomethyl)pyrazole-1-carboxylic acid tert-butyl ester 586373-04-8P,
1-Benzyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl 4-bromobenzenesulfonate
586373-18-4P, 1-Benzyl-3-bromo-4-hydroxypyridin-2(1H)-one 586373-21-9P,
1-Benzyl-3-bromo-4-(phenylethynyl)pyridin-2(1H)-one 586373-24-2P,
3-Acetyl-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586373-25-3P, 1-(2,6-Dichlorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586373-26-4P, 4-(Benzyloxy)-1-(2,6-dichlorophenyl)-6-methylpyridin-2(1H)-
      586373-29-7P, 1-Benzyl-2-oxo-1, 2-dihydropyridin-4-yl
N-methyl-N-phenylcarbamate 586373-31-1P, 4-(Benzyloxy)-1-(3-
fluorobenzyl)-3-iodopyridin-2(1H)-one 586373-32-2P, 4-(Benzyloxy)-1-(3-
fluorobenzyl)-3-[(trimethylsilyl)ethynyl]pyridin-2(1H)-one 586373-34-4P,
1-(3-Fluorobenzyl)-4-hydroxypyridin-2(1H)-one 586373-35-5P,
4-(Benzylamino)-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                     586373-37-7P,
4-[(4-Fluorobenzyl)oxy]pyridine-1-oxide 586373-38-8P,
4-[(4-Fluorobenzyl)oxy]pyridine-2(1H)-one 586373-39-9P,
3-Bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one
                                                   586373-51-5P,
3-[(tert-Butyldimethylsilyloxy)methyl]benzonitrile 586373-57-1P,
4-[(2,4-Difluorobenzyl)oxy]pyridine-1-oxide 586373-58-2P,
4-[(2,4-Difluorobenzyl)oxy]pyridin-2(1H)-one
                                             586373-59-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one 586373-60-6P,
3-Bromo-1-(4-chloromethylbenzyl)-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-
      586373-67-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
586373-68-4P, 3-Chloro-1-(4-chloromethylbenzyl)-4-[(2,4-
difluorobenzyl)oxy]-1H-pyridin-2-one
                                      586373-70-8P, 1-Chloromethyl-3-
(methanesulfonyl)benzene
                          586373-73-1P, Methyl 4-[[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzoate
                                                           586373-76-4P,
5-Bromomethylisoquinoline hydrobromide 586373-79-7P,
[5-(Carboxymethyl)indol-1-yl]carbamic acid tert-butyl ester
586373-80-0P, [5-Hydroxymethylindol-1-yl]carbamic acid tert-butyl ester
586373-81-1P, [5-Bromomethylindol-1-yl]carbamic acid tert-butyl ester
586373-82-2P, [5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]indol-1-yl]carbamic acid tert-butyl ester
                                                     586373-93-5P,
4-[(2,4-Difluorobenzyl)oxy]-1-(2,4-difluorobenzyl)-1H-pyridin-2-one
586374-02-9P, 3-Bromo-1-(3-bromomethyl-2-fluorobenzyl)-4-[(2,4-bromomethyl-2-fluorobenzyl)]
                                     586374-04-1P, Methyl
difluorobenzyl)oxy]-1H-pyridin-2-one
2-fluoro-3-methylbenzoate 586374-07-4P, 3-Bromo-1-(3-fluorobenzyl)-4-
                         586374-12-1P, 4-[(2,4-Difluorobenzyl)oxy]-1-(3-
hydroxypyridin-2(1H)-one
fluorobenzyl)-1H-pyridin-2-one
                                586374-29-0P, Methyl [2-[[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetate
586374-37-0P, 1-(3-Fluorobenzyl)-4-methoxy-2-oxo-1, 2-dihydropyridine-3-
              586374-38-1P, 1-(3-Fluorobenzyl)-4-hydroxy-2-oxo-1,2-
carbonitrile
dihydropyridine-3-carbonitrile
                               586374-40-5P, Methyl 1-cyclohexyl-4-
hydroxy-2, 5-dimethyl-6-oxo-1, 6-dihydropyridine-3-carboxylate
586374-41-6P, 1-Cyclohexyl-4-hydroxy-2,5-dimethyl-6-oxo-1,6-
dihydropyridine-3-carboxylic acid 586374-42-7P, 1-Cyclohexyl-4-hydroxy-
3,6-dimethyl-1H-pyridin-2-one 586374-44-9P, 4-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazole-1-
```

```
carboxylic acid tert-butyl ester
                                  586374-45-0P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-09-9P,
4-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]benzonitrile
                                                     586375-14-6P,
1-(4-Cyanophenyl)-4-hydroxy-2(1H)-pyridinone 586375-15-7P,
4-[4-[(2,4-Difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]benzonitrile
586375-16-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1(2H)-
vl]benzoate
             586375-18-0P, 4-Hydroxy-1-[3-(hydroxymethyl)phenyl]-6-
methylpyridin-2(1H)-one 586375-19-1P, 1-[3-(Hydroxymethyl)phenyl]-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586375-21-5P, Methyl
4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate
                                                     586375-22-6P,
Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzoate 586375-29-3P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]methyl]benzaldehyde 586375-31-7P,
1-(4-Methoxybenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one
                                                        586375-35-1P,
4-Hydroxy-4-methylpiperidine hydrochloride 586375-72-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
             586375-98-6P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-
586375-93-1P
1-yl)benzoate 586376-00-3P, Methyl 3-[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
586376-21-8P, Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl] benzoate 586376-24-1P, 1-[3-(Chloromethyl)phenyl]-4-
[(2, 4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586376-25-2P,
1-[3-(Aminomethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
           586376-34-3P 586376-39-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-[3-
2(1H)-one
[(dimethylamino)methyl]phenyl]-6-methylpyridin-2(1H)-one 586376-52-5P,
3,4-Dibromo-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                586376-56-9P,
4-Azido-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                     586376-58-1P.
4-Amino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one hydrochloride
586376-62-7P, 1-(4-Bromo-2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-
           586376-74-1P, 4-[(2,4-Difluorobenzyl)oxy]-6-(hydroxymethyl)-1-
2(1H)-one
(2, 4, 6-trifluorophenyl)pyridin-2(1H)-one
                                         586376-80-9P,
4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-yl)phenyl]-6-
methylpyridin-2(1H)-one 586376-91-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-
difluoro-4-hydroxyphenyl)-6-methylpyridin-2(1H)-one 586376-95-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-hydroxyphenyl)-6-
methylpyridin-2(1H)-one
                         586376-99-0P, 1-(2,6-Difluorophenyl)-4-[[4-
fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one
586377-01-7P, 1-(2,6-Difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586377-08-4P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-
                586377-09-5P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-
methylbenzoate
methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoate
                                               586377-10-8P,
3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
methylbenzoic acid
                    586377-11-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
6-methyl-2-oxo-2H-pyridin-1-yl]-2-methylbenzoic acid
                                                     586377-32-4P,
3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
methylbenzoic acid 586377-38-0P, tert-Butyl [4-[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]carbamate
586377-40-4P, tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]-3,5-difluorobenzyl](methyl)carbamate
                                                   586377-41-5P,
tert-Butyl [4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-
3,5-difluorobenzyl](cyclopropylmethyl)carbamate 586377-43-7P,
4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-
difluorobenzamide
                   586377-45-9P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-
2-oxo-2H-pyridin-1-yl]-3-fluoro-5-hydroxybenzonitrile
                                                       586377-46-0P,
4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-
                                   586377-58-4P, 1-(3-Fluorobenzyl)-4-
hydroxybenzonitrile potassium salt
hydroxy-6-methylpyridin-2(1H)-one
                                   586377-59-5P, 3-Bromo-1-(3-
fluorobenzyl)-4-hydroxy-6-methylpyridin-2(1H)-one
                                                   586377-60-8P,
3-Bromo-1-(3-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl
                           586377-61-9P, 3-Bromo-1-(3-fluorobenzyl)-6-
trifluoromethanesulfonate
methyl-4-(phenylethynyl)pyridin-2(1H)-one 586377-66-4P,
```

```
1-(2,6-Dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
                                                           586377-67-5P.
3-Bromo-1-(2,6-dimethylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586377-72-2P, 3-Bromo-1-(2,6-dichlorophenyl)-4-hydroxy-6-methylpyridin-
           586377-76-6P, 4-Hydroxy-1-(2-methoxy-6-methylphenyl)-6-
2(1H)-one
methylpyridin-2(1H)-one 586377-77-7P, 3-Bromo-4-hydroxy-1-(2-methoxy-6-
methylphenyl)-6-methylpyridin-2(1H)-one
                                         586377-79-9P,
3,5-Dichloro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-
yl)benzenesulfonamide 586377-81-3P, 3-Bromo-1-(2,6-difluorophenyl)-4-
hydroxy-6-methylpyridin-2(1H)-one 586377-84-6P, 3,5-Difluoro-N,N-
dimethylbenzene-1,2-diamine 586377-85-7P, 1-[2-(Dimethylamino)-4,6-
difluorophenyl]-4-hydroxy-6-methylpyridin-2(1H)-one 586377-86-8P,
3-Bromo-1-[2-(dimethylamino)-4,6-difluorophenyl]-4-hydroxy-6-methylpyridin-
2(1H)-one
          586378-01-0P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4-
hydroxy-6-methylpyridin-2(1H)-one 586378-02-1P, 1-[(4-Amino-2-
methylpyrimidin-5-yl)methyl]-3-bromo-4-hydroxy-6-methylpyridin-2(1H)-one
586378-06-5P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-
hydroxy-6-methylpyridin-2(1H)-one 586378-26-9P, 4-Hydroxy-6-methyl-1-[(5-
methylpyrazin-2-yl)methyl]pyridin-2(1H)-one 586378-27-0P,
3-Bromo-4-hydroxy-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-
      586378-30-5P, Ethyl 5-(bromomethyl)pyrazine-2-carboxylate
586378-34-9P, 3-Bromo-1-[[5-(chloromethyl)pyrazin-2-yl]methyl]-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586378-40-7P,
5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
vl]methyl]pyrazine-2-carboxylic acid
                                     586378-50-9P, 1-(3-Fluorobenzyl)-4-
                                586378-55-4P, 4-Amino-1-(3-
hydroxy-3-iodopyridin-2(1H)-one
                               586378-56-5P, 4-Fluoro-N-[1-(3-
fluorobenzyl)pyridin-2(1H)-one
fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]benzamide
                                                     586378-58-7P,
3-Chloro-1-(2,6-difluorophenyl)-4-hydroxy-6-methylpyridin-2(1H)-one
586378-60-1P, 1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)amino]-6-methylpyridin-
           586378-64-5P, 3-Bromo-4-hydroxy-6-methyl-1-(pyridin-4-
2(1H)-one
ylmethyl)pyridin-2(1H)-one
                           586378-66-7P, 3-Bromo-4-hydroxy-6-methyl-1-
(pyridin-3-ylmethyl)pyridin-2(1H)-one 586378-68-9P, 3-Bromo-4-hydroxy-6-
                                               586378-69-0P
methyl-1-(pyridin-2-ylmethyl)pyridin-2(1H)-one
586378-84-9P, 3-Bromo-6-methyl-2-oxo-1-[(pyridin-3-yl)methyl]-1,2-
dihydropyridin-4-yl trifluoromethanesulfonate 586378-85-0P,
3-Bromo-4-[2-(4-fluorophenyl)ethynyl]-6-methyl-1-[(pyridin-3-
                            586378-88-3P, 3-Chloro-4-hydroxy-6-methyl-1-
yl)methyl]pyridin-2(1H)-one
(pyridin-3-ylmethyl)pyridin-2(1H)-one
                                      586378-99-6P, 3-Chloro-4-hydroxy-6-
methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-one
                                                         586379-10-4P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrazine-2-carboxylic acid
                                     586379-14-8P, 1-Allyl-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                             586379-16-0P,
1-Allyl-3-chloro-4-hydroxy-6-methylpyridin-2(1H)-one
                                                      586379-19-3P.
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-prop-2-ynylpyridin-2(1H)-one
586379-26-2P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-
dihydropyridine-2-carboxaldehyde
                                 586379-27-3P, 4-[(2,4-
Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-
      586379-36-4P, Methyl 4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-3-
one
               586379-37-5P, Methyl 4-(3-bromo-4-hydroxy-6-methyl-2-oxo-
methylbenzoate
2H-pyridin-1-yl)-3-methylbenzoate
                                   586379-43-3P, 1-(4-Bromo-2-
methylphenyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586379-44-4P,
1-(4-Bromo-2-methylphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
           2(1H)-one
4-vinylphenyl)pyridin-2(1H)-one
                                 586379-48-8P, Methyl
4-chloro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate
586379-49-9P, Methyl 4-chloro-3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl] benzoate 586379-52-4P, 4-Hydroxy-1-[5-
(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one
                                                         586379-53-5P,
4-[(2,4-Difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-
methylpyridin-2(1H)-one 586379-55-7P, 1-[2-Chloro-5-
(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one
                                                           586379-56-8P,
```

```
1-[2-Chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586379-58-0P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzaldehyde
586379-61-5P, Methyl 3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-
                586379-62-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-
methylbenzoate
methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586379-63-7P,
3-[4-[(2,4-Difluorobenzy1)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
                   586379-64-8P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
methylbenzoic acid
6-\text{methyl}-2-\text{oxo}-2\text{H-pyridin}-1-\text{yl}-4-\text{methylbenzoic} acid 586379-70-6P,
Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]-4-methylbenzoate 586379-73-9P, Methyl 3-chloro-4-(4-hydroxy-6-methyl-
2-oxo-2H-pyridin-1-yl)benzoate 586379-74-0P, Methyl 3-chloro-4-[4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
586379-77-3P, 4-[(2,4-Difluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-
2(1H)-one 586379-82-0P, 4-[(2,4-Difluorobenzyl)amino]-6-methyl-1-
(pyridin-4-ylmethyl)pyridin-2(1H)-one 586379-86-4P, 4-[(2,4-
Difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one
586379-89-7P, 3-[(4-Hydroxy-6-methyl-2-oxo-2H-pyridin-1-
yl) methyl] benzonitrile 586379-90-0P, 3-[[4-[(2,4-Difluorobenzyl) amino]-6-
methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile 586379-94-4P,
1-[2-Fluoro-5-(hydroxymethyl)phenyl]-4-hydroxy-6-methylpyridin-2(1H)-one
586379-95-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[2-fluoro-5-
(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one
                                                  586379-97-7P, Methyl
4-fluoro-3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)benzoate
586379-98-8P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-fluorobenzoate 586379-99-9P, Methyl 3-[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoate
586380-12-3P, Methyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-
2H-pyridin-1-yl]-4-fluorobenzoate
                                  586380-14-5P, Methyl
3-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-4-methoxybenzoate
586380-15-6P, Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-methoxybenzoate 586380-16-7P, Methyl
3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
                586380-20-3P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methoxybenzoate
methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzamide
                                                 586380-49-6P
586380-51-0P, 4-[(2,4-Difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyridin-2-
yl]methyl]-6-methylpyridin-2(1H)-one
                                      586380-53-2P
                                                     586380-54-3P,
6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]nicotinic acid
                          586380-58-7P, 4-Hydroxy-6-methyl-1-[2-
(trifluoromethyl)phenyl]pyridin-2(1H)-one
                                          586380-59-8P,
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-
2(1H)-one
            586380-65-6P, 4-(Benzyloxy)-1-(2,6-difluorophenyl)-6-
methylpyridin-2(1H)-one 586380-83-8P
                                       586380-84-9P
                                                        586380-85-0P
586380-88-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-3-chlorobenzoic acid 586380-90-7P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
586381-05-7P, Methyl 3-fluoro-4-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-
             586381-06-8P, Methyl 4-[4-[(2,4-difluorobenzyl)oxy]-6-methyl-
yl)benzoate
2-oxo-2H-pyridin-1-yl]-3-fluorobenzoate
                                         586381-12-6P,
1-[4-(Aminomethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586381-13-7P, [2-[[4-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]amino]-2-
                    586381-16-0P, tert-Butyl [4-[[3-bromo-4-[(2,4-
oxoethyl] acetate
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]carbamate
586381-33-1P, 4-Bromomethyl-N-(2-hydroxyethyl) benzenesulfonamide
586381-36-4P, 4-Bromomethyl-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
586381-39-7P, 3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]pyrazole-1-carboxylic acid tert-butyl ester
586381-41-1P, [5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-1]
pyridin-1-yl]methyl]indol-1-yl]carbamic acid tert-butyl ester
586381-42-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-indol-5-
```

```
ylmethyl)-1H-pyridin-2-one 586381-44-4P, 5-[[3-Chloro-4-[(2,4-
       difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-3,3-dibromo-1H-
                           586381-53-5P 586381-55-7P, 4-Hydroxy-1-(1H-indazol-5-yl)-6-
       indol-2-one
                                           586381-57-9P, 4-Hydroxy-1-(1H-indazol-6-yl)-6-
       methylpyridin-2(1H)-one
                                            586381-59-1P, Methyl 3-[4-[(2-cyano-4-
       methylpyridin-2(1H)-one
       fluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate
       586381-61-5P, Methyl 3-[4-[[2-(aminomethyl)-4-fluorobenzyl]oxy]-6-methyl-2-
       oxo-2H-pyridin-1-yl]-4-methylbenzoate trifluoroacetate
                                                                                         586381-62-6P
       586381-63-7P, 3-[4-[[4-Fluoro-2-[[(methoxycarbonyl)amino]methyl]benzyl]oxy
       ]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
                                                                                         586381-64-8P,
       3-[3-Bromo-4-[[4-fluoro-2-[[(methoxycarbonyl)amino]methyl]benzyl]oxy]-6-
       methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
                                                                                  586381-72-8P, Methyl
       3-[4-[[2-[[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-
       oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-73-9P
, 3-[4-[[2-[[(Ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-
       2H-pyridin-1-yl]-4-methylbenzoic acid 586381-74-0P, 3-[3-Bromo-4-[[2-
       [[(ethoxycarbonyl)amino]methyl]-4-fluorobenzyl]oxy]-6-methyl-2-oxo-2H-
       pyridin-1-yl]-4-methylbenzoic acid 586381-76-2P, Methyl
       methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate 586381-77-3P,
       3-[4-[[2-[[[(Cyclopropylamino)carbonyl]amino]methyl]-4-fluorobenzyl]oxy]-6-
       methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
                                                                                    586381-79-5P, Ethyl
       (5-fluoro-2-methylphenoxy) acetate 586381-80-8P, Ethyl
       [2-(bromomethyl)-5-fluorophenoxy]acetate
                                                                    586381-81-9P, Ethyl
       [2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
       yl]oxy]methyl]-5-fluorophenoxy]acetate 586381-82-0P,
       [2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
       yl]oxy]methyl]-5-fluorophenoxy]acetic acid 586381-84-2P,
       3-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-2-oxopropyl acetate
       RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
       (Reactant or reagent)
           (intermediate; preparation of pyridinones as modulators of p38 MAP kinase
           for treatment of inflammatory conditions, ischemia,
           viral infections, autoimmune diseases, and other conditions)
ΙT
       586381-85-3P, Methyl 3-[6-[(acetyloxy)methyl]-4-hydroxy-2-oxo-2H-pyridin-1-
       yl]-4-methylbenzoate
                                        586381-86-4P, Methyl 3-[6-[(acetyloxy)methyl]-3-
       bromo-4-hydroxy-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate
                                                                                           586381-93-3P,
       (2E)-4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
       yl]-2-butenoic acid
                                      586381-96-6P, 2-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
       6-methyl-2-oxo-2H-pyridin-1-yl]-4-[(methylamino)carbonyl]benzoic acid
       586382-03-8P, 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-
       methylpyridin-2(1H)-one
                                            586382-08-3P, 1-[4-(Aminomethyl)benzyl]-3-chloro-
       4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                        586382-14-1P,
       [1-[3-(Aminocarbonyl)phenyl]-4-hydroxy-6-oxo-1,6-dihydropyridin-2-
                                   586382-15-2P, [1-[3-(Aminocarbonyl)phenyl]-4-[(2,4-
       yl]methyl acetate
       difluorobenzyl)oxy]-6-oxo-1,6-dihydropyridin-2-yl]methyl acetate
       586382-17-4P, 5-(Chloromethyl)-2-(methylthio)pyrimidine
                                                                                           586382-19-6P,
       3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-(methylthio)pyrimidin-5-
       yl]methyl]pyridin-2(1H)-one trifluoroacetate
                                                                         586382-21-0P,
       3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-
       (methylsulfonyl)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate
       586382-26-5P, Ethyl 3-[3-[3-bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-
       oxo-2H-pyridin-1-yl]-4-methylphenyl]-3-oxopropanoate
                                                                                       586382-30-1P,
       3-Bromo-4-[(2,4-difluorobenzyl)oxy]quinolin-2(1H)-one
                                                                                         586382-31-2P,
       Methyl 4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-
                                   586382-33-4P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
       yl]methyl]benzoate
       6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoic acid
                                                                                       586382-35-6P,
       Methyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yl)-2-furoate
       586382-36-7P, Methyl 5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-fine the second of th
       2H-pyridin-1-yl]-2-furoate 586382-37-8P, 5-[3-Bromo-4-[(2,4-
       difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-furoic acid
```

```
586382-39-0P, Dimethyl 5-(4-hydroxy-6-methyl-2-oxo-2H-pyridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-1-yridin-
                         586382-40-3P, Dimethyl 5-(3-bromo-4-hydroxy-6-methyl-2-
vl)isophthalate
oxo-2H-pyridin-1-yl)isophthalate
                                                      586382-41-4P, Dimethyl
5-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]isophthalate 586382-42-5P, 5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]isophthalic acid 586382-48-1P, tert-Butyl
[3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
fluorophenyl]carbamate
                                      586382-50-5P, 2-[[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-
                               586382-52-7P, 2-[[3-[3-Bromo-4-[(2,4-
2-oxoethyl acetate
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]amino]-
                                                  586382-54-9P, 4-[3-Bromo-4-[(2,4-
1,1-dimethyl-2-oxoethyl acetate
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluorobenzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
     (intermediate; preparation of pyridinones as modulators of p38 MAP kinase
    for treatment of inflammatory conditions, ischemia,
    viral infections, autoimmune diseases, and other conditions)
586375-79-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-4]
[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
     (p38 kinase inhibitor; hydrochloride)
586379-66-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-
[(methylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one
586380-87-2P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-3-chlorobenzamide
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical
process); PYP (Physical process); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC
(Process); USES (Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
                       586414-49-5P
586414-48-4P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
                       571168-92-8P, 1-Benzyl-4-(benzyloxy)-3-iodopyridin-2(1H)-
108379-95-9P
         586372-64-7P, 4-(Benzyloxy)-1-(4-methylbenzyl)pyridin-2(1H)-one
586372-72-7P, 4-(Benzyloxy)-1-[(3-fluorophenyl)methyl]pyridin-2(1H)-one
586372-73-8P, 4-(Benzyloxy)-3-bromo-1-[(3-fluorophenyl)methyl]pyridin-
                586372-76-1P, 4-(Benzyloxy)-3-bromopyridin-2(1H)-one
586372-77-2P, 4-(Benzyloxy)-1-[4-(benzyloxy)benzyl]-3-bromopyridin-2(1H)-
         586372-81-8P, 4-(Benzyloxy)-1-[(4-cyanophenyl)methyl]pyridin-2(1H)-
one
                                586372-87-4P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-
one
         586372-82-9P
2(1H)-one hydrobromide
                                      586373-00-4P, 1-Benzyl-4-(benzyloxy)-6-
                                        586373-03-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]-6-586373-06-0P, 1-Benzyl-4-[(2,6-
methylpyridin-2(1H)-one
methylpyridin-2(1H)-one
                                                             586373-14-0P, 1-Benzyl-4-
dichlorobenzyl)oxy]pyridin-2(1H)-one
(benzyloxy)-3-vinylpyridin-2(1H)-one
                                                            586373-20-8P, 1-Benzyl-3-bromo-2-
oxo-1,2-dihydropyridin-4-yl trifluoromethanesulfonate
                                                                                       586373-50-4P
586373-55-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[2-
(hydroxymethyl)benzyl]pyridin-2(1H)-one 586373-64-0P,
[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]
```

TΤ

ΙT

ΤТ

ΤТ

```
yl]methyl]benzyl]carbamic acid tert-butyl ester
                                                                                                                                         586373-75-3P.
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(isoquinolin-5-yl)methyl]-1H-
pyridin-2-one trifluoroacetate
                                                                                        586373-78-6P, 3-Chloro-4-[(2,4-
\verb|difluorobenzyl| oxy| -1 - (1 + -indol -5 - y + indol -5 - y + -indol -2 - one + 
586373-84-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-
indol-5-yl)methyl]pyridin-2(1H)-one
                                                                                                       586373-95-7P, 2-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
586373-97-9P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]benzoate 586374-03-0P, Methyl 3-[[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-fluorobenzoate
586374-06-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl)oxy]-1-(3-4-difluorobenzyl
fluorobenzyl)pyridin-2(1H)-one 586374-28-9P, 2-[2-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide
586374-30-3P, Ethyl [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]phenyl]acetate 586374-34-7P, 4-[(2,4-
Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-
                                     586374-39-2P, 1-Cyclohexyl-4-[(2,4-difluorobenzyl)oxy]-3,6-
carbonitrile
dimethylpyridin-2(1H)-one 586374-46-1P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-
2H-pyridin-1-yl]methyl]benzonitrile 586374-47-2P, 2-[[4-(Benzyloxy)-3-
bromo-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
                                                                                                                                     586374-55-2P,
4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile
586374-59-6P, 2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]benzonitrile 586374-61-0P, 3-[[3-Bromo-4-[(2,4-1)]methyl]benzonitrile 586374-61-0P
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
586374-62-1P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]benzonitrile 586374-63-2P, 4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide
586374-65-4P, Methyl 3-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl]methyl]benzoate
                                                                                                    586374-70-1P, 3-Bromo-1-[4-
(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586374-72-3P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-80-3P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                                                    586375-08-8P, Methyl 4-[4-(benzyloxy)-3-bromo-2-
yl]methyl]benzoic acid
oxo-2H-pyridin-1-yl]benzoate
                                                                                    586375-10-2P, 4-[4-(Benzyloxy)-3-bromo-2-
oxo-2H-pyridin-1-yl]benzoic acid
                                                                                             586375-20-4P, Methyl
4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                      586375-23-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]benzoic acid
                                                                                                                       586375-25-9P,
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                                                   586375-26-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
yl]methyl]benzoic acid
1-[4-(hydroxymethyl)benzyl]-6-methylpyridin-2(1H)-one 586375-30-6P,
4-[(2,4-Difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-methylpyridin-2(1H)-one
586375-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-methoxybenzyl)-6-
methylpyridin-2(1H)-one
                                                                    586375-66-8P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[4-(1-pyrrolidinylcarbonyl)phenyl]pyridin-
                                                                   586375-71-5P, Methyl 4-[[3-chloro-4-[(2,4-
2(1H)-one hydrochloride
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoate
586375-97-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]benzoic acid 586375-99-7P, Methyl 3-[4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
586376-20-7P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl] benzoic acid 586376-23-0P, 1-[3-(Aminomethyl)phenyl]-3-
bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586376-64-9P, 1-(4-Bromo-2,6-difluorophenyl)-4-[(2,4-difluorobenzyl)oxy]-6-
                                                                       586376-66-1P, 3-Bromo-4-[(2,4-
methylpyridin-2(1H)-one
difluorobenzyl)oxy]-6-methyl-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one
586376-70-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(2,4,6-methyl-1)oxy]
trifluorophenyl)pyridin-2(1H)-one 586377-36-8P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzonitrile
586377-37-9P, 1-[4-(Aminomethyl)-2,6-difluorophenyl]-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-chloro-4-[(2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difluorophenyl)-3-((2,4-difl
```

```
difluorobenzyl)oxy]pyridin-2(1H)-one hydrochloride
                                                                                                                                                      586377-80-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-
                                 586377-82-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
2(1H)-one
difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-one
                                                                                                                                               586377-88-0P,
2-[[[3-Bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzonitrile
                                                                                                       586377-90-4P, 4-[[2-(Aminomethyl)-4-
fluorobenzyl]oxy]-3-bromo-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one
                                                     586377-96-0P, 4-[[2-(Aminomethyl)-4-fluorobenzyl]oxy]-3-
trifluoroacetate
chloro-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one trifluoroacetate
586378-00-9P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
586378-03-2P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-bromo-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl)methylpyrimidin-5-yl
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride
586378-05-4P, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-((2,4-methylpyrimidin-5-yl]-3-((2,4-methylpyrimidin-5-yl)-3-((2,
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
586378-12-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-methyl-1-1]]
(methylthio)pyrimidin-4-yl]methyl]pyridin-2(1H)-one
                                                                                                                                                       586378-13-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-
(methylsulfonyl)pyrimidin-4-yl]methyl]pyridin-2(1H)-one 586378-15-6P,
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrimidine-2-carbonitrile trifluoroacetate 586378-29-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(hydroxymethyl)pyrazin-2-
y1]methyl]-6-methylpyridin-2(1H)-one 586378-31-6P, Ethyl
5-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]pyrazine-2-carboxylate 586378-38-3P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[[5-[(4-methylpiperazin-1-
yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one trifluoroacetate
\overline{586378-49-6P}, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-iodopyridin-
2(1H)-one
                              586379-02-4P, Ethyl 5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazine-2-carboxylate
                                                                                                                                                                        586379-25-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
                                                                                             586379-30-8P, 5-Bromo-4-[(2,4-
(hydroxymethyl)pyridin-2(1H)-one
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-
                                              586379-42-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
carboxaldehyde
methyl-1-(2-methyl-4-vinylphenyl)pyridin-2(1H)-one
                                                                                                                                                    586379-51-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-6-
methylpyridin-2(1H)-one
                                                                       586379-72-8P, Methyl 4-[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-chlorobenzoate
586379-96-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-fluorobenzoic acid
                                                                                                      586380-11-2P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzoic acid
586380-13-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-methoxybenzoic acid
                                                                                                         586380-19-0P, 1-[5-(Aminomethyl)-2-
fluorophenyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-
one hydrochloride
                                                       586380-26-9P, 2-[[[3-Chloro-1-(2,6-difluorophenyl)-6-
methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile
586380-60-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
                                                                                           586380-61-2P, 3-Bromo-4-[(2,4-
methyl-5-vinylpyridin-2(1H)-one
\verb|difluorobenzyl| oxy| -1 - (2,6 - \verb|difluorophenyl|) -5 - (1,2 - \verb|dihydroxyethyl|) -6 - (2,6 - \verb|difluorophenyl|) -6 - (3,6 - \verb|difluorophenyl|) -6 - (4,2 - \verb|dihydroxyethyl|) -6 - (4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4,2 - 4
                                                                     586380-62-3P, 3-Bromo-4-[(2,4-
methylpyridin-2(1H)-one
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(hydroxymethyl)-6-
                                                                     586380-63-4P, 5-Bromo-4-[(2,4-
methylpyridin-2(1H)-one
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-
dihydropyridine-3-carboxaldehyde
                                                                                                  586380-64-5P, 4-(Benzyloxy)-3-bromo-1-
(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one
                                                                                                                                          586380-67-8P,
5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-methyl-6-oxo-
1,6-dihydropyridine-3-carboxaldehyde oxime 586380-73-6P,
4-(Allylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-
                 586380-75-8P, Ethyl 3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-1,2'-bipyridine-5'-carboxylate 586380-82-7P 586381-04-6P,
Methyl 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
```

```
586381-07-9P, 4-[[3-Chloro-4-[(2,4-
yl]-3-fluorobenzoate
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzoic acid
586381-08-0P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
                                               586381-15-9P, 1-(4-Aminobenzyl)-3-bromo-4-
pyridin-1-yl]methyl]benzamide
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586381-40-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(2,3-dihydro-1H-indol-5-
yl)methyl]-1H-pyridin-2-one 586381-58-0P, Methyl [2-[[[3-bromo-6-methyl-
1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-1, 2-dihydropyridin-4-
vl]oxy]methyl]-5-fluorobenzyl]carbamate
                                                             586381-78-4P,
3-[3-Bromo-4-[[2-[[(cyclopropylamino)carbonyl]amino]methyl]-4-
fluorobenzyl]oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
586381-89-7P
                      586381-94-4P, Methyl 5-[[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-2-furoate
586381-95-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-met
pyridin-1-yl]-4-(hydroxymethyl)-N-methylbenzamide 586382-02-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluoro-4-vinylphenyl)-6-
methylpyridin-2(1H)-one 586382-04-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2,6-difluorophenyl]-6-
methylpyridin-2(1H)-one 586382-05-0P, 4-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-
difluorobenzaldehyde 586382-16-3P 586382-46-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[4-(1-hydroxy-1-methylethyl)phenyl]-6-methylpyridin-
2(1H)-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
     (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
    kinase for treatment of inflammatory conditions,
    ischemia, viral infections, autoimmune diseases, and other
    conditions)
4241-21-8P, 2-0xo-6-phenethyl-1,2-dihydropyridine-3-carbonitrile
39883-43-7P, 6-0xo-1,6-dihydro-[2,3']bipyridinyl-5-carbonitrile
43083-13-2P, 2-0xo-6-phenyl-1,2-dihydropyridine-3-carbonitrile
53179-13-8P, 5-Methyl-1-phenyl-1H-pyridin-2-one 54923-34-1P,
4-Benzyloxy-3-methyl-1H-pyridin-2-one
                                                            56304-43-9P, 6-Oxo-1,6-dihydro-
[2,3']bipyridinyl-5-carboxylic acid 123100-43-6P, 1-(2-Bromobenzyl)-3-
[(2-bromobenzy1)oxy]pyridin-2(1H)-one 242472-06-6P, 5-[[4-(3-bromobenzy1)oxy]
Chlorophenyl)piperazin-1-yl]carbonyl]-1-(3,4-dichlorobenzyl)-1H-pyridin-2-
         242472-09-9P, N-Allyl-2-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-
vl)carbonvl]hydrazinecarbothioamide
                                                       338774-98-4P, N-[5-Acetyl-1-(4-
chlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]-4-chlorobenzamide
338782-59-5P, 1-(3,4-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(2,4-difluorophenyl)amide
                                                                    338978-39-5P
                                                                                           338981-04-7P,
1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
N-(3-dimethylaminopropyl) amide 338981-05-8P, 1-(2,6-Dichlorobenzyl)-6-
oxo-1,6-dihydropyridine-3-carboxylic acid N-(2-dimethylaminoethyl)amide
339008-61-6P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(2,4-difluorophenyl)amide 339008-62-7P,
1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
N-(4-\text{chlorophenyl}) amide 339008-63-8P, 1-(2,6-\text{Dichlorobenzyl})-6-\text{ox}-1,6-
dihydropyridine-3-carboxylic acid N-(3-trifluoromethylphenyl)amide
339008-64-9P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(4-trifluoromethoxyphenyl)amide
                                                                              339008-65-0P,
1-(2,6-Dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid
                    339008-68-3P, 1-(2,6-Dichlorobenzyl)-6-oxo-1,6-
benzylamide
dihydropyridine-3-carboxylic acid N-[2-(morpholin-4-yl)ethyl]amide
339009-09-5P, 5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-
carboxylic acid N-(2,4-difluorophenyl)amide 339023-89-1P,
5-Chloro-1-(2,6-dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic
acid N-(3-trifluoromethylphenyl)amide 339023-98-2P, 5-Chloro-1-(2,6-
dichlorobenzyl)-6-oxo-1,6-dihydropyridine-3-carboxylic acid benzylamide
```

ΙT

```
339024-00-9P
               400087-49-2P, Methyl 5-chloro-1-(4-chlorobenzyl)-6-oxo-1,6-
dihydropyridine-3-carboxylate 477852-96-3P, 1-Benzyl-5-[5-[(3,4-
dichlorobenzyl)sulfanyl]-[1,3,4]oxadiazol-2-yl]-1H-pyridin-2-one
477858-09-6P, 1-(4-Chlorobenzyl)-5-[3-(4-chlorophenyl)-[1,2,4] oxadiazol-5-
yl]-1H-pyridin-2-one
                      477864-11-2P, N'-[[(1-Benzyl-6-oxo-1,6-
dihydropyridin-3-yl)carbonyl]oxy]pyridine-4-carboximidamide
478065-97-3P, 1-Benzyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid
N-[2-(morpholin-4-yl)ethyl] amide 478066-00-1P, 1-(2,6-Dichlorobenzyl)-6-
oxo-1,6-dihydropyridine-3-carboxylic acid N-(3-trifluoromethylbenzyl)amide
478247-73-3P, 3-Benzyl-4-hydroxy-1-(2-phenylethyl)pyridin-2(1H)-one
565156-95-8P, 4-Bromo-2-(2,6-dichlorophenyl)-5-[[2-
(hydroxymethyl)benzyl]oxy]pyridazin-3(2H)-one
                                               565157-26-8P,
4-Bromo-2-(2,6-dichlorophenyl)-5-[(2,4-difluorobenzyl)oxy]pyridazin-3(2H)-
      586372-66-9P, 4-(Benzyloxy)-3-bromo-1-(4-methylbenzyl)pyridin-2(1H)-
one
      586372-68-1P, 4-(Benzyloxy)-1-[(4-bromophenyl)methyl]pyridin-2(1H)-
one
      586372-69-2P, 4-(Benzyloxy)-3-bromo-1-[(4-bromophenyl)methyl]pyridin-
one
            586372-70-5P, 4-(Benzyloxy)-1-[(4-chlorophenyl)methyl]pyridin-
2(1H)-one
            586372-71-6P, 4-(Benzyloxy)-3-bromo-1-[(4-
2(1H)-one
chlorophenyl)methyl]pyridin-2(1H)-one 586372-74-9P, 4-(Benzyloxy)-1-[(2-
fluorophenyl)methyl]pyridin-2(1H)-one 586372-75-0P, 4-(Benzyloxy)-3-
bromo-1-[(2-fluorophenyl)methyl]pyridin-2(1H)-one 586372-78-3P,
4-(Benzyloxy)-1-[[4-(methoxycarbonyl)phenyl]methyl]pyridin-2(1H)-one
586372-79-4P, 4-(Benzyloxy)-3-bromo-1-[[4-(methoxycarbonyl)phenyl]methyl]p
vridin-2(1H)-one
                  586372-80-7P, 4-(Benzyloxy)-3-bromo-1-[(4-
carboxyphenyl)methyl]pyridin-2(1H)-one
                                         586372-83-0P,
4-(Benzyloxy)-1-[(4-tert-butylphenyl)methyl]pyridin-2(1H)-one
586372-84-1P, 4-(Benzyloxy)-3-bromo-1-[(4-tert-butylphenyl)methyl]pyridin-
2(1H)-one
           586372-85-2P, 4-(Benzyloxy)-3-bromo-1-ethylpyridin-2(1H)-one
586372-86-3P, 3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one
586372-88-5P, 4-(Benzyloxy)-3-bromo-1-methylpyridin-2(1H)-one
586372-89-6P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]-N'-
hydroxybenzenecarboximidamide 586372-90-9P, 4-(Benzyloxy)-3-bromo-1-
(piperidin-4-ylmethyl)pyridin-2(1H)-one hydrochloride
                                                       586372-91-0P,
4-(Benzyloxy)-1-[4-(trifluoromethyl)benzyl]pyridin-2(1H)-one
586372-92-1P, 4-(Benzyloxy)-3-bromo-1-[4-(trifluoromethyl)benzyl]pyridin-
            586372-93-2P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-
ylmethyl)pyridin-2(1H)-one hydrochloride
                                           586372-94-3P,
4-(Benzyloxy)-3-bromo-1-[2-(thien-3-yl)ethyl]pyridin-2(1H)-one
586372-95-4P, 4-(Benzyloxy)-3-bromo-1-[2-(thien-2-yl)ethyl]pyridin-2(1H)-
      586372-96-5P, 4-(Benzyloxy)-3-bromo-1-[3-
(trifluoromethyl)benzyl]pyridin-2(1H)-one
                                            586372-97-6P,
4-(Benzyloxy)-3-bromo-1-[2-(trifluoromethyl)benzyl]pyridin-2(1H)-one
586372-98-7P, 4-(Benzyloxy)-1-[4-(trifluoromethoxy)benzyl]pyridin-2(1H)-
one
      586372-99-8P, 4-(Benzyloxy)-3-bromo-1-[4-
(trifluoromethoxy)benzyl]pyridin-2(1H)-one
                                             586373-01-5P,
                                                           586373-02-6P.
1-Benzyl-4-(benzyloxy)-3-bromo-6-methylpyridin-2(1H)-one
1-Benzyl-4-(benzyloxy)-3,5-dibromo-6-methylpyridin-2(1H)-one
586373-05-9P, 1-Benzyl-3-bromo-4-[(3-chlorobenzyl)oxy]-6-methylpyridin-
           586373-07-1P, 1-Benzyl-3-bromo-4-[(2,6-
2(1H)-one
dichlorobenzyl)oxy]pyridin-2(1H)-one 586373-08-2P, 1-Benzyl-4-[(2-
chlorobenzyl)oxy]pyridin-2(1H)-one 586373-09-3P, 1-Benzyl-3-bromo-4-[(2-
chlorobenzyl)oxy]pyridin-2(1H)-one 586373-10-6P, 1-Benzyl-3-bromo-4-[(4-
methylbenzyl)oxy]pyridin-2(1H)-one 586373-11-7P, 1-Benzyl-4-[(3-chlorobenzyl)oxy]pyridin-2(1H)-one 586373-12-8P, 1-Benzyl-4-(benzylthio)-
                          586373-13-9P, 1-Benzyl-3-bromo-4-[[2-
3-bromopyridin-2(1H)-one
                                                586373-15-1P,
(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one
1-Benzyl-4-(benzyloxy)-3-ethylpyridin-2(1H)-one 586373-16-2P,
3-Acetyl-4-(benzyloxy)-1-(2-chlorophenyl)-6-methylpyridin-2(1H)-one
586373-17-3P, 1-Benzyl-3-bromo-4-(2-phenylethyl)pyridin-2(1H)-one
586373-22-0P, 3-Bromo-1-(3-fluorobenzyl)-6-methyl-4-(2-phenylethyl)pyridin-
          586373-23-1P, 4-(Benzyloxy)-3-bromo-1-(2,6-dichlorophenyl)-6-
2(1H)-one
```

```
586373-27-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(2-
methylpyridin-2(1H)-one
phenylethyl)pyridin-2(1H)-one 586373-28-6P, 1-Benzyl-3-bromo-2-oxo-1,2-
                                                586373-30-0P,
dihydropyridin-4-yl N-methyl-N-phenylcarbamate
4-(Benzyloxy)-3-ethynyl-1-(3-fluorobenzyl)pyridin-2(1H)-one
586373-33-3P, 4-(Benzylamino)-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one
586373-36-6P, 3-Bromo-1-(cyclopropylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-
2(1H)-one
           586373-40-2P, 3-Bromo-1-[(pyridin-4-yl)methyl]-4-[(4-
fluorobenzyl)oxy]pyridin-2(1H)-one 586373-41-3P, 3-Bromo-1-[(pyridin-3-
vl)methvl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
                                                     586373-42-4P,
3-Bromo-1-(4-tert-butylbenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
586373-43-5P, 3-Bromo-1-(3-trifluoromethylbenzyl)-4-[(4-
fluorobenzyl)oxy]pyridin-2(1H)-one 586373-44-6P, 3-Bromo-1-[(biphenyl-2-
y1)methy1]-4-[(4-fluorobenzy1)oxy]pyridin-2(1H)-one 586373-45-7P,
3-Bromo-1-(4-methoxybenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
              586373-47-9P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-1-[4-
586373-46-8P
(trifluoromethyl)benzyl]pyridin-2(1H)-one 586373-48-0P,
3-Bromo-1-[(biphenyl-4-yl)methyl]-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
586373-49-1P, 3-Bromo-1-(cyclohexylmethyl)-4-[(4-fluorobenzyl)oxy]pyridin-
          586373-52-6P, 1-[3-(Aminomethyl)benzyl]-3-bromo-4-[(4-
2(1H)-one
fluorobenzyl)oxy]pyridin-2(1H)-one 586373-53-7P, 1-(3-Aminomethylbenzyl)-
3-bromo-4-[(4-fluorobenzyl)oxy]-1H-pyridin-2-one trifluoroacetate
           586373-54-8P, Methyl 2-[[3-bromo-4-[(4-fluorobenzyl)oxy]-2-oxo-
(1:1.125)
                                586373-56-0P, 3-Bromo-4-[(2,4-
2H-pyridin-1-yl]methyl]benzoate
difluorobenzyl)oxy]-1-[4-[(dimethylamino)methyl]benzyl]-1H-pyridin-2-one
586373-61-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-
[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one 586373-62-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-(dimethylaminomethyl)benzyl]-1H-
pyridin-2-one
               586373-63-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[3-
[(methylamino)methyl]benzyl]-1H-pyridin-2-one 586373-65-1P,
1-[(3-Aminomethyl)benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-
     586373-66-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-
[(isopropylamino)methyl]benzyl]-1H-pyridin-2-one
                                                  586373-69-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(methanesulfonyl)benzyl]-1H-
               586373-71-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[4-
pyridin-2-one
(methanesulfonyl)benzyl]-1H-pyridin-2-one
                                          586373-72-0P,
4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]benzamide
                    586373-77-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
[(1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]pyridin-2(1H)-one
586373-83-3P, 1-[(1-Acetyl-1H-indol-5-yl)methyl]-3-chloro-4-[(2,4-
difluorobenzyl)oxy]pyridin-2(1H)-one
                                     586373-85-5P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
586373-86-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(pyridin-4-
                            586373-87-7P, 3-Bromo-4-[(2,4-
ylmethyl)pyridin-2(1H)-one
difluorobenzyl)oxy]-1-[(pyridin-2-yl)methyl]-1H-pyridine-2-one
586373-88-8P, 3-Bromo-1-(4-tert-butylbenzyl)-4-[(2,4-
                                      586373-89-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]pyridin-2(1H)-one
difluorobenzyl)oxy]-1-(3-methoxybenzyl)pyridin-2(1H)-one
                                                         586373-90-2P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(benzodioxol-5-yl)methyl]pyridine-
           586373-91-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-
2(1H)-one
                               586373-92-4P, 3-Bromo-1-(2,4-
fluorobenzyl)pyridin-2(1H)-one
difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
586373-94-6P, [3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
                              586373-96-8P, 1-[2-(Aminomethyl)benzyl]-3-
yl]methyl]phenyl]acetonitrile
bromo-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
                                                    586373-98-0P, Methyl
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]benzoate 586373-99-1P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
2-oxo-2H-pyridin-1-yl]methyl]benzamide 586374-00-7P,
4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]benzamide 586374-01-8P, 1-(3-Aminomethyl-2-fluorobenzyl)-3-
bromo-4-[(2,4-difluorobenzyl)oxy]-1H-pyridin-2-one 586374-05-2P,
3-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-
```

```
586374-08-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2,3,4-
fluorobenzamide
trifluorobenzyl)oxy]-1H-pyridin-2-one 586374-10-9P
                                                     586374-11-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(3-fluorobenzyl)-1H-pyridin-2-one
586374-13-2P, 3-Bromo-4-[(3-chlorobenzyl)oxy]-1-(3-fluorobenzyl)pyridin-
           586374-14-3P, 3-Bromo-4-[(3,4-difluorobenzyl)oxy]-1-(3-
2(1H)-one
                                586374-15-4P, 3-Bromo-1-(3-fluorobenzyl)-
fluorobenzyl)pyridin-2(1H)-one
4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586374-16-5P,
3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)oxy]pyridin-2(1H)-one
586374-18-7P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3-methoxybenzyl)oxy]pyridin-
           586374-19-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[(4-tert-
2(1H)-one
butylbenzyl)oxy]-1H-pyridin-2-one 586374-20-1P, 3-Bromo-1-(3-
fluorobenzyl)-4-[(3-methylbenzyl)oxy]pyridin-2(1H)-one
                                                       586374-21-2P,
3-Bromo-1-(3-fluorobenzyl)-4-[[4-(trifluoromethyl)benzyl]oxy]pyridin-2(1H)-
      586374-22-3P 586374-23-4P, 3-Bromo-1-(3-fluorobenzyl)-4-[(2-
methylbenzyl)oxy]pyridin-2(1H)-one 586374-24-5P 586374-25-6P,
3-Bromo-1-(3-fluorobenzyl)-4-[(4-methoxybenzyl)oxy]pyridin-2(1H)-one
586374-27-8P, 3-Bromo-1-(3-fluorobenzyl)-4-[[2-
(hydroxymethyl)benzyl]oxy]pyridin-2(1H)-one 586374-31-4P,
2-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]phenyl]acetamide 586374-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-
(3-fluorobenzyl)-3-methylpyridin-2(1H)-one
                                           586374-33-6P,
4-[(2,4-Difluorobenzyl)oxy]-1-(3-fluorobenzyl)-3-iodo-1H-pyridin-2-one
586374-43-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-
4-ylmethyl)-1H-pyridin-2-one 586374-48-3P, 1-[4-(Aminomethyl)benzyl]-4-
(benzyloxy)-3-bromopyridin-2(1H)-one
                                     586374-49-4P, 1-[3-
(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one
586374-50-7P, 1-[2-(Aminomethyl)benzyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-
      586374-51-8P, 4-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
yl]methyl]benzamide 586374-52-9P, 3-[[4-(Benzyloxy)-3-bromo-2-oxo-2H-
pyridin-1-yl]methyl]benzamide
                               586374-53-0P, 2-[[4-(Benzyloxy)-3-bromo-2-
oxo-2H-pyridin-1-yl]methyl]benzamide
                                     586374-54-1P, Methyl
3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]benzoate
586374-56-3P, 2-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzonitrile
586374-57-4P, [4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
                             586374-58-5P
                                             586374-64-3P, Methyl
yl]methyl]phenyl]acetic acid
4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                    586374-66-5P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
yl]methyl]benzoate
6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide
                                                 586374-67-6P,
2-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                     586374-68-7P, 1-[2-(Aminomethyl)benzyl]-3-bromo-4-
vl]methvl]benzamide
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                     586374-69-8P,
3-Bromo-1-[3-(bromomethyl)benzyl]-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                         586374-71-2P, 1-[4-(Aminomethyl)benzyl]-3-bromo-
4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                       586374-73-4P,
1-[3-[(Morpholin-4-yl)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
                         586374-74-5P, 1-[3-[(Dimethylamino)methyl]benzyl
methylpyridin-2(1H)-one
]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586374-75-6P, 1-[3-[(Isopropylamino)methyl]benzyl]-3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586374-76-7P,
1-[3-[(Piperidin-1-y1)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                         586374-77-8P, 1-[3-[[(2-
Hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                         586374-78-9P, 1-[3-[[Bis(2-
hydroxyethyl)amino]methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
                        586374-79-0P, 1-[3-[(Piperazin-1-
methylpyridin-2(1H)-one
y1)methyl]benzyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
2(1H)-one
           586374-81-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
[3-[(acetylamino)methyl]benzyl]pyridin-2(1H)-one
                                                  586374-82-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(methoxycarbonylamino)methyl]benzyl]pyridin-2(1H)-one
                                                        586374-83-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
```

```
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-difluorobenzyl)oxy]]
                                                                                                                                                  586374-85-8P.
            hydroxyacetylamino)methyl]benzyl]pyridin-2(1H)-one
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
            [(aminocarbonylamino)methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                                       586374-86-9P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
            [(isopropylamino)methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                             586374-87-0P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(morpholin-4-
            vl)methyl|benzyl|pyridin-2(1H)-one
                                                                                                        586374-88-1P, 3-Bromo-4-[(2,4-
            difluorobenzyl)oxy]-6-methyl-1-[4-[(dimethylamino)methyl]benzyl]pyridin-
                                          586374-89-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
            [4-[(piperidin-1-yl)methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                                     586374-90-5P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-methyl-1)oxy]]]
            hydroxyethyl)amino]methyl]benzyl]pyridin-2(1H)-one 586374-91-6P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[(2-methyl-1)oxy]]]
            hydroxyethyl)amino]methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                                  586374-92-7P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(piperazin-1-4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1)oxy]-6-methyl-1-[4-[(piperazin-1-4-1
                                                                                                      586374-93-8P, 3-Bromo-4-[(2,4-
            yl)methyl]benzyl]pyridin-2(1H)-one
            difluorobenzyl)oxy]-6-methyl-1-[4-[[(methoxycarbonyl)amino]methyl]benzyl]p
                                                         586374-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
            yridin-2(1H)-one
            methyl-1-[4-[(acetylamino)methyl]benzyl]pyridin-2(1H)-one 586374-95-0P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
            [[(methylsulfonyl)amino]methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                                              586374-96-1P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
            [[(aminocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                                           586374-97-2P,
            4-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
            yl]methyl]benzoyl]piperazine-1-carboxamide 586374-99-4P,
            N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
            yl]methyl]benzyl]-2-methoxyacetamide 586375-00-\overline{0P}, 3-Bromo-\overline{4-[(2,4-1)]}
            difluorobenzyl)oxy]-6-methyl-1-[4-[[[(methoxycarbonyl)methyl]carbonyl]ami
            no]methyl]benzyl]pyridin-2(1H)-one 586375-01-1P, 3-Bromo-4-[(2,4-
            difluorobenzyl)oxy]-6-methyl-1-[4-[[[(1-hydroxy-1-
            methylethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                                                      586375-02-2P
            586375-03-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
            [[[(aminomethy1)carbony1]amino]methy1]benzy1]pyridin-2(1H)-one
            hydrochloride
                                                    586375-04-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
            1-[4-[[[(hydroxymethyl)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
            586375-05-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
            [[[[(acetylamino)methyl]carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
            586375-06-6P, 1-[4-[(4-Acetylpiperazin-1-yl)carbonyl]benzyl]-3-bromo-4-
            [(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[4-
            (methylsulfonyl)piperazin-1-yl]carbonyl]benzyl]pyridin-2(1H)-one
            586375-11-3P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]benzamide
            586375-12-4P, 1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-2(1H)-1-(benzyloxy)-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridin-3-bromopyridi
                           586375-13-5P, Methyl 4-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
            one
                                                                               586375-17-9P, 3-Bromo-4-[(2,4-
            2H-pyridin-1-yl]benzoate
            difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one
            586375-24-8P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-(trifluoromethyl)pyridin-
                                          586375-27-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1-4)]
            2(1H)-one
            hydroxy-1-methylethyl)benzyl]-6-methylpyridin-2(1H)-one
                                                                                                                                                              586375-28-2P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
            [(methylamino)methyl]benzyl]pyridin-2(1H)-one
                                                                                                                                     586375-33-9P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(4-hydroxybenzyl)-6-methylpyridin-
                                          586375-34-0P
                                                                               586375-36-2P, 4-[[3-Bromo-4-[(2,4-
            2(1H)-one
            difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-
            methylpropyl)benzamide
                                                                        586375-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
            1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]benzyl]-6-methylpyridin-2(1H)-one
            586375-38-4P, 4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2-oxo-2H-methyl-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2
            pyridin-1-yl]methyl]-N-(2-hydroxyethyl)benzamide 586375-39-5P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
```

[(methylsulfonylamino)methyl]benzyl]pyridin-2(1H)-one

586374-84-7P.

```
[(piperazino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                  586375-40-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(2-methyl-1)oxy]]
                                                                                                          586375-41-9P,
aminoethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(3-
                                                                                                            586375-42-0P,
aminopropyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                      586375-43-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
                                                                                                    586375-44-2P,
[(methylamino)carbonyl]benzyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                         586375-45-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(morpholino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                  586375-46-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-methyl-1)oxy]]]
hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                              586375-47-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(cyclopentylamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                              586375-48-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                          586375-49-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(1-
pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one 586375-50-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[(4-interpretation for a second for a second
methylpiperazinyl)carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                           586375-51-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[2-
(dimethylamino)ethyl]amino]carbonyl]benzyl]pyridin-2(1H)-one
methoxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one
                                                                                                           586375-53-3P,
methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-54-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[N-(2-methoxyethyl)-N-(3-methyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methoxyethyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methoxyethyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methoxyethyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methoxyethyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl)]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-1-[4-[N-(3-methoxyethyl]]oxyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-
methylamino]carbonyl]benzyl]pyridin-2(1H)-one 586375-55-5P,
4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
                                                      586375-56-6P, 3-Bromo-4-[(2,4-
(2-hydroxyethyl)benzamide
difluorobenzyl)oxy]-6-methyl-1-[4-(piperazinocarbonyl)phenyl]pyridin-2(1H)-
                                      586375-57-7P, N-(2-Aminoethyl)-4-[3-bromo-4-[(2,4-
one hydrochloride
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride
586375-58-8P, N-(3-Aminopropy1)-4-[3-bromo-4-[(2,4-difluorobenzy1)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]benzamide hydrochloride
                                                                                                              586375-59-9P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586375-60-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586375-61-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-<math>1-[4-4]
[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586375-62-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
(morpholinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride
                                                                                                                          586375-63-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-[[bis(2-methyl-1)oxy]])
hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586375-64-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
(piperidinocarbonyl)phenyl]pyridin-2(1H)-one hydrochloride
                                                                                                                          586375-65-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-
[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586375-67-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]benzamide
                                                  586375-68-0P, 4-(Benzyloxy)-3-bromo-1-[4-
(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one
                                                                                                     586375-69-1P,
4-(Benzyloxy)-3-bromo-1-[4-(piperazin-1-ylcarbonyl)phenyl]pyridin-2(1H)-
one hydrochloride
                                        586375-70-4P, 4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-
pyridin-1-yl]-N-hydroxybenzamide
                                                                     586375-73-7P, 3-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-
                                  586375-74-8P 586375-75-9P, 3-Bromo-4-[(2,4-
methylbenzamide
difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-aminoethyl)amino]carbonyl]benzyl]py
```

```
ridin-2(1H)-one hydrochloride 586375-76-0P, 3-Bromo-4-[(2,4-
                    difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-aminopropyl)amino]carbonyl]benzyl]p
                    yridin-2(1H)-one hydrochloride
                    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
                     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
                                  (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
                                kinase for treatment of inflammatory conditions,
                                 ischemia, viral infections, autoimmune diseases, and other
                                 conditions)
ΙT
                    586375-77-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                    [(hydroxyamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
                    586375-78-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-4]
                    [(dimethylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
                    586375-80-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[
                     (morpholinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride 586375-81-7P,
                    3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-methyl-1)oxy]]]
                    hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
                    586375-82-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobenzyl]oxy]-6-methyl-1-[[bis(2-difluorobe
                    hydroxyethyl)amino]carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
                    586375-83-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                     (piperidinocarbonyl)benzyl]pyridin-2(1H)-one hydrochloride
                                                                                                                                                                                                                                                                      586375-84-0P,
                    3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                     [(isopropylamino)carbonyl]benzyl]pyridin-2(1H)-one hydrochloride
                    586375-85-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(1-3-(1-3-1))]
                    pyrrolidinylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride
                    586375-86-2P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
                    pyridin-1-yl]methyl]benzyl]-2-methoxyacetamide 586375-87-3P
                    586375-88-4P
                                                                               586375-89-5P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
                    methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-acetoxyacetamide
                                                                                  586375-90-8P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-
                    hydrochloride
                    methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-2-hydroxy-2-methylpropanamide
                    586375-91-9P, N-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
                    pyridin-1-yl]methyl]benzyl]-1-hydroxycyclopropanecarboxamide
                    586375-92-0P, N'-[3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-
                    2H-pyridin-1-yl]methyl]benzyl]-N,N-dimethylurea
                                                                                                                                                                                                                           586375-94-2P,
                    3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                     [[(piperazinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one hydrochloride
                    586375-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                    [[[(methylamino)carbonyl]amino]methyl]benzyl]pyridin-2(1H)-one
                    hvdrochloride
                                                                                     586375-96-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
                    1-[3-[[(morpholinocarbonyl)amino]methyl]benzyl]pyridin-2(1H)-one
                    hydrochloride
                                                                                     586376-01-4P, Ethyl 3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-
                    6-methyl-2-oxo-2H-pyridin-1-yl]benzoate
                                                                                                                                                                                          586376-02-5P,
                    3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
                                                                                             586376-03-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
                    methylbenzamide
                    methyl-1-[3-[(piperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
                    586376-04-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-dif
                    aminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
                    586376-05-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[(3-4-difluorobenzyl)oxy]-6-met
                    aminopropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
                    586376-06-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                     [(hydroxyamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
                    586376-07-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                     [(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
                    586376-08-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[3-methyl-1-[
                     [(morpholino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
                    586376-09-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-difluorobenzyl)oxy]-6-methyl-1-[[(2-diflu
                    hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
                    586376-10-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
                    [(piperidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
```

```
586376-11-6P, 3-Bromo-4-[(2,4-difluorobenzyl))oxy]-6-methyl-1-[3-
[(isopropylamino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-12-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(pyrrolidino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-13-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobenzyl)oxy]-6-methyl-1-[(4-difluorobe
methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-14-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-methyl-1-[(4-4-difluorobenzyl)oxy]-6-m
dimethylaminoethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-15-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[[(2-4-difluorobenzyl]oxy]-6-methyl-1-[[(2-4-difluorobenzyl]oxy]-6-methyl-1-[[(2-4-di
methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one hydrochloride
586376-16-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl)oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[3-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-1-[[N-(2-difluorobenzyl]oxy]-6-methyl-
dimethylaminoethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
hydrochloride
                                                   586376-17-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[3-[[N-(2-hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
hydrochloride 586376-18-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[3-[[N-(2-methoxyethy1)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
hydrochloride 586376-19-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]benzamide 586376-22-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(hydroxymethyl)phenyl]-6-
methylpyridin-2(1H)-one 586376-26-3P, N-[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]methanesulfonamide 586376-27-4P, N-[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]acetamide
                                                586376-29-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
586376-28-5P
methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-methoxyacetamide 586376-30-9P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-2-acetoxyacetamide hydrochloride 586376-31-0P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-2-aminoacetamide hydrochloride 586376-32-1P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-2-hydroxyacetamide hydrochloride 586376-33-2P,
N'-[3-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
yl]benzyl]-N,N-dimethylurea 586376-35-4P, N-[3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzyl]-N'-methylurea
586376-36-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[
[[(morpholinocarbonyl)amino]methyl]phenyl]pyridin-2(1H)-one
586376-37-6P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]benzyl]urea
                                                                                           586376-38-7P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[3-[(dimethylamino)methyl]phenyl]-6-methylpyridin-
                                         586376-41-2P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
2(1H)-one
                                                                          586376-44-5P, N-[4-[4-(Benzyloxy)-3-bromo-2-oxo-2H-
yl]benzyl]acetamide
pyridin-1-yl]benzyl]-2-hydroxyacetamide
                                                                                                                                            586376-45-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(morpholin-4-
yl)ethyl]pyridin-2(1H)-one
                                                                                                586376-47-8P, Ethyl 3-[4-(benzyloxy)-3-bromo-
2-oxo-2H-pyridin-1-yl]propanoate
                                                                                                                    586376-48-9P, Methyl
3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoate
                                                                                                                                                                                                             586376-50-3P,
N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,6-
                                                                    586376-60-5P, 3-Bromo-1-(4-bromo-2,6-difluorophenyl)-4-
difluorobenzamide
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                                                                                                       586376-68-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(2,4,6-
trifluorophenyl)pyridin-2(1H)-one
                                                                                                                         586376-72-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-
                                         586376-76-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
2(1H)-one
(hydroxymethyl)-1-(2,4,6-trifluorophenyl)pyridin-2(1H)-one
                                                                                                                                                                                                                586376-78-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(morpholin-4-
yl)phenyl]-6-methylpyridin-2(1H)-one
                                                                                                                                    586376-82-1P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-
methylpyridin-2(1H)-one 586376-83-2P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl]-6-
methylpyridin-2(1H)-one 586376-87-6P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-difluorophenyl]-6-
```

```
methylpyridin-2(1H)-one 586376-89-8P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-hydroxyethyl)(methyl)amino]pheny
1]-6-methylpyridin-2(1H)-one 586376-90-1P, 3-Bromo-1-(3,5-dibromo-2,6-
difluoro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                            586376-93-4P, 2-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
2(1H)-one
methyl-2-oxo-2H-pyridin-1-yl]-3,5-difluorophenoxy]acetamide
586376-97-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2,6-difluoro-4-(2-4)]-1-[2,6-difluoro-4-(2-4)]-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluoro-4-(2-4)]-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl)oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl]oxyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenzyl-1-[2,6-difluorobenz
hydroxyethoxy)phenyl]-6-methylpyridin-2(1H)-one 586376-98-9P,
3-Bromo-1-(2,6-difluorophenyl)-4-[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-
methylpyridin-2(1H)-one 586377-04-OP, 3-Chloro-1-(2,6-difluorophenyl)-4-
[[4-fluoro-2-(hydroxymethyl)benzyl]oxy]-6-methylpyridin-2(1H)-one
586377-06-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)]-6-methyl-2-oxo-2H-
pyridin-1-yl]-2-methyl-N-[2-(morpholin-4-yl)ethyl]benzamide
586377-13-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl)oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl]oxy]-6-methyl-1-[3-[(3-4-difluorobenzyl]oxy]-6-methyl-1-[3-[(3-4-difluoroben
methoxyethyl)amino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one
586377-15-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-4]
[(dimethylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one
                                                                                                                                               586377-17-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(2-difluorobenzyl)oxy]]
hydroxyethyl)amino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one
586377-18-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
[(methylamino)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-19-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[N-(2-hydroxyethyl)-N-
methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-21-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1]oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1]oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-1]oxy]-6-methyl-1-[3-[(4-methylpipera
yl)carbonyl]-2-methylphenyl]pyridin-2(1H)-one 586377-23-3P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(morpholinocarbonyl)-2-
methylphenyl]pyridin-2(1H)-one 586377-24-4P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[3-[[N-(2-methoxyethyl)-N-
methylamino]carbonyl]-2-methylphenyl]pyridin-2(1H)-one
                                                                                                                                     586377-26-6P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-(aminocarbonyl)-2-
methylphenyl]pyridin-2(1H)-one
                                                                            586377-28-8P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[3-(hydroxymethyl)-2-methylphenyl]-6-methylpyridin-
                          586377-30-2P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
2(1H)-one
2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-2-methylbenzamide
                                                                                                                                                    586377-33-5P
586377-34-6P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-N-(2-hydroxyethyl)-2-methylbenzamide
                                                                                                                               586377-35-7P,
3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
methylbenzamide
                                          586377-39-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
[2,6-difluoro-4-[(methylamino)methyl]phenyl]pyridin-2(1H)-one
                                   586377-42-6P, 4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
hydrochloride
oxo-2H-pyridin-1-yl]-3,5-difluoro-N,N-dimethylbenzamide
                                                                                                                                           586377-44-8P,
4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3-fluoro-5-
methoxybenzonitrile 586377-47-1P, N-[4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]urea
586377-48-2P, 2-[[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
1-y1]-3,5-difluorobenzyl]amino]-1,1-dimethyl-2-oxoethyl acetate
586377-49-3P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
                                                                                     586377-50-6P, N-[4-[3-Chloro-4-[(2,4-
1-yl]-3,5-difluorobenzyl]acetamide
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-
                                             586377-51-7P, N-[4-[3-Chloro-4-[(2,4-
methoxyacetamide
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-difluorobenzyl]-2-furamide
586377-52-8P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
1-y1]-3,5-difluorobenzyl]-1H-imidazole-4-carboxamide
                                                                                                                                 586377-53-9P
586377-54-0P, N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-
1-yl]-3,5-difluorobenzyl]-3-hydroxy-3-methylbutanamide
                                                                                                                                        586377-55-1P,
N-[4-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-
difluorobenzyl]-1-hydroxycyclopropanecarboxamide
                                                                                                                         586377-56-2P,
difluorobenzyl]-2-hydroxy-2-methylpropanamide 586377-57-3P,
4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-3,5-
                                                   586377-62-0P, 3-Bromo-1-(3-fluorobenzyl)-4-(1-
difluorobenzonitrile
```

```
586377-63-1P, 3-Bromo-1-(3-fluorobenzyl)-
phenylethoxy)pyridin-2(1H)-one
4-[(E)-2-(4-fluorophenyl)ethenyl]pyridin-2(1H)-one
                                                                            586377-64-2P,
4-(Benzyloxy)-3-bromo-1-[(6-fluoropyridin-3-yl)methyl]pyridin-2(1H)-one
586377-65-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-dimethylphenyl)-6-
methylpyridin-2(1H)-one
                                     586377-68-6P, 3-Bromo-1-(2,6-dimethylphenyl)-4-
[(4-fluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-69-7P,
3-Bromo-1-(2,6-dimethylphenyl)-6-methyl-4-[(2,4,6-dimethylphenyl)]
trifluorobenzyl)oxy]pyridin-2(1H)-one 586377-70-0P, 3-Bromo-4-[(2,6-
difluorobenzyl)oxyl-1-(2,6-dimethylphenyl)-6-methylpyridin-2(1H)-one
586377-71-1P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-fluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586377-73-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586377-74-4P,
3-Bromo-1-(2,6-dichlorophenyl)-4-[(2,6-difluorobenzyl)oxy]-6-methylpyridin-
2(1H)-one
                 586377-75-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2-methoxy-
6-methylphenyl)-6-methylpyridin-2(1H)-one 586377-78-8P,
4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,5-
dichlorobenzenesulfonamide 586377-83-5P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-
methylpyridin-2(1H)-one 586377-87-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2,4-difluoro-6-[(2-hydroxyethyl)(methyl)amino]pheny
1]-6-methylpyridin-2(1H)-one 586377-91-5P, N-[2-[[[3-Bromo-1-(2,6-
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]urea 586377-92-6P, Methyl [2-[[[3-bromo-1-(2,6-
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]carbamate 586377-93-7P, N-[2-[[[3-Bromo-1-(2,6-
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]-2-hydroxyacetamide 586377-94-8P, Ethyl
[2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-97-1P, Isobutyl
[2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate 586377-98-2P, Cyclopropylmethyl
[2-[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate 586378-07-6P,
1-[(4-A\min o-2-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methyl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl)methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-chloro-4-[(2,4-methylpyrimidin-5-yl]-3-((2,4-methylpyrimidin-5-yl)methylpyrimidin-5-((2,4-methylpyrimidin-5-yl)methylpyrimidin-5-((2,4-methylpyrimidin-5-yl)methylpyrimidin-5-((2,4-methylpyrimidin-5-yl)m
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one hydrochloride
586378-09-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-
ylmethyl)-6-methylpyridin-2(1H)-one trifluoroacetate
                                                                                586378-11-2P
586378-17-8P
                      586378-19-0P, Methyl 4-[[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-
                                             586378-21-4P, 3-Bromo-4-[(2,4-
carboxylate trifluoroacetate
difluorobenzyl)oxy]-1-[(2-hydroxypyrimidin-4-yl)methyl]-6-methylpyridin-
2(1H)-one trifluoroacetate 586378-23-6P, 4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidine-2-
carboxamide trifluoroacetate 586378-24-7P, Methyl [4-[[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrimidin-2-
yl]methylcarbamate
                              586378-25-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-1-[(5-methylpyrazin-2-yl)methyl] pyridin-2(1H)-one
                                                                                       586378-28-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyrazin-2-ylmethyl)pyridin-
                 586378-33-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
[(dimethylamino)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
                           586378-36-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
trifluoroacetate
[[(2-hydroxyethyl)(methyl)amino]methyl]pyrazin-2-yl]methyl]-6-
methylpyridin-2(1H)-one trifluoroacetate
                                                            586378-37-2P,
586378-41-8P,
yl)carbonyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one
5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-(2-hydroxyethyl)-N-methylpyrazine-2-carboxamide
586378-42-9P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2,3-dihydroxypropyl)pyrazine-2-carboxamide
586378-43-0P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2-hydroxyethyl)pyrazine-2-carboxamide
```

```
586378-44-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
            (methoxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
           586378-45-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(2-
           methoxyethoxy)methyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
           586378-46-3P, Carbamic acid [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
           methyl-2-oxo-2H-pyridin-1-yl]methyl]pyrazin-2-yl]methyl ester
           586378-48-5P, 4-(Benzyloxy)-1-(3-fluorobenzyl)-3-methylpyridin-2(1H)-one
           586378-51-0P, 1-(3-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]-3-methylpyridin-
           2(1H)-one
                                         586378-52-1P, 1-Benzyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
           methylpyridin-2(1H)-one 586378-54-3P, N-[3-Bromo-1-(3-fluorobenzyl)-2-
           oxo-1,2-dihydropyridin-4-yl]-4-fluorobenzamide
                                                                                                                                    586378-57-6P,
           3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
           methylpyridin-2(1H)-one 586378-59-8P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl)-4-[(4-fluorobenzyl
           fluorobenzyl)amino]-6-methylpyridin-2(1H)-one 586378-61-2P,
           3-Bromo-1-(cyclopropylmethyl)-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                                     586378-63-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
           2(1H)-one
            (pyridin-4-ylmethyl)pyridin-2(1H)-one 586378-65-6P, 3-Bromo-4-[(2,4-
           difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
           586378-67-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(pyridin-2-methyl-1-(pyridin-2-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl-1-methyl
           ylmethyl)pyridin-2(1H)-one 586378-70-3P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-
           6-methyl-1-[(pyridin-4-yl)methyl]pyridin-2(1H)-one 586378-71-4P,
           3-Bromo-4-[(2,4,6-trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-4-
                                                                                 586378-72-5P, 3-Bromo-4-[(2,6-
           yl)methyl]pyridin-2(1H)-one
           difluorobenzyl)oxy]-6-methyl-1-[(pyridin-4-yl)methyl]pyridin-2(1H)-one
           586378-73-6P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-
           y1) methy1]pyridin-2(1H)-one 586378-74-7P, 3-Bromo-4-[(2,4,6-1)]
           trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-75-8P, 3-Bromo-4-[(2-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-
           y1) methy1]pyridin-2(1H)-one 586378-76-9P, 3-Bromo-4-[(2,4,5-4)]
           trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-77-0P, 3-Bromo-4-[(4-chloro-2-fluorobenzyl)oxy]-6-methyl-1-
            [(pyridin-3-yl)methyl]pyridin-2(1H)-one 586378-78-1P,
           3-Bromo-4-[(2-chloro-4-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-
           yl)methyl]pyridin-2(1H)-one 586378-79-2P, 3-Bromo-4-[(2,6-
           difluorobenzyl)oxy]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-80-5P, 3-Bromo-4-[(4-fluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-
           yl)methyl]pyridin-2(1H)-one
                                                                                    586378-81-6P, 3-Bromo-4-[(2,4,6-
           trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-2-yl)methyl]pyridin-2(1H)-one
           586378-82-7P, 3-Bromo-4-[(2,4,5-trifluorobenzyl)oxy]-6-methyl-1-[(pyridin-
           2-y1) methyl pyridin -2(1H) one 586378-83-8P, 3-Bromo -4-[2-(4-y)]
           fluorophenyl)ethyl]-6-methyl-1-[(pyridin-3-yl)methyl]pyridin-2(1H)-one
           586378-86-1P, 3-Bromo-4-[2-(4-fluorophenyl)ethyl]-6-methyl-1-[(pyridin-4-
           yl)methyl]pyridin-2(1H)-one 586378-87-2P, 3-Chloro-4-[(2,4-
           difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
           586378-91-8P
, 1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl]-3-bromo-6-methyl-4-[(2,4,6-methyl-4-1)methyl-4-[(2,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,6-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4-methyl-4-1)methyl-4-[(4,4,4,4,4-methyl-4-1
           trifluorobenzyl)oxy]pyridin-2(1H)-one trifluoroacetate
                                                                                                                                                        586378-93-0P,
           3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[2-methyl-4-
            (methylamino)pyrimidin-5-yl]methyl]pyridin-2(1H)-one trifluoroacetate
                                                                                  586378-98-5P, 3-Chloro-4-[(2,4-
           586378-95-2P
                                                586378-97-4P
           difluorobenzyl)oxy]-6-methyl-1-[(5-methylpyrazin-2-yl)methyl]pyridin-2(1H)-
                          586379-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-
            [(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one
           trifluoroacetate
                                                          586379-03-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
            [[5-(hydroxymethyl)pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
           586379-04-6P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
           pyridin-1-yl]methyl]-N,N-dimethylpyrazine-2-carboxamide
                                                                                                                                                         586379-05-7P,
            5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
           yl]methyl]-N-methylpyrazine-2-carboxamide 586379-06-8P,
            3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-(1-hydroxy-1-methylethyl)pyrazin-
           2-yl]methyl]-6-methylpyridin-2(1H)-one 586379-07-9P,
```

```
5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                                                                                                                                               586379-08-0P,
yl]methyl]-N-(2-methoxyethyl)pyrazine-2-carboxamide
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-(morpholin-4-
ylcarbonyl)pyrazin-2-yl]methyl]pyridin-2(1H)-one
                                                                                                                                                     586379-09-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[5-[(4-hydroxypiperidin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-indin-1-in
yl)carbonyl]pyrazin-2-yl]methyl]-6-methylpyridin-2(1H)-one
                                                                                                                                                                                 586379-11-5P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-(3-hydroxy-2,2-dimethylpropyl)pyrazine-2-carboxamide
586379-12-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2,2,2-trifluoroethyl)pyrazine-2-carboxamide
586379-13-7P, 1-Allyl-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                                   586379-15-9P, 1-Allyl-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586379-17-1P, Methyl (2E)-4-[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-butenoate
586379-18-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-prop-2-
ynylpyridin-2(1H)-one 586379-21-7P, 4-[(2,4-Difluorobenzyl)oxy]-6-
(hydroxymethyl)-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-23-9P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(pyridin-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl)-1-(hydroxymethyl
ylmethyl) pyridin-2(1H)-one 586379-24-0P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-[(dimethylamino)methyl]-1-(pyridin-3-
ylmethyl)pyridin-2(1H)-one 586379-29-5P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridin-2(1H)-
                  586379-31-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
difluorophenyl)-6-[(dimethylamino)methyl]pyridin-2(1H)-one 586379-32-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(morpholin-4-incomplex)
ylmethyl)pyridin-2(1H)-one 586379-33-1P, 3-Bromo-4-[(2,4-1)]
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[[(2-
methoxyethyl)amino]methyl]pyridin-2(1H)-one 586379-34-2P,
5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-
dihydropyridine-2-carboxylic acid 586379-35-3P, Methyl
4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
                                                586379-38-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methylbenzoate
methyl-1-(2-methyl-4-carboxyphenyl)pyridin-2(1H)-one
                                                                                                                                                              586379-39-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influorobenzyl]oxy]-6-methyl-1-[2-methyl-4-influor
(hydroxymethyl)phenyl]pyridin-2(1H)-one
                                                                                                                           586379-40-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methy
methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-methyl-4-
[(methylamino)carbonyl]phenyl]pyridin-2(1H)-one
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(1,2-dihydroxyethyl)-2-
                                                                                                                        586379-47-7P, Methyl
methylphenyl]-6-methylpyridin-2(1H)-one
3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
chlorobenzoate
                                                  586379-50-2P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]-4-chlorobenzoic acid
                                                                                                                                                             586379-54-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[5-(hydroxymethyl)-2-methylphenyl]-
                                                                               586379-57-9P, 3-Bromo-4-[(2,4-
6-methylpyridin-2(1H)-one
difluorobenzyl)oxy]-1-[5-[(dimethylamino)methyl]-2-methylphenyl]-6-
                                                                                                                  586379-59-1P, 3-Bromo-4-[(2,4-
methylpyridin-2(1H)-one hydrochloride
difluorobenzyl)oxy]-1-[5-[(isopropylamino)methyl]-2-methylphenyl]-6-
methylpyridin-2(1H)-one hydrochloride 586379-60-4P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)-4-
                                                   586379-65-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-
methylbenzamide
[[(2-methoxyethyl)amino]carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-
                  586379-67-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-686379-67-1P]
[(dimethylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one
586379-68-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-
(morpholinocarbonyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one
586379-69-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1-hydroxy-1-1)]
methylethyl)-2-methylphenyl]-6-methylpyridin-2(1H)-one 586379-71-7P,
Methyl 3-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]-4-methylbenzoate 586379-76-2P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-
```

```
1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                                          586379-78-4P, 3-Bromo-1-(3-
fluorobenzyl)-4-[[3-(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one
586379-79-5P, 3-Bromo-1-(3-fluorobenzyl)-4-[[4-fluoro-2-
(trifluoromethyl)benzyl]amino]pyridin-2(1H)-one
                                                                                                   586379-80-8P,
3-Bromo-4-[(4-chloro-2-fluorobenzyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-
            586379-81-9P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-6-methyl-1-
(pyridin-4-ylmethyl)pyridin-2(1H)-one
                                                                                586379-83-1P, 3-Bromo-4-[(2,4-
difluorobenzyl)amino]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one
586379-85-3P, 3-Bromo-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-
6-methylpyridin-2(1H)-one trifluoroacetate 586379-87-5P,
3-Chloro-4-[(2,4-difluorobenzyl)amino]-1-(2,6-difluorophenyl)-6-
methylpyridin-2(1H)-one 586379-88-6P, 3-[[3-Chloro-4-[(2,4-
difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzonitrile
586379-91-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-1]
pyridin-1-yl]methyl]benzonitrile 586379-93-3P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-fluoro-5-(hydroxymethyl)phenyl]-6-methylpyridin-
2(1H)-one trifluoroacetate 586380-00-9P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-
methylbenzamide 586380-01-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-1-[2-fluoro-5-[(dimethylamino)carbonyl]phenyl]pyridin-2(1H)-one
586380-02-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[[(2-hydroxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                                        586380-03-2P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(4-difluorobenzyl)oxy]]
methylpiperazino)carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                         586380-04-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586380-05-4P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]
methoxyethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-06-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-fluorobenzyl)oxy]]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-me
hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
586380-07-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[[(3-hydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-08-7P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[(2,3-difluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxy]-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl)oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-1-[2-fluorobenzyl]oxyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-methyl-6-me
dihydroxypropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
                                                                                                                   586380-09-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[(2-hydroxy-
1,1-dimethylethyl)amino]carbonyl]phenyl]pyridin-2(1H)-one 586380-10-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
(piperazinocarbonyl)phenyl]pyridin-2(1H)-one
                                                                                               586380-17-8P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
methoxy-N-methylbenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
      (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
      kinase for treatment of inflammatory conditions,
      ischemia, viral infections, autoimmune diseases, and other
      conditions)
586380-18-9P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-methoxy-N, N-dimethylbenzamide
                                                                                              586380-21-4P,
3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-
fluoro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]benzamide
                                                                                                                586380-22-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[(acetylamino)methyl]phenyl]pyridin-2(1H)-one 586380-23-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[(methoxyacetylamino)methyl]phenyl]pyridin-2(1H)-one
                                                                                                                586380-24-7P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-indicated]
[(methylsulfonylamino)methyl]phenyl]pyridin-2(1H)-one
                                                                                                                  586380-25-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[(aminocarbonylamino)methyl]phenyl]pyridin-2(1H)-one
                                                                                                               586380-27-0P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[(methoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one
```

ΙT

```
586380-28-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[(trifluoromethyl)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-29-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[(isopropoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-30-5P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[(ethylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-31-6P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[(tetrahydrofuran-3-yloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-
           586380-32-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-
2-[[(propoxycarbonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-33-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[(allyloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-34-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[(propargyloxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-35-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-methyl-4-[[4-fluoro-2-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl
[[[(tert-butoxy)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-36-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[[(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-37-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[(propylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-38-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[(ethylsulfonyl)amino]methyl]benzyl]oxy]pyridin-2(1H)-one
                                                                                                                     586380-39-4P,
3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[4-fluoro-2-index)
[[[(isopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-40-7P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[(methoxymethyl)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-41-8P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-
[[[(methylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-2(1H)-one
586380-42-9P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-fluoro-2-methyl-4-[[4-fluoro-2-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl-4-methyl
[[[N-methyl-N-(tert-butyl)amino]carbonyl]amino]methyl]benzyl]oxy]pyridin-
                      586380-43-0P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-
2(1H)-one
fluoro-2-[[[(cyclopropylamino)carbonyl]amino]methyl]benzyl]oxy]pyridin-
                       586380-44-1P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-4-[[4-
2(1H)-one
fluoro-2-[[[[(2,2,2-trifluoroethyl)amino]carbonyl]amino]methyl]benzyl]oxy]
pyridin-2(1H)-one
                                   586380-45-2P, 3-Chloro-1-(2,6-difluorophenyl)-6-methyl-
4-[[4-fluoro-2-[[[[(cyclopropylmethyl)amino]carbonyl]amino]methyl]benzyl]o
                                           586380-46-3P, 3-Chloro-1-(2,6-difluorophenyl)-6-
xy]pyridin-2(1H)-one
methyl-4-[[4-fluoro-2-[[[(2,2-dimethylpropylamino)carbonyl]amino]methyl]be
nzyl]oxy]pyridin-2(1H)-one
                                                       586380-47-4P, 3-Chloro-1-(2,6-difluorophenyl)-
6-methyl-4-[[4-fluoro-2-[[[(dimethylamino)carbonyl]amino]methyl]benzyl]oxy
                                        586380-48-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-
]pvridin-2(1H)-one
[[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-
           586380-50-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[5-
(hydroxymethyl)pyridin-2-yl]methyl]-6-methylpyridin-2(1H)-one
586380-52-1P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2-hydroxyethyl)-N-methylnicotinamide
586380-55-4P, 6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N-(2-hydroxyethyl)nicotinamide
                                                                                                        586380-56-5P,
6-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N,N-dimethylnicotinamide
                                                                      586380-57-6P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2(1H)-
           586380-66-7P, Carbamic acid [5-bromo-4-[(2,4-difluorobenzyl)oxy]-1-
one
(2,6-difluorophenyl)-2-methyl-6-oxo-1,6-dihydropyridin-3-yl]methyl ester
586380-68-9P, 5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-
methyl-6-oxo-1,6-dihydropyridine-3-carbonitrile
                                                                                                586380-69-0P,
4-(Benzyloxy)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-2(1H)-
           586380-70-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
difluorophenyl)-6-methyl-5-(oxiran-2-yl)pyridin-2(1H)-one
                                                                                                                    586380-71-4P,
4-(Benzylamino)-3-bromo-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-
                       586380-72-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-
2(1H)-one
difluorophenyl)-6-methyl-5-((E)-2-phenylethenyl)pyridin-2(1H)-one
```

```
586380-74-7P, 4-(Allylamino)-1-(2,6-difluorophenyl)-5-iodo-6-methylpyridin-
                       586380-76-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-5'-(1-
hydroxy-1-methylethyl)-6-methyl-2H-1,2'-bipyridin-2-one
                                                                                                              586380-77-0P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(furyl-2-ylmethyl)-6-methylpyridin-
2(1H)-one
                       586380-78-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
(thien-2-ylmethyl) pyridin-2(1H)-one 586380-79-2P, 3-Bromo-1-(2,6-
difluorophenyl)-4-(furyl-2-ylmethoxy)-6-methylpyridin-2(1H)-one
586380-80-5P, 3-Bromo-1-[2-fluoro-6-(furyl-3-ylmethoxy)phenyl]-4-(furyl-3-
vlmethoxy) -6-methylpyridin-2(1H)-one 586380-81-6P, 3-Bromo-1-[2-fluoro-6-
(thien-3-ylmethoxy)phenyl]-6-methyl-4-(thien-3-ylmethoxy)pyridin-2(1H)-one
586380-86-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-(1-hydroxy-1-methylethyl)-N-methylbenzamide
586380-89-4P, 3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-methylbenzamide
                                                                  586380-91-8P
                                                                                             586380-92-9P,
N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2H-pyridin-1-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-2-yl-2-oxo-
4-fluorobenzyl]propanamide 586380-93-0P, N-[3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-N',N'-
                          586380-94-1P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
dimethylurea
methyl-2-oxo-2H-pyridin-1-yl]-4-fluorobenzyl]-2-hydroxyacetamide
586380-95-2P, N-[3-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-fluorobenzyl]-2-hydroxy-2-methylpropanamide 586380-96-3P
586380-97-4P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)]-6-methyl-2-oxo-2H-
pyridin-1-y1]-4-fluorobenzamide 586380-98-5P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N-
methylbenzamide
                               586380-99-6P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]-4-fluoro-N, N-dimethylbenzamide
586381-00-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[2-fluoro-5-[(4-
methylpiperazin-1-yl)carbonyl]phenyl]-6-methylpyridin-2(1H)-one
586381-01-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
(morpholinocarbonyl)phenyl]pyridin-2(1H)-one 586381-02-4P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-[[N-(2-fluorobenzyl)oxy]]-6-methyl-1-[2-fluorobenzyl)oxyl-1-[1-fluorobenzyl]oxyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl]oxyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluorobenzyl-1-[1-fluo
hydroxyethyl)-N-methylamino]carbonyl]phenyl]pyridin-2(1H)-one
586381-03-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-fluoro-5-
[[(2-hydroxy-2-methylpropyl)amino]carbonyl]phenyl]pyridin-2(1H)-one
586381-09-1P, 4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N, N-dimethylbenzamide
                                                                                     586381-10-4P,
4-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-(2-hydroxy-2-methylpropyl)benzamide
                                                                                                  586381-11-5P,
N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)]]-6-methyl-2-oxo-2H-pyridin-1-
vl]benzvl]-2-hydroxyacetamide
                                                              586381-14-8P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide
586381-17-1P, 1-(3-Aminobenzyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
                                                 586381-18-2P, N-[4-[[3-Bromo-4-[(2,4-
methylpyridin-2(1H)-one
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]acetamide
586381-19-3P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-1]
pyridin-1-yl]methyl]phenyl]-2-hydroxyacetamide
                                                                                             586381-20-6P,
N-[4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                                                          586381-21-7P
yl]methyl]phenyl]-2-acetoxyacetamide
                                                                                                         586381-22-8P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
v_1]methyl]phenyl]acetamide 586381-23-9P, N-[4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-
methylurea
                        586381-24-0P, N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-N'-(2-hydroxy-2-
                                       586381-25-1P, N-[4-[[3-Bromo-4-[(2,4-
methylpropyl)urea
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]piperidine-1-carboxamide
                                                                                     586381-26-2P,
N-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-]
yl]methyl]benzyl]morpholine-4-carboxamide 586381-27-3P,
N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]piperazine-1-carboxamide hydrochloride 586381-28-4P,
N-[4-[(3-Bromo-4-((2,4-difluorobenzyl))oxy]-6-methyl-2-oxo-2H-pyridin-1-
```

```
yl]methyl]benzyl]-N'-(2-hydroxyethyl)urea 586381-29-5P,
N'-[4-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-N,N-dimethylurea 586381-30-8P, N-[4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-4-
                                                586381-31-9P, 4-[[3-Bromo-4-[(2,4-
hydroxypiperidine-1-carboxamide
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N,N-
dimethylbenzenesulfonamide 586381-32-0P, 4-[[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-
hydroxyethyl) benzenesulfonamide 586381-35-3P, 4-[[3-Bromo-4-[(2,4-Bromo-4,5])]
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]-N-(2-hydroxy-2-
methylpropyl)benzenesulfonamide 586381-38-6P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-(1H-pyrazol-3-ylmethyl)-1H-pyridin-2-one
586381-43-3P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-1,3-dihydroindol-2-one 586381-45-5P,
N-[[5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-]]
yl]methyl]pyrazin-2-yl]methyl]-N-methylmethanesulfonamide 586381-46-6P,
Methyl [5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-
1-yl]methyl]pyrazin-2-yl]methyl(methyl)carbamate 586381-47-7P
586381-48-8P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2H-methyl-2-oxo-2-oxo-2H-methyl-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2-oxo-2
pyridin-1-yl]methyl]-N-(2-hydroxy-2-methylpropyl)pyrazine-2-carboxamide
586381-50-2P, 1-[(5-Aminopyrazin-2-y1)methy1]-3-bromo-4-[(2,4-y1)methy1]
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one trifluoroacetate
586381-52-4P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[(3-methyl-1-1)]
1,2,4-triazin-6-yl)methyl]pyridin-2(1H)-one trifluoroacetate
586381-54-6P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-indazol-5-yl)-6-
methylpyridin-2(1H)-one 586381-56-8P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(1H-indazol-6-yl)-6-methylpyridin-2(1H)-one
586381-65-9P, Methyl [2-[[[3-bromo-1-[5-[[(2-hydroxyethyl)amino]carbonyl]-
2-methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]carbamate 586381-66-0P, Methyl [2-[[[3-bromo-1-[5-[[(2-
hydroxy-2-methylpropyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-
dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586381-67-1P,
Methyl [2-[[[3-bromo-1-[5-[[(2-methoxyethyl)amino]carbonyl]-2-
methylphenyl]-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]carbamate 586381-68-2P, O-Methyl [2-[[[1-[5-(aminocarbonyl)-
2-methylphenyl]-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-
5-fluorobenzyl]carbamate 586381-69-3P, N-[2-[[[3-Chloro-1-(2,6-
difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl]-5-
fluorobenzyl]-N'-phenylurea
                                           586381-70-6P, (Thien-3-yl) methyl
[2-[[[3-chloro-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-5-fluorobenzyl]carbamate
                                                             586381-71-7P, Ethyl
[2-[[3-bromo-6-methyl-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-2-oxo-
1,2-dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate
586381-75-1P
                      586381-83-1P, Methyl 3-[6-[(acetyloxy)methyl]-3-bromo-4-
[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]-4-methylbenzoate
586381-87-5P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-
oxo-2H-pyridin-1-yl]-4-methylbenzoic acid
                                                               586381-88-6P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-
1-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
                                                                 586381-90-0P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-(hydroxymethyl)-2-oxo-2H-pyridin-
1-y1]-4-methylbenzamide 586381-91-1P, [5-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-methyl-5-[(methylamino)carbonyl]phenyl]-6-oxo-1,6-
dihydropyridin-2-yl]methyl acetate
                                                      586381-92-2P, (2E)-4-[3-Bromo-4-[(2,4-
\verb|difluorobenzyl| oxy| -6 - methyl -2 - oxo -2 \\ H-pyridin -1 -yl] -N - methyl -2 -butenamide
                                            586381-99-9P
586381-97-7P
                      586381-98-8P
                                                                  586382-00-5P
                                                                                         586382-01-6P,
Carbamic acid 2-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-4-[(methylamino)carbonyl]benzyl ester
                                                                                586382-06-1P,
Carbamic acid 4-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-3,5-difluorobenzyl ester
                                                           586382-07-2P,
N-[4-[(3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-2-hydroxyacetamide 586382-09-4P, N-[4-[[3-Chloro-4-
```

```
hydroxycyclopropanecarboxamide 586382-10-7P, Carbamic acid
         4-[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
         yl]methyl]benzyl ester
                                                          586382-11-8P, (S)-2-[[4-[[3-Bromo-4-[(2,4-
         difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-1-
         methyl-2-oxoethyl acetate 586382-12-9P, 2-[[4-[[3-Bromo-4-[(2,4-
         difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]phenyl]amino]-
         1,1-dimethyl-2-oxoethyl acetate 586382-13-0P, [1-[3-
         (Aminocarbonyl) phenyl]-5-chloro-4-[(2, 4-difluorobenzyl) oxy]-6-oxo-1,6-
         dihydropyridin-2-y1]methyl acetate 586382-20-9P, 3-Bromo-4-[(2,4-
         difluorobenzyl)oxy]-6-methyl-1-[[2-(methylsulfonyl)pyrimidin-5-
         yl]methyl]pyridin-2(1H)-one 586382-22-1P, Ethyl [2-[[[3-bromo-1-[5-[[(2-
         hydroxyethyl)amino]carbonyl]-2-methylphenyl]-6-methyl-2-oxo-1,2-
         dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzyl]carbamate 586382-24-3P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(1H-imidazol-2-yl)-2-
         methylphenyl]-6-methylpyridin-2(1H)-one trifluoroacetate 586382-25-4P,
         3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-(5-hydroxy-1H-pyrazol-3-yl)-2-
         methylphenyl]-6-methylpyridin-2(1H)-one 586382-27-6P 586382-28-7P
         586382-29-8P, Methyl 4-[[4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-quinolin-1-
         yl]methyl]benzoate 586382-32-3P, 5-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
         6-\text{methyl}-2-\text{oxo}-2\text{H-pyridin}-1-\text{yl}] methyl]-2-furamide 586382-34-5P,
         5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2-
                             586382-38-9P, 1-[3,5-Bis(hydroxymethyl)phenyl]-3-bromo-4-[(2,4-
         difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586382-43-6P,
         5-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
         yl]isophthalamide 586382-44-7P, 1-[3,5-Bis(1-hydroxy-1-
         methylethyl)phenyl]-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                                 586382-45-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-
         2(1H)-one
          (hydroxymethyl)phenyl]-6-methylpyridin-2(1H)-one 586382-47-0P,
         1-(5-Amino-2-fluorophenyl)-3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-
         methylpyridin-2(1H)-one hydrochloride
                                                                                       586382-49-2P, N-[3-[3-Bromo-4-
         [(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-
                                                  586382-51-6P, N-[3-[3-Bromo-4-[(2,4-
         2-hydroxyacetamide
         difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-4-fluorophenyl]-2-
         hydroxy-2-methylpropanamide 586382-53-8P, 4-[3-Bromo-4-[(2,4-
         difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-fluoro-N,N-
                                                586382-55-0P
                                                                             586382-56-1P, 3-Chloro-4-[(2,4-
         dimethylbenzamide
         difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
         indol-5-yl]methyl]-6-methylpyridin-2(1H)-one
                                                                                                        586382-57-2P,
         3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-2,3-dihydro-1H-
         indol-5-yl]methyl]-6-methylpyridin-2(1H)-one
                                                                                                        586382-58-3P
, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
         yl]methyl]-N, N-dimethylindoline-1-carboxamide
                                                                                                        586382-59-4P
         586382-60-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(methoxyacetyl)-1-(1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxyacetyl)-1-(methoxy
         2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                   586382-61-8P,
         5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-N,N-
         dimethylindoline-1-carboxamide 586382-62-9P, 1-Benzyl-4-(benzyloxy)-3-
                                                           586382-63-0P, 3-Bromo-1-(4-fluorobenzyl)-4-[(4-
         bromopyridin-2(1H)-one
         fluorobenzyl)oxy]pyridin-2(1H)-one
                                                                                 586382-64-1P, 4-(Benzyloxy)-3-bromo-1-
          (4-fluorobenzyl)pyridin-2(1H)-one
                                                                                  586382-65-2P, 4-(Benzyloxy)-3-bromo-1-
          [4-(methylthio)benzyl]pyridin-2(1H)-one
                                                                                              586382-66-3P,
         1-Benzyl-4-(benzyloxy)-3-chloropyridin-2(1H)-one
                                                                                                                586382-67-4P,
         3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-fluorobenzyl)pyridin-2(1H)-one
         586382-68-5P, 1-Benzyl-3-bromo-4-[(4-chlorobenzyl)oxy]pyridin-2(1H)-one 586382-69-6P, 3-Bromo-1-(4-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-
                                 586382-70-9P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-[2-
         2(1H)-one
          (phenylthio)ethyl]pyridin-2(1H)-one
                                                                                     586382-71-0P, 3-Bromo-4-[(4-
         chlorobenzyl)oxy]-1-(2-phenylethyl)pyridin-2(1H)-one
                                                                                                                        586382-72-1P
         586382-73-2P, 1-Benzyl-2-oxo-4-phenoxy-1,2-dihydropyridine-3-
                                            586382-74-3P, 3-Bromo-4-[(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)oxy]-1-(4-chlorobenzyl)
         carboxaldehyde
         methoxybenzyl)pyridin-2(1H)-one 586382-75-4P, 3-Bromo-4-[(4-
```

[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzyl]-1-

```
fluorobenzyl)oxy]-1-(3-phenylpropyl)pyridin-2(1H)-one 586382-76-5P,
1-Benzyl-4-(benzyloxy)-3-(hydroxymethyl)pyridin-2(1H)-one
                                                                                                                                                                                                         586382-77-6P.
3-Bromo-1-(4-methylbenzyl)-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-one
586382-78-7P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-chlorobenzyl)oxy]pyridin-
2(1H)-one
                                        586382-79-8P, 3-Bromo-1-(3-chlorobenzyl)-4-[(4-
fluorobenzyl)oxy]pyridin-2(1H)-one
                                                                                                                         586382-80-1P, 5-Bromo-1-(2-chloro-6-
fluorobenzyl)-3-methylpyridin-2(1H)-one
                                                                                                                                             586382-81-2P,
1-Benzyl-4-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
586382-82-3P, 1-Benzyl-4-chloro-2-oxo-1,2-dihydropyridine-3-carboxaldehyde
586382-83-4P, 1-Benzyl-4-hydroxy-2-oxo-1,2-dihydropyridine-3-
carboxaldehyde
                                                         586382-84-5P, 1-Benzyl-4-(benzyloxy)-3-methylpyridin-
                                        586382-85-6P, 4-(Benzyloxy)-1-(4-fluorobenzyl)pyridin-2(1H)-
2(1H)-one
one
                    586382-86-7P, 1-Benzyl-4-(benzyloxy)-3,5-dibromopyridin-2(1H)-one
586382-87-8P, 1-Benzyl-3-bromo-4-(3-phenylpropyl)pyridin-2(1H)-one
586382-88-9P, 1-Benzyl-3-methyl-4-(2-phenylethyl)pyridin-2(1H)-one
586382-89-0P, 1-Benzyl-3-methyl-4-(3-phenylpropyl)pyridin-2(1H)-one
586382-90-3P, 1-Benzyl-4-(benzylthio)-3-methylpyridin-2(1H)-one
586382-91-4P, 1-Benzyl-2-oxo-1,2-dihydropyridin-4-yl methanesulfonate
586382-92-5P, 6-(Benzyloxy)-1-methyl-2-oxo-1, 2-dihydropyridine-3-methyl-2-oxo-1, 2-dihydropyridin
                                              586382-93-6P, 3-Benzoyl-6-(benzyloxy)-1-methylpyridin-2(1H)-
carbonitrile
                    586382-94-7P, 3-Benzyl-6-(benzyloxy)-1-methylpyridin-2(1H)-one
586382-95-8P, 1-Benzyl-4-(benzylthio)pyridin-2(1H)-one
                                                                                                                                                                                             586382-96-9P,
4-Amino-1-benzylpyridin-2(1H)-one 586382-97-0P, 4-[(2,6-
Dichlorobenzyl)oxy]pyridine-1-oxide 586382-98-1P, 3-Bromo-1-(3-
fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one 586382-99-2P
586383-00-8P, 1-(1-Acetyl-2,3-dihydro-1H-indol-5-yl)-3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-01-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-
2,3-dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-02-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-2,3-individual oxidation o
dihydro-1H-indol-5-yl]pyridin-2(1H)-one
                                                                                                                                         586383-03-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-2,3-dihydro-
1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-04-2P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-2,3-individual oxidation of the state of the stat
dihydro-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-05-3P,
5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]indoline-1-carboxamide
                                                                                             586383-06-4P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-
yl]pyridin-2(1H)-one
                                                                         586383-07-5P, 1-(1-Acetyl-1H-indol-5-yl)-3-chloro-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                                                                                                      586383-08-6P
586383-09-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy-2-1]-1-[1-(2-hydroxy-2-1)oxy
methylpropanoyl)-1H-indol-5-yl]-6-methylpyridin-2(1H)-one 586383-10-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
indol-5-yl]pyridin-2(1H)-one
                                                                                                       586383-11-1P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-indol-5-yl]-6-
methylpyridin-2(1H)-one 586383-12-2P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-indol-5-yl]-6-
methylpyridin-2(1H)-one 586383-13-3P, 5-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-indole-1-
                                                586383-14-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
carboxamide
1-[1-(methylsulfonyl)-1H-indol-5-yl]pyridin-2(1H)-one
                                                                                                                                                                                             586383-15-5P,
1-(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-chloro-4-[(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-ight)-3-(2,4-
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                                                                                   586383-16-6P
586383-17-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
methylglycyl)-2,3-dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one
586383-20-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-
hydroxypropanoyl)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
586383-21-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-hydroxy-3-
methylbutanoy1)-2,3-dihydro-1H-isoindol-5-yl]-6-methylpyridin-2(1H)-one
```

```
586383-22-4P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide 586383-23-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-2,3-
dihydro-1H-isoindol-5-yl]pyridin-2(1H)-one 586383-24-6P,
1-(2-Acetyl-1,2,3,4-tetrahydroisoguinolin-6-yl)-3-chloro-4-[(2,4-yl)-3-chloro-4-[(2,4-yl)-3-yl)-3-yl]
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-25-7P
586383-26-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-2(1H)-
               586383-27-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-
methylglycyl)-1,2,3,4-tetrahydroisoguinolin-6-yl] pyridin-2(1H)-one
586383-28-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-d
hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-methylpyridin-
2(1H)-one
                           586383-29-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-
hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-6-
methylpyridin-2(1H)-one 586383-30-4P, 6-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-
dihydroisoquinoline-2(1H)-carboxamide 586383-31-5P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-
tetrahydroisoquinolin-6-yl]pyridin-2(1H)-one 586383-32-6P,
1-(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-chloro-4-[(2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl)-3-((2,4-tetrahydroisoquinolin-7-yl
difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-33-7P
586383-34-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(2-hydroxy-2-
methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-2(1H)-
               586383-35-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-(N-
methylglycyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one
586383-36-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-difluorobenzyl)oxy]-1-[2-(3-4-d
hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-methylpyridin-
2(1H)-one
                          586383-37-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[2-(3-
hydroxy-3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-
methylpyridin-2(1H)-one 586383-38-2P, 7-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3,4-
dihydroisoquinoline-2(1H)-carboxamide 586383-39-3P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[2-(methylsulfonyl)-1,2,3,4-
tetrahydroisoquinolin-7-yl]pyridin-2(1H)-one 586383-40-6P,
methylpyridin-2(1H)-one
                                                               586383-41-7P 586383-42-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
                                                                                                              586383-43-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
benzimidazol-5-yl] pyridin-2(1H)-one
                                                                                             586383-44-0P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-benzimidazol-5-yl]-6-
methylpyridin-2(1H)-one 586383-45-1P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-benzimidazol-5-
y1]-6-methylpyridin-2(1H)-one 586383-47-3P, 5-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-benzimidazole-1-
carboxamide
                                  586383-48-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-benzimidazol-5-yl]pyridin-2(1H)-one
586383-49-5P, 3-Chloro-1-(1,3-diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                                                586383-50-8P
586383-51-9P, 1-[3-Acetyl-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                             586383-52-0P, 1-[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-
2(1H)-one
benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                            586383-53-1P, 1-[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-
2(1H)-one
1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                             586383-54-2P, 1-[3-Acetyl-1-(3-hydroxy-3-methylbutanoyl)-2,3-
2(1H)-one
dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                                                           586383-55-3P, 3-Acety1-5-[3-chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-
benzimidazole-1-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
```

```
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
          (Uses)
                (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
               kinase for treatment of inflammatory conditions,
               ischemia, viral infections, autoimmune diseases, and other
               conditions)
                                                                                                                                586383-60-0P
ΙT
         586383-56-4P
                                       586383-57-5P
                                                                     586383-58-6P
                                                                                                   586383-59-7P
         586383-61-1P
                                     586383-62-2P 586383-63-3P 586383-64-4P,
         1-[1-Acetyl-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-
         y1]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
         586383-65-5P, 1-[1,3-Bis(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-
         benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
         2(1H)-one
                                 586383-66-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-
         hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-
         5-y1]-6-methylpyridin-2(1H)-one 586383-67-7P, 3-Chloro-4-[(2,4-4)]
         difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-methylpropanoyl)-1-(3-
         hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
                     586383-68-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-
         methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
         benzimidazol-5-yl]-6-methylpyridin-2(1H)-one 586383-69-9P,
         5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
          (2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-benzimidazole-1-carboxamide
         586383-70-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(2-hydroxy-2-
         methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-
                                                          586383-71-3P, 1-[1-Acetyl-3-(N-methylglycyl)-2,3-
         methylpyridin-2(1H)-one
         dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
         methylpyridin-2(1H)-one 586383-72-4P 586383-73-5P,
         3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-
          (N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
                     586383-74-6P, 1-[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-
         one
         5-y1]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
         586383-75-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-difluorobenzyl)oxy]-1-[1-(3-4-d
         hydroxypropanoy1)-3-(N-methylglycy1)-2,3-dihydro-1H-benzimidazol-5-y1]-6-
         methylpyridin-2(1H)-one 586383-76-8P, 3-Chloro-4-[(2,4-
         difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-
         2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
         586383-77-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
         pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-
                                    586383-78-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
         1-[3-(N-methylglycyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
         yl]pyridin-2(1H)-one
                                                       586383-79-1P, 1-[1-Acetyl-3-(3-hydroxypropanoyl)-
         2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
         methylpyridin-2(1H)-one
                                                             586383-80-4P
                                                                                           586383-81-5P,
         3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-3-
         (3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-
                                 586383-82-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-4)]
         2(1H)-one
         hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-
         methylpyridin-2(1H)-one 586383-83-7P, 1-[1,3-Bis(3-hydroxypropanoy1)-2,3-
         dihydro-1H-benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
                                                          586383-84-8P, 3-Chloro-4-[(2,4-
         methylpyridin-2(1H)-one
         difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-3-(3-
         hydroxypropanov1)-2,3-dihydro-1H-benzimidazol-5-y1]-6-methylpyridin-2(1H)-
                     586383-85-9P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-
         2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-
                                     586383-86-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-difluorobenzyl)oxy]-1-[3-(3-4-d
         carboxamide
         hydroxypropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-
         methylpyridin-2(1H)-one
                                                             586383-87-1P, 1-[1-Acetyl-3-(3-hydroxy-3-
         methylbutanoy1)-2,3-dihydro-1H-benzimidazol-5-y1]-3-chloro-4-[(2,4-
         difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one 586383-88-2P
         586383-89-3P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-
         methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-
```

```
benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
                                                                                           586383-90-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-
(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
           586383-91-7P, 1-[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-
                       586383-92-8P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
2-oxo-2H-pyridin-1-yl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide 586383-93-9P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-
2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-one
586383-94-0P, 3-Acetyl-6-[3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
oxo-2H-pyridin-1-yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide
586383-95-1P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-3-(2-hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazole-
1-carboxamide 586383-96-2P, 6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]-3-(N-methylglycyl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide 586383-97-3P, 6-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(3-hydroxypropanoyl)-
2,3-dihydro-1H-benzimidazole-1-carboxamide 586383-98-4P,
6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586383-99-5P, 5-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-1H-benzimidazole-1,3(2H)-dicarboxamide 586384-00-1P,
6-[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586384-01-2P, 1-[1-Acetyl-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
yl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
586384-02-3P
                          586384-03-4P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-
hydroxy-2-methylpropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-
5-y1]-6-methylpyridin-2(1H)-one 586384-04-5P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-3-(methylsulfonyl)-2,3-
dihydro-1H-benzimidazol-5-yl]pyridin-2(1H)-one 586384-05-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[-1-(3-hydroxypropanoyl)-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-6-methylpyridin-2(1H)-
           586384-06-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-
methylbutanoy1)-3-(methylsulfony1)-2,3-dihydro-1H-benzimidazol-5-y1]-6-
methylpyridin-2(1H)-one
                                                 586384-07-8P, 5-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-3-(methylsulfonyl)-2,3-
dihydro-1H-benzimidazole-1-carboxamide
                                                                              586384-08-9P,
1-[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-4-
[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                         586384-09-0P,
1-[3-Acetyl-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]-3-chloro-
4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                                                                             586384-10-3P,
1-(1-Acetyl-1H-pyrrol-3-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                                                 586384-11-4P 586384-12-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
pyrrol-3-yl]-6-methylpyridin-2(1H)-one
                                                                             586384-13-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglycyl)-1H-(N-methylglyc
pyrrol-3-yl]pyridin-2(1H)-one
                                                              586384-14-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrrol-3-yl]-6-
methylpyridin-2(1H)-one 586384-15-8P, 3-Chloro-4-[(2,4-
\verb|difluorobenzyl| oxy| -1 - [1 - (3 - hydroxy - 3 - methylbutanoyl) - 1 + pyrrol - 3 - yl] - 6 - 3 - yl - 1 - [1 - (3 - hydroxy - 3 - methylbutanoyl) - 2 - yl - 3 - yl] - 6 - 3 - yl - 3 - yl
methylpyridin-2(1H)-one
                                                586384-16-9P, 3-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrrole-1-
                           586384-17-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
carboxamide
1-[1-(methylsulfonyl)-1H-pyrrol-3-yl]pyridin-2(1H)-one
                                                                                                               586384-18-1P,
1-(1-Acetyl-1H-imidazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
                                                  586384-19-2P 586384-20-5P,
methylpyridin-2(1H)-one
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
imidazol-4-yl]-6-methylpyridin-2(1H)-one 586384-21-6P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
```

```
imidazol-4-yl]pyridin-2(1H)-one
                                               586384-22-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-imidazol-4-yl]-6-
methylpyridin-2(1H)-one 586384-23-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-imidazol-4-yl]-6-
methylpyridin-2(1H)-one 586384-24-9P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-imidazole-1-
                    586384-25-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[1-(methylsulfonyl)-1H-imidazol-4-yl] pyridin-2(1H)-one
                                                                                       586384-26-1P,
1-(1-Acetyl-1H-pyrazol-4-yl)-3-chloro-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one
                                    586384-27-2P 586384-28-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[1-(2-hydroxy-2-methylpropanoyl)-1H-
pyrazol-4-yl]-6-methylpyridin-2(1H)-one 586384-29-4P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[1-(N-methylglycyl)-1H-
pyrazol-4-yl]pyridin-2(1H)-one 586384-30-7P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxypropanoyl)-1H-pyrazol-4-yl]-6-
methylpyridin-2(1H)-one 586384-31-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[1-(3-hydroxy-3-methylbutanoyl)-1H-pyrazol-4-yl]-6-
methylpyridin-2(1H)-one 586384-32-9P, 4-[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-1H-pyrazole-1-
                   586384-33-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
carboxamide
1-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridin-2(1H)-one 586384-34-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-isoquinolin-7-yl-6-methylpyridin-1-isoquinolin-7-yl-6-methylpyridin-1-isoquinolin-7-yl-6-methylpyridin-1-isoquinolin-7-yl-6-methylpyridin-1-isoquinolin-7-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-isoquinolin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridin-1-yl-6-methylpyridi
                586384-35-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
(isoquinolin-6-ylmethyl)pyridin-2(1H)-one 586384-36-3P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-
dihydro-2H-indol-2-one 586384-37-4P, 1-[(1-Acetyl-2,3-dihydro-1H-indol-5-
yl)methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
586384-38-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one
586384-39-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-1]]
2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-40-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-
dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one 586384-41-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-
2,3-dihydro-1H-indol-5-yl]methyl]pyridin-2(1H)-one
                                                                            586384-42-1P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
                                                  586384-43-2P, 3-Chloro-4-[(2,4-
yl]methyl]indoline-1-carboxamide
difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-indol-5-
yl]methyl]pyridin-2(1H)-one
                                           586384-44-3P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-isoindol-5-yl)methyl]pyridin-2(1H)-
         586384-45-4P, 1-[(2-Acetyl-2,3-dihydro-1H-isoindol-5-yl)methyl]-3-
chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
                                                                               586384-46-5P
586384-47-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-
methylpropanoyl)-2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one
586384-48-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1]]
2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one
                                                                                 586384-49-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-2,3-
dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-50-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-
2,3-dihydro-1H-isoindol-5-yl]methyl]pyridin-2(1H)-one 586384-51-2P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-
dihydro-2H-isoindole-2-carboxamide
                                                    586384-52-3P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-2,3-dihydro-1H-isoindol-5-
yl]methyl]pyridin-2(1H)-one
                                           586384-53-4P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[(1,2,3,4-tetrahydroisoquinolin-6-yl)methyl]pyridin-
                 586384-54-5P, 1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-6-
2(1H)-one
y1)methy1]-3-chloro-4-[(2,4-difluorobenzy1)oxy]pyridin-2(1H)-one
                      586384-56-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-
586384-55-6P
hydroxy-2-methylpropanoyl)-1,2,3,4-tetrahydroisoquinolin-6-
yl]methyl]pyridin-2(1H)-one 586384-57-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1,2,3,4-tetrahydroisoquinolin-6-
```

```
yl]methyl]pyridin-2(1H)-one
                                                                        586384-58-9P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[2-(3-hydroxypropanoyl)-1,2,3,4-
tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one 586384-59-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-3-methylbutanoyl)-
1,2,3,4-tetrahydroisoquinolin-6-yl]methyl]pyridin-2(1H)-one
586384-60-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide
                                                                                                                                    586384-61-4P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-1,2,3,4-
tetrahydroisoguinolin-6-yl]methyl]pyridin-2(1H)-one 586384-62-5P,
1-[(2-Acetyl-1,2,3,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyl]-3-chloro-4-[(2,4-tetrahydroisoquinolin-5-yl)methyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethyllamethylla
difluorobenzyl)oxy] pyridin-2(1H)-one 586384-63-6P
                                                                                                                                     586384-64-7P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(2-hydroxy-2-methylpropanoyl)-
1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one
586384-65-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(N-methylglycyl)-1]]
1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one
586384-66-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-
hydroxypropanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-
              586384-67-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(3-hydroxy-
3-methylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-
              586384-68-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-3,4-dihydroisoquinoline-2(1H)-carboxamide
586384-69-2P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[2-(methylsulfonyl)-
1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]pyridin-2(1H)-one
586384-70-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-
benzimidazol-5-yl)methyl]pyridin-2(1H)-one 586384-71-6P,
1-[(1-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-
difluorobenzyl)oxy]pyridin-2(1H)-one 586384-72-7P 586384-73-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-
2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-74-9P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-75-0P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxypropanoyl)-2,3-
dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586384-76-1P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl)-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbutanoyl]-1-[1-(3-hydroxy-3-methylbu
2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                                                             586384-77-2P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-
dihydro-1H-benzimidazole-1-carboxamide 586384-78-3P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(methylsulfonyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                                            586384-79-4P,
1-[(3-Acetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl)methyl]-3-chloro-4-[(2,4-benzimidazol-5-yl]-3-[(2,4-benzimidazol-5-yl]-3-[(2,4-benzimidazol-5-yl]-3-[(2,4-benzimidazol-5-yl]-3-[(2,4-benzimidazol-5-yl]-3-[(2,4-benzimidazol-5-yl]-3-[(2,4-benzi
                                                                                                586384-80-7P, 3-Chloro-1-[(1,3-
difluorobenzyl)oxy] pyridin-2(1H)-one
diacetyl-2,3-dihydro-1H-benzimidazol-5-yl)methyl]-4-[(2,4-
difluorobenzyl)oxy] pyridin-2(1H)-one
                                                                                                 586384-81-8P
                                                                                                                                     586384-82-9P,
1-[[3-Acetyl-1-(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
586384-83-0P, 1-[[3-Acetyl-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-
5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
586384-84-1P, 1-[[3-Acetyl-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
pyridin-2(1H)-one 586384-85-2P, 1-[[3-Acetyl-1-(3-hydroxy-3-
methylbutanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
                                                                                           586384-86-3P, 3-Acetyl-5-[[3-chloro-
difluorobenzyl)oxy]pyridin-2(1H)-one
4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-dihydro-1H-
benzimidazole-1-carboxamide
                                                                        586384-87-4P, 1-[[3-Acetyl-1-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
difluorobenzyl)oxy]pyridin-2(1H)-one
                                                                                              586384-88-5P
                                                                                                                                   586384-89-6P
586384-90-9P
                                    586384-91-0P
                                                                       586384-92-1P
                                                                                                            586384-93-2P
                                                                                                                                                 586384-94-3P
                                    586384-96-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-
586384-95-4P
hydroxy-2-methylpropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-
                            586384-97-6P, 1-[[1-Acetyl-3-(2-hydroxy-2-methylpropanoy1)-2,3-
2(1H)-one
dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
```

```
586384-98-7P
                                       586384-99-8P, 1-[[1,3-Bis(2-hydroxy-2-
    pyridin-2(1H)-one
    methylpropanoy1)-2,3-dihydro-1H-benzimidazol-5-y1]methyl]-3-chloro-4-[(2,4-
                                         586385-00-4P, 3-Chloro-4-[(2,4-
    difluorobenzyl)oxy]pyridin-2(1H)-one
    difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-(N-methylglycyl)-
    2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                               586385-01-5P,
    3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-methylpropanoyl)-1-
    (3-hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
          586385-02-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-
    3-methylbutanov1)-3-(2-hydroxy-2-methylpropanov1)-2,3-dihydro-1H-
    benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                586385-03-7P,
    5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
    (2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-benzimidazole-1-carboxamide
    586385-04-8P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(2-hydroxy-2-
    methylpropanoyl)-1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
    y1]methy1]pyridin-2(1H)-one 586385-05-9P, 3-Chloro-4-[(2,4-
    difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
    yl]methyl]pyridin-2(1H)-one 586385-06-0P, 1-[[1-Acetyl-3-(N-
    methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
    difluorobenzyl)oxy]pyridin-2(1H)-one 586385-07-1P 586385-08-2P,
    3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-
    (N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
    586385-09-3P, 1-[[1,3-Bis(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
    yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
    586385-10-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-
    hydroxypropanoyl)-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
    y1]methy1]pyridin-2(1H)-one 586385-11-7P, 3-Chloro-4-[(2,4-
    difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-
    2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-12-8P,
    5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
    (N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
    586385-13-9P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(N-methylglycyl)-1]]
    1-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
          586385-14-0P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-
    hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
          586385-15-1P, 1-[[1-Acetyl-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-
    benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
                                      586385-17-3P, 3-Chloro-4-[(2,4-
    pyridin-2(1H)-one
                       586385-16-2P
    difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-(3-
    hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
          hydroxypropanoyl)-1-(N-methylglycyl)-2,3-dihydro-1H-benzimidazol-5-
    yl]methyl]pyridin-2(1H)-one
                                 586385-19-5P, 1-[[1,3-Bis(3-
    hydroxypropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-
    [(2,4-difluorobenzyl)oxy] pyridin-2(1H)-one
                                                 586385-20-8P,
    3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-
    (3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
          586385-21-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
    pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-
                  586385-22-0P
    carboxamide
, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxypropanoyl)-1-
    (methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
    586385-23-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-
    methylbutanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
    586385-24-2P, 1-[[1-Acetyl-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
    benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
                        586385-25-3P
                                      586385-26-4P, 3-Chloro-4-[(2,4-
    pyridin-2(1H)-one
    difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(2-hydroxy-2-
    methylpropanoy1)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
    586385-27-5P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-
    methylbutanoy1)-1-(N-methylglycy1)-2,3-dihydro-1H-benzimidazol-5-
    y1]methy1]pyridin-2(1H)-one 586385-28-6P, 3-Chloro-4-[(2,4-
```

```
difluorobenzyl)oxy]-1-[[3-(3-hydroxy-3-methylbutanoyl)-1-(methylsulfonyl)-
2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                      586385-29-7P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-30-0P, 1-[[1,3-Bis(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]
pyridin-2(1H)-one
                            586385-31-1P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-
[[3-(3-hydroxy-3-methylbutanoyl)-1-(3-hydroxypropanoyl)-2,3-dihydro-1H-
benzimidazol-5-yl]methyl]pyridin-2(1H)-one 586385-32-2P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2,3-
dihydro-1H-benzimidazole-1-carboxamide 586385-33-3P,
3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-34-4P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(2-hydroxy-2-methylpropanoy1)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-35-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(N-methylglycyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-36-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(3-hydroxypropanoyl)-2,3-dihydro-1H-benzimidazole-1-
carboxamide 586385-37-7P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-
                                          586385-38-8P, 5-[[3-Chloro-4-[(2,4-
benzimidazole-1-carboxamide
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1H-benzimidazole-1,3(2H)-
dicarboxamide
                     586385-39-9P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl] methyl]-3-(methylsulfonyl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide 586385-40-2P, 3-Chloro-4-[(2,4-4)]
difluorobenzyl)oxy]-1-[[3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]pyridin-2(1H)-one 586385-41-3P, 1-[[1-Acetyl-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]-3-chloro-4-[(2,4-
difluorobenzyl)oxy]pyridin-2(1H)-one 586385-42-4P
                                                                             586385-43-5P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(2-hydroxy-2-methylpropanoyl)-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
586385-44-6P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(N-methylglycyl)-
3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-
        586385-45-7P, 3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-[[1-(3-
hydroxypropanoyl)-3-(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]pyridin-2(1H)-one
                                          586385-46-8P, 3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-1-[[1-(3-hydroxy-3-methylbutanoyl)-3-(methylsulfonyl)-
2,3-dihydro-1H-benzimidazol-5-yl]methyl]pyridin-2(1H)-one
                                                                                       586385-47-9P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(methylsulfonyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-48-0P, 1-[[1,3-Bis(methylsulfonyl)-2,3-dihydro-1H-benzimidazol-5-
yl]methyl]-3-chloro-4-[(2,4-difluorobenzyl)oxy]pyridin-2(1H)-one
586385-49-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one
                                                                   586385-50-4P,
1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one
                                                                   586385-51-5P
586385-52-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-
        586385-53-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-54-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-55-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-
        586385-56-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586385-57-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-1]
yl]methyl]-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-58-2P, 1-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-difluorobenzyl)oxy]-2-oxo-2H-[(3,4-dif
pyridin-1-yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one 586385-59-3P,
```

```
586385-60-6P
         yl]methyl]-1,3-dihydro-2H-benzimidazol-2-one
         586385-61-7P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
         pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
         benzimidazol-2-one 586385-62-8P, 3-Acetyl-5-[[3-chloro-4-[(2,4-4-4)]]]
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-
         dihydro-2H-benzimidazol-2-one 586385-63-9P, 3-Acetyl-5-[[3-chloro-4-
         [(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-
         hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-64-0P,
         3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
         yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-
                      586385-65-1P, 3-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-
         oxo-2H-pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
         carboxamide
                                  586385-66-2P, 3-Acetyl-5-[[3-chloro-4-[(2,4-
         \verb|difluorobenzyl| oxy| -2 - oxo -2H - pyridin -1 -yl| methyl| -1 - (methylsulfonyl) -1, 3 - (m
                                                                        586385-67-3P
                                                                                                        586385-68-4P
                                                                                                                                      586385-69-5P
         dihydro-2H-benzimidazol-2-one
                                                                   586385-72-0P 586385-73-1P
          586385-70-8P
                                      586385-71-9P
                                                                                                                                  586385-74-2P
         586385-75-3P
                                       586385-76-4P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
         oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
                                                586385-77-5P, 1-Acetyl-5-[[3-chloro-4-[(2,4-
         benzimidazol-2-one
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-
         methylpropanoyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-78-6P
         586385-79-7P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
         yl]methyl]-1,3-bis(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
         benzimidazol-2-one 586385-80-0P, 5-[[3-Chloro-4-[(2,4-
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-
         methylpropanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
         RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
          (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
          (Uses)
                (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
               kinase for treatment of inflammatory conditions,
                ischemia, viral infections, autoimmune diseases, and other
                conditions)
ΙT
         586385-81-1P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
         yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(3-hydroxypropanoyl)-1,3-
         dihydro-2H-benzimidazol-2-one
                                                                         586385-82-2P, 5-[[3-Chloro-4-[(2,4-
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-
         methylbutanoyl)-3-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
         benzimidazol-2-one
                                                   586385-83-3P, 5-[[3-Chloro-4-[(2,4-
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-
         methylpropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
         586385-84-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
         yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-1-(methylsulfonyl)-1,3-dihydro-
                                                       586385-85-5P, 6-[[3-Chloro-4-[(2,4-
         2H-benzimidazol-2-one
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(N-methylglycyl)-1,3-
         dihydro-2H-benzimidazol-2-one 586385-86-6P, 1-Acetyl-5-[[3-chloro-4-
          [(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(N-methylglycyl)-
                                                                                586385-87-7P 586385-88-8P,
         1,3-dihydro-2H-benzimidazol-2-one
         5-[[3-Chloro-4-[(2,4-difluorobenzyl)]]-2-oxo-2H-pyridin-1-yl]methyl]-1-
          (2-hydroxy-2-methylpropanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-
                                                  586385-89-9P, 5-[[3-Chloro-4-[(2,4-
         benzimidazol-2-one
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(N-methylglycyl)-
         1,3-dihydro-2H-benzimidazol-2-one
                                                                               586385-90-2P, 5-[[3-Chloro-4-[(2,4-
         difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxypropanoyl)-3-
          (N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one 586385-91-3P,
          5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-
          (3-hydroxy-3-methylbutanoyl)-3-(N-methylglycyl)-1,3-dihydro-2H-
         benzimidazol-2-one 586385-92-4P, 5-[[3-Chloro-4-[(2,4-
         \label{local_diffuor_obenzyl} \verb| oxy| -2 - oxo - 2H - pyridin -1 - yl| methyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| methylglycyl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - pyridin -1 - yl| -3 - (N - methylglycyl) -2 - oxo -2H - yl| -3 - (N - methylglycyl) -2 - oxo -2H - yl| -3 - (N - methylglycyl) -3 - (N - met
         2,3-dihydro-1H-benzimidazole-1-carboxamide 586385-93-5P,
```

1,3-Diacetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-

```
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(N-methylglycyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-94-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-one
586385-95-7P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-benzimidazol-2-
      586385-96-8P
                    586385-97-9P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-
methylpropanov1)-3-(3-hydroxypropanov1)-1,3-dihydro-2H-benzimidazol-2-one
586385-98-0P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(3-hydroxypropanoyl)-1-(N-methylqlycyl)-1,3-dihydro-2H-
                     586385-99-1P, 5-[[3-Chloro-4-[(2,4-
benzimidazol-2-one
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1,3-bis(3-
hydroxypropanoy1)-1,3-dihydro-2H-benzimidazol-2-one 586386-00-7P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-yl]
(3-hydroxy-3-methylbutanoyl)-3-(3-hydroxypropanoyl)-1,3-dihydro-2H-
benzimidazol-2-one 586386-01-8P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxypropanoyl)-2-
oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 586386-02-9P,
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(3-hydroxypropanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-03-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-2-
      586386-04-1P, 1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-
benzimidazol-2-one 586386-05-2P
                                   586386-06-3P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-
methylbutanoyl)-1-(2-hydroxy-2-methylpropanoyl)-1,3-dihydro-2H-
benzimidazol-2-one 586386-07-4P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-
methylbutanoyl)-1-(N-methylglycyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-08-5P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1,3-bis(3-hydroxy-3-methylbutanoyl)-1,3-dihydro-2H-benzimidazol-
        586386-09-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
2-one
pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-1H-
benzimidazole-1-carboxamide
                             586386-10-9P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-
methylbutanoyl)-1-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-11-0P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
vl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586386-12-1P, 3-Acetyl-6-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-
pyridin-1-yl]methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586386-13-2P
              586386-14-3P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
oxo-2H-pyridin-1-yl]methyl]-3-(2-hydroxy-2-methylpropanoyl)-2-oxo-2,3-
dihydro-1H-benzimidazole-1-carboxamide
                                        586386-15-4P,
6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-
(N-methylglycyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide
586386-16-5P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(3-hydroxypropanoyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-
             586386-17-6P, 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
carboxamide
2H-pyridin-1-yl]methyl]-3-(3-hydroxy-3-methylbutanoyl)-2-oxo-2,3-dihydro-
1H-benzimidazole-1-carboxamide 586386-18-7P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-2-oxo-1H-benzimidazole-
                       586386-19-8P, 6-[[3-Chloro-4-[(2,4-
1,3(2H)-dicarboxamide
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-3-(methylsulfonyl)-2-oxo-
2,3-dihydro-1H-benzimidazole-1-carboxamide
                                            586386-20-1P,
 6-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-yl] \\
(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one 586386-21-2P,
1-Acetyl-5-[[3-chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-22-3P
              586386-23-4P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-
```

```
oxo-2H-pyridin-1-yl]methyl]-1-(2-hydroxy-2-methylpropanoyl)-3-
                                                   586386-24-5P,
(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-
(N-methylglycyl)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-25-6P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-1-(3-hydroxypropanoyl)-3-(methylsulfonyl)-1,3-dihydro-2H-
benzimidazol-2-one
                     586386-26-7P, 5-[[3-Chloro-4-[(2,4-
difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-yl]methyl]-1-(3-hydroxy-3-
methylbutanov1)-3-(methylsulfonyl)-1,3-dihydro-2H-benzimidazol-2-one
586386-27-8P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-2H-pyridin-1-
yl]methyl]-3-(methylsulfonyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-
            586386-28-9P, 5-[[3-Chloro-4-[(2,4-difluorobenzyl)oxy]-2-oxo-
carboxamide
2H-pyridin-1-yl]methyl]-1,3-bis(methylsulfonyl)-1,3-dihydro-2H-
benzimidazol-2-one 586386-30-3P, 3-Bromo-1-(2,6-dichlorophenyl)-4-[(4-
fluorophenyl)ethynyl]-6-methylpyridin-2(1H)-one 586386-31-4P,
3-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzaldehyde
586386-32-5P, 4-[(2,4-Difluorobenzyl)oxy]-1-[4-(dimethylamino)-2,6-
                                          586386-33-6P,
difluorophenyl]-6-methylpyridin-2(1H)-one
4-[(2,4-Difluorobenzyl)oxy]-1-[2,6-difluoro-4-[(2-difluorobenzyl)oxy]]
hydroxyethyl) (methyl) amino]phenyl]-6-methylpyridin-2(1H)-one
586386-34-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[4-(hydroxymethyl)-2-
methoxyphenyl]-6-methylpyridin-2(1H)-one 586386-35-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-[(4-methylpiperazin-1-
vl)carbonyl]phenyl]pyridin-2(1H)-one
                                     586386-36-9P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-
(dimethylamino)ethyl]benzamide 586386-37-0P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-
methoxyethyl) benzamide
                       586386-38-1P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-[2-
(dimethylamino)ethyl]-N-methylbenzamide 586386-39-2P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
(2-hydroxyethyl)-N-methylbenzamide 586386-40-5P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-methoxyethyl)-N-
                586386-41-6P, 4-[4-[(2,4-Difluorobenzyl)oxy]-6-methyl-2-
methylbenzamide
oxo-2H-pyridin-1-yl]-3-methylbenzoic acid 586386-42-7P, Methyl
[2-[[[3-bromo-1-(2,6-difluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-4-
yl]oxy]methyl]-3,5-difluorobenzyl]carbamate
                                             586386-43-8P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperidin-1-
ylcarbonyl)benzyl]-1H-pyridin-2-one
                                     586386-44-9P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-[(ethoxyamino)methyl]pyridin-
            586386-45-0P, N-(3-Aminopropyl)-4-[[3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]methyl]benzamide
hydrochloride
               586386-46-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(1H-
indazol-5-ylmethyl)pyridin-2(1H)-one
                                      586386-47-2P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-[2-(dimethylamino)-4,6-difluorophenyl]-6-
methylpyridin-2(1H)-one hydrochloride 586386-48-3P, N-(2-Aminoethyl)-4-
[[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzamide hydrochloride 586386-49-4P, N-(2-Aminoethyl)-3-[3-
bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]benzamide
586386-50-7P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[4-(piperazin-
1-ylcarbonyl)benzyl]pyridin-2(1H)-one hydrochloride
                                                     586386-51-8P,
3-Chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-
[(dimethylamino)methyl]pyridin-2(1H)-one
                                          586386-52-9P
                                                          586386-53-0P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
                     586386-54-1P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
isopropylbenzamide
methyl-1-[3-(morpholin-4-ylcarbonyl)benzyl]-1H-pyridin-2-one
586386-55-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]methyl]-N, N-bis(2-hydroxyethyl)benzamide
                                                        586386-56-3P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
                                586386-57-4P, 3-Bromo-4-[(2,4-
yl]methyl]-N-hydroxybenzamide
difluorobenzyl)oxy]-1-(3-hydroxymethylbenzyl)-6-methyl-1H-pyridin-2-one
```

```
586386-58-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl)oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[3-4-difluorobenzyl]oxy]-6-methyl-1-[
(pyrrolidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-59-6P,
3-Bromo-1-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-5-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-6-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-6-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-6-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-6-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-6-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-6-(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymethyl)phenyl]-4-[2-chloro-6-(hydroxymet
methylpyridin-2(1H)-one 586386-60-9P, 3-Chloro-1-[2-chloro-5-
(hydroxymethyl)phenyl]-4-[(2,4-difluorobenzyl)oxy]-6-methylpyridin-2(1H)-
           586386-61-0P 586386-62-1P, 3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-
6-methyl-2-oxo-2H-pyridin-1-yl]-N-(2-hydroxyethyl)benzamide
586386-63-2P, 3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-vl]methyl]-N-(2-hydroxyethyl)benzamide 586386-64-3P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N,N-dimethylbenzamide 586386-65-4P, 3-[3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-hydroxybenzamide
586386-66-5P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[3-
(pyrrolidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one 586386-67-6P,
3-[[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]-N-isopropylbenzamide 586386-68-7P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[3-(morpholin-4-ylcarbonyl)phenyl]pyridin-
                       586386-69-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
2(1H)-one
[3-(piperidin-1-ylcarbonyl)benzyl]-1H-pyridin-2-one 586386-70-1P,
3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N,N-
dimethylbenzamide
                                    586386-71-2P, 4-(Benzylamino)-1-(3-fluorobenzyl)-6-
methyl-3-nitropyridin-2(1H)-one 586386-72-3P, tert-Butyl
4-[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]piperazine-1-
carboxylate 586386-73-4P, Ethyl [4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-
                             586386-74-5P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-
1-vllacetate
dihydropyridin-4-yl]benzenesulfonamide
                                                                             586386-75-6P,
N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-1-
phenylmethanesulfonamide 586386-76-7P, 3-Bromo-4-[(2,4-
difluorophenyl)amino]-1-(3-fluorobenzyl)pyridin-2(1H)-one
                                                                                                                    586386-77-8P,
4-Anilino-3-bromo-1-(3-fluorobenzyl)pyridin-2(1H)-one 586386-78-9P,
Methyl 4-[[3-bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-
                                     586386-79-0P, 3-Bromo-1-(3-fluorobenzyl)-4-[(3,4,5-
yl]amino]benzoate
trimethoxyphenyl)amino]pyridin-2(1H)-one
                                                                                  586386-80-3P,
3-Bromo-1-(3-fluorobenzyl)-4-[4-(4-fluorophenyl)piperazin-1-yl]pyridin-
                       586386-82-5P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-methylpiperazin-
1-yl)pyridin-2(1H)-one trifluoroacetate
                                                                                 586386-83-6P,
N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-2,5-
difluorobenzamide
                                      586386-84-7P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-
dihydropyridin-4-yl]-2,4-difluorobenzamide
                                                                                      586386-85-8P,
3-[4-(Benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]propanoic acid
586386-86-9P, N-[3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]-
N'-(2,4-difluorophenyl)urea
                                                          586386-87-0P, 3-[4-(Benzyloxy)-3-bromo-2-oxo-
2H-pyridin-1-yl]propanamide
                                                          586386-88-1P, 4-(Benzyloxy)-3-bromo-1-[3-
(morpholin-4-yl)-3-oxopropyl]pyridin-2(1H)-one
                                                                                               586386-89-2P,
N-(3-Aminopropyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
                                                            586386-90-5P, 4-(Benzyloxy)-3-bromo-1-[3-
yl]propanamide hydrochloride
oxo-3-(piperazin-1-yl)propyl]pyridin-2(1H)-one hydrochloride
586386-92-7P, N-(2-Aminoethyl)-3-[4-(benzyloxy)-3-bromo-2-oxo-
2H-pyridin-1-yl]propanamide hydrochloride 586386-93-8P,
[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]acetic
             586386-94-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-
[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-one
                                                                                                 586386-95-0P,
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-[(tetrahydrofuran-2-
yl)methyl]pyridin-2(1H)-one 586386-96-1P, Methyl 3-bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridine-1-carboxylate
586386-97-2P, 1-Allyl-3-(2,4-difluorobenzyl)-4-[(2,4-difluorobenzyl)oxy]-6-
methylpyridin-2(1H)-one 586386-98-3P, 4-(Benzyloxy)-1-(2,2-
diethoxyethyl)pyridin-2(1H)-one
                                                                  586386-99-4P
                                                                                               586387-00-0P
                             586387-02-2P, 4-(Benzyloxy)-1-(2-oxopropyl)pyridin-2(1H)-
586387-01-1P
           586387-03-3P, 5-[[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]-5-
```

```
methylimidazolidine-2,4-dione 586387-04-4P, Ethyl
    [4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]acetate 586387-05-5P,
    2-[4-(Benzyloxy)-2-oxo-2H-pyridin-1-yl] acetamide 586387-06-6P,
    4-(Benzyloxy)-1-ethylpyridin-2(1H)-one 586387-07-7P, tert-Butyl
    3-[[4-(benzyloxy)-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-carboxylate
    586387-08-8P, 1,3-Dibenzyl-4-hydroxy-6-methylpyridin-2(1H)-one
    586387-09-9P, 1-Benzyl-6-methyl-2-oxo-1, 2-dihydropyridin-4-yl
    methanesulfonate
                       586387-10-2P, 1-Benzyl-4-(naphthyl-1-ylmethoxy)pyridin-
    2(1H)-one
                586387-11-3P, 1-Benzyl-4-(benzylthio)-3,5-dibromopyridin-2(1H)-
          586387-12-4P, 1-Benzyl-3-[(benzylamino)methyl]-4-(benzyloxy)pyridin-
                586387-13-5P, 1-Benzyl-4-(benzyloxy)-3-[[(2-
    2(1H)-one
    cyclohexylethyl)amino]methyl]pyridin-2(1H)-one 586387-14-6P,
    1-Benzyl-4-(benzylthio)-5-methylpyridin-2(1H)-one 586387-15-7P,
    1-Benzyl-3-bromo-6-methyl-2-oxo-1, 2-dihydropyridin-4-yl methanesulfonate
    586387-16-8P, 1-Benzyl-3-bromo-6-methyl-4-[[2-
    (trifluoromethyl)benzyl]oxy]pyridin-2(1H)-one
                                                    586387-17-9P,
    1-Benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl
                             586387-18-0P, 4-Phenoxy-1-[[2-
    4-bromobenzenesulfonate
    (trimethylsilyl)ethoxy]methyl]pyridin-2(1H)-one 586387-19-1P,
    1-Benzyl-4-phenoxypyridin-2(1H)-one 586387-20-4P 586387-21-5P,
    3-Bromo-4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one hydrochloride
    586387-22-6P, 4-(Benzyloxy)-3-bromo-1-(piperidin-3-ylmethyl)pyridin-2(1H)-
         586387-23-7P, Benzyl (5-nitro-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-
    yl)acetate 586387-24-8P, Methyl (2E)-4-[4-[(2,4-difluorobenzyl)oxy]-6-
    methyl-2-oxo-2H-pyridin-1-yl]-2-butenoate 586387-25-9P, tert-Butyl
    4-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]methyl]piperidine-1-
    carboxylate 586387-26-0P, 1-Benzyl-4-[(4-methylbenzyl)oxy]pyridin-2(1H)-
          586387-27-1P, 2-[[[3-Bromo-2-oxo-1-(pyridin-3-ylmethyl)-1,2-
    dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile
                                                           586387-28-2P,
    tert-Butyl 3-[[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-
    yl]methyl]piperidine-1-carboxylate 586387-29-3P, 4-Benzyloxy-3-bromo-1-
    (methanesulfonyl)-1H-pyridin-2-one 586387-30-6P, tert-Butyl
    4-[4-(benzyloxy)-3-bromo-2-oxo-2H-pyridin-1-yl]piperidine-1-carboxylate
    586387-31-7P, 4-(Benzyloxy)-1-[4-(methylthio)benzyl]pyridin-2(1H)-one
    586387-32-8P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2-methyl-4-
    methylaminopyrimidin-5-yl)methyl]-1H-pyridin-2-one
                                                         586387-33-9P,
    4-(Benzyloxy)-1-[4-(methylsulfonyl)benzyl]pyridin-2(1H)-one
    586387-34-0P, 4-Phenoxy-1H-pyridin-2-one
                                              586387-35-1P,
    4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-
          586387-36-2P, 1-(3-Fluorobenzyl)-4-(phenylethynyl)pyridin-2(1H)-one
    586387-37-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[2-
    (methylthio)pyrimidin-4-yl]pyridin-2(1H)-one 586387-38-4P,
    4-(Benzyloxy)-3-bromo-1-piperidin-4-ylpyridin-2(1H)-one hydrochloride
    586387-39-5P
, 4-Benzyloxy-1-difluoromethyl-1H-pyridin-2-one
                                                 586387-40-8P,
    4-Benzyloxy-3-bromo-1-(2-chlorophenyl)-6-methyl-1H-pyridin-2-one
    586387-41-9P, 3-Bromo-6-methyl-1-(pyridin-3-ylmethyl)-4-[(pyridin-3-
                                      586387-42-0P, 2-Chloro-N-[1-(2,6-
    ylmethyl)amino]-1H-pyridin-2-one
    dichlorobenzyl)-6-oxo-5-trifluoromethyl-1,6-dihydropyridin-3-yl]-4-
    fluorobenzamide 586387-43-1P, N-[1-(2,6-Dichlorobenzy1)-6-oxo-5-
    trifluoromethyl-1,6-dihydropyridin-3-yl]-4-isopropoxybenzamide
    586387-44-2P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-methoxyphenyl)-1H-pyridin-2-
          586387-45-3P, 3-Bromo-1-(3-fluorobenzyl)-4-(3-isopropylphenyl)-1H-
                    586387-46-4P, 3'-Bromo-1'-(3-fluorobenzyl)-6-methoxy-1'H-
    pyridin-2-one
                               586387-47-5P, 4-Benzo[1,3]dioxol-5-yl-3-bromo-1-
    [3,4']bipyridinyl-2'-one
    (3-fluorobenzyl)-1H-pyridin-2-one
                                        586387-48-6P, 3-Bromo-1-(3-
    fluorobenzyl)-4-thiophen-3-yl-1H-pyridin-2-one
                                                     586387-49-7P,
    3-Bromo-1-(3-fluorobenzyl)-4-(3-trifluoromethylphenyl)-1H-pyridin-2-one
    586387-50-0P, 3-Bromo-1-(3-fluorobenzyl)-4-naphthalen-2-yl-1H-pyridin-2-
          586387-51-1P, 3-Bromo-1-(3-fluorobenzyl)-4-(4-fluorophenyl)-1H-
    pyridin-2-one 586387-52-2P, 1-Benzenesulfonyl-4-benzyloxy-3-bromo-1H-
```

```
586387-53-3P, 4-[3-Amino-1-(2,4-difluorophenyl)propoxy]-3-
pyridin-2-one
bromo-6-methyl-1-[(pyridin-3-yl)methyl]-1H-pyridin-2-one
                                                                                      586387-54-4P,
2-[[[1-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-3-bromo-6-methyl-2-oxo-1,2-
dihydropyridin-4-yl]oxy]methyl]-5-fluorobenzonitrile
                                                                               586387-55-5P,
1-(2-Chloro-4-hydroxyphenyl)-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1H-
                      586387-56-6P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-
pyridin-2-one
methyl-5-vinyl-1H-pyridin-2-one
                                                586387-57-7P
                                                                        586387-58-8P,
1-(2,6-Difluorophenyl)-4-methoxy-6-methyl-5-phenethyl-1H-pyridin-2-one
586387-59-9P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-
phenethyl-1H-pyridin-2-one 586387-60-2P, 1-(1H-Indazol-5-yl)-4-(1H-
indazol-5-ylamino)-6-methylpyridin-2(1H)-one
                                                                  586387-61-3P,
5-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-2-[2-(2,4-difluorobenzyl)oxy]
difluorophenyl)ethyl]-6-oxo-1,6-dihydropyridine-3-carboxaldehyde
586387-62-4P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)]0xy]-6-methyl-2-oxo-2H-
pyridin-1-yl]pyrimidine-2-carbonitrile 586387-63-5P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-
carboxylic acid 586387-64-6P, 3-Bromo-4-[(5-carboxypyridin-2-y1)oxy]-6-
methyl-2-oxo-2H-[1,2'] bipyridinyl-5'-carboxylic acid 586387-65-7P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6,6'-dimethyl-2-oxo-2H-
[1,2']bipyridinyl-3'-carbonitrile 586387-66-8P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-2-oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid
                   586387-67-9P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-
methvlamide
oxo-2H-[1,2']bipyridinyl-5'-carboxylic acid N-(2-hydroxyethyl)amide
586387-68-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
[1,2']bipyridinyl-5'-carboxylic acid N-(2-methoxyethyl)amide
586387-69-1P, 3-Bromo-1-(2,6-difluorophenyl)-4-methoxy-6-methyl-5-(4-
methylbenzyl)-1H-pyridin-2-one 586387-70-4P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-5-(1,2-dihydroxy-2-phenylethyl)-
6-methylpyridin-2(1H)-one
                                       586387-71-5P, 3-Chloro-1-(4-fluorobenzyl)-4-
[(4-fluorobenzyl)oxy]pyridin-2(1H)-one 586387-72-6P,
4-[[3-Chloro-4-[(2,4-difluorobenzyl)amino]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzonitrile trifluoroacetate 586387-74-8P
                                                                                 586387-75-9P,
4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-yl]-N-
methylbenzamide
                        586387-76-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-1-[3-(piperidin-1-ylcarbonyl)phenyl] pyridin-2(1H)-one
586387-77-1P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-N-hydroxybenzamide
                                                  586387-78-2P, 3-Bromo-1-(2,6-
dichlorophenyl)-4-[2-(4-fluorophenyl)ethyl]-6-methylpyridin-2(1H)-one
586387-79-3P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-N-isopropylbenzamide
                                                      586387-80-6P, 3-Bromo-4-[(2,4-
difluorobenzyl)oxy]-6-methyl-1-[4-(pyrrolidin-1-ylcarbonyl)phenyl]
pyridin-2(1H)-one
                           586387-81-7P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
methyl-2-oxo-2H-pyridin-1-yl]-N, N-bis(2-hydroxyethyl)benzamide
586387-83-9P, 4-(Benzyloxy)-1-(piperidin-3-ylmethyl)pyridin-2(1H)-one
                            586387-84-0P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
trifluoroacetate
methyl-1-[4-(morpholin-4-ylcarbonyl)phenyl]pyridin-2(1H)-one
586387-85-1P
                     586387-86-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-
1-[4-(piperidin-1-ylcarbonyl)phenyl]pyridin-2(1H)-one
                                                                                586387-87-3P,
3-Bromo-1-(3-fluorobenzyl)-4-[(3-fluorobenzyl)amino]pyridin-2(1H)-one
                     586387-89-5P, N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-
586387-88-4P
methyl-2-oxo-2H-pyridin-1-yl]benzyl]-2-hydroxyacetamide
                                                                                    586387-90-8P,
1-(4-Fluorobenzyl)-4-[(4-fluorobenzyl)oxy]pyridin-2(1H)-one
586387-91-9P, 4-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-
pyridin-1-yl]-N,N-dimethylbenzamide
                                                        586387-92-0P, 4-(Allylamino)-3-bromo-
1-(2,6-difluorophenyl)-6-methylpyridin-2(1H)-one
                                                                          586387-93-1P,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[(2,3-dihydro-1H-indol-5-yl)methyl]-
1H-pyridin-2-one
                           586387-94-2P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[[1-
(2-hydroxyacetyl)-2,3-dihydro-1H-indol-5-yl]methyl]-6-methyl-1H-pyridin-2-
         586387-95-3P, 3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-(1H-final content of the conten
pyrazol-3-ylmethyl)-1H-pyridin-2-one 586396-12-5P, 3-Chloro-1-[4-
[[(cyclopropylmethyl)amino]methyl]-2,6-difluorophenyl]-4-[(2,4-
```

```
difluorobenzyl)oxy] pyridin-2(1H)-one hydrochloride 586396-39-6P,
N-[3-[3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxo-2H-pyridin-1-
yl]methyl]benzyl]-2-acetoxyacetamide 586396-68-1P 586397-52-6P
586397-63-9P
              586397-73-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (p38 kinase inhibitor; preparation of pyridinones as modulators of p38 MAP
   kinase for treatment of inflammatory conditions,
  ischemia, viral infections, autoimmune diseases, and other
   conditions)
165245-96-5, p38\alpha MAP kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
   (preparation of pyridinones as modulators of p38 MAP kinase for
   treatment of inflammatory conditions, ischemia, viral
   infections, autoimmune diseases, and other conditions)
586374-26-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
   (preparation of pyridinones as modulators of p38 MAP kinase for
   treatment of inflammatory conditions, ischemia, viral
   infections, autoimmune diseases, and other conditions)
56-37-1, Benzyltriethylammonium chloride 75-31-0, Isopropylamine,
reactions
          79-44-7, Dimethylcarbamyl chloride 86-95-3,
4-Hydroxy-1,2-dihydroquinolin-2-one 87-62-7, 2,6-Dimethylaniline
88-17-5, 2-(Trifluoromethyl) aniline 95-02-3, 4-Amino-5-aminomethyl-2-
methylpyrimidine 96-33-3, Methyl acrylate 98-00-0, Furfuryl alcohol
98-58-8, 4-Bromobenzenesulfonyl chloride 98-79-3 99-27-4, Dimethyl
5-aminoisophthalate 100-82-3, 3-Fluorobenzylamine 103-64-0,
\beta-Bromostyrene 103-71-9, Phenyl isocyanate, reactions 104-81-4,
4-Methylbenzyl bromide 105-36-2, Ethyl bromoacetate 106-96-7,
Propargyl bromide 107-11-9, Allylamine 109-01-3, 1-Methylpiperazine
109-08-0, 2-Methylpyrazine 109-83-1, 2-(Methylamino)ethanol 109-85-3,
2-Methoxyethylamine 110-89-4, Piperidine, reactions 110-91-8,
Morpholine, reactions 140-75-0, 4-Fluorobenzylamine 140-88-5, Ethyl
acrylate 315-14-0, 2,4,6-Trifluoronitrobenzene
                                                 315-31-1,
2-Fluoro-3-methylbenzoic acid 363-81-5, 2,4,6-Trifluoroaniline
402-23-3, 3-Trifluoromethylbenzyl bromide 403-43-0, 4-Fluorobenzoyl
chloride 405-99-2, 4-Fluorostyrene 452-85-7, 5-Fluoro-2-methylphenol
453-71-4, 4-Fluoro-3-nitrobenzoic acid 455-87-8, 4-Amino-3-fluorobenzoic
      456-41-7, 3-Fluorobenzyl bromide 459-46-1, 4-Fluorobenzyl bromide
459-56-3, 4-Fluorobenzyl alcohol 527-69-5, 2-Furoyl chloride
Phenylacetylene
                 541-41-3, Ethyl chloroformate
                                                543-27-1, Isobutyl
                                                 585-71-7,
              582-33-2, Ethyl 3-aminobenzoate
chloroformate
                      594-61-6, 2-Hydroxyisobutyric acid
                                                            616-30-8.
(1-Bromoethyl)benzene
3-Amino-1,2-propanediol 617-88-9, 2-(Chloromethyl)furan
                                                           619-45-4,
Methyl 4-aminobenzoate 625-45-6, Methoxyacetic acid 626-03-9,
2,4-Dihydroxypyridine 626-15-3, \alpha,\alpha'-Dibromo-m-xylene
674-82-8, Diketene 675-10-5, 4-Hydroxy-6-methyl-2H-pyran-2-one
765-50-4, 2-(Chloromethyl)thiophene 766-98-3, 4-Fluorophenylacetylene
867-44-7 873-63-2, 3-Chlorobenzyl alcohol 1011-65-0, Methyl
indole-5-carboxylate
                     1071-46-1, Monoethyl malonate 1072-84-0,
4-Imidazolecarboxylic acid 1117-71-1, Methyl 4-bromocrotonate
1121-76-2, 4-Chloropyridine 1-oxide
                                     1124-33-0, 4-Nitropyridine N-oxide
1129-28-8, Methyl 3-bromomethylbenzoate 1194-02-1, 4-Fluorobenzonitrile
1453-58-3\text{, }3-\text{Methyl-1H-pyrazole} \qquad 1465-76-5\text{, }1-\text{tert-Butyl-4-oxopiperidine}
1877-77-6, 3-Aminobenzyl alcohol 2038-03-1, 4-(2-Aminoethyl)morpholine
2144-37-8 2393-23-9, 4-Methoxybenzylamine 2417-72-3, Methyl
4-(bromomethyl)benzoate 2486-74-0, 4-Amino-2-methylmethyl benzoate
2840-26-8, 3-Amino-4-methoxybenzoic acid 2854-16-2, 3-Amino-2-methyl-2-
```

ΙT

ΙT

```
3240-94-6, 4-(2-Chloroethyl)morpholine 3320-83-0,
propanol
                            3544-24-9, 3-Aminobenzamide 3731-51-9,
2-Chlorophenyl isocyanate
2-(Aminomethyl)pyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1,
4-(Aminomethyl)pyridine 3739-30-8, 2-Hydroxy-2-methylbutyric acid
4285-42-1, N-Methyl-N-phenylcarbamoyl chloride
                                                 4385-35-7,
                  4412-91-3, 3-Furylmethanol 4518-10-9, Methyl
Isochroman-3-one
3-aminobenzoate
                  4530-20-5, Boc-glycine
                                          5345-27-7,
3-(Methylsulfonyl)benzoic acid 5382-16-1, 4-Hydroxypiperidine
5394-63-8, 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 5470-70-2, Methyl
6-methylnicotinate 5509-65-9, 2,6-Difluoroaniline 5521-55-1,
5-Methylpyrazine-2-carboxylic acid 5571-03-9, Methyl
2-methyl-5-pyrimidinecarboxylate 6482-24-2, 2-Methoxyethyl bromide
6723-30-4, [(Tetrahydro-2H-pyranyl-2-yl)oxy]amine 70\overline{5}1-3\overline{4}-5,
Cyclopropylmethyl bromide 7554-65-6, 4-Methyl-1H-pyrazole 7693-46-1,
4-Nitrophenyl chloroformate 10406-24-3, 3-(Aminomethyl)benzonitrile
13737-36-5, 4-(Bromomethyl)phenylacetic acid 13831-30-6, Acetoxyacetic
     13831-31-7, Acetoxyacetyl chloride 14001-63-9,
4-Methyl-2-methylthiopyrimidine 15781-71-2, 2-Methylmalonic acid bis(2,4,6-trichlorophenyl) ester 17201-43-3, \alpha-Bromo-p-tolunitrile
17994-25-1, 1-Hydroxy-1-cyclopropanecarboxylic acid 18063-02-0,
2,6-Difluorobenzoyl chloride 18583-89-6, Methyl 3-amino-2-methylbenzoate
18595-18-1, Methyl 3-amino-4-methylbenzoate 19335-11-6, 5-Aminoindazole
                                            22115-41-9,
20274-69-5, 4-Fluoro-3-nitrobenzyl alcohol
\alpha-Bromo-o-tolunitrile 22134-75-4 22600-30-2, Methyl
2-amino-5-furoate 23063-36-7, \alpha, \alpha-Dichloro-p-xylene
23915-07-3, 2,4-Difluorobenzyl bromide 24424-99-5, Di-tert-butyl
dicarbonate 24964-64-5, 3-Cyanobenzaldehyde 25006-86-4, 2,6-Bis(bromomethyl)fluorobenzene 30533-50-7, 1-Amino-2-methyl-2-
propanol hydrochloride 36394-75-9, (S)-(-)-2-Acetoxypropionyl chloride
38870-89-2, 2-Methoxyacetyl chloride 39920-37-1, 2,6-Dichlorophenyl
           40061-55-0, m-Tolylacetic acid ethyl ester
                                                          40635-66-3,
isocyanate
2-Acetoxy-2-methylpropionyl chloride 40872-87-5, Methyl
3-amino-4-chlorobenzoate 49608-01-7, Ethyl 6-chloronicotinate
50628-37-0, 3,3-Dimethoxy-2-methoxycarbonylpropen-1-ol sodium salt
53937-02-3, 4-Benzyloxy-2(1H)-pyridone 55912-20-4, 3-Nitro-4-
chlorobenzyl alcohol
                       56456-47-4, 2,4-Difluorobenzyl alcohol
57260-71-6, N-(tert-Butyloxycarbonyl)piperazine 57791-63-6,
3-(Cyclohexylamino)-2-butenoic acid methyl ester 60728-41-8,
3-Amino-4-(methoxycarbonyl)benzoic acid 62558-08-1, 1,2-
Bis(hydroxymethyl)-4-fluorobenzene
                                    66176-39-4, 4-
(Bromomethyl) benzenesulfonyl chloride 67567-26-4, 4-Bromo-2,6-
difluoroaniline
                 71637-34-8, Thien-3-ylmethanol 72235-52-0,
2,4-Difluorobenzylamine 77532-79-7, 5-Fluoro-2-methylbenzonitrile
80278-67-7, Isoquinoline-5-carboxaldehyde 81863-45-8,
3-Amino-4-methylbenzyl alcohol
                                84257-12-5, 5-(1-Hydroxy-3-oxobutylidene)-
2,2-dimethyl-1,3-dioxane-4,6-dione 105827-74-5,
5-Bromomethyl-2-fluoropyridine 114896-64-9, Methanesulfonic acid
2-(thiophen-3-yl)ethyl ester 120100-15-4, Methyl 3-amino-2-
chlorobenzoate 132664-85-8, 5-Aminomethyl-2-methylpyrazine
134227-45-5, 3,4,5-Trifluorobenzonitrile 135394-68-2 161975-39-9,
4-(Methanesulfonyloxymethyl)-1-piperidine-1-carboxylic acid tert-butyl
        162166-99-6, 3-[(Methanesulfonyloxy)methyl]piperidine-1-carboxylic
acid tert-butyl ester 192369-91-8, 5-(Bromomethyl)-1-(tetrahydro-2H-
                          586373-19-5, 1-Benzyl-4-hydroxypyridin-2(1H)-one
pyran-2-yl)-1H-indazole
586374-17-6, 1-(3-Fluorobenzyl)-4-[(3-fluorobenzyl)oxy]-1H-pyridin-2-one
586374-35-8 586374-60-9, 3-Bromo-4-(2,4-difluorophenoxy)-6-methylpyridin-
2(1H)-one
          586374-98-3, 3-Bromo-4-(2,4-difluorophenoxy)-6-methyl-1-[4-
(piperazin-1-ylcarbonyl)benzyl]pyridin-2(1H)-one
                                                    586376-42-3,
1-[4-(Aminomethyl)phenyl]-4-(benzyloxy)-3-bromopyridin-2(1H)-one
hydrochloride 586376-54-7, 3-Bromo-1-(3-fluorobenzyl)-2-oxo-1,2-
dihydropyridin-4-yl trifluoromethanesulfonate 586376-85-4,
```

```
yl)phenyl]-6-methylpyridin-2(1H)-one
                                      586378-53-2, 1-Benzyl-3-bromo-4-
hydroxy-6-methylpyridin-2(1H)-one
                                  586378-62-3, 3-Bromo-1-
(cyclopropylmethyl)-4-hydroxy-6-methylpyridin-2(1H)-one 586378-89-4,
4-Hydroxy-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-one 586379-00-2,
3-Bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-1-[[5-
[(methylamino)methyl]pyrazin-2-yl]methyl]pyridin-2(1H)-one
                                                            586379-20-6,
4-[(2,4-Difluorobenzyl)oxy]-6-methylpyridin-2(1H)-one
                                                      586379-22-8,
4-[(2,4-Difluorobenzyl)oxy]-6-methyl-1-(pyridin-3-ylmethyl)pyridin-2(1H)-
RL: RCT (Reactant); RACT (Reactant or reagent)
   (preparation of pyridinones as modulators of p38 MAP kinase for
   treatment of inflammatory conditions, ischemia, viral
   infections, autoimmune diseases, and other conditions)
             586378-47-4P 586381-34-2P 586381-37-5P
58804-19-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
   (preparation of pyridinones as modulators of p38 MAP kinase for
   treatment of inflammatory conditions, ischemia, viral
   infections, autoimmune diseases, and other conditions)
 5 ANSWERS
            CAPLUS COPYRIGHT 2008 ACS on STN
ICM C07D209-00
34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 7, 28
Preparation of novel multicyclic compounds and their amino acid
derivatives as inhibitors of enzymes such as poly(ADP-ribose) polymerase
clopentapyrrolocarbazole prepn inhibitor poly ADP ribose polymerase; PARP
inhibitor multicyclic compd prepn; pyrrolocarbazole prepn inhibitor VEGFR2
kinase; furanopyrrolocarbazole prepn inhibitor VEGFR2 kinase;
neurodegenerative disease treatment multicyclic compd prepn;
inflammation treatment multicyclic compd prepn; ischemia
treatment multicyclic compd prepn; MLK3 kinase inhibitor
multicyclic compd prepn
Nervous system
   (Huntington's chorea; preparation of novel multicyclic compds. and their
   amino acid derivs. as inhibitors of enzymes for treatment of
   diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2
   kinase, and MLK3 kinase)
Amides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
   (amino; preparation of novel multicyclic compds. and their amino acid
   derivs. as inhibitors of enzymes for treatment of diseases
   related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,
   and MLK3 kinase)
Nervous system
   (central, injury; preparation of novel multicyclic compds. and their amino
   acid derivs. as inhibitors of enzymes for treatment of
   diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2
   kinase, and MLK3 kinase)
Nervous system
   (degeneration; preparation of novel multicyclic compds. and their amino acid
   derivs. as inhibitors of enzymes for treatment of diseases
   related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase,
   and MLK3 kinase)
Eye, disease
   (diabetic retinopathy; preparation of novel multicyclic compds. and their
   amino acid derivs. as inhibitors of enzymes for treatment of
   diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2
   kinase, and MLK3 kinase)
```

ΙT

L35

IC

CC

ST

ΙT

ΙT

ΙT

IT Cell proliferation

(disorders; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Uterus, disease

(endometriosis; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease

(intraocular neovascular syndromes; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Brain, disease

Heart, disease

(ischemia; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Eye, disease

(macula, degeneration; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Heterocyclic compounds

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nitrogen, aromatic; preparation of novel multicyclic compds. and their amino

acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Alzheimer's disease

Angiogenesis inhibitors

Anti-inflammatory agents

Antidiabetic agents

Antitumor agents

Parkinson's disease

Psoriasis

Rheumatoid arthritis

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Amino acids, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT Shock (circulatory collapse)

(septic; preparation of novel multicyclic compds. and their amino acid derivs. as inhibitors of enzymes for treatment of diseases related to enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3 kinase)

IT 374069-00-8P 374069-03-1P 374069-12-2P 374069-14-4P 374069-19-9P

```
374069-21-3P
               374069-22-4P
                               374069-23-5P
                                              374069-25-7P
                                                              374069-26-8P
374069-31-5P
               374069-33-7P
                               374069-35-9P
                                              374069-36-0P
                                                              374069-43-9P
                                              374069-75-7P
                                                              374070-30-1P
374069-44-0P
               374069-53-1P
                               374069-62-2P
374070-33-4P
               374070-38-9P
                               374070-39-0P
                                              374070-57-2P
                                                              374070-59-4P
                                                              374070-80-1P
374070-64-1P
               374070-73-2P
                               374070-77-6P
                                              374070-79-8P
374070-83-4P
               374070-95-8P
                               374070-96-9P
                                              374071-01-9P
                                                              374071-12-2P
374071-16-6P
               374071-28-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)
   (preparation of novel multicyclic compds. and their amino acid derivs. as
   inhibitors of enzymes for treatment of diseases related to
   enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
   kinase)
154114-97-3P
               374068-99-2P
                               374069-01-9P
                                              374069-02-0P
                                                              374069-04-2P
374069-05-3P
               374069-06-4P
                               374069-07-5P
                                              374069-08-6P
                                                              374069-09-7P
               374069-11-1P
                               374069-13-3P
                                              374069-15-5P
                                                              374069-16-6P
374069-10-0P
374069-17-7P
               374069-18-8P
                               374069-20-2P
                                              374069-24-6P
                                                              374069-27-9P
374069-28-0P
               374069-29-1P
                               374069-30-4P
                                              374069-32-6P
                                                              374069-34-8P
374069-37-1P
               374069-38-2P
                               374069-39-3P
                                              374069-40-6P
                                                              374069-41-7P
374069-42-8P
               374069-45-1P
                               374069-46-2P
                                              374069-47-3P
                                                              374069-48-4P
374069-49-5P
               374069-50-8P
                               374069-51-9P
                                              374069-52-0P
                                                              374069-54-2P
374069-55-3P
               374069-56-4P
                               374069-57-5P
                                              374069-58-6P
                                                              374069-59-7P
               374069-61-1P
                               374069-63-3P
374069-60-0P
                                              374069-64-4P
                                                              374069-65-5P
374069-66-6P
               374069-67-7P
                               374069-68-8P
                                              374069-69-9P
                                                              374069-70-2P
374069-71-3P
               374069-72-4P
                               374069-73-5P
                                              374069-74-6P
                                                              374069-76-8P
374069-77-9P
               374069-78-0P
                               374069-79-1P
                                              374069-80-4P
                                                              374069-81-5P
374069-82-6P
                               374069-84-8P
               374069-83-7P
                                              374069-85-9P
                                                              374069-87-1P
               374069-89-3P
374069-88-2P
                               374069-90-6P
                                              374069-91-7P
                                                              374069-92-8P
374069-93-9P
               374069-94-0P
                               374069-95-1P
                                              374069-96-2P
                                                              374069-97-3P
374069-98-4P
               374069-99-5P
                               374070-00-5P
                                              374070-01-6P
                                                              374070-02-7P
                                                              374070-07-2P
374070-03-8P
               374070-04-9P
                               374070-05-0P
                                              374070-06-1P
374070-08-3P
               374070-09-4P
                               374070-10-7P
                                              374070-11-8P
                                                              374070-12-9P
374070-13-0P
               374070-14-1P
                               374070-15-2P
                                              374070-16-3P
                                                              374070-17-4P
374070-18-5P
               374070-19-6P
                               374070-20-9P
                                              374070-21-0P
                                                              374070-22-1P
374070-23-2P
               374070-24-3P
                               374070-25-4P
                                              374070-26-5P
                                                              374070-27-6P
374070-28-7P
               374070-29-8P
                               374070-31-2P
                                              374070-32-3P
                                                              374070-34-5P
374070-35-6P
               374070-36-7P
                               374070-37-8P
                                              374070-40-3P
                                                              374070-41-4P
               374070-43-6P
                               374070-44-7P
                                              374070-45-8P
374070-42-5P
                                                              374070-46-9P
374070-47-0P
               374070-48-1P
                               374070-49-2P
                                              374070-50-5P
                                                              374070-51-6P
374070-52-7P
               374070-53-8P
                              374070-54-9P
                                              374070-55-0P
                                                              374070-56-1P
374070-58-3P
               374070-60-7P
                              374070-62-9P
                                              374070-63-0P
                                                              374070-65-2P
                                                              374070-70-9P
374070-66-3P
               374070-67-4P
                               374070-68-5P
                                              374070-69-6P
                               374070-74-3P
                                                              374070-76-5P
374070-71-0P
               374070-72-1P
                                              374070-75-4P
374070-78-7P
               374070-81-2P
                               374070-82-3P
                                              374070-84-5P
                                                              374070-85-6P
374070-86-7P
               374070-87-8P
                               374070-88-9P
                                                              374070-90-3P
                                              374070-89-0P
                                                              374070-97-0P
374070-91-4P
               374070-92-5P
                               374070-93-6P
                                              374070-94-7P
374070-98-1P
                                                              374071-03-1P
               374070-99-2P
                               374071-00-8P
                                              374071-02-0P
374071-04-2P
               374071-05-3P
                               374071-06-4P
                                              374071-07-5P
                                                              374071-08-6P
374071-09-7P
               374071-10-0P
                               374071-11-1P
                                              374071-13-3P
                                                              374071-14-4P
374071-15-5P
               374071-17-7P
                               374071-18-8P
                                              374071-19-9P
                                                              374071-20-2P
374071-21-3P
               374071-22-4P
                               374071-23-5P
                                              374071-24-6P
                                                              374071-25-7P
374071-26-8P
               374071-27-9P
                                                              374071-31-5P
                               374071-29-1P
                                              374071-30-4P
374071-32-6P
               374071-33-7P
                               374071-34-8P
                                              374071-35-9P
                                                              374071-36-0P
374071-37-1P
               374071-38-2P
                               374071-39-3P
                                              374071-40-6P
                                                              374071-41-7P
374071-42-8P
               374071-43-9P
                               374071-44-0P
                                              374071-45-1P
                                                              374071-46-2P
374071-47-3P
               374071-48-4P
                               374071-49-5P
                                              374071-50-8P
                                                              374071-51-9P
374071-52-0P
                               374071-54-2P
                                                              374071-56-4P
               374071-53-1P
                                              374071-55-3P
374071-57-5P
               374071-58-6P
                               374072-29-4P
                                              374553-23-8P
                                                              374553-24-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
```

```
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
   (preparation of novel multicyclic compds. and their amino acid derivs. as
   inhibitors of enzymes for treatment of diseases related to
   enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
   kinase)
9055-67-8, Poly(ADP-ribose) polymerase 150977-45-0, VEGFR2 kinase
153190-46-6, MLK3 kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC
(Miscellaneous); BIOL (Biological study); PROC (Process)
   (preparation of novel multicyclic compds. and their amino acid derivs. as
   inhibitors of enzymes for treatment of diseases related to
   enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
   kinase)
50-00-0, Formaldehyde, reactions 60-34-4 62-55-5, Thioacetamide
62-56-6, Thiourea, reactions 64-19-7, Acetic acid, reactions 68-12-2,
DMF, reactions 74-88-4, Methyl iodide, reactions 75-36-5, Acetyl
chloride 79-03-8, Propionyl chloride 79-09-4, Propionic acid, reactions 79-30-1, Isobutyryl chloride 79-37-8, Oxalyl chloride
95-15-8, Benzothiophene 98-09-9, Phenylsulfonyl chloride 98-59-9
, p-Toluenesulfonyl chloride 100-39-0, Benzyl bromide 105-36-2, Ethyl
bromoacetate 107-13-1, Acrylonitrile, reactions 107-92-6, Butyric
acid, reactions 108-00-9, N, N-Dimethylethylenediamine 108-12-3,
Isovaleryl chloride 108-30-5, Succinic anhydride, reactions
Glutaric anhydride 109-01-3, N-Methylpiperazine 109-86-4,
2-Methoxyethanol 109-89-7, Diethylamine, reactions 109-90-0, Ethyl isocyanate 109-97-7, Pyrrole 110-89-4, Piperidine, reactions
110-91-8, Morpholine, reactions
                                 120-72-9, Indole, reactions 120-92-3,
Cvclopentanone
                123-75-1, Pyrrolidine, reactions 124-63-0,
Methanesulfonyl chloride 140-88-5, Ethyl acrylate 141-43-5,
Ethanolamine, reactions 141-75-3, Butyryl chloride 271-89-6,
             288-88-0, 1H-1,2,4-Triazole 399-52-0, 5-Fluoroindole
Benzofuran
541-59-3, Maleimide 544-92-3, Copper(I) cyanide 557-21-1, Zinc cyanide
591-08-2, N-Acetylthiourea 594-27-4, Tetramethyltin 598-21-0,
Bromoacetyl bromide 598-52-7, N-Methylthiourea 614-96-0,
5-Methylindole
                623-91-6, Diethyl fumarate 630-08-0, Carbon monoxide,
           638-29-9, Valeryl chloride 690-76-6, 2-(tert-
reactions
Butoxycarbonyl)thioacetamide
                               762-42-5, Dimethyl acetylenedicarboxylate
933-67-5, 7-Methylindole
                           999-97-3, Hexamethyldisilazane 1121-92-2
1462-37-9, Benzyl 2-bromoethyl ether 1501-27-5, Glutaric acid monomethyl
        2038-03-1, 4-(2-Aminoethyl)morpholine 2114-02-5
L-Proline methyl ester hydrochloride
                                       2812-46-6
                                                     3303-84-2,
N-tert-Butoxycarbonyl-\beta-alanine
                                  3878-55-5, Succinic acid monomethyl
ester
        4023-34-1, Cyclopropanecarbonyl chloride
                                                    4377-33-7, 2-Picolyl
          4524-93-0, Cyclopentanecarbonyl chloride 4530-20-5,
chloride
N-tert-Butoxycarbonyl-glycine 4744-50-7, Furo[3,4-b]pyrazine-5,7-
        5070-13-3, Bis(4-nitrophenyl) carbonate
                                                   5332-06-9,
                      5332-26-3
                                   5437-45-6, Benzyl bromoacetate
4-Bromobutyronitrile
5699-40-1, N-Acetylguanidine 6940-76-7, 1-Chloro-3-iodopropane
6971-44-4, 4-(N-Methylaminomethyl)pyridine 7148-07-4,
1-(Cyclopenten-1-yl)pyrrolidine 7531-52-4, L-Prolinamide
Triisopropylsilyl chloride 15098-69-8 16503-22-3, N-Methylhistamine dihydrochloride 18107-18-1, Trimethylsilyldiazomethane 19099-93-5,
Benzyl 4-oxo-1-piperidinecarboxylate 21035-59-6, 2-(N-
Methylaminomethyl)pyridine
                              24424-99-5, Di-tert-butyl dicarbonate
            49548-40-5 53300-47-3, 2-(Methanesulfonyl)thioacetamide
40594-97-6
53654-35-6, 2-Vinylindole 54663-78-4, 2-(Tributylstannyl)thiophene
57260-71-6 57260-73-8, N-tert-Butoxycarbonylethylenediamine 57294-38-9, 4-(tert-Butoxycarbonylamino)butyric acid 76822-35-0
86864-60-0, (2-Bromoethoxy)-tert-butyldimethylsilane 89031-84-5,
```

(3-Bromopropoxy)-tert-butyldimethylsilane 98518-10-6 118486-97-8,

ΙΤ

```
2-(Tributylstannyl)-1-methylpyrrole 124252-41-1, 4-
     (Tributylstannyl)pyridine 133565-49-8
                                              136088-69-2
                                                            138585-09-8,
     p-(tert-Butyldimethylsilyloxy)benzyl chloride 155440-58-7,
     3-(Furan-3-yl)indole
                           175277-31-3, 2-(tert-Butanesulfonyl)thioacetamide
     175334-72-2, 5-Isoxazolecarbothioamide 374071-64-4, 5-
     (Triisopropylsilyloxy)-2-(1-hydroxycyclopentyl)indole 374071-66-6,
     5-Methoxy-2-(1-hydroxycyclopentyl)indole 374071-67-7,
     5-(2-Ethoxyethoxy)-2-(1-hydroxycyclopentyl)indole 374071-68-8,
     5-[2-(Diethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-69-9,
     5-[2-(Dimethylamino)ethoxy]-2-(1-hydroxycyclopentyl)indole 374071-70-2,
     5-[2-Morpholinoethoxy]-2-(1-hydroxycyclopentyl)indole
                                                              374071-71-3,
     2-(tert-Butoxycarbonyloxy)thioacetamide 374071-77-9,
     2-(2-Buten-2-yl)indole 374071-87-1 374071-90-6, 2-(3-Hepten-3-
               374071-91-7, 3-(Cyclohexen-1-yl)-1-methylindole
     yl)indole
                                                                    374071-92-8,
     2-(2,3-Dihydrofuran-4-yl)indole 374071-93-9 374071-94-0
                                                                    374071-96-2,
     6-Methoxy-2-(1-hydroxycyclopentyl)indole
                                                374071-97-3,
     4-Methoxy-2-(1-hydroxycyclopentyl)indole
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of novel multicyclic compds. and their amino acid derivs. as
        inhibitors of enzymes for treatment of diseases related to
        enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
        kinase)
ΙT
     90971-74-7P, 3-(Cyclopenten-1-yl)-1-(triisopropylsilyl)pyrrole
     118959-02-7P, 2-(Cyclopenten-1-yl)benzofuran 374071-59-7P, 2-(1-Hydroxycyclopentyl)indole 374071-60-0P, 2-(1-Cyclopentenyl)indole
                                                 374071-65-5P 374071-72-4P 374071-76-8P 374071-78-0P
     374071-61-1P
                    374071-62-2P
                                 374071-63-3P
     374071-73-5P
                    374071-74-6P
                                  374071-75-7P
     374071-79-1P, 2-(Cyclopenten-1-yl)pyrrole
                                                 374071-80-4P,
     3-(Cyclopenten-1-yl)pyrrole 374071-81-5P, 2-(Cyclopenten-1-yl)-1-
     (triisopropylsilyl)pyrrole
                                  374071-82-6P 374071-83-7P 374071-84-8P
     374071-85-9P, 1,6,7,8-Tetrahydrocyclopenta[g]indole-4,5-dicarboxylic acid
     374071-86-0P
                    374071-88-2P 374071-89-3P 374071-95-1P 374071-98-4P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of novel multicyclic compds. and their amino acid derivs. as
        inhibitors of enzymes for treatment of diseases related to
        enzymes such as poly(ADP-ribose) polymerase, VEGFR2 kinase, and MLK3
        kinase)
ALL ANSWERS HAVE BEEN SCANNED
=> s (method? or procedure? or assay?) and (identifying or screening) and
("angiogenesis inhibitor?")
          1075 (METHOD? OR PROCEDURE? OR ASSAY?) AND (IDENTIFYING OR SCREENING)
L37
                AND ("ANGIOGENESIS INHIBITOR?")
=> s 137 and phenanthrene
             0 L37 AND PHENANTHRENE
L38
=> s 137 and phenanthroline
             3 L37 AND PHENANTHROLINE
L39
=> d 139 1-3 hitstr ibib all
L39 ANSWER 1 OF 3
                       MEDLINE on STN
ACCESSION NUMBER:
                    2005611849
                                   MEDLINE
DOCUMENT NUMBER:
                    PubMed ID: 16236503
TITLE:
                    C8c-C15 monoseco-analogues of the phenanthroquinolizidine
                    alkaloids julandine and cryptopleurine exhibiting potent
                    anti-angiogenic properties.
```

AUTHOR: Banwell Martin G; Bezos Anna; Burns Christopher;

Kruszelnicki Irma; Parish Christopher R; Su Stephen; Sydnes

Magne 0

CORPORATE SOURCE: Research School of Chemistry, The Australian National

University, Canberra ACT 0200, Australia...

mgb@rsc.anu.edu.au

SOURCE: Bioorganic & medicinal chemistry letters, (2006 Jan 1) Vol.

16, No. 1, pp. 181-5. Electronic Publication: 2005-10-19.

Journal code: 9107377. ISSN: 0960-894X.

PUB. COUNTRY: England: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200603

ENTRY DATE: Entered STN: 22 Nov 2005

Last Updated on STN: 22 Mar 2006 Entered Medline: 21 Mar 2006

AN 2005611849 MEDLINE

DN PubMed ID: 16236503

TI C8c-C15 monoseco-analogues of the phenanthroquinolizidine alkaloids julandine and cryptopleurine exhibiting potent anti-angiogenic properties.

AU Banwell Martin G; Bezos Anna; Burns Christopher; Kruszelnicki Irma; Parish Christopher R; Su Stephen; Sydnes Magne O

CS Research School of Chemistry, The Australian National University, Canberra ACT 0200, Australia.. mgb@rsc.anu.edu.au

SO Bioorganic & medicinal chemistry letters, (2006 Jan 1) Vol. 16, No. 1, pp. 181-5. Electronic Publication: 2005-10-19.

Journal code: 9107377. ISSN: 0960-894X.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 200603

ED Entered STN: 22 Nov 2005 Last Updated on STN: 22 Mar 2006 Entered Medline: 21 Mar 2006

AB Four enantiomerically pure monoseco-analogues, 5, 7, 9, and 11, of the phenanthroquinolizidine alkaloid julandine (1) and four of congener cryptopleurine (2), viz. compounds 6, 8, 10, and 12, have been prepared and subjected to preliminary biological evaluation. These analogues show dramatically reduced cytotoxicity compared with the parent system 2 but they are, nevertheless, potent anti-angiogenic agents.

CT \*Alkaloids: CH, chemistry

Alkaloids: PD, pharmacology

Angiogenesis Inhibitors: PD, pharmacology

Animals

Aorta: DE, drug effects

Cell Line, Tumor

Drug Screening Assays, Antitumor: MT, methods

Humans

Inhibitory Concentration 50

Mice

Models, Chemical

\*Phenanthrolines: CH, chemistry Phenanthrolines: PD, pharmacology

\*Quinolizines: CH, chemistry Quinolizines: PD, pharmacology

Rats

Stereoisomerism

Stilbenes: PD, pharmacology

117048-59-6 (combretastatin A-4); 482-22-4 (cryptopleurine) RN

CN 0 (Alkaloids); 0 (Angiogenesis Inhibitors); 0 (

Phenanthrolines); 0 (Quinolizines); 0 (Stilbenes); 0 (julandine)

L39 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:332055 CAPLUS

DOCUMENT NUMBER: 136:350543

TITLE: Metalloprotease inhibitors for treatment of

angiogenesis

INVENTOR(S): Pan, Duojia; Rubin, Gerald M.; Zhang, Hongbing PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.					KIND		DATE		APPLICATION NO.						DATE			
									WO 2001-US45612										
		W:	ΑE,	AG,	AL,	ΑM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BΖ,	CA	, СН,	CN,	
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD	, GE,	GH,	
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC	, LK,	LR,	
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MΖ,	NO,	ΝZ	, PH,	PL,	
			PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ	, UA,	UG,	
			UZ,	VN,	YU,	ZA,	ZW												
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	ΑT,	ΒE	, СН,	CY,	
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE	, TR,	BF,	
			ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD	, TG	·	
	US 6436629 CA 2426043												·						
	CA	2426	043			A1		2002	0502	(	CA 2	001-	2426	043			20011	025	
	ΑU	2002	0200	98		А		2002	0506		AU 2	002-	2009	8			20011	025	
		1333															20011		
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE	, MC,	PT,	
								RO,											
	JΡ	2004	5227	02		Τ		2004	0729		JP 2	002-	5373	40			20011	025	
	ΑU	2002	2200	98		В2		2005	0127		AU 2	002-	2200	98			20011	025	
	US	2002	0132	778		A1		2002	0919	1	US 2	002-	6859	1			20020	206	
	US	6872	750			В2		2005	0329										
	US	2005	0171	024		A1		2005	0804	1	US 2	005-	8594	9			20050	321	
PRIO		APP								1	US 2	000-	6978	54		Α	20030	027	
										1	WO 2	001-	US45	612		W	20011	025	
																	20020		
AN	200	2:33	2055	CA:	PLUS														
DN	136	5:350	543																
ED	Entered STN: 03 May 2002																		
ΓΙ	Metalloprotease inhibitors for treatment of angiogenesis																		
IN		ı, Du											-						
PA		Reg	_								_	_	A						
SO		ΓInt						-											

CODEN: PIXXD2

DT Patent

LA English

ICM A61K039-00

ICS A61K039-395; A61K049-00; C12Q001-00; G01N033-53; G01N033-48

CC 1-6 (Pharmacology)

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

```
WO 2002034289
                        A1 20020502 WO 2001-US45612 20011025
PΤ
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
            UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    US 6436629
                        В1
                             20020820 US 2000-697854 20001027
                               20020502
                                          CA 2001-2426043
    CA 2426043
                        A1
                                                                 20011025
                        A 20020506 AU 2002-20098
A1 20030813 EP 2001-988593
    AU 2002020098
                                                                 20011025
                        А
    EP 1333856
                                                                 20011025
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                             20040729
                                         JP 2002-537340
    JP 2004522702
                        Τ
                                                                  20011025
                                          AU 2002-220098
    AU 2002220098
                        В2
                               20050127
                                                                  20011025
    US 20020132778
                        A1
                                          US 2002-68591
                               20020919
                                                                  20020206
                        В2
    US 6872750
                               20050329
                       A1
A
W
    US 20050171024
                               20050804
                                          US 2005-85949
                                                                  20050321
PRAI US 2000-697854
                               20001027
    WO 2001-US45612
                               20011025
    US 2002-68591
                        А3
                              20020206
CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
WO 2002034289
                ICM
                       A61K039-00
                ICS
                       A61K039-395; A61K049-00; C12Q001-00; G01N033-53;
                       G01N033-48
                       A61K0039-00 [ICM, 7]; A61K0039-395 [ICS, 7]; A61K0049-00
                TPCT
                       [ICS, 7]; C12Q0001-00 [ICS, 7]; G01N0033-53 [ICS, 7];
                       G01N0033-48 [ICS, 7]
                IPCR
                       G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
                       [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*];
                       A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
                       [I,A]; A61K0038-43 [I,C^*]; A61K0038-48 [I,A];
                       A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
                       [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                       [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                       C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
                       [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
                       G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
                ECLA
                       A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
                       C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N;
                        S01N; S01N
US 6436629
                       C12Q0001-00 [ICM, 7]; C12N0005-00 [ICS, 7]; A61K0049-00
                IPCI
                IPCR
                       G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
                        [I,C^*]; A61K0031-198 [I,A]; A61K0031-381 [I,C^*];
                       A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
                        [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
                       A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
                       [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                       [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                       C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
                       [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
                       G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
```

```
[I,A]
                NCL.
                       435/004.000; 424/009.100; 424/009.200; 435/375.000
                ECLA
                       A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
                       C07K016/18; C12Q001/37; G01N033/573
CA 2426043
                IPCI
                       A61K0039-00 [ICM, 7]; A61K0049-00 [ICS, 7]; C12Q0001-00
                       [ICS,7]; A61K0039-395 [ICS,7]; G01N0033-48 [ICS,7];
                       G01N0033-53 [ICS, 7]
                       G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
                IPCR
                       [I,C^*]; A61K0031-198 [I,A]; A61K0031-381 [I,C^*];
                       A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
                       [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
                       A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
                       [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                       [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                       C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
                       [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
                       G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
                       [I,A]
AU 2002020098
                IPCI
                       A61K0039-00 [ICM, 7]; A61K0039-395 [ICS, 7]; A61K0049-00
                       [ICS, 7]; C12Q0001-00 [ICS, 7]; G01N0033-53 [ICS, 7];
                       G01N0033-48 [ICS, 7]
                IPCR
                       G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
                       [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*];
                       A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
                       [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
                       A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
                       [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                       [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                       C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
                       [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
                       G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
                       [I,A]
EP 1333856
                IPCI
                       A61K0039-00 [ICM, 7]; A61K0039-395 [ICS, 7]; A61K0049-00
                       [ICS, 7]; C12Q0001-00 [ICS, 7]; G01N0033-53 [ICS, 7];
                       G01N0033-48 [ICS, 7]
                IPCR
                       G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
                       [I,C^*]; A61K0031-198 [I,A]; A61K0031-381 [I,C^*];
                       A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
                       [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
                       A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
                       [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                       [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                       C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
                       [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
                       G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
                       [I,A]
                       A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
                ECLA
                       C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N;
                       S01N; S01N
JP 2004522702
                IPCI
                       A61K0045-00 [ICM, 7]; A61K0031-198 [ICS, 7]; A61K0031-185
                       [ICS, 7, C*]; A61K0039-395 [ICS, 7]; A61P0035-00 [ICS, 7];
                       A61P0043-00 [ICS,7]; G01N0033-48 [ICS,7]; G01N0033-53
                       [ICS, 7]; G01N0033-574 [ICS, 7]
                IPCR
                       A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381
                       [I,A]; A61K0031-381 [I,C*]; A61K0031-403 [I,C*];
                       A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48
                       [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*];
                       C12Q0001-37 [I,A]; C12Q0001-37 [I,C*]; G01N0033-573
```

```
[I,A]; G01N0033-573 [I,C*]
                        2G045/AA29; 2G045/BB20; 2G045/BB50; 2G045/CB01;
                 FTERM
                        2G045/CB02; 2G045/FA16; 4C084/AA17; 4C084/ZB26;
                        4C085/AA13; 4C085/CC03; 4C085/CC04; 4C085/CC22;
                        4C085/DD23; 4C085/EE03; 4C206/FA53; 4C206/MA04;
                        4C206/ZB26; 4C206/ZC78
 AU 2002220098
                 IPCI
                        A61K0039-00 [ICS, 7]; G01N0033-48 [ICS, 7]; G01N0033-53
                        [ICS, 7]; C12Q0001-00 [ICS, 7]; A61K0049-00 [ICS, 7];
                        A61K0039-395 [ICS,7]
                 IPCR
                        G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
                        [I,C*]; A61K0031-198 [I,A]; A61K0031-381 [I,C*];
                        A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
                        [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
                        A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
                        [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
                        A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                        [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                        C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
                        [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
                        G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
                        [I,A]
                 ECLA
                        A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
                        C07K016/18; C12Q001/37; G01N033/573; K61K; M07K; S01N;
                        S01N; S01N
 US 20020132778
                        A61K0038-05 [ICM, 7]; A61K0039-395 [ICS, 7]; A61K0031-19
                 IPCI
                        [ICS, 7]; A61K0031-185 [ICS, 7, C*]
                 IPCR
                        G01N0033-48 [I,C*]; G01N0033-48 [I,A]; A61K0031-185
                        [I,C^*]; A61K0031-198 [I,A]; A61K0031-381 [I,C^*];
                        A61K0031-381 [I,A]; A61K0031-403 [I,C*]; A61K0031-405
                        [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
                        A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00
                        [I,C*]; A61K0045-00 [I,A]; A61P0035-00 [I,C*];
                        A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                        [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                        C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-53
                        [I,C*]; G01N0033-53 [I,A]; G01N0033-573 [I,C*];
                        G01N0033-573 [I,A]; G01N0033-574 [I,C*]; G01N0033-574
                        [I,A]
                 NCL
                        514/019.000; 514/575.000
                 ECLA
                        A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
                        C07K016/18; C12Q001/37; G01N033/573
 US 20050171024
                IPCI
                        A61K0038-04 [ICM, 7]; A61K0031-405 [ICS, 7]; A61K0031-403
                        [ICS, 7, C*]; A61K0031-19 [ICS, 7]; A61K0031-185
                        [ICS, 7, C*]
                        A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-381
                 IPCR
                        [I,C^*]; A61K0031-381 [I,A]; A61K0031-403 [I,C^*];
                        A61K0031-405 [I,A]; A61K0038-43 [I,C*]; A61K0038-48
                        [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A];
                        C12Q0001-37 [I,C*]; C12Q0001-37 [I,A]; G01N0033-573
                        [I,C*]; G01N0033-573 [I,A]
                 NCL
                        514/019.000; 514/419.000; 514/575.000
                        A61K031/198; A61K031/381; A61K031/405; A61K038/48N;
                 ECLA
                        C07K016/18; C12Q001/37; G01N033/573
     The invention provides methods and compns. relating to Kuz
AB
     involvement in angiogenesis. In various embodiments, the invention
     provides methods for modulating angiogenesis by specifically
     modulating the activity of Kuz in a vertebrate animal predetd. to have a
     pathogenic angiogenesis; and subsequently detecting a resultant angiogenic
     modulation in the animal. Methods are provided for
     identifying a modulator of angiogenesis by (a) contacting an
     angiogenic assay system comprising a predetd. amount of Kuz with a
```

```
candidate agent, under conditions whereby but for the presence of the
     agent, the system provides a reference angiogenesis; and (b) detecting an
     agent-biased angiogenesis of the system.
     angiogenesis antitumor metalloprotease inhibitor Kuz protein
ST
    Antibodies and Immunoglobulins
TT
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (Kuz mutant fused to Fc region of; metalloprotease inhibitors for
        treatment of angiogenesis)
ΙΤ
     Antibodies and Immunoglobulins
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (Kuz-specific; metalloprotease inhibitors for treatment of
        angiogenesis)
ΙT
     Proteins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (Kuzbanian (Kuz); metalloprotease inhibitors for treatment of
        angiogenesis)
     Carboxylic acids, biological studies
ΤТ
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (carboxylates; metalloprotease inhibitors for treatment of
        angiogenesis)
ΙT
     Hydroxamic acids
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (hydroxamates; metalloprotease inhibitors for treatment of
        angiogenesis)
ΙT
     Angiogenesis inhibitors
     Antitumor agents
     Chelating agents
        (metalloprotease inhibitors for treatment of angiogenesis)
ΤТ
     Flavanols
     Thiols, biological studies
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (metalloprotease inhibitors for treatment of angiogenesis)
ΙΤ
     81669-70-7, Metalloprotease
                                  151769-16-3, TACE
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (inhibitor; metalloprotease inhibitors for treatment of angiogenesis)
ΙT
     60-00-4, EDTA, biological studies 66-71-7, 1,10-Phenanthroline
     120-80-9D, o-Hydroxyphenol, derivs. 130370-60-4, Batimastat
     142880-36-2, GM6001 421553-77-7, IC 3 421567-09-1, GW 9471
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (metalloprotease inhibitors for treatment of angiogenesis)
RE.CNT 3
              THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Fambrough; Proc Natl Acad Sci 1996, V93, P13233 CAPLUS
(2) Pan; Cell 1997, V90, P271 CAPLUS
(3) Wen; Development 1997, V124, P4759 CAPLUS
L39 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:
                         1999:194336 CAPLUS
DOCUMENT NUMBER:
                         130:232477
TITLE:
                         Methods using NGR receptor binding for
                         identifying molecules that home to angiogenic
                        vasculature in tumors
INVENTOR(S):
                        Ruoslahti, Erkki; Pasqualini, Renata
PATENT ASSIGNEE(S):
                        The Burnham Institute, USA
SOURCE:
                        PCT Int. Appl., 180 pp.
                        CODEN: PIXXD2
```

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

	PATENT NO.	KIND	DATE		APP	LICATI	ON N	. O		DZ	ATE	
		A1			WO 1998-US18895							
	RW: AT, BE, CI		E, DK, ES,	FI,	FR	, GB,	GR,	IE,	IT,	LU,	MC,	NL,
			20030610			1997-9						
	US 6180084	B1	20010130		US	1998-1	3980	2		19	9980	325
	AU 9894773 EP 1015884	Α Δ1	19990329 20000705		AU EP	1998-9	)4773 )4814	. N		19	9980: 9980:	908 ans
	R: CH, DE, FI	, GB, I	LI								,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	700
	JP 2001516055 US 6491894 US 20030113320 US 20040096441	T	20010925								9980	
	US 6491894	B1	20021210		US	2000-6 $2002-2$	55978	16		21	0000! 0021	911
	US 20030113320 US 20040096441	A1 A9	20030619		0.5	2002-2	2043/	4		۷ ک	JUZI	JU3
	US 20030152578	A1	20030814		US	2003-3	7599	2		20	0030	227
DDTO	US 20040131623		20040708			1007.0	0.001	4	_	. 1	0070	210
PRIC	PRITY APPLN. INFO.:				US	1997-9 1998-1 1996-6	398N	. 4	E Z	A 19	997U: 9980:	91U 825
					US	1996-6	50947	'P	I	P 19	9960	910
					IIS	1996-7	71006	7	7	Δ 1 (	9960	910
					MO	1998-U 2000-6	JS188	195	7	M = 19	9980:	908
ED	Entered STN: 25 Methods using NGR molecules that hor	receptor						ors				
ED TI IN PA SO DT LA IC	Methods using NGR molecules that how Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology CNT 2	receptore to and Pasqual: ute, USA 0 pp.	giogenic v Ini, Renat	ascu a	ılat	ure ir	n tum			D2	<b>A</b> TE	
	Methods using NGR molecules that how Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology: CNT 2 PATENT NO.	receptore to and Pasqual: ute, USA 0 pp.	giogenic v Ini, Renat A DATE	ascu a	APP	ure ir	ON N	10.		_		
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that how Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology: CNT 2 PATENT NO WO 9913329 W: AU, CA, JI	receptore to and Pasqual: ute, USA 0 pp.  KIND A1	DATE	ascu a	APP  WO	LICATI	ON N	10 <b>.</b> 		19	9980	908
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology CNT 2 PATENT NO WO 9913329	receptore to and Pasqual: ute, USA 0 pp.  KIND A1	DATE	ascu a	APP  WO	LICATI	ON N	10 <b>.</b> 		19	9980	908
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology CNT 2 PATENT NO	receptore to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1	DATE 19990318 DK, ES, 20030610	FI,	APP  WO FR US	LICATI  1998-U , GB,	ON N JS188 GR,	IO.  95 IE,		19 LU,	MC,	908 NL, 910
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology CNT 2 PATENT NO	receptore to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1 B1	DATE  19990318  DATE  20030610 20010130	FI,	APPWO FR	LICATI  1998-U , GB, 1997-9	ON N  JS188 GR, 92691	IO. 195 IE, 4		LU,	MC,	908 NL 910 825
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology) CNT 2 PATENT NO. ———————— WO 9913329 W: AU, CA, JI RW: AT, BE, CI PT, SE US 6576239 US 6180084 AU 9894773	receptore to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1	DATE 19990318  DATE 19990318  DATE 19990329	FI,	APP	LICATI  1998-U , GB, 1997-9 1998-1	CON N  JS188 GR, 02691 .3980	IO. 195 IE,		LU, 19	MC, 99809	908 NL, 910 825 908
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology) CNT 2 PATENT NO	receptor e to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1 B1 A A1 , GB, II	DATE 19990318  DATE 19990318  DATE 19990329 20000705	FI,	APP  WO FR US US AU EP	LICATI  1998-U , GB, 1997-9 1998-9 1998-9	CON N  JS188 GR, 92691 3980 94773	IO. 195 IE, 4		19 LU, 19 19	MC, 99709 99709 99809	908 NL, 910 825 908 908
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology) CNT 2 PATENT NO	receptor e to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1 B1 A A1 , GB, IT	DATE 19990318 E, DK, ES, 20030610 20010130 19990329 20000705 E, LI 20010925	FI,	APP WO FR US US AU EP JP	LICATI  1998-U , GB, 1997-9 1998-9 1998-9 2000-5	GN N  JS188 GR, 92691 3980 94773 94814	IO.  95 IE, 42		LU, 19 19 19 19	MC, 99709 99709 99809 99809	908 NL 910 825 908 908
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology CNT 2 PATENT NO	receptor e to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1 B1 A A1 , GB, IT B1	DATE 19990318 E, DK, ES, 20030610 20010130 19990329 20000705 F, LI 20010925 20021210	FI,	APP	LICATI  1998-U , GB, 1997-9 1998-9 1998-9 2000-5 2000-6	GN N  JS188 GR, 92691 3980 94773 94814 51106	IO.  95 IE, 42 		19 LU, 19 19 19 19	MC, 99709 99809 99809 99809 99809	908 NL 910 825 908 908 908
ED TI IN PA SO DT LA IC	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology) CNT 2 PATENT NO	receptor e to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1 B1 A A1 , GB, IT	DATE 19990318 E, DK, ES, 20030610 20010130 19990329 20000705 E, LI 20010925	FI,	APP	LICATI  1998-U , GB, 1997-9 1998-9 1998-9 2000-5	GN N  JS188 GR, 92691 3980 94773 94814 51106	IO.  95 IE, 42 		19 LU, 19 19 19 19	MC, 99709 99709 99809 99809	908 NL, 910 825 908 908
ED TI IN PA SO DT LA IC CC FAN.	Methods using NGR molecules that hor Ruoslahti, Erkki; The Burnham Instit PCT Int. Appl., 18 CODEN: PIXXD2 Patent English ICM G01N033-50 ICS G01N033-574 1-6 (Pharmacology CNT 2 PATENT NO	receptor e to and Pasqual: ute, USA 0 pp.  KIND A1 , CY, DE B1 B1 A A1 , GB, IT B1 A1	DATE 19990318 E, DK, ES, 20030610 20010130 19990329 20000705 T, LI 20010925 20021210 20030619	FI,	APP	LICATI  1998-U , GB, 1997-9 1998-9 1998-9 2000-5 2000-6	GON N  JS188 GR, 02691 3980 04773 04814 51106 55978	IO. 195 IE, 42 20		19 LU, 19 19 19 19 20 20	MC, 99709 99809 99809 99809 99809	908 NL 910 825 908 908 911

```
US 1998-139802 A
                               19980825
    US 1996-60947P
                        P
                               19960910
                        A
    US 1996-710067
                               19960910
                        W
    WO 1998-US18895
                               19980908
                        A3
    US 2000-659786
                              20000911
CLASS
PATENT NO.
               CLASS PATENT FAMILY CLASSIFICATION CODES
                ____
WO 9913329
               ICM
                       G01N033-50
                       G01N033-574
                ICS
                IPCI
                       G01N0033-50 [ICM, 6]; G01N0033-574 [ICS, 6]
                       G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122
                IPCR
                       [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*];
                       A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704
                       [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
                       A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00
                        [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                        [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A];
                       G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50
                        [I,C^*]; G01N0033-50 [I,A]; G01N0033-574 [I,C^*];
                       G01N0033-574 [I,A]
                ECLA
                       G01N033/50D2B; G01N033/574V4
US 6576239
                IPCI
                       A61K0039-00 [ICM, 7]
                IPCR
                       A61K0047-48 [I,C*]; A61K0047-48 [I,A]; G01N0033-50
                        [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*];
                       G01N0033-574 [I,A]
                NCL
                       424/185.100; 424/001.570; 514/002.000; 514/008.000;
                        530/300.000; 530/324.000; 530/328.000
                ECLA
                       A61K047/48R2
US 6180084
                IPCI
                       A61K0049-00 [ICM, 7]; G01N0033-53 [ICS, 7]; G01N0033-566
                       [ICS, 7]
                       G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574
                TPCR
                       [I,C*]; G01N0033-574 [I,A]
                NCL
                       424/009.100; 424/009.200; 435/007.800; 436/501.000
                ECLA
                       G01N033/50D2B; G01N033/574V4
AU 9894773
                IPCI
                       G01N0033-50 [ICM, 6]; G01N0033-574 [ICS, 6]
                IPCR
                       G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122
                       [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*];
                       A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704
                       [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
                       A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00
                       [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                        [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A];
                       G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50
                        [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*];
                       G01N0033-574 [I,A]
EP 1015884
                       G01N0033-50 [ICM, 6]; G01N0033-574 [ICS, 6]
                IPCI
                       G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122
                IPCR
                        [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*];
                       A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704
                        [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
                       A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00
                        [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*];
                       A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                       [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A];
                       G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50
                       [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*];
                       G01N0033-574 [I,A]
                ECLA
                       G01N033/50D2B; G01N033/574V4; S01N; S01N
```

```
JP 2001516055
                 TPCT
                        G01N0033-566 [ICM, 7]; A61K0031-122 [ICS, 7];
                        A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*];
                        A61K0031-704 [ICS, 7]; A61K0031-7028 [ICS, 7, C*];
                        A61K0045-00 [ICS,7]; A61K0047-48 [ICS,7]; A61K0051-00
                        [ICS, 7]; A61P0035-00 [ICS, 7]; A61P0043-00 [ICS, 7];
                        C07K0007-00 [ICS, 7]; G01N0033-15 [ICS, 7]; G01N0033-50
                        [ICS, 7]; G01N0033-574 [ICS, 7]
                 IPCR
                        G01N0033-566 [I,C*]; G01N0033-566 [I,A]; A61K0031-122
                        [I,C^*]; A61K0031-122 [I,A]; A61K0031-185 [I,C^*];
                        A61K0031-198 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704
                        [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
                        A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-00
                        [I,C*]; A61K0051-00 [I,A]; A61P0035-00 [I,C*];
                        A61P0035-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00
                        [I,A]; C07K0007-00 [I,C*]; C07K0007-00 [I,A];
                        G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-50
                        [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*];
                        G01N0033-574 [I,A]
US 6491894
                        A61K0049-00 [ICM, 7]
                 IPCI
                 IPCR
                        G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574
                        [I,C*]; G01N0033-574 [I,A]
                        424/009.100; 424/009.200; 424/093.200; 435/007.230;
                 NCL
                        435/007.800; 436/501.000; 514/002.000; 530/300.000
                 ECLA
                        G01N033/50D2B; G01N033/574V4
 US 20030113320
                 IPCI
                        A61K0039-395 [ICM, 7]; C07H0021-04 [ICS, 7]; C07H0021-00
                        [ICS, 7, C*]; C12P0021-02 [ICS, 7]; C12N0005-06 [ICS, 7];
                        C07K0014-705 [ICS, 7]; C07K0014-435 [ICS, 7, C*]
                 IPCR
                        G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-574
                        [I,C*]; G01N0033-574 [I,A]
                 NCL
                        424/143.100; 435/069.100; 435/320.100; 435/325.000;
                        530/350.000; 536/023.500
                 ECLA
                        G01N033/50D2B; G01N033/574V4
 US 20030152578
                 IPCI
                        G01N0033-574 [ICM, 7]; A61K0039-395 [ICS, 7]
                 IPCR
                        A61K0047-48 [I,C*]; A61K0047-48 [I,A]; G01N0033-50
                        [I,C*]; G01N0033-50 [I,A]; G01N0033-574 [I,C*];
                        G01N0033-574 [I,A]
                 NCL
                        424/178.100; 435/007.230
                        A61K047/48R2; G01N033/50D2B; G01N033/574V4
AΒ
     A method is disclosed for identifying a tumor homing
     mol. that homes to angiogenic vasculature by contacting a substantially
     purified NGR receptor with one or more mols. and determining specific binding
of
     a mol. to the NGR receptor, where the presence of specific binding
     identifies the mol. as a tumor homing mol. that homes to angiogenic
     vasculature. The invention also provides a method of directing
     a moiety to angiogenic vasculature in a subject by administering to the
     subject a conjugate including a moiety linked to a tumor homing mol. that
     exhibits specific binding to an NGR receptor, whereby the moiety is
     directed to angiogenic vasculature. In addition, the invention provides a
     method of imaging the angiogenic vasculature of a tumor in a
     subject by administering to the subject a conjugate having a detectable
     moiety linked to a tumor homing mol. that exhibits specific binding to an
     NGR receptor and detecting the conjugate.
     NGR receptor tumor homing mol identification; angiogenic vasculature tumor
ST
     homing NGR receptor; imaging conjugate angiogenic vasculature tumor
     Antitumor agents
ΙΤ
     Antitumor agents
        (Hodgkin's disease inhibitors; methods using NGR receptor
        binding for identifying mols. that home to angiogenic
        vasculature in tumors, and therapeutic and imaging methods)
ΤТ
     Sarcoma
```

```
(Kaposi's; methods using NGR receptor binding for
        identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
     Peptides, biological studies
ΙT
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (NGR-containing; methods using NGR receptor binding for
        identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
ΙT
     Leukemia
        (acute myelogenous; methods using NGR receptor binding for
        identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
ΙT
     Mammary gland
        (carcinoma, inhibitors; methods using NGR receptor binding
        for identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
ΙT
     Ovary, neoplasm
        (carcinoma; methods using NGR receptor binding for
        identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
ΙT
    Mammary gland
        (carcinoma; tumor homing peptide identification by in vivo panning
        against a breast tumor)
ΤТ
     Blood vessel
        (endothelium; methods using NGR receptor binding for
        identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
ΙT
    Hodgkin's disease
     Hodgkin's disease
        (inhibitors; methods using NGR receptor binding for
        identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
IT
     Antitumor agents
        (mammary gland carcinoma; methods using NGR receptor binding
        for identifying mols. that home to angiogenic vasculature in
        tumors, and therapeutic and imaging methods)
     Angiogenesis
ΤТ
       Angiogenesis inhibitors
     Blood vessel
     Drug screening
     Drug targeting
     Hodgkin's disease
     Imaging agents
     Immobilization, biochemical
    Melanoma
     Neoplasm
     Peptide library
     Phage display library
     Scintigraphic agents
        (methods using NGR receptor binding for identifying
        mols. that home to angiogenic vasculature in tumors, and therapeutic
        and imaging methods)
     RGD peptides
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (methods using NGR receptor binding for identifying
        mols. that home to angiogenic vasculature in tumors, and therapeutic
        and imaging methods)
TΤ
     Receptors
```

RL: BPR (Biological process); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); PROC (Process) (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) Proliferation inhibition (proliferation inhibitors, tumor homing mol. conjugates; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) Antitumor agents Cytotoxic agents Drugs (tumor homing mol. conjugates; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) Radionuclides, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tumor homing mol. conjugates; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) 9031-94-1, Aminopeptidase RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (CD13-like, inhibitors; methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) 189023-66-3 205117-84-6 221230-70-2 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) 221230-69-9P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) 221230-66-6P 221230-67-7P 221230-68-8P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) 149635-29-0D, conjugates 189023-64-1D, conjugates 205117-83-5D, 221230-65-5D, conjugates conjugates RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods) 66-71-7, o-Phenanthroline 13434-13-4, Actinonin 23214-92-8D, Doxorubicin, tumor homing mol. conjugates 58970-76-6, Bestatin RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

ΙT

ΤТ

ΤТ

ΙT

ΙT

ΙT

ΙT

ΙT

(Uses)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 162901-68-0 168179-57-5

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(methods using NGR receptor binding for identifying

mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 9054-63-1P, Aminopeptidase N

RL: BPR (Biological process); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); PROC (Process)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 152880-65-4

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

IT 14133-76-7D, Technetium-99, tumor homing mol. conjugates, biological studies 14333-33-6D, Carbon-11, tumor homing mol. conjugates, biological studies 14762-74-4D, Carbon-13, tumor homing mol. conjugates, biological studies 15750-15-9D, Indium-111, tumor homing mol. conjugates, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods using NGR receptor binding for identifying mols. that home to angiogenic vasculature in tumors, and therapeutic and imaging methods)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD RE

- (1) Burnham Inst; WO 9810795 A 1998 CAPLUS
- (2) Erkki, R; US 5536814 A 1996 CAPLUS
- (3) Jolla Cancer Res Found; WO 9514714 A 1995 CAPLUS
- (4) Jolla Cancer Res Found; WO 9710507 A 1997 CAPLUS
- (5) Koivunen, E; BIO/TECHNOLOGY 1995, V13(3), P265 CAPLUS
- (6) Koivunen, E; JOURNAL OF BIOLOGICAL CHEMISTRY 1993, V268(27), P20205 CAPLUS
- => SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L39 3

L39 WAS CREATED DURING MULTIFILE PROCESSING AND CANNOT BE USED WHEN CREATING E#S Enter SET SMARTSELECT ON before using SELECT to create an L-number of terms extracted from an L-number that contains answers or terms from more than one file. SET SMARTSELECT ON must be entered before you execute the SELECT command.

=> SET SMA ON

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L39 3

## SmartSELECT INITIATED New TRANSFER and ANALYZE Commands Now Available See HELP TRANSFER and HELP ANALYZE for Details

L40 SEL L39 3 1 : 1 TERM

=>

=>

=> SET SMA LOGIN

=> FIL CAPLUS

SET COMMAND COMPLETED

=> S L40

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 237.04 442.09 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -16.00-23.20

FILE 'CAPLUS' ENTERED AT 10:49:25 ON 11 JUN 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2008 VOL 148 ISS 24 FILE LAST UPDATED: 10 Jun 2008 (20080610/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> D L39 BIB, ABS

L41 1 L40

=> DEL L40 Y

YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y)/N:n

```
=>
=> FIL MEDLINE CAPLUS EMBASE BIOSIS SCISEARCH
COST IN U.S. DOLLARS
```

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
5.00 447.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE TOTAL
ENTRY SESSION
-23.20

FILE 'MEDLINE' ENTERED AT 10:52:54 ON 11 JUN 2008

FILE 'CAPLUS' ENTERED AT 10:52:54 ON 11 JUN 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:52:54 ON 11 JUN 2008 Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:52:54 ON 11 JUN 2008 Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:52:54 ON 11 JUN 2008 Copyright (c) 2008 The Thomson Corporation

=> => => d his

L1

(FILE 'HOME' ENTERED AT 09:45:41 ON 11 JUN 2008)

FILE 'CAPLUS' ENTERED AT 09:46:02 ON 11 JUN 2008 E US2007-599748/APPS

E US2006-599748/APPS 1 S E3 SEL RN L1

FILE 'REGISTRY' ENTERED AT 09:47:17 ON 11 JUN 2008

L2 162 S E1-E162

L3 22 S L2 AND DIONE

L4 0 S L2 AND PHENANTHROLINEDIONE

L5 2 S L2 AND PHENANTHROLINE

L6 0 S "SUBSTITUTED PHENANTHROLINE"

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 09:54:34 ON 11 JUN 2008

L7 224329 S L2

L8 13877 S L3 L9 406 S L5

L10 224329 S L7 OR L8 OR L9

L11 3300 S 10 AND ANTIANGIOGENIC

L12 56 S L11 AND ISCHEMIA

L13 28 S L11 AND ("HEART DISEASE")

L14 2 S L13 AND L12

L15 7 S (L3 OR L5) AND ANTIANGIOGENIC

L16 587 S "1,10-PHENANTHROLINE-5,6-DIONE"

L17 4 S L16 AND PHENANTHRENE

FILE 'REGISTRY' ENTERED AT 10:17:54 ON 11 JUN 2008

```
L18
               STR 27318-90-7
L19
              1 S L18 FAM SAM
                SET SMA OFF
                SET SMA ON
     FILE 'HOME' ENTERED AT 10:25:40 ON 11 JUN 2008
     FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:26:36 ON
     11 JUN 2008
L20
           1303 S ("1,4-NAPHTHALENEDIONE?")
L21
            129 S L20 AND (TREAT OR TREATMENT OR TREATING)
L22
              0 S L21 AND ("HEART ATTACK")
L23
              0 S L21 AND ("MYOCARDIAL INFARCTION")
             4 S L21 AND ISCHEMIA
L24
             1 S L16 AND ("MYOCARDIAL INFARCTION")
L25
             0 S L16 AND ("ANGIOGENESIS INHIBITOR?")
L26
L27
           552 S L2 AND ("ANGIOGENESIS INHIBITOR?")
L28
            24 S L3 AND ("ANGIOGENESIS INHIBITOR?")
L29
             2 S L5 AND ("ANGIOGENESIS INHIBITOR?")
L30
            53 S (L27 OR L28 OR L29) AND HEART
L31
             24 S L30 AND ISCHEMIA
L32
             19 S L31 AND (TREAT OR TREATING OR TREATMENT)
              0 S L32 AND ("5,6-DIONE")
L33
             0 S L32 AND ("1,10-PHENANTHRENE")
L34
L35
             5 S L32 AND DIONE
L36
             19 DUP REM L32 L35 (5 DUPLICATES REMOVED)
L37
           1075 S (METHOD? OR PROCEDURE? OR ASSAY?) AND (IDENTIFYING OR SCREENI
L38
              0 S L37 AND PHENANTHRENE
              3 S L37 AND PHENANTHROLINE
L39
                SET SMA OFF
                SET SMA ON
L40
            SEL L39 3 1 :
                               1 TERM
                SET SMA LOGIN
     FILE 'CAPLUS' ENTERED AT 10:49:25 ON 11 JUN 2008
L41
             1 S L40
     FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, SCISEARCH' ENTERED AT 10:52:54 ON
```

11 JUN 2008

=> =>